var images_info;if (!images_info) images_info =[]; images_info["79"]={"79000":{"type":"graphic_table","displayName":"Elbow examination findings and diagnosis","title":"Examination of the elbow: Findings and diagnosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examination of the elbow: Findings and diagnosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"50%\"></colgroup><colgroup span=\"2\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Examination signs</td> <td class=\"subtitle1\">Diagnosis</td> <td class=\"subtitle1\">Confirmation</td> </tr> <tr> <td>Tenderness of the lateral epicondyle*</td> <td class=\"divider_bottom\" rowspan=\"4\">#1 - Lateral epicondylitis</td> <td class=\"divider_bottom\" rowspan=\"4\">Local anesthetic block at the lateral epicondyle (optional)</td> </tr> <tr> <td>Pain reproduced by resisted wrist extension</td> </tr> <tr> <td>Pain reproduced by resisted radial deviation of the wrist</td> </tr> <tr> <td class=\"divider_bottom\">Diminished grip strength</td> </tr> <tr> <td>Tenderness of the medial epicondyle*</td> <td class=\"divider_bottom\" rowspan=\"4\">#2 - Medial epicondylitis</td> <td class=\"divider_bottom\" rowspan=\"4\">Local anesthetic block at the medial epicondyle (optional)</td> </tr> <tr> <td>Pain reproduced by resisted wrist flexion</td> </tr> <tr> <td>Pain reproduced by resisted ulnar deviation of the wrist</td> </tr> <tr> <td class=\"divider_bottom\">Diminished grip strength</td> </tr> <tr> <td>Cystic swelling or thickening over the olecranon process*</td> <td class=\"divider_bottom\" rowspan=\"2\">Olecranon bursitis</td> <td class=\"divider_bottom\" rowspan=\"2\">Aspiration of the bursa for cell count, gram stain, and crystal analysis</td> </tr> <tr> <td class=\"divider_bottom\">Normal range of motion</td> </tr> <tr> <td>Loss of full elbow extension*</td> <td class=\"divider_bottom\" rowspan=\"4\">Radiohumeral arthritis</td> <td class=\"divider_bottom\" rowspan=\"4\">Aspiration of the joint from the lateral approach</td> </tr> <tr> <td>Lateral bulge sign half way between the lateral epicondyle and the olecranon process</td> </tr> <tr> <td>Loss of full flexion</td> </tr> <tr> <td class=\"divider_bottom\">Loss of supination or pronation</td> </tr> <tr> <td>Pain \"through\" the elbow, extending distally*</td> <td rowspan=\"4\">Referred pain from the neck or shoulder</td> <td rowspan=\"4\">Screening neck and shoulder examination</td> </tr> <tr> <td>Normal elbow range of motion</td> </tr> <tr> <td>No local epicondylar tenderness</td> </tr> <tr> <td>No olecranon swelling</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">#1 and #2 refer to the two most common conditions affecting the elbow.</div><div class=\"graphic_footnotes\">* Is used to identify the hallmark sign; that is, the sign that has the greatest specificity for the diagnosis listed.</div><div id=\"graphicVersion\">Graphic 79000 Version 3.0</div></div></div>"},"79002":{"type":"graphic_diagnosticimage","displayName":"Left hip involvement in a patient with ankylosing spondylitis","title":"Left hip involvement in a patient with ankylosing spondylitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Left hip involvement in a patient with ankylosing spondylitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/RHEUM/79002_Left_hip_invol_ankyl_spondy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There are destructive changes in the left hip joint.</div><div class=\"graphic_reference\">Courtesy of Dr. Sheng Guang Li, The First Affiliated Hospital of PLA General Hospital, China.</div><div id=\"graphicVersion\">Graphic 79002 Version 3.0</div></div></div>"},"79003":{"type":"graphic_picture","displayName":"Patient position for exenteration","title":"Patient position for exenteration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Patient position for exenteration</div><div class=\"cntnt\"><img style=\"width:382px; height:260px;\" src=\"images/OBGYN/79003_Pt_position_for_exenteratio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient in modified dorsal lithotomy position. Arrow indicates thermal drape used to prevent excessive heat loss during procedure.</div><div id=\"graphicVersion\">Graphic 79003 Version 2.0</div></div></div>"},"79004":{"type":"graphic_diagnosticimage","displayName":"Ultrasound image of subchorionic hematoma","title":"Subchorionic hematoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subchorionic hematoma</div><div class=\"cntnt\"><img style=\"width:428px; height:355px;\" src=\"images/OBGYN/79004_Ultrasn_subchor_hem.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posterior fundal placenta (arrows) with an anterior organized subchorionic hematoma (arrowheads) arising from the superior edge of the placenta.</div><div class=\"graphic_reference\">Courtesy of Wendy L Kinzler, MD.</div><div id=\"graphicVersion\">Graphic 79004 Version 3.0</div></div></div>"},"79005":{"type":"graphic_diagnosticimage","displayName":"Prepatellar bursitis MRI","title":"Prepatellar bursitis with fluid and debris","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prepatellar bursitis with fluid and debris</div><div class=\"cntnt\"><img style=\"width:416px; height:405px;\" src=\"images/RHEUM/79005_Prepatellar_bursitis_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This sagittal short tau inversion recovery (STIR) magnetic resonance image of the knee shows a inhomogenous high signal fluid in the prepatellar bursa (arrow) consistent with bursitis and intrabursal debris.</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD, and Celia M Jude, MD.</div><div id=\"graphicVersion\">Graphic 79005 Version 2.0</div></div></div>"},"79008":{"type":"graphic_waveform","displayName":"Intermediate case 16 answer","title":"Coarse atrial fibrillation","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Coarse atrial fibrillation</div><div class=\"cntnt\"><img style=\"width:539px; height:97px;\" src=\"images/CARD/79008_Intermediate_case_16_answer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coarse atrial fibrillatory waves are seen with an irregular ventricular response at a moderate rate. This arrhythmia may be mistaken for atrial flutter. However, the atrial waves are all identical in atrial flutter; in comparison, the rapid atrial waves vary in rate and shape from one section of the rhythm strip to the next in atrial fibrillation.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 79008 Version 2.0</div></div></div>"},"79013":{"type":"graphic_picture","displayName":"KS yellow perilesional halo","title":"Kaposi's sarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Kaposi's sarcoma</div><div class=\"cntnt\"><img style=\"width:358px; height:252px;\" src=\"images/ONC/79013_KS_yellow_perilesional_halo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin lesion in a patient with AIDS-related Kaposi's sarcoma with a yellow perilesional halo.</div><div class=\"graphic_reference\">By permission from: van den Brink MR, Dezube BJ, J Clin Oncol 1997; 15:1283.</div><div id=\"graphicVersion\">Graphic 79013 Version 3.0</div></div></div>"},"79015":{"type":"graphic_figure","displayName":"Ascaris lumbricoides life cycle","title":"<em>Ascaris lumbricoides</em> life cycle","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\"><em>Ascaris lumbricoides</em> life cycle</div><div class=\"cntnt\"><img style=\"width:508px; height:478px;\" src=\"images/ID/79015_Ascariasis_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Adult worms (females 20 to 35 cm; males 15 to 30 cm) <STRONG>(1)</STRONG> live in the lumen of the small intestine. A female may produce approximately 200,000 eggs per day, which are passed with the feces <STRONG>(2)</STRONG>. Unfertilized eggs may be ingested but are not infective. Fertile eggs embryonate and become infective after 18 days to several weeks <STRONG>(3)</STRONG>, depending on the environmental conditions (optimum: moist, warm, shaded soil). After infective eggs are swallowed <STRONG>(4)</STRONG>, the larvae hatch <STRONG>(5)</STRONG>, invade the intestinal mucosa, and are carried via the portal, then systemic circulation to the lungs <STRONG>(6)</STRONG>. The larvae mature further in the lungs (10 to 14 days), penetrate the alveolar walls, ascend the bronchial tree to the throat, and are swallowed <STRONG>(7)</STRONG>. Upon reaching the small intestine, they develop into adult worms <STRONG>(1)</STRONG>. Between&nbsp;two and&nbsp;three months are required from ingestion of the infective eggs to oviposition by the adult female. Adult worms can live&nbsp;one to&nbsp;two years.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Ascariasis. Available at: <A href=\"http://www.cdc.gov/dpdx/ascariasis/index.html\">http://www.cdc.gov/dpdx/ascariasis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 79015 Version 6.0</div></div></div>"},"79016":{"type":"graphic_picture","displayName":"Leg with filariasis","title":"Leg with filariasis","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Leg with filariasis</div><div class=\"cntnt\"><img style=\"width:474px; height:334px;\" src=\"images/ID/79016_Leg_with_filariasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Tish DJ, Edwin M, Kazura JW. Mass chemotherapy options to control lymphatic filariasis: a systematic review. The Lancet Infectious Diseases 2005; 5: 514. Copyright Â© 2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 79016 Version 2.0</div></div></div>"},"79019":{"type":"graphic_figure","displayName":"Cytotoxicity assays III","title":"Flow cytometry based cytotoxicity assay","html":"<div class=\"graphic\"><div style=\"width: 487px\" class=\"figure\"><div class=\"ttl\">Flow cytometry based cytotoxicity assay</div><div class=\"cntnt\"><img style=\"width:467px; height:236px;\" src=\"images/ALLRG/79019_Cytotoxicity_assays_III.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upregulation of LAMP-1/CD107a on NK cells as an indicator of granular exocytosis.</div><div class=\"graphic_footnotes\">LAMP-1: lysosomal associated membrane protein-1; NK: natural killer.</div><div id=\"graphicVersion\">Graphic 79019 Version 2.0</div></div></div>"},"79020":{"type":"graphic_waveform","displayName":"Doppler US artery","title":"Normal Doppler arterial waveform","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal Doppler arterial waveform</div><div class=\"cntnt\"><img style=\"width:350px; height:444px;\" src=\"images/SURG/79020_Doppler_US_artery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Longitudinal ultrasound image of the right neck with color and spectral Doppler demonstrates the normal sharp upstroke of the common carotid artery waveform. The variety of colors shown within the carotid artery (deep to the internal jugular vein) is called &quot;aliasing,&quot; a phenomenon seen when the color scale is set too low for the vessel interrogated. In this case, a venous preset was chosen and a lower velocity scale was selected by the machine.</div><div class=\"graphic_reference\">Courtesy of Lauren W Averill, MD.</div><div id=\"graphicVersion\">Graphic 79020 Version 3.0</div></div></div>"},"79023":{"type":"graphic_figure","displayName":"VH of atherosclerotic plaque","title":"VH of atherosclerotic plaque","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">VH of atherosclerotic plaque</div><div class=\"cntnt\"><img style=\"width:516px; height:256px;\" src=\"images/CARD/79023_VH_of_atherosclerotic_plaqu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Color-coded maps of the coronary arterial plaques constructed by three-dimensional (3D) integrated backscatter intravascular ultrasound imaging at baseline and after statin therapy. (A) At baseline, the plaque consisted of a large lip core (blue), which is covered with a fibrous cap (green). (B) After stain therapies, the lip core (blue) decreased and the fibrous area (green) increased.</div><div class=\"graphic_reference\">Reproduced with permission from Kawasaki M, Sano K, Okubo M, et al. Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound. J Am Coll Cardiol 2005; 45:1946. Copyright &#169; 2005 The American College of Cardiology Foundation.</div><div id=\"graphicVersion\">Graphic 79023 Version 2.0</div></div></div>"},"79025":{"type":"graphic_picture","displayName":"Ankle cutaneous larva migrans","title":"Cutaneous larva migrans","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Cutaneous larva migrans</div><div class=\"cntnt\"><img style=\"width:504px; height:353px;\" src=\"images/ID/79025_Ankle_cutan_larva_mig.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Serpiginous track left by the migrating&nbsp;parasite is seen on the ankle of this patient.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 79025 Version 3.0</div></div></div>"},"79028":{"type":"graphic_table","displayName":"Thyroid volume in children","title":"Thyroid volume in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Thyroid volume in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Age, years</td> <td class=\"subtitle1\">Volume (mL), mean &#177; SD</td> </tr> <tr> <td class=\"centered\">7</td> <td class=\"centered\">3.1 &#177; 1.3</td> </tr> <tr> <td class=\"centered\">8</td> <td class=\"centered\">3.3 &#177; 1.2</td> </tr> <tr> <td class=\"centered\">9</td> <td class=\"centered\">3.6 &#177; 1.3</td> </tr> <tr> <td class=\"centered\">10</td> <td class=\"centered\">4.0 &#177; 1.5</td> </tr> <tr> <td class=\"centered\">11</td> <td class=\"centered\">4.9 &#177; 1.5</td> </tr> <tr> <td class=\"centered\">12</td> <td class=\"centered\">5.3 &#177; 1.4</td> </tr> <tr> <td class=\"centered\">13</td> <td class=\"centered\">6.1 &#177; 1.6</td> </tr> <tr> <td class=\"centered\">14</td> <td class=\"centered\">6.3 &#177; 1.5</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Thyroid volume in Italian children without iodine deficiency, as measured by ultrasound. Thyroid volume is calculated using the formula of a rotation ellipsoid model: width x length x thickness x 0.52 for each lobe.</div><div class=\"graphic_reference\">Data from: Aghini-Lombardi F, Antonangeli L, Pinchera A, et al, J Clin Endocrinol Metab 1997; 82:1136.</div><div id=\"graphicVersion\">Graphic 79028 Version 5.0</div></div></div>"},"79030":{"type":"graphic_figure","displayName":"Toxicodendron radicans range US","title":"US range of toxicodendron radicans subspecies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">US range of toxicodendron radicans subspecies</div><div class=\"cntnt\"><img style=\"width:432px; height:317px;\" src=\"images/PC/79030_Toxicodendron_radicans_rang.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Bolognia, J, et al. Dermatology. Elsevier, Boston 2003. Copyright &#169; 2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 79030 Version 1.0</div></div></div>"},"79032":{"type":"graphic_picture","displayName":"Primary biliary cholangitis VIII - high power","title":"Liver histology of primary biliary cholangitis in a 35-year-old woman whose chief complaint was pruritus (high power, H&E)","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Liver histology of primary biliary cholangitis in a 35-year-old woman whose chief complaint was pruritus (high power, H&amp;E)</div><div class=\"cntnt\"><img style=\"width:454px; height:342px;\" src=\"images/GAST/79032_PrimbilicirrhVIIIhighed.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A bile duct is surrounded by and invaded by primarily lymphocytes. There are several eosinophils. This finding is consistent with the florid bile duct lesion of primary biliary cholangitis.</div><div class=\"graphic_reference\">Courtesy of Marshall M Kaplan, MD.</div><div id=\"graphicVersion\">Graphic 79032 Version 5.0</div></div></div>"},"79033":{"type":"graphic_figure","displayName":"Mitochondrial pedigree","title":"Example of a pedigree demonstrating mitochondrial inheritance","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Example of a pedigree demonstrating mitochondrial inheritance</div><div class=\"cntnt\"><img style=\"width:460px; height:316px;\" src=\"images/PEDS/79033_Mitochondrial_pedigree.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note that all offspring of an affected female are affected, while none of the offspring of affected males are affected.</div><div class=\"graphic_reference\">Courtesy of V Reid Sutton, MD.</div><div id=\"graphicVersion\">Graphic 79033 Version 1.0</div></div></div>"},"79035":{"type":"graphic_table","displayName":"Immune Rx systemic sclerosis","title":"Immunosuppressive therapies for systemic sclerosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Immunosuppressive therapies for systemic sclerosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Treatment</td> <td class=\"subtitle1\">Mechanism of action</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Selective immunosuppression</td> </tr> <tr> <td class=\"indent1\">Cyclosporine</td> <td>Inhibits T-helper cell actions by reducing IL-2 release, may reduce collagen synthesis</td> <td>Reported beneficial effects on skin sclerosis may be confounded by increased incidence of renal crisis</td> </tr> <tr> <td class=\"indent1\">Antithymocyte globulin</td> <td rowspan=\"2\">Temporary suppression of cell-mediated immunity</td> <td rowspan=\"2\">Possible benefit for skin sclerosis, although controlled trial of ATG confirms considerable therapy-associated morbidity</td> </tr> <tr> <td class=\"indent1\">Antilymphocyte globulin</td> </tr> <tr> <td class=\"indent1\">CAMPATH-1H</td> <td>Lympholytic humanized monoclonal antibody</td> <td>Anecdotal benefit in case reports</td> </tr> <tr> <td class=\"indent1\">Photopheresis</td> <td>Extracorporeal photoactivated 8-methoxypsoralen inhibits activated T-cells</td> <td>Benefit has been reported, but good placebo-controlled clinical trial is needed</td> </tr> <tr> <td class=\"indent1\">Plasmapheresis</td> <td>Removes circulating immune mediators</td> <td>Equivocal results but anecdotal benefit</td> </tr> <tr> <td class=\"indent1\">Anti-CD20</td> <td>Depletion of B lymphocytes</td> <td>Little evidence for skin improvement; some cases suggest improvement of lung fibrosis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Nonselective immunosuppression</td> </tr> <tr> <td class=\"indent1\">Methotrexate</td> <td>Folic acid antagonist</td> <td>Two trials suggest potential benefit for skin disease</td> </tr> <tr> <td class=\"indent1\">Cyclophosphamide</td> <td>Alkylating agent</td> <td>Evidence of benefit for lung fibrosis in randomized trials and open-label studies; cyclophosphamide often combined with glucocorticoids</td> </tr> <tr> <td class=\"indent1\">Azathioprine</td> <td>Antimetabolite</td> <td>Anecdotal benefit reported in open studies</td> </tr> <tr> <td class=\"indent1\">Autologous stem cell transplantation</td> <td>High-dose immunosuppression (often with cyclophosphamide) followed by stem cell transplantation</td> <td>Limited evidence suggesting benefit for skin and on functional assessment; awaiting results from ongoing large randomized trials</td> </tr> <tr> <td class=\"indent1\">Mycophenolate mofetil</td> <td>Inhibits lymphocyte purine biosynthesis which leads to decreased B- and T-cell proliferation</td> <td>Benefit suggested in observational studies</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IL-2: interleukin-2; ATG: antithymocyte globulin.</div><div id=\"graphicVersion\">Graphic 79035 Version 5.0</div></div></div>"},"79036":{"type":"graphic_figure","displayName":"Parapharyngeal space anatomy","title":"Parapharyngeal space","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Parapharyngeal space</div><div class=\"cntnt\"><img style=\"width:542px; height:694px;\" src=\"images/ID/79036_Parapharyngeal_space_edt.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 79036 Version 2.0</div></div></div>"},"79038":{"type":"graphic_diagnosticimage","displayName":"Chest radiograph in myocarditis","title":"Sequential chest radiographs in myocarditis","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Sequential chest radiographs in myocarditis</div><div class=\"cntnt\"><img style=\"width:455px; height:225px;\" src=\"images/CARD/79038_Chestradiographinmyocard.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view sequential chest radiographs in a young man with acute myocarditis (left) and three months later (right). Acutely, cardiomegaly and pulmonary congestion are apparent. Three months later, the lungs have cleared, but the patient has developed dilated cardiomyopathy with persistent cardiomegaly.</div><div class=\"graphic_reference\">Courtesy of Walter Abelmann, MD.</div><div id=\"graphicVersion\">Graphic 79038 Version 5.0</div></div></div>"},"79039":{"type":"graphic_table","displayName":"Topics in a birth plan","title":"Topics commonly discussed in birth plans","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Topics commonly discussed in birth plans</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Comfort measures</td>\n</tr>\n<tr>\n<td>Mobility during labor</td>\n</tr>\n<tr>\n<td>Eating and drinking during labor</td>\n</tr>\n<tr>\n<td>Massage</td>\n</tr>\n<tr>\n<td>Acupressure</td>\n</tr>\n<tr>\n<td>Birth balls</td>\n</tr>\n<tr>\n<td>Music</td>\n</tr>\n<tr>\n<td>Positioning for pushing</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Pharmacological pain relief</td>\n</tr>\n<tr>\n<td>Opiates</td>\n</tr>\n<tr>\n<td>Neuraxial analgesia and anesthesia (eg, epidural)</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Support</td>\n</tr>\n<tr>\n<td>Who will be present during labor and delivery</td>\n</tr>\n<tr>\n<td>Use of professional labor support</td>\n</tr>\n<tr>\n<td>Children at birth and visiting postpartum</td>\n</tr>\n<tr>\n<td>Attendance at childbirth education classes</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Medical procedures</td>\n</tr>\n<tr>\n<td>Types of electronic fetal monitoring and contraction monitoring</td>\n</tr>\n<tr>\n<td>Use of intravenous fluids and medications</td>\n</tr>\n<tr>\n<td>Artificial rupture of membranes</td>\n</tr>\n<tr>\n<td>Oxytocin</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Newborn</td>\n</tr>\n<tr>\n<td>Mother and baby together for at least one hour after birth</td>\n</tr>\n<tr>\n<td>Delay in administering vitamin K and eye medication</td>\n</tr>\n<tr>\n<td>Breast-feeding within the first hour</td>\n</tr>\n<tr>\n<td>Rooming-in with no separation of mother and baby</td>\n</tr>\n<tr>\n<td>No water or formula for a breast-fed baby</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 79039 Version 1.0</div></div></div>"},"79040":{"type":"graphic_picture","displayName":"EUS biopsy core Light","title":"Trucut biopsy sample","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Trucut biopsy sample</div><div class=\"cntnt\"><img style=\"width:323px; height:478px;\" src=\"images/GAST/79040_EUS_biopsy_core_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medium power view of a tissue core obtained with a trucut biopsy.</div><div class=\"graphic_reference\">Courtesy of Michael J Levy, MD and Maurits J Wiersema, MD.</div><div id=\"graphicVersion\">Graphic 79040 Version 1.0</div></div></div>"},"79041":{"type":"graphic_picture","displayName":"Straddle injury6","title":"Trauma of child","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Trauma of child</div><div class=\"cntnt\"><img style=\"width:504px; height:338px;\" src=\"images/EM/79041_Straddleinjury6.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note 2nd degree laceration noted on separation and traction of labia.</div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright Â© 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 79041 Version 8.0</div></div></div>"},"79043":{"type":"graphic_diagnosticimage","displayName":"Obstructing lymphocele","title":"Obstructing lymphocele","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Obstructing lymphocele</div><div class=\"cntnt\"><img style=\"width:288px; height:230px;\" src=\"images/NEPH/79043_Obstructing_lymphocele.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Longitudinal sonogram of a transplanted kidney. Dilated calyces (C) indicate hydronephrosis, which is due to a large lymphocele (L) obstructing the ureter at the hilum.</div><div class=\"graphic_reference\">Courtesy of W Charles O'Neill, MD.</div><div id=\"graphicVersion\">Graphic 79043 Version 2.0</div></div></div>"},"79045":{"type":"graphic_picture","displayName":"Fungal infection","title":"Peristomal fungal infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peristomal fungal infection</div><div class=\"cntnt\"><img style=\"width:324px; height:324px;\" src=\"images/GAST/79045_Fungal_infection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fungal infection presents as a maculopapular rash with distinct satellite lesions.</div><div class=\"graphic_reference\">Courtesy of Dorothy B Doughty, MN, RN, CWOCN, FAAN.</div><div id=\"graphicVersion\">Graphic 79045 Version 1.0</div></div></div>"},"79046":{"type":"graphic_diagnosticimage","displayName":"LLL atelectasis PA","title":"Left lower lobe atelectasis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left lower lobe atelectasis</div><div class=\"cntnt\"><img style=\"width:267px; height:260px;\" src=\"images/PULM/79046_LLL_atelectasis_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view demonstrating left lower lobe collapse, as seen by elevation of the left hemidiaphragm and increased retrocardiac opacification adjacent to the spine. This is accompanied by plate-like atelectasis of the lingula (NordenstrÃ¶m's sign).</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 79046 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"79047":{"type":"graphic_table","displayName":"Opioids commonly used in children","title":"Opioid analgesics commonly used in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Opioid analgesics commonly used in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"10%\"></colgroup><colgroup span=\"2\" width=\"35%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Drug</td> <td class=\"subtitle1\" colspan=\"2\">Equianalgesic dose*</td> <td class=\"subtitle1\" rowspan=\"2\">Oral dose and frequency<sup>&#182;</sup></td> <td class=\"subtitle1\" rowspan=\"2\">IV dose and frequency<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2\">Oral<br /> (mg)</td> <td class=\"subtitle2\">IV<br /> (mg)</td> </tr> <tr> <td>Morphine<sup>&#916;</sup></td> <td class=\"centered\">30</td> <td class=\"centered\">10</td> <td>0.3 mg/kg every three to four hours</td> <td>0.05 to 0.1 mg/kg every two to four hours</td> </tr> <tr> <td>Hydromorphone</td> <td class=\"centered\">7.5</td> <td class=\"centered\">1.5</td> <td>0.03 to 0.06 mg/kg every three to four hours</td> <td>0.015 mg/kg every two to four hours</td> </tr> <tr> <td>Oxycodone<sup>&#9674;</sup></td> <td class=\"centered\">20</td> <td class=\"centered\">N/A</td> <td>0.1 to 0.2 mg/kg every four to six hours</td> <td>N/A</td> </tr> <tr> <td>Hydrocodone<sup>&#9674;</sup></td> <td class=\"centered\">30</td> <td class=\"centered\">&nbsp;N/A</td> <td>0.1 to 0.2 mg/kg every&nbsp;four to six hours</td> <td>N/A</td> </tr> <tr> <td>Fentanyl</td> <td class=\"centered\">N/A</td> <td class=\"centered\">0.1 (100 mcg)</td> <td>N/A</td> <td>0.5 to 1 mcg/kg every one to two hours</td> </tr> <tr> <td>Methadone</td> <td class=\"centered\">&#167;</td> <td class=\"centered\">&#167;</td> <td>0.1 mg/kg every&nbsp;4 to&nbsp;8 hours</td> <td>0.05 to 0.1 mg/kg every&nbsp;4 to&nbsp;8 hours</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">N/A: not available.<br />* Approximate equianalgesic dose for estimation when changing opioid agents. <br />Â¶ Doses are for individuals &gt;6 months&nbsp;old with a maximum weight of 50 kg. Suggested dose ranges are for management of acute pain. Oral doses refer to immediate release products.<br />Î Dose adjustment for renal insufficiency may be required. Not recommended in severe renal insufficiency.<br /><FONT class=lozenge>â</FONT> If&nbsp;a combined opioid-acetaminophen product is prescribed, caregivers should be instructed not to give the child other acetaminophen-containing medications as this can lead to acetaminophen overdose and hepatotoxicity.<br />Â§ Due to gradual drug accumulation at tissue sites, the dose and frequency of methadone differs for initial compared with repeated use; dose and interval given is usual after repeated use; methadone should be initiated and titrated by a clinician experienced with its use.</div><div class=\"graphic_reference\">Adapted&nbsp;from: Gutstein HB, Akil H. Opioid analgesics. In: Goodman &amp; Gilmans pharmacological basis of therapeutics, 11th ed, McGraw-Hill, New York 2006.</div><div id=\"graphicVersion\">Graphic 79047 Version 9.0</div></div></div>"},"79049":{"type":"graphic_diagnosticimage","displayName":"Left upper lobe TB infiltrate","title":"Left upper lobe infiltrate and possible cavity in pulmonary tuberculosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left upper lobe infiltrate and possible cavity in pulmonary tuberculosis</div><div class=\"cntnt\"><img style=\"width:338px; height:396px;\" src=\"images/ID/79049_Left_upper_lobe_infiltrate.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left upper lobe infiltrate and possible cavity in an adolescent with sputum smear-positive pulmonary tuberculosis. This patient had a one month history of cough,&nbsp;eight pound weight loss, and night sweats.</div><div class=\"graphic_reference\">Courtesy of Jeffrey R Starke, MD.</div><div id=\"graphicVersion\">Graphic 79049 Version 6.0</div></div></div>"},"79052":{"type":"graphic_figure","displayName":"Dorsal penile block","title":"Dorsal penile nerve block","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Dorsal penile nerve block</div><div class=\"cntnt\"><img style=\"width:540px; height:363px;\" src=\"images/EM/79052_Dorsal_penile_block.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The dorsal penile nerves are located beneath Buck's fascia at the 1 and 11 o'clock positions. The sites for injection in dorsal penile nerve block are at the 2 and 10 o'clock positions (black dots in A) with the needle directed medially.</div><div id=\"graphicVersion\">Graphic 79052 Version 3.0</div></div></div>"},"79053":{"type":"graphic_figure","displayName":"TfR ferritin index","title":"Transferrin receptor-ferritin index in anemic patients","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transferrin receptor-ferritin index in anemic patients</div><div class=\"cntnt\"><img style=\"width:427px; height:497px;\" src=\"images/HEME/79053_TfR_ferritin_index.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows the transferrin receptor-ferritin index (TfR-F index), the ratio of the serum TfR to the logarithm (base 10) of the serum ferritin in iron deficiency anemia (IDA, red circles), anemia of chronic disease (ACD, green squares) and those with both conditions (IDA/ACD, blue triangles). Median values are indicated by the horizontal bars. A value of â¤1.0 suggests ACD, while values â¥2 suggest IDA or IDA/ACD.</div><div class=\"graphic_reference\">Reproduced with permission from: Punnonen K, Irjala K, Rajamaki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 1997; 89:1052. Copyright Â© 1997 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 79053 Version 2.0</div></div></div>"},"79054":{"type":"graphic_diagnosticimage","displayName":"Cesarean scar preg B","title":"Cesarean scar pregnancy at 6 weeks - transvaginal ultrasonography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cesarean scar pregnancy at 6 weeks - transvaginal ultrasonography</div><div class=\"cntnt\"><img style=\"width:374px; height:283px;\" src=\"images/OBGYN/79054_Cesarean_scar_preg_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image shows the gestational sac (arrow) without surrounding myometrium. Note the empty endometrial cavity (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 79054 Version 2.0</div></div></div>"},"79055":{"type":"graphic_table","displayName":"Muscarinic receptors in lung","title":"Muscarinic receptors in the lung and the effect of selected anticholinergic medications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Muscarinic receptors in the lung and the effect of selected anticholinergic medications</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Type\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Predominant location\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Action\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Atropine\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Ipratropium Oxitropium Tiquizium\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Tiotropium\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"2\">\r\n  \r\n   M1\r\n  \r\n   </td>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"2\">\r\n  \r\n   Peribronchial ganglion cells\r\n  \r\n   </td>\r\n  \r\n   <td>Bronchoconstriction</td>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"2\">\r\n  \r\n   Inhibits\r\n  \r\n   </td>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"2\">\r\n  \r\n   Inhibits\r\n  \r\n   </td>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"2\">\r\n  \r\n   Inhibits\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Increased secretion</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"2\">\r\n  \r\n   M2\r\n  \r\n   </td>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"2\">\r\n  \r\n   Postganglionic nerves\r\n  \r\n   </td>\r\n  \r\n   <td>Inhibit Ach release</td>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"2\">\r\n  \r\n   Inhibits\r\n  \r\n   </td>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"2\">\r\n  \r\n   Inhibits\r\n  \r\n   </td>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"2\">\r\n  \r\n   Does not inhibit\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Bronchodilation</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"2\">\r\n  \r\n   M3\r\n  \r\n   </td>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"2\">\r\n  \r\n   Smooth muscle mucous glands\r\n  \r\n   </td>\r\n  \r\n   <td>Bronchoconstriction</td>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"2\">\r\n  \r\n   Inhibits\r\n  \r\n   </td>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"2\">\r\n  \r\n   Inhibits\r\n  \r\n   </td>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"2\">\r\n  \r\n   Inhibits\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Increased secretion</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 79055 Version 1.0</div></div></div>"},"79058":{"type":"graphic_picture","displayName":"Visible vessel DU Endosc","title":"Duodenal ulcer with visible vessel","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Duodenal ulcer with visible vessel</div><div class=\"cntnt\"><img style=\"width:515px; height:254px;\" src=\"images/GAST/79058_Visible_vessel_DU_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Duodenal ulcer in a patient with recent upper gastrointestinal bleeding. The ulcer base (arrows) is visible as the whitish rim underlying the protruding vessel. The erythematous mound in the center of the ulcer represents an arteriole that has eroded into the lumen of the duodenum.</div><div class=\"graphic_reference\">Courtesy of Eric D Libby, MD.</div><div id=\"graphicVersion\">Graphic 79058 Version 2.0</div></div></div>"},"79059":{"type":"graphic_picture","displayName":"Hordeolum stye","title":"Hordeolum / Stye","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hordeolum / Stye</div><div class=\"cntnt\"><img style=\"width:432px; height:310px;\" src=\"images/PC/79059_Stye.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acute plugging of a meibomian gland and associate inflammation results in a tender, red bump seen in the medial lower lid.</div><div id=\"graphicVersion\">Graphic 79059 Version 3.0</div></div></div>"},"79060":{"type":"graphic_diagnosticimage","displayName":"Knee dislocation with intact PCL","title":"Anterior knee dislocation with PCL intact","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anterior knee dislocation with PCL intact</div><div class=\"cntnt\"><img style=\"width:320px; height:448px;\" src=\"images/EM/79060_Knee_dislocatn_ant1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lateral knee radiograph above shows an anterior knee dislocation with the posterior cruciate ligament (PCL) intact. Note the parallel alignment of the patellofemoral joint with the femur in the complete bicruciate injury and the close proximity of the femur and tibia.</div><div class=\"graphic_reference\">Reproduced with permission from: Bucholz RW, Heckman JD. Rockwood &amp; Green's Fractures in Adults, 5th ed. Lippincott, Williams &amp; Wilkins, 2001. Copyright Â© Lippincott, Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 79060 Version 3.0</div></div></div>"},"79062":{"type":"graphic_figure","displayName":"Reverse causality","title":"Reverse causality","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Reverse causality</div><div class=\"cntnt\"><img style=\"width:524px; height:160px;\" src=\"images/PC/79062_Reverse-causality.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reverse causality occurs when the outcome causes changes in the exposure.</div><div id=\"graphicVersion\">Graphic 79062 Version 1.0</div></div></div>"},"79063":{"type":"graphic_figure","displayName":"Dietary sources fiber PI","title":"Foods with fiber","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Foods with fiber</div><div class=\"cntnt\"><img style=\"width:524px; height:698px;\" src=\"images/PI/79063_Dietary-sources-fiber-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Foods with a lot of fiber include prunes, apples, oranges, bananas, peas, green beans, kidney beans, cooked oatmeal, almonds, peanuts, and whole-wheat bread.</div><div id=\"graphicVersion\">Graphic 79063 Version 1.0</div></div></div>"},"79064":{"type":"graphic_picture","displayName":"H E no duct portal tract","title":"Idiopathic adulthood ductopenia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Idiopathic adulthood ductopenia</div><div class=\"cntnt\"><img style=\"width:432px; height:322px;\" src=\"images/GAST/79064_H_E_no_duct_portal_tract.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view of an H&amp;E stain of a liver biopsy from a patient with idiopathic adulthood ductopenia. The portal triad has an artery and vein easily visible, but no bile duct of comparable size is present.</div><div class=\"graphic_reference\">Courtesy of John Hart, MD.</div><div id=\"graphicVersion\">Graphic 79064 Version 2.0</div></div></div>"},"79068":{"type":"graphic_figure","displayName":"Nerves of the anterior chest and abdomen","title":"Nerves of the anterior chest and abdomen","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Nerves of the anterior chest and abdomen</div><div class=\"cntnt\"><img style=\"width:542px; height:710px;\" src=\"images/SURG/79068_Thoracoabdominal_nerves.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The chest and abdominal walls are supplied by the thoracic and thoracoabdominal intercostal nerves, as well as nerves from the lumbar plexus. The intercostal nerves arise from the ventral rami of the thoracic spinal nerves from T1 to T11. The corresponding nerve associated with T12 is the subcostal nerve.</div><div class=\"graphic_footnotes\">n.: nerve; ns.: nerves.</div><div id=\"graphicVersion\">Graphic 79068 Version 3.0</div></div></div>"},"79069":{"type":"graphic_diagnosticimage","displayName":"TEE color Doppler severe AR","title":"Color flow Doppler of severe aortic regurgitation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Color flow Doppler of severe aortic regurgitation</div><div class=\"cntnt\"><img style=\"width:291px; height:220px;\" src=\"images/CARD/79069_TEE_color_Doppler_severe_AR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Color-flow Doppler mid-esophageal five-chamber&nbsp;view from a transesophageal echocardiogram. The outflow tract is completely occupied by the aortic regurgitant color flow jet (AR jet); when the jet exceeds 65 percent of the left ventricular outflow tract (LVOT) width, the regurgitation is judged severe.</div><div class=\"graphic_footnotes\">Ao: aorta; LV: left ventricle.</div><div id=\"graphicVersion\">Graphic 79069 Version 6.0</div></div></div>"},"79072":{"type":"graphic_picture","displayName":"SLE subendothelial tubuloreticular","title":"Subendothelial deposits and tubuloreticular inclusions in lupus nephritis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subendothelial deposits and tubuloreticular inclusions in lupus nephritis</div><div class=\"cntnt\"><img style=\"width:378px; height:243px;\" src=\"images/NEPH/79072_SLE_Tubuloreticular.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph in diffuse proliferative lupus nephritis shows massive subendothelial deposits (D) and characteristic tubuloreticular structures (arrow) in the endothelial cells (En). The subendothelial deposits cause marked thickening of the glomerular capillary wall, leading to a wire loop appearance on light microscopy.</div><div class=\"graphic_footnotes\">Ep: epithelial cell; GBM: glomerular basement membrane.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 79072 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Electron micrograph of a normal glomerulus</div><div class=\"cntnt\"><img style=\"width:377px; height:266px;\" src=\"images/NEPH/50018_Normal_glomerulus_EM_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron-dense deposits are present. Two normal platelets are seen in the capillary lumen.</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 50018 Version 7.0</div></div></div>"},"79073":{"type":"graphic_diagnosticimage","displayName":"Superior sulcus CT","title":"Superior sulcus tumor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superior sulcus tumor</div><div class=\"cntnt\"><img style=\"width:367px; height:235px;\" src=\"images/PULM/79073_Superior_sulcus_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan confirms the tumor and demonstrates chest wall invasion with partial rib destruction.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 79073 Version 3.0</div></div></div>"},"79074":{"type":"graphic_table","displayName":"Autoantibodies in Addison's","title":"Incidence of antiadrenal and other autoantibodies in patients with autoimmune adrenal insufficiency","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Incidence of antiadrenal and other autoantibodies in patients with autoimmune adrenal insufficiency</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Tissue</td> <td class=\"subtitle1\">Incidence of antibodies (%)</td> </tr> <tr> <td>Adrenal</td> <td>60 to 70</td> </tr> <tr> <td>Thyroid peroxidase</td> <td>50</td> </tr> <tr> <td>Parathyroid</td> <td>26</td> </tr> <tr> <td>Islet cell</td> <td>8</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Gonad</td> </tr> <tr> <td class=\"sublist1\">Ovary</td> <td class=\"sublist_other\">22</td> </tr> <tr> <td class=\"sublist1\">Testes</td> <td class=\"sublist_other\">5</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Stomach</td> </tr> <tr> <td class=\"sublist1\">Parietal cell</td> <td class=\"sublist_other\">30</td> </tr> <tr> <td class=\"sublist1\">Intrinsic factor</td> <td class=\"sublist_other\">9</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 79074 Version 2.0</div></div></div>"},"79075":{"type":"graphic_diagnosticimage","displayName":"IDUS polypoid mass CBD","title":"Intraductal ultrasound showing a polypoid mass in the distal common bile duct","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intraductal ultrasound showing a polypoid mass in the distal common bile duct</div><div class=\"cntnt\"><img style=\"width:407px; height:288px;\" src=\"images/GAST/79075_IDUS_polypoid_mass_CBD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Polypoid mass within the distal common bile duct as seen by intraductal ultrasound.</div><div class=\"graphic_reference\">Courtesy of Michael J Levy, MD, Enrique Vazquez-Sequeiros, MD, and Maurits J Wiersema, MD.</div><div id=\"graphicVersion\">Graphic 79075 Version 4.0</div></div></div>"},"79076":{"type":"graphic_figure","displayName":"Open oophorectomy b","title":"Open oophorectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Open oophorectomy</div><div class=\"cntnt\"><img style=\"width:394px; height:304px;\" src=\"images/OBGYN/79076_Open_oophorectomy_b.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After the ureter is identified, a window is created in the broad ligament and the ovarian vessels are doubly clamped and divided.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 79076 Version 2.0</div></div></div>"},"79078":{"type":"graphic_figure","displayName":"Role of the Wnt signaling pathway","title":"Role of the Wnt signaling pathway","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Role of the Wnt signaling pathway</div><div class=\"cntnt\"><img style=\"width:586px; height:337px;\" src=\"images/ENDO/79078_RoleWntsignalpathway.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Wnt signaling diverts the mesenchymal stem cells down the pathway of osteoblast differentiation. DKK-1 binds to the Wnt receptor complex on the surface of the osteoblast lineage cell and blocks Wnt signaling, arresting osteoblast proliferation and differentiation. The precursors of the mature osteoblast enhance bone resorption by boosting RANKL-induced osteoclastogenesis. Blockade of DKK-1 permits progression of osteoblast differentiation. Activation of the Wnt signaling pathway in the mature osteoblast upregulates OPG, which blocks RANKL-induced osteoclastogenesis, resulting in inhibition of bone resorption.</div><div class=\"graphic_footnotes\">RANKL: receptor activator of nuclear factor kappa- ligand; DKK-1: Dickkopf-1; TNF-Î±: tumor necrosis factor-alpha; OPG: osteoprotegerin.</div><div class=\"graphic_reference\">Reprinted by permission from: Macmillan Publishers Ltd: Goldring SR, Goldring MB. Eating bone or adding it: the Wnt pathway decides. Nat Med 2007; 13:133. Copyright Â© 2007.</div><div id=\"graphicVersion\">Graphic 79078 Version 3.0</div></div></div>"},"79079":{"type":"graphic_figure","displayName":"Isolated intest transplant","title":"Isolated intestinal transplantation","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Isolated intestinal transplantation</div><div class=\"cntnt\"><img style=\"width:534px; height:529px;\" src=\"images/GAST/79079_Isolated_intest_transplant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Isolated intestinal transplantation is performed in patients who have only isolated intestinal failure and no associated liver disease. The arterial inflow is usually from the recipient infrarenal aorta and venous outflow to the portal vein. In patients with mesenteric thrombosis, the venous outflow is created to the inferior vena cava (systemic drainage).</div><div class=\"graphic_footnotes\">SMA: superior mesenteric artery; SMV: superior mesenteric vein.</div><div class=\"graphic_reference\">Modified with permission from: Khan FA, Tzakis AG. Intestinal and multivisceral transplantation. In: Transplantation, Ginnis LC, Cosmi AB, and Morris PJ (Eds), Blackwell, Malden 1999. p.422.</div><div id=\"graphicVersion\">Graphic 79079 Version 4.0</div></div></div>"},"79081":{"type":"graphic_figure","displayName":"Suicide trends adol females","title":"Suicide trends among adolescent females United States, 1990-2004","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Suicide trends among adolescent females United States, 1990-2004</div><div class=\"cntnt\"><img style=\"width:478px; height:558px;\" src=\"images/PEDS/79081_Suicide_trends_adol_females.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A) Yearly suicide rates per 100,000 population for females aged 10 to 14 years, by method, National Vital Statistics System, United States 1990-2004. Panel B) Yearly suicide rates per 100,000 population for females aged 15 to 19 years, by method, National Vital Statistics System, United States 1990-2004.</div><div class=\"graphic_footnotes\">* Per 100,000 population.<br>&#8224; Standardized Pearson residual &gt;2.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention (CDC). Suicide trends among youths and young adults aged 10-24 years-United States. MMWR Morb Mortal Wkly Rep 2007; 56:905.</div><div id=\"graphicVersion\">Graphic 79081 Version 1.0</div></div></div>"},"79083":{"type":"graphic_figure","displayName":"Sternal space omental flap","title":"Omental flap to fill sternal defect","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Omental flap to fill sternal defect</div><div class=\"cntnt\"><img style=\"width:442px; height:413px;\" src=\"images/SURG/79083_Sternal_space_omental_flap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Omental flap placed into the sternal space.</div><div class=\"graphic_reference\">Reproduced with permission from: Orgill DP, Austen WG, Butler CE, et al. Guidelines for Treatment of Complex Chest Wounds with Negative Pressure Wound Therapy [review]. Wounds 2004; Suppl B: A compendium of clinical research and practice. Copyright &#169; 2004 HMP Communications, LLC.</div><div id=\"graphicVersion\">Graphic 79083 Version 1.0</div></div></div>"},"79084":{"type":"graphic_table","displayName":"Dietary guidelines children","title":"Dietary guidelines for children older than one year","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dietary guidelines for children older than one year</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">General guidelines</td> </tr> <tr> <td>A variety of nutrient-dense foods from the basic food groups (cow milk/milk products or fortified soy products, meat/protein, grains, fruits/vegetables) should be offered each day.</td> </tr> <tr> <td>Foods and beverages should contain or be prepared with little added salt, sugar, or caloric sweeteners.</td> </tr> <tr> <td class=\"subtitle1_single\">Fat</td> </tr> <tr> <td>1 to 2 years: Fat and cholesterol intake are not restricted.</td> </tr> <tr> <td>2 to 3 years: Fat should comprise 30 to 40 percent of total energy intake; saturated fats should be limited to &#60;10 percent of total energy intake; intake of trans fats should be as low as possible.</td> </tr> <tr> <td>4 to 18 years: Fat should comprise 25 to 35 percent of total energy intake; fat intake should not be restricted to &#60;20 percent of total energy intake; saturated fats should be limited to &#60;10 percent of total energy intake; intake of trans fats should be as low as possible.</td> </tr> <tr> <td class=\"subtitle1_single\">Meat/protein</td> </tr> <tr> <td>Select and prepare meat, poultry, fish, and dried beans with as little fat as possible.</td> </tr> <tr> <td class=\"subtitle1_single\">Fruits, vegetables, and fruit juice</td> </tr> <tr> <td>A colorful variety of fruits and vegetables should be offered each day.</td> </tr> <tr> <td>Whole fruit is preferred to fruit juice, but one-half of the recommended daily servings can be provided in the form of 100 percent fruit juice. </td> </tr> <tr> <td>Consumption of 100 percent fruit juice should be limited to 4&nbsp;ounces (120 mL)&nbsp;in children aged 1 through 3 years, 4 to 6 ounces (120 to 180 mL) in children aged&nbsp;4 through 6 years, and 8 ounces (240 mL) in children older than 7 years.</td> </tr> <tr> <td class=\"subtitle1_single\">Grains</td> </tr> <tr> <td>At least one-half of total grains consumed should be whole grains. When reading the label, \"whole grain\" should be the first ingredient.</td> </tr> <tr> <td class=\"subtitle1_single\">Cow milk or fortified soy milk</td> </tr> <tr> <td>1 to 2 years: At least 2 cups (approximately 480 mL) of whole cow milk per day (or equivalent products).</td> </tr> <tr> <td>2 to 8 years: At least 2 to 3 cups (approximately 480 to 720 mL) of fat-free or low-fat milk per day (or equivalent products).</td> </tr> <tr> <td>&#8805;9 years: At least 3 cups (approximately 720 mL) of fat-free or low-fat milk per day (or equivalent products).</td> </tr> <tr> <td class=\"subtitle1_single\">Beverages</td> </tr> <tr> <td>Plain, unflavored water is the preferred beverage for children, particularly when fluids are consumed outside of meals and snacks.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Committee on Nutrition American Academy of Pediatrics. Feeding the Child. In: Pediatric Nutrition Handbook, 6<SUP>th</SUP> ed, Kleinman RE (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2009. p.145. </LI>&#xD;&#xA;<LI>US Department of Health and Human Services. Dietary Guidelines for Americans, 2015. <A spellcheck=true href=\"http://www.health.gov/dietaryguidelines/\" target=_blank>www.health.gov/dietaryguidelines/</A> (Accessed on January 08, 2016).&nbsp;</LI>&#xD;&#xA;<LI>Gidding SS, Dennison BA, Birch LL, et al. Dietary recommendations for children and adolescents:&nbsp;A guide for practitioners: Consensus statement from the American Heart Association. Circulation 2005; 112:2061. </LI>&#xD;&#xA;<LI>National Academies of Sciences, Engineering, and Medicine. Dietary reference intakes for calcium and vitamin D. Available at:&nbsp;<A spellcheck=true href=\"http://www.nationalacademies.org/hmd/Reports/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D/DRI-Values.aspx\" target=_blank>www.nationalacademies.org/hmd/Reports/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D/DRI-Values.aspx</A> (Accessed on August 18, 2016).</LI>&#xD;&#xA;<LI>Heyman MB, Abrams SA, AAP Section on Gastroenterology, Hepatology, and Nutrition, Committee on Nutrition. Fruit juice in infants, children, and adolescents: Current recommendations. Pediatrics 2017; 139:e20170967.</LI></OL></div><div id=\"graphicVersion\">Graphic 79084 Version 12.0</div></div></div>"},"79085":{"type":"graphic_diagnosticimage","displayName":"Metastatic ca to pleura II CT","title":"Metastatic breast cancer to pleura and pericardium","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Metastatic breast cancer to pleura and pericardium</div><div class=\"cntnt\"><img style=\"width:360px; height:295px;\" src=\"images/PULM/79085_Metastatic_ca_to_pleura_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Status post bilateral mastectomies. CT scan shows bilateral pleural effusions, free on the left, and loculated on the right. High attenuation material in the right hemithorax is due to talcum from an attempted pleurodesis. Tumor nodules are seen in the pericardium.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 79085 Version 3.0</div></div></div>"},"79089":{"type":"graphic_picture","displayName":"Microcystic ser adeno","title":"Histologic appearance of microcystic serous adenoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histologic appearance of microcystic serous adenoma</div><div class=\"cntnt\"><img style=\"width:334px; height:484px;\" src=\"images/ONC/79089_Microcystic_ser_adeno_edit1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Microcystic serous adenoma of the pancreas. Numerous small spaces are lined by cuboidal epithelium. Hematoxylin and eosin-stained section.<br />(B) Periodic Acid Schiff (PAS) staining of serous pancreatic cystadenoma. Note positive staining (arrows) identifying glycogen-rich cells lining cystic spaces.</div><div class=\"graphic_reference\">Panel A: Courtesy of Daniel S Longnecker, MD.<br />Panel B: Courtesy of Michael Steer, MD.</div><div id=\"graphicVersion\">Graphic 79089 Version 5.0</div></div></div>"},"79090":{"type":"graphic_waveform","displayName":"Intermediate case 7 with answer","title":"Atrial fibrillation with left bundle branch block","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Atrial fibrillation with left bundle branch block</div><div class=\"cntnt\"><img style=\"width:505px; height:127px;\" src=\"images/CARD/79090_Intermediate_case_7_with_an.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atrial fibrillation, as evidenced by the rapid fibrillatory (f) waves and the irregularly irregular R-R interval, with left bundle branch block, as evidenced by the prolonged QRS complex (0.16 sec) which has a QS pattern in V1.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 79090 Version 2.0</div></div></div>"},"79091":{"type":"graphic_figure","displayName":"VF incongr incompl HH","title":"Visual fields: Incongruous incomplete homonymous hemianopia","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Visual fields: Incongruous incomplete homonymous hemianopia</div><div class=\"cntnt\"><img style=\"width:473px; height:399px;\" src=\"images/NEURO/79091_VF_incongr_incompl_HH.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Humphrey visual field showing a right incongruous incomplete homonymous hemianopia secondary to a left optic tract tumor.</div><div class=\"graphic_reference\">Reproduced with permission from: Zhang X, Kedar S, Lynn MJ, et al. Homonymous hemianopias: clinical-anatomic correlations in 904 cases. Neurology 2006; 66:906. Copyright Â© 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 79091 Version 13.0</div></div></div>"},"79093":{"type":"graphic_picture","displayName":"Hereditary angioedema prodromal rash","title":"Hereditary angioedemaÂ prodromal rash","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hereditary angioedema&nbsp;prodromal rash</div><div class=\"cntnt\"><img style=\"width:432px; height:326px;\" src=\"images/ALLRG/79093_HAE_prodromal_rash.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Annular erythematous lesions mimicking chicken-wire appearance.</div><div class=\"graphic_reference\">Reproduced with permission from: Yucelten D, Kus S. Chicken-wire erythema, but not urticaria, as the presenting sign of hereditary angioedema. Eur J Dermatol 2006; 16:197. Copyright Â© 2006 John Libbey Eurotext.</div><div id=\"graphicVersion\">Graphic 79093 Version 3.0</div></div></div>"},"79095":{"type":"graphic_table","displayName":"Features of parkinsonian syndromes","title":"Distinguishing features of parkinsonian syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distinguishing features of parkinsonian syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Corticobasal degeneration</td> <td class=\"subtitle1\">Progressive supranuclear palsy</td> <td class=\"subtitle1\">Parkinson disease</td> <td class=\"subtitle1\">Multiple system atrophy</td> </tr> <tr> <td><strong>Age at onset, years</strong></td> <td>45 to 77<sup>[1]</sup></td> <td>65 to 75</td> <td>65 to 80</td> <td>50 to 60</td> </tr> <tr> <td><strong>Resting tremor</strong></td> <td>No</td> <td>No</td> <td>Characteristic</td> <td>Sometimes</td> </tr> <tr> <td><strong>Action tremor</strong></td> <td>Sometimes</td> <td>No</td> <td>Sometimes</td> <td>Yes</td> </tr> <tr> <td><strong>Asymmetry</strong></td> <td>Characteristic</td> <td>No</td> <td>Frequent</td> <td>No</td> </tr> <tr> <td><strong>Dystonia</strong></td> <td>Focal</td> <td>Axial</td> <td>Sometimes</td> <td>Bilateral</td> </tr> <tr> <td><strong>Memory</strong></td> <td>Sometimes</td> <td>Sometimes</td> <td>Sometimes</td> <td>Sometimes</td> </tr> <tr> <td><strong>Aphasia</strong></td> <td>Often</td> <td>No</td> <td>No</td> <td>No</td> </tr> <tr> <td><strong>Apraxia</strong></td> <td>Characteristic</td> <td>Sometimes</td> <td>No</td> <td>No</td> </tr> <tr> <td><strong>Alien hand</strong></td> <td>Characteristic</td> <td>No</td> <td>No</td> <td>No</td> </tr> <tr> <td><strong>Behavior</strong></td> <td>Disinhibited</td> <td>Apathetic or disinhibited</td> <td>Impulsive</td> <td>No</td> </tr> <tr> <td><strong>Cognitive</strong></td> <td>Parietal</td> <td>Slowing, dysexecutive</td> <td>Dysexecutive</td> <td>Dysexecutive and others</td> </tr> <tr> <td><strong>Autonomic</strong></td> <td>No</td> <td>No</td> <td>Moderate</td> <td>Severe</td> </tr> <tr> <td><strong>Gaze palsy</strong></td> <td>Often</td> <td>Characteristic</td> <td>No</td> <td>Sometimes</td> </tr> <tr> <td><strong>Pseudobulbar</strong></td> <td>No</td> <td>Yes</td> <td>No</td> <td>No</td> </tr> <tr> <td><strong>Falls</strong></td> <td>Later</td> <td>Earlier</td> <td>Later</td> <td>Earlier</td> </tr> <tr> <td><strong>Duration (median)</strong></td> <td>6&nbsp;to 8 years</td> <td>6 to 12 years</td> <td>6 to 22 years</td> <td>6 to 10 years</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reference:<br /><OL>&#xD;&#xA;<LI>Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013; 80:496.</LI></OL>Adapted with permission from: Kertesz A, Fealey RD, Keegan BM, Parisi JE. A 74-year-old woman with progressive right-hand tremor and inability to use her right side. Neurology 2009; 73:1399. Copyright Â© 2009 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 79095 Version 10.0</div></div></div>"},"79097":{"type":"graphic_table","displayName":"Timing of surgical prophylaxis","title":"Timing of prophylactic antibiotic administration and subsequent rates of SSIs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Timing of prophylactic antibiotic administration and subsequent rates of SSIs</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Time of administration*</td> <td class=\"subtitle1\">Percent with SSI</td> <td class=\"subtitle1\">Odds ratio<sup>&#182;</sup></td> <td class=\"subtitle1\">95 percent CI</td> </tr> <tr> <td>Early</td> <td>3.8</td> <td>4.3</td> <td>1.8-10.4</td> </tr> <tr> <td>Preoperative</td> <td>0.6</td> <td>1</td> <td>-</td> </tr> <tr> <td>Perioperative</td> <td>1.4</td> <td>2.1</td> <td>0.6-7.4</td> </tr> <tr> <td>Postoperative</td> <td>3.3</td> <td>5.8</td> <td>2.4-13.8</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SSI: surgical site infection.<br />* \"Early\" denotes 2 to 24 hours before incision, \"preoperative\" 0 to 2 hours before incision, \"perioperative\" within 3 hours after incision, and \"postoperative\" more than 3 hours after incision.<br />Â¶ Odds ratio determined by logistic-regression analysis.</div><div class=\"graphic_reference\">Adapted from: Classen DC, Evans RS, Pestotnik SL, et al, N Engl J Med 1992; 326:281.</div><div id=\"graphicVersion\">Graphic 79097 Version 7.0</div></div></div>"},"79098":{"type":"graphic_table","displayName":"MR spectroscopy brain tumors","title":"MR spectroscopy parameters","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">MR spectroscopy parameters</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Brain process</td>\n<td class=\"subtitle1\">N-Acetylaspartate</td>\n<td class=\"subtitle1\">Choline</td>\n<td class=\"subtitle1\">Lactate</td>\n</tr>\n<tr>\n<td>Neoplasm</td>\n<td>&#8595;</td>\n<td>&#8593;</td>\n<td>&#8593;</td>\n</tr>\n<tr>\n<td>Infarction</td>\n<td>&#8595;</td>\n<td>&#8595;</td>\n<td>&#8593;</td>\n</tr>\n<tr>\n<td>Infection</td>\n<td>&#8595;</td>\n<td>-</td>\n<td>&#8593;</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 79098 Version 1.0</div></div></div>"},"79099":{"type":"graphic_picture","displayName":"Marginal TM perforation","title":"True marginal perforation of the tympanic membrane","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">True marginal perforation of the tympanic membrane</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/ALLRG/79099_Marginalperforation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Keratinizing squamous epithelium can enter the middle ear from the ear canal through a perforation of the outer edge of the drum from a marginal perforation (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 120, Pages 603-8, Copyright Â© 2007 by the AAP.</div><div id=\"graphicVersion\">Graphic 79099 Version 14.0</div></div></div>"},"79101":{"type":"graphic_figure","displayName":"Tompkins metroplasty CD","title":"Tompkins metroplasty (C and D)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Tompkins metroplasty (C and D)</div><div class=\"cntnt\"><img style=\"width:504px; height:624px;\" src=\"images/OBGYN/79101_Tompkins_metroplasty_CD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(C) Repair then proceeds as in the Jones technique, with the anterior and the posterior aspects being approximated with continuous or interrupted sutures. (D) The deep myometrium is repaired.</div><div id=\"graphicVersion\">Graphic 79101 Version 1.0</div></div></div>"},"79105":{"type":"graphic_waveform","displayName":"Basic case 5 with answer","title":"Sinus bradycardia","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Sinus bradycardia</div><div class=\"cntnt\"><img style=\"width:540px; height:79px;\" src=\"images/CARD/79105_Basic_case_5_with_answer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Marked sinus bradycardia at a rate of 25 to 30 beats/min. The normal P waves (upright in lead II) and PR interval are consistent with a sinus mechanism with normal atrioventricular (AV) conduction.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 79105 Version 3.0</div></div></div>"},"79109":{"type":"graphic_figure","displayName":"Temporomandibular joint dislocation","title":"Temporomandibular joint dislocation","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">Temporomandibular joint dislocation</div><div class=\"cntnt\"><img style=\"width:562px; height:817px;\" src=\"images/EM/79109_TMJdislocation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The temporomandibular joint (TMJ) is the articulation of the temporal and mandibular bones. TMJ dislocation occurs when the condyle travels anteriorly along the articular eminence and becomes locked in the anterior superior aspect of the eminence, preventing closure of the mouth.</div><div id=\"graphicVersion\">Graphic 79109 Version 3.0</div></div></div>"},"79110":{"type":"graphic_diagnosticimage","displayName":"Scarring in sarcoidosis CT","title":"Scarring in sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scarring in sarcoidosis</div><div class=\"cntnt\"><img style=\"width:352px; height:233px;\" src=\"images/PULM/79110_Scarring_in_sarcoidosis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sarcoidosis with marked scarring and parenchymal distortion in the upper lobes, bulla formation, and cavities. These changes are irreversible.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 79110 Version 2.0</div></div></div>"},"79112":{"type":"graphic_picture","displayName":"Bullous pemphigoid on urticarial plaque","title":"Bullous pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Bullous pemphigoid</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/79112_Bullous_pemphigoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arm skin with tense bullae arising on urticarial plaques and eroded blister bases.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 79112 Version 4.0</div></div></div>"},"79113":{"type":"graphic_figure","displayName":"Malaria life cycle drug targets","title":"Life cycle of <em>Plasmodium</em>*","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Life cycle of <em>Plasmodium</em>*</div><div class=\"cntnt\"><img style=\"width:580px; height:588px;\" src=\"images/ID/79113_Malaria_life_cycle_treat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><strong>(1)</strong> <em>Plasmodium</em>-infected <em>Anopheles</em> mosquito bites a human and transmits sporozoites into the bloodstream. <strong>(2)</strong> Sporozoites migrate through the blood to the liver where they invade hepatocytes and divide to form multinucleated schizonts (preerythrocytic stage). Atovaquone-proguanil and primaquine have activity against hepatic-stage schizonts. <strong>(3)</strong> Hypnozoites are a quiescent stage in the liver that exist only in the setting of <em>P. vivax</em> and <em>P. ovale</em> infection. This liver stage does not cause clinical symptoms, but with reactivation and release into the circulation, late-onset or relapsed disease can occur up to many months after initial infection. 8-aminoquinolines are active against the quiescent hypnozoites of <em>P. vivax</em> and <em>P. ovale</em>. <strong>(4)</strong> The schizonts rupture and release merozoites into the circulation where they invade red blood cells. Within red cells, merozoites mature from ring forms to trophozoites to multinucleated schizonts (erythrocytic stage). Blood-stage schizonticides interrupt schizogony within red cells. <strong>(5)</strong> Some merozoites differentiate into male or female gametocytes. These cells are ingested by the <em>Anopheles</em> mosquito and mature in the midgut, where sporozoites develop and migrate to the salivary glands of the mosquito. The mosquito completes the cycle of transmission by biting another host.</div><div class=\"graphic_footnotes\">* There is strong evidence that drugs listed in parentheses are active against designated stage of parasitic life cycle.<br />&#182; Quinoline derivatives are blood stage schizonticides with the exception of primaquine.<br />&Delta; Primaquine is a blood stage schizonticide with activity against schizonts of <em>P. vivax</em> but not those of <em>P. falciparum</em>. Quinoline derivatives include chloroquine, amodiaquine, quinine, quinidine, mefloquine, primaquine, lumefantrine, and halofantrine. Antifolates include sulfadoxine-pyrimethamine and atovaquone-proguanil. Antimicrobials include tetracycline, doxycycline, and clindamycin.</div><div id=\"graphicVersion\">Graphic 79113 Version 6.0</div></div></div>"},"79114":{"type":"graphic_table","displayName":"Differential diagnosis of vomiting and GER in children","title":"Differential diagnosis of vomiting and gastroesophageal refluxÂ in infants and children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of vomiting and gastroesophageal reflux&nbsp;in infants and children</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Gastrointestinal disorders</td> </tr> <tr> <td class=\"subtitle2_single\">Obstruction</td> </tr> <tr> <td class=\"indent1\">Intussusception*&nbsp;</td> </tr> <tr> <td class=\"indent1\">Hypertrophic pyloric stenosis*&nbsp;</td> </tr> <tr> <td class=\"indent1\">Foreign body<sup><span style=\"font-size: 13px;\">&#916;</span></sup>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Hirschsprung disease&nbsp;</td> </tr> <tr> <td class=\"indent1\">Intestinal malrotation or volvulus<sup><span style=\"font-size: 13px;\">&#916;</span></sup>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Duodenal or intestinal hematoma&nbsp;</td> </tr> <tr> <td class=\"indent1\">Esophageal, pyloric or intestinal stenosis, atresia, or web</td> </tr> <tr> <td class=\"indent1\">Esophageal, gastric, or intestinal duplication</td> </tr> <tr> <td class=\"indent1\">Gastric bezoar, volvulus, or tumor</td> </tr> <tr> <td class=\"indent1\">Superior mesenteric artery syndrome</td> </tr> <tr> <td class=\"indent1\">Intestinal pseudo-obstruction</td> </tr> <tr> <td class=\"indent1\">Adhesions, including congenital adhesions</td> </tr> <tr> <td class=\"indent1\">Incarcerated hernia</td> </tr> <tr> <td class=\"indent1\">Tumors</td> </tr> <tr> <td class=\"indent1\">Meconium ileus or equivalent</td> </tr> <tr> <td class=\"indent1\">Imperforate anus</td> </tr> <tr> <td class=\"subtitle2_single\">Other GI disorders</td> </tr> <tr> <td class=\"indent1\">Gastroesophageal reflux*</td> </tr> <tr> <td class=\"indent1\">Gastritis, esophagitis*</td> </tr> <tr> <td class=\"indent1\">Eosinophilic esophagitis/gastroenteritis&nbsp;</td> </tr> <tr> <td class=\"indent1\">Food intolerance or allergy*&nbsp;</td> </tr> <tr> <td class=\"indent1\">Gastroparesis&nbsp;(eg, postviral)</td> </tr> <tr> <td class=\"indent1\">Appendicitis<sup><span style=\"font-size: 13px;\">&#916;</span></sup></td> </tr> <tr> <td class=\"indent1\">Cholecystitis, cholelithiasis&nbsp;</td> </tr> <tr> <td class=\"indent1\">Pancreatitis</td> </tr> <tr> <td class=\"indent1\">Ulcerative colitis or Crohn disease&nbsp;</td> </tr> <tr> <td class=\"indent1\">Peptic ulcer&nbsp;</td> </tr> <tr> <td class=\"indent1\">Achalasia or chalasia</td> </tr> <tr> <td class=\"indent1\">Tracheoesophageal fistula</td> </tr> <tr> <td class=\"indent1\">Choledochal cyst</td> </tr> <tr> <td class=\"subtitle1_single\">Genitourinary causes</td> </tr> <tr> <td class=\"indent1\">Hydronephrosis</td> </tr> <tr> <td class=\"indent1\">Urinary tract obstruction</td> </tr> <tr> <td class=\"indent1\">Renal stones</td> </tr> <tr> <td class=\"indent1\">Hydrometrocolpos</td> </tr> <tr> <td class=\"indent1\">Testicular or ovarian torsion</td> </tr> <tr> <td class=\"indent1\">Renal insufficiency</td> </tr> <tr> <td class=\"subtitle1_single\">Toxic ingestions</td> </tr> <tr> <td class=\"indent1\">Lead intoxication</td> </tr> <tr> <td class=\"indent1\">Iron intoxication</td> </tr> <tr> <td class=\"indent1\">Alcohol intoxication (ethanol or other toxic alcohol)&nbsp;</td> </tr> <tr> <td class=\"indent1\">Vitamin A or D intoxication</td> </tr> <tr> <td class=\"indent1\">Organophosphate exposure</td> </tr> <tr> <td class=\"indent1\">Medications (ipecac, digoxin, theophylline)</td> </tr> <tr> <td class=\"indent1\">Cannabinoid hyperemesis syndrome (chronic&nbsp;cannabis use)</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Infectious causes</td> </tr> <tr> <td class=\"indent1\">Gastroenteritis*</td> </tr> <tr> <td class=\"indent1\">Group A streptococcal infections* (including pharyngitis)&nbsp;</td> </tr> <tr> <td class=\"indent1\">Otitis media*&nbsp;</td> </tr> <tr> <td class=\"indent1\">Sepsis</td> </tr> <tr> <td class=\"indent1\">Meningitis, encephalitis, or brain abscess<sup><span style=\"font-size: 13px;\">&#916;</span></sup></td> </tr> <tr> <td class=\"indent1\">Pneumonia</td> </tr> <tr> <td class=\"indent1\">Pyelonephritis<sup><span style=\"font-size: 13px;\">&#916; </span></sup><span style=\"font-size: 13px;\">or other urinary tract infection</span></td> </tr> <tr> <td class=\"indent1\">Hepatitis</td> </tr> <tr> <td class=\"indent1\">Hepatic abscess</td> </tr> <tr> <td class=\"subtitle1_single\">Endocrine and metabolic causes</td> </tr> <tr> <td class=\"indent1\">Diabetic ketoacidosis<sup><span style=\"font-size: 13px;\">&#916;</span></sup></td> </tr> <tr> <td class=\"indent1\">Uremia (eg, from obstructive uropathy or renal insufficiency)</td> </tr> <tr> <td class=\"indent1\">Renal tubular acidosis&nbsp;</td> </tr> <tr> <td class=\"indent1\">Hypercalcemia</td> </tr> <tr> <td class=\"indent1\">Congenital adrenal hyperplasia<sup><span style=\"font-size: 13px;\">&#916;</span></sup></td> </tr> <tr> <td class=\"indent1\">Diabetes insipidus</td> </tr> <tr> <td class=\"indent1\">Inborn errors of metabolism, including:&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Disorders of carbohydrate intolerance<sup>&#916;</sup> (eg, galactosemia, hereditary fructose intolerance)</td> </tr> <tr> <td class=\"sublist2\">Amino acid and organic acid disorders<sup>&#916;</sup>&nbsp;<sup><span>â</span><span>â</span><span>â</span><span>â</span><span>â</span></sup><span>â</span><span>â</span><span>â</span><span>â</span><span>â</span><span>â</span><span>â</span><span>â</span><span>â</span><span>â</span><span>â</span><span>â</span><span>â</span><span>â</span><span>â</span>(eg, maple syrup urine disease)</td> </tr> <tr> <td class=\"sublist2\">Urea cycle defects</td> </tr> <tr> <td class=\"sublist2\">Fatty acid oxidation defects&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Mitochondrial disorders&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\">Neurologic causes</td> </tr> <tr> <td class=\"indent1\">Migraine</td> </tr> <tr> <td class=\"indent1\">Trauma<span style=\"font-size: 13px;\"> (postconcussive)</span><sup><span style=\"font-size: 13px;\">&#916;</span></sup></td> </tr> <tr> <td class=\"indent1\">Increased intracranial pressure<sup><span style=\"font-size: 13px;\">&#916; </span></sup><span style=\"font-size: 13px;\">(eg, hydrocephalus, intracranial mass)</span></td> </tr> <tr> <td class=\"indent1\">Epilepsy</td> </tr> <tr> <td class=\"indent1\">Subdural hematoma<sup><span style=\"font-size: 13px;\">&#916;</span></sup></td> </tr> <tr> <td class=\"indent1\">Intracranial hemorrhage<sup><span style=\"font-size: 13px;\">&#916;</span></sup></td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous causes</td> </tr> <tr> <td class=\"sublist2_start\">Coughing (postussive)*&nbsp;</td> </tr> <tr> <td class=\"sublist2_start\">Pregnancy<sup><span style=\"font-size: 13px;\">&#916;</span></sup>&nbsp;</td> </tr> <tr> <td class=\"sublist2_start\">Falsely reported or induced illness (Munchausen syndrome by proxy)&nbsp;</td> </tr> <tr> <td class=\"sublist2_start\">Poor feeding technique</td> </tr> <tr> <td class=\"sublist2\">Improper formula preparation</td> </tr> <tr> <td class=\"sublist2\">Excessive air swallowing</td> </tr> <tr> <td class=\"sublist2\">Inappropriate handling after feeding</td> </tr> <tr> <td class=\"indent1\">Psychogenic vomiting or bulimia</td> </tr> <tr> <td class=\"indent1\">Rumination syndrome</td> </tr> <tr> <td class=\"indent1\">Postnasal drip</td> </tr> <tr> <td class=\"indent1\">Cyclic vomiting syndrome</td> </tr> <tr> <td class=\"indent1\">Cricopharyngeal incoordination</td> </tr> <tr> <td class=\"indent1\">Vestibular injury or inflammation</td> </tr> <tr> <td class=\"indent1\">Heart failure</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Common causes<br />Î Important causes to remember, because&nbsp;these disorders may not be obvious, and&nbsp;prompt diagnosis affects outcome.</div><div class=\"graphic_reference\">References:&nbsp;<br /><OL>&#xD;&#xA;<LI>Vomiting. In: Signs and Symptoms in Pediatrics, 3rd ed, Tunnessen WW Jr, Roberts KB (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 1999. p.491 and Pediatrics GE reflux clinical practice guidelines. J Pediatr Gastroenterol and Nutr 2001; 32:S1.</LI>&#xD;&#xA;<LI>Vandenplas Y, Rudolph CD, Di Lorenzo C, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr 2009; 49:498.</LI></OL></div><div id=\"graphicVersion\">Graphic 79114 Version 10.0</div></div></div>"},"79116":{"type":"graphic_figure","displayName":"Measurement of popliteal angle","title":"Measurement of popliteal angle","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Measurement of popliteal angle</div><div class=\"cntnt\"><img style=\"width:529px; height:383px;\" src=\"images/PEDS/79116_Measurement-of-popliteal-angle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With the patient in the supine position, the hip and knee are flexed 90 degrees, then the knee is extended to the point of resistance. The popliteal angle is the angle between the axis of the tibia and the axis of the femur, as depicted above.</div><div id=\"graphicVersion\">Graphic 79116 Version 3.0</div></div></div>"},"79117":{"type":"graphic_figure","displayName":"Standard cricothyrotomy step four","title":"Standard cricothyrotomy step four","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Standard cricothyrotomy step four</div><div class=\"cntnt\"><img style=\"width:372px; height:323px;\" src=\"images/EM/79117_Cric_standard_step_four.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><FONT class=red><FONT color=black>Insert the tracheal hook and ask an assistant to provide upward traction.</FONT></FONT></div><div class=\"graphic_reference\">Reproduced with permission from: Custalow CB. Color Atlas of Emergency Department Procedures, Elsevier Saunders, Philadelphia 2005. Copyright &#169;2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 79117 Version 2.0</div></div></div>"},"79118":{"type":"graphic_figure","displayName":"ERT minimizes recurrent UTI","title":"Estrogen minimizes recurrent urinary tract infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Estrogen minimizes recurrent urinary tract infection</div><div class=\"cntnt\"><img style=\"width:412px; height:241px;\" src=\"images/ENDO/79118_ERT_minimizes_recurrent_UTI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The effect of intravaginal estriol or placebo on the incidence of UTI in postmenopausal women with recurrent UTIs. Estrogen therapy was associated with a much greater likelihood of remaining free of infection.</div><div class=\"graphic_footnotes\">UTI: urinary tract infection.</div><div class=\"graphic_reference\">Data from: Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 1993; 329:753.</div><div id=\"graphicVersion\">Graphic 79118 Version 3.0</div></div></div>"},"79119":{"type":"graphic_movie","displayName":"Aortic stenosis continuous wave Doppler","title":"Continuous wave Doppler in aortic stenosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Continuous wave Doppler in aortic stenosis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/79119_aoscwdopconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:338px; height:234px;\" src=\"images/CARD/79119_aoscwdop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peak velocity is 4 m/sec and a peak gradient of 64 mmHg.</div><div id=\"graphicVersion\">Graphic 79119 Version 3.0</div></div></div>"},"79122":{"type":"graphic_figure","displayName":"Limited efficacy of TID ISDN","title":"Limited efficacy of three times daily isordil dinitrate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Limited efficacy of three times daily isordil dinitrate</div><div class=\"cntnt\"><img style=\"width:396px; height:235px;\" src=\"images/CARD/79122_Limited_efficacy_of_TID_ISD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mean duration of exercise time to angina at different hours during days on which eight men with stable angina were given isosorbide dinitrate (ISDN) or placebo at 8 AM, 1 PM, and 6 PM (arrows). A signficant increase in exercise duration occurred after each dose of ISDN; however, the total duration of benefit was only about six hours.</div><div class=\"graphic_reference\">Data from Bassan MM. J Am Coll Cardiol 1990; 16:936.</div><div id=\"graphicVersion\">Graphic 79122 Version 2.0</div></div></div>"},"79123":{"type":"graphic_diagnosticimage","displayName":"Short axis left main CA","title":"Short axis view of left main coronary artery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Short axis view of left main coronary artery</div><div class=\"cntnt\"><img style=\"width:203px; height:296px;\" src=\"images/CARD/79123_Short_axis_left_main_CA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The short axis view, with the imaging plane through the aortic root (AO) just above the aortic valve, demonstrates the left main coronary artery (LMCA). Panel B shows the M-mode echocardiogram of the LMCA.</div><div class=\"graphic_footnotes\">PV: pulmonary valve.</div><div id=\"graphicVersion\">Graphic 79123 Version 2.0</div></div></div>"},"79124":{"type":"graphic_figure","displayName":"1st trimester Down syn markers in affected and unaffected pregs","title":"First trimester Down syndrome markers in affected and unaffected pregnancies","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">First trimester Down syndrome markers in affected and unaffected pregnancies</div><div class=\"cntnt\"><img style=\"width:525px; height:866px;\" src=\"images/OBGYN/79124_1stTDwnSmrkaffunafpreg.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">NT: nuchal translucency; MoM: multiples of the median; PAPP-A: pregnancy-associate plasma protein A; hCG: human chorionic gonadotropin.</div><div class=\"graphic_reference\">Courtesy of Glenn E Palomaki, PhD.</div><div id=\"graphicVersion\">Graphic 79124 Version 2.0</div></div></div>"},"79125":{"type":"graphic_figure","displayName":"Essential features meiosis","title":"Essential features of meiosis","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Essential features of meiosis</div><div class=\"cntnt\"><img style=\"width:531px; height:308px;\" src=\"images/ALLRG/79125_Essential_features_meiosis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The first meiotic division is summarized in the top panels and the second meiotic division is summarized in the bottom panels. Crossing-over occurs at the 4-strand stage between pairs of non-sister chromatids. The first meiotic division precedes centromere replication, and leads to segregation of non-sister chromatids. The centromeres replicate prior to the second meiotic division, resulting in sister chromatid segregation.</div><div id=\"graphicVersion\">Graphic 79125 Version 1.0</div></div></div>"},"79126":{"type":"graphic_picture","displayName":"Amyloidosis tongue enlargement","title":"Amyloidosis tongue enlargement","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Amyloidosis tongue enlargement</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/HEME/79126_Amyloidosis_tongue_enlarge.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Physical examination showed an enlarged tongue protruding outside the mouth and showing scalloping of the lateral borders due to teeth indentations.</div><div class=\"graphic_reference\">Reproduced from: Guijarro-Martinez R, Miragall Alba L, Villar Puchades R, et al. Rational management of macroglossia due to acquired systemic amyloidosis: does surgery play a role? J Oral Maxillofac Surg 2009; 67:2013. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 79126 Version 1.0</div></div></div>"},"79127":{"type":"graphic_figure","displayName":"Variation serum testosterone","title":"Variation in serum total testosterone concentrations","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Variation in serum total testosterone concentrations</div><div class=\"cntnt\"><img style=\"width:435px; height:303px;\" src=\"images/ENDO/79127_Variation_serum_testosteron.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Serum total testosterone concentrations have a diurnal variation in young men (dashed line); concentrations are highest at 8 AM and lowest around 8 PM. In contrast, older men have little variation throughout the day (solid line). To convert serum testosterone values to nmol/L, multiply by 3.47.</div><div class=\"graphic_reference\">Data from: Bremner WJ, Vitiello V, Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men.&nbsp;J Clin Endocrinol Metab 1983; 56:1278.</div><div id=\"graphicVersion\">Graphic 79127 Version 3.0</div></div></div>"},"79128":{"type":"graphic_table","displayName":"Immunohistochemistry of GISTs","title":"Immunohistochemical schema for the differential diagnosis of spindle cell tumors of the gastrointestinal tract","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Immunohistochemical schema for the differential diagnosis of spindle cell tumors of the gastrointestinal tract</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12.5%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">CD117</td> <td class=\"subtitle1\">DOG-1</td> <td class=\"subtitle1\">PKC-theta</td> <td class=\"subtitle1\">CD34</td> <td class=\"subtitle1\">SMA*</td> <td class=\"subtitle1\">S100 protein</td> <td class=\"subtitle1\">Desmin</td> </tr> <tr class=\"divider_bottom\"> <td>GISTs</td> <td class=\"centered\">+<br /> (&#62;95%)</td> <td class=\"centered\">+<br /> (97%)</td> <td class=\"centered\">+<br /> (72%)</td> <td class=\"centered\">+<br /> (60 to 70%)</td> <td class=\"centered\">+/&ndash;<br /> (30 to 40%)</td> <td class=\"centered\">&ndash;<br /> (5% +)</td> <td class=\"centered\">Very rare</td> </tr> <tr class=\"divider_bottom\"> <td>Leiomyoma</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+<br /> (10 to 15%)</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> </tr> <tr class=\"divider_bottom\"> <td>Leiomyosarcoma</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+<br /> (10%)</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> </tr> <tr> <td>Schwannoma</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+<br /> (10%)</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DOG-1: discovered on GIST-1; PKC-theta: protein kinase C theta; GISTs: gastrointestinal stromal tumors.<br />* Alpha smooth muscle actin.</div><div class=\"graphic_reference\">Adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol 2002; 10:81.</li>&#xD;&#xA;    <li>Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol 2000; 10:1134.</li>&#xD;&#xA;    <li>Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol 2009; 33:1401.</li>&#xD;&#xA;    <li>Duensing A, Joseph NE, Medeiros F, et al. Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). Cancer Res 2004; 64:5127.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 79128 Version 5.0</div></div></div>"},"79129":{"type":"graphic_picture","displayName":"Dry AMD with atrophy","title":"Dry type ARMD with drusen and chorioretinal atrophy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dry type ARMD with drusen and chorioretinal atrophy</div><div class=\"cntnt\"><img style=\"width:347px; height:294px;\" src=\"images/PC/79129_Dry_AMD_with_atrophy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The bright yellow drusen are coalescing, and a large area of atrophy is seen in the macula (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from the Massachusetts Eye &amp; Ear Infirmary, Photographer, David Walsh.</div><div id=\"graphicVersion\">Graphic 79129 Version 1.0</div></div></div>"},"79131":{"type":"graphic_diagnosticimage","displayName":"Hydrocephalus due to a vein of Galen malformation","title":"Hydrocephalus due to a vein of Galen malformation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hydrocephalus due to a vein of Galen malformation</div><div class=\"cntnt\"><img style=\"width:301px; height:434px;\" src=\"images/PEDS/79131_Hydrocephalus_vein_Gal_mal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vein of Galen malformation, causing hydrocephalus.<br> (Panels A-D) Axial T2 weighted magnetic resonance imaging (MRI).<br> (Panels E, F) Cerebral angiogram.</div><div class=\"graphic_reference\">Courtesy of Drs. Abilash Haridas and Tadanori Tomita.</div><div id=\"graphicVersion\">Graphic 79131 Version 2.0</div></div></div>"},"79132":{"type":"graphic_picture","displayName":"Miniaturized MIC test card for auto susceptibility instrument","title":"Miniaturized minimum inhibitory concentration test card for automated susceptibility instrument","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Miniaturized minimum inhibitory concentration test card for automated susceptibility instrument</div><div class=\"cntnt\"><img style=\"width:468px; height:333px;\" src=\"images/ID/79132_Vitek_MIC_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Automated systems use microdilution trays or cards inoculated with known quantities of bacteria to determine minimum inhibitory concentrations.&nbsp;Growth is monitored using photometric, fluorometric, or turbidimetric systems.</div><div class=\"graphic_reference\">Courtesy of Mary Jane Ferraro, PhD, MPH.</div><div id=\"graphicVersion\">Graphic 79132 Version 4.0</div></div></div>"},"79133":{"type":"graphic_diagnosticimage","displayName":"Osteonecrosis of hip","title":"Osteonecrosis of the femoral head","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Osteonecrosis of the femoral head</div><div class=\"cntnt\"><img style=\"width:392px; height:300px;\" src=\"images/RHEUM/79133_Osteonecrosis_of_hip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiograph of the pelvis and hips of a 41-year-old man who has received a cardiac transplant and who is on corticosteroids. There is stage III (moderately late) avascular necrosis of both femoral heads manifested by increased density within each femoral head but no collapse (arrows). The increased density reflects marrow infarcts with calcification.</div><div class=\"graphic_reference\">Courtesy of Mark Robbins, MD.</div><div id=\"graphicVersion\">Graphic 79133 Version 3.0</div></div></div>"},"79134":{"type":"graphic_diagnosticimage","displayName":"Subcostal view IVC during cardiac tamponade","title":"Subcostal view IVC during cardiac tamponade","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Subcostal view IVC during cardiac tamponade</div><div class=\"cntnt\"><img style=\"width:549px; height:196px;\" src=\"images/CARD/79134_Subcostal_IVC_tamponade.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) The subcostal view of the inferior vena cava (IVC) in a patient with tamponade. The IVC is plethoric measuring over 20 mm in diameter.<br />(Panel B) During inspiration, the IVC diameter fails to decrease. There is a large pericardial effusion (PE) surrounding the right atrium (RA).</div><div id=\"graphicVersion\">Graphic 79134 Version 4.0</div></div></div>"},"79136":{"type":"graphic_figure","displayName":"Identifying poison ivy PI","title":"How to identify poison ivy, oak, and sumac","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">How to identify poison ivy, oak, and sumac</div><div class=\"cntnt\"><img style=\"width:425px; height:372px;\" src=\"images/PI/79136_Identifying_poison_ivy_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Poison ivy, poison oak, and poison sumac have certain features that make them easy to identify. Poison ivy and poison oak have 3 leaves coming off each stem and flowers that sprout where 2 branches meet. Poison sumac often has 5, 7, or more leaves coming off a single stem, and the leaves angle upward toward the top of the stem.</div><div class=\"graphic_reference\">Reproduced with permission from: Bolognia J, et al. Dermatology. Elsevier, Boston 2003. Copyright Â© 2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 79136 Version 5.0</div></div></div>"},"79137":{"type":"graphic_table","displayName":"Incidence of heart failure","title":"Incidence of heart failure in the Framingham study: 44-year follow-up of cohort and 20-year follow-up of offspring","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Incidence of heart failure in the Framingham study: 44-year follow-up of cohort and 20-year follow-up of offspring</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">Age</td>\n\n      <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">Average annual incidence per 1000</td>\n\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td class=\"subtitle2\">Men</td>\n\n      <td class=\"subtitle2\">Women</td>\n\n    </tr>\n\n    <tr>\n\n      <td>45 to 54</td>\n\n      <td>2</td>\n\n      <td>1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>55 to 64</td>\n\n      <td>4</td>\n\n      <td>2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>65 to 74</td>\n\n      <td>9</td>\n\n      <td>6</td>\n\n    </tr>\n\n    <tr>\n\n      <td>75 to 84</td>\n\n      <td>18</td>\n\n      <td>12</td>\n\n    </tr>\n\n    <tr>\n\n      <td>85 to 94</td>\n\n      <td>39</td>\n\n      <td>31</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 79137 Version 1.0</div></div></div>"},"79138":{"type":"graphic_picture","displayName":"Vallecular cyst","title":"Vallecular cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vallecular cyst</div><div class=\"cntnt\"><img style=\"width:366px; height:282px;\" src=\"images/PEDS/79138_Vallecular_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Congenital vallecular cysts arise in the hypopharynx. They contain respiratory epithelium and mucous glands.</div><div class=\"graphic_footnotes\">u: uvula; vc: vallecular cyst.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 79138 Version 2.0</div></div></div>"},"79140":{"type":"graphic_waveform","displayName":"Pericarditis myocarditis spectrum","title":"Pericarditis myocarditis spectrum","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Pericarditis myocarditis spectrum</div><div class=\"cntnt\"><img style=\"width:527px; height:444px;\" src=\"images/CARD/79140_Pericard_myocard_spectrum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 53-year-old man with apparently idiopathic acute pericarditis: nearly ubiquitous J (ST) elevations with corresponding J (ST) depression in lead aVR. As is common in leads III and aVF when the QRS axis is horizontal (or these leads are of small voltage), the J (ST) is not elevated. The height of J (ST) is &gt;25 percent of the height of the T-wave peak in leads V5 and V6. Most PR segments are slightly depressed with respect to the T-P baseline (corresponding PR elevation in lead aVR). In the clinical setting, a spectrum of myopericardial inflammatory syndromes can be encountered, ranging from pure pericarditis to forms with increasing myocardial involvement (sometimes mimicking an acute coronary syndrome).</div><div class=\"graphic_reference\">Reproduced with permission from: Imazio M, Spodick DH, Brucato A, et al. Controversial Issues in the Management of Pericardial Diseases. Circulation 2010; 121:916. Copyright Â© 2010 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 79140 Version 8.0</div></div></div>"},"79141":{"type":"graphic_figure","displayName":"Dracunculiasis life cycle","title":"Dracunculiasis life cycle","html":"<div class=\"graphic\"><div style=\"width: 637px\" class=\"figure\"><div class=\"ttl\">Dracunculiasis life cycle</div><div class=\"cntnt\"><img style=\"width:617px; height:467px;\" src=\"images/ID/79141_Dracunculiasis_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Humans become infected by drinking unfiltered water containing copepods (small crustaceans) that are infected with larvae of <em>D. medinensis</em> <strong>(1)</strong>. Following ingestion, the copepods die and release the larvae, which penetrate the host stomach and intestinal wall and enter the abdominal cavity and retroperitoneal space <strong>(2)</strong>. After maturation into adults and copulation, the male worms die and the females (length: 70 to 120 cm) migrate in the subcutaneous tissues towards the skin surface <strong>(3)</strong>. Approximately one year after infection, the female worm induces a blister on the skin, generally on the distal lower extremity, which ruptures. When this lesion comes into contact with water, a contact that the patient seeks to relieve the local discomfort, the female worm emerges and releases larvae <strong>(4)</strong>. The larvae are ingested by a copepod <strong>(5)</strong> and after two weeks (and two molts) have developed into infective larvae <strong>(6)</strong>. Ingestion of the copepods closes the cycle <strong>(1)</strong>.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Dracunculiasis. Available at: <a href=\"http://www.cdc.gov/dpdx/dracunculiasis/index.html\" target=\"_blank\">http://www.cdc.gov/dpdx/dracunculiasis/index.html</a>.</div><div id=\"graphicVersion\">Graphic 79141 Version 4.0</div></div></div>"},"79145":{"type":"graphic_table","displayName":"Measures RR variability","title":"Definitions for time and frequency domain measures of heart period variability","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definitions for time and frequency domain measures of heart period variability</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Variable</td> <td class=\"subtitle1\">Units</td> <td class=\"subtitle1\">Definition</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Time Domain - Statistical measures</td> </tr> <tr> <td class=\"indent1\">Night-day difference</td> <td>ms</td> <td>Difference between the average of all the normal RR intervals at night (24:00 to 05:00) and the average of all the normal RR intervals during the day (07:30 to 21:30).</td> </tr> <tr> <td class=\"indent1\">SDNN</td> <td>ms</td> <td>Standard deviation of all normal RR intervals in the entire 24-hour ECG recording.</td> </tr> <tr> <td class=\"indent1\">SDANN</td> <td>ms</td> <td>Standard deviation of the average normal RR intervals for all 288 5-minute segments of a 24-hour ECG recording (each average is weighted by the fraction of the 5 minutes that has normal RR intervals).</td> </tr> <tr> <td class=\"indent1\">ASDNN</td> <td>ms</td> <td>Average of the standard deviations of normal RR intervals for all 288 5-minute segments of a 24-hour ECG recording.</td> </tr> <tr> <td class=\"indent1\">r-MSSD</td> <td>ms</td> <td>Root mean square successive difference, the square root of the mean of the squared differences between adjacent normal RR intervals over the entire 24-hour ECG recording.</td> </tr> <tr> <td class=\"indent1\">pNN50</td> <td>percent</td> <td>Percent of differences between adjacent normal RR intervals that are greater than 50 ms computed over the entire 24-hour ECG recording.</td> </tr> <tr> <td class=\"indent1\">NN50</td> <td>none</td> <td>Number of adjacent normal RR intervals that are greater than 50 ms counted over the entire 24-hour ECG recording.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Time Domain - Geometric measures</td> </tr> <tr> <td class=\"indent1\">HRV triangular index</td> <td>none</td> <td>Total number of NN intervals divided by the number of NN intervals in the modal bin of a histogram of all NN intervals with a bin width of 7.8125 msec (for a sampling rate of 128/sec).</td> </tr> <tr> <td class=\"indent1\">TINN</td> <td>ms</td> <td>Baseline width of the minimum square difference triangular interpolation of the highest peak of the histogram of all NN intervals.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Frequency Domain Measures</td> </tr> <tr> <td class=\"indent1\">Total power</td> <td>ms<sup>2</sup></td> <td>The energy in the heart period power spectrum up to 0.40 Hz.</td> </tr> <tr> <td class=\"indent1\">Ultra low frequency (ULF) power</td> <td>ms<sup>2</sup></td> <td>The energy in the heart period power spectrum up to 0.0033 Hz.</td> </tr> <tr> <td class=\"indent1\">Very low frequency (VLF) power</td> <td>ms<sup>2</sup></td> <td>The energy in the heart period power spectrum between 0.0033 and 0.04 Hz.</td> </tr> <tr> <td class=\"indent1\">Low frequency (LF) power</td> <td>ms<sup>2</sup></td> <td>The energy in the heart period power spectrum between 0.04 and 0.15 Hz.</td> </tr> <tr> <td class=\"indent1\">High frequency (HF) power</td> <td>ms<sup>2</sup></td> <td>The energy in the heart period power spectrum between 0.15 and 0.40 Hz.</td> </tr> <tr> <td class=\"indent1\">LF/HF ratio </td> <td>none</td> <td>The ratio of low to high frequency power.</td> </tr> <tr> <td class=\"indent1\">beta</td> <td>none</td> <td>Slope of log (power) on log (frequency) between 0.01 and 0.0001 Hz on a log-log plot.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 79145 Version 4.0</div></div></div>"},"79147":{"type":"graphic_table","displayName":"Intraabdominal sepsis bacteria","title":"Bacteriology of intraabdominal sepsis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bacteriology of intraabdominal sepsis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_left\">Cases studied</td> <td>759</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Bacteriology</td> </tr> <tr> <td>Aerobes only</td> <td>132 (17)*</td> </tr> <tr> <td>Anaerobes only</td> <td>7 (1)*</td> </tr> <tr> <td>Anaerobes plus aerobes</td> <td>620 (82)*</td> </tr> <tr> <td class=\"subtitle1\">Bacterial isolates</td> <td class=\"subtitle1\">Number of isolates<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\">Aerobes</td> <td>1256</td> </tr> <tr> <td class=\"indent1\"><em>Escherichia coli</em></td> <td>306</td> </tr> <tr> <td class=\"indent1\"><em>Pseudomonas aeruginosa</em></td> <td>121</td> </tr> <tr> <td class=\"indent1\"><em>Klebsiella</em></td> <td>119</td> </tr> <tr> <td class=\"indent1\">Other gram-negative bacilli</td> <td>270</td> </tr> <tr> <td class=\"indent1\"><em>Enterococcus</em></td> <td>277</td> </tr> <tr> <td class=\"indent1\"><em>Staphylococcus aureus</em></td> <td>111</td> </tr> <tr> <td class=\"indent1\">Other gram-positive cocci</td> <td>62</td> </tr> <tr> <td class=\"subtitle2_left\">Anaerobes</td> <td>1187</td> </tr> <tr> <td class=\"indent1\"><em>Bacteroides </em>species</td> <td>443</td> </tr> <tr> <td class=\"indent1\"><em>Bacteroides fragilis</em></td> <td>133</td> </tr> <tr> <td class=\"indent1\"><em>Clostridium</em> species</td> <td>306</td> </tr> <tr> <td class=\"indent1\"><em>Peptostreptococcus</em></td> <td>220</td> </tr> <tr> <td class=\"indent1\"><em>Fusobacterium</em></td> <td>35</td> </tr> <tr> <td class=\"indent1\">Miscellaneous</td> <td>116</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Number of isolates (percent).<br />Â¶&nbsp;Numbers of isolates are greater than numbers of cases since the majority of cases had more than one microorganism isolated.</div><div class=\"graphic_reference\">Data from Stone HH et al. Arch Surg 1983.</div><div id=\"graphicVersion\">Graphic 79147 Version 5.0</div></div></div>"},"79149":{"type":"graphic_table","displayName":"Features of HIDS","title":"Features of hyperimmunoglobulin D syndrome (HIDS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Features of hyperimmunoglobulin D syndrome (HIDS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">General</td> </tr> <tr> <td>High IgD (&#62;14 mg/dL), measured on two occasions, at least one month apart</td> </tr> <tr> <td>Elevated IgA (&#62;260 mg/dL)</td> </tr> <tr> <td>Recurrent attacks</td> </tr> <tr> <td>Mutations in MVK gene (<strong>classic</strong> HIDS)</td> </tr> <tr> <td>Decreased MVK activity (<strong>classic</strong> HIDS)</td> </tr> <tr> <td class=\"subtitle1_single\">During Attacks</td> </tr> <tr> <td>Elevated inflammatory markers (ESR, CRP, SAA, and leukocytosis)</td> </tr> <tr> <td>Abrupt onset of fever (&#62;38.5&#176;C or 101.3&#176;F)</td> </tr> <tr> <td>Lymphadenopathy (predominantly cervical)</td> </tr> <tr> <td>Abdominal distress (vomiting, diarrhea, pain)</td> </tr> <tr> <td>Skin manifestations (varying erythematous macules, papules, petichiae, and purpura)</td> </tr> <tr> <td>Arthralgias/arthritis</td> </tr> <tr> <td>Splenomegaly</td> </tr> <tr> <td>Mildly elevated urinary mevalonic acid concentration (<strong>classic</strong> HIDS)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgD: immunoglobulin D; IgA: immunoglobulin A; MVK: mevalonate kinase; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; SAA: serum amyloid A.</div><div class=\"graphic_reference\">Data from: Drenth JP, Haagsma CJ, van der Meer JW. Medicine (Baltimore) 1994; 73:133 and Drenth JP, van Deuren M, van der Ven-Jongekrijg J, et al. Blood 1995; 85:3586.</div><div id=\"graphicVersion\">Graphic 79149 Version 3.0</div></div></div>"},"79150":{"type":"graphic_table","displayName":"Mnemonic for tracheal intubation preparation","title":"Mnemonic for tracheal intubation preparation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mnemonic for tracheal intubation preparation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>S</strong>: Suction</td> </tr> <tr> <td><strong>T</strong>: Tools for intubation (laryngoscope blades, handle, video laryngoscope and other preferred devices)</td> </tr> <tr> <td><strong>O</strong>: Oxygen source for preoxygenation and ongoing ventilation</td> </tr> <tr> <td><strong>P</strong>: Positioning</td> </tr> <tr> <td>&nbsp;</td> </tr> <tr> <td><strong>M</strong>: Monitors, including ECG, pulse oximetry, blood pressure, EtCO<sub>2</sub>, and esophageal detectors</td> </tr> <tr> <td><strong>A</strong>: Assistant; Ambu bag with face mask; Airway devices (ETTs, syringe, stylets, LMA); Airway assessment</td> </tr> <tr> <td><strong>I</strong>: Intravenous access</td> </tr> <tr> <td><strong>D</strong>: Drugs, including induction agent, neuromuscular blocking agent, and desired adjuncts (eg, IV fluids, vasopressor, fentanyl)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; EtCO<SUB>2</SUB>; end-tidal carbon dioxide; ETTs: endotracheal tubes; IV: intravenous;&nbsp;LMA: laryngeal mask airway.</div><div id=\"graphicVersion\">Graphic 79150 Version 4.0</div></div></div>"},"79151":{"type":"graphic_table","displayName":"Options warfarin-associated bleeding","title":"Reversing anticoagulation in warfarin-associated bleeding","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Reversing anticoagulation in warfarin-associated bleeding</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Management option</td> <td class=\"subtitle1\">Time to anticoagulation reversal</td> <td class=\"subtitle1\">Comments and cautions</td> </tr> <tr class=\"divider_bottom\"> <td>Discontinuing warfarin therapy</td> <td>5 to 14 days</td> <td>Five days is typical for patients with an INR in the therapeutic range</td> </tr> <tr class=\"divider_bottom\"> <td>Vitamin K*</td> <td>6 to 24 hours to correct the INR, longer to fully reverse anticoagulation</td> <td> <p>Recovery of factors X and II (prothrombin) takes longer than 24 hours</p> <p>Risk of anaphylaxis with intravenous injection</p> Impaired response to warfarin lasting up to one week may occur after large doses (ie, &#62;5 mg)</td> </tr> <tr class=\"divider_bottom\"> <td>Fresh frozen plasma</td> <td>Depends on the time it takes to complete the infusion; typically 12 to 32 hours for complete reversal</td> <td> <p>Effect is transient and concomitant vitamin K must be administered</p> <p>Potential for volume overload (2 to 4 L to normalize INR)</p> <p>Potential for TRALI</p> Potential for viral transmission</td> </tr> <tr class=\"divider_bottom\"> <td>Prothrombin complex concentrate</td> <td>15 minutes after 10-minute to 1-hour infusion</td> <td> <p>Effect is transient, and concomitant vitamin K must be administered; limited availability</p> <p>Cost</p> <p>Variable factor VII content depending on the product: a 4-factor PCC is preferred</p> Potentially prothrombotic</td> </tr> <tr> <td>Recombinant factor VIIa</td> <td>15 minutes after bolus infusion</td> <td> <p>Effect is transient, and concomitant vitamin K must be administered</p> <p>Cost</p> Potentially prothrombotic</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Please refer to the UpToDate topic on warfarin reversal in intracerebral hemorrhage for further details of management.</div><div class=\"graphic_footnotes\">INR: international normalized ratio; TRALI: transfusion-related acute lung injury; PCC: prothrombin complex concentrate.<br />* A total of 10 mg intravenously by slow infusion given over 10 minutes.</div><div class=\"graphic_reference\">Adapted with permission from: Aguilar MI, Hart RG, Kase CS, et al. Treatment of warfarin-associated intercerebral hemorrhage: Literature review and expert opinion. Mayo Clin Proc 2007; 82:82. Copyright &copy; 2007 Dowden Health Media.</div><div id=\"graphicVersion\">Graphic 79151 Version 16.0</div></div></div>"},"79152":{"type":"graphic_picture","displayName":"Dilatory eustachian tube dysfunction","title":"Dilatory eustachian tube dysfunction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dilatory eustachian tube dysfunction</div><div class=\"cntnt\"><img style=\"width:395px; height:294px;\" src=\"images/PC/79152_Dilatory_dys.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left eustachian tube with a large adenoid mass compressing posterior cushion causing a dilatory dysfunction.</div><div id=\"graphicVersion\">Graphic 79152 Version 1.0</div></div></div>"},"79154":{"type":"graphic_figure","displayName":"Bookwalter retractor","title":"Bookwalter retractor","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Bookwalter retractor</div><div class=\"cntnt\"><img style=\"width:480px; height:605px;\" src=\"images/SURG/79154_Bookwalter_retractor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The retractor is positioned in the abdomen (A-C).</div><div id=\"graphicVersion\">Graphic 79154 Version 2.0</div></div></div>"},"79155":{"type":"graphic_algorithm","displayName":"Evaluation intractable hiccups","title":"Diagnostic evaluation of persistent or intractable hiccups","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Diagnostic evaluation of persistent or intractable hiccups</div><div class=\"cntnt\"><img style=\"width:482px; height:243px;\" src=\"images/PC/79155_Evaluation_intractable_hicc.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CXR: chest x-ray; sx: symptoms; ENT: ear, nose, and throat; LP: lumbar puncture; LFTs: liver function tests.</div><div id=\"graphicVersion\">Graphic 79155 Version 3.0</div></div></div>"},"79158":{"type":"graphic_figure","displayName":"Cervical dermatomes 2","title":"Cervical dermatomes","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Cervical dermatomes</div><div class=\"cntnt\"><img style=\"width:542px; height:552px;\" src=\"images/ID/79158_Cervical_dermatomes_2.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 79158 Version 2.0</div></div></div>"},"79159":{"type":"graphic_picture","displayName":"Mucositis","title":"Mucositis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mucositis</div><div class=\"cntnt\"><img style=\"width:285px; height:240px;\" src=\"images/PEDS/79159_Mucositis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severe mucositis during bone marrow transplantation in a 13-year-old.</div><div class=\"graphic_reference\">Reproduced with permission from: Delaney, JE, Keels, MA. Pediatric oral pathology. Soft tissue and periodontal conditions. Pediatr Clin North Am 2000; 47:1125. Copyright &#169; 2000, W.B. Saunders.</div><div id=\"graphicVersion\">Graphic 79159 Version 1.0</div></div></div>"},"79160":{"type":"graphic_diagnosticimage","displayName":"Lymphangitic cancer CT II","title":"CT appearance of asymmetric lymphangitic carcinomatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT appearance of asymmetric lymphangitic carcinomatosis</div><div class=\"cntnt\"><img style=\"width:375px; height:252px;\" src=\"images/PULM/79160_Lymphangitic_cancer_CT_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Asymmetric lymphangitic spread of bronchogenic carcinoma, primarily involving the right lung. Thickened bronchovascular bundles and a fine reticular pattern are seen and probably represent thickened interlobular and intralobular septae. Polygon formation is seen in the anterior and medial aspect of the right lung. Several thickened interlobular septa are present, abutting the medial pleura of the right lung.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 79160 Version 4.0</div></div></div>"},"79161":{"type":"graphic_picture","displayName":"Bacteria in resting zone","title":"Bacteria in the resting zone","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bacteria in the resting zone</div><div class=\"cntnt\"><img style=\"width:432px; height:274px;\" src=\"images/GAST/79161_Bacteria_in_resting_zone.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Habitual colonic bacteria in the healthy wild-type mouse are diffusely distributed and have similar high concentrations at the center of stool and in the \"germinal\" zone indicating normal function of colonic bioreactor. <br />(B) Bacteria are suppressed in a 28-week-old mouse with IL-10 deficiency, at the center of stool, but are unchanged at the \"germinal\" zone. The reaction is general and is indicative for any disturbance of the colonic bioreactor. Bacteroides is orange, Eubacterium rectale is red, all other bacteria are green (x400). The suppression of bacteria precedes the inflammation. The animals had no symptoms.</div><div class=\"graphic_reference\">Courtesy of Alexander Swidsinski, MD, and Vera Loening-Baucke, MD.</div><div id=\"graphicVersion\">Graphic 79161 Version 3.0</div></div></div>"},"79165":{"type":"graphic_table","displayName":"Outcomes chemo nondysgerm OGCT","title":"Outcomes of cisplatin-based chemotherapy for women with nondysgerminomatous malignant ovarian germ cell tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Outcomes of cisplatin-based chemotherapy for women with nondysgerminomatous malignant ovarian germ cell tumors</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n  <tbody>\n\n\n\n    <tr>\n\n\n      <td class=\"subtitle1\">Author, year</td>\n\n\n      <td class=\"subtitle1\">Regimen</td>\n\n\n      <td class=\"subtitle1\">Progression-free/total (percent)</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">Adjuvant chemotherapy</td>\n\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Williams, SD; 1994</td>\n\n\n      <td>BEP</td>\n\n\n      <td>89/93 (96)</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Segelov, E; 1994</td>\n\n\n      <td>Multiple</td>\n\n\n      <td>9/10 (90)</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Rogers, P; 2004</td>\n\n\n      <td>BEP</td>\n\n\n      <td>70/74 (95)</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Gershenson, D; 1986</td>\n\n\n      <td>PVB</td>\n\n\n      <td>4/4 (100)</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Culine, S; 1997</td>\n\n\n      <td>Cisplatin-based</td>\n\n\n      <td>23/24 (96)</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Bafna, UD; 2001</td>\n\n\n      <td>BEP</td>\n\n\n      <td>14/16 (88)</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Gershenson, D; 1990</td>\n\n\n      <td>BEP</td>\n\n\n      <td>20/20 (100)</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Lai, CH; 2005</td>\n\n\n      <td>Multiple</td>\n\n\n      <td>66/67 (99)</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Dimopoulos, MA; 1998</td>\n\n\n      <td>BEP, PVB</td>\n\n\n      <td>17/19 (89)</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">Advanced disease</td>\n\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Williams, SD; 1989</td>\n\n\n      <td>PVB</td>\n\n\n      <td>47/89 (53)</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Segelov, E; 1994</td>\n\n\n      <td>Multiple</td>\n\n\n      <td>42/46 (91)</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Gershenson, D; 1986</td>\n\n\n      <td>PVB</td>\n\n\n      <td>7/11 (64)</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Culine, S; 1997</td>\n\n\n      <td>Cisplatin-based</td>\n\n\n      <td>17/30 (57)</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Pawinski, A; 1998</td>\n\n\n      <td>PVB</td>\n\n\n      <td>12/18 (67)</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Bafna, UD; 2001</td>\n\n\n      <td>BEP</td>\n\n\n      <td>3/6 (50)</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Gershenson, D; 1990</td>\n\n\n      <td>BEP</td>\n\n\n      <td>5/6 (83)</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Dimopoulos, MA; 1998</td>\n\n\n      <td>BEP, PVB</td>\n\n\n      <td>17/21 (80)</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Lai, CH; 2005</td>\n\n\n      <td>Multiple</td>\n\n\n      <td>15/19 (79)</td>\n\n\n    </tr>\n\n\n  \n  </tbody>\n</table></div><div class=\"graphic_footnotes\">BEP: bleomycin, etoposide and cisplatin; PVB: cisplatin, vinblastine and bleomycin.</div><div id=\"graphicVersion\">Graphic 79165 Version 1.0</div></div></div>"},"79166":{"type":"graphic_table","displayName":"Etiology of chorea","title":"Etiology of chorea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology of chorea</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">1. Developmental/aging choreas</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Physiological chorea of infancy</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Cerebral palsy - anoxic, kernicterus</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Minimal cerebral dysfunction</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Buccal-oral-lingual dyskinesia and edentulous orodyskinesia in elderly</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Senile chorea (probably several causes)</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">2. Hereditary choreas</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Huntington's disease</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Benign hereditary chorea</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Neuroacanthocytosis</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Other CNS \"degenerations\": OPCAs, Azorean disease, ataxia telangiectasia, tuberous sclerosis, Hallervorden-Spatz, Dentato-rubral-pallido-luysian atrophy (DRPLA), familial calcification of basal ganglia, others</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n\n      <td>Neurometabolic disorders: Wilson disease, Lesch Nyhan, lysosomal storage disorders, amino acid disorders, Leigh, porphyria</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">3. Drug induced</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\">Neuroleptics (tardive dyskinesia), antiparkinsonian drugs, amphetamines, tricyclics, oralcontraceptives, anticonvulsants, anticholinergics, others</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">4. Toxins</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">5. Metabolic</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Hyperthyroidism</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Hypoparathyroidism (various types)</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Pregnancy (Chorea Gravidarum)</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Hyper and hyponatremia, hypomagnesemia, hypocalcemia</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Hypo and hyperglycemia (latter may cause hemichorea, hemiballism)</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Acquired hepatocerebral degeneration</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Nutritional (eg, beriberi, pellagra, B12 deficiency in infants)</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">6. Infectious</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Sydenham's chorea</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Encephalitis lethargica</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Various other infections and postinfectious encephalitides, including Creutzfeldt-Jakob disease</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">7. Immunological</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>SLE (including ANF negative cases with lupus anticoagulant)</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Henoch-Schonlein</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Others rarely: Sarcoid, MS, Behcet's, polyarteritis nodosa, myeloproliferative disorder</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">8. Vascular (often hemichorea)</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Infarction</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Hemorrhage</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>AVM</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Polycythemia rubra vera</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td>Migraine</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">9. Tumors</td>\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">10.Trauma </td>\n\n\n\n    </tr>\n\n    <tr>\n      <td>Including subdural and epidural hematoma</td>\n    </tr>\n    <tr>\n\n      <td class=\"subtitle1_single\">11. Miscellaneous</td>\n\n\n\n    </tr>\n    <tr>\n      <td>Including paroxysmal choreoathetosis</td>\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Data from Jankovic, J, Lang, AE. Classification of movement disorders. In: Germano, IM, (Ed), Surgical Treatment of Movement Disorders, The American Association of Neurological Surgeons (AANS), Lebanon, NH, 1998. p.3.</div><div id=\"graphicVersion\">Graphic 79166 Version 1.0</div></div></div>"},"79167":{"type":"graphic_picture","displayName":"Pustular psoriasis 1","title":"Pustular psoriasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pustular psoriasis</div><div class=\"cntnt\"><img style=\"width:432px; height:283px;\" src=\"images/OBGYN/79167_Pustular_psoriasis_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 28-year-old woman developed fever, hypotension, leukocytosis, widespread erythema, and pustules at 34 weeks gestation during her first pregnancy. She was hospitalized for several months, and the eruption resolved within the first month after delivery of a normal full-term infant. A skin biopsy showed changes typical of pustular psoriasis.</div><div class=\"graphic_reference\">Copyright Â© Bernard Cohen, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 79167 Version 7.0</div></div></div>"},"79168":{"type":"graphic_table","displayName":"Tips for avoiding dust mites in your home PI","title":"Tips for avoiding dust mites in your home","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tips for avoiding dust mites in your home</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">First: Bedrooms</td> </tr> <tr> <td class=\"indent1\">Cover your pillows and mattresses with special zippered covers that keep dust mites away from you.</td> </tr> <tr> <td class=\"indent1\">Every week, wash your sheets, pillowcases, and blankets in hot water with detergent or dry them in an electric dryer on the hot setting. If possible, do not use a comforter. Instead, use a blanket that can be washed.</td> </tr> <tr> <td class=\"indent1\">Use washable, vinyl, or roll-type window covers.</td> </tr> <tr> <td class=\"indent1\">Remove clutter, stuffed animals and other soft toys, and fabric-covered furniture. If you cannot take the stuffed animals out of the bedroom, wash them every week.</td> </tr> <tr> <td class=\"indent1\">If possible, remove carpets. Instead, use area rugs that can be cleaned or washed.</td> </tr> <tr> <td class=\"subtitle1_single\">Second: Rest of house</td> </tr> <tr> <td class=\"indent1\">Try to reduce the amount of fabric-covered furniture you have, especially old sofas.</td> </tr> <tr> <td class=\"indent1\">If possible, replace carpets with (noncarpet) flooring. This includes carpets on concrete slabs or over poorly ventilated crawl spaces.</td> </tr> <tr> <td class=\"indent1\">Every week, vacuum the house with a vacuum that has a \"HEPA filter.\" For cleaning floors, use a mop rather than a broom.</td> </tr> <tr> <td class=\"indent1\">Use washable, vinyl, or roll-type window covers.</td> </tr> <tr> <td class=\"indent1\">Make sure that the humidity in the home is less than 50%. Do not use a humidifier.</td> </tr> <tr> <td class=\"subtitle1_single\">Third: Changing houses*</td> </tr> <tr> <td class=\"indent1\">People with allergies and asthma do not usually need to move, except if they live in a basement or in a home that is very damp and wet.</td> </tr> <tr> <td class=\"indent1\">If you are allergic to dust mites or mold, you might have fewer symptoms if you move to:</td> </tr> <tr> <td class=\"indent2\">&#8226; An apartment on or above the second floor.</td> </tr> <tr> <td class=\"indent2\">&#8226; A home with wooden floors and bedrooms on the second floor.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HEPA filter: high-efficiency particulate air filter.<br />* The average family in the United States moves about every four years.</div><div id=\"graphicVersion\">Graphic 79168 Version 11.0</div></div></div>"},"79169":{"type":"graphic_table","displayName":"Tdap Td contraindications","title":"Contraindications and precautions to diphtheria, tetanus, and pertussis vaccines for children and adolescents aged 7 through 18 years","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contraindications and precautions to diphtheria, tetanus, and pertussis vaccines for children and adolescents aged 7 through 18 years</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Vaccine</td> <td class=\"subtitle1\">Contraindications</td> <td class=\"subtitle1\">Precautions*</td> <td class=\"subtitle1\">Neither contraindications nor precautions</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Tdap</td> </tr> <tr> <td rowspan=\"7\">&nbsp;</td> <td>Severe allergic reaction (eg, anaphylaxis) after a previous vaccine dose or to a vaccine component</td> <td>Moderate or severe acute illness with or without fever</td> <td>History of extensive limb-swelling reaction after a previous dose of DTwP/DTaP or Td immunization that was not an Arthus-type hypersensitivity reaction</td> </tr> <tr> <td>Encephalopathy (eg, coma, decreased level of consciousness, prolonged seizures) not attributable to another identifiable cause within 7 days of administration of previous doses of DTwP/DTaP/Tdap</td> <td>Guillain-Barr&#233; syndrome within 6 weeks of tetanus toxoid-containing vaccine</td> <td>Stable&nbsp;neurologic disorder (eg, well-controlled seizures, history of seizure disorder, cerebral palsy)</td> </tr> <tr> <td>&nbsp;</td> <td>Progressive or unstable neurologic disorder, uncontrolled seizures or progressive encephalopathy until a treatment regimen has been established and the condition stabilized</td> <td>Brachial neuritis</td> </tr> <tr> <td>&nbsp;</td> <td>History of Arthus-type hypersensitivity reaction following diphtheria or tetanus toxoid-containing vaccine (including MCV4)</td> <td>Non-anaphylactic latex allergy<sup>&#182;</sup></td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>Breastfeeding</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>Immunosuppression, including HIV infection</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>Use of antimicrobials</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Tetanus toxoid, reduced diphtheria toxoid (Td, adult Td, dT)</td> </tr> <tr> <td rowspan=\"3\">&nbsp;</td> <td>Severe allergic reaction (eg, anaphylaxis) after a previous vaccine dose or to a vaccine component</td> <td>Moderate or severe acute illness with or without fever</td> <td>(As for Tdap)</td> </tr> <tr> <td>&nbsp;</td> <td>Guillain-Barr&#233; syndrome within 6 weeks of tetanus toxoid-containing vaccine</td> <td>&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>History of Arthus-type hypersensitivity reaction following diphtheria or tetanus toxoid-containing vaccine (including MCV4)</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Tdap: tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine; DTaP: diphtheria toxoid, tetanus toxoid, acellular pertussis vaccine; DTwP: diphtheria tetanus, whole-cell pertussis vaccine; Td: tetanus toxoid, reduced diphtheria toxoid (adult Td, dT); MCV4: quadrivalent meningococcal vaccine; HIV: human immunodeficiency virus.<br />* Precautions should be reviewed carefully. Benefits and risks of administering specific vaccines to a person under these circumstances should be considered. If the risk from the vaccine is believed to outweigh the benefit, the vaccine should not be administered.<br />Â¶&nbsp;<FONT color=black>Vaccines that contain latex (eg, in the tip or rubber plunger) are contraindicated in patients with anaphylactic reactions to latex. Check the prescribing information for information about latex.</FONT></div><div class=\"graphic_reference\">Adapted from:<br /><OL>&#xD;&#xA;<LI>Immunization Action Coalition. Guide to contraindications and precautions to commonly used vaccines. Available at: <A spellcheck=true href=\"http://www.immunize.org/catg.d/p3072A.pdf\" target=_blank>www.immunize.org/catg.d/p3072A.pdf</A>. Accessed on April 27, 2017. </LI>&#xD;&#xA;<LI>Kroger AT, Duchin J, VÃ¡zquez M. General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Available at: <A spellcheck=true href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html\" target=_blank>www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html</A>. Accessed on April 27, 2017. &nbsp;</LI>&#xD;&#xA;<LI>American Academy of Pediatrics. Pertussis (whooping cough). In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th, Kimberlin DW, Brady MT, Jackson MA, Long SS. (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.609.</LI></OL></div><div id=\"graphicVersion\">Graphic 79169 Version 8.0</div></div></div>"},"79172":{"type":"graphic_diagnosticimage","displayName":"Silicosis CXR PA I","title":"Silicosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Silicosis</div><div class=\"cntnt\"><img style=\"width:357px; height:350px;\" src=\"images/PULM/79172_SilicosisPAI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows multiple nodules, 3 to 5 mm in diameter, with a bias for the upper lobes. Note calcification in some of the pulmonary nodules and the hilar lymph nodes.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 79172 Version 6.0</div></div></div>"},"79173":{"type":"graphic_table","displayName":"Predisposing factors and clinical aspects of infectious syndrome","title":"Predisposing factors and clinical aspects of infectious syndromes in older adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Predisposing factors and clinical aspects of infectious syndromes in older adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Syndrome</td> <td class=\"subtitle1\">Predisposition</td> <td class=\"subtitle1\">Pertinent considerations in older adults</td> </tr> <tr> <td><strong>Bacteremia and sepsis</strong></td> <td> <ul> <li>Comorbidities </li> <li>Poor immune function </li> <li>Thin/dry mucosa </li> <li>Vascular grafts/prosthetic devices </li> </ul> </td> <td> <ul> <li>Greater incidence of urinary or gastrointestinal source increases risk of Gram-negative organisms, particularly in oldest-old. </li> <li>Aggressive therapies, including use of activated protein C, effective even in those over 75 years. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td><strong>Bone and joint infection</strong></td> <td> <ul> <li>Prosthetic devices </li> <li>Peripheral neuropathy </li> <li>Peripheral vascular disease </li> </ul> </td> <td> <ul> <li>Preservation of functional status paramount concern and may alter approach to therapy. </li> <li>Insurance coverage (Medicare) for outpatient antibiotic costs may be limited and necessitate LTC stay. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td><strong>Fever of unknown origin</strong></td> <td> <ul> <li>Age-related increases in <em>Mycobacterium tuberculosis</em> </li> <li>Cancer risk </li> <li>Degenerative valve disease </li> <li>Collagen vascular diseases of aging (eg, giant cell arteritis) </li> </ul> </td> <td> <ul> <li>Increased rates of tuberculosis, infective endocarditis and abdominal as cause of FUO. </li> <li>Elevated ESR and alkaline phosphatase increase pretest probability of positive biopsy for giant cell arteritis, but relatively low threshold for biopsy should be maintained. </li> <li>Lymphoma most likely neoplasm. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td><strong>Fever in hospitalized patients</strong></td> <td> <ul> <li>More procedures </li> <li>More indwelling devices/catheters </li> <li>Poor bowel/bladder function </li> <li>Pressure ulcers </li> </ul> </td> <td> <ul> <li>Infection accounts for&nbsp;three-fourths of all nosocomial febrile episodes. </li> <li>Consider noninfectious causes: venous thrombosis, drug reactions, MI. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td><strong>Foodborne illness, and intra-abdominal infections</strong></td> <td> <ul> <li>Achlorhydria </li> <li>Poor immunity versus intra-cellular bacteria (<em>Salmonella</em> and <em>Listeria</em> spp) </li> <li>Mesenteric peripheral vascular disease </li> <li>Diverticular disease </li> </ul> </td> <td> <ul> <li>Higher incidence of diverticulitis, bowel obstruction and mesenteric ischemia/bowel infarction in older adults. </li> <li>Greater risk of mortality with appendicitis due to poor recognition of the syndrome. </li> <li>Consider <em>Clostridium&nbsp;difficile</em> colitis in patients with diarrhea and recent antimicrobial therapy or institutionalized. </li> <li>Infection control important to prevent spread <em>C. difficile</em>. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td><strong>HIV infection/AIDS</strong></td> <td> <ul> <li>Don't perceive HIV as a threat </li> <li>Poor awareness of STDs </li> <li>No need for pregnancy prevention </li> </ul> </td> <td> <ul> <li>More likely to present already AIDS-defined. </li> <li>Untreated, HIV progresses more rapidly, but response to combined antiretroviral therapy similar. </li> <li>Concerns re: atherosclerosis and bone loss due to HIV or its treatment. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td><strong>Infective endocarditis</strong></td> <td> <ul> <li>Degenerative/calcified valvular disease </li> </ul> </td> <td> <ul> <li>Clinical manifestations frequently subtle. TTE less sensitive than in young adults due to valve calcification/degeneration. </li> <li>Microbiology and therapy similar but increased adverse drug effects (eg, aminoglycoside-induced nephrotoxicity). </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td><strong>Influenza</strong></td> <td> <ul> <li>Institutionalization </li> <li>Comorbidities increase the risk of morbidity and mortality </li> </ul> </td> <td> <ul> <li>Often exacerbates underlying illness, resulting in hospitalization or death. </li> <li>Early therapy (&#60;24 hours after onset) may reduce hospitalization and need for antibiotics due to bacterial superinfection. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td><strong>Meningitis</strong></td> <td> <ul> <li>Increased risk of bacteremia </li> <li>Poor clearance of encapsulated organisms </li> </ul> </td> <td> <ul> <li><em>Streptococcus&nbsp;pneumoniae </em>remains most likely organism. </li> <li>Gram-negative bacilli, <em>Listeria monocytogenes</em>, and&nbsp;<em>M. tuberculosis</em> are more common than in younger adults. </li> <li>Treatment similar to that of young adults. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td><strong>Ocular infection</strong></td> <td> <ul> <li>Dry eyes prevalent </li> <li>Common reactivation of herpes viruses </li> <li>Cataract surgery and implants </li> </ul> </td> <td> <ul> <li>Increased likelihood of viral keratitis (usually due to HSV) and ocular complications of herpes zoster. </li> <li>Endophthalmitis may be associated with cataract surgery/implants. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td><strong>Pneumonia</strong></td> <td> <ul> <li>Comorbid disease (eg, COPD) </li> <li>Stroke and swallowing abnormalities </li> <li>Poor immunity to encapsulated organisms </li> <li>Increased severity of viral illnesses </li> </ul> </td> <td> <ul> <li>Rate and severity of illness increases with far advanced age (&#62;85 yrs), comorbidities, and&nbsp;LTC residence. </li> <li>Clinical manifestations often subtle. </li> <li>Microbiology more often polymicrobial or TB. </li> <li>Broader antibiotic coverage needed for aspiration, LTC residence and in some comorbid illnesses (eg, severe COPD). </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td><strong>Skin/soft tissue</strong></td> <td> <ul> <li>Dry/thin skin </li> <li>Poor cell-mediated immunity </li> <li>Reactivation of herpes viruses </li> <li>Poor mobility/pressure ulcers </li> <li>Comorbidities (eg, diabetes mellitus, chronic edema, peripheral vascular disease) </li> </ul> </td> <td> <ul> <li>Zoster and PHN occur more frequently. </li> <li>Immunization reduces risk of zoster and PHN. </li> <li>Aggressive skin/soft tissue infections (eg, necrotizing fasciitis, malignant otitis externa, Fornier's gangrene) more common, particularly with comorbidities (eg, diabetes and chronic edema). </li> <li>Antibiotic resistance more common with prior therapy and/or&nbsp;LTC residence. </li> <li>If chronic edema and recurrent cellulitis, look for onychomycosis as source of entry. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td><strong>Urinary tract infection</strong></td> <td> <ul> <li>Incomplete bladder emptying due to detrusor dysfunction or obstruction (eg, BPH) </li> <li>Comorbidity </li> <li>Indwelling or condom catheters </li> </ul> </td> <td> <ul> <li>Asymptomatic bacteriuria does not require treatment; occurs in 10 to 15 percent of community-dwelling older adults and in up to 50 percent of LTC residents. </li> <li>Clinical manifestations of true UTI often subtle (eg, change in functional status). </li> <li><em>Escherichia coli</em> and other Gram-negative bacilli still most likely, but more enterococci and <em>Streptococcus agalactiae</em> than in younger adults. </li> <li>Prevention aimed at alleviating obstruction, increasing bladder emptying, and reducing in-dwelling catheter use. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LTC: long-term care; FUO: fever of unknown origin; ESR: erythrocyte sedimentation rate; MI: myocardial infarction; HIV: human immunodeficiency virus; AIDS: acquired immunodeficiency syndrome; STD: sexually transmitted disease; TTE: transthoracic echocardiogram; COPD: chronic obstructive pulmonary disease; TB: tuberculosis; PHN: postherpetic neuralgia; BPH: benign prostatic hyperplasia; UTI: urinary tract infection.</div><div id=\"graphicVersion\">Graphic 79173 Version 5.0</div></div></div>"},"79174":{"type":"graphic_diagnosticimage","displayName":"Sacroiliitis grade 3 example 2","title":"Sacroiliitis grade 3 example 2","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Sacroiliitis grade 3 example 2</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/RHEUM/79174_Sacroiliitis_grade_3_ex_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral sacroiliitis grade 3.</div><div class=\"graphic_reference\">Courtesy of Dr. Sheng Guang Li, PLA Hospital, China.</div><div id=\"graphicVersion\">Graphic 79174 Version 2.0</div></div></div>"},"79177":{"type":"graphic_movie","displayName":"Pulmonary regurgitation short axis color Doppler echocardiogram","title":"Pulmonary regurgitation","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary regurgitation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/79177_prssaxbcconv.mp4\" style=\"width:360px;height:272px\"></div><img style=\"width:256px; height:433px;\" src=\"images/CARD/79177_prssaxbc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The basal short axis view from a 2-D echocardiogram with color flow Doppler shows significant pulmonary regurgitation.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 79177 Version 2.0</div></div></div>"},"79178":{"type":"graphic_figure","displayName":"Uric acid pathways","title":"Endogenous production of uric acid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endogenous production of uric acid</div><div class=\"cntnt\"><img style=\"width:292px; height:284px;\" src=\"images/NEPH/79178_Uric_acid_pathways.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Excessive purine catabolism results in the production of hypoxanthine and xanthine, which are metabolized to uric acid via the enzymatic action of XO. This pathway can be blocked by the use of allopurinol, a hypoxanthine analog that competitively inhibits XO, and febuxostat, a non-purine thiazolecarboxylic acid derivative that selectively inhibits XO. After about two to three days, allopurinol and febuxostat result in increased excretion of both hypoxanthine, which is more soluble than uric acid, and xanthine, which is less soluble than uric acid. Preformed uric acid is not altered by allopurinol or febuxostat. UO, present in most mammals but not humans, oxidizes preformed uric acid to allantoin, which is 5 to 10 times more soluble than uric acid in acid urine. When exogenous UO (uricase, rasburicase, pegloticase) is administered, serum and urinary uric acid levels decrease markedly within approximately four hours.</div><div class=\"graphic_footnotes\">XO: xanthine oxidase; UO: urate oxidase.<br />* UO is not normally present in humans.</div><div id=\"graphicVersion\">Graphic 79178 Version 3.0</div></div></div>"},"79179":{"type":"graphic_table","displayName":"ACR fibromyalgia classification","title":"The American College of Rheumatology 1990 criteria for the classification of fibromyalgia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The American College of Rheumatology 1990 criteria for the classification of fibromyalgia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">1. History of widespread pain.</td> </tr> <tr> <td><strong>Definition.</strong> Pain is considered widespread when all of the following are present: Pain in the left side of the body, pain in the right side of the body, pain above the waist, and pain below the waist. In addition, axial skeletal pain (cervical spine or anterior chest or thoracic spine or low back) must be present. In this definition, shoulder and buttock pain is considered as pain for each involving side. \"Low back\" pain is considered lower segment pain.</td> </tr> <tr> <td class=\"subtitle1_single\">2. Pain in 11 of 18 tender point sites on digital palpation.</td> </tr> <tr> <td><strong>Definition.</strong> Pain, on digital palpation, must be present in at least 11 of the following 18 tender point sites:</td> </tr> <tr> <td class=\"indent1\">Occiput: Bilateral, at the suboccipital muscle insertions.</td> </tr> <tr> <td class=\"indent1\">Low cervical: Bilateral, at the anterior aspects of the intertransverse spaces at C5-C7.</td> </tr> <tr> <td class=\"indent1\">Trapezius: Bilateral, at the midpoint of the upper border.</td> </tr> <tr> <td class=\"indent1\">Supraspinatus: Bilateral, at origins, above the scapula spine near the medial border.</td> </tr> <tr> <td class=\"indent1\">Second rib: Bilateral, at the second costochondral junctions, just lateral to the junctions on upper surfaces.</td> </tr> <tr> <td class=\"indent1\">Lateral epicondyle: Bilateral, 2 cm distal to the epicondyles.</td> </tr> <tr> <td class=\"indent1\">Gluteal: Bilateral, in upper outer quadrants of buttocks in anterior fold of muscle.</td> </tr> <tr> <td class=\"indent1\">Greater trochanter: Bilateral, posterior to the trochanteric prominence.</td> </tr> <tr> <td class=\"indent1\">Knee: Bilateral, at the medial fat pad proximal to the joint line.</td> </tr> <tr> <td>Digital palpation should be performed with an approximate force of 4 kg. For tender point to be considered \"positive\" the subject must state the palpation was painful. \"Tender\" is not to be considered \"painful.\"</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">For classification purposes, patients will be said to have fibromyalgia if both criteria are satisfied. Widespread pain must have been present for at least three months. The presence of a second clinical disorder does not exclude the diagnosis of fibromyalgia.</div><div class=\"graphic_reference\">Reproduced with permission from: Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33:160. Copyright &copy; 1990 John Wiley &amp; Sons.</div><div id=\"graphicVersion\">Graphic 79179 Version 3.0</div></div></div>"},"79182":{"type":"graphic_table","displayName":"Sample questions for diagnosis and initial assessment of asthma","title":"Sample questions* for the diagnosis and initial assessment of asthma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sample questions* for the diagnosis and initial assessment of asthma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">A \"yes\" answer to any question suggests that an asthma diagnosis is likely.</td> </tr> <tr> <td class=\"subtitle2_single\">In the past 12 months, have you<sup>&#182;</sup>...</td> </tr> <tr> <td class=\"indent1\">Had a sudden severe episode or recurrent episodes of coughing, wheezing (high-pitched whistling sounds when breathing out), chest tightness, or shortness of breath?</td> </tr> <tr> <td class=\"indent1\">Had colds that \"go to the chest\" or take more than 10 days to get over?</td> </tr> <tr> <td class=\"indent1\">Had coughing, wheezing, or shortness of breath during a particular season or time of the year?</td> </tr> <tr> <td class=\"indent1\">Had coughing, wheezing, or shortness of breath in certain places or when exposed to certain things (eg, animals, tobacco smoke, perfumes)?</td> </tr> <tr> <td class=\"indent1\">Used any medications that help you breathe better? How often?</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Had symptoms relieved when the medications are used?</td> </tr> <tr> <td class=\"subtitle2_single\">In the past four weeks, have you<sup>&#182;</sup> had coughing, wheezing, or shortness of breath...</td> </tr> <tr> <td class=\"indent1\">At night that has awakened you?</td> </tr> <tr> <td class=\"indent1\">Upon awakening?</td> </tr> <tr> <td class=\"indent1\">After running, moderate exercise, or other physical activity?</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* These questions are examples and do not represent a standardized assessment or diagnostic instrument. The validity and reliability of these questions have not been assessed.<br />Â¶ Or \"your child,\" if a parent/caregiver is answering the questions for a child.</div><div class=\"graphic_reference\">Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.</div><div id=\"graphicVersion\">Graphic 79182 Version 7.0</div></div></div>"},"79183":{"type":"graphic_figure","displayName":"RBC membrane model","title":"Multiprotein complexes in the red blood cell membrane","html":"<div class=\"graphic\"><div style=\"width: 664px\" class=\"figure\"><div class=\"ttl\">Multiprotein complexes in the red blood cell membrane</div><div class=\"cntnt\"><img style=\"width:644px; height:372px;\" src=\"images/HEME/79183_RBC_membrane_model.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of two types of multiprotein complexes in the red blood cell membrane.<br />(Left) Band 3-based macromolecular complex (referred to as Ankyrin complex in the image). This protein complex attaches to spectrin near the center of the tetramer (dimer-dimer interaction site). Tetrameric band 3 is bound to ankyrin, which is bound to spectrin. The membrane skeletal protein 4.2 has binding sites for band 3 and for ankyrin. Transmembrane glycoproteins GPA, Rh, and RhAG bind to band 3, and CD47 and LW associate with Rh/RhAG. The two cytoplasmic domains of band 3 contain binding sites for soluble proteins, the short C-terminal domain for CA II, the large N-terminal domain for deoxyhemoglobin, glycolytic enzymes, aldolase, PFK, and GAPDH.<br />(Right) Protein 4.1R-based macromolecular complex. This protein complex forms at membrane skeletal junctions. The junctions contain the ternary complex of spectrin, F-actin, and protein 4.1R, as well as the actin-binding proteins tropomyosin, tropomodulin, adducin, and dematin. Protein 4.1R enters into an additional ternary interaction with the transmembrane proteins GPC and p55 and can also bind to band 3, in the form of a dimer, which also carries GPA. The blood group proteins Rh, Kell, and XK also have binding sites on protein 4.1R. Note, however, that the abundances of all transmembrane proteins except GPA and GPC are low and therefore not all proteins will be present on all complexes.</div><div class=\"graphic_footnotes\">4.1R: protein 4.1R; GLUT1: glucose transporter 1; GPA: glycophorin A; CA II: carbonic anhydrase II; GPC: glycophorin C; PFK: phosphofructokinase; Hb: hemoglobin; GAPDH: glyceraldehyde 3-phosphate dehydrogenase.</div><div class=\"graphic_reference\">Modified with permission from: Salomao, M, Zhang, X, Yang, Y, et al. Protein 4.1R-dependent multiprotein complex; new insights into the structural organization of the red blood cell membrane. Proc Natl Acad Sci USA 2008; 105:8026. Copyright &copy; 2008 National Academy of Sciences, USA.</div><div id=\"graphicVersion\">Graphic 79183 Version 5.0</div></div></div>"},"79184":{"type":"graphic_picture","displayName":"Infil UC lymphoepith-like","title":"Infiltrating urothelial carcinoma, lymphoepithelioma-like variant","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Infiltrating urothelial carcinoma, lymphoepithelioma-like variant</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ONC/79184_Infil_UC_lymphoepith-like.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lymphoepithelioma-like variant of urothelial carcinoma is characterized by sheets of undifferentiated cells with large nuclei and poorly defined cytoplasmic borders in a prominent inflammatory background.</div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 79184 Version 1.0</div></div></div>"},"79185":{"type":"graphic_table","displayName":"Differential diagnosis of prolonged crying","title":"Selected identifiable causes of prolonged/excessive crying in an infant younger than four months of age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected identifiable causes of prolonged/excessive crying in an infant younger than four months of age</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">General</td> </tr> <tr> <td class=\"indent1\">Drug ingestion or overdosage (eg, pseudoephedrine)</td> <td>History of medication administration</td> </tr> <tr> <td class=\"indent1\">Hunger/inadequate feeding</td> <td>Signs of hypovolemia or undernutrition (eg, sunken fontanelle, dry mucous membranes, decreased subcutaneous fat, etc)</td> </tr> <tr> <td class=\"indent1\">Neonatal abstinence syndrome</td> <td>Maternal history of prenatal substance use or positive urine screen (maternal or fetal)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Skin</td> </tr> <tr> <td class=\"indent1\">Hair tourniquet of digit or penis&nbsp;</td> <td>Apparent on&nbsp;physical examination&nbsp;</td> </tr> <tr> <td class=\"indent1\">Open diaper pin poking the skin, diaper rash</td> <td>Apparent on physical examination</td> </tr> <tr> <td class=\"indent1\">Trauma (abusive or nonabusive)</td> <td>Bruising, laceration&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Eyes</td> </tr> <tr> <td class=\"indent1\">Corneal abrasion or foreign body</td> <td>May have photophobia, positive fluorescein examination</td> </tr> <tr> <td class=\"indent1\">Glaucoma</td> <td>Chronic or intermittent tearing, photophobia, corneal enlargement, corneal clouding, optic nerve cupping, ocular enlargement</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Ears, nose, oropharynx</td> </tr> <tr> <td class=\"indent1\">Otitis media</td> <td>Bulging tympanic membrane</td> </tr> <tr> <td class=\"indent1\">Thrush</td> <td>White plaques on the buccal mucosa, tongue, or palate</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Cardiovascular</td> </tr> <tr> <td class=\"indent1\">Anomalous origin of the left coronary artery&nbsp;</td> <td>Cardiomegaly, heart failure</td> </tr> <tr> <td class=\"indent1\">Heart failure</td> <td>Feeding intolerance, tachycardia, poor perfusion, tachypnea</td> </tr> <tr> <td class=\"indent1\">Supraventricular tachycardia</td> <td>Pallor, irritability, poor feeding, cyanosis, restlessness</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Gastrointestinal</td> </tr> <tr> <td class=\"indent1\">Anal fissures</td> <td>Apparent on physical examination</td> </tr> <tr> <td class=\"indent1\">Constipation</td> <td>Passage of hard stools</td> </tr> <tr> <td class=\"indent1\">Gastroenteritis&nbsp;</td> <td>Vomiting, diarrhea</td> </tr> <tr> <td class=\"indent1\">Gastroesophageal reflux&nbsp;</td> <td>Vomiting, poor weight gain, feeding refusal, gross or occult blood in the stool</td> </tr> <tr> <td class=\"indent1\">Gastrointestinal obstruction (eg, pyloric stenosis, intussusception, volvulus)</td> <td>Vomiting (may or may not be bilious or forceful), gastrointestinal bleeding, forceful vomiting, abdominal tenderness, distension, right-sided sausage-shaped abdominal mass (intussusception), palpable&nbsp;\"olive\" (pyloric stenosis)&nbsp;</td> </tr> <tr> <td class=\"indent1\">Inguinal hernia</td> <td>Bulge in the groin area (may be intermittent), vomiting and abdominal distension may indicate incarceration</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Genitourinary</td> </tr> <tr> <td class=\"indent1\">Meatal ulcer&nbsp;</td> <td>Apparent on examination</td> </tr> <tr> <td class=\"indent1\">Ovarian torsion &nbsp;</td> <td>Feeding intolerance, vomiting, abdominal distension, fussiness/irritability</td> </tr> <tr> <td class=\"indent1\">Testicular torsion</td> <td>Acute testicular swelling and tenderness&nbsp;</td> </tr> <tr> <td class=\"indent1\">Urinary tract infection</td> <td>Fever, suprapubic tenderness, poor feeding, poor weight gain</td> </tr> <tr> <td class=\"indent1\">Urinary tract obstruction</td> <td>Abdominal distension (due to enlarged bladder), difficulty voiding, poor urinary stream, straining or grunting during voiding</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Skeletal</td> </tr> <tr> <td class=\"indent1\">Fracture</td> <td>Decreased movement of extremity, asymmetric Moro reflex, localized swelling and crepitation, increased pain response with movement of the extremity</td> </tr> <tr> <td class=\"indent1\">Osteomyelitis or septic arthritis</td> <td>Fever, decreased movement of extremity, asymmetric Moro reflex, increased pain response with movement of the extremity</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Neurologic</td> </tr> <tr> <td class=\"indent1\">Abusive head trauma</td> <td>Seizures, respiratory difficulty or apnea, retinal hemorrhages, cutaneous bruising, associated injuries</td> </tr> <tr> <td class=\"indent1\">Meningitis</td> <td>Fever, bulging fontanelle, lethargy, irritability, meningismus (often not present in infants)</td> </tr> <tr> <td class=\"indent1\">Neuromuscular disease, CNS disorder, metabolic disease&nbsp;</td> <td>Abnormal tone, muscular weakness</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Drug and Therapeutics Bulletin. Management of infantile colic. BMJ 2013; 347:f4102.</li>&#xD;&#xA;    <li>Parker S, Magee T. Colic. In: The Zuckerman Parker Handbook of Developmental and Behavioral Pediatrics for Primary Care, 3rd ed, Augustyn M, Zuckerman B, Caronna EB (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.182.</li>&#xD;&#xA;    <li>Roberts DM, Ostapchuk M, O'Brien JG. Infantile colic. Am Fam Physician 2004; 70:735.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 79185 Version 7.0</div></div></div>"},"79186":{"type":"graphic_diagnosticimage","displayName":"Classic metaphyseal corner (or bucket handle) fracture","title":"Classic metaphyseal fracture of child abuse (metaphyseal corner or bucket handleÂ fracture)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Classic metaphyseal fracture of child abuse (metaphyseal corner or bucket handle&nbsp;fracture)</div><div class=\"cntnt\"><img style=\"width:362px; height:376px;\" src=\"images/PEDS/79186_Metaphyseal_corner_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Metaphyseal corner fracture of the distal femur (arrows). This classic metaphyseal lesion occurs when the extremity is pulled or twisted, or the child is shaken. The resultant shearing force undercuts an isolated fragment of the metaphysis that includes the subperiosteal bone collar. When viewed tangentially, the lesion appears as a triangular fragment of the metaphysis (ie, the &quot;corner&quot; fracture).</div><div class=\"graphic_reference\">Courtesy of Susan A Scherl, MD.</div><div id=\"graphicVersion\">Graphic 79186 Version 5.0</div></div></div>"},"79187":{"type":"graphic_picture","displayName":"Finger web intertrigo","title":"Candidal intertrigo of the finger web","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Candidal intertrigo of the finger web</div><div class=\"cntnt\"><img style=\"width:339px; height:504px;\" src=\"images/PC/79187_Finger_web_intertrigo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erosio interdigitalis blastomycetica (interdigital candidal infection) in a bartender whose hands were constantly wet. In the acute phase, erosio interdigitalis blastomycetica may have a more macerated appearance.</div><div class=\"graphic_reference\">Reproduced with permission from: Habif T. Clinical Dermatology: A Color Guide to Diagnosis and Therapy, 4th ed, Mosby, New York 2004. Copyright Â© 2004 Elsevier.</div><div id=\"graphicVersion\">Graphic 79187 Version 4.0</div></div></div>"},"79190":{"type":"graphic_figure","displayName":"Major pathways of cortisol metabolism","title":"Major pathways of cortisol metabolism","html":"<div class=\"graphic\"><div style=\"width: 629px\" class=\"figure\"><div class=\"ttl\">Major pathways of cortisol metabolism</div><div class=\"cntnt\"><img style=\"width:609px; height:789px;\" src=\"images/ENDO/79190_Major_pathways_cort_metab.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The major pathways of hepatic metabolism of glucocorticoids involve enzymatic processing by 5Î± and 5Î² reductases, 3Î± hydroxysteroid dehydrogenase, and 20Î± and 20Î² hydroxysteroid dehydrogenases. The tetrahydrocortisols and tetrahydrocortisone are the most abundant urinary glucocorticoid metabolites - comprising, on average, 65 percent of total. The cortols and cortolones account for about 30 percent of total urinary glucocorticoid metabolites.</div><div class=\"graphic_reference\">Created using: NCBI - The PubChem Project. Retreived from: <a href=\"http://pubchem.ncbi.nlm.nih.gov/\" target=\"_blank\">http://pubchem.ncbi.nlm.nih.gov/</a> on March 15, 2011.</div><div id=\"graphicVersion\">Graphic 79190 Version 1.0</div></div></div>"},"79191":{"type":"graphic_picture","displayName":"Facial psoriasis","title":"Psoriasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Psoriasis</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/DERM/79191_Facial_psoriasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On the face, the appearance of psoriasis is often more eczematous than papulosquamous. Most patients with facial psoriasis also&nbsp;have extensive generalized psoriasis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 79191 Version 4.0</div></div></div>"},"79192":{"type":"graphic_picture","displayName":"Paraneoplastic pemphigus multiple lesions","title":"Paraneoplastic pemphigus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Paraneoplastic pemphigus</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/79192_paraneo_pemph_multi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bullae, erosions, and crusts are present on the skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 79192 Version 3.0</div></div></div>"},"79194":{"type":"graphic_table","displayName":"Parenteral rx severe malaria","title":"Parenteral regimens for treatment of severe malaria*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Parenteral regimens for treatment of severe malaria*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">I. Artemisinin derivatives</td> </tr> <tr> <td>Artesunate (preferred)<sup>&#182;</sup></td> <td>Individuals &#8805;20 kg: 2.4 mg/kg intravenously (first dose), followed by 2.4 mg/kg at 12 and 24 hours, followed by 2.4 mg/kg once daily<br /> Individuals &#60;20 kg: 3 mg/kg intravenously (first dose), followed by 3 mg/kg at 12 and 24 hours, followed by 3 mg/kg once daily</td> </tr> <tr> <td>Artemether<sup>&#916;</sup></td> <td>3.2 mg/kg intramuscularly to the anterior thigh (first dose), followed by 1.6 mg/kg intramuscularly once daily</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">II. Quinine or quinidine<sup>&#9674;</sup></td> </tr> <tr> <td>Quinine dihydrochloride<sup>&#916;&#167;</sup></td> <td>16.7 mg base/kg (= 20 mg salt/kg) up to a maximum of 1150 mg base (1400 mg salt) in 5% dextrose loading dose over&nbsp;4 hours, followed by 8.35 mg base/kg (= 10 mg salt/kg) over&nbsp;4 hours at 8- or 12-hour intervals (maximum 1530 mg base/day [2100 mg salt/day]), starting&nbsp;8 hours after the beginning of the loading dose </td> </tr> <tr> <td rowspan=\"2\">Quinidine gluconate<sup>&#165;</sup></td> <td>6.25 mg base/kg (= 10 mg salt/kg) loading dose intravenously (maximum 600 mg salt) in normal saline over&nbsp;1 to&nbsp;2&nbsp;hours, followed by 0.0125 mg base/kg/minute (= 0.02 mg salt/kg/minute) continuous infusion for at least 24 hours</td> </tr> <tr> <td>Alternative: 15 mg base/kg (= 24 mg salt/kg) loading dose intravenously in normal saline over&nbsp;4 hours, followed by 7.5 mg base/kg (= 12 mg salt/kg) infused over&nbsp;4 hours every&nbsp;8 hours, starting&nbsp;8 hours after the beginning of the loading dose</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>PLUS</strong> one of the following:</td> </tr> <tr> <td class=\"indent2\">Doxycycline<sup>&#135;</sup></td> <td> <p>Adults: 100 mg twice daily.</p> <p>Children: 2.2 mg/kg (up to 100 mg) twice daily.</p> <p>Doxycycline may be administered intravenously initially; switch to oral dosing once patient is able to swallow. </p> <p>Treatment course is&nbsp;7 days.</p> </td> </tr> <tr> <td class=\"indent2\">Clindamycin</td> <td> <p>Adults and children: 10 mg base/kg once (maximum 900 mg) followed by 15 mg base/kg per day (maximum 1350 mg) divided into three equal doses.</p> <p>Clindamycin may be administered intravenously initially; switch to oral dosing once patient is able to swallow: 20 mg base/kg/day orally (maximum 1800 mg) divided into three equal doses.</p> <p>Treatment course is&nbsp;7 days.</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Severe malaria is a medical emergency; patients with severe malaria who cannot receive&nbsp;intravenous therapy immediately should receive pre-referral treatment (eg, single dose of artesunate&nbsp;intramuscularly in adults and children â¥6 years or artesunate rectal suppository in children &lt;6 years); refer to the&nbsp;accompanying UpToDate text. Following administration of parenteral therapy (for at least 24 hours and until oral medication can be tolerated), an oral regimen should be administered. (Refer to the UpToDate&nbsp;table summarizing oral regimens for completion of treatment for severe malaria.)<br />Â¶ If&nbsp;intravenous administration is unavailable, artesunate may be administered by&nbsp;intramuscular injection into the anterior thigh. In the United States, intravenous artesunate is not approved by the US Food and Drug Administration (FDA)&nbsp;but is available for emergency use under an investigational protocol by enrollment with the United States&nbsp;Centers for Disease Control and Prevention&nbsp;(CDC). Artesunate is unstable in solution so is dispensed as a dry powder of artesunic acid together with an ampule of diluent (5% sodium bicarbonate solution or sodium phosphate solution as supplied by the CDC). The powder and liquid are mixed to provide a concentration of 10 mg/mL; the artesunate solution should be administered within one hour of preparation. Once the patient has received four doses of intravenous artesunate and is able to swallow, the treatment can be completed with a course of an active oral antimalarial drug based on known susceptibility data.<br />Î Parenteral formulation is not available in the United States.<br />â&nbsp;Important adverse effects include hypoglycemia, QT prolongation, tinnitus, reversible hearing loss, nausea, vomiting, dizziness, and visual disturbances. To avoid cardiotoxicity, a loading dose of quinine/quinidine should not be administered to patients who received mefloquine or other quinine derivatives within the previous 12 hours.<br />Â§&nbsp;Quinine dihydrochloride should be given by rate-controlled intravenous infusion at a maximum rate of 5 mg salt/kg per hour and never by rapid intravenous injection (which can be lethal). Quinine can also be administered via intramuscular injection if intravenous infusions cannot be given: two injections of 10 mg salt/kg quinine dihydrochloride (diluted to 60 mL) should be administered four hours apart. The anterior thigh is preferred over the gluteal region to minimize the risk of sciatic nerve damage.&nbsp;In patients with acute kidney injury or if parenteral therapy is required for more than 48 hours in patients who are not receiving hemodialysis or hemofiltration, the dose of&nbsp;intravenous quinine should be reduced by one-third to one-half (eg, to 10 mg salt/kg every 12 hours or 5 mg salt/kg every 8 hours). Dose adjustments are not necessary for patients receiving hemodialysis or hemofiltration.<br />Â¥&nbsp;In the United States, intravenous quinidine gluconate is available for treatment of severe malaria. Quinidine can cause QT prolongation and should be administered by rate-controlled intravenous infusion with continuous electrocardiographic and hemodynamic monitoring in an intensive care unit. Quinidine may be significantly adsorbed to PVC tubing; tubing length should be minimized to approximately 12 inches.<br />â¡&nbsp;Doxycycline is preferred over other tetracyclines because it does not accumulate in renal failure and has a longer half-life. Tetracycline may be used as an alternative to doxycycline (adult dosing: 250 mg&nbsp;orally four times daily&nbsp;for seven days; pediatric dosing: 6.25 mg/kg&nbsp;[maximum 250 mg] orally every&nbsp;six hours&nbsp;for seven&nbsp;days). Clindamycin is preferred to tetracyclines in pregnancy and children &lt;8 years of age in whom teeth are still developing.</div><div class=\"graphic_reference\">Data from: World Health Organization. Guidelines for the treatment of malaria, 3rd ed, WHO, Geneva 2015. http://www.who.int/malaria/publications/atoz/9789241549127/en/ (Accessed on March 22, 2016).<br />United States Centers for Disease Control guidelines for treatment of malaria http://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf. &nbsp;(Accessed on March 23, 2016.) </div><div id=\"graphicVersion\">Graphic 79194 Version 10.0</div></div></div>"},"79196":{"type":"graphic_diagnosticimage","displayName":"Enteric duplication cyst","title":"Enteric duplication cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Enteric duplication cyst</div><div class=\"cntnt\"><img style=\"width:432px; height:352px;\" src=\"images/PEDS/79196_Enteric_duplication_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance image of an enteric duplication cyst.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 79196 Version 2.0</div></div></div>"},"79197":{"type":"graphic_table","displayName":"WHO discharge criteria","title":"Criteria for discharge from care for malnutrition","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for discharge from care for malnutrition</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Criteria</td> </tr> <tr> <td class=\"subtitle2_single\">Child (6 to 59 months&nbsp;of age)*</td> </tr> <tr> <td class=\"indent1\">Weight-for-height increased&nbsp;to at least 2 SD below&nbsp;WHO median reference values (ie, Z-score &#8805; -2)<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">&nbsp;-- OR --</td> </tr> <tr> <td class=\"indent1\">Mid-upper arm circumference &#8805;12.5 cm<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">No edema for at least 1 to 2&nbsp;weeks</td> </tr> <tr> <td class=\"indent1\">Infections have been empirically treated and other conditions have been or are being addressed, including anemia, diarrhea, intestinal parasitic infections, malaria, tuberculosis, and HIV.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Full immunization program started</td> </tr> <tr> <td class=\"subtitle2_single\">Mother or caretaker</td> </tr> <tr> <td class=\"indent1\">Able and willing to look after the child</td> </tr> <tr> <td class=\"indent1\">Knows how to prepare appropriate foods and to feed the child</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Knows how to give home treatment for diarrhea, fever and acute respiratory infections, and how to recognize the signs that mean she must seek medical assistance</td> </tr> <tr> <td class=\"subtitle2_single\">Health worker</td> </tr> <tr> <td class=\"indent1\">Able to ensure follow-up of the child and support for the mother</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Infants younger than six months of age can be discharged from treatment when they are feeding well on breastmilk or replacement feeds, have adequate weight gain, and have a weight-for-length Z-score â¥ -2, and the caregiver is linked with community-based follow-up and support.<br />Â¶ In general, the anthropometric indicator used to determine nutritional recovery and discharge from a treatment program should be the one that was used for entry into the program. Percentage weight gain is no longer recommended as a criterion for discharge.</div><div class=\"graphic_reference\">Reproduced with permission from: Management of Severe Malnutrition: A Manual for Physicians and other Senior Health Workers. World Health Organization, Geneva, 1999. Copyright &copy; 1999 World Health Organization.<br />Modified based on the World Health Organization Guideline: Updates on the management of severe acute malnutrition in infants and children, 2013.</div><div id=\"graphicVersion\">Graphic 79197 Version 7.0</div></div></div>"},"79198":{"type":"graphic_picture","displayName":"Vitiligo generalized","title":"Generalized vitiligo","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Generalized vitiligo</div><div class=\"cntnt\"><img style=\"width:396px; height:327px;\" src=\"images/PC/79198_Vitiligo_generalized.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient has generalized vitiligo with extensive involvement.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright Â©2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 79198 Version 2.0</div></div></div>"},"79199":{"type":"graphic_diagnosticimage","displayName":"Normal upper airway MRI","title":"Mid-sagittal MRI in a normal subject highlighting the four upper airway regions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mid-sagittal MRI in a normal subject highlighting the four upper airway regions</div><div class=\"cntnt\"><img style=\"width:442px; height:344px;\" src=\"images/PULM/79199_Normal_upper_airway_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Nasopharynx, which is defined from the nasal turbinates to the hard palate; B) retropalatal (RP) oropharynx extending from the hard palate to the caudal margin of the soft palate, C) retroglossal (RG) region from the caudal margin of the soft palate to the base of the epiglottis; and D) hypopharynx, which is defined from the base of the tongue to the larynx.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Richard J Schwab, MD.</div><div id=\"graphicVersion\">Graphic 79199 Version 3.0</div></div></div>"},"79200":{"type":"graphic_picture","displayName":"Punctal occlusion","title":"Punctal occlusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Punctal occlusion</div><div class=\"cntnt\"><img style=\"width:397px; height:264px;\" src=\"images/RHEUM/79200_Punctal_occlusion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Punctal occlusion, in this case with a collagen plug, may be performed easily at the slit lamp. This procedure maximizes tear conservation in patients with severe dry eyes by diminishing tear drainage through the lacrimal puncta.</div><div class=\"graphic_reference\">Courtesy of Reza Dana, MD, MSc, MPH.</div><div id=\"graphicVersion\">Graphic 79200 Version 2.0</div></div></div>"},"79202":{"type":"graphic_table","displayName":"Risk factors for macrosomia","title":"Maternal risk factors for having a macrosomic infant","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Maternal risk factors for having a macrosomic infant</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Maternal obesity</td> </tr> <tr> <td>Multiparity</td> </tr> <tr> <td>Advanced maternal age</td> </tr> <tr> <td>Maternal diabetes</td> </tr> <tr> <td>Post-term pregnancy</td> </tr> <tr> <td>Male infant</td> </tr> <tr> <td>Previous macrosomic infant</td> </tr> <tr> <td>Excessive gestational or interpregnancy weight gain</td> </tr> <tr> <td>Hispanic or African American ethnicity</td> </tr> <tr> <td>Maternal birth weight over 4000 g</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 79202 Version 3.0</div></div></div>"},"79203":{"type":"graphic_figure","displayName":"Generating DNA knockout mice","title":"Generation of target gene for knockout mice","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Generation of target gene for knockout mice</div><div class=\"cntnt\"><img style=\"width:468px; height:283px;\" src=\"images/PC/79203_Generating_DNA_knockout_mic.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic of targeting vector and positive/negative selection. A schematic depicting a targeting vector is shown at the top. Plasmid backbone sequences are shown with thin lines. The herpes simplex virus-thymidine kinase (HSV-TK) box represents the negatively selected marker herpes virus thymidine kinase. The hatched boxes represent sequences present in the target gene. The NEOR box represents the positively selected marker neomycin resistance. When this targeting construct is transfected into (embryonic stem) ES cells, a small fraction of the transfected cells will undergo homologous recombination mediated by the target gene sequences included in the vector. This is shown schematically by the Xs representing crossover points. The location of the transcript of the target gene is shown by the heavy black arrow. A double recombination, as pictured, will substitute the neomycin resistance marker for the native portion of the gene lying between the crossover points. This deletion disrupts the gene, thereby &quot;knocking out&quot; its function. Positive selection is applied by growing the transfected cells in the presence of G418, a toxic drug that is inactivated by NEOR. Negative selection is applied by growing the transfected cells in the presence of gancyclovir, which is converted to a toxin by HSV-TK. Thus, the population is enriched for cells retaining NEOR and simultaneously losing HSV-TK.</div><div class=\"graphic_reference\">Courtesy of Robert D Blank, MD, PhD.</div><div id=\"graphicVersion\">Graphic 79203 Version 1.0</div></div></div>"},"79204":{"type":"graphic_picture","displayName":"Skin biopsy incision technique","title":"Skin biopsy incision parallel to wrinkle lines","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skin biopsy incision parallel to wrinkle lines</div><div class=\"cntnt\"><img style=\"width:378px; height:414px;\" src=\"images/PC/79204_Skinbiopsyincisiontechni.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin tension lines (Langer's lines) can be revealed by compressing the skin. A diamond-shaped or elliptical excision is outlined with its long axis parallel to the wrinkle lines. Incisions performed parallel to tension lines will close more easily and with a better cosmetic result than those performed at right angles to the tension lines.</div><div id=\"graphicVersion\">Graphic 79204 Version 4.0</div></div></div>"},"79205":{"type":"graphic_table","displayName":"Contraindications bronchoscopy","title":"Contraindications to bronchoscopy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contraindications to bronchoscopy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Life-threatening arrhythmia</td> </tr> <tr> <td>Refractory hypoxemia</td> </tr> <tr> <td>Poor ability to cooperate with procedure</td> </tr> <tr> <td>Recent myocardial infarction or unstable angina</td> </tr> <tr> <td>Serum creatinine &#62;3*</td> </tr> <tr> <td>Platelets &#60;50,000*</td> </tr> <tr> <td>Uncorrected coagulopathy*</td> </tr> <tr> <td>Superior vena cava obstruction*<sup>&#182;</sup></td> </tr> <tr> <td>Pulmonary hypertension*</td> </tr> <tr> <td>Unstable neck or cervical spine immobility<sup>&#916;</sup></td> </tr> <tr> <td>Limited motion of temporo-mandibular joint<sup>&#916;</sup></td> </tr> <tr> <td>Pregnancy<sup>&#9674;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Relative contraindication for biopsy, but not inspection.<br />Â¶ Relative risk of bleeding with biopsy in this setting is not well-defined.<br />Î Contraindication to rigid bronchoscopy only.<br /><FONT class=lozenge>â</FONT> Bronchoscopy is possible during pregnancy, however medications must be assessed careful for potential maternal and fetal toxicity.</div><div id=\"graphicVersion\">Graphic 79205 Version 2.0</div></div></div>"},"79209":{"type":"graphic_movie","displayName":"Parasternal long axis echo close up aortic valve vegetation","title":"Parasternal long axis echocardiogram with close-up view showing aortic valve vegetation in patient with endocarditis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Parasternal long axis echocardiogram with close-up view showing aortic valve vegetation in patient with endocarditis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/79209_laxzavenconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:269px; height:395px;\" src=\"images/CARD/79209_laxzaven.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Parasternal long axis view from 2-D echocardiogram with close-up of aortic valve shows large vegetations of both leaflets as a result of bacterial endocarditis.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 79209 Version 4.0</div></div></div>"},"79212":{"type":"graphic_figure","displayName":"Vaginoscopy of a child","title":"Initiating vaginoscopy in a child","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Initiating vaginoscopy in a child</div><div class=\"cntnt\"><img style=\"width:336px; height:396px;\" src=\"images/OBGYN/79212_Vaginoscopy_of_a_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After carefully placing the irrigating endoscope approximately 3 to 4 cm into the vagina, the vulvar tissues are gently pressed against the endoscope, trapping the irrigating fluid in the vagina. At this point, the endoscope is withdrawn to approximately 1 cm from the introitus for full visualization of the vaginal canal.</div><div id=\"graphicVersion\">Graphic 79212 Version 1.0</div></div></div>"},"79214":{"type":"graphic_picture","displayName":"Hands in acromegaly PI","title":"Hands in acromegaly","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hands in acromegaly</div><div class=\"cntnt\"><img style=\"width:360px; height:232px;\" src=\"images/PI/79214_Hands_in_acromegaly_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Swelling of the hands in a patient with acromegaly, which resulted in an increase in glove size and the need to remove rings.</div><div class=\"graphic_reference\">Courtesy of Verna Wright, MD, FRCP.</div><div id=\"graphicVersion\">Graphic 79214 Version 1.0</div></div></div>"},"79215":{"type":"graphic_diagnosticimage","displayName":"Morquio syndrome radiograph of C-spine","title":"Spine radiograph in a patient with mucopolysaccharidosis IV (MPS IV, Morquio syndrome)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spine radiograph in a patient with mucopolysaccharidosis IV (MPS IV, Morquio syndrome)</div><div class=\"cntnt\"><img style=\"width:308px; height:332px;\" src=\"images/PEDS/79215_Mrq_spn_rdgr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiograph of the cervical spine in mucopolysaccharidosis IV (MPS IV, Morquio syndrome). The odontoid is severely hypoplastic (arrow), and there is anterior displacement of C1 on C2 (arrowheads).</div><div class=\"graphic_reference\">Courtesy of Ed Wraith, MD.</div><div id=\"graphicVersion\">Graphic 79215 Version 5.0</div></div></div>"},"79216":{"type":"graphic_figure","displayName":"Malignant calcification pattern","title":"Patterns of malignant calcification","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Patterns of malignant calcification</div><div class=\"cntnt\"><img style=\"width:363px; height:345px;\" src=\"images/PULM/79216_Malignant_calcification_pat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of different patterns of malignant calcification. In clockwise orientation from top left: reticular, psammomatous (punctate), eccentric, and amorphous calcification.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 79216 Version 1.0</div></div></div>"},"79217":{"type":"graphic_table","displayName":"Isolated musculoskeletal chest pain syndromes","title":"Characteristics of isolated musculoskeletal chest pain syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of isolated musculoskeletal chest pain syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Disorder</td>\n<td class=\"subtitle1\">Clinical manifestations</td>\n</tr>\n<tr>\n<td>Costosternal syndromes (costochondritis)</td>\n<td>Multiple areas of tenderness that reproduce the described pain, usually in the upper costal cartilages at the costochondral or costosternal junctions; there is no swelling.</td>\n</tr>\n<tr>\n<td>Tietze's syndrome</td>\n<td>Painful, nonsuppurative localized swelling of the costosternal, sternoclavicular, or costochondral joints, most often involving one joint in the area of the second and third ribs; rare, primarily affects young adults.</td>\n</tr>\n<tr>\n<td>Sternalis syndrome</td>\n<td>Localized tenderness over the body of the sternum or overlying sternalis muscle; palpation often causes radiation of pain bilaterally.</td>\n</tr>\n<tr>\n<td>Xiphoidalgia</td>\n<td>Localized discomfort over the sternum at the xiphoid process.</td>\n</tr>\n<tr>\n<td>Spontaneous sternoclavicular subluxation</td>\n<td>Most often occurs in the dominant side, associated with moderate to heavy repetitive tasks; almost exclusively occurs in middle-aged women.</td>\n</tr>\n<tr>\n<td>Lower rib pain syndromes</td>\n<td>Pain in the lower chest or upper abdomen with a tender spot on the costal margin; pain can be reproduced by pressing on the spot.</td>\n</tr>\n<tr>\n<td>Posterior chest wall syndromes</td>\n<td>May be caused by herniated thoracic disc, leading to band-like chest pain that may have a unilateral dermatomal distribution. Also induced by costovertebral joint dysfunction; tenderness over the affected area, worse with coughing or deep breathing.</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">15.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=71321&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Isolated_chest_pain_syndrom.htm</title></head></div><div id=\"graphicVersion\">Graphic 79217 Version 2.0</div></div></div>"},"79218":{"type":"graphic_figure","displayName":"Dermoscopic asymmetry","title":"The concept of asymmetry in dermoscopy","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">The concept of asymmetry in dermoscopy</div><div class=\"cntnt\"><img style=\"width:550px; height:313px;\" src=\"images/DERM/79218_Dermoscopic_asymmetry.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Asymmetry refers to the distribution of colors and structures within the lesion in one or two perpendicular axes. The lesion on the left is asymmetrical; the lesion on the right is symmetrical, despite its irregular contour.</div><div class=\"graphic_reference\">Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 79218 Version 3.0</div></div></div>"},"79221":{"type":"graphic_picture","displayName":"Dissecting instrument","title":"Laparoscopic instrument for tissue dissection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laparoscopic instrument for tissue dissection</div><div class=\"cntnt\"><img style=\"width:439px; height:233px;\" src=\"images/OBGYN/79221_Dissecting_instrument.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 79221 Version 1.0</div></div></div>"},"79226":{"type":"graphic_picture","displayName":"Bladder endometriosis with anterior adhesions","title":"Bladder endometriosis: Laparoscopic view of obliteration of the vesicouterine space","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bladder endometriosis: Laparoscopic view of obliteration of the vesicouterine space</div><div class=\"cntnt\"><img style=\"width:432px; height:346px;\" src=\"images/OBGYN/79226_Bladder_endo_ant_adhesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Laparoscopic view of an obliterated vesicouterine space due to bladder endometriosis.</div><div id=\"graphicVersion\">Graphic 79226 Version 1.0</div></div></div>"},"79227":{"type":"graphic_figure","displayName":"Potential spaces for abscess formation on the dorsum of the hand","title":"Potential spaces for abscess formation on the dorsum of the hand","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">Potential spaces for abscess formation on the dorsum of the hand</div><div class=\"cntnt\"><img style=\"width:562px; height:431px;\" src=\"images/SURG/79227_Poten_spaces_abscess_form.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The dorsal skin of the hand is loosely anchored to the underlying tissue, allowing the spread of infection into two potential spaces: the dorsal subcutaneous space, which is superficial to the extensor tendons, and the dorsal subaponeurotic space, which is deep to the extensor tendons. </div><div id=\"graphicVersion\">Graphic 79227 Version 2.0</div></div></div>"},"79228":{"type":"graphic_diagnosticimage","displayName":"Ascariasis - abdominal film 1","title":"Ascariasis - abdominal film 1","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ascariasis - abdominal film 1</div><div class=\"cntnt\"><img style=\"width:255px; height:353px;\" src=\"images/ID/79228_Ascariasis_abdominal_film_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><EM>Ascaris</EM>-induced intestinal obstruction. Radiograph of abdomen of the patient with three days' history of abdominal pain, distension, and abdominal tenderness. The radiograph revealed evidence of dilated bowel loop with multiple parallel echogenic structures (aggregated worms).</div><div class=\"graphic_reference\">Reproduced from: Khuroo MS. Ascariasis. Gastroenterol Clin North Am 1996; 25:553. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 79228 Version 4.0</div></div></div>"},"79230":{"type":"graphic_figure","displayName":"Structure of penicillins and related beta-lactam drugs","title":"Structure of penicillins and related beta-lactam drugs","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Structure of penicillins and related beta-lactam drugs</div><div class=\"cntnt\"><img style=\"width:500px; height:356px;\" src=\"images/ALLRG/79230_Struc_pen_beta_lactam_drugs.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Structure of the beta-lactam antibiotics. Arrows point to the beta-lactam rings.</div><div class=\"graphic_footnotes\">R: side chain group.</div><div id=\"graphicVersion\">Graphic 79230 Version 9.0</div></div></div>"},"79231":{"type":"graphic_figure","displayName":"TMLR  improves left ventricular myocardial perfusion","title":"Transmyocardial laser revascularization improves left ventricular myocardial perfusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transmyocardial laser revascularization improves left ventricular myocardial perfusion</div><div class=\"cntnt\"><img style=\"width:382px; height:329px;\" src=\"images/CARD/79231_TMLR_myocardial_perfusion.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The percentage change in myocardial perfusion is calculated as the number of defects at baseline minus the number of defects at follow-up, divided by the number of defects at baseline. Myocardial perfusion improved with transmyocardial laser revascularization (TMLR) but worsened with medical therapy; the percent change in myocardial perfusion differed significantly at each point in time of evaluation (p = 0.001 at three&nbsp;months, p = 0.02 at&nbsp;six months, and p = 0.002 at 12 months). At one year, myocardial perfusion improved by 20 percent in patients undergoing TMLR while is worsened by 27 percent in the medical treatment group.</div><div class=\"graphic_reference\">Data from Frazier OH, March RJ, Horvath KA. N Engl J Med 1999; 341:1021.</div><div id=\"graphicVersion\">Graphic 79231 Version 3.0</div></div></div>"},"79232":{"type":"graphic_figure","displayName":"Central line IJ anatomy","title":"External landmarks for the central venous catheter placement in the internal jugular vein","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">External landmarks for the central venous catheter placement in the internal jugular vein</div><div class=\"cntnt\"><img style=\"width:434px; height:577px;\" src=\"images/EM/79232_Central_line_IJ_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">UpToDate acknowledges the invaluable assistance of the University of Massacusetts Medical School, Department of Anatomy and Department of Emergency Medicine, including Thomas Ellis, MD and Jean Marcelin, MD, for the photographs of central venous catheter placement.</div><div id=\"graphicVersion\">Graphic 79232 Version 5.0</div></div></div>"},"79234":{"type":"graphic_figure","displayName":"ARF advancement flap","title":"Advancement flap for coverage of an anorectal fistula","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Advancement flap for coverage of an anorectal fistula</div><div class=\"cntnt\"><img style=\"width:541px; height:324px;\" src=\"images/SURG/79234_ARFAdvancementflap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a schematic diagram of&nbsp;creating an advancement&nbsp;mucosal flap. A probe is inserted from the external opening of the fistula to the internal opening. The fistulous tract is curetted and debrided.&nbsp;The flap includes mucosa, submucosa, and a portion of the sphincter muscle fibers and is advanced to cover the internal primary opening. The lateral view shows the fistulous tract and the&nbsp;components of the advancement flap.</div><div id=\"graphicVersion\">Graphic 79234 Version 8.0</div></div></div>"},"79235":{"type":"graphic_picture","displayName":"Inky cap mushroom","title":"Inky cap mushroom (\"Coprinus plicatillis\")","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inky cap mushroom (&quot;Coprinus plicatillis&quot;)</div><div class=\"cntnt\"><img style=\"width:432px; height:328px;\" src=\"images/EM/79235_Inky_cap_mushroom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This mushroom, which is similar to <em>Coprinus atramentarius</em>, causes a disulfiram-like reaction because of the inhibition of aldehyde dehydrogenase by the toxin, coprine. The onset of effects (eg, flushing, headache, tachycardia, chest pain, anxiety) typically occurs when ethanol is consumed after mushroom ingestion. Even remote ethanol consumption (up to seven days after mushroom ingestion) may produce toxicity.</div><div class=\"graphic_reference\">Courtesy of Paul Dengler. Identification by William Hollenbaugh.</div><div id=\"graphicVersion\">Graphic 79235 Version 2.0</div></div></div>"},"79236":{"type":"graphic_figure","displayName":"Male perineum muscles","title":"Muscles of the male perineum","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Muscles of the male perineum</div><div class=\"cntnt\"><img style=\"width:536px; height:437px;\" src=\"images/SURG/79236_Male-perineum-muscles.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure illustrates the muscles and fascia of the male perineum. Note the anococcygeal raphe, the levator ani (iliococcygeus) muscles, the deep and superficial transverse perineal muscles.</div><div id=\"graphicVersion\">Graphic 79236 Version 2.0</div></div></div>"},"79240":{"type":"graphic_figure","displayName":"Bone fractures post heart transplant","title":"Fractures occur early after cardiac transplantation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fractures occur early after cardiac transplantation</div><div class=\"cntnt\"><img style=\"width:424px; height:299px;\" src=\"images/ENDO/79240_Bone_fx_post_heart_transpla.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Time to first bone fracture in men and postmenopausal women who sustained a fracture after cardiac transplantation. Fracture occurred in 36 percent of all patients and 54 percent of women; 85 percent of the fractures occurred within the first six months.</div><div class=\"graphic_reference\">Data from: Shane E, Rivas M, Staron RB, et al. Fracture after cardiac transplantation: a prospective longitudinal study.&nbsp;J Clin Endocrinol Metab 1996; 81:1740.</div><div id=\"graphicVersion\">Graphic 79240 Version 2.0</div></div></div>"},"79242":{"type":"graphic_picture","displayName":"Hives PI","title":"Hives","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hives</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/PI/79242_New_onset_urt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hives are raised, red patches of skin that are usually very itchy. They usually come and go within a few hours, but they can show up again and again in some people.</div><div class=\"graphic_reference\">Courtesy of Andrew Samel, MD.</div><div id=\"graphicVersion\">Graphic 79242 Version 6.0</div></div></div>"},"79243":{"type":"graphic_picture","displayName":"Sweet syndrome facial lesion","title":"Sweet syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sweet syndrome</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/79243_Sweets_syndr_facial_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A brightly erythematous plaque with a pustular component is present on the face of this patient with Sweet syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 79243 Version 5.0</div></div></div>"},"79244":{"type":"graphic_diagnosticimage","displayName":"Pseudoaneurysm of the splenic artery","title":"Pseudoaneurysm of the splenic artery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pseudoaneurysm of the splenic artery</div><div class=\"cntnt\"><img style=\"width:432px; height:318px;\" src=\"images/SURG/79244_Pseudoaneurysm_splen_art.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pseudoaneurysm of the splenic artery seen on contrast enhanced CT scan showing outline of contained pseudoaneurysm (arrows) and internal contrast blush (star).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Thomas J Howard, MD, FACS.</div><div id=\"graphicVersion\">Graphic 79244 Version 7.0</div></div></div>"},"79245":{"type":"graphic_table","displayName":"Preparation of rectal formulations of thionamides","title":"Preparation of rectal formulations of thionamides","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Preparation of rectal formulations of thionamides</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Methimazole</td> </tr> <tr> <td class=\"indent1\">Suppository</td> <td>Dissolve 1200 mg methimazole in 12 mL of water and add to 52 mL cocoa butter containing two drops of polysorbate (Span) 80. Stir mixture to form an emulsion and pour into 2.6 mL suppository molds to cool.<sup>[1]</sup></td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Propylthiouracil</td> </tr> <tr> <td class=\"indent1\">Suppository</td> <td>Dissolve 200 mg of propylthiouracil in a polyethylene glycol base and put into suppository tablets</td> </tr> <tr> <td class=\"indent1\">Retention enema</td> <td> <p>Dissolve eight to twelve 50 mg tablets of propylthiouracil in 90 mL of sterile water</p> <p><strong>OR</strong></p> <p>Dissolve eight 50 mg tablets of propylthiouracil in 60 mL of mineral oil enema (eg, Fleet mineral oil) or in 60 mL of sodium phosphates enema solution* (eg, Fleet enema phospho soda)<sup>[2]</sup></p> For either enema preparation: Administer by Foley catheter inserted into the rectum, with balloon inflated to prevent leakage for two hour retention</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Additional information on preparation described in:&#xD;&#xA;<ul class=\"decimal_heading\">&#xD;&#xA;    <li>Nayak B, Burman K. Thyrotoxicosis and thyroid storm. Endocrinol Metab Clin North Am 2006; 35:663. </li>&#xD;&#xA;    <li>Yeung SC, Go R, Balasubramanyam A. Rectal administration of iodide and propylthiouracil in the treatment of thyroid storm. Thyroid 1995; 5:403. </li>&#xD;&#xA;    <li>Jongjaroenprasert W, Akarawut W, Chantasart D, et al. Rectal administration of propylthiouracil in hyperthyroid patients: comparison of suspension enema and suppository form. Thyroid 2002; 12:627.</li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">* Avoid phosphate containing rectal preparations in patients with renal insufficiency or heart failure.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Nabil N, Miner DJ, Amatruda JM. Methimazole: an alternative route of administration. J Clin Endocrinol Metab 1982; 54:180. </li>&#xD;&#xA;    <li>Walter RM Jr, Bartle WR. Rectal administration of propylthiouracil in the treatment of Graves' disease. Am J Med 1990; 88:69.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 79245 Version 6.0</div></div></div>"},"79248":{"type":"graphic_figure","displayName":"LV diastolic pressure volume relationship 1","title":"Left ventricular diastolic pressure/volume relationships","html":"<div class=\"graphic\"><div style=\"width: 676px\" class=\"figure\"><div class=\"ttl\">Left ventricular diastolic pressure/volume relationships</div><div class=\"cntnt\"><img style=\"width:656px; height:370px;\" src=\"images/CARD/79248_LV_press_vol_relation_edit2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left ventricular (LV) pressure/volume relationships at rest and during exercise at early-, mid-, and end-diastole are shown. The simultaneous measurements of LV diastolic pressure and volume define distensibility or compliance. In the normal individual with normal compliance (left panel), exercise causes a downward shift of the diastolic pressure/volume curve in early diastole, indicating an increase in LV distensibility; the increase in cardiac output occurs without an increase in LV diastolic pressure. In a patient with ischemia (middle panel), exercise causes a marked upward shift in the curve, indicating a reduction in LV distensibility, or diastolic dysfunction, and there is a significant increase in LV and pulmonary capillary wedge pressures as LV volume or cardiac output increases. This may result in the development of pulmonary congestion and respiratory symptoms.</div><div class=\"graphic_reference\">Panels 1 and 2: Data from: Carroll JD, Hess OM, Hirzel HO, et al. Dynamics of left ventricular filling at rest and during exercise. Circulation 1983; 68:59.<br />Panel 3: Reproduced with permission from: Borlaug BA, Jaber WA, Ommen SR, et al. Diastolic relaxation and compliance reserve during dynamic exercise in heart failure with preserved ejection fraction. Heart 2011; 97:964. Copyright Â© 2011 BMJ Publishing Group Ltd.</div><div id=\"graphicVersion\">Graphic 79248 Version 7.0</div></div></div>"},"79251":{"type":"graphic_diagnosticimage","displayName":"Dorsal sinus tract","title":"MRI demonstrating a dorsal sinus tract","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI demonstrating a dorsal sinus tract</div><div class=\"cntnt\"><img style=\"width:301px; height:554px;\" src=\"images/PEDS/79251_Dorsal_sinus_tract.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T2 sagittal magnetic resonance imaging (MRI) showing a dorsal sinus tract (arrow).</div><div class=\"graphic_reference\">Courtesy of Chaouki El-Khoury, BS, MD.</div><div id=\"graphicVersion\">Graphic 79251 Version 3.0</div></div></div>"},"79252":{"type":"graphic_picture","displayName":"Tympanostomy tube placement","title":"Tympanostomy tube placement","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Tympanostomy tube placement</div><div class=\"cntnt\"><img style=\"width:504px; height:333px;\" src=\"images/PEDS/79252_Tympanostomy_tube_placement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">1) Otitis media with effusion, 2) anterior incision of the drum, 3) aspiration of effusion, 4) tube inserted with cuff forceps, 5) completed tube placement.</div><div class=\"graphic_reference\">Courtesty of Glenn C Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 79252 Version 1.0</div></div></div>"},"79253":{"type":"graphic_figure","displayName":"RV and late asthmatic reaction","title":"Rhinovirus and late asthmatic reaction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rhinovirus and late asthmatic reaction</div><div class=\"cntnt\"><img style=\"width:450px; height:524px;\" src=\"images/PULM/79253_RV_and_late_asthmatic_react.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A comparison of FEV<sub>1</sub> response with inhaled ragweed in patients without (left column) and with (right column) LAR at baseline (upper panel) during acute rhinovirus URI (middle panel) and after recovery (lower panel). Only 1 of 10 patients had an LAR at baseline versus 8 of 10 during acute URI (middle panel).</div><div class=\"graphic_footnotes\">FEV<sub>1</sub>: forced expiratory volume at one second; LAR: late asthmatic reaction; URI: upper respiratory infection.</div><div class=\"graphic_reference\">Redrawn from: Lemanske RF, Dick EC, Swenson CA, et al. Rhinovirus upper respiratory infection increases airway hyperreactivity and late asthmatic reactions. J Clin Invest 1989; 83:1.</div><div id=\"graphicVersion\">Graphic 79253 Version 4.0</div></div></div>"},"79254":{"type":"graphic_table","displayName":"Classification of juvenile localized scleroderma","title":"Classification of juvenile localized scleroderma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of juvenile localized scleroderma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Main group</td> <td class=\"subtitle1\">Subtype</td> <td class=\"subtitle1\">Description</td> </tr> <tr> <td rowspan=\"2\">(1) Circumscribed morphea</td> <td>(a) Superficial</td> <td>Oval or round circumscribed areas of induration limited to epidermis and dermis, often with altered pigmentation and violaceous, erythematous halo (lilac ring). They can be single or multiple.</td> </tr> <tr> <td>(b) Deep</td> <td>Oval or round circumscribed deep induration of the skin involving subcutaneous tissue extending to fascia and may involve underlying muscle. The lesions can be single or multiple. Sometimes the primary site of involvement is in the subcutaneous tissue without involvement of the skin.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">(2) Linear scleroderma</td> <td>(a) Trunk/limbs</td> <td>Linear induration involving dermis, subcutaneous tissue and, sometimes, muscle and underlying bone and affecting the limbs and the trunk.</td> </tr> <tr> <td rowspan=\"2\">(b) Head</td> <td><em>En coup de sabre</em> (ECDS). Linear induration that affects the face and the scalp and sometimes involves muscle and underlying bone.</td> </tr> <tr> <td>Parry Romberg or progressive hemifacial atrophy loss of tissue on one side of the face that may involve dermis, subcutaneous tissue, muscle, and bone. The skin is mobile.</td> </tr> <tr class=\"divider_top\"> <td>(3) Generalized morphea</td> <td>&nbsp;</td> <td>Induration of the skin starting as individual plaques (four or more and larger than 3 cm) that become confluent and involve at least two out of seven anatomic sites (head-neck, right upper extremity, left upper extremity, right lower extremity, left lower extremity, anterior trunk, posterior trunk).</td> </tr> <tr class=\"divider_top\"> <td>(4) Panclerotic morphea</td> <td>&nbsp;</td> <td>Circumferential involvement of limb(s) affecting the skin, subcutaneous tissue, muscle, and bone. The lesion may also involve other areas of the body without internal organs involvement.</td> </tr> <tr class=\"divider_top\"> <td>(5) Mixed morphea</td> <td>&nbsp;</td> <td>Combination of two or more of the previous subtypes. The order of the concomitant subtypes, specified in brackets, will follow their predominant representation in the individual patient (ie, mixed morphea [linear-circumscribed]).</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Associated conditions: lichen sclerosus et atrophicus (LSA) and atrophoderma of Pasini and Pierini (APP) can be associated with the previous subtypes but are not included in the above classification. Source: Consensus conference, Padua, Italy, 2004.</div><div class=\"graphic_reference\">Reproduced with permission from: Laxer RM, Zulian F. Localized scleroderma. Curr Opin Rheumatol 2006; 18:606. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 79254 Version 8.0</div></div></div>"},"79255":{"type":"graphic_diagnosticimage","displayName":"Chagas heart disease Angio","title":"Chronic Chagas' heart disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic Chagas' heart disease</div><div class=\"cntnt\"><img style=\"width:309px; height:363px;\" src=\"images/CARD/79255_Chagas_heart_disease_Angio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronary angiography and left ventriculography from a patient with chronic Chagas' disease complaining of chest pain. Myocardial perfusion imaging showed a large defect involving the anterolateral, apical, and posterolateral walls. Coronary angiography (upper panel) demonstarted normal right and left coronary arteries. However, the left ventriculogram in the right anterior oblique (RAO, middle panel) and left anterior oblique (LAO, bottom panel) views show normal global left ventricular function but mild hypokinesis of the anterolateral, apical, and posterolateral walls (arrows).</div><div id=\"graphicVersion\">Graphic 79255 Version 3.0</div></div></div>"},"79256":{"type":"graphic_figure","displayName":"Roux en Y gastric bypass","title":"Roux-en-Y gastric bypass","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Roux-en-Y gastric bypass</div><div class=\"cntnt\"><img style=\"width:422px; height:572px;\" src=\"images/GAST/79256_Roux_en_Y_gastric_bypass.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the stomach's appearance after Roux-en-Y gastric bypass, which creates a small stomach pouch by dividing the stomach and attaching it to the small intestine. The pouch is only able to hold about an ounce of food, causing a feeling of fullness after consuming a very small amount; over time, the pouch stretches to hold about one cup. In addition, the body absorbs fewer calories since food bypasses the majority of the stomach as well as the upper small intestine (duodenum). This intestinal arrangement (Roux-en-Y) seems to cause decreased appetite and improved metabolism by changing the release of various hormones.</div><div id=\"graphicVersion\">Graphic 79256 Version 4.0</div></div></div>"},"79257":{"type":"graphic_diagnosticimage","displayName":"Clubfoot1","title":"Clubfoot","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Clubfoot</div><div class=\"cntnt\"><img style=\"width:396px; height:257px;\" src=\"images/OBGYN/79257_Clubfoot1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The plantar surface of the entire fetal right foot can be seen in the same plane as the fibula and tibia.</div><div class=\"graphic_reference\">Courtesy of Urania Magriples, MD.</div><div id=\"graphicVersion\">Graphic 79257 Version 2.0</div></div></div>"},"79258":{"type":"graphic_picture","displayName":"Nodular basal cell carcinoma pathology 20x","title":"Nodular basal cell carcinoma (20x)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nodular basal cell carcinoma (20x)</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/ONC/79258_Nodular_BCC_20x.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Gary Goldenberg, MD.</div><div id=\"graphicVersion\">Graphic 79258 Version 3.0</div></div></div>"},"79259":{"type":"graphic_table","displayName":"Sonographic findings ovarian CA","title":"Sonographic findings suggestive of malignancy in patients with a pelvic mass","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sonographic findings suggestive of malignancy in patients with a pelvic mass</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Solid component that is not hyperechoic and is often nodular or papillary</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Septations, if present, that are thick (&#62;2 to 3 mm)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Color or power Doppler demonstration of flow in the solid component</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"1\">Presence of ascites (any peritoneal fluid in postpostmenopausal women and more than a small amount of peritoneal fluid in premenopausal women is abnormal)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Peritoneal masses, enlarged nodes, or matted bowel (may be difficult to detect)</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 79259 Version 1.0</div></div></div>"},"79261":{"type":"graphic_picture","displayName":"Disk diffusion antimicrobial susceptibility testing, Kirby-Bauer","title":"Disk diffusion antimicrobial susceptibility testing (Kirby-Bauer procedure)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Disk diffusion antimicrobial susceptibility testing (Kirby-Bauer procedure)</div><div class=\"cntnt\"><img style=\"width:328px; height:313px;\" src=\"images/ID/79261_Kirby-Bauer_susceptibility.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The susceptibility of a bacterial isolate to antimicrobials is determined by measuring the diameter of the zone of growth inhibition (in millimeters) around each of the antibiotic-impregnated disks. The zone sizes are then classified as susceptible, intermediate, or resistant based on breakpoint tables published by the Clinical and Laboratory Standards Institute&nbsp;(CLSI), the European Committee on Antimicrobial Susceptibility Testing&nbsp;(EUCAST), or the United States Food and Drug Administration&nbsp;(FDA).</div><div class=\"graphic_reference\">Courtesy of Mary Jane Ferraro, PhD, MPH.</div><div id=\"graphicVersion\">Graphic 79261 Version 4.0</div></div></div>"},"79262":{"type":"graphic_figure","displayName":"Zoster and PHN by age","title":"Rates* of zoster and postherpetic neuralgia (PHN)â¢, by age - United States","html":"<div class=\"graphic\"><div style=\"width: 515px\" class=\"figure\"><div class=\"ttl\">Rates* of zoster and postherpetic neuralgia (PHN)&#8226;, by age - United States</div><div class=\"cntnt\"><img style=\"width:495px; height:362px;\" src=\"images/ID/79262_Zoster_and_PHN_by_age.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Per 1000 person-years.<br>&#8226; Defined as &#8805;30 days of pain.</div><div class=\"graphic_reference\">Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of Herpes Zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57:1.</div><div id=\"graphicVersion\">Graphic 79262 Version 2.0</div></div></div>"},"79263":{"type":"graphic_table","displayName":"Hemoperfusion devices","title":"Available hemoperfusion devices","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Available hemoperfusion devices</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Manufacturer</td> <td class=\"subtitle1\">Device</td> <td class=\"subtitle1\">Sorbent type</td> <td class=\"subtitle1\">Amount of sorbent</td> <td class=\"subtitle1\">Polymer coating</td> </tr> <tr> <td>Asahi</td> <td>Hemosorba</td> <td>Spherical charcoal</td> <td>170 g</td> <td>Polyhema</td> </tr> <tr> <td>Gambro</td> <td>Adsorba</td> <td>Norit charcoal</td> <td>100 or 300 g</td> <td>Cellulose acetate</td> </tr> <tr> <td>Toray Industries</td> <td>Toraymyxin*</td> <td>Toraymycin</td> <td>?</td> <td>None</td> </tr> <tr> <td>Cytosorbents</td> <td>Cytosorb*</td> <td>Polystyrene divinylbenzene copolymer</td> <td>300 g</td> <td>None&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*Only in Europe or Japan.</div><div id=\"graphicVersion\">Graphic 79263 Version 4.0</div></div></div>"},"79264":{"type":"graphic_table","displayName":"OTC fiber supplements PI","title":"Over-the-counter fiber supplements","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Over-the-counter fiber supplements</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Product </td> <td class=\"subtitle1\">Amount </td> <td class=\"subtitle1\">Frequency </td> </tr> <tr> <td rowspan=\"3\">Metamucil </td> <td>12 years and over: 1 teaspoon or 1 tablespoon, depending on concentration and formulation</td> <td rowspan=\"3\">1 to 3 times daily </td> </tr> <tr> <td>6 to 12 years: 1/2 to 1 teaspoon or 1/2 tablespoon, depending on concentration and formulation</td> </tr> <tr> <td>Under age 6: 1/4 to 1/2 teaspoon</td> </tr> <tr> <td rowspan=\"3\">Benefiber </td> <td>12 years and over: 1 to 2 tablespoons</td> <td rowspan=\"3\">1 to 3 times daily </td> </tr> <tr> <td>7 to 11 years: 1/2 to 1 tablespoon</td> </tr> <tr> <td>Under age 7: 1/4 to 1/2 tablespoon</td> </tr> <tr> <td rowspan=\"3\">Citrucel </td> <td>12 years and over: 1 rounded tablespoon</td> <td rowspan=\"3\">1 to 3 times daily </td> </tr> <tr> <td>6 to 12 years: 1/2 tablespoon</td> </tr> <tr> <td>Under age 6: 1/4 to 1/2 tablespoon</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 79264 Version 2.0</div></div></div>"},"79266":{"type":"graphic_picture","displayName":"Neonate knee dislocation","title":"Neonate knee dislocation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Neonate knee dislocation</div><div class=\"cntnt\"><img style=\"width:368px; height:432px;\" src=\"images/PEDS/79266_Neonate_knee_dislocation.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Gerardo Cabrera-Meza, MD.</div><div id=\"graphicVersion\">Graphic 79266 Version 2.0</div></div></div>"},"79269":{"type":"graphic_picture","displayName":"Mini radial probe","title":"Endobronchial ultrasound (EBUS) mini radial probe","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endobronchial ultrasound (EBUS) mini radial probe</div><div class=\"cntnt\"><img style=\"width:428px; height:508px;\" src=\"images/PULM/79269_Mini_radial_probe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) A 20 MHz miniaturized radial probe in the 2.8 mm working channel of a flexible bronchoscope. B) The balloon sheath that surrounds the miniaturized radial probe is inflated with water.</div><div id=\"graphicVersion\">Graphic 79269 Version 3.0</div></div></div>"},"79270":{"type":"graphic_diagnosticimage","displayName":"Chest radiograph with rupture of the left hemidiaphragm","title":"Chest radiograph with rupture of the left hemidiaphragm","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Chest radiograph with rupture of the left hemidiaphragm</div><div class=\"cntnt\"><img style=\"width:453px; height:434px;\" src=\"images/SURG/79270_Chest_radio_rupt_left_hemi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain antero-posterior radiograph of the chest in a patient with rupture of the left hemidiaphragm following motor vehicle accident. The stomach is located in the chest (arrow A) and can be identified from the abnormal location of the nasogastric tube (arrow B).</div><div id=\"graphicVersion\">Graphic 79270 Version 3.0</div></div></div>"},"79271":{"type":"graphic_figure","displayName":"B12 and folate in DNA synthesis","title":"Effects of cobalamin and folic acid on DNA synthesis","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Effects of cobalamin and folic acid on DNA synthesis</div><div class=\"cntnt\"><img style=\"width:564px; height:394px;\" src=\"images/HEME/79271_B12_and_folate_in_DNA_synth.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Interdependent cofactor activity of cobalamin and folate in intracellular DNA synthesis and metabolism. The + signs indicate enhancement, and the - signs indicate inhibition. Demethylation of methyl-tetrahydrofolate (CH3-THF) to THF is a critical step in DNA synthesis because THF is the substrate for the enzyme that converts (THF)-1 to the polyglutamated form (THF)n. Only polyglutamated (THF)n participates in purine synthesis.</div><div class=\"graphic_footnotes\">CH3-THF: methyl-tetrahydrofolate.&nbsp;</div><div class=\"graphic_reference\">Reproduced with permission from Tefferi, A, Pruthi, RK. The Biochemical Basis of Cobalamin Deficiency. Mayo Clin Proc 1994; 69:181</div><div id=\"graphicVersion\">Graphic 79271 Version 3.0</div></div></div>"},"79274":{"type":"graphic_picture","displayName":"Inverse psoriasis","title":"Inverse psoriasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inverse psoriasis</div><div class=\"cntnt\"><img style=\"width:217px; height:145px;\" src=\"images/PC/79274_Inverse_psoriasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inverse psoriasis of the axilla (armpit) is characterized by erythema without visible scaling.</div><div class=\"graphic_reference\">Courtesy of James C Shaw, MD.</div><div id=\"graphicVersion\">Graphic 79274 Version 2.0</div></div></div>"},"79276":{"type":"graphic_picture","displayName":"Thymic carcinoma Low","title":"Poorly differentiated thymic carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Poorly differentiated thymic carcinoma</div><div class=\"cntnt\"><img style=\"width:360px; height:235px;\" src=\"images/PULM/79276_Thymic_carcinoma_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph shows cystic changes within a thymic carcinoma. The cysts are filled with pale eosinophilic secretions and are reminiscent of an acquired multilocular thymic cyst. (Hematoxylin and eosin, magnification 2.5x).</div><div class=\"graphic_reference\">Courtesy of William Travis, MD.</div><div id=\"graphicVersion\">Graphic 79276 Version 1.0</div></div></div>"},"79278":{"type":"graphic_diagnosticimage","displayName":"Thoracic aortic aneurysm plain chest radiograph","title":"Thoracic aortic aneurysm plain chest radiograph","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thoracic aortic aneurysm plain chest radiograph</div><div class=\"cntnt\"><img style=\"width:365px; height:294px;\" src=\"images/CARD/79278_Aortic_arch_aneurysm_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thoracic aortic aneurysm on chest radiograph. The plain frontal chest radiograph demonstrates marked aneurysmal dilatation of the entire arch of the aorta (arrows). Patency of the aorta or dissection within the lumen cannot be inferred from the plain film and contrast or echocardiographic studies are required to make this distinction.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 79278 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"79279":{"type":"graphic_table","displayName":"Stress fracture risk factors","title":"Risk factors for stress fractures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for stress fractures</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Established&nbsp;risk factors</td> </tr> <tr> <td>Prior stress fracture</td> </tr> <tr> <td>Poor bone health (osteopenia and osteoporosis)</td> </tr> <tr> <td>Substantial increase in intensity&nbsp;or volume of activity (eg, military&nbsp;boot camp)</td> </tr> <tr> <td>Decreased physical fitness (poor muscle strength or endurance)</td> </tr> <tr> <td>Dietary disorders (eg,&nbsp;insufficient calcium intake, vitamin D deficiency,&nbsp;eating disorders)</td> </tr> <tr> <td>Family history of osteopenia or osteoporosis</td> </tr> <tr> <td>Poor running biomechanics</td> </tr> <tr> <td>Female gender</td> </tr> <tr> <td>Menstrual irregularity in females</td> </tr> <tr> <td>Low body mass index&nbsp;</td> </tr> <tr> <td>Prolonged glucocorticoid use</td> </tr> <tr> <td>Older&nbsp;age&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\">Factors of uncertain risk</td> </tr> <tr> <td>Shoe type; Worn-out shoes</td> </tr> <tr> <td>Running surface</td> </tr> <tr> <td>Foot anatomy (eg, extreme high arch)</td> </tr> <tr> <td>Muscle inflexibility</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 79279 Version 2.0</div></div></div>"},"79282":{"type":"graphic_table","displayName":"Staging cervical cancer","title":"Staging cervical cancer (TNM and International Federation of Gynecology and Obstetrics [FIGO])","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Staging cervical cancer (TNM and International Federation of Gynecology and Obstetrics [FIGO])</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr> <td class=\"subtitle2\">TNM categories</td> <td class=\"subtitle2\">FIGO stages</td> <td class=\"subtitle2\" colspan=\"2\">Definition</td> </tr> <tr> <td>TX</td> <td>&nbsp;</td> <td colspan=\"2\">Primary tumor cannot be assessed</td> </tr> <tr> <td>T0</td> <td>&nbsp;</td> <td colspan=\"2\">No evidence of primary tumor</td> </tr> <tr> <td>Tis*</td> <td>&nbsp;</td> <td colspan=\"2\">Carcinoma in situ (preinvasive carcinoma)</td> </tr> <tr> <td class=\"sublist1_start\">T1</td> <td class=\"sublist_other_start\">I</td> <td class=\"sublist_other_start\" colspan=\"2\">Cervical carcinoma confined to uterus (extension to corpus should be disregarded)</td> </tr> <tr> <td class=\"sublist1\">T1a<sup>&#182;</sup></td> <td class=\"sublist_other\">IA</td> <td class=\"sublist_other\" colspan=\"2\">Invasive carcinoma diagnosed only by microscopy. Stromal invasion with a maximum depth of 5.0 mm measured from the base of the epithelium and a horizontal spread of 7.0 mm or less. Vascular space involvement, venous or lymphatic, does not affect classification.</td> </tr> <tr> <td class=\"sublist2\">T1a1</td> <td class=\"sublist_other\">IA1</td> <td class=\"sublist_other\" colspan=\"2\">Measured stromal invasion 3.0 mm or less in depth and 7.0 mm or less in horizontal spread</td> </tr> <tr> <td class=\"sublist2\">T1a2</td> <td class=\"sublist_other\">IA2</td> <td class=\"sublist_other\" colspan=\"2\">Measured stromal invasion more than 3.0 mm and not more than 5.0 mm in depth with a horizontal spread 7.0 mm or less</td> </tr> <tr> <td class=\"sublist1\">T1b</td> <td class=\"sublist_other\">IB</td> <td class=\"sublist_other\" colspan=\"2\">Clinically visible lesion confined to the cervix or microscopic lesion greater than T1a/IA2</td> </tr> <tr> <td class=\"sublist2\">T1b1</td> <td class=\"sublist_other\">IB1</td> <td class=\"sublist_other\" colspan=\"2\">Clinically visible lesion 4.0 cm or less in greatest dimension</td> </tr> <tr> <td class=\"sublist2\">T1b2</td> <td class=\"sublist_other\">IB2</td> <td class=\"sublist_other\" colspan=\"2\">Clinically visible lesion more than 4.0 cm in greatest dimension</td> </tr> <tr> <td class=\"sublist1_start\">T2</td> <td class=\"sublist_other_start\">II</td> <td class=\"sublist_other_start\" colspan=\"2\">Cervical carcinoma invades beyond uterus but not to pelvic wall or to lower third of vagina</td> </tr> <tr> <td class=\"sublist1\">T2a</td> <td class=\"sublist_other\">IIA</td> <td class=\"sublist_other\" colspan=\"2\">Tumor without parametrial invasion or involvement of the lower one-third of the vagina<sup>[1,2]</sup></td> </tr> <tr> <td class=\"sublist2\">T2a1</td> <td class=\"sublist_other\">IIA1</td> <td class=\"sublist_other\" colspan=\"2\">Clinically visible lesion 4.0 cm or less in greatest dimension with involvement of less than the upper two-thirds of the vagina</td> </tr> <tr> <td class=\"sublist2\">T2a2</td> <td class=\"sublist_other\">IIA2</td> <td class=\"sublist_other\" colspan=\"2\">Clinically visible lesion more than 4.0 cm in greatest dimension with involvement of less than the upper two-thirds of the vagina</td> </tr> <tr> <td class=\"sublist1\">T2b</td> <td class=\"sublist_other\">IIB</td> <td class=\"sublist_other\" colspan=\"2\">Tumor with parametrial invasion</td> </tr> <tr> <td class=\"sublist1_start\">T3</td> <td class=\"sublist_other_start\">III</td> <td class=\"sublist_other_start\" colspan=\"2\">Tumor extends to pelvic wall and/or involves lower third of vagina, and/or causes hydronephrosis or nonfunctioning kidney</td> </tr> <tr> <td class=\"sublist1\">T3a</td> <td class=\"sublist_other\">IIIA</td> <td class=\"sublist_other\" colspan=\"2\">Tumor involves lower third of vagina, no extension to pelvic wall</td> </tr> <tr> <td class=\"sublist1\">T3b</td> <td class=\"sublist_other\">IIIB</td> <td class=\"sublist_other\" colspan=\"2\">Tumor extends to pelvic wall and/or causes hydronephrosis or nonfunctioning kidney</td> </tr> <tr> <td>T4</td> <td>IVA</td> <td colspan=\"2\">Tumor invades mucosa of bladder or rectum, and/or extends beyond true pelvis (bullous edema is not sufficient to classify a tumor as T4)</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr> <td class=\"subtitle2\">TNM categories</td> <td class=\"subtitle2\">FIGO stages</td> <td class=\"subtitle2\" colspan=\"2\">Definition</td> </tr> <tr> <td>NX</td> <td>&nbsp;</td> <td colspan=\"2\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td>N0</td> <td>&nbsp;</td> <td colspan=\"2\">No regional lymph node metastasis</td> </tr> <tr> <td>N1</td> <td>&nbsp;</td> <td colspan=\"2\">Regional lymph node metastasis</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr> <td class=\"subtitle2\">TNM categories</td> <td class=\"subtitle2\">FIGO stages</td> <td class=\"subtitle2\" colspan=\"2\">Definition</td> </tr> <tr> <td>M0</td> <td>&nbsp;</td> <td colspan=\"2\">No distant metastasis</td> </tr> <tr> <td>M1</td> <td>IVB</td> <td colspan=\"2\">Distant metastasis (including peritoneal spread, involvement of supraclavicular, mediastinal, or paraaortic lymph nodes, lung, liver, or bone)</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"4\">Anatomic stage/prognostic groups</td> </tr> <tr> <td>Stage 0*</td> <td>Tis</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage I</td> <td>T1</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage IA</td> <td>T1a</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage IA1</td> <td>T1a1</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage IA2</td> <td>T1a2</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage IB</td> <td>T1b</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage IB1</td> <td>T1b1</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage IB2</td> <td>T1b2</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage II</td> <td>T2</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage IIA</td> <td>T2a</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage IIA1</td> <td>T2a1</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage IIA2</td> <td>T2a2</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage IIB</td> <td>T2b</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage III</td> <td>T3</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage IIIA</td> <td>T3a</td> <td>N0</td> <td>M0</td> </tr> <tr> <td rowspan=\"2\">Stage IIIB</td> <td>T3b</td> <td>Any N</td> <td>M0</td> </tr> <tr> <td>T1-3</td> <td>N1</td> <td>M0</td> </tr> <tr> <td>Stage IVA</td> <td>T4</td> <td>Any N</td> <td>M0</td> </tr> <tr> <td>Stage IVB</td> <td>Any T</td> <td>Any N</td> <td>M1</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOTE: cTNM is the clinical classification, pTNM is the pathologic classification.</div><div class=\"graphic_footnotes\">* FIGO no longer includes Stage 0 (Tis).<br />&para; All macroscopically visible lesions-even with superficial invasion-are T1b/IB.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Pecorelli S. Revised FIGO staging for carcinoma of the cervix. Int J Gynecol Obstet 2009; 105:107. </li>&#xD;&#xA;    <li>Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynecol Obstet 2009; 105:103. </li>&#xD;&#xA;</ol>&#xD;&#xA;Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.</div><div id=\"graphicVersion\">Graphic 79282 Version 21.0</div></div></div>"},"79283":{"type":"graphic_picture","displayName":"KS erythematous papules","title":"Kaposi's sarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Kaposi's sarcoma</div><div class=\"cntnt\"><img style=\"width:302px; height:424px;\" src=\"images/ONC/79283_KS_erythematous_papules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Erythematous papules on the leg of a 54-year-old African-American patient. B) Close up view of same patient. It may be more difficult to identify KS lesions in dark-skinned patients.</div><div id=\"graphicVersion\">Graphic 79283 Version 1.0</div></div></div>"},"79285":{"type":"graphic_picture","displayName":"Nailfold capillaroscopy - Raynaud phenomenon","title":"Nailfold capillaroscopy - Raynaud phenomenon","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nailfold capillaroscopy - Raynaud phenomenon</div><div class=\"cntnt\"><img style=\"width:366px; height:479px;\" src=\"images/RHEUM/79285_Nailfold_capillarosc_RP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A) The normal nailfold capillaroscopic pattern, showing regular disposition of the capillary loops along the nailbed (original magnification 200x, M Cutolo). Panel B) A decreased number of loops should be considered highly specific for secondary Raynaud's phenomenon and induce \"desertification\" of the nailbed (original magnification 200x, M Cutolo).</div><div class=\"graphic_reference\">Reproduced from: Cutolo M, Pizzorni&nbsp;C, Secchi ME, Sulli A. Capillaroscopy. Best Pract Res Clin Rheumatol 2008; 22:1093. Copyright Â© 2008. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 79285 Version 4.0</div></div></div>"},"79286":{"type":"graphic_figure","displayName":"Bladder removal PI","title":"How urine leaves the body after the bladder is removed","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">How urine leaves the body after the bladder is removed</div><div class=\"cntnt\"><img style=\"width:612px; height:366px;\" src=\"images/PI/79286_Bladder_removal_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After removing a person's bladder, the surgeon must create a new way for urine to leave the body. There are 3 ways to do this:<br />(A) The surgeon can connect the ureters to a tube that drains through a hole on the surface of the skin. This is called a stoma. People who have a stoma must attach a bag around the outside of the stoma to collect urine.<br />(B) The surgeon can connect the ureters to a pouch that collects urine and then connect it to a stoma. People who have a pouch must drain the pouch every few hours by inserting a tube into the stoma.<br />(C) The surgeon can connect the ureters to a pouch that collects urine and then connect it to the urethra. That way, urine can leave the body the same way it did before. (The pouch used in this procedure is basically a new bladder. Surgeons call it a \"neobladder\".)<br />These options are not possible in all people. Ask your doctor which options could work for you. Then work with him or her to choose the best approach for you.</div><div id=\"graphicVersion\">Graphic 79286 Version 7.0</div></div></div>"},"79287":{"type":"graphic_picture","displayName":"Pyoderma gangrenosum - histopathology","title":"Pyoderma gangrenosum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pyoderma gangrenosum</div><div class=\"cntnt\"><img style=\"width:432px; height:288px;\" src=\"images/DERM/79287_Pyoderma_gangr_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dense neutrophilic infiltrate in pyoderma gangrenosum.</div><div id=\"graphicVersion\">Graphic 79287 Version 1.0</div></div></div>"},"79289":{"type":"graphic_figure","displayName":"Reconstruction with pedicled - attached - TRAM flap PI","title":"Reconstruction with pedicled (attached) TRAM flap","html":"<div class=\"graphic\"><div style=\"width: 578px\" class=\"figure\"><div class=\"ttl\">Reconstruction with pedicled (attached) TRAM flap</div><div class=\"cntnt\"><img style=\"width:558px; height:721px;\" src=\"images/PI/79289_Reconst_ped_TRAM_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Women who have reconstruction with a pedicled TRAM flap have a flap of tissue cut out of their belly. The flap is made up of skin, fat, and a chunk of muscle. When surgeons cut the flap, they free the muscle from the belly but they do not detach it completely. Instead, they leave the muscle attached at the top, by the chest. They create a tunnel between the belly and the chest and pull the flap up through that tunnel. Then they attach the flap to the chest, and it becomes the new breast. The flap still has blood coming to it, because it was never completely detached. Later, surgeons can also reconstruct a nipple. TRAM stands for &quot;transverse rectus abdominus myocutaneous.&quot;</div><div id=\"graphicVersion\">Graphic 79289 Version 3.0</div></div></div>"},"79290":{"type":"graphic_table","displayName":"Vascular structures 1","title":"Vascular structures most commonly seen in melanocytic tumors<sup>[1-3]</sup>","html":"<div class=\"graphic\"><div style=\"width: 642px\" class=\"figure\"><div class=\"ttl\">Vascular structures most commonly seen in melanocytic tumors<sup>[1-3]</sup></div><div class=\"cntnt\"><img style=\"width:622px; height:602px;\" src=\"images/DERM/79290_Vascularstructure1edt3.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Zalaudek I, Kreusch J, Giacomel J, et al. How to diagnose nonpigmented skin tumors: a review of vascular structures seen with dermoscopy: part II. Nonmelanocytic skin tumors. J Am Acad Dermatol 2010; 63:377.</li>&#xD;&#xA;    <li>Zalaudek I, Kreusch J, Giacomel J, et al. How to diagnose nonpigmented skin tumors: a review of vascular structures seen with dermoscopy: part I. Melanocytic skin tumors. J Am Acad Dermatol 2010; 63:361.</li>&#xD;&#xA;    <li>Argenziano G, Zalaudek I, Corona R, et al. Vascular structures in skin tumors: a dermoscopy study. Arch Dermatol 2004; 140:1485.</li>&#xD;&#xA;    <li>Jaimes N, Braun RP, Thomas L, Marghoob AA. Clinical and dermoscopic characteristics of amelanotic melanomas that are not of the nodular subtype. J Eur Acad Dermatol Venereol 2012; 26:591.</li>&#xD;&#xA;    <li>Jaimes N, Chen L, Dusza SW, et al. Clinical and dermoscopic characteristics of desmoplastic melanomas. JAMA Dermatol 2013; 149:413.</li>&#xD;&#xA;    <li>Menzies SW, Moloney FJ, Byth K, et al. Dermoscopic evaluation of nodular melanoma. JAMA Dermatol 2013; 149:699.</li>&#xD;&#xA;    <li>Ka VS, Clark-Loeser L, Marghoob AA. Vascular pattern in seborrheic keratoses and melanoma. Dermatol Surg 2004; 30:75.</li>&#xD;&#xA;    <li>Jaimes N, Halpern JA, Puig S, et al. Dermoscopy: an aid to the detection of amelanotic cutaneous melanoma metastases. Dermatol Surg 2012; 38:1437.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 79290 Version 10.0</div></div></div>"},"79291":{"type":"graphic_diagnosticimage","displayName":"Pediatric femoral neck stress fracture","title":"Femoral neck stress fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Femoral neck stress fracture</div><div class=\"cntnt\"><img style=\"width:432px; height:307px;\" src=\"images/EM/79291_Fem_neck_stress_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Compression side stress fracture of the femoral neck in a seven year old &quot;select&quot; soccer player. This healed uneventfully after restriction of activity.</div><div class=\"graphic_reference\">Courtesy of Klane White, MD.</div><div id=\"graphicVersion\">Graphic 79291 Version 2.0</div></div></div>"},"79294":{"type":"graphic_table","displayName":"Causes of unintentional death in the home","title":"Leading causes of unintentional-injury deaths, United States, 2007","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Leading causes of unintentional-injury deaths, United States, 2007</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Motor vehicle</td> <td>43,495</td> </tr> <tr> <td>Poisoning</td> <td>29,846</td> </tr> <tr> <td>Falls </td> <td>22,631 </td> </tr> <tr> <td>Choking</td> <td>3,515 </td> </tr> <tr> <td>Drowning</td> <td>3,443</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Deaths&nbsp;due to uninentional&nbsp;injuries in the home</td> </tr> <tr> <td colspan=\"2\">These data represent figures from 2007</td> </tr> <tr> <td colspan=\"2\">In the home, there is a fatal injury every 18 minutes and a disabling injury every 4 seconds</td> </tr> <tr> <td colspan=\"2\">There has been minimal change since 2002</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: National Safety Council. Injury facts, 2011 Edition&nbsp;(<A href=\"http://www.nsc.org/\">http://www.nsc.org</A>).</div><div id=\"graphicVersion\">Graphic 79294 Version 2.0</div></div></div>"},"79295":{"type":"graphic_figure","displayName":"Myofascial pain points posterio","title":"Posterior trigger points associated with the myofascial pain syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior trigger points associated with the myofascial pain syndrome</div><div class=\"cntnt\"><img style=\"width:360px; height:474px;\" src=\"images/RHEUM/79295_Myofascial_pain_points_post.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Trigger points and zones of reference are also present posteriorly in patients with the myofascial pain syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.</div><div id=\"graphicVersion\">Graphic 79295 Version 1.0</div></div></div>"},"79296":{"type":"graphic_table","displayName":"Classic Li-Fraumeni syndrome - Diagnostic criteria","title":"Classic Li-Fraumeni syndrome<sup>[1]</sup> - Diagnostic criteria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classic Li-Fraumeni syndrome<sup>[1]</sup> - Diagnostic criteria</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t<td class=\"subtitle1_single\">All of the following:</td>\n\t</tr>\n    <tr>\n        <td>&bull; A proband with sarcoma diagnosed before age 45 years</td>\n    </tr>\n    <tr>\n        <td>&bull; A first-degree relative with any cancer before age 45 years</td>\n    </tr>\n    <tr>\n        <td>&bull; A first- or second-degree relative with any cancer before age 45 years or a sarcoma at any age</td>\n    </tr>\n\n</tbody>\n</table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">&lt;div&gt;&lt;/div&gt;</mso:Media_Notes>\n<mso:ContentType msdt:dt=\"string\">Media Content Type</mso:ContentType>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=77964&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title></title></head></div><div class=\"graphic_reference\">Reference:<br> <ol> <li>Li FP, Fraumeni JF, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988; 48:5358. </li> </ol></div><div id=\"graphicVersion\">Graphic 79296 Version 9.0</div></div></div>"},"79298":{"type":"graphic_diagnosticimage","displayName":"Apical 4 chamber normal","title":"Apical 4 chamber view of normal heart","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Apical 4 chamber view of normal heart</div><div class=\"cntnt\"><img style=\"width:504px; height:392px;\" src=\"images/EM/79298_Apical_4_chamber_normal_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image shows normal cardiac anatomy as seen from an apical four chamber view.</div><div class=\"graphic_footnotes\">LA: left atrium; LV: left ventricle; RA: right atrium; RV: right ventricle.</div><div class=\"graphic_reference\">Courtesy of Greg Snead, MD.</div><div id=\"graphicVersion\">Graphic 79298 Version 1.0</div></div></div>"},"79300":{"type":"graphic_diagnosticimage","displayName":"TEE descending thoracic aorta","title":"Descending thoracic aorta on transesophageal echocardiogram","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Descending thoracic aorta on transesophageal echocardiogram</div><div class=\"cntnt\"><img style=\"width:546px; height:424px;\" src=\"images/CARD/79300_TEE_descending_aorta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A: Horizontal (0Âº) imaging plane shows the descending thoracic aorta which is circular in appearance. Panel B: Vertical (90Âº) imaging plane shows the superior regions on the right and inferior regions on the left. Panel C: Color flow Doppler obtained in the vertical (90Âº) imaging plane confirms the normal direction of blood flow in the descending thoracic aorta with flow towards the transducer (yellow-red) followed by flow of blood away from the transducer (blue).</div><div class=\"graphic_reference\">Courtesy of Warren Manning, MD.</div><div id=\"graphicVersion\">Graphic 79300 Version 3.0</div></div></div>"},"79301":{"type":"graphic_figure","displayName":"GERD PI","title":"Gastroesophageal reflux disease (GERD)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Gastroesophageal reflux disease (GERD)</div><div class=\"cntnt\"><img style=\"width:504px; height:547px;\" src=\"images/PI/79301_GERD_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When we eat, food is carried from the mouth through the esophagus, a tube-like structure that is approximately 10 inches long and 1 inch wide in adults. At the lower end of the esophagus, where it joins the stomach, there is a circular ring of muscle that relaxes and opens when food reaches that point, called the lower esophageal sphincter (LES). This allows food to enter the stomach and then closes to prevent the back-up of food and acid into the esophagus. Reflux can occur if the LES is weak or stays relaxed too long.</div><div id=\"graphicVersion\">Graphic 79301 Version 3.0</div></div></div>"},"79302":{"type":"graphic_figure","displayName":"Allis clamps on myometrium","title":"Placement of allis clamps for traction on the myometrium during myomectomy","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Placement of allis clamps for traction on the myometrium during myomectomy</div><div class=\"cntnt\"><img style=\"width:466px; height:375px;\" src=\"images/OBGYN/79302_Allis_clamps_fibroid_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 79302 Version 4.0</div></div></div>"},"79304":{"type":"graphic_table","displayName":"Caffeine content in foods and beverages","title":"Caffeine content in foods and beverages","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Caffeine content in foods and beverages</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">Coffees</td> <td class=\"subtitle2_left\">Serving size, oz (mL)</td> <td class=\"subtitle2_left\">Caffeine, mg</td> </tr> <tr> <td class=\"indent1\">Coffee, brewed</td> <td>8 (235)</td> <td>133 (range: 102 to 200)</td> </tr> <tr> <td class=\"indent1\">Coffee, generic instant</td> <td>8 (235)</td> <td>93 (range: 27 to 173)</td> </tr> <tr> <td class=\"indent1\">Coffee, generic decaffeinated</td> <td>8 (235)</td> <td>5 (range: 3 to 12)</td> </tr> <tr> <td class=\"indent1\">Espresso</td> <td>1 (30)</td> <td>40 (range: 30 to 90)</td> </tr> <tr> <td class=\"indent1\">Espresso decaffeinated</td> <td>1 (30)</td> <td>4</td> </tr> <tr> <td class=\"subtitle2_left\">Teas</td> <td class=\"subtitle2_left\">Serving size, oz (mL)</td> <td class=\"subtitle2_left\">Caffeine, mg</td> </tr> <tr> <td class=\"indent1\">Tea, brewed</td> <td>8 (235)</td> <td>53 (range: 40 to 120)</td> </tr> <tr> <td class=\"indent1\">Arizona Iced Tea, black</td> <td>16 (470)</td> <td>32</td> </tr> <tr> <td class=\"indent1\">Arizona Iced Tea, green</td> <td>16 (470)</td> <td>15</td> </tr> <tr> <td class=\"indent1\">Nestea</td> <td>12 (355)</td> <td>26</td> </tr> <tr> <td class=\"indent1\">Snapple, Just Plain Unsweetened</td> <td>16 (470)</td> <td>18</td> </tr> <tr> <td class=\"indent1\">Snapple, Kiwi Teawi</td> <td>16 (470)</td> <td>10</td> </tr> <tr> <td class=\"indent1\">Snapple, Lemon, Peach, or Raspberry</td> <td>16 (470)</td> <td>42</td> </tr> <tr> <td class=\"indent1\">Starbucks Tazo Chai Tea Latte (Grande)</td> <td>16 (470)</td> <td>100</td> </tr> <tr> <td class=\"subtitle2_left\">Soft drinks</td> <td class=\"subtitle2_left\">Serving size, oz (mL)</td> <td class=\"subtitle2_left\">Caffeine, mg</td> </tr> <tr> <td class=\"indent1\"><strong>FDA official limit for cola and pepper soft drinks</strong></td> <td><strong>12 (355)</strong></td> <td><strong>71</strong></td> </tr> <tr> <td class=\"indent1\">7-Up, regular or diet</td> <td>12 (355)</td> <td>0</td> </tr> <tr> <td class=\"indent1\">Barq's Diet Root Beer</td> <td>12 (355)</td> <td>0</td> </tr> <tr> <td class=\"indent1\">Barq's Root Beer</td> <td>12 (355)</td> <td>22</td> </tr> <tr> <td class=\"indent1\">Coke, regular or diet</td> <td>12 (355)</td> <td>35 to 47</td> </tr> <tr> <td class=\"indent1\">Dr. Pepper, regular or diet</td> <td>12 (355)</td> <td>42 to 44</td> </tr> <tr> <td class=\"indent1\">Fanta, all flavors</td> <td>12 (355)</td> <td>0</td> </tr> <tr> <td class=\"indent1\">Fresca, all flavors</td> <td>12 (355)</td> <td>0</td> </tr> <tr> <td class=\"indent1\">Jolt Cola</td> <td>12 (355)</td> <td>72</td> </tr> <tr> <td class=\"indent1\">Mellow Yellow</td> <td>12 (355)</td> <td>53</td> </tr> <tr> <td class=\"indent1\">Mountain Dew, regular or diet</td> <td>12 (355)</td> <td>54 (20 oz = 90)</td> </tr> <tr> <td class=\"indent1\">Mountain Dew MDX, regular or diet</td> <td>12&nbsp;(355)</td> <td>71 (20 oz = 118)</td> </tr> <tr> <td class=\"indent1\">Mug Root Beer, regular or diet</td> <td>12 (355)</td> <td>0</td> </tr> <tr> <td class=\"indent1\">Pepsi, regular or diet</td> <td>12 (355)</td> <td>36 to 38</td> </tr> <tr> <td class=\"indent1\">Sierra Mist, regular or free</td> <td>12 (355)</td> <td>0</td> </tr> <tr> <td class=\"indent1\">Sprite, regular or diet</td> <td>12 (355)</td> <td>0</td> </tr> <tr> <td class=\"indent1\">TAB</td> <td>12 (355)</td> <td>46.5</td> </tr> <tr> <td class=\"subtitle2_left\">Energy drinks</td> <td class=\"subtitle2_left\">Serving size, oz (mL)</td> <td class=\"subtitle2_left\">Caffeine, mg</td> </tr> <tr> <td class=\"indent1\">5-hour ENERGY</td> <td>2 (60)</td> <td>215*</td> </tr> <tr> <td class=\"indent1\">Amp</td> <td>8.4 (250)</td> <td>74</td> </tr> <tr> <td class=\"indent1\">Cocaine</td> <td>8.4 (250)</td> <td>288&nbsp;</td> </tr> <tr> <td class=\"indent1\">Enviga</td> <td>12 (355)</td> <td>100</td> </tr> <tr> <td class=\"indent1\">Full Throttle</td> <td>16 (470)</td> <td>144</td> </tr> <tr> <td class=\"indent1\">Glaceau Vitamin Water Energy Citrus</td> <td>20 (590)</td> <td>50</td> </tr> <tr> <td class=\"indent1\">Monster Energy</td> <td>16 (470)</td> <td>160</td> </tr> <tr> <td class=\"indent1\">Red Bull</td> <td>8.3 (245)</td> <td>80</td> </tr> <tr> <td class=\"indent1\">Red Bull Sugarfree</td> <td>8.3&nbsp;(245)</td> <td>80</td> </tr> <tr> <td class=\"indent1\">Rip It, all varieties</td> <td>8 (235)</td> <td>100</td> </tr> <tr> <td class=\"indent1\">Rockstar Energy Drink</td> <td>8 (235)</td> <td>80</td> </tr> <tr> <td class=\"indent1\">SoBe Adrenaline Rush</td> <td>8.3 (245)</td> <td>79</td> </tr> <tr> <td class=\"indent1\">SoBe Essential Energy, Berry or Orange</td> <td>8 (235)</td> <td>48</td> </tr> <tr> <td class=\"indent1\">SoBe No Fear</td> <td>8 (235)</td> <td>83</td> </tr> <tr> <td class=\"indent1\">Spike Shooter</td> <td>8.4 (250)</td> <td>300</td> </tr> <tr> <td class=\"indent1\">Tab Energy</td> <td>10.5 (310)</td> <td>95</td> </tr> <tr> <td class=\"subtitle2_left\">Frozen desserts</td> <td class=\"subtitle2_left\">Serving size, oz (mL)</td> <td class=\"subtitle2_left\">Caffeine, mg</td> </tr> <tr> <td class=\"indent1\">Ben &#38; Jerry's Coffee Ice Cream</td> <td>8 (235)</td> <td>68 to 84</td> </tr> <tr> <td class=\"indent1\">H&#228;agen-Dazs Coffee Ice Cream or Yogurt</td> <td>8 (235)</td> <td>58</td> </tr> <tr> <td class=\"indent1\">Starbucks Coffee Ice Cream</td> <td>8 (235)</td> <td>50 to 60</td> </tr> <tr> <td class=\"subtitle2_left\">Chocolates/candies/other</td> <td class=\"subtitle2_left\">Serving size, various units</td> <td class=\"subtitle2_left\">Caffeine, mg</td> </tr> <tr> <td class=\"indent1\">Hershey's Chocolate Bar</td> <td>1.55 oz (45 g)</td> <td>9</td> </tr> <tr> <td class=\"indent1\">Hershey's Kisses</td> <td>41 g (9 pieces)</td> <td>9</td> </tr> <tr> <td class=\"indent1\">Hershey's Special Dark Chocolate Bar</td> <td>1.45 oz (41 g)</td> <td>31</td> </tr> <tr> <td class=\"indent1\">Hot cocoa</td> <td>8 oz (235 mL)</td> <td>3 to 13</td> </tr> <tr> <td class=\"indent1\">Powdered caffeine</td> <td>1/16 tsp </td> <td>200 </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FDA: US Food and Drug Administration.<br />* Reported by Consumer Reports.<br />Oz: ounce</div><div class=\"graphic_reference\">References:<br> <ol> <li>Harland BF. Caffeine and nutrition. Nutrition 2000; 16:522. </li> <li>Juliano LM, Griffiths RR. Caffeine. In: Substance Abuse: A Comprehensive Textbook, Fourth Edition, Lowinson JH, Ruiz P, Millman RB, Langrod JG (Eds), Baltimore: Lippincott Williams, &amp; Wilkins, 2005. </li> <li>Center for Science in the Public Interest. Caffeine Content of Food and Drugs. </li> </ol></div><div id=\"graphicVersion\">Graphic 79304 Version 9.0</div></div></div>"},"79305":{"type":"graphic_figure","displayName":"Shoe shape PI","title":"Shoe shape must match foot shape","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Shoe shape must match foot shape</div><div class=\"cntnt\"><img style=\"width:265px; height:179px;\" src=\"images/PI/79305_Shoe_shape_PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 79305 Version 1.0</div></div></div>"},"79307":{"type":"graphic_figure","displayName":"Transplant vasculopathy and age","title":"Donor age and preexisting coronary artery disease predict transplant vasculopathy","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Donor age and preexisting coronary artery disease predict transplant vasculopathy</div><div class=\"cntnt\"><img style=\"width:543px; height:294px;\" src=\"images/CARD/79307_Transplant_vasculopathy_and.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The incidence of allograft coronary artery disease (TxCAD) is greater in those who receive a heart from a donor with CAD (left panel). New TxCAD is less frequent during the first three years and occurs later in patients receiving a donor heart from younger (&lt;40 years) compared to older donors (right panel). However, at five years there is no significant difference between older and younger donors.</div><div class=\"graphic_reference\">Data from Gao, SZ, Hunt, SA, Alderman, EL, et al, J Am Coll Cardiol 1997; 29:623.</div><div id=\"graphicVersion\">Graphic 79307 Version 1.0</div></div></div>"},"79308":{"type":"graphic_diagnosticimage","displayName":"Spinous process fracture","title":"Spinous process (clay shoveler's) fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spinous process (clay shoveler's) fracture</div><div class=\"cntnt\"><img style=\"width:267px; height:480px;\" src=\"images/PEDS/79308_Spinous_process_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The spinous process fracture, also called the clay shoveler's fracture, is an avulsion fracture of the tip of the spinous process, most commonly involving C7.</div><div class=\"graphic_reference\">Reproduced with permission from Amilcare Gentili, MD. Copyright Â© Amilcare Gentili, MD.</div><div id=\"graphicVersion\">Graphic 79308 Version 2.0</div></div></div>"},"79311":{"type":"graphic_table","displayName":"Staging of thymic tumors","title":"Clinical staging of thymic epithelial tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical staging of thymic epithelial tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Masaoka's clinical stage<sup>[1]</sup></td> </tr> <tr> <td colspan=\"4\">Stage I: Macroscopically completely encapsulated and microscopically no capsular invasion</td> </tr> <tr> <td colspan=\"4\">Stage II: Macroscopic invasion into surrounding fatty tissue or mediastinal pleura, or microscopic invasion into capsule</td> </tr> <tr> <td colspan=\"4\">Stage III: Macroscopic invasion into neighboring organs (ie, pericardium, great vessels, or lung)</td> </tr> <tr> <td colspan=\"4\">Stage IVa: Pleural or pericardial dissemination</td> </tr> <tr> <td colspan=\"4\">Stage IVb: Lymphogenous or hematogenous metastasis</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Koga's proposed pathologic tumor extent of thymic epithelial tumors<sup>[2]</sup></td> </tr> <tr> <td colspan=\"4\">Stage I: Grossly and microscopically completely encapsulated</td> </tr> <tr> <td colspan=\"4\">Stage II: Microscopic transcapsular invasion or macroscopic invasion into thymic or surrounding fatty tissue, or grossly adherent to but not breaking through mediastinal pleura or pericardium</td> </tr> <tr> <td colspan=\"4\">Stage III: Macroscopic invasion of neighboring organ (eg, pericardium, great vessels, or lung)</td> </tr> <tr> <td colspan=\"4\">Stage IVa: Pleural or pericardial dissemination</td> </tr> <tr> <td colspan=\"4\">Stage IVb: Lymphogenous or hematogenous metastasis</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Yamakawa-Masaoka TNM classification and staging<sup>[3]</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">T factor:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">T1: Macroscopically completely encapsulated and microscopically no capsular invasion</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">T2: Macroscopically adhesion or invasion into surrounding fatty tissue or mediastinal pleura, or microscopic invasion into capsule</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">T3: Invasion into neighboring organs, such as pericardium, great vessels, and lung</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">T4: Pleural or pericardial dissemination</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">N factor:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">N0: No lymph node metastasis</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">N1: Metastasis to anterior mediastinal lymph nodes</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">N2: Metastasis to intrathoracic lymph nodes except anterior mediastinal lymph nodes</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">N3: Metastasis to extrathoracic lymph nodes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">M factor:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">M0: No hematogenous metastasis</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">M1: Hematogenous metastasis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Stage:</td> </tr> <tr> <td class=\"indent1\">Stage I</td> <td>T1</td> <td>N0</td> <td>M0</td> </tr> <tr> <td class=\"indent1\">Stage II</td> <td>T2</td> <td>N0</td> <td>M0</td> </tr> <tr> <td class=\"indent1\">Stage III</td> <td>T3</td> <td>N0</td> <td>M0</td> </tr> <tr> <td class=\"indent1\">Stage IVa</td> <td>T4</td> <td>N0</td> <td>M0</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Stage IVb</td> <td>Any T</td> <td>N1, 2, 3</td> <td>M0</td> </tr> <tr> <td>Any T</td> <td>Any N</td> <td>M1</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br> <ol> <li>Masaoka A, Monden Y, Nakahara K, et al. Cancer 1981; 48:2485. </li> <li>Koga K, Matsuno Y, Noguchi M, et al. Pathol Int 1994; 44:359. </li> <li>Yamakawa Y, Masaoka A, Hashimot T, et al. Cancer 1991; 68:1984. </li> </ol></div><div id=\"graphicVersion\">Graphic 79311 Version 5.0</div></div></div>"},"79312":{"type":"graphic_diagnosticimage","displayName":"MRI of greater trochanteric pain syndrome","title":"MRI of greater trochanteric pain syndrome","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">MRI of greater trochanteric pain syndrome</div><div class=\"cntnt\"><img style=\"width:504px; height:504px;\" src=\"images/RADIOL/79312_MRI_grtr_trochanteric_pain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Greater trochanteric pain syndrome. Coronal inversion recovery MRI of the pelvis shows edema and partial tear of the gluteus medius muscle insertion at the greater trochanter of the left femur (arrow).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD.</div><div id=\"graphicVersion\">Graphic 79312 Version 4.0</div></div></div>"},"79314":{"type":"graphic_picture","displayName":"Two nuclei diagnostic Reed-Sternberg cell","title":"Diagnostic Reed-Sternberg cell with two nuclei","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Diagnostic Reed-Sternberg cell with two nuclei</div><div class=\"cntnt\"><img style=\"width:505px; height:756px;\" src=\"images/HEME/79314_2nucleiDxReedSterncell.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A diagnostic Reed-Sternberg cell with two nuclei is seen in the center (arrow) with a prominent eosinophilic nucleolus present in each nucleus. There is some chromatin clearing around each nucleolus. Several mononuclear Reed-Sternberg variants are also present in the upper half of the field (dashed arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Weiss LM, Warnke RA, Hansmann ML, et al. Pathology of Hodgkin Lymphoma. In: Hodgkin Lymphoma, 2nd ed, Hoppe RT, Mauch PT, Armitage JO, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright Â© 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 79314 Version 8.0</div></div></div>"},"79316":{"type":"graphic_figure","displayName":"Type2 DM weight and exercise","title":"Importance of body weight and exercise on development of type 2 diabetes","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Importance of body weight and exercise on development of type 2 diabetes</div><div class=\"cntnt\"><img style=\"width:538px; height:247px;\" src=\"images/ENDO/79316_Type2_DM_weight_and_exercis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Adjusted incidence of type 2 diabetes mellitus in 5990 men in relation to&nbsp;BMI (in kg/m<SUP>2</SUP>) and the level of physical activity (in kcal/week). The risk of type 2 diabetes was directly related to BMI, while regular exercise was protective except for in men with a BMI below 24.</div><div class=\"graphic_footnotes\">BMI: body mass index.</div><div class=\"graphic_reference\">Data from: Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS Jr.&nbsp;Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med 1991; 325:147.</div><div id=\"graphicVersion\">Graphic 79316 Version 4.0</div></div></div>"},"79319":{"type":"graphic_picture","displayName":"Mucinous carcinoma of the breast","title":"Mucinous carcinoma of the breast","html":"<div class=\"graphic\"><div style=\"width: 607px\" class=\"figure\"><div class=\"ttl\">Mucinous carcinoma of the breast</div><div class=\"cntnt\"><img style=\"width:587px; height:237px;\" src=\"images/ONC/79319_Mucinous_breast_ca_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) Low power view of a mucinous breast carcinomashows small nests of tumor cells dispersed in large pools of extracellular mucous.<br />(Panel B) High power view demonstrates that the nests are composed of cells with relatively uniform, low grade nuclei.</div><div class=\"graphic_reference\">Courtesy of Stuart Schnitt, MD.</div><div id=\"graphicVersion\">Graphic 79319 Version 3.0</div></div></div>"},"79320":{"type":"graphic_waveform","displayName":"Intracardiac electrogram Mahaim fiber ablation","title":"Intracardiac electrogram during ablation of Mahaim fiber tachycardia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intracardiac electrogram during ablation of Mahaim fiber tachycardia</div><div class=\"cntnt\"><img style=\"width:382px; height:431px;\" src=\"images/CARD/79320_Mahaim_tachy_RF_ablation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Top panel shows surface leads I and V1 and intracardiac recordings from the right ventricular apex (RVA), His-bundle (HBE), and a mapping catheter (MaP) located at the tricuspid annulus. A Mahaim potential (M) is seen in the MaP recording, located between the atrial (A) and ventricular (V) electrogram. In bottom panel, radiofrequency current is applied at the site of the M potential, resulting in loss of Mahaim conduction and termination of the tachycardia.</div><div id=\"graphicVersion\">Graphic 79320 Version 4.0</div></div></div>"},"79321":{"type":"graphic_diagnosticimage","displayName":"DAH CT","title":"Diffuse alveolar hemorrhage CT","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diffuse alveolar hemorrhage CT</div><div class=\"cntnt\"><img style=\"width:396px; height:297px;\" src=\"images/PULM/79321_DAH_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 79321 Version 3.0</div></div></div>"},"79323":{"type":"graphic_diagnosticimage","displayName":"Lateral RV angiogram tetralogy","title":"Right ventricular angiogram in tetralogy of Fallot","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right ventricular angiogram in tetralogy of Fallot</div><div class=\"cntnt\"><img style=\"width:314px; height:331px;\" src=\"images/CARD/79323_Lateral_RV_angiogram_tetral.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lateral projection of a right ventricular (RV) angiogram in tetralogy of Fallot shows an hypertrophied infundibulum (INF) with anterior and cephalad deviation of the septum, resulting in significant subpulmonary obstruction; the pulmonary valve annulus (*) is much larger than the subvalvar area.</div><div class=\"graphic_reference\">Photo courtesy of Thomas Doyle, MD.</div><div id=\"graphicVersion\">Graphic 79323 Version 2.0</div></div></div>"},"79324":{"type":"graphic_figure","displayName":"Anomalies of the urachus","title":"Anomalies of the urachus","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Anomalies of the urachus</div><div class=\"cntnt\"><img style=\"width:539px; height:528px;\" src=\"images/PEDS/79324_Urachal_anomalies.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 79324 Version 3.0</div></div></div>"},"79326":{"type":"graphic_diagnosticimage","displayName":"Medial plica of the knee MRI","title":"Magnetic resonance imaging of medial plica of the knee explaining dry tap","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance imaging of medial plica of the knee explaining dry tap</div><div class=\"cntnt\"><img style=\"width:324px; height:279px;\" src=\"images/RHEUM/79326_Medial_plica_of_the_knee_MR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial T2 weighted image through the midportion of the patella shows a prominent medial plica (arrow). Placement of a needle from the medial approach in such a patient could result in the plica behaving as a valve, preventing the aspiration of fluid despite the presence of a moderate effusion.</div><div class=\"graphic_footnotes\">M: medial; L: lateral.</div><div class=\"graphic_reference\">From: Hayes CW, Conway WF. Magnetic resonance imaging of miscellaneous knee disorders. In: Magnetic Resonance Imaging and Computerized Tomography of the Musculoskeletal System: A Text-Atlas, Bloem JI, Sartoris DJ (Eds), Williams &amp; Wilkins, Baltimore 1992.</div><div id=\"graphicVersion\">Graphic 79326 Version 2.0</div></div></div>"},"79327":{"type":"graphic_diagnosticimage","displayName":"Necrotizing right lower lobe pneumonia","title":"Necrotizing right lower lobe pneumonia due to anaerobes","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Necrotizing right lower lobe pneumonia due to anaerobes</div><div class=\"cntnt\"><img style=\"width:465px; height:464px;\" src=\"images/ID/79327_Necrotizingrtlowerlobe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Postanterior (A) and lateral (B) chest radiographs show areas of consolidation and several air-fluid levels within the right lower lobe. Less extensive consolidation is evident in the right middle lobe. Computed tomography (CT) image (C) confirms the radiographic findings and also demonstrates a few centrilobular nodules in the right middle lobe (arrow). The patient was a 50-year-old man with pneumonia due to anaerobic organisms.</div><div class=\"graphic_reference\">Reproduced with permission from: MÃ¼ller NL, Franquet T, Lee KS, Silva CIS. Bacterial pneumonia. In: Imaging of pulmonary infections, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright Â© 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 79327 Version 10.0</div></div></div>"},"79328":{"type":"graphic_diagnosticimage","displayName":"Arcuate uterus HSG","title":"Hysterosalpingogram of arcuate uterus","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Hysterosalpingogram of arcuate uterus</div><div class=\"cntnt\"><img style=\"width:586px; height:586px;\" src=\"images/OBGYN/79328_Arcuate_uterus_HSG.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Robert L Barbieri, MD.</div><div id=\"graphicVersion\">Graphic 79328 Version 3.0</div></div></div>"},"79329":{"type":"graphic_table","displayName":"Products of well-differentiated neuroendocrine tumors","title":"Products of well-differentiated neuroendocrine tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Products of well-differentiated neuroendocrine tumors</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"subtitle1_single\">Amines</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Serotonin</td>\n\n\t\t\t\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>5-Hydroxytryptophan</td>\n\n\t\t\t\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Norepinephrine</td>\n\n\t\t\t\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Dopamine</td>\n\n\t\t\t\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Histamine</td>\n\n\t\t\t\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"subtitle1_single\">Polypeptides</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Kallikrein</td>\n\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Pancreatic polypeptide</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Bradykinin</td>\n\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Motilin</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Somatostatin</td>\n\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Vasoactive intestinal peptide</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Neuropeptide K</td>\n\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Substance P</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Neurokinin A</td>\n\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Neurokinin B</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Corticotropin (ACTH)</td>\n\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Gastrin</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Growth hormone</td>\n\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Peptide YY</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Glucagon</td>\n\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Beta-endorphin</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Neurotensin</td>\n\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Chromogranin A</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"subtitle1_single\">Prostaglandins</td>\n\n\t\t\t\n\t\t</tr>\n\t</tbody>\n</table>\n\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">4.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=15795&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Products_of_carcinoid_tumor.htm</title></head></div><div id=\"graphicVersion\">Graphic 79329 Version 2.0</div></div></div>"},"79331":{"type":"graphic_figure","displayName":"Vaginal transection","title":"Transection of the vagina during hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transection of the vagina during hysterectomy</div><div class=\"cntnt\"><img style=\"width:371px; height:385px;\" src=\"images/OBGYN/79331_Vaginal_transection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With the ureters retracted laterally, the bladder is reflected inferiorly so that at least one-third to one-half of the vagina is visible anteriorly. The posterior rectal space is developed so that at least one-third to one-half of the vagina is visible posteriorly, the operative specimen is resected, and the cuff either closed or dealt with by running the edge.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 79331 Version 2.0</div></div></div>"},"79332":{"type":"graphic_diagnosticimage","displayName":"Prenatal ultrasound bilateral MCDK","title":"Prenatal ultrasound of bilateral multicystic dysplastic kidneys showing the circumferential arrangement of the cysts","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound of bilateral multicystic dysplastic kidneys showing the circumferential arrangement of the cysts</div><div class=\"cntnt\"><img style=\"width:396px; height:282px;\" src=\"images/OBGYN/79332_Bilateral_MCDK_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Follow-up ultrasound examination of this pregnancy in the third trimester revealed anyhydramnios and reduction in size of both kidneys.</div><div class=\"graphic_footnotes\">RK: right kidney; LK: left kidney.</div><div class=\"graphic_reference\">Courtesy of Tulin Ozcan, MD.</div><div id=\"graphicVersion\">Graphic 79332 Version 7.0</div></div></div>"},"79333":{"type":"graphic_figure","displayName":"Posterior vaginal wall prolapse 9","title":"Repair of posterior vaginal wall prolapse","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Repair of posterior vaginal wall prolapse</div><div class=\"cntnt\"><img style=\"width:444px; height:346px;\" src=\"images/OBGYN/79333_Tx_post_vaginal_wall_def_10.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Graft-augmented rectocele repair. A graft is trimmed and placed over a posterior colporrhaphy or site-specific repair.</div><div class=\"graphic_reference\">Reproduced with permission from: Walters, MD, Karram, MM. Urogynecology and reconstructive pelvic surgery, 3rd ed, Mosby-Elsevier, 2007. Copyright &#169;2007 Elsevier.</div><div id=\"graphicVersion\">Graphic 79333 Version 2.0</div></div></div>"},"79334":{"type":"graphic_table","displayName":"Priority groups for flu vaccine if supply limited","title":"When influenza vaccine supply is limited, vaccination efforts should focus on individuals who:","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">When influenza vaccine supply is limited, vaccination efforts should focus on individuals who:</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Are at high risk for influenza-related complications, including those who:</td> </tr> <tr> <td class=\"indent1\">Are 6 months through 4 years (59 months) of age</td> </tr> <tr> <td class=\"indent1\">Are &#8805;50 years of age</td> </tr> <tr> <td class=\"indent1\">Have chronic pulmonary (including asthma), cardiovascular (except hypertension), renal, hepatic, hematologic (including sickle cell disease), metabolic (including diabetes mellitus),&nbsp;or neurologic (disorders of the brain and spinal cord, cerebral palsy, epilepsy, stroke, intellectual disability, moderate to severe developmental delay, muscular dystrophy, spinal cord injury) disorders</td> </tr> <tr> <td class=\"indent1\">Are immunosuppressed (including immunosuppression caused by medications or by HIV infection)</td> </tr> <tr> <td class=\"indent1\">Are or will be pregnant during the influenza season</td> </tr> <tr> <td class=\"indent1\">Are 6 months through 18 years of age and receiving long-term aspirin therapy (and may be at risk for Reye syndrome after influenza virus infection)</td> </tr> <tr> <td class=\"indent1\">Are residents of nursing homes or other chronic-care facilities</td> </tr> <tr> <td class=\"indent1\">Are Native Americans, including Alaska Natives</td> </tr> <tr> <td class=\"indent1\">Are&nbsp;extremely obese (body mass index [BMI] &#8805;40)</td> </tr> <tr> <td class=\"subtitle1_single\">Live with or care for persons at high risk of influenza-related complications, including:</td> </tr> <tr> <td class=\"indent1\">Health care personnel</td> </tr> <tr> <td class=\"indent1\">Household contacts or caregivers of children &#8804;59 months (&#60;5 years) or adults &#8805;50 years of age, particularly contacts of children &#60;6 months</td> </tr> <tr> <td class=\"indent1\">Household contacts or caregivers of persons with medical conditions that put them at increased risk for severe complications of influenza</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<DIV></DIV>&#xD;&#xA;<OL>&#xD;&#xA;<LI>Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices â United States, 2017â18 influenza season. MMWR Recomm Rep 2017; 66:1.</LI>&#xD;&#xA;<LI>Centers for Disease Control and Prevention. People at high risk of developing flu-related complications. <A spellcheck=true href=\"http://www.cdc.gov/flu/about/disease/high_risk.htm \" target=_blank>http://www.cdc.gov/flu/about/disease/high_risk.htm </A>(Accessed on August 24, 2017.) &nbsp;</LI></OL></div><div id=\"graphicVersion\">Graphic 79334 Version 11.0</div></div></div>"},"79335":{"type":"graphic_figure","displayName":"Time course cardiac ischemia","title":"Manifestations of myocardial ischemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Manifestations of myocardial ischemia</div><div class=\"cntnt\"><img style=\"width:430px; height:269px;\" src=\"images/CARD/79335_Timecoursecardiacischemi.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the relative development of the manifestations of myocardial ischemia as the rate-pressure product is increased. Regional myocardial dysfunction, which can be detected as regional wall motion abnormalities on echocardiography, occurs before ECG changes or anginal chest pain.</div><div class=\"graphic_footnotes\">PCW: pulmonary capillary wedge pressure; ECG: electrocardiogram.</div><div class=\"graphic_reference\">Modified from: Beller GA. Am J Cardiol 1988; 61:22F.</div><div id=\"graphicVersion\">Graphic 79335 Version 5.0</div></div></div>"},"79337":{"type":"graphic_figure","displayName":"Survival alcoholic cardiomyop","title":"Outcome is poor in patients with alcoholic cardiomyopathy who continue to drink","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Outcome is poor in patients with alcoholic cardiomyopathy who continue to drink</div><div class=\"cntnt\"><img style=\"width:515px; height:344px;\" src=\"images/CARD/79337_Surv_alcoholic_cardiomy_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Survival curves of cardiac deaths show no difference in survival between patients with an idiopathic dilated cardiomyopathy and those with an alcoholic cardiomyopathy who abstain from further drinking. However, survival is significantly lower in those with an alcoholic cardiomyopathy who continue to drink (p = 0.002).</div><div class=\"graphic_reference\">Data from: Fauchier L, Babuty D, Poret P, et al, Eur Heart J 2000; 21:306.</div><div id=\"graphicVersion\">Graphic 79337 Version 5.0</div></div></div>"},"79338":{"type":"graphic_diagnosticimage","displayName":"RPL CT and MRI findings A","title":"CT and MRI images in reversible posterior leukoencephalopathy syndrome (RPLS) (A)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT and MRI images in reversible posterior leukoencephalopathy syndrome (RPLS) (A)</div><div class=\"cntnt\"><img style=\"width:430px; height:506px;\" src=\"images/NEURO/79338_RPL_CT_and_MRI_findings_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT image (A) shows hypodensity in the posterior white matter. MRI was obtained one day following CT, and T2-weighted image (B) shows hyperintensity in the white matter of the occipital lobes. FLAIR image (C) obtained more rostrally shows multifocal areas of hyperintensity both posteriorly and anteriorly; note that on the FLAIR image, the hyperintensity involves the gray as well as the white matter. Post-contrast T1-weighted coronal image (D) shows gyriform and nodular enhancement in the occipital lobes consistent with breakdown of the blood brain barrier.</div><div class=\"graphic_footnotes\">CT: computed tomography; MRI: magnetic resonance imaging; FLAIR: fluid-attenuated recovery inversion.</div><div class=\"graphic_reference\">Courtesy of Eric D Schwartz, MD.</div><div id=\"graphicVersion\">Graphic 79338 Version 5.0</div></div></div>"},"79339":{"type":"graphic_diagnosticimage","displayName":"Cozen fracture","title":"Cozen fracture","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Cozen fracture</div><div class=\"cntnt\"><img style=\"width:500px; height:515px;\" src=\"images/PEDS/79339_Cozen_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Right proximal tibial fracture.<br />(B) Healed fracture with valgus deformity in proximal tibia.<br />(C) Teleogram demonstrating right lower extremity with valgus alignment.</div><div class=\"graphic_reference\">Courtesy of William Phillips, MD, and Scott B Rosenfeld, MD, Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 79339 Version 4.0</div></div></div>"},"79340":{"type":"graphic_picture","displayName":"Incision and drainage for breast abscess","title":"Incision and drainage for breast abscess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Incision and drainage for breast abscess</div><div class=\"cntnt\"><img style=\"width:396px; height:366px;\" src=\"images/PC/79340_Skin_compromise_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large incisions are not necessary to drain breast abscesses.</div><div class=\"graphic_reference\">Courtesy of Michael J Dixon, MD.</div><div id=\"graphicVersion\">Graphic 79340 Version 3.0</div></div></div>"},"79342":{"type":"graphic_figure","displayName":"HLA-DR4 prevalence by age JRA","title":"Prevalence of HLA-DR4 in children with chronic arthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prevalence of HLA-DR4 in children with chronic arthritis</div><div class=\"cntnt\"><img style=\"width:435px; height:486px;\" src=\"images/RHEUM/79342_HLA-DR4_prevalence_by_age_J.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among children with juvenile rheumatoid arthritis (JRA), the proportion of the study population with the HLA-DR4 allele is shown by disease-onset type (top graph) and by gender (bottom). Horizontal line shows the frequency of the allele in the control group. HLA-DR4 was less common than in controls in younger males and patients with oligoarticular disease and more common than in controls in older children with polyarticular disease.</div><div class=\"graphic_footnotes\">HLA: human leukocyte antigen.</div><div class=\"graphic_reference\">Data from Murray KJ, Moroldo MB, Donnelly P, et al. Arthritis Rheum 1999; 42:1843.</div><div id=\"graphicVersion\">Graphic 79342 Version 3.0</div></div></div>"},"79343":{"type":"graphic_picture","displayName":"Adenocarcinoma in small biopsy and cytology","title":"Adenocarcinoma in small biopsy and cytology","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Adenocarcinoma in small biopsy and cytology</div><div class=\"cntnt\"><img style=\"width:512px; height:391px;\" src=\"images/ONC/79343_Adenocarcin_sm_biop_cyto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Poorly differentiated non-small cell carcinoma, favor adenocarcinoma.<br> (A) This core biopsy shows a solid pattern of growth, and morphologically, it lacks any acinar, papillary, or lepidic patterns. The mucin stain was also negative.<br> (B) The TTF-1 stain is strongly positive.<br> (C) The p63 stain is very focally positive. The strongly and diffusely positive TTF-1 and only focal p63 staining favor adenocarcinoma. In this case, EGFR mutation was positive.<br> (D) Cytology from different adenocarcinoma shows large malignant cells with abundant cytoplasm and prominent nuclei growing in an acinar structure.</div><div class=\"graphic_footnotes\">EGFR: epidermal growth factor receptor; TTF: thyroid transcription factor.</div><div class=\"graphic_reference\">Reproduced with permission from: Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 2011; 6:244. Copyright Â© 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 79343 Version 8.0</div></div></div>"},"79344":{"type":"graphic_table","displayName":"Modified NCI CTCAE v4 radiation dermatitis","title":"Proposed modifications to the NCI-CTCAE v4.03 grading and grade-specific management strategies for patients developing radiation dermatitis during treatment with cetuximab plus radiotherapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Proposed modifications to the NCI-CTCAE v4.03 grading and grade-specific management strategies for patients developing radiation dermatitis during treatment with cetuximab plus radiotherapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>Grade 1</strong>*<strong>:</strong> Faint erythema or dry desquamation</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>General management approaches<sup>&#916;</sup> </li> <li>Weekly follow-up is adequate, unless rapid progression is noted </li> </ul> </td> </tr> <tr> <td><strong>Grade 2</strong>*<sup>&#9674;</sup><strong>:</strong> Moderate to brisk erythema and/or dry desquamation; patchy moist desquamation, or nonhemorrhagic crusts mostly confined to skin folds and creases</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>General management approaches<sup>&#916;</sup> </li> <li>Consider twice-weekly assessments to monitor for rapid change </li> </ul> </td> </tr> <tr> <td class=\"indent1\">A. Dry desquamation without crusts:<br /> <ul class=\"decimal_heading\"> <li>Consider glucocorticosteroid cream or ointment for a limited period (one to two weeks) </li> <li>Consider topical antiseptics and antibiotics for the prevention of more severe reaction </li> <li>Topical antiseptics and antibiotics at any sign of superinfection </li> </ul> </td> </tr> <tr> <td class=\"indent1\">B. Moist desquamation in skin folds:<br /> <ul class=\"decimal_heading\"> <li>Topical antiseptic </li> <li>Consider adding daily topical glucocorticosteroid lotion to reduce inflammation for a limited period (one to two weeks) </li> <li>Topical antibiotics active against S. aureus at any sign of superinfection; consider systemic antibiotics if superinfection becomes more severe </li> <li>Topical eosin or soft zinc preparations in the skin folds. A thin layer of a soft zinc preparation may be used in skin folds, but should be removed before treatment with radiotherapy to avoid radiation dosimetric problems. Topical eosin in skin folds or on erosive lesions may also be a useful treatment approach. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">C. Dry desquamation with isolated non-hemorrhagic crusts:<br /> <ul class=\"decimal_heading\"> <li>Topical antiseptic </li> <li>Consider adding daily topical glucocorticosteroid lotion to reduce inflammation for a limited period (one to two weeks) </li> <li>Topical antibiotics active against S. aureus at any sign of superinfection. Consider systemic antibiotics if superinfection becomes more severe. </li> <li>Topical eosin or soft zinc preparations in the skin folds. A thin layer of a soft zinc preparation may be used in skin folds but should be removed before treatment with radiotherapy to avoid radiation dosimetric problems. </li> <li>Hydrogels can be used to keep crusts flexible </li> <li>Consider debridement using hydrogels; skin trauma should be avoided to prevent superinfection </li> </ul> </td> </tr> <tr> <td><strong>Grade 3</strong>*<sup>&#9674;</sup><strong>:</strong> Moist desquamation or hemorrhagic crusts; nonhemorrhagic crusts other than in skin folds and mostly confined to skin folds and creases; bleeding induced by minor trauma or abrasion; superinfection requiring oral antibiotics</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>General management approaches<sup>&#9674;</sup> </li> <li>Evaluate the need for daily assessment </li> <li>Closely monitor for signs of local or systemic infection </li> <li>For grade 3 reactions occurring at &#60;50 Gy, consider brief interruption in treatment </li> </ul> </td> </tr> <tr> <td class=\"indent1\">A. Confluent moist desquamation without crusts:<br /> <ul class=\"decimal_heading\"> <li>Topical antiseptic </li> <li>Consider adding daily topical glucocorticosteroid lotion to reduce inflammation for a limited period (one to two weeks) </li> <li>Topical antibiotics active against S. aureus at any sign of superinfection </li> <li>If superinfection becomes more severe, consider the use of IV antibiotics if unresponsive to oral antibiotics </li> <li>Topical eosin or soft zinc preparations in the skin folds. A thin layer of a soft zinc preparation may be used in skin folds, but should be removed before treatment with radiotherapy to avoid radiation dosimetric problems. Topical eosin in skin folds or on erosive lesions may also be a useful treatment approach. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">B. Confluent moist desquamation with crusts:<br /> <ul class=\"decimal_heading\"> <li>Topical antiseptic </li> <li>If superinfection becomes more severe, consider the use of IV antibiotics if unresponsive to oral antibiotic </li> <li>Consider debridement using hydrogels; skin trauma should be avoided to prevent superinfection </li> <li>If hydrocolloid dressings are used, the thickness of the dressing should be taken into account for the radiotherapy dosimetry; hydrofiber dressings can be used after completion of radiotherapy </li> </ul> </td> </tr> <tr> <td><strong>Grade 3</strong>*<sup>&#9674;</sup><strong>:</strong> Life-threatening consequences; extensive confluent hemorrhagic crusts or ulceration (&#62;50 percent of involved field); extensive spontaneous bleeding from involved site (&#62;40 percent of the involved site); skin necrosis or ulceration of full-thickness dermis or any size ulcer with extensive destruction, tissue necrosis or damage to muscle, bone or supporting structures with or without full-thickness skin loss<sup>&#167;</sup>; skin graft indicated; ulceration associated with extensive superinfection with IV antibiotics indicated</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>General management approaches<sup>&#916;</sup> </li> <li>Consider interrupting treatment with both radiotherapy and cetuximab; cetuximab should be interrupted until the skin reaction has resolved to at least grade 2 </li> <li>In the case of severe superinfection, consider IV antibiotics if unresponsive to oral antibiotics </li> <li>Hospitalize the patient </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Based upon modified National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE).<br />&Delta; General management approach: Patients should be provided with written information on how to manage skin reactions. Patients should keep the affected skin clean, wash their hands before touching the affected area, and use clean towels. The affected area should be washed once in the morning and once in the evening, using pH 5 (pH skin neutral) soaps and/or showering oils for sensitive skin, followed by moisturization with an unperfumed moisturizer recommended for dry skin. There is no evidence of any benefit of aloe vera and it may aggravate the reaction to treatment. Moisturizers that contain urea (&lt;3 percent) and/or have a high glycerol content are recommended. Shaving with a sharp, disinfected wet razor should be encouraged to reduce the risk for folliculitis; care should be taken to avoid local trauma. Patients should avoid sunbathing/sun exposure, scratching and mechanical trauma, and the use of skin irritants such as alcohol-based lotions and perfumes. Debridement of crusts may reduce the risk for superinfection and bleeding and may help pain management. Local trauma should be avoided. Hydrogels can be used to keep crusts flexible and reduce the risk for skin trauma and pain as well as to facilitate debridement. Following debridement, emollients can be used to moisturize the skin, and/or hydrocolloid or hydrofiber dressings can be used to protect the skin from further trauma. All dressings should be transparent, so that signs of superinfection can be observed. Care should be taken to ensure that anything used on the skin (eg, dressings or creams) does not alter the dose of radiation. The patient should be closely monitored for signs of systemic inflammatory response and changes in the clinical presentation of dermatitis. Where superinfection is suspected in cases of dermatitis up to grade 2, local antiseptics and/or topical antibiotics may be beneficial. The use of systemic antibiotics may be considered if superinfection becomes more severe. Before the initiation of any antibiotic treatment, cultures should be obtained.<br /><span class=\"lozenge\">&loz;</span> Possibility of local superinfection as indicated by the clinical appearance (moist desquamation and crusts, with yellowing) and by microbiological assessment (from swabs of the area and blood tests); suspected systemic superinfection is indicated by the presence of at least two of the following four variables of systemic inflammatory response syndrome: fever with a core temperature &gt;38&deg;C or &lt;36&deg;C, heart rate &gt;90 beats per min, respiratory rate &gt;20 breaths per min, leukocytosis (&gt;12 x 10<sup>9</sup>/L) or leukopenia (&lt;4 x 10<sup>9</sup>/L).<br />&sect; Skin necrosis of full-thickness dermis is rarely seen with the recommended doses of cetuximab plus radiotherapy and this type of diagnosis should be based only on a biopsy of tissue from the involved site.</div><div class=\"graphic_reference\">From: Bernier J, Russi EG, Homey B, et al.&nbsp;Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines. Ann Oncol 2011; 22:2191. By permission of the European Society for Medical Oncology. Copyright Â© 2013 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 79344 Version 15.0</div></div></div>"},"79346":{"type":"graphic_diagnosticimage","displayName":"Bilateral facet dislocation CT","title":"Bilateral facet dislocations","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Bilateral facet dislocations</div><div class=\"cntnt\"><img style=\"width:507px; height:301px;\" src=\"images/EM/79346_Facet_dislocatn_bilat2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These CT images show a bilateral facet dislocation (arrows) at the C6-C7 level.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Mary Hochman, MD.</div><div id=\"graphicVersion\">Graphic 79346 Version 3.0</div></div></div>"},"79347":{"type":"graphic_figure","displayName":"Malaria eradication phases","title":"Phases of malaria eradication","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Phases of malaria eradication</div><div class=\"cntnt\"><img style=\"width:514px; height:244px;\" src=\"images/ID/79347_Malaria_eradication_phases.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Modified with permission from: World Health Organization. World Malaria Report, 2008. p. 31. Available at http://apps.who.int/malaria/wmr2008/malaria2008.pdf. Copyright &#169; 2008 World Health Organization.</div><div id=\"graphicVersion\">Graphic 79347 Version 1.0</div></div></div>"},"79348":{"type":"graphic_movie","displayName":"TEE ASD","title":"Transesophageal echocardiogram of an atrial septal defect","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transesophageal echocardiogram of an atrial septal defect</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/79348_atsepdetconv.mp4\" style=\"width:312px;height:224px\"></div><img style=\"width:314px; height:209px;\" src=\"images/CARD/79348_atsepdet.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transesophageal echocardiogram shows a large defect in the mid interatrial septum compatible with an ostium secundum atrial septal defect (ASD).</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 79348 Version 4.0</div></div></div>"},"79351":{"type":"graphic_table","displayName":"Beta-lactam oral desensitization protocol","title":"Beta-lactam oral desensitization protocol","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Beta-lactam oral desensitization protocol</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Beta-lactam concentration<br /> (mg/mL)*</td> <td class=\"subtitle1\">Dose number<sup>&#182;</sup></td> <td class=\"subtitle1\">Amount given<sup>&#916;</sup><br /> (mL)</td> <td class=\"subtitle1\">Dose given during step<br /> (mg)</td> <td class=\"subtitle1\">Cumulative dose<br /> (mg)<sup>[1]</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"7\">0.5</td> <td class=\"centered\">1</td> <td class=\"centered\">0.1</td> <td class=\"centered\">0.05</td> <td class=\"centered\">0.05</td> </tr> <tr> <td class=\"centered\">2</td> <td class=\"centered\">0.2</td> <td class=\"centered\">0.10</td> <td class=\"centered\">0.15</td> </tr> <tr> <td class=\"centered\">3</td> <td class=\"centered\">0.4</td> <td class=\"centered\">0.20</td> <td class=\"centered\">0.35</td> </tr> <tr> <td class=\"centered\">4</td> <td class=\"centered\">0.8</td> <td class=\"centered\">0.40</td> <td class=\"centered\">0.75</td> </tr> <tr> <td class=\"centered\">5</td> <td class=\"centered\">1.6</td> <td class=\"centered\">0.80</td> <td class=\"centered\">1.55</td> </tr> <tr> <td class=\"centered\">6</td> <td class=\"centered\">3.2</td> <td class=\"centered\">1.60</td> <td class=\"centered\">3.15</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">7</td> <td class=\"centered\">6.4</td> <td class=\"centered\">3.20</td> <td class=\"centered\">6.35</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">5</td> <td class=\"centered\">8</td> <td class=\"centered\">1.2</td> <td class=\"centered\">6</td> <td class=\"centered\">12.35</td> </tr> <tr> <td class=\"centered\">9</td> <td class=\"centered\">2.4</td> <td class=\"centered\">12</td> <td class=\"centered\">24.35</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">10</td> <td class=\"centered\">4.8</td> <td class=\"centered\">24</td> <td class=\"centered\">49.35</td> </tr> <tr> <td rowspan=\"4\">50</td> <td class=\"centered\">11</td> <td class=\"centered\">1</td> <td class=\"centered\">50</td> <td class=\"centered\">100</td> </tr> <tr> <td class=\"centered\">12</td> <td class=\"centered\">2</td> <td class=\"centered\">100</td> <td class=\"centered\">200</td> </tr> <tr> <td class=\"centered\">13</td> <td class=\"centered\">4</td> <td class=\"centered\">200</td> <td class=\"centered\">400</td> </tr> <tr> <td class=\"centered\">14</td> <td class=\"centered\">8</td> <td class=\"centered\">400</td> <td class=\"centered\">800</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Upon completion of the steps above, observe patient for 30 minutes. Additional therapeutic doses can then be given by the route of choice, at normal dosing intervals.</div><div class=\"graphic_footnotes\">* Dilutions prepared from antibiotic syrup, 250 mg/5 mL.<br />&para; Dose approximately doubled every 15 minutes.<br />&Delta; Drug amount given in 30 mL water or flavored beverage.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol 2010; 105:259.</li>&#xD;&#xA;</ol>&#xD;&#xA;Original figure modified for this publication. Sullivan TJ. Drug allergy. In: Allergy: Principles and Practice, 4th Edition, Middleton EJ, Reed CE, Eliss EF, et al (Eds), St. Louis: Mosby, 1993. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 79351 Version 16.0</div></div></div>"},"79352":{"type":"graphic_diagnosticimage","displayName":"Hyperplastic gastric polyps UGI","title":"Hyperplastic gastric polyps","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hyperplastic gastric polyps</div><div class=\"cntnt\"><img style=\"width:267px; height:279px;\" src=\"images/GAST/79352_Hyperplastic_gastric_polyps.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Double contrast upper gastrointestinal study shows multiple well-circumscribed uniformly sized hyperplastic polyps arising from the gastric mucosa (arrows).</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 79352 Version 2.0</div></div></div>"},"79353":{"type":"graphic_diagnosticimage","displayName":"Gallstones OCG","title":"Oral cholecystogram showing gallstones","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oral cholecystogram showing gallstones</div><div class=\"cntnt\"><img style=\"width:263px; height:390px;\" src=\"images/GAST/79353_Gallstones_OCG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An oral cholecystogram showing floating cholesterol gallstones.</div><div class=\"graphic_reference\">Courtesy of Salam F Zakko, MD, FACP.</div><div id=\"graphicVersion\">Graphic 79353 Version 4.0</div></div></div>"},"79355":{"type":"graphic_picture","displayName":"Butterfly rash PI","title":"Butterfly rash caused by lupus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Butterfly rash caused by lupus</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/PI/79355_Butterfly_rash_PI_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lupus can cause a rash on the face that looks like this. Doctors sometimes call it a \"butterfly rash.\"</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 79355 Version 7.0</div></div></div>"},"79356":{"type":"graphic_table","displayName":"Effects violence exposure","title":"Effects of exposure to intimate partner violence","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Effects of exposure to intimate partner violence</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Infants and toddlers</td> </tr> <tr> <td class=\"indent1\">Emotional distress and fear of being alone</td> </tr> <tr> <td class=\"indent1\">Attachment problems</td> </tr> <tr> <td class=\"subtitle1_single\">Pre-schoolers</td> </tr> <tr> <td class=\"indent1\">Difficulty developing empathy</td> </tr> <tr> <td class=\"indent1\">Poor self-esteem</td> </tr> <tr> <td class=\"indent1\">Nightmares</td> </tr> <tr> <td class=\"indent1\">Sleep difficulties</td> </tr> <tr> <td class=\"indent1\">Separation/anxiety issues</td> </tr> <tr> <td class=\"subtitle1_single\">School-age</td> </tr> <tr> <td class=\"indent1\">Feeling guilty, blaming themselves</td> </tr> <tr> <td class=\"indent1\">Adoption of antisocial rationales for abusive behavior</td> </tr> <tr> <td class=\"indent1\">Poor social skills</td> </tr> <tr> <td class=\"indent1\">Peer difficulties</td> </tr> <tr> <td class=\"indent1\">Bullying/aggressive behavior</td> </tr> <tr> <td class=\"indent1\">Parentification</td> </tr> <tr> <td class=\"subtitle1_single\">Adolescents</td> </tr> <tr> <td class=\"indent1\">Difficulty forming healthy relationships</td> </tr> <tr> <td class=\"indent1\">Avoidant attachment style</td> </tr> <tr> <td class=\"indent1\">Aggression</td> </tr> <tr> <td class=\"indent1\">Abusive behaviors in their own intimate relationships</td> </tr> <tr> <td class=\"indent1\">Mental and emotional disengagement</td> </tr> <tr> <td class=\"indent1\">Parentification</td> </tr> </tbody></table></div><div class=\"graphic_reference\">1. Holt S, Buckley H, Whelan S. The impact of exposure to domestic violence on children and young people:&nbsp;A review of the literature. Child Abuse Negl 2008; 32:797.<br />2. Hurley DJ, Jaffe P. Adoption of values and attitudes about violence and treatment of women. Can J Psychiatry 1990; 35:471.<br />3. Levendosky AA, Huth-Bocks AC, Semel MA. Adolescent peer relationships and mental health functioning in families with domestic violence. J Clin Child Adolesc Psychol 2002; 31:206. <br />4. Lundy M, Grossman SF. The mental health and service needs of young children exposed to domestic violence: Supportive data. Fam Soc 2005: 86:17.&nbsp; </div><div id=\"graphicVersion\">Graphic 79356 Version 8.0</div></div></div>"},"79357":{"type":"graphic_table","displayName":"Evaluation of the patient with postoperative fever","title":"Evaluation of the patient with postoperative fever","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation of the patient with postoperative fever</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">History</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle2_single\">Review record for:</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Preoperative course and presentation</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Operation (emergent or elective, intraoperative complications)</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Postoperative course</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Past medical history and underlying medical problems</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Allergies</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Medications</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Location of catheters and time of placement</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle2_single\">Ask nursing staff about:</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Sputum amount and quality</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Diarrhea</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Any areas of skin breakdown or rashes</td>\n\t\t\t\t\t\t</tr>\n\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle2_single\">Ask patient about:</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Cough</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Pain</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_single\">Physical examination</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Review record for vital signs. Determine range in the past day and peak daily values during hospital stay. Check nurses' notes for fevers not recorded in the vital signs chart.</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Temperature</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Heart rate</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Respiratory rate</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle2_single\">Examine:</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Skin for rash, ecchymoses, injection site erythema, and hematoma</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Lungs</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Heart for tachycardia or new murmur</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Abdomen for tenderness, bloating, bowel sounds</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Operative site and lymphatic drainage</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Catheter entry sites</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Lower legs for evidence of deep vein thrombosis</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td colspan=\"2\" rowspan=\"1\" class=\"subtitle1_single\">Laboratory*</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td colspan=\"2\" rowspan=\"1\">Urinalysis and culture</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td colspan=\"2\" rowspan=\"1\">Sputum gram stain and culture</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td colspan=\"2\" rowspan=\"1\">Blood culture (from catheters and peripherally - minimum of two)</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td colspan=\"2\" rowspan=\"1\">Wound culture</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td colspan=\"2\" rowspan=\"1\">Complete blood count with differential</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td colspan=\"2\" rowspan=\"1\">Chest radiograph</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td colspan=\"2\" rowspan=\"1\">Additional blood or radiographic studies might be indicated by specific findings. As examples, abdominal pain might indicate the need for blood tests for hepatic and pancreatic enzymes or abdominal CT scanning; unilateral leg edema might indicate the need for ultrasound to rule out DVT.</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table></div><div class=\"graphic_footnotes\">* Studies should be ordered based upon the patient evaluation; no test is mandatory to obtain.</div><div id=\"graphicVersion\">Graphic 79357 Version 2.0</div></div></div>"},"79358":{"type":"graphic_table","displayName":"Patient selection for noninvasive ventilation","title":"Guidelines for selecting patients with chronic respiratory failure for noninvasive nocturnal ventilation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guidelines for selecting patients with chronic respiratory failure for noninvasive nocturnal ventilation</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Chronic hypoventilation\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Daytime PaCO2 &#8805;45 mmHg <strong>OR</strong>\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Nocturnal hypoventilation with sustained O2 desaturation (eg, O2 saturation below 88 mmHG for more than 5 consecutive minutes) <strong>AND</strong> symptoms (eg, morning headache, hypersomnolence, etc)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Appropriate diagnosis\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\" colspan=\"1\">\r\n  \r\n   Slowly progressive neuromuscular disease - post-polio syndrome, muscular dystrophy, etc\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Chest wall deformity\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Reversible contributing factors treated - heart failure, obstructive sleep apnea, etc\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Adequate upper airway function</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 79358 Version 2.0</div></div></div>"},"79359":{"type":"graphic_table","displayName":"Etiology of nasal obstruction","title":"Etiology of nasal obstruction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology of nasal obstruction</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Mucosal</td> </tr> <tr> <td class=\"subtitle2_left\">Inflammatory</td> </tr> <tr> <td class=\"indent1\">Rhinosinusitis (may also have infectious etiology)</td> </tr> <tr> <td class=\"indent1\">Rhinitis, allergic and non-allergic</td> </tr> <tr> <td class=\"indent1\">Nasal polyps</td> </tr> <tr> <td class=\"indent1\">Granulomatosis with polyangiitis (Wegener's)</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> </tr> <tr> <td class=\"indent1\">Histiocytosis X</td> </tr> <tr> <td class=\"subtitle2_left\">Infectious</td> </tr> <tr> <td class=\"indent1\">HIV</td> </tr> <tr> <td class=\"indent1\">Syphilis</td> </tr> <tr> <td class=\"indent1\">Tuberculosis</td> </tr> <tr> <td class=\"indent1\">Nasal vestibulitis</td> </tr> <tr> <td class=\"subtitle2_left\">Medication</td> </tr> <tr> <td class=\"indent1\">Antithyroid medications</td> </tr> <tr> <td class=\"sublist2_start\">Antihypertensive medications</td> </tr> <tr> <td class=\"sublist2\">Alpha-blockers</td> </tr> <tr> <td class=\"sublist2\">Angiotensin-converting enzyme (ACE) inhibitors</td> </tr> <tr> <td class=\"sublist2\">Beta-blockers</td> </tr> <tr> <td class=\"sublist2\">Calcium channel blockers</td> </tr> <tr> <td class=\"sublist2\">Hydralazine</td> </tr> <tr> <td class=\"indent1\">Some antidepressants</td> </tr> <tr> <td class=\"indent1\">Benzodiazepines</td> </tr> <tr> <td class=\"indent1\">Erectile dysfunction agents (phosphodiesterase 5-inhibitors)</td> </tr> <tr> <td class=\"indent1\">Estrogen and progesterone</td> </tr> <tr> <td class=\"indent1\">Nonsteroidal antiinflammatory drugs (NSAIDs)</td> </tr> <tr> <td class=\"indent1\">Rhinitis medicamentosa (rebound nasal congestion with intranasal decongestants such as oxymetazoline or neosynephrine)</td> </tr> <tr> <td class=\"subtitle1_single\">Structural</td> </tr> <tr> <td><strong>Congenital abnormalities</strong> (eg, pyriform aperture stenosis, choanal atresia)</td> </tr> <tr> <td class=\"subtitle2_left\">Acquired abnormalities</td> </tr> <tr> <td class=\"indent1\">Enlarged adenoids</td> </tr> <tr> <td class=\"indent1\">Foreign bodies</td> </tr> <tr> <td class=\"indent1\">Septal disorders (eg, septal perforation due to intranasal cocaine, septal deviation due to trauma)</td> </tr> <tr> <td class=\"indent1\">Nasal valve abnormalities</td> </tr> <tr> <td class=\"indent1\">Mucoceles</td> </tr> <tr> <td><strong>Tumors</strong> (eg, inverted papilloma, squamous cell carcinoma, adenoid cystic carcinoma, olfactory neuroblastoma)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 79359 Version 5.0</div></div></div>"},"79360":{"type":"graphic_figure","displayName":"Risk groups and survival ET","title":"Risk groups and survival in patients with essential thrombocythemia","html":"<div class=\"graphic\"><div style=\"width: 575px\" class=\"figure\"><div class=\"ttl\">Risk groups and survival in patients with essential thrombocythemia</div><div class=\"cntnt\"><img style=\"width:555px; height:416px;\" src=\"images/HEME/79360_Risk_groups_and_survival_ET.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Overall survival according to risk stratification in patients with essential thrombocythemia. Overall survival rates at 5, 10, and 20 years according to risk group with 95% confidence intervals (CIs) are as follows: low risk-100.0% (95% CI, 100.0-100.0), 94.6% (95% CI, 90.5-98.9), and 72.0% (95% CI, 62.4-82.8); intermediate risk-95.2% (95% CI, 91.1-99.4), 82.9% (95% CI, 75.8-90.7), and 29.0% (95% CI, 19.3-43.5); and high risk-87.7% (95% CI, 75.2-100.0), 52.6% (95% CI, 35.7-77.5), and 0%.</div><div class=\"graphic_reference\">Reproduced with permission from: Wolanskyj AP, Schwager SM, McClure RF, et al. Essential Thrombocythemia Beyond the First Decade: Life Expectancy, Long-term Complication Rates, and Prognostic Factors. Mayo Clin Proc 2006; 81:159. Copyright &#169; 2006 Mayo Foundation.</div><div id=\"graphicVersion\">Graphic 79360 Version 5.0</div></div></div>"},"79361":{"type":"graphic_table","displayName":"Virulence factors K pneum","title":"Major virulence factors in pathogenicity of Klebsiella pneumoniae","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major virulence factors in pathogenicity of Klebsiella pneumoniae</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">Virulence factor</td>\n\t\t\t\t\t<td class=\"subtitle1\">Main components</td>\n\t\t\t\t\t<td class=\"subtitle1\">Major function(s)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Capsule (77 K serotypes)</td>\n\t\t\t\t\t<td>K1 or K2 capsular polysaccharide</td>\n\t\t\t\t\t<td>Antiphagocytosis</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Hypermucoviscosity phenotype</td>\n\t\t\t\t\t<td>Extracapsular polysaccharide</td>\n\t\t\t\t\t<td>Serum resistance</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td rowspan=\"2\">Lipopolysaccharide (O-antigen 9 serotypes: O1, O2, O2ac, O3, O4, O5, O7, O8, and O12)</td>\n\t\t\t\t\t<td>Lipopolysaccharide</td>\n\t\t\t\t\t<td>Endotoxin</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>O side chain</td>\n\t\t\t\t\t<td>Serum resistance</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Siderophores</td>\n\t\t\t\t\t<td>Enterobactin, aerobactin, aerobactin receptor, kfu iron uptake system</td>\n\t\t\t\t\t<td>Enhanced growth</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td rowspan=\"3\">Pili (fimbriae)</td>\n\t\t\t\t\t<td>Adhesin</td>\n\t\t\t\t\t<td>Attachment</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Type 1 pili (FimH adhesion)</td>\n\t\t\t\t\t<td>Mannose-sensitive</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Type 3 pili (MrkD adhesion)</td>\n\t\t\t\t\t<td>Mannose-resistant</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 79361 Version 1.0</div></div></div>"},"79363":{"type":"graphic_picture","displayName":"Nasal dermoid","title":"Nasal dermoid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nasal dermoid</div><div class=\"cntnt\"><img style=\"width:182px; height:152px;\" src=\"images/PEDS/79363_Nasal_dermoid2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nasal dermoids typically present as a midline pit or punctum anywhere along the dorsal surface of the nose.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 79363 Version 2.0</div></div></div>"},"79365":{"type":"graphic_table","displayName":"Potential adverse effects of GH therapy","title":"Potential adverse effects of growth hormone therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential adverse effects of growth hormone therapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Unmet expectations</td> </tr> <tr> <td>Metabolic effects</td> </tr> <tr> <td>Antibodies to growth hormone</td> </tr> <tr> <td>Progression of pre-existing scoliosis</td> </tr> <tr> <td>Slipped capital femoral epiphysis</td> </tr> <tr> <td class=\"sublist1_start\">Fluid retention or edema</td> </tr> <tr> <td class=\"sublist1_start\">Idiopathic intracranial hypertension (pseudotumor cerebri)</td> </tr> <tr> <td class=\"sublist1_start\">Pancreatitis</td> </tr> <tr> <td class=\"sublist1_start\">Transient gynecomastia</td> </tr> <tr> <td class=\"sublist1_start\">Increased growth and pigmentation of nevi</td> </tr> <tr> <td class=\"sublist1_start\">Carpal tunnel syndrome</td> </tr> <tr> <td class=\"sublist1_start\">Arthralgia</td> </tr> <tr> <td class=\"sublist1_start\">Second neoplasms</td> </tr> <tr> <td class=\"sublist1\">Meningioma</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 79365 Version 4.0</div></div></div>"},"79367":{"type":"graphic_figure","displayName":"VF temporal crescent defect","title":"Temporal crescent defect","html":"<div class=\"graphic\"><div style=\"width: 581px\" class=\"figure\"><div class=\"ttl\">Temporal crescent defect</div><div class=\"cntnt\"><img style=\"width:561px; height:259px;\" src=\"images/NEURO/79367_VF_temporal_crescent_defect.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Goldmann visual field showing a left monocular temporal crescent defect</div><div class=\"graphic_reference\">Reproduced with permission from: Zhang X, Kedar S, Lynn MJ, et al. Homonymous hemianopias: clinical-anatomic correlations in 904 cases. Neurology 2006; 66:906. Copyright Â© 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 79367 Version 6.0</div></div></div>"},"79368":{"type":"graphic_table","displayName":"Disorders treated HCT","title":"Immunodeficiency diseases which may be corrected by hematopoietic cell transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Immunodeficiency diseases which may be corrected by hematopoietic cell transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Lymphocyte defects </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Severe combined immunodeficiency (multiple types)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Wiskott-Aldrich syndrome</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>CD40 ligand deficiency (X-linked hyper IgM syndrome)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>CD40 deficiency (autosomal recessive hyper IgM syndrome)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>X-linked lymphoproliferative disease</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Interferon gamma receptor defects</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>NF kappa B essential modifier (NEMO) deficiency</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Hemophagocytic lymphohistiocytosis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Phagocyte defects </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Chronic granulomatous disease</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Leukocyte adhesion deficiency type 1</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Griscelli syndrome type 2</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Chediak-Higashi syndrome</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div id=\"graphicVersion\">Graphic 79368 Version 2.0</div></div></div>"},"79369":{"type":"graphic_diagnosticimage","displayName":"Waters view facial bones","title":"Water's view of facial bones","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Water's view of facial bones</div><div class=\"cntnt\"><img style=\"width:396px; height:320px;\" src=\"images/EM/79369_Waters_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Zygomaticomaxillary complex fracture on the left. Water's view shows soft tissue swelling over the entire face. However, there is asymmetry between the bony structures. Notice the fractures of the floor of the orbit (open arrow), lateral maxillary wall (long arrow), and lateral wall of the orbit (arrowhead) on the left.</div><div class=\"graphic_reference\">Reproduced with permission from: Wolters Kluwer. Copyright Â© 2008.</div><div id=\"graphicVersion\">Graphic 79369 Version 3.0</div></div></div>"},"79370":{"type":"graphic_diagnosticimage","displayName":"Technet RBC scan divertic bleed","title":"Technetium labeled red blood cell scan","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Technetium labeled red blood cell scan</div><div class=\"cntnt\"><img style=\"width:412px; height:301px;\" src=\"images/GAST/79370_Technet_RBC_scan_divertic_b.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A technetium labeled red blood cell scan from a 63-year-old patient with a 24-hour history of bright red blood per rectum reveals increased activity in the distal transverse colon near the splenic flexure (arrow) which progresses toward the descending colon and sigmoid colon by termination of the examination at one hour. These findings are consistent with bleeding from a source in the distal transverse colon near the splenic flexure.</div><div id=\"graphicVersion\">Graphic 79370 Version 2.0</div></div></div>"},"79371":{"type":"graphic_picture","displayName":"Immunoglobulin light chain (AL) amyloid bone marrow","title":"Monoclonal plasma cells inÂ immunoglobulin light chain (AL)Â amyloidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Monoclonal plasma cells in&nbsp;immunoglobulin light chain (AL)&nbsp;amyloidosis</div><div class=\"cntnt\"><img style=\"width:432px; height:295px;\" src=\"images/HEME/79371_Primary_amyloid_bone_marrow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunoperoxidase stain of a bone marrow biopsy from a patient with&nbsp;immunoglobulin light chain&nbsp;(AL) amyloidosis. Evidence for a monoclonal plasma cell disease is provided by the intense staining for lambda light chains (left panel) with almost no staining for kappa light chains (right panel).</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 79371 Version 2.0</div></div></div>"},"79373":{"type":"graphic_figure","displayName":"Diary record of peak flow values","title":"Peak flow diary in asthma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peak flow diary in asthma</div><div class=\"cntnt\"><img style=\"width:432px; height:322px;\" src=\"images/PULM/79373_Diary_record_of_PEFR.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diary record of peak expiratory flow (PEF) from an asthmatic patient over a one week period. The patient recorded PEF three times a day at waking (AM), noon (N) and upon retiring (PM). The red zone is set at 50 percent of the personal best, whereas the yellow is from 50 to 80 percent and the green zone is &gt;80 percent. Notice the reproducible morning (AM) falls in PEF characteristic of the patient with nocturnal asthma. Also note the improvement in PEF as&nbsp;glucocorticoids are added to the treatment regimen.</div><div id=\"graphicVersion\">Graphic 79373 Version 2.0</div></div></div>"},"79374":{"type":"graphic_diagnosticimage","displayName":"Malignant mesothelioma III CT","title":"Malignant mesothelioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Malignant mesothelioma</div><div class=\"cntnt\"><img style=\"width:323px; height:317px;\" src=\"images/PULM/79374_Malignant_mesothelioma_III.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan shows right sided circumferential pleural thickening and accompanying pleural effusion.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 79374 Version 3.0</div></div></div>"},"79375":{"type":"graphic_figure","displayName":"Dietary sources calcium and vitamin D PI","title":"Foods and drinks with calcium and vitamin D","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Foods and drinks with calcium and vitamin D</div><div class=\"cntnt\"><img style=\"width:526px; height:574px;\" src=\"images/PI/79375_Dietary_sources_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Foods rich in calcium include ice cream, soy milk, breads, kale, broccoli, milk, cheese, cottage cheese, almonds, yogurt, ready-to-eat cereals, beans, and tofu. Foods rich in vitamin D include milk, canned tuna fish, cod liver oil, yogurt, ready-to-eat-cereals, cooked salmon, canned sardines, mackerel, and eggs. Some of these foods are rich in both.</div><div id=\"graphicVersion\">Graphic 79375 Version 3.0</div></div></div>"},"79376":{"type":"graphic_table","displayName":"Clinical manifestations diabetic autonomic neuropathy","title":"Clinical manifestations of diabetic autonomic neuropathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of diabetic autonomic neuropathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">System</td> <td class=\"subtitle1\">Symptoms</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Cardiovascular</strong></td> <td> <ul> <li>Sinus tachycardia </li> <li>Postural tachycardia </li> <li>Bradycardia, fixed heart rate (more advanced disease) </li> <li>Systolic and diastolic dysfunction </li> <li>Decreased exercise tolerance&nbsp; </li> <li>Orthostatic hypotension with supine (nocturnal) hypertension </li> <li>Cardiac denervation syndrome </li> <li>Intraoperative and perioperative cardiovascular instability </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Gastrointestinal</strong></td> <td> <ul> <li>Esophageal dysmotility </li> <li>Gastroparesis </li> <li>Diarrhea </li> <li>Constipation </li> <li>Fecal incontinence </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Genitourinary</strong></td> <td> <ul> <li>Erectile dysfunction </li> <li>Retrograde ejaculation </li> <li>Neurogenic bladder and cystopathy </li> <li>Female sexual dysfunction (eg, loss of vaginal lubrication) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Sudomotor and vasomotor</strong></td> <td> <ul> <li>Anhidrosis </li> <li>Hyperhidrosis </li> <li>Heat intolerance </li> <li>Gustatory sweating </li> <li>Dry skin </li> <li>Decreased thermoregulation </li> <li>Altered blood flow </li> <li>Impaired vasomotion </li> <li>Edema </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Pupillary</strong></td> <td> <ul> <li>Pupillomotor function impairment (eg, decreased diameter of dark adapted pupil) </li> <li>Pseudo Argyll-Robertson pupil </li> </ul> </td> </tr> <tr> <td><strong>Metabolic</strong></td> <td> <ul> <li>Hypoglycemia unawareness </li> <li>Hypoglycemia unresponsiveness (delayed epinephrine secretion, reduced glucagon secretion) </li> </ul> </td> </tr> <tr> <td><strong>Other</strong></td> <td> <ul> <li>Sleep apnea </li> <li>Anxiety/depression </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 79376 Version 5.0</div></div></div>"},"79377":{"type":"graphic_table","displayName":"Infant hypoallergenic formula","title":"Formula options for infants with dietary protein-induced conditions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Formula options for infants with dietary protein-induced conditions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Manufacturer</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Extensively hydrolyzed casein-based formulas</td> </tr> <tr> <td class=\"indent1\">Enfamil Nutramigen</td> <td>Mead Johnson Nutrition</td> </tr> <tr> <td class=\"indent1\">Enfamil Nutramigen with Enflora LGG</td> <td>Mead Johnson Nutrition</td> </tr> <tr> <td class=\"indent1\">Pregestimil DHA and ARA</td> <td>Mead Johnson Nutrition</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Similac Expert Care Alimentum*</td> <td>Abbott Nutrition</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Extensively hydrolyzed whey-based formulas</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Gerber Extensive HA</td> <td>Gerber</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Amino acid-based formulas</td> </tr> <tr> <td class=\"indent1\">Elecare for infants</td> <td>Abbott Nutrition</td> </tr> <tr> <td class=\"indent1\">Neocate Infant DHA and ARA</td> <td>Nutricia</td> </tr> <tr> <td class=\"indent1\">PurAmino DHA and ARA</td> <td>Mead Johnson Nutrition</td> </tr> <tr> <td class=\"indent1\">Alfamino Infant</td> <td>Nestle</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LGG: <EM>Lactobacillus rhamnosus</EM> GG; DHA: docosahexaenoic acid; ARA: arachidonic acid.<br />* The ready-to-feed form of Similac Expert Care Alimentum is corn-free. All of the other formulas on this list, including the powder form of Similac Expert Care Alimentum, contain corn. </div><div id=\"graphicVersion\">Graphic 79377 Version 20.0</div></div></div>"},"79378":{"type":"graphic_picture","displayName":"Hyperacute rejection fibrin","title":"Renal allograft biopsy showing hyperacute rejection with marked vascular injury by light microscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Renal allograft biopsy showing hyperacute rejection with marked vascular injury by light microscopy</div><div class=\"cntnt\"><img style=\"width:360px; height:236px;\" src=\"images/NEPH/79378_Hyperacute_rejection_Fibrin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph in hyperacute rejection showing marked vascular injury with visible fibrin strands on the intimal surface (arrow). The vascular wall is largely replaced by fibrinoid necrosis; there is only minimal neutrophil infiltration despite the extensive vascular damage.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 79378 Version 3.0</div></div></div>"},"79379":{"type":"graphic_figure","displayName":"Sellheim spoon","title":"Sellheim spoon","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Sellheim spoon</div><div class=\"cntnt\"><img style=\"width:492px; height:176px;\" src=\"images/OBGYN/79379_Sellheim_spoon.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 79379 Version 3.0</div></div></div>"},"79380":{"type":"graphic_diagnosticimage","displayName":"Solitary pulmonary nodule FDG","title":"Fluorodeoxyglucose scan of lung cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fluorodeoxyglucose scan of lung cancer</div><div class=\"cntnt\"><img style=\"width:432px; height:223px;\" src=\"images/PULM/79380_Solitary_pulmonary_nodule_F.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Solitary pulmonary nodule in the left upper lobe, as shown on three different views. Scan performed with 18-Fluorine 5 fluorodeoxyglucose on a positron emission tomography unit shows vivid uptake of radionuclide, without any activity in the left hilum or in the mediastinum. These findings correspond to a stage 1 bronchogenic carcinoma.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 79380 Version 2.0</div></div></div>"},"79381":{"type":"graphic_figure","displayName":"Intrauterine position","title":"Intrauterine position","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Intrauterine position</div><div class=\"cntnt\"><img style=\"width:513px; height:569px;\" src=\"images/PEDS/79381_Intrauterine_position_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For most of gestation, the tibiae and feet are medially (internally) rotated, and the hips and femora are laterally (externally) rotated. The tibiae, feet, and femora become molded in these positions as the fetus grows.</div><div id=\"graphicVersion\">Graphic 79381 Version 4.0</div></div></div>"},"79383":{"type":"graphic_table","displayName":"Etiology of ataxia by age","title":"Etiology of ataxia by age of presentation and temporal course","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology of ataxia by age of presentation and temporal course</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Infants and younger children</td> </tr> <tr> <td class=\"subtitle2_single\">Acute</td> </tr> <tr> <td class=\"indent1\">Brain tumor*</td> </tr> <tr> <td class=\"indent1\">Neuroblastoma*</td> </tr> <tr> <td class=\"indent1\">Head trauma*</td> </tr> <tr> <td class=\"indent1\">Cerebellar abscess*</td> </tr> <tr> <td class=\"indent1\">Brainstem encephalitis*</td> </tr> <tr> <td class=\"indent1\">Acute demyelinating encephalomyelitis*</td> </tr> <tr> <td class=\"indent1\">Acute cerebellar ataxia<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Anticonvulsant toxicity<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Guillain-Barr&#233; syndrome<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Lead encephalopathy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tick paralysis</td> </tr> <tr> <td class=\"subtitle2_single\">Intermittent</td> </tr> <tr> <td class=\"indent1\">Benign paroxysmal vertigo<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Seizure<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist2_start\">Inborn errors of metabolism</td> </tr> <tr> <td class=\"sublist2\">Arginosuccinic aciduria</td> </tr> <tr> <td class=\"sublist2\">Citrullinemia</td> </tr> <tr> <td class=\"sublist2\">Ornithine transcarbamylase deficiency</td> </tr> <tr> <td class=\"sublist2\">Hartnup disease</td> </tr> <tr> <td class=\"sublist2\">Maple syrup urine disease</td> </tr> <tr> <td class=\"sublist2\">Pyruvate dehydrogenase deficiency</td> </tr> <tr> <td class=\"sublist2\">Pyruvate decarboxylase deficiency</td> </tr> <tr> <td class=\"sublist2\">Isovaleric acidemia</td> </tr> <tr> <td class=\"sublist2\">Biotinidase deficiency</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist2\">Leigh disease</td> </tr> <tr> <td class=\"subtitle2_single\">Chronic</td> </tr> <tr> <td class=\"sublist2_start\">Congenital anomaly of posterior fossa</td> </tr> <tr> <td class=\"sublist2\">Dandy-Walker syndrome</td> </tr> <tr> <td class=\"sublist2\">Chiari malformation</td> </tr> <tr> <td class=\"sublist2\">Encephalocele</td> </tr> <tr> <td class=\"sublist2\">Cerebellar vermis agenesis</td> </tr> <tr> <td class=\"sublist2\">Cerebellar aplasia, dysplasia, or hypoplasia</td> </tr> <tr> <td class=\"sublist2_start\">Hereditary ataxias</td> </tr> <tr> <td class=\"sublist2\">Ataxia-telangiectasia</td> </tr> <tr> <td class=\"sublist2\">Roussy-Levy disease</td> </tr> <tr> <td class=\"sublist2\">Marinesco-Sjogren syndrome</td> </tr> <tr> <td class=\"sublist2_start\">Degenerative CNS disease</td> </tr> <tr> <td class=\"sublist2\">Spinocerebellar ataxia</td> </tr> <tr> <td class=\"sublist2\">Pelizaeus-Merzbacher disease</td> </tr> <tr> <td class=\"sublist2\">Neuronal ceroid lipofuscinosis</td> </tr> <tr> <td class=\"sublist2\">Niemann-Pick disease</td> </tr> <tr> <td class=\"sublist2\">Sialidosis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Older children and adolescents</td> </tr> <tr> <td class=\"subtitle2_single\">Acute</td> </tr> <tr> <td class=\"indent1\">Brain tumor*</td> </tr> <tr> <td class=\"indent1\">Head trauma*</td> </tr> <tr> <td class=\"indent1\">Vertebrobasilar dissection*</td> </tr> <tr> <td class=\"indent1\">Stroke</td> </tr> <tr> <td class=\"indent1\">Cerebellar abscess*</td> </tr> <tr> <td class=\"indent1\">Brainstem encephalitis*</td> </tr> <tr> <td class=\"indent1\">Acute demyelinating encephalomyelitis*</td> </tr> <tr> <td class=\"indent1\">Acute labyrinthitis<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Alcohol toxicity<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Drugs of abuse (other ingestion)<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Guillain-Barr&#233; syndrome<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Acute cerebellar ataxia</td> </tr> <tr> <td class=\"indent1\">Tick paralysis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Conversion reaction</td> </tr> <tr> <td class=\"subtitle2_single\">Intermittent</td> </tr> <tr> <td class=\"indent1\">Basilar migraine<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Benign paroxysmal vertigo<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Seizure<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist2_start\">Inborn errors of metabolism</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist2\">Pyruvate decarboxylase deficiency</td> </tr> <tr> <td class=\"subtitle2_single\">Chronic</td> </tr> <tr> <td class=\"sublist2_start\">Congenital anomaly of posterior fossa</td> </tr> <tr> <td class=\"sublist2\">Chiari malformation</td> </tr> <tr> <td class=\"sublist2_start\">Hereditary ataxias</td> </tr> <tr> <td class=\"sublist2\">Friedreich ataxia</td> </tr> <tr> <td class=\"sublist2\">Olivopontocerebellar atrophy</td> </tr> <tr> <td class=\"sublist2_start\">Degenerative CNS disease</td> </tr> <tr> <td class=\"sublist2\">Abetalipoproteinemia</td> </tr> <tr> <td class=\"sublist2\">Vitamin E deficiency</td> </tr> <tr> <td class=\"sublist2\">GM2 gangliosidosis</td> </tr> <tr> <td class=\"sublist2\">Refsum disease</td> </tr> <tr> <td class=\"sublist2\">Niemann-Pick disease</td> </tr> <tr> <td class=\"sublist2\">Neuronal ceroid lipofuscinosis</td> </tr> <tr> <td class=\"sublist2\">Sialidosis</td> </tr> <tr> <td class=\"sublist2\">Dyssynergia cerebellaris myoclonica (previously, Ramsay Hunt syndrome type I)</td> </tr> <tr> <td class=\"sublist2\">Spinocerebellar ataxia</td> </tr> <tr> <td class=\"indent1\">Multiple sclerosis</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system.<br />* Life-threatening condition.<br />Â¶ Common condition.</div><div id=\"graphicVersion\">Graphic 79383 Version 9.0</div></div></div>"},"79384":{"type":"graphic_table","displayName":"Causes of thyroiditis","title":"Causes of thyroiditis according to the presence or absence of pain and tenderness","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of thyroiditis according to the presence or absence of pain and tenderness</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Synonyms or causes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Thyroid pain and tenderness</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Subacute thyroiditis</td> <td>Subacute granulomatous thyroiditis</td> </tr> <tr> <td>Subacute nonsuppurative thyroiditis</td> </tr> <tr> <td>de Quervain's thyroiditis</td> </tr> <tr> <td class=\"indent1\">Infectious thyroiditis</td> <td>Acute or chronic thyroiditis</td> </tr> <tr> <td class=\"indent1\">Radiation-induced thyroiditis</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Palpation- or trauma-induced thyroiditis</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">No thyroid pain and tenderness</td> </tr> <tr> <td class=\"sublist2_start\" rowspan=\"3\">Painless thyroiditis</td> <td>Silent thyroiditis</td> </tr> <tr> <td>Lymphocytic thyroiditis with spontaneously resolving hyperthyroidism</td> </tr> <tr> <td class=\"sublist_other_start\">Subacute lymphocytic thyroiditis</td> </tr> <tr> <td class=\"sublist2\">- Occurring postpartum</td> <td class=\"sublist_other\">Postpartum thyroiditis</td> </tr> <tr> <td class=\"sublist2\" rowspan=\"5\">- Associated with drugs</td> <td class=\"sublist_other\">Interferon-alpha</td> </tr> <tr> <td class=\"sublist_other\">Interleukin-2</td> </tr> <tr> <td class=\"sublist_other\">Lithium</td> </tr> <tr> <td class=\"sublist_other\">Tyrosine kinase inhibitors</td> </tr> <tr> <td class=\"sublist_other\">Checkpoint inhibitor immunotherapy</td> </tr> <tr> <td class=\"sublist2_start\">Chronic lymphocytic thyroiditis</td> <td class=\"sublist_other_start\">Hashimoto's thyroiditis</td> </tr> <tr> <td class=\"sublist2\">- Postpartum exacerbation</td> <td class=\"sublist_other\">Postpartum thyroiditis</td> </tr> <tr> <td class=\"indent1\">Amiodarone-associated thyroiditis</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Fibrous thyroiditis</td> <td>Riedel's thyroiditis</td> </tr> <tr> <td>Invasive thyroiditis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 79384 Version 4.0</div></div></div>"},"79387":{"type":"graphic_table","displayName":"IV rx IVC-related infxs","title":"Intravenous antimicrobial treatment of intravenous catheter-related bloodstream infection according to the specific pathogen isolated","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intravenous antimicrobial treatment of intravenous catheter-related bloodstream infection according to the specific pathogen isolated</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Pathogen</td> <td class=\"subtitle1\">Preferred antimicrobial agent</td> <td class=\"subtitle1\">Alternative antimicrobial agent</td> <td class=\"subtitle1\">Comment</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Gram-positive cocci</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"><em>Staphylococcus aureus</em></td> </tr> <tr> <td class=\"indent2\">Methicillin susceptible</td> <td>Nafcillin or oxacillin*</td> <td>Cefazolin or vancomycin</td> <td>--</td> </tr> <tr> <td class=\"indent2\">Methicillin resistant</td> <td>Vancomycin</td> <td>Daptomycin<sup>&#182;&#916;</sup></td> <td>Strains of <em>S. aureus</em> with reduced susceptibility or resistance to vancomycin have been reported; strains resistant to linezolid and strains resistant to daptomycin have been reported</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Coagulase-negative staphylococci</td> </tr> <tr> <td class=\"indent2\">Methicillin susceptible</td> <td>Nafcillin or oxacillin</td> <td>First-generation cephalosporin or vancomycin<sup>&#916;</sup></td> <td>Vancomycin has dosing advantages over nafcillin and oxacillin, but the latter are preferred because of concerns about increasing vancomycin resistance</td> </tr> <tr> <td class=\"indent2\">Methicillin resistant</td> <td>Vancomycin</td> <td>Daptomycin or&nbsp;linezolid<sup>&#182;</sup></td> <td>Strains resistant to linezolid have been reported</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"><em>Enterococcus faecalis/Enterococcus faecium</em></td> </tr> <tr> <td class=\"indent2\">Ampicillin susceptible</td> <td>Ampicillin (or penicillin) &#177; gentamicin</td> <td>Vancomycin</td> <td>Preliminary studies demonstrate efficacy of ampicillin and ceftriaxone is comparable to ampicillin and gentamicin for <em>E. faecalis </em>endocarditis<sup>[1]</sup></td> </tr> <tr> <td class=\"indent2\">Ampicillin resistant, vancomycin susceptible</td> <td>Vancomycin &#177; gentamicin</td> <td>Linezolid or daptomycin<sup>&#182;</sup></td> <td>Telavancin is active against vancomycin-susceptible <em>E. faecalis </em>while quinupristin/dalfopristin is not effective against <em>E. faecalis</em></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Ampicillin resistant, vancomycin resistant</td> <td>Linezolid or daptomycin<sup>&#182;</sup></td> <td>Quinupristin/dalfopristin<sup>&#182;</sup></td> <td>Susceptibility of vancomycin-resistant enterococci isolates varies; quinupristin/dalfopristin is not effective against <em>E. faecalis</em></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Gram-negative bacilli<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"><em>Escherichia coli</em> and <em>Klebsiella</em> species</td> </tr> <tr> <td class=\"indent2\">ESBL negative</td> <td>Third-generation cephalosporin (eg, ceftriaxone)</td> <td>Ciprofloxacin or aztreonam</td> <td>Susceptibility of strains varies</td> </tr> <tr> <td class=\"indent2\">ESBL positive</td> <td>Carbapenem (eg, ertapenem, imipenem, meropenem, or doripenem)</td> <td>Ciprofloxacin or newer beta-lactamase inhibitor combinations (ceftolozane-tazobactam<sup>[2]</sup> or ceftazidime-avibactam<sup>[3]</sup>)</td> <td>Susceptibility of strains varies</td> </tr> <tr> <td class=\"indent1\"><em>Enterobacter species</em> and <em>Serratia marcescens</em></td> <td>Carbapenem (eg, ertapenem, imipenem, or meropenem)</td> <td>Cefepime or ciprofloxacin</td> <td>Susceptibility of strains varies</td> </tr> <tr> <td class=\"indent1\"><em>Acinetobacter</em> species</td> <td>Ampicillin/sulbactam or carbapenem (eg, imipenem or meropenem)</td> <td>Polymyxins (polymyxin B/colistin) or tigecycline&nbsp;(often combination of agents needed for resistant isolates)</td> <td>Susceptibility of strains varies</td> </tr> <tr> <td class=\"indent1\"><em>Stenotrophomonas maltophilia</em></td> <td>TMP-SMX</td> <td>Ticarcillin-clavulanate</td> <td>--</td> </tr> <tr> <td class=\"indent1\"><em>Pseudomonas aeruginosa</em></td> <td>Fourth-generation cephalosporin (cefepime) or piperacillin-tazobactam, with or without aminoglycoside (tobramycin)</td> <td>Carbapenem (imipenem or meropenem), ciprofloxacin, or aztreonam</td> <td>Susceptibility of strains varies</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><em>Burkholderia cepacia</em></td> <td>TMP-SMX</td> <td>Carbapenem (imipenem or meropenem)</td> <td>Other species, such as <em>B. acidovorans</em> and <em>B. pickieii</em>, may be susceptible to same antimicrobial agents</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Uncommon pathogens</td> </tr> <tr> <td class=\"indent1\"><em>Corynebacterium jeikeium</em> (group JK)</td> <td>Vancomycin</td> <td>Linezolid (based on in vitro activity)</td> <td>Check susceptibilities for other corynebacteria</td> </tr> <tr> <td class=\"indent1\"><em>Chryseobacterium (Flavobacterium)</em> species</td> <td>Levofloxacin</td> <td>TMP-SMX, carbapenem (imipenem or meropenem)</td> <td>Based on in vitro activity</td> </tr> <tr> <td class=\"indent1\"><em>Ochrobacterium anthropi</em></td> <td>TMP-SMX or ciprofloxacin</td> <td>Imipenem, meropenem, ertapenem, or doripenem plus aminoglycoside</td> <td>--</td> </tr> <tr> <td class=\"indent1\"><em>Malassezia furfur</em></td> <td>Amphotericin B</td> <td>Voriconazole</td> <td>Intravenous lipids should be discontinued; some experts recommend removal of catheter</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">See <EM>S. aureus</EM> section of the text regarding important antibiotic management issues concerning linezolid.</div><div class=\"graphic_footnotes\">TMP-SMX: trimethoprim-sulfamethoxazole; ESBL: extended-spectrum beta-lactamase.<br />* Penicillin, if the strain is susceptible.<br />Â¶ Pediatric experience is limited.<br />Î Additional alternative agents include linezolid, tedizolid, ceftaroline, telavancin, dalbavancin, and oritavancin.<br />â Pending susceptibility results for the isolate.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>âFernandez-Hidalgo N, Almirante B, Gavalda J, et al. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating Enterococcus faecalis infective endocarditis. Clin Infect Dis 2013; 56:1261.</LI>&#xD;&#xA;<LI>Farrell DJ, Flamm RK, Sader HS, et al. Antimicrobial activity of ceftolozane-tazobactam tested against Enteriobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011-2012). Antimicrob Agents Chemother 2013; 57:6305.</LI>&#xD;&#xA;<LI>Zhanel GG, Lawson CD, Adam H, et al. Ceftazidime-avibactam: a novel cephalosporin/B-lactamase inhibitor combination. Drugs 2013; 2:159.</LI></OL></div><div id=\"graphicVersion\">Graphic 79387 Version 10.0</div></div></div>"},"79389":{"type":"graphic_waveform","displayName":"Basic case 4","title":"Basic case 4","html":"<div class=\"graphic normal\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Basic case 4</div><div class=\"cntnt\"><img style=\"width:520px; height:142px;\" src=\"images/CARD/79389_Basic_case_4.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 79389 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"79390":{"type":"graphic_diagnosticimage","displayName":"Multiple nodules in sarcoidosis","title":"Sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sarcoidosis</div><div class=\"cntnt\"><img style=\"width:324px; height:315px;\" src=\"images/PULM/79390_Multiple_nodules_in_sarcoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph demonstrates multiple bilateral pulmonary nodules and masses in a patient with the nummular form of pseudoalveolar sarcoidosis.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 79390 Version 3.0</div></div></div>"},"79391":{"type":"graphic_figure","displayName":"Flexible bronchoscope tip","title":"Diagram of a flexible bronchoscope's distal tip (ie, working tip)","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Diagram of a flexible bronchoscope's distal tip (ie, working tip)</div><div class=\"cntnt\"><img style=\"width:457px; height:606px;\" src=\"images/PULM/79391_Bronchoscope-tip.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 79391 Version 5.0</div></div></div>"},"79392":{"type":"graphic_picture","displayName":"Zone 2 blunt injury","title":"Forty-five year-old woman with blunt injury to the right eye","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Forty-five year-old woman with blunt injury to the right eye</div><div class=\"cntnt\"><img style=\"width:299px; height:485px;\" src=\"images/EM/79392_Zone_2_blunt_injury_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Clinically she was noted to have subconjunctival hemorrhage superiorly with a conjunctival laceration, hyphema (blood clot in inferior anterior chamber), and iridodialysis (separation of the iris from the ciliary body) superiorly. <br />(B) CT scan showed a hyperdense rim opposed to the sclera representing a scleral buckle from a prior surgery and aphakia (absence of the lens) also from prior surgery. There is significant deformity of the posterior sclera with vitreous volume loss. This woman had a 3 mm scleral laceration 2 mm posterior to the limbus.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 79392 Version 6.0</div></div></div>"},"79394":{"type":"graphic_figure","displayName":"Anatomy of thoracic inlet","title":"Anatomic relationships of the thoracic inlet","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomic relationships of the thoracic inlet</div><div class=\"cntnt\"><img style=\"width:328px; height:287px;\" src=\"images/ENDO/79394_Anatomy_of_thoracic_inlet.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 79394 Version 1.0</div></div></div>"},"79397":{"type":"graphic_figure","displayName":"Manual tender point survey","title":"Diagram of painful points in fibromyalgia","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Diagram of painful points in fibromyalgia</div><div class=\"cntnt\"><img style=\"width:528px; height:502px;\" src=\"images/PEDS/79397_Manual_tender_point_survey.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Okifuji A, Turk DC, Sinclair JD, et al. A standardized manual tender point survey. I. Development and determination of a threshold point for the identification of positive tender points in fibromyalgia syndrome. J Rheumatol 1997; 24:377. Copyright Â©1997 The Journal of Rheumatology Publishing Company Limited.</div><div id=\"graphicVersion\">Graphic 79397 Version 2.0</div></div></div>"},"79398":{"type":"graphic_table","displayName":"Anthrax vaccine target groups","title":"Recommendations for use of anthrax vaccine absorbed, by type of population","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for use of anthrax vaccine absorbed, by type of population</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Population</td> <td class=\"subtitle1\">Pre-event*</td> <td class=\"subtitle1\">Postexposure prophylaxis (PEP)<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td><strong>General public</strong></td> <td>Not recommended</td> <td>Recommended</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Special populations in the general public</td> </tr> <tr> <td class=\"indent1\">Pregnant women</td> <td>Not recommended</td> <td>Recommended</td> </tr> <tr> <td class=\"indent1\">Breastfeeding women</td> <td>Not recommended</td> <td>Recommended</td> </tr> <tr> <td class=\"indent1\">Children (aged &#60;18 yrs)</td> <td>Not recommended</td> <td>Determined on an event-by-event basis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Medical professionals</td> <td>Not recommended</td> <td>Recommended</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Populations at risk for occupational exposure</td> </tr> <tr> <td class=\"indent1\">Persons who handle animals or animal products</td> <td>Not routinely recommended<sup>&#916;</sup></td> <td>Recommended</td> </tr> <tr> <td class=\"indent1\">Persons who perform certain types of laboratory work</td> <td>Recommended<sup>&#9674;</sup></td> <td>Based on pre-event vaccination status</td> </tr> <tr> <td class=\"indent1\">Persons who work in postal facilities</td> <td>Not recommended</td> <td>Recommended</td> </tr> <tr> <td class=\"indent1\">Military personnel</td> <td>As recommended by the Department of Defense</td> <td>As recommended by the Department of Defense</td> </tr> <tr> <td class=\"indent1\">Persons involved in environmental investigations or remediation efforts</td> <td>Recommended</td> <td>Based on pre-event vaccination status</td> </tr> <tr> <td class=\"indent1\">Persons involved in emergency response activities<sup>&#167;</sup></td> <td>Not routinely recommended; may be offered on a voluntary basis under the direction of a comprehensive occupational health and safety program</td> <td>Recommended</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Five 0.5-mL doses administered intramuscularly at 0 weeks, 4 weeks, 6 months, 12 months, and 18 months; annual boosters are required to maintain immunity.<br />Â¶ Three 0.5-mL doses administered subcutaneously at 0, 2, and 4 weeks after exposure to aerosolized <EM>Bacillus anthracis</EM> spores for persons who have not completed the pre-event vaccination schedule.<br />Î Recommended only if handling potentially infected animals in research settings or in areas with a high incidence of enzootic anthrax or when standards and restrictions are insufficient to prevent exposure to <EM>B. anthracis</EM> spores.<br /><FONT class=lozenge>â</FONT> Laboratorians who work (1) with pure cultures of <EM>B. anthracis</EM> or preparations of <EM>B. anthracis</EM> spores, (2) with environmental samples associated with anthrax investigations, or (3) in spore-contaminated areas or other settings with exposure to aerosolized <EM>B. anthracis</EM> spores. Laboratorians who do not work in these settings are not recommended for pre-event vaccine.<br />Â§ Persons involved in emergency response activities might include persons who work in police departments, fire departments, hazardous material units, and the National Guard, as well as other government responders. These persons might perform site investigations, respond to suspicious substance reports (also known as white powder incidents), and perform other related activities, such as evacuation procedures or other activities critical to the maintenance of infrastructure.</div><div class=\"graphic_reference\">Modified from: Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2010; 59(RR-6):1-36.</div><div id=\"graphicVersion\">Graphic 79398 Version 7.0</div></div></div>"},"79399":{"type":"graphic_figure","displayName":"Metacarpal shaft fracture with apex dorsal angulation","title":"Metacarpal shaft fracture with apex dorsal angulation","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Metacarpal shaft fracture with apex dorsal angulation</div><div class=\"cntnt\"><img style=\"width:524px; height:191px;\" src=\"images/SURG/79399_Apex_dors_angl_metacarp_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A metacarpal shaft fracture often develops an apex dorsal angulation due to the intrinsic muscle and the long flexors that cross volar to the axis of the metacarpophalangeal joint (MCPJ).</div><div id=\"graphicVersion\">Graphic 79399 Version 7.0</div></div></div>"},"79400":{"type":"graphic_figure","displayName":"EP study in BBRVT","title":"EP study in BBRVT","html":"<div class=\"graphic\"><div style=\"width: 630px\" class=\"figure\"><div class=\"ttl\">EP study in BBRVT</div><div class=\"cntnt\"><img style=\"width:610px; height:358px;\" src=\"images/CARD/79400_EP_study_in_BBRVT_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Twelve surface ECG leads and intracardiac recordings from the ablation catheter (Carto D: placed at the location of the distal His recording), a decapolar His catheter (H1,2 to H9,10), and the RV catheter are shown during bundle branch reentrant VT. There are spontaneous cycle length variations in the tachycardia. Changes in the H-H interval predict the subsequent changes in the V-V interval, suggesting the dependence of the tachycardia on the His Purkinje network. This finding strongly supports the diagnosis of BBRVT.</div><div id=\"graphicVersion\">Graphic 79400 Version 1.0</div></div></div>"},"79405":{"type":"graphic_picture","displayName":"Infil UC plasmacytoid var","title":"Infiltrating urothelial carcinoma, plasmacytoid variant","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Infiltrating urothelial carcinoma, plasmacytoid variant</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ONC/79405_Infil_UC_plasmacytoid_var.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The plasmacytoid variant of urothelial carcinoma is characterized by cords or single malignant cells with eosinophilic cytoplasm and eccentrically placed, enlarged hyperchromatic nuclei.</div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 79405 Version 1.0</div></div></div>"},"79406":{"type":"graphic_diagnosticimage","displayName":"Nonossifying fibroma prox tibia","title":"Nonossifying fibroma of the proximal tibia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nonossifying fibroma of the proximal tibia</div><div class=\"cntnt\"><img style=\"width:410px; height:503px;\" src=\"images/PEDS/79406_Nonoss_fibroma_prox_tibia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This eccentrically placed, well-defined radiolucent lesion displays typical features of a slowly developing neoplasm, which is distorted with long bone growth (arrow). Its length far exceeds its width.</div><div class=\"graphic_reference\">Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &#169; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 79406 Version 2.0</div></div></div>"},"79407":{"type":"graphic_picture","displayName":"LAM in tuberous sclerosis","title":"Lymphangioleiomyomatosis in tuberous sclerosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphangioleiomyomatosis in tuberous sclerosis</div><div class=\"cntnt\"><img style=\"width:411px; height:271px;\" src=\"images/PULM/79407_LAM_in_tuberous_sclerosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph of lung tissue from a woman with tuberous sclerosis demonstrates cystic changes and postive actin staining (arrows) of smooth muscle fascicles in the cyst walls that are characteristic of lymphangioleiomyomatosis.</div><div class=\"graphic_reference\">From Colby, TV, Koss, MN, Travis, WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.</div><div id=\"graphicVersion\">Graphic 79407 Version 1.0</div></div></div>"},"79408":{"type":"graphic_figure","displayName":"Port placement splenectomy","title":"Port placement splenectomy*","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Port placement splenectomy*</div><div class=\"cntnt\"><img style=\"width:457px; height:587px;\" src=\"images/SURG/79408_Ports_lap_spleen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An open technique is used to enter the peritoneal cavity at the umbilicus (enlarged spleen) or in the subcostal location (normal-sized spleen). A 5 to 12 mm Hasson trocar is placed. A port is placed in the left flank region in the anterior axillary line between the left subcostal margin and the left iliac crest. This port is used to pass a stapler to transect the hilar vessels after dissection has been completed. Two additional 5 mm ports are placed for dissection and counter-traction. After the hilum has been transected and the perisplenic attachments divided, the spleen is captured into a large laparoscopic bag placed through the primary port site and removed by morselization (cutting it up). Alternatively, if the integrity of the spleen is important for pathologic analysis, a mini-laparotomy is performed.</div><div class=\"graphic_footnotes\">* Port placement and technique may vary amongst laparoscopic surgeons.</div><div id=\"graphicVersion\">Graphic 79408 Version 4.0</div></div></div>"},"79410":{"type":"graphic_figure","displayName":"Dirofilaria immitis life cycle","title":"<em>Dirofilaria immitis</em> life cycle","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\"><em>Dirofilaria immitis</em> life cycle</div><div class=\"cntnt\"><img style=\"width:564px; height:477px;\" src=\"images/ID/79410_Dirofil_immitis_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During a blood meal, an infected mosquito (<EM>Aedes</EM>, <EM>Culex</EM>, <EM>Anopheles</EM>, <EM>Mansonia</EM>) introduces third-stage filarial larvae of <EM>Dirofilaria immitis</EM> into the skin of the definitive host, which is usually a domestic dog or coyote in the United States (although a wide variety of other animals can also be infected, including felids, mustelids, pinnipeds, beaver, horses, and humans), where they penetrate into the bite wound <STRONG>(1)</STRONG>. In the definitive host, the L3 larvae undergo two more molts into L4 and adults. Adults reside in pulmonary arteries and are occasionally found in the right ventricle of the heart <STRONG>(2)</STRONG>. Adult females are usually 230 to 310 mm long by 350 mcm wide; males are usually 120 to 190 mm long by 300 mcm wide. Adults can live for 5 to 10 years. In the heart, the female worms are capable of producing microfilariae over their lifespan. The microfilariae are found in peripheral blood <STRONG>(3)</STRONG>. A mosquito ingests the microfilariae during a blood meal <STRONG>(4)</STRONG>. After ingestion, the microfilariae migrate from the mosquito's midgut through the hemocoel to the Malpighian tubules in the abdomen <STRONG>(5)</STRONG>. There, the microfilariae develop into first-stage larvae <STRONG>(6)</STRONG> and subsequently into third-stage infective larvae <STRONG>(7)</STRONG>. The third-stage infective larvae migrate to the mosquito's proboscis <STRONG>(8)</STRONG> and can infect another definitive host when it takes a blood meal <STRONG>(1)</STRONG>. In humans <STRONG>(9)</STRONG>, <EM>D. immitis</EM> larvae tend to follow the same migratory pathway as in the canine host, ending up in the lungs, where they often lodge in small-caliber vessels, causing infarcts and typical \"coin lesions\" visible on radiographs.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Dirofilariasis. Available at: <a href=\"http://www.cdc.gov/dpdx/dirofilariasis/index.html\" target=\"_blank\">http://www.cdc.gov/dpdx/dirofilariasis/index.html</a>.</div><div id=\"graphicVersion\">Graphic 79410 Version 5.0</div></div></div>"},"79411":{"type":"graphic_figure","displayName":"Risk of clinical reactivity among related fruits and vegetables","title":"Risk of clinical reactivity (allergy) among related fruits and vegetables","html":"<div class=\"graphic\"><div style=\"width: 501px\" class=\"figure\"><div class=\"ttl\">Risk of clinical reactivity (allergy) among related fruits and vegetables</div><div class=\"cntnt\"><img style=\"width:481px; height:235px;\" src=\"images/ALLRG/79411_OAS_food_food_cross_rxn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The numeric risks cited here are based upon findings in limited series of patients and may not be generalizable to all populations.</div><div class=\"graphic_reference\">Adapted from: Sicherer SH. Clinical implications of cross-reactive food allergens. J Allergy Clin Immunol 2001; 108:881.</div><div id=\"graphicVersion\">Graphic 79411 Version 4.0</div></div></div>"},"79414":{"type":"graphic_picture","displayName":"Transverse palmar crease","title":"Transverse palmar crease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transverse palmar crease</div><div class=\"cntnt\"><img style=\"width:271px; height:360px;\" src=\"images/PEDS/79414_Transverse_palmar_crease.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Clark DA. Atlas of Neonatology, WB Saunders, Philadelphia 2000. Copyright &#169; 2000 Elsevier.</div><div id=\"graphicVersion\">Graphic 79414 Version 2.0</div></div></div>"},"79418":{"type":"graphic_table","displayName":"Defibrillation cardioversion tips","title":"Clinical tips for defibrillation and cardioversion","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical tips for defibrillation and cardioversion</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>&#8226; Precise coordination between CPR and defibrillation is essential to minimize the time between a chest compression and shock delivery as well as the time to resume compressions immediately after a shock.</td> </tr> <tr> <td class=\"sublist1_start\">&#8226; Electrode pads offer several advantages over electrode paddles:</td> </tr> <tr> <td class=\"sublist1\">- Designed to monitor the heart rhythm without the need for additional electrocardiogram electrodes that may interfere with pad placement</td> </tr> <tr> <td class=\"sublist1\">- No need for application of creams or gels; arcing of electrical current is less likely</td> </tr> <tr> <td class=\"sublist1\">- Not associated with sparks that may ignite fires</td> </tr> <tr> <td class=\"sublist1\">- A rescuer is less likely to contact the patient's stretcher during shock delivery</td> </tr> <tr> <td class=\"sublist1\">- Application of improper paddle pressure is eliminated as a possible reason for failure of defibrillation</td> </tr> <tr> <td>&#8226; Paddles and electrode pads designed for adults should be used for children who weigh more than 10 kg. Of these, those 12 cm in diameter are superior to those that are 8 cm. Infant paddles or pads are to be used for smaller infants weighing &#60;10 kg.</td> </tr> <tr> <td>&#8226; When using paddles, use conductive materials such as electrode cream or paste to decrease transthoracic impedance.</td> </tr> <tr> <td>&#8226; Interface materials that should not be used include saline, alcohol, and ultrasound gel, as well as the use of bare paddles.</td> </tr> <tr> <td>&#8226; Paddles and electrode pads must not contact each other and care must be taken to avoid interface materials on one side of the chest contacting the material placed on the opposite side.</td> </tr> <tr> <td>&#8226; The optimal energy dose for defibrillation in children has not been established. For manual defibrillators, use 2 J/kg for the first attempt, 4 J/kg for the second attempt, and 4 J/kg or higher for subsequent attempts.</td> </tr> <tr> <td>&#8226; For synchronized cardioversion, use 0.5 to 1 J/kg for the first attempt and 2 J/kg for subsequent attempts.</td> </tr> <tr> <td>&#8226; For AEDs, for children older than 8 years, a standard AED without a dose attenuator should be used. For those 1 to 8 years of age, an initial pediatric attenuated dose should be used. If it is the only device available, a standard AED without a dose attenuator is acceptable for those 1 to 8 years of age.</td> </tr> <tr> <td>&#8226; To avoid fires, all oxygen sources must be removed from the patient before defibrillation.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 79418 Version 4.0</div></div></div>"},"79423":{"type":"graphic_figure","displayName":"Systolic diastolic dysfunction","title":"Systolic versus diastolic dysfunction in HF","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">Systolic versus diastolic dysfunction in HF</div><div class=\"cntnt\"><img style=\"width:451px; height:190px;\" src=\"images/CARD/79423_Systolic_diastolic_dysfunct.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pressure-volume loops in normal subjects (in blue) and those with heart failure due to systolic (left panel) or diastolic (right panel) dysfunction. The pressure-volume loop is shifted to the right with systolic dysfunction. The end-diastolic pressure is increased compared to normal (25 versus 10 mmHg in this example), but at a higher ventricular volume and lower ejection fraction. In contrast, the pressure-volume loop is shifted to the left with isolated diastolic dysfunction. Contractility is normal in this setting, but the increase in ventricular stiffness results in an elevated end-diastolic pressure at a lower left ventricular volume.</div><div class=\"graphic_reference\">Data from: Zile, MR, Concepts Cardiovasc Dis 1990; 59:1.</div><div id=\"graphicVersion\">Graphic 79423 Version 1.0</div></div></div>"},"79425":{"type":"graphic_picture","displayName":"Uterine septum at hysteroscopy","title":"Uterine septum separating uterine cavity into two horns","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Uterine septum separating uterine cavity into two horns</div><div class=\"cntnt\"><img style=\"width:504px; height:396px;\" src=\"images/OBGYN/79425_Uterineseptumathysterosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright Â© 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 79425 Version 12.0</div></div></div>"},"79426":{"type":"graphic_movie","displayName":"Apical three-chamber echo HCM","title":"Apical three-chamber (long-axis) echocardiogram in a patient with hypertrophic cardiomyopathy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Apical three-chamber (long-axis) echocardiogram in a patient with hypertrophic cardiomyopathy</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/79426_ap2chhcmconv.mp4\" style=\"width:383px;height:276px\"></div><img style=\"width:426px; height:235px;\" src=\"images/CARD/79426_ap2chhcm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The apical three-chamber view from a two-dimensional echocardiogram shows a thickened intraventricular septum (IVS), almost total obliteration of the left ventricle (LV) during systole, and systolic anterior movement of the mitral valve (MV) and obstruction of the LV outflow tract in systole.</div><div class=\"graphic_footnotes\">LA: left atrium.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 79426 Version 4.0</div></div></div>"},"79429":{"type":"graphic_picture","displayName":"Ear polyp","title":"Ear polyp","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Ear polyp</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/PC/79429_Ear_polyp.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Vaibhav Parekh, MD, MBA.</div><div id=\"graphicVersion\">Graphic 79429 Version 1.0</div></div></div>"},"79430":{"type":"graphic_figure","displayName":"Pfannenstiel incision","title":"Pfannenstiel incision","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Pfannenstiel incision</div><div class=\"cntnt\"><img style=\"width:472px; height:606px;\" src=\"images/SURG/79430_Pfannenstiel_incision.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) &quot;Low&quot; Pfannenstiel: the skin incision is placed lower for cosmetic reasons. The subcutaneous tissues are dissected to allow standard placement of rectus sheath incision. (B) Fascia is separated from rectus muscle superiorly and inferiorly. (C) The rectus muscle is separated in the midline and the peritoneum is incised longitudinally. (D) Sutures may be placed in the rectus muscle to close a rectus diastasis. (E) Sheath is closed with continuous suture. Skin is approximated with a subcuticular suture.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 79430 Version 3.0</div></div></div>"},"79431":{"type":"graphic_algorithm","displayName":"Pathogenesis preeclampsia","title":"Model for pathogenesis of preeclampsia","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Model for pathogenesis of preeclampsia</div><div class=\"cntnt\"><img style=\"width:529px; height:441px;\" src=\"images/OBGYN/79431_Pathogenesis_preeclampsia.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 79431 Version 2.0</div></div></div>"},"79434":{"type":"graphic_picture","displayName":"Hereditary nephritis IF","title":"Diminished anti-GBM antibody binding in hereditary nephritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diminished anti-GBM antibody binding in hereditary nephritis</div><div class=\"cntnt\"><img style=\"width:378px; height:243px;\" src=\"images/NEPH/79434_Hereditary_nephritis_IF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Indirect immunofluorescence microscopy with anti-glomerular basement membrane antibodies shows extensive binding to a normal glomerulus (left panel), but minimal binding to a glomerulus from a patient with hereditary nephritis (right panel).</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 79434 Version 3.0</div></div></div>"},"79435":{"type":"graphic_picture","displayName":"Low grade dysplasia","title":"Gastric mucosa with low grade dysplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric mucosa with low grade dysplasia</div><div class=\"cntnt\"><img style=\"width:396px; height:297px;\" src=\"images/ONC/79435_Low_grade_dysplasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Abnormal tubulo-glandular structures lined by crowded epithelial cells with dark, elongated nuclei. Metaplastic glands are seen among the dysplastic elements.</div><div id=\"graphicVersion\">Graphic 79435 Version 1.0</div></div></div>"},"79437":{"type":"graphic_figure","displayName":"Left atrial enlargement","title":"Left atrial enlargement","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Left atrial enlargement</div><div class=\"cntnt\"><img style=\"width:464px; height:193px;\" src=\"images/CARD/79437_Left_atrial_enlargement.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left panel shows the normal pattern of atrial activation as it would appear on lead II of the electrocardiogram; activation of the right atrium (RA) occurs first, followed by left atrial (LA) activation. The right panel shows the pattern in a patient with left atrial enlargement. Delay of left atrial activation causes notching and a prolonged duration of the P wave, and the presence of left atrial hypertrophy results in increased P wave amplitude.</div><div id=\"graphicVersion\">Graphic 79437 Version 1.0</div></div></div>"},"79438":{"type":"graphic_diagnosticimage","displayName":"Elbow fracture dislocation","title":"Dislocation with incarceration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dislocation with incarceration</div><div class=\"cntnt\"><img style=\"width:351px; height:396px;\" src=\"images/EM/79438_Elbowfxdislocation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">AP view showing a posterolateral elbow dislocation. The presence of the medial epicondyle within the elbow joint (arrow) prevented a closed reduction.</div><div class=\"graphic_reference\">Reproduced with permission from: Beaty JH, Kasser JR. The elbow: Physeal fractures, apophyseal injuries of the distal humerus, avascular necrosis of the trochlea, and T-condylar fractures. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2006. Copyright Â© 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 79438 Version 13.0</div></div></div>"},"79439":{"type":"graphic_diagnosticimage","displayName":"Histo in AIDS","title":"HIV patient with histoplasmosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">HIV patient with histoplasmosis</div><div class=\"cntnt\"><img style=\"width:397px; height:295px;\" src=\"images/ID/79439_Histo_in_AIDS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiograph shows diffuse fine nodular infiltrates.</div><div class=\"graphic_reference\">Courtesy of Dr. John W Baddley.</div><div id=\"graphicVersion\">Graphic 79439 Version 2.0</div></div></div>"},"79440":{"type":"graphic_picture","displayName":"Phase-contrast micrograph showing dysmorphic red cells in urine","title":"Phase-contrast micrograph showing dysmorphic red cells in urine sediment","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Phase-contrast micrograph showing dysmorphic red cells in urine sediment</div><div class=\"cntnt\"><img style=\"width:378px; height:231px;\" src=\"images/NEPH/79440_Dysmorphic_rbc_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Phase-contrast microscopy showing dysmorphic red cells in a patient with glomerular bleeding. Acanthocytes can be recognized as ring forms with vesicle-shaped protrusions (arrows).</div><div class=\"graphic_reference\">Courtesy of Hans K&ouml;hler, MD.</div><div id=\"graphicVersion\">Graphic 79440 Version 4.0</div></div></div>"},"79441":{"type":"graphic_figure","displayName":"LV pressure diastolic dysfunct","title":"Left ventricular pressure tracing in diastolic dysfunction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left ventricular pressure tracing in diastolic dysfunction</div><div class=\"cntnt\"><img style=\"width:431px; height:228px;\" src=\"images/CARD/79441_LV_pressure_diastolic_dysfu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left ventricular pressure is initially recorded with a scale of 0 to 200 mmHg and then at 0 to 40 mmHg. Although the systolic and diastolic pressures are normal, the pressure waveform in diastole is abnormal; there is a continuing decline of pressure over the mid-diastolic period (as opposed to the gradual rise seen in normal subjects) with the pressure nadir occurring midway through the diastolic period and there is a prominent &quot;a&quot; wave generated by left atrial contraction.</div><div class=\"graphic_reference\">Reproduced with permission from Kern MJ. ACC Current Journal Review, 1997.</div><div id=\"graphicVersion\">Graphic 79441 Version 2.0</div></div></div>"},"79443":{"type":"graphic_diagnosticimage","displayName":"Proximal type I endoleak","title":"Proximal type I endoleak","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Proximal type I endoleak</div><div class=\"cntnt\"><img style=\"width:584px; height:337px;\" src=\"images/SURG/79443_Proximal_type_I_endoleak.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Aortogram showing an infrarenal abdominal aortic aneurysm with a severely angulated aortic neck.<BR>(B) After endograft placement, a&nbsp;type Ia endoleak&nbsp;is seen laterally on the right on the completion aortogram. The endoleak persists in spite of&nbsp;balloon angioplasty. <BR>(C) The endoleak has resolved with the placement of a proximal aortic cuff.</div><div id=\"graphicVersion\">Graphic 79443 Version 2.0</div></div></div>"},"79444":{"type":"graphic_figure","displayName":"Anatomy of the growth plate (physis)","title":"Anatomy of the growth plate (physis)","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Anatomy of the growth plate (physis)</div><div class=\"cntnt\"><img style=\"width:541px; height:406px;\" src=\"images/EM/79444_Growth_plate_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The germinal zone of the physis borders the epiphysis. The epiphyseal cartilage cells grow toward the metaphysis and form columns of cells. These columns degenerate, undergo hypertrophy, and then calcify at the metaphysis to form new bone. The hypertrophic zone (shaded red) is the usual site of physeal fractures.</div><div id=\"graphicVersion\">Graphic 79444 Version 4.0</div></div></div>"},"79445":{"type":"graphic_figure","displayName":"Perineal resection","title":"Perineal resection","html":"<div class=\"graphic\"><div style=\"width: 487px\" class=\"figure\"><div class=\"ttl\">Perineal resection</div><div class=\"cntnt\"><img style=\"width:467px; height:472px;\" src=\"images/SURG/79445_Perineal-resection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figure depicts the dissection of the perineum. The anus is closed with a purse string suture, the skin is incised and the dissection includes the external sphincter muscles. Note the levator muscle attachment along the pelvic side wall. These muscles are divided for mobilization of the rectum.</div><div id=\"graphicVersion\">Graphic 79445 Version 1.0</div></div></div>"},"79446":{"type":"graphic_table","displayName":"Skin lesions and rashes in coma","title":"Skin lesions and rashes in coma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Skin lesions and rashes in coma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Lesion or rash </td> <td class=\"subtitle1\">Possible cause </td> </tr> <tr> <td>Ecchymosis</td> <td>Trauma, corticosteroid use, abnormal coagulation from liver disease or anticoagulants</td> </tr> <tr> <td>Petechial-purpuric rash</td> <td>Meningococcemia, other bacterial sepsis (rarely), gonococcemia, staphylococcemia, pseudomonas, subacute bacterial endocarditis, allergic vasculitis, purpura fulminans, Rocky Mountain spotted fever, typhus, fat emboli</td> </tr> <tr> <td>Petechiae</td> <td>Disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, drugs</td> </tr> <tr> <td>Icterus</td> <td>Hepatic dysfunction or hemolytic anemia</td> </tr> <tr> <td>Cherry-red skin</td> <td>Carbon monoxide poisoning</td> </tr> <tr> <td>Generalized cyanosis</td> <td>Hypoxemia or carbon dioxide poisoning</td> </tr> <tr> <td>Grayish-blue cyanosis</td> <td>Methemoglobin (aniline or nitrobenzene) intoxication</td> </tr> <tr> <td>Localized cyanosis</td> <td>Arterial emboli or vasculitis</td> </tr> <tr> <td>Antecubital needle marks</td> <td>Opiate drug abuse</td> </tr> <tr> <td>Pale skin</td> <td>Anemia or hemorrhage</td> </tr> <tr> <td>Sallow, puffy appearance</td> <td>Hypopituitarism</td> </tr> <tr> <td>Hypermelanosis (increased pigment)</td> <td>Porphyria, Addison's disease, chronic nutritional deficiency, disseminated malignant melanoma, chemotherapy</td> </tr> <tr> <td>Telangiectasia</td> <td>Chronic alcoholism, occasionally vascular malformations of the brain</td> </tr> <tr> <td>Vesicular rash</td> <td>Herpes simplex, varicella, Behcet disease, or drugs</td> </tr> <tr> <td>Macular-papular rash</td> <td>Typhus, candida, cryptococcus, toxoplasmosis, subacute bacterial endocarditis, staphylococcal toxic shock, typhoid, leptospirosis, Pseudomonas sepsis, immunologic disorders (systemic lupus erythematosus, dermatomyositis, serum sickness)</td> </tr> <tr> <td>Ecthyma gangrenosum</td> <td>Necrotic eschar often seen in the anogenital or axillary area in Pseudomonas sepsis</td> </tr> <tr> <td>Splinter hemorrhages</td> <td>Linear hemorrhages under the nail, seen in subacute bacterial endocarditis, anemia, leukemia, and sepsis</td> </tr> <tr> <td>Osler nodes</td> <td>Purplish or erythematous painful, tender nodules on palms and soles, seen in subacute bacterial endocarditis</td> </tr> <tr> <td>Gangrene of digits' extremities</td> <td>Emboli to larger peripheral arteries</td> </tr> <tr> <td>Pigmented macules</td> <td>Tuberous sclerosis, neurofibromatosis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Berger JR. Clinical Approach to Stupor and Coma. In: Neurology in Clinical Practice: Principles of Diagnosis and Management, 4th ed, Bradley WG, Daroff RB, Fenichel GM, Jankovic J (Eds), Butterworth Heinmann, Philadelphia, PA 2004. p.51. Copyright Â© 2004 Elsevier.</div><div id=\"graphicVersion\">Graphic 79446 Version 2.0</div></div></div>"},"79447":{"type":"graphic_table","displayName":"Causes of oligohydramnios","title":"Causes of oligohydramnios","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of oligohydramnios</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Maternal</td> </tr> <tr> <td>Medical or obstetrical conditions associated with uteroplacental insufficiency (eg, preeclampsia, chronic hypertension, collagen vascular disease, nephropathy, thrombophilia)</td> </tr> <tr> <td>Medications (eg, angiotensin converting enzyme inhibitors, prostaglandin synthetase inhibitors, trastuzumab)</td> </tr> <tr> <td class=\"subtitle1_single\">Placental</td> </tr> <tr> <td>Abruption</td> </tr> <tr> <td>Twin to twin transfusion (ie, twin polyhydramnios-oligohydramnios sequence)</td> </tr> <tr> <td>Placental thrombosis or infarction</td> </tr> <tr> <td class=\"subtitle1_single\">Fetal</td> </tr> <tr> <td>Chromosomal abnormalities</td> </tr> <tr> <td>Congenital abnormalities, especially those associated with impaired urine production</td> </tr> <tr> <td>Growth restriction</td> </tr> <tr> <td>Demise</td> </tr> <tr> <td>Postterm pregnancy</td> </tr> <tr> <td>Ruptured fetal membranes</td> </tr> <tr> <td class=\"subtitle1_single\">Idiopathic</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 79447 Version 3.0</div></div></div>"},"79448":{"type":"graphic_table","displayName":"Clinical manifestations of IgE-mediated reactions","title":"Clinical manifestations of IgE-mediated reactions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of IgE-mediated reactions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Clinical features</td> </tr> <tr> <td class=\"indent1\">Dermatologic -&nbsp;Pruritus, flushing, urticaria/angioedema, diaphoresis</td> </tr> <tr> <td class=\"indent1\">Eyes - Conjunctival injection, lacrimation, periorbital edema, pruritus</td> </tr> <tr> <td class=\"indent1\">Respiratory tract -&nbsp;Nose/oropharynx (sneezing, rhinorrhea, nasal congestion, oral pruritus, metallic taste), upper airway (hoarseness, stridor, sense of choking, laryngeal edema), lower airway (dyspnea, tachypnea, wheezing, cough, cyanosis)</td> </tr> <tr> <td class=\"indent1\">Cardiovascular - Conduction disturbances, tachycardia, bradycardia (if severe), arrhythmias, hypotension, cardiac arrest</td> </tr> <tr> <td class=\"indent1\">Gastrointestinal -&nbsp;Nausea/vomiting, abdominal cramping, bloating, diarrhea</td> </tr> <tr> <td class=\"indent1\">Neurologic -&nbsp;Sense of impending doom, syncope, dizziness, seizures</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgE: immunoglobulin E.</div><div id=\"graphicVersion\">Graphic 79448 Version 5.0</div></div></div>"},"79450":{"type":"graphic_figure","displayName":"Cardiac resynchronization leads","title":"Pacing leads for cardiac resynchronization therapy","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pacing leads for cardiac resynchronization therapy</div><div class=\"cntnt\"><img style=\"width:504px; height:585px;\" src=\"images/CARD/79450_Cardiac-resynchronization-leads.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two leads (right atrial and right ventricular leads) permit pacing of the right atrium and right ventricle. The third lead (coronary sinus lead), which is advanced through the coronary sinus into a venous branch that runs along the free wall of the left ventricle, paces the lateral wall and enables synchronized left ventricular contraction.</div><div id=\"graphicVersion\">Graphic 79450 Version 5.0</div></div></div>"},"79451":{"type":"graphic_picture","displayName":"Trunk rash secondary syphilis","title":"Trunk rash secondary syphilis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Trunk rash secondary syphilis</div><div class=\"cntnt\"><img style=\"width:216px; height:325px;\" src=\"images/ID/79451_Trunk_rash_secondary_syphil.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Dylewski, J, Duong, M. The rash of secondary syphilis. CMAJ 2007; 176:33. Copyright &#169;2007 Canadian Medical Association.</div><div id=\"graphicVersion\">Graphic 79451 Version 1.0</div></div></div>"},"79453":{"type":"graphic_diagnosticimage","displayName":"Metastatic neuroblastoma skull","title":"Metastatic neuroblastoma of the skull","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Metastatic neuroblastoma of the skull</div><div class=\"cntnt\"><img style=\"width:504px; height:521px;\" src=\"images/PEDS/79453_Metastatic_neuroblastoma_sk.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The bone itself has developed an osteoclastic reaction. There is an intracranial component of the metastasis putting pressure on the brain and causing a midline shift.</div><div class=\"graphic_reference\">Courtesy of Heidi V Russell, MD, Jason M Shohet, MD, and Jed G Nuchtern, MD.</div><div id=\"graphicVersion\">Graphic 79453 Version 2.0</div></div></div>"},"79454":{"type":"graphic_table","displayName":"Fish servings for EPA DHA","title":"Weekly servings of fish to achieve 250 mg/day of EPA + DHA","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Weekly servings of fish to achieve 250 mg/day of EPA + DHA</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Fish name</td> <td class=\"subtitle1\">Number of 3.5 ounce<br /> (100 gram) servings*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Oily fish</td> </tr> <tr> <td class=\"indent1\">Anchovy, canned</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Herring, Atlantic</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Salmon, Atlantic</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Tuna, Bluefin</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\">Mackerel, Atlantic</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\">Bluefish</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\">Trout, Rainbow</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\">Sardines, Atlantic canned</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\">Striped Bass</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\">Tilefish</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\">Swordfish</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\">Tuna, Albacore canned</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Salmon, Sockeye</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Carp</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"indent1\">Salmon, smoked (lox)</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"indent1\">King Mackerel</td> <td class=\"centered\">5</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">White fish</td> </tr> <tr> <td class=\"indent1\">Sea Bass</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Pollock, Atlantic</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"indent1\">Snapper</td> <td class=\"centered\">6</td> </tr> <tr> <td class=\"indent1\">Flounder and Sole</td> <td class=\"centered\">6</td> </tr> <tr> <td class=\"indent1\">Tuna, light canned</td> <td class=\"centered\">7</td> </tr> <tr> <td class=\"indent1\">Grouper</td> <td class=\"centered\">8</td> </tr> <tr> <td class=\"indent1\">Catfish, wild</td> <td class=\"centered\">8</td> </tr> <tr> <td class=\"indent1\">Halibut</td> <td class=\"centered\">8</td> </tr> <tr> <td class=\"indent1\">Haddock</td> <td class=\"centered\">12</td> </tr> <tr> <td class=\"indent1\">Cod, Atlantic</td> <td class=\"centered\">12</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Shellfish</td> </tr> <tr> <td class=\"indent1\">Mussels</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Crab, Alaska King</td> <td class=\"centered\">5</td> </tr> <tr> <td class=\"indent1\">Oysters, eastern raw</td> <td class=\"centered\">6</td> </tr> <tr> <td class=\"indent1\">Clams</td> <td class=\"centered\">7</td> </tr> <tr> <td class=\"indent1\">Shrimp</td> <td class=\"centered\">7</td> </tr> <tr> <td class=\"indent1\">Lobster, northern</td> <td class=\"centered\">10</td> </tr> <tr> <td class=\"indent1\">Scallops</td> <td class=\"centered\">11</td> </tr> <tr> <td class=\"indent1\">Crab, Blue</td> <td class=\"centered\">11</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid.<BR>* Servings rounded up&nbsp;to a whole number of servings.<BR></div><div class=\"graphic_reference\">Data from: United States Department of Agriculture (USDA) National Nutrient<br />Database for Standard Reference. USDA website 2012. Available at:<br /><a href=\"http://ndb.nal.usda.gov/\" target=\"_blank\">http://ndb.nal.usda.gov/</a>. (Accessed June 10, 2013.)</div><div id=\"graphicVersion\">Graphic 79454 Version 2.0</div></div></div>"},"79455":{"type":"graphic_diagnosticimage","displayName":"TEE right left atria","title":"Left and right atria on transesophageal echocardiography","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Left and right atria on transesophageal echocardiography</div><div class=\"cntnt\"><img style=\"width:526px; height:203px;\" src=\"images/CARD/79455_TEE_right_left_atria.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Recorded in the horizontal (0Âº) plane, panel A shows the left atrium (LA), right atrium (RA), interatrial septum, tricuspid valve (TV) leaflets, and right upper pulmonary vein (RUPV). Panel B shows normal color Doppler flow (red/orange) of blood entering the LA from the RUPV.</div><div class=\"graphic_reference\">Courtesy of Warren Manning, MD.</div><div id=\"graphicVersion\">Graphic 79455 Version 2.0</div></div></div>"},"79457":{"type":"graphic_picture","displayName":"Laryngomalacia","title":"Laryngomalacia","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Laryngomalacia</div><div class=\"cntnt\"><img style=\"width:520px; height:223px;\" src=\"images/PEDS/79457_Laryngomalacia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A: Flexible laryngoscopy of laryngomalacia during inspiration. Note collapse of the epiglottis. Panel B: Flexible laryngoscopy of laryngomalacia during expiration. Note the omega-shaped epiglottis.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 79457 Version 1.0</div></div></div>"},"79458":{"type":"graphic_figure","displayName":"Network meta-analysis of antihypertensive drugs","title":"Network meta-analysis of antihypertensive drugs and the risk of cancer","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Network meta-analysis of antihypertensive drugs and the risk of cancer</div><div class=\"cntnt\"><img style=\"width:597px; height:409px;\" src=\"images/PC/79458_Network_meta_analysis_drugs.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The numbers represent the number of trial groups providing direct comparison between the drug classes.</div><div class=\"graphic_footnotes\">ARBs: angiotensin receptor blockers; ACEi: angiotensin converting enzyme inhibitor; CCBs: calcium channel blockers.</div><div class=\"graphic_reference\">Reproduced from: Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol 2011; 12:65. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 79458 Version 1.0</div></div></div>"},"79459":{"type":"graphic_table","displayName":"Ventricular and atrial pacers","title":"Types of cardiac pacemakers and NBG codes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Types of cardiac pacemakers and NBG codes</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\t<tbody><tr>\n\t\t<td class=\"subtitle1\">Code</td>\n\t\t\n\t\t<td class=\"subtitle1\">Meaning</td>\n\t</tr><tr><td>VOO</td><td>Asynchronous ventricular pacemaker; no adaptive rate control or antitachyarrhythmia functions</td></tr><tr><td>VVI</td><td>Ventricular \"demand\" pacemaker with electrogram-waveform telemetry; no adaptive rate control or antitachyarrhythmia functions</td></tr><tr><td>DVI</td><td>Multiprogrammable atrioventricular-sequential pacemaker; no adaptive rate control</td></tr><tr><td>DDD</td><td>Multiprogrammable \"physiologic\" dual-chamber pacemaker; no adaptive rate control or antitachyarrhythmia functions</td></tr><tr><td>DDI</td><td>Multiprogrammable\nDDI pacemaker (with dual-chamber pacing and sensing but without\natrial-synchronous ventricular pacing); no adaptive rate control or\nantitachycardia functions</td></tr><tr><td>VVIR</td><td>Adaptive-rate VVI pacemaker with escape interval controlled adaptively by one or more unspecified variables</td></tr><tr><td>DDDR</td><td>Programmable DDD pacemaker with escape interval controlled adaptively by one or more unspecified variables</td></tr>\n\t\n\t\n\t</tbody></table></div><div id=\"graphicVersion\">Graphic 79459 Version 1.0</div></div></div>"},"79461":{"type":"graphic_algorithm","displayName":"Algorithm for treatment of metastatic neuroendocrine tumors","title":"Algorithm for treatment of metastatic neuroendocrine tumors","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Algorithm for treatment of metastatic neuroendocrine tumors</div><div class=\"cntnt\"><img style=\"width:554px; height:479px;\" src=\"images/ONC/79461_Treat_met_neuroendo_tum.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">VEGF: vascular endothelial growth factor.</div><div id=\"graphicVersion\">Graphic 79461 Version 3.0</div></div></div>"},"79462":{"type":"graphic_table","displayName":"Cardiac involvement in vasculitis","title":"Principle features and cardiovascular/pericardial involvement in vasculitides","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Principle features and cardiovascular/pericardial involvement in vasculitides</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Vasculitis</td> <td class=\"subtitle1\">Principle features</td> <td class=\"subtitle1\">Estimated frequency of cardiac/pericardial involvement (percent)</td> <td class=\"subtitle1\">Type of cardiac/pericardial involvement</td> </tr> <tr> <td rowspan=\"2\">Takayasu arteritis</td> <td rowspan=\"2\">Chronic inflammatory and obliterative disease of the aorta and its major branches.</td> <td>Cardiac: rare</td> <td>Fibrosis, narrowing and aneurysm of the aorta, its branches, and pulmonary arteries.</td> </tr> <tr> <td>Pericardial: rare (case reports)</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Giant cell arteritis</td> <td rowspan=\"2\">Vasculitis that affects large and medium-sized blood vessels (especially cranial arteries branching from the carotid artery).</td> <td>Cardiac: &#60;10</td> <td>Aneurysm, coronary arteritis, myocardial infarction.</td> </tr> <tr> <td>Pericardial: rare (case reports)</td> <td>Pericarditis, pericardial effusion.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Polyarteritis nodosa</td> <td rowspan=\"2\">Necrotizing arteritis involving medium-sized and small-sized arteries with inflammation and ischemia of affected organs.</td> <td>Cardiac: &#60;50</td> <td>Hypertension (renal vasculitis), aneurysm, and myocardial infarction.</td> </tr> <tr> <td>Pericardial: rare (case reports, limited series)</td> <td>Pericarditis.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Kawasaki disease</td> <td rowspan=\"2\">Systemic necrotizing medium-sized vessel vasculitis mainly affecting blood vessels, skin, mucous membranes and lymph nodes.</td> <td>Cardiac: 30</td> <td>Coronary arteritis and aneurysm, myocardial infarction, myocarditis, heart failure.</td> </tr> <tr> <td>Pericardial: 30</td> <td>Pericardial effusion, pericarditis.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif';\">Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)</span></td> <td rowspan=\"2\">Systemic necrotizing vasculitis affecting small-sized to medium-sized vessels, characterized by asthma, hypereosinophilia, and eosinophil-rich granulomatous inflammation of the respiratory tract.</td> <td>Cardiac: &#62;50</td> <td>Eosinophilic endomyocarditis, heart failure, heart block.</td> </tr> <tr> <td>Pericardial: 25-50</td> <td>Pericarditis, pericardial effusion.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Granulomatosis with polyangiitis</td> <td rowspan=\"2\">Necrotizing vasculitis that mainly affects arteries in the respiratory tract and kidneys.</td> <td>Cardiac: 10-40</td> <td>Coronary arteritis, valve lesions, heart block, aortic aneurysm.</td> </tr> <tr> <td>Pericardial: &#60;10</td> <td>Pericarditis, pericardial effusion.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 79462 Version 2.0</div></div></div>"},"79463":{"type":"graphic_picture","displayName":"Recluse spider B","title":"Female recluse spider B","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Female recluse spider B</div><div class=\"cntnt\"><img style=\"width:432px; height:289px;\" src=\"images/ALLRG/79463_Recluse_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spider appears larger than actual size. Mature recluse spiders have a body length (not including legs) of 7 to 10 mm.</div><div class=\"graphic_reference\">Courtesy of Richard S Vetter, MS.</div><div id=\"graphicVersion\">Graphic 79463 Version 4.0</div></div></div>"},"79464":{"type":"graphic_table","displayName":"Systemic inflammatory response","title":"Criteria for the systemic inflammatory response syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for the systemic inflammatory response syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"sublist1_start\">The systemic inflammatory response syndrome (SIRS) is clinically recognized by the presence of <strong>two or more</strong> of the following:</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Temperature &#62;38&ordm;C or &#60;36&ordm;C</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Heart rate &#62;90 beats/min</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Respiratory rate &#62;20 breaths/min or PaCO2 &#60;32 mmHg</td>\n</tr>\n<tr>\n<td class=\"sublist1\">WBC &#62;12,000 cells/mm3, &#60;4000 cells/mm3, or &#62;10 percent immature (band) forms</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 79464 Version 1.0</div></div></div>"},"79465":{"type":"graphic_picture","displayName":"Verrucous hyperplasia Light","title":"Verrucous hyperplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Verrucous hyperplasia</div><div class=\"cntnt\"><img style=\"width:412px; height:246px;\" src=\"images/ONC/79465_Verrucous_hyperplasia_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Distinguishing this lesion from verrucous carcinoma may be difficult. The surface is keratotic, ie, layered with acellular keratin. The absence of downward growth below the level of adjacent uninvolved mucosa helps to exclude verrucous carcinoma.</div><div class=\"graphic_reference\">Courtesy of Kenneth Haines, MD.</div><div id=\"graphicVersion\">Graphic 79465 Version 4.0</div></div></div>"},"79466":{"type":"graphic_picture","displayName":"Circinate exudate","title":"Circinate exudate: Appearance on fundus photograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Circinate exudate: Appearance on fundus photograph</div><div class=\"cntnt\"><img style=\"width:396px; height:294px;\" src=\"images/ENDO/79466_Circinate_exudate.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Color fundus photograph of extensive yellow circinate exudate in the macula; intraretinal hemorrhages and previous peripheral laser treatment are also visible.</div><div id=\"graphicVersion\">Graphic 79466 Version 3.0</div></div></div>"},"79468":{"type":"graphic_table","displayName":"Loading dose gent and tobra","title":"Recommended loading dose for traditional, intermittent dosing of gentamicin or tobramycin in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended loading dose for traditional, intermittent dosing of gentamicin or tobramycin in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"55%\"></colgroup><colgroup span=\"3\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Site of infection or indication</td> <td class=\"subtitle1\" colspan=\"2\">Desired peak concentration</td> <td class=\"subtitle1\" rowspan=\"2\">Loading dose, mg/kg*<sup>&#182;</sup><sup>&#916;</sup></td> </tr> <tr> <td class=\"subtitle2\">Conventional unit</td> <td class=\"subtitle2\">SI unit</td> </tr> <tr> <td>Gentamicin synergy with beta-lactams for treatment of serious gram-positive infections</td> <td>3 to 4 mcg/mL</td> <td>6 to 8.5 micromol/L</td> <td>1 (initial dose, not a loading dose)</td> </tr> <tr> <td>Uncomplicated lower urinary tract infection</td> <td>2 to 4 mcg/mL</td> <td>4 to 8.5 micromol/L</td> <td>1 (initial dose, not a loading dose)</td> </tr> <tr> <td>Gram-negative sepsis or other serious gram-negative infections, including pseudomonal infection, gram-negative pneumonia, and acute life-threatening gram-negative infection in a critically ill patient<sup>&#9674;</sup></td> <td>7 to 10 mcg/mL</td> <td>14 to 21 micromol/L</td> <td>2.5 to 3</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These loading doses are used when a traditional, intermittent dosing strategy is being employed. For many patients, the preferred dosing strategy is extended-interval. Refer to aminoglycosides topic discussion of selection of dosing strategy.</div><div class=\"graphic_footnotes\">* The loading dose is not adjusted for renal impairment.<br />&para; For overweight or obese patients, ideal body weight or dosing weight (respectively) should be used for scaling dose. A calculator to determine ideal body weight and dosing weight is available in UpToDate.<br />&Delta; These loading dose recommendations do not apply to special populations (ie, pregnant women, patients with ascites, severe burns, critical illness, fluid overload, cystic fibrosis) who may have altered aminoglycoside pharmacokinetics. A modified loading dose and approach to dose adjustment may be needed. Refer to topic discussion.<br /><span class=\"lozenge\">&loz;</span> Aminoglycosides should generally not be used as single agent therapy for serious infections due to typical gram-negative rods. Exceptions include uncomplicated lower urinary tract infections, tularemia, and plague.</div><div class=\"graphic_reference\">This table lists doses recommended by UpToDate contributors based on pharmacokinetic data and institutional experience.</div><div id=\"graphicVersion\">Graphic 79468 Version 7.0</div></div></div>"},"79471":{"type":"graphic_diagnosticimage","displayName":"Displaced medial epicondylar fracture","title":"Displaced medial epicondylar fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Displaced medial epicondylar fracture</div><div class=\"cntnt\"><img style=\"width:329px; height:396px;\" src=\"images/EM/79471_Displacedmedepicondylefx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Type III displaced medial epicondylar fracture. AP view of an elbow in which the epicondyle (arrow) is significantly displaced both distally and medially. In addition, the fragment is rotated medially.</div><div class=\"graphic_reference\">Reproduced with permission from: Beaty JH, Kasser JR. The elbow: Physeal fractures, apophyseal injuries of the distal humerus, avascular necrosis of the trochlea, and T-condylar fractures. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2006. Copyright Â© 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 79471 Version 14.0</div></div></div>"},"79472":{"type":"graphic_figure","displayName":"Thyroglossal duct remnant","title":"Position of thyroglossal duct remnants","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Position of thyroglossal duct remnants</div><div class=\"cntnt\"><img style=\"width:472px; height:497px;\" src=\"images/ENDO/79472_Thyroglossal_duct_remnant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the position of thyroglossal duct remnants: (1) intralingual - 2 percent, (2) suprahyoid - 24 percent, (3) thyrohyoid - 61 percent, (4) suprasternal - 13 percent.</div><div class=\"graphic_footnotes\">Note: percentages taken from Allard RH, Head Neck Surg 1982; 5:134.</div><div id=\"graphicVersion\">Graphic 79472 Version 1.0</div></div></div>"},"79473":{"type":"graphic_picture","displayName":"Transformation FL","title":"Histologic transformation of follicular lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histologic transformation of follicular lymphoma</div><div class=\"cntnt\"><img style=\"width:255px; height:360px;\" src=\"images/HEME/79473_Transformation_FL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The upper lymph node shows involvement by follicular lymphoma, while the lower node shows a diffuse pattern, due to diffuse growth of large lymphoid cells.</div><div class=\"graphic_reference\">From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 79473 Version 2.0</div></div></div>"},"79474":{"type":"graphic_table","displayName":"Influenza vaccines summary","title":"Influenza vaccine information - United States,Â 2017-2018 influenza season*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Influenza vaccine information - United States,&nbsp;2017-2018 influenza season*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"10\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Vaccine<sup>&#182;</sup></td> <td class=\"subtitle1\">Trade name</td> <td class=\"subtitle1\">Manufacturer</td> <td class=\"subtitle1\">Presentation</td> <td class=\"subtitle1\">Mercury content from thimerosal<br /> (mcg Hg/0.5 mL dose)</td> <td class=\"subtitle1\">Ovalbumin content<br /> (mcg/0.5 mL dose)<sup>&#916;</sup></td> <td class=\"subtitle1\">Age indications</td> <td class=\"subtitle1\">Number of doses</td> <td class=\"subtitle1\">Latex</td> <td class=\"subtitle1\">Route</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">IIV4</td> <td class=\"divider_bottom\" rowspan=\"5\">Fluzone Quadrivalent</td> <td class=\"divider_bottom\" rowspan=\"5\">Sanofi Pasteur</td> <td>0.25 mL single-dose syringe</td> <td>0</td> <td>&#9674;</td> <td>6 through 35 months</td> <td>1 or 2<sup>&#167;</sup></td> <td>No</td> <td>IM<sup>&#165;</sup></td> </tr> <tr> <td>5 mL multi-dose vial</td> <td>25</td> <td>&#9674;</td> <td>&#8805;6&nbsp;months</td> <td>1 or 2<sup>&#167;</sup></td> <td>No</td> <td>IM<sup>&#165;</sup></td> </tr> <tr> <td>0.5 mL single-dose syringe</td> <td>0</td> <td>&#9674;</td> <td>&#8805;3 years</td> <td>1 or 2<sup>&#167;</sup></td> <td>No</td> <td>IM<sup>&#165;</sup></td> </tr> <tr> <td>0.5 mL single-dose vial</td> <td>0</td> <td>&#9674;</td> <td>&#8805;3 years</td> <td>1 or 2<sup>&#167;</sup></td> <td>No</td> <td>IM<sup>&#165;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td><sup></sup></td> <td>&nbsp;</td> <td>IM<sup>&#165;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>IIV4</td> <td>Fluarix Quadrivalent</td> <td>GlaxoSmithKline</td> <td>0.5 mL single-dose syringe</td> <td>0</td> <td>&#8804;0.05</td> <td><span style=\"color: black;\">&#8805;6 months</span></td> <td>1 or 2<sup>&#167;</sup></td> <td>No</td> <td>IM<sup>&#165;</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">IIV4</td> <td class=\"divider_bottom\" rowspan=\"2\">FluLaval Quadrivalent</td> <td class=\"divider_bottom\" rowspan=\"2\">ID Biomedical Corp of Quebec (distributed by GlaxoSmithKline)</td> <td>0.5 mL single-dose syringe</td> <td>0</td> <td>&#8804;0.3</td> <td>&#8805;6 months</td> <td>1 or 2<sup>&#167;</sup></td> <td>No</td> <td>IM<sup>&#165;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>5 mL multi-dose vial</td> <td>&#60;25</td> <td>&#8804;0.3</td> <td>&#8805;6 months</td> <td>1 or 2<sup>&#167;</sup></td> <td>No</td> <td>IM<sup>&#165;</sup></td> </tr> <tr class=\"divider_bottom\"> <td rowspan=\"2\">ccIIV4</td> <td rowspan=\"2\">Flucelvax Quadrivalent</td> <td rowspan=\"2\">Seqirus</td> <td>0.5 mL single-dose syringe</td> <td>0</td> <td>&#135;</td> <td>&#8805;4 years</td> <td>1 or 2<sup>&#167;</sup></td> <td>No</td> <td>IM<sup>&#165;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>5 mL multi-dose vial&nbsp;</td> <td>25</td> <td>&#135;</td> <td>&#8805;4 years</td> <td>1 or 2<sup>&#167;</sup></td> <td>No</td> <td>IM<sup>&#165;</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">IIV3</td> <td class=\"divider_bottom\" rowspan=\"2\">Fluvirin</td> <td class=\"divider_bottom\" rowspan=\"2\">Seqirus</td> <td>0.5 mL single-dose syringe</td> <td>&#8804;1</td> <td>&#8804;1</td> <td>&#8805;4 years</td> <td>1 or 2<sup>&#167;</sup></td> <td>Yes<sup>&#134;</sup></td> <td>IM<sup>&#165;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>5 mL&nbsp;multi-dose vial</td> <td>25</td> <td>&#8804;1</td> <td>&#8805;4 years</td> <td>1 or 2<sup>&#167;</sup></td> <td>No</td> <td>IM<sup>&#165;</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">IIV3</td> <td class=\"divider_bottom\" rowspan=\"2\">Afluria</td> <td class=\"divider_bottom\" rowspan=\"2\">Seqirus</td> <td>0.5 mL single-dose syringe</td> <td>0</td> <td>&#60;1</td> <td>&#8805;5 years</td> <td>1</td> <td>No</td> <td>IM<sup>&#165;,**</sup></td> </tr> <tr class=\"divider_bottom\"> <td>5 mL multi-dose vial</td> <td>24.5</td> <td>&#60;1</td> <td>&#8805;5 years</td> <td>1</td> <td>No</td> <td>IM<sup>&#165;,</sup><sup>**</sup></td> </tr> <tr class=\"divider_bottom\"> <td rowspan=\"2\">IIV4&nbsp;</td> <td rowspan=\"2\">Afluria&nbsp;Quadrivalent&nbsp;&nbsp;</td> <td rowspan=\"2\">Seqirus&nbsp;</td> <td>0.5 mL single-dose syringe</td> <td>0</td> <td>&#60;1&nbsp;</td> <td>&#8805;18 years</td> <td>1&nbsp;</td> <td>No</td> <td>IM<sup>&#165;,**</sup>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>5 mL multi-dose vial&nbsp;</td> <td>24.5</td> <td>&#60;1&nbsp;</td> <td>&#8805;18 years</td> <td>1&nbsp;</td> <td>No</td> <td>IM<sup>&#165;,**</sup></td> </tr> <tr class=\"divider_bottom\"> <td>RIV3</td> <td>Flublok</td> <td>Protein Sciences </td> <td>0.5 mL single-dose vial</td> <td>0</td> <td>0</td> <td>&#8805;18 years</td> <td>1</td> <td>No</td> <td>IM<sup>&#165;</sup>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>RIV4</td> <td>Flublok&nbsp; Quadrivalent</td> <td>Protein Sciences</td> <td>0.5 mL single-dose vial&nbsp;</td> <td>0</td> <td>0</td> <td>&#8805;18 years&nbsp;</td> <td>1&nbsp;</td> <td>No</td> <td>IM<sup>&#165;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>IIV4-ID<sup>&#182;&#182;</sup></td> <td> <p>Fluzone Intradermal</p> <p>Quadrivalent</p> </td> <td>Sanofi Pasteur</td> <td>0.1 mL single-dose microinjection system</td> <td>0</td> <td>&#9674;</td> <td>18 through 64 years</td> <td>1</td> <td>No</td> <td>ID<sup>&#916;&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>IIV3</td> <td>Fluad<sup>&#9674;&#9674;</sup></td> <td>Seqirus</td> <td>0.5 mL single-dose syringe</td> <td>0</td> <td>&#60;0.4 mcg</td> <td>&#8805;65 years</td> <td>1</td> <td>Yes<sup>&#134;</sup></td> <td>IM<sup>&#165;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>IIV3-HD<sup>&#167;&#167;</sup></td> <td>Fluzone High-Dose</td> <td>Sanofi Pasteur</td> <td>0.5 mL single-dose syringe</td> <td>0</td> <td>&#9674;</td> <td>&#8805;65 years</td> <td>1</td> <td>No</td> <td>IM<sup>&#165;</sup></td> </tr> <tr> <td>LAIV4</td> <td>FluMist Quadrivalent</td> <td>MedImmune</td> <td colspan=\"6\"><strong>The Advisory Committee on Immunization Practices recommends against use of LAIV for the 2017-2018 influenza season in the United States.</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IIV4: inactivated influenza vaccine, quadrivalent; ccIIV4: cell culture-based inactivated influenza vaccine, quadrivalent; IIV3: inactivated influenza vaccine, trivalent; RIV3: recombinant influenza vaccine, trivalent; IIV4-ID: inactivated influenza vaccine, quadrivalent-intradermal; IIV4-HD: inactivated influenza vaccine, quadrivalent-high dose; LAIV4: live attenuated influenza vaccine, quadrivalent; IM: intramuscular; ID: intradermal.<br />* Immunization providers should check US Food and Drug Administration (FDA)-approved prescribing information for&nbsp;2017-2018 influenza vaccines for the most complete and updated information, including (but not limited to) indications, contraindications, warnings, and precautions. Package inserts for United States-licensed vaccines are available at <A href=\"http://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm093833.htm\" target=_blank>www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm093833.htm</A>.<br />Â¶ Trivalent influenza vaccines contain three different vaccine viral antigens, one each from an influenza A (H1N1) virus, an influenza A (H3N2) virus, and an influenza B virus. Quadrivalent influenza vaccines contain the same three antigens as trivalent vaccines, along with an antigen from a second influenza B vaccine virus strain.<br />Î Data on maximum ovalbumin content are supplied in package inserts of certain vaccines. Persons with a history of egg allergy may receive any influenza vaccine. (Refer to UpToDate topic on influenza vaccination in individuals with egg allergy.)<br /><FONT class=lozenge>â</FONT> Ovalbumin content not listed in package insert. Data supplied by Sanofi Pasteur medical information (<FONT class=baec5a81-e4d6-4674-97f3-e9220f0136c1 style=\"WHITE-SPACE: nowrap\">1-800-822-2463<A title=\"Call: 1-800-822-2463\" style=\"OVERFLOW: hidden; CURSOR: hand; BORDER-TOP: medium none; HEIGHT: 16px; BORDER-RIGHT: medium none; WIDTH: 16px; VERTICAL-ALIGN: middle; WHITE-SPACE: nowrap; RIGHT: 0px; BORDER-BOTTOM: medium none; POSITION: static !important; FLOAT: none; LEFT: 0px; MARGIN: 0px; BORDER-LEFT: medium none; DISPLAY: inline; TOP: 0px; BOTTOM: 0px\" href=\"#\"><IMG title=\"Call: 1-800-822-2463\" style=\"OVERFLOW: hidden; CURSOR: hand; BORDER-TOP: medium none; HEIGHT: 16px; BORDER-RIGHT: medium none; WIDTH: 16px; VERTICAL-ALIGN: middle; WHITE-SPACE: nowrap; RIGHT: 0px; BORDER-BOTTOM: medium none; POSITION: static !important; FLOAT: none; LEFT: 0px; MARGIN: 0px; BORDER-LEFT: medium none; DISPLAY: inline; TOP: 0px; BOTTOM: 0px\" src=\"data:image/png;base64,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\"></A></FONT>, or email, <A href=\"mailto:MIS.Emails@sanofipasteur.com\">MIS.Emails@sanofipasteur.com</A>).<br />Â§ Refer to UpToDate content on seasonal influenza vaccination in children for details of the schedule for children six months through eight years.<br />Â¥ For adults and older children, the recommended site of vaccination is the deltoid muscle. The preferred site for infants and young children is the anterolateral aspect of the thigh.<br />â¡ Information not included in package insert. Because the vaccine seed strain used to make Flucelvax is passaged in eggs, traces of ovalbumin may be present. Flucelvax is estimated to contain &lt;50 femtograms (5 x 10<SUP>â8</SUP> mcg) of total egg protein (of which ovalbumin is a fraction) per 0.5 mL dose of Flucelvax.<br />â  Syringe tip cap may contain natural rubber latex.<br />**&nbsp;For adults 18 through 64 years of age, Afluria may be administered by IM injection with the FDA-approved PharmJet Stratis needle-free injection device or with a sterile needle and syringe.<br />Â¶Â¶&nbsp;A 0.1 mL dose contains 9 mcg of each vaccine antigen (36 mcg total).<br />ÎÎ&nbsp;The preferred injection site is over the deltoid muscle. Fluzone Intradermal is administered using the delivery system included with the vaccine.<br />ââ&nbsp;Fluad includes the adjuvant MF-59.<br />Â§Â§&nbsp;A 0.5 mL dose contains 60 mcg of each vaccine antigen (180 mcg total).</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices â United States, 2017-18 influenza season. MMWR Recomm Rep 2017; 66:1.</LI>&#xD;&#xA;<LI>US Food and Drug Administration. Complete list of vaccines licensed for immunization and distribution in the US. Available at: <A spellcheck=true href=\"http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm\" target=_blank>www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm</A> (Accessed on January 18, 2018).</LI></OL></div><div id=\"graphicVersion\">Graphic 79474 Version 32.0</div></div></div>"},"79475":{"type":"graphic_figure","displayName":"FABERE test (Patrick test, \"figure of four\" test)","title":"FABERE test (Patrick test, \"figure of four\" test)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">FABERE test (Patrick test, \"figure of four\" test)</div><div class=\"cntnt\"><img style=\"width:356px; height:424px;\" src=\"images/EM/79475_FABERE_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The FABERE test (Patrick test or \"figure of four\" test) consists of <STRONG>F</STRONG>lexion of the hip and knee, with <STRONG>AB</STRONG>duction and <STRONG>E</STRONG>xternal <STRONG>R</STRONG>otation at the hip, so that the ankle of one leg is on top of the opposite knee (a figure four configuration). Force is applied downwards on the bent knee and the opposite hip, causing <STRONG>E</STRONG>xtension at the sacroiliac joint ipsilateral to the bent leg. Pain in the sacral region from pelvic torque during the FABERE test, in the absence of pain with passive motion of the hip joint, suggests discomfort arising from the sacroiliac joint. </div><div id=\"graphicVersion\">Graphic 79475 Version 5.0</div></div></div>"},"79476":{"type":"graphic_figure","displayName":"Sensor modal","title":"Continuous glucose monitoring","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Continuous glucose monitoring</div><div class=\"cntnt\"><img style=\"width:532px; height:370px;\" src=\"images/ENDO/79476_Sensor_modal.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Glucose values in the interstitial fluid of the patient under consideration on three consecutive days (Thursday, Friday, and Saturday) and parts of two other days during continuous glucose monitoring. The device used in this patient measures glucose in the range of 40 to 400 mg/dL. Values below 40 mg/dL are depicted as a straight line at 40 mg/dL on the ordinate. See text for discussion of these results.</div><div class=\"graphic_reference\">Courtesy of Lloyd Axelrod, MD.</div><div id=\"graphicVersion\">Graphic 79476 Version 2.0</div></div></div>"},"79477":{"type":"graphic_table","displayName":"ASCA pANCA dx IBD","title":"Test characteristics of anti-saccaromyces cervisiae antibodies (ASCA) and perinuclear antineutrophil cytoplasmic antibodies (pANCA) in the diagnosis of inflammatory bowel disease (IBD)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Test characteristics of anti-saccaromyces cervisiae antibodies (ASCA) and perinuclear antineutrophil cytoplasmic antibodies (pANCA) in the diagnosis of inflammatory bowel disease (IBD)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Antibody</td> <td class=\"subtitle1\">Sensitivity, percent</td> <td class=\"subtitle1\">Specificity, percent</td> <td class=\"subtitle1\">PPV, percent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Sensitivity, specificity, and positive predictive value (PPV) in patients with IBD compared to non-IBD controls</td> </tr> <tr> <td class=\"indent1\">ASCA +</td> <td>60</td> <td>91</td> <td>88</td> </tr> <tr> <td class=\"indent1\">pANCA +</td> <td>50</td> <td>95</td> <td>69</td> </tr> <tr> <td class=\"indent1\">ASCA +/pANCA -</td> <td>56</td> <td>94</td> <td>91</td> </tr> <tr> <td class=\"indent1\">pANCA +/ASCA -</td> <td>44</td> <td>97</td> <td>78</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Sensitivity, specificity, and positive predictive value in differentiating ulcerative colitis (UC) from Crohn disease (CD) in patients with IBD*</td> </tr> <tr> <td class=\"indent1\">ASCA +/CD +</td> <td>60</td> <td>86</td> <td>92</td> </tr> <tr> <td class=\"indent1\">pANCA +/UC +</td> <td>50</td> <td>94</td> <td>76</td> </tr> <tr> <td class=\"indent1\">ASCA +/pANCA -/CD +</td> <td>56</td> <td>92</td> <td>95</td> </tr> <tr> <td class=\"indent1\">pANCA +/ASCA -/UC +</td> <td>44</td> <td>98</td> <td>88</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Where CD + or UC +, the control group for comparison is the other type of IBD.</div><div class=\"graphic_reference\">Data from: Peeters M, Joosens S, Vermeire S, et al. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001; 96:730.</div><div id=\"graphicVersion\">Graphic 79477 Version 4.0</div></div></div>"},"79478":{"type":"graphic_picture","displayName":"Bartholin abscess","title":"Bartholin abscess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bartholin abscess</div><div class=\"cntnt\"><img style=\"width:402px; height:448px;\" src=\"images/OBGYN/79478_Bartholins_gland_abscess.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient's left labial area is swollen and erythematous.</div><div class=\"graphic_reference\">Reproduced with permission from: Aron Schuftan, MD. Copyright Â© Aron Schuftan, MD.</div><div id=\"graphicVersion\">Graphic 79478 Version 3.0</div></div></div>"},"79479":{"type":"graphic_picture","displayName":"FSGS EM","title":"Electron micrograph in focal segmental glomerulosclerosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electron micrograph in focal segmental glomerulosclerosis</div><div class=\"cntnt\"><img style=\"width:377px; height:243px;\" src=\"images/NEPH/79479_FSGS_EM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph in focal segmental glomerulosclerosis shows diffuse epithelial cell foot process fusion with occasional loss of the epithelial cells (arrows). The other major finding is massive subendothelial hyaline deposits (asterisk) under the glomerular basement membrane (&Delta;). These deposits reflect insudation of plasma proteins, not the deposition of immunoglobulins. These deposits contribute to narrowing of the capillary lumens.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 79479 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Electron micrograph of a normal glomerulus</div><div class=\"cntnt\"><img style=\"width:377px; height:266px;\" src=\"images/NEPH/50018_Normal_glomerulus_EM_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron-dense deposits are present. Two normal platelets are seen in the capillary lumen.</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 50018 Version 7.0</div></div></div>"},"79481":{"type":"graphic_algorithm","displayName":"Evaluation of polyarthritis","title":"Evaluation of polyarthritis or polyarthralgia","html":"<div class=\"graphic\"><div style=\"width: 672px\" class=\"figure\"><div class=\"ttl\">Evaluation of polyarthritis or polyarthralgia</div><div class=\"cntnt\"><img style=\"width:652px; height:478px;\" src=\"images/RHEUM/79481_Evaluation_of_polyarthritis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An initial approach to the patient with polyarticular joint symptoms.</div><div class=\"graphic_footnotes\">CCP: citrulline containing peptide; CBC: complete blood cell count; ESR: erythrocyte sedimentation rate; RF: rheumatoid factor; ANA: antinuclear antibodies.</div><div class=\"graphic_reference\">Adapted from American College of Rheumatology Ad Hoc Committee on Clinical Guidelines, Arthritis Rheum 1996; 39:1.</div><div id=\"graphicVersion\">Graphic 79481 Version 3.0</div></div></div>"},"79482":{"type":"graphic_picture","displayName":"Signet ring cancer CPC Light","title":"Gastric signet ring carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric signet ring carcinoma</div><div class=\"cntnt\"><img style=\"width:370px; height:538px;\" src=\"images/GAST/79482_Signet_ring_cancer_CPC_Ligh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">At low power (upper panel) the normal lamina propria is replaced by an infiltrate that has either destroyed or separated the normal gastric glands. At high power (lower panel) the infiltrate consist of sheets of neoplastic cells with hyperchromatic and pleomorphic nuclei. In some cells, the nuclei are compressed at the cell membrane secondary to the accumulation of large amounts of cytoplasmic glycoproteins and appear as classic &quot;signet ring&quot; cells (arrow). Signet ring cell cancer usually presents as a diffusely infiltrative tumor. Gastric cancers that spread through the submucosa are known as &quot;Linitis Plastica&quot; but not all such cancers are of the signet ring type.</div><div class=\"graphic_reference\">Courtesy of Heather Crowley, MD and Donald Antonioli, MD.</div><div id=\"graphicVersion\">Graphic 79482 Version 1.0</div></div></div>"},"79484":{"type":"graphic_figure","displayName":"Antibodies to GBS conjugates","title":"Immunogenicity of candidate conjugate vaccines against Group B streptococcus in healthy women of childbearing age","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Immunogenicity of candidate conjugate vaccines against Group B streptococcus in healthy women of childbearing age</div><div class=\"cntnt\"><img style=\"width:440px; height:553px;\" src=\"images/ID/79484_Antibodies_to_GBS_conjugate.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Type Ia-TT and Ib-TT conjugate vaccines were well tolerated by healthy, childbearing-age women, and the serotype-specific IgG response was significantly greater in recipients of the conjugate compared with the uncoupled CPS vaccine. Subjects were randomized to receive (panel A) Ia-TT vaccine (red line, n = 30), uncoupled Ia CPS (blue line, n = 30), or saline placebo (green line, n = 15); or (panel B) Ib-TT vaccine (red line, n = 30), uncoupled Ib CPS (blue line, n = 15), or saline placebo (green line, n = 10).</div><div class=\"graphic_footnotes\">CPS: capsular polysaccharide; TT: tetanus toxoid.</div><div class=\"graphic_reference\">Data from: Baker CJ, Paoletti LC, Wessels MR, et al. J Infect Dis 1999; 179:142.</div><div id=\"graphicVersion\">Graphic 79484 Version 3.0</div></div></div>"},"79485":{"type":"graphic_movie","displayName":"Triple vessel coronary disease","title":"Triple vessel coronary disease","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Triple vessel coronary disease</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/79485_3vescadconv.mp4\" style=\"width:176px;height:272px\"></div><img style=\"width:176px; height:256px;\" src=\"images/CARD/79485_3vescad.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left coronary artery is shown in the LAO-Cranial projection. There is a severe stenosis in the circumflex artery, the proximal and mid-LAD artery and the diagonal branch. Not seen is the stenosis in the right coronary artery.</div><div class=\"graphic_reference\">Courtesy of John D. Carroll, MD. This type of movie will be part of The Multimedia Textbook of Coronary Arteriography and Interventions, Williams &amp; Wilkins, Baltimore, Fall 1996.</div><div id=\"graphicVersion\">Graphic 79485 Version 2.0</div></div></div>"},"79487":{"type":"graphic_diagnosticimage","displayName":"Autonomous thyroid nodule scan","title":"Autonomous thyroid nodule: Appearance on thyroid scintigraphy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Autonomous thyroid nodule: Appearance on thyroid scintigraphy</div><div class=\"cntnt\"><img style=\"width:352px; height:293px;\" src=\"images/ENDO/79487_Autonomous_thyroid_nodule_s.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Iodine 123 (123-I) thyroid scan demonstrating an autonomous (\"hot\") nodule with suppression of isotope uptake elsewhere. The total 24-hour isotope uptake was normal (12 percent).</div><div class=\"graphic_footnotes\">SSN: suprastenal notch. </div><div class=\"graphic_reference\">Courtesy of Douglas Ross, MD.</div><div id=\"graphicVersion\">Graphic 79487 Version 4.0</div></div></div>"},"79488":{"type":"graphic_diagnosticimage","displayName":"Hemangioma blood pool scan","title":"Hepatic hemangioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hepatic hemangioma</div><div class=\"cntnt\"><img style=\"width:351px; height:291px;\" src=\"images/GAST/79488_Hemangioma_blood_pool_scan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">99mTc-RBC pool study demonstrates retention of radiolabelled tracer in the right lobe of the liver on delayed images consistent with a hepatic hemangioma.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 79488 Version 2.0</div></div></div>"},"79494":{"type":"graphic_table","displayName":"Methionine challenge","title":"Plasma homocysteine response to methionine challenge","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Plasma homocysteine response to methionine challenge</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Gender</td>\n\n      <td class=\"subtitle1\">Baseline</td>\n\n      <td class=\"subtitle1\">4 hours</td>\n\n      <td class=\"subtitle1\">8 hours</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Male</td>\n\n      <td>6.2</td>\n\n      <td>16.3</td>\n\n      <td>17.5</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\" colspan=\"4\" rowspan=\"1\">Female</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Premenopausal</td>\n\n      <td class=\"sublist_other\">6.3</td>\n\n      <td class=\"sublist_other\">14.7</td>\n\n      <td class=\"sublist_other\">17.6</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Postmenopausal</td>\n\n      <td class=\"sublist_other\">4.8</td>\n\n      <td class=\"sublist_other\">22.4</td>\n\n      <td class=\"sublist_other\">24.7</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_lgnd\">Plasma homocysteine levels (mean plus two standard deviations, in &#181;mol/L) at baseline and four and eight hours after an oral mathionine load in men and women. Homocysteine metabolism is considered to be impaired if values above these levels are obtained.</div><div class=\"graphic_reference\">Data from Dudman, NP, Wilcken, DE, Wang, J, et al, Arterioscl Thromb 1993; 13:2253.</div><div id=\"graphicVersion\">Graphic 79494 Version 1.0</div></div></div>"},"79495":{"type":"graphic_picture","displayName":"Intestinal metaplasia of the distal esophagus","title":"Intestinal metaplasia of the distal esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intestinal metaplasia of the distal esophagus</div><div class=\"cntnt\"><img style=\"width:360px; height:266px;\" src=\"images/GAST/79495_Intestinal_metaplasia_CPC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medium power view of a biopsy specimen from the distal esophagus revealed intestinal metaplasia diagnostic of Barrett's esophagus. The diagnostic feature is the presence of goblet cells (arrow), characterized by apical basophilic cytoplasm, a dilated lateral cell border and a compressed basal nucleous.</div><div class=\"graphic_reference\">Courtesy of Donald Antonioli, MD.</div><div id=\"graphicVersion\">Graphic 79495 Version 2.0</div></div></div>"},"79496":{"type":"graphic_figure","displayName":"Menstrual cycle PI","title":"Menstrual cycle","html":"<div class=\"graphic\"><div style=\"width: 575px\" class=\"figure\"><div class=\"ttl\">Menstrual cycle</div><div class=\"cntnt\"><img style=\"width:555px; height:712px;\" src=\"images/PI/79496_Menstrual_cycle_PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 79496 Version 2.0</div></div></div>"},"79497":{"type":"graphic_figure","displayName":"Tessari method of foam sclerosant preparation","title":"Tessari method of foam sclerosant preparation","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Tessari method of foam sclerosant preparation</div><div class=\"cntnt\"><img style=\"width:512px; height:644px;\" src=\"images/SURG/79497_Tessari-method.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 79497 Version 2.0</div></div></div>"},"79500":{"type":"graphic_picture","displayName":"Cyclic neutropenia periodontal disease","title":"Periodontal disease in cyclic neutropenia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Periodontal disease in cyclic neutropenia</div><div class=\"cntnt\"><img style=\"width:432px; height:298px;\" src=\"images/PEDS/79500_Cyclicneutropenia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A three-year-old child presenting with lower incisor mobility who was diagnosed with cyclic neutropenia. Gingival recession and splaying of the lower incisors is caused by the advancing periodontal disease.</div><div class=\"graphic_reference\">Reproduced with permission from: Delaney JE, Keels MA. Pediatric oral pathology. Soft tissue and periodontal conditions. Pediatr Clin North Am 2000; 47:1125. Copyright Â© 2000 W.B. Saunders.</div><div id=\"graphicVersion\">Graphic 79500 Version 4.0</div></div></div>"},"79502":{"type":"graphic_table","displayName":"Max doses ticarcillin and piperacillin in renal failure","title":"Adjusted maximum dose of ticarcillin and piperacillin in renal disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adjusted maximum dose of ticarcillin and piperacillin in renal disease</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">Drug </td>\n\n      <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">GFR (mL/min)</td>\n\n\n\n\n      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">Removal by dialysis</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td class=\"subtitle2\">&#62;50</td>\n\n\n      <td class=\"subtitle2\"> 10-50</td>\n\n      <td class=\"subtitle2\">&#60;10</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td>Ticarcillin </td>\n\n      <td>3g Q4h</td>\n\n\n      <td>3g Q6h </td>\n\n      <td>2g Q12h </td>\n\n      <td>Yes (H, P)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Piperacillin </td>\n\n      <td>4g Q6h</td>\n\n\n      <td>4g Q8h </td>\n\n      <td>4g Q12h </td>\n\n      <td>Yes (H), No (P)</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">8.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=31588&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Max_doses_PCNs_in_renal_fai.htm</title></head></div><div class=\"graphic_footnotes\">H: hemodialysis; P: peritoneal dialysis.</div><div id=\"graphicVersion\">Graphic 79502 Version 2.0</div></div></div>"},"79503":{"type":"graphic_figure","displayName":"Trends in smoking rates among US youth and adults","title":"30-day prevalence of daily use of cigarettes amongÂ students, United States, 1976 to 2015","html":"<div class=\"graphic\"><div style=\"width: 613px\" class=\"figure\"><div class=\"ttl\">30-day prevalence of daily use of cigarettes among&nbsp;students, United States, 1976 to 2015</div><div class=\"cntnt\"><img style=\"width:593px; height:410px;\" src=\"images/PEDS/79503_TrendsmokeUSythadlts.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Johnston LD, O&rsquo;Malley PM, Miech RA, et al. Monitoring the Future national survey results on drug use, 1975-2015: Overview, key findings on adolescent drug use. Ann Arbor, MI: Institute for Social Research, The University of Michigan 2016. Available at: <a href=\"http://www.monitoringthefuture.org/pubs/monographs/mtf-overview2015.pdf\" target=\"_blank\">http://www.monitoringthefuture.org/pubs/monographs/mtf-overview2015.pdf</a> (accessed on October 4, 2017).</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced from: Adolescents and Tobacco: Trends. U.S. Department of Health and Human Services. Available at: <a href=\"https://www.hhs.gov/ash/oah/adolescent-development/substance-use/drugs/tobacco/trends/index.html\" target=\"_blank\">https://www.hhs.gov/ash/oah/adolescent-development/substance-use/drugs/tobacco/trends/index.html</a> (accessed on October 4, 2017).</div><div id=\"graphicVersion\">Graphic 79503 Version 8.0</div></div></div>"},"79504":{"type":"graphic_table","displayName":"Congenital features difficult airway","title":"Congenital features associated with airway abnormalities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Congenital features associated with airway abnormalities</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Features</td> <td class=\"subtitle1\">Abnormalities*</td> </tr> <tr> <td>Misshapen head</td> <td>Apert syndrome, Crouzon syndrome, Pfeiffer syndrome</td> </tr> <tr> <td>Maxillary hypolasia</td> <td>Apert syndrome, Crouzon syndrome, Pfeiffer syndrome</td> </tr> <tr> <td>Abnormal neck mobility</td> <td>Down syndrome, Klippel-Feil syndrome, mucopolysaccharidoses</td> </tr> <tr> <td>Microstomia</td> <td>Freeman-Sheldon syndrome, Hallermann-Streiff syndrome</td> </tr> <tr> <td>Mandibular hypoplasia</td> <td>Hallermann-Streiff syndrome, Pierre-Robin sequence, Treacher-Collins syndrome, unilateral hypoplasia of the mandible (Goldenhar syndrome)</td> </tr> <tr> <td>High arched or narrow palate</td> <td>Achondroplasia, Apert syndrome, Crouzon syndrome, de Lange syndrome, Hallermann-Streiff syndrome, Pfeiffer syndrome, Treacher-Collins syndrome</td> </tr> <tr> <td>Cleft palate</td> <td>Branchio-Oculo-Facial syndrome, Cleft lip sequence, Ectrodactyly-Ectodermal Dysplasia-Clefting syndrome</td> </tr> <tr> <td>Large or protuding tongue</td> <td>Beckwith-Wiedemann syndrome, Down syndrome, mucopolysaccharidoses, Pierre-Robin sequence</td> </tr> <tr> <td>Neck masses</td> <td>Cystic hygroma, hemangioma</td> </tr> <tr> <td>Laryngeal or subglottic abnormalities</td> <td>Laryngeal cystes or webs, subglottic stenosis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Partial list of representative disorders.</div><div id=\"graphicVersion\">Graphic 79504 Version 4.0</div></div></div>"},"79505":{"type":"graphic_picture","displayName":"Cerv interstit brachyther","title":"Cervical interstitial brachytherapy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cervical interstitial brachytherapy</div><div class=\"cntnt\"><img style=\"width:312px; height:422px;\" src=\"images/OBGYN/79505_Cerv_interstit_brachyther.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Syed-type interstitial implant used for cervical brachytherapy.</div><div class=\"graphic_reference\">Courtesy of Kristin Bradley, MD and Derek McHaffie, MD.</div><div id=\"graphicVersion\">Graphic 79505 Version 2.0</div></div></div>"},"79506":{"type":"graphic_figure","displayName":"Vulvoperineoplasty","title":"Vulvoperineoplasty","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vulvoperineoplasty</div><div class=\"cntnt\"><img style=\"width:399px; height:284px;\" src=\"images/OBGYN/79506_Vulvoperineoplasty.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Mucocutaneous incision, (B) Dissection of the posterior vaginal wall, (C) Excision of a triangular patch of perineal skin, (D and E) radial incision of the fibrous perineal body to reduce its height, (F) Individualization of a vaginal flap, (G) The vaginal flap is drawn down, making a cover for the perineal defect, and sutured.</div><div class=\"graphic_reference\">Reproduced with permission from Ridley CM, Neill SM (Eds), The Vulva, 2nd ed, Blackwell Science, Oxford 1999. Copyright Â© 1999 Blackwell Science. <A spellcheck=true href=\"http://www.wiley.com/wiley-blackwell\" target=_blank>http://www.blackwell-science.com</A>.</div><div id=\"graphicVersion\">Graphic 79506 Version 3.0</div></div></div>"},"79510":{"type":"graphic_figure","displayName":"Survival with arterial versus venous aortocoronary grafts","title":"Survival with arterial versus venous aortocoronary grafts","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Survival with arterial versus venous aortocoronary grafts</div><div class=\"cntnt\"><img style=\"width:332px; height:238px;\" src=\"images/CARD/79510_CABG_graft_survival.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In patients with three-vessel coronary artery disease, survival is better when the internal mammary artery was used as compared to the use of only vein grafts</div><div class=\"graphic_reference\">Data from Loop FD, Lytle BW, Cosgrove DM, et al. N Engl J Med 1986; 314:1.</div><div id=\"graphicVersion\">Graphic 79510 Version 3.0</div></div></div>"},"79511":{"type":"graphic_table","displayName":"Common causes cholestasis","title":"Most common causes of neonatal cholestasis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Most common causes of neonatal cholestasis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\"><span class=\"subtitle1\">Diagnosis</span>&nbsp;</td> <td class=\"subtitle1_single\"> <p>&nbsp;Proportion of young infants with</p> <p>conjugated&nbsp;hyperbilirubinemia</p> </td> </tr> <tr> <td>Extrahepatic biliary atresia</td> <td>25 percent (range 2 to 55 percent)</td> </tr> <tr> <td>Idiopathic neonatal hepatitis</td> <td>25 percent (range 4 to 45 percent)</td> </tr> <tr> <td>Infectious hepatitis (eg, CMV)</td> <td>11 percent&nbsp;(range 3 to 38 percent)</td> </tr> <tr> <td>Parenteral nutrition-associated&nbsp;</td> <td>6 percent&nbsp;&nbsp;(range 7 to 30 percent)</td> </tr> <tr> <td>Metabolic disease (eg,&nbsp;galactosemia)</td> <td>4 percent&nbsp;</td> </tr> <tr> <td>Alpha-1-antitrypsin deficiency</td> <td>4 percent&nbsp;</td> </tr> <tr> <td>Alagille syndrome</td> <td>1 percent&nbsp;</td> </tr> <tr> <td>Progressive familial intrahepatic cholestasis</td> <td>1 percent&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The percentages shown here are based upon a systematic review of 17 studies encompassing 1692 infants.<SUP innerHtml> </SUP>Most but not all of the studies were from resource-rich&nbsp;countries. The proportion&nbsp;of infants in each category varied substantially across the studies,&nbsp;likely due to differences in infectious diseases in the population as well as&nbsp;the methods uses to make the diagnoses. &nbsp;</div><div class=\"graphic_footnotes\">CMV: cytomegalovirus.</div><div class=\"graphic_reference\">Data from:&nbsp; Gottesman LE, Del Vecchio MT, Aronoff SC. Etiologies of conjugated hyperbilirubinemia in infancy: A systematic review of 1692 subjects. BMC Pediatrics 2015; 15:192.</div><div id=\"graphicVersion\">Graphic 79511 Version 4.0</div></div></div>"},"79512":{"type":"graphic_picture","displayName":"Geographic tongue - distal","title":"Geographic tongue","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Geographic tongue</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/79512_Geographic_tongue_distal.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 79512 Version 3.0</div></div></div>"},"79514":{"type":"graphic_table","displayName":"Antibiotics C diff PI","title":"Antimicrobial agents that may induce <EM>Clostridium difficile </EM>diarrhea and colitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antimicrobial agents that may induce <EM>Clostridium difficile </EM>diarrhea and colitis</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\r\n \r\n   <tr>\r\n   <td class=\"container\">\r\n   <table cellspacing=\"0\">\r\n  \r\n   <tr>\r\n   <td  class=\"subtitle1_single\">Frequently associated</td>\r\n   </tr>\r\n  \r\n   <tr>\r\n   <td>Fluoroquinolones</td>\r\n   </tr>\r\n  \r\n   <tr>\r\n   <td>Clindamycin</td>\r\n   </tr>\r\n  \r\n   <tr>\r\n   <td>Penicillins (broad spectrum)</td>\r\n   </tr>\r\n  \r\n   <tr>\r\n   <td>Cephalosporins (broad spectrum)</td>\r\n   </tr>\r\n  \r\n   </table>\r\n   </td>\r\n  \r\n   <td class=\"container\">\r\n   <table cellspacing=\"0\">\r\n  \r\n   <tr>\r\n   <td  class=\"subtitle1_single\">Occasionally associated</td>\r\n   </tr>\r\n  \r\n   <tr>\r\n   <td>Macrolides</td>\r\n   </tr>\r\n  \r\n   <tr>\r\n   <td>Trimethoprim</td>\r\n   </tr>\r\n  \r\n   <tr>\r\n   <td>Sulfonamides</td>\r\n   </tr>\r\n  \r\n   </table>\r\n   </td>\r\n  \r\n   <td class=\"container\">\r\n   <table cellspacing=\"0\">\r\n  \r\n   <tr>\r\n   <td  class=\"subtitle1_single\">Rarely associated</td>\r\n   </tr>\r\n  \r\n   <tr>\r\n   <td>Aminoglycosides</td>\r\n   </tr>\r\n  \r\n   <tr>\r\n   <td>Tetracyclines</td>\r\n   </tr>\r\n  \r\n   <tr>\r\n   <td>Chloramphenicol</td>\r\n   </tr>\r\n  \r\n   <tr>\r\n   <td>Metronidazole</td>\r\n   </tr>\r\n  \r\n   <tr>\r\n   <td>Vancomycin</td>\r\n   </tr>\r\n  \r\n   </table>\r\n   </td>\r\n   </tr>\r\n\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">12.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=48803&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Antibiotics_C_diff_PI.htm</title></head></div><div id=\"graphicVersion\">Graphic 79514 Version 3.0</div></div></div>"},"79515":{"type":"graphic_picture","displayName":"Loop mark","title":"Loop mark","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Loop mark</div><div class=\"cntnt\"><img style=\"width:146px; height:216px;\" src=\"images/EM/79515_Loop_mark.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the characteristic bruising pattern.</div><div class=\"graphic_reference\">Courtesy of Joan E Shook, MD.</div><div id=\"graphicVersion\">Graphic 79515 Version 2.0</div></div></div>"},"79517":{"type":"graphic_table","displayName":"HIV-associated lymphomas","title":"WHO classification of lymphoid malignancies associated with HIV infection (2008)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">WHO classification of lymphoid malignancies associated with HIV infection (2008)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Lymphomas also occurring in immunocompetent patients</td> </tr> <tr> <td>Burkitt and Burkitt-like lymphomas</td> </tr> <tr> <td>Diffuse large B-cell lymphomas</td> </tr> <tr> <td class=\"indent1\">- Centroblastic</td> </tr> <tr> <td class=\"indent1\">- Immunoblastic (including primary CNS lymphoma)</td> </tr> <tr> <td>Extranodal MALT lymphoma (rare)</td> </tr> <tr> <td>Peripheral T-cell lymphoma (rare)</td> </tr> <tr> <td>Classical Hodgkin lymphoma</td> </tr> <tr> <td class=\"subtitle1_single\">Lymphoma occurring more specifically in HIV-positive patients</td> </tr> <tr> <td>Primary effusion lymphoma</td> </tr> <tr> <td>Plasmablastic lymphoma of the oral cavity</td> </tr> <tr> <td class=\"subtitle1_single\">Lymphoma also occurring in other immunodeficiency states</td> </tr> <tr> <td>Polymorphic B-cell lymphoma (PTLD-like) (rare)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MALT: marginal zone lymphoma of mucosa-associated lymphoid tissue; PTLD: post transplant lymphoproliferative disorder; CNS: central nervous system.</div><div class=\"graphic_reference\">Source: Swerdlow, SH, Campo, E, Harris, NL, et al. (Eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon 2008.</div><div id=\"graphicVersion\">Graphic 79517 Version 1.0</div></div></div>"},"79518":{"type":"graphic_picture","displayName":"Paraneoplastic pemphigus tongue","title":"Paraneoplastic pemphigus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Paraneoplastic pemphigus</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/79518_Paraneo_pemph_tongue.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erosions are present on the tongue.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 79518 Version 3.0</div></div></div>"},"79519":{"type":"graphic_picture","displayName":"Candida denture stomatitis","title":"<i>Candida</i> denture stomatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><i>Candida</i> denture stomatitis</div><div class=\"cntnt\"><img style=\"width:360px; height:242px;\" src=\"images/ID/79519_Candida_denture_stomatitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In patients with dentures, candidal stomatitis frequently causes erythematous lesions on the hard palate without pseudomembranes.</div><div class=\"graphic_reference\">Courtesy of Kenneth Shay, DDS.</div><div id=\"graphicVersion\">Graphic 79519 Version 4.0</div></div></div>"},"79520":{"type":"graphic_diagnosticimage","displayName":"Thickening of distal ileum","title":"AbdominalÂ computed tomographyÂ scan showing thickening of the distal ileum","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Abdominal&nbsp;computed tomography&nbsp;scan showing thickening of the distal ileum</div><div class=\"cntnt\"><img style=\"width:468px; height:351px;\" src=\"images/ID/79520_Thickening_of_distal_ileum.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Ramos L, Alonso C, Guilarte M, et al. Anisakis simplex-induced small bowel obstruction after fish ingestion: preliminary evidence for response to parenteral corticosteroids. Clin Gastroenterol Hepatol 2005; 3:667. Copyright Â© 2005 Elsevier Science, Inc.</div><div id=\"graphicVersion\">Graphic 79520 Version 4.0</div></div></div>"},"79521":{"type":"graphic_figure","displayName":"TMLR event free survival","title":"Cardiac event-free survival in refractory angina is better with transmyocardial laser revascularization","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Cardiac event-free survival in refractory angina is better with transmyocardial laser revascularization</div><div class=\"cntnt\"><img style=\"width:454px; height:309px;\" src=\"images/CARD/79521_TMLR_event_free_survival.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among 192 patients with refractory angina, the survival free of a cardiac event (acute myocardial infarction, unstable angina, or class IV angina) was better with transmyocardial laser revascularization (TMLR) compared to continued medical therapy (66 versus 11 percent, p &lt;0.001); this was primarily due to a lower incidence of unstable angina (2 versus 69 percent).</div><div class=\"graphic_reference\">Data from Frazier OH, March RJ, Horvath KA. N Engl J Med 1999; 341:1021.</div><div id=\"graphicVersion\">Graphic 79521 Version 2.0</div></div></div>"},"79522":{"type":"graphic_table","displayName":"Triage scoring systems","title":"Examples of prehospital triage scoring systems","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of prehospital triage scoring systems</div><div class=\"cntnt\"><table cellspacing=\"0\" cellpadding=\"0\">\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td class=\"subtitle1_single\">Name</td>\r\n\t\t\t\t\t<td class=\"subtitle1_single\">Parameters</td>\r\n\t\t\t\t\t<td class=\"subtitle1_single\">Notes</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Prehospital Index</td>\r\n\t\t\t\t\t<td><p>Systolic BP</p>\r\n\t\t\t\t\t\t<p>Pulse rate</p>\r\n\t\t\t\t\t\t<p>Respiratory rate</p>\r\n\t\t\t\t\t\t<p>Consciousness</p>\r\n\t\t\t\t\t\t<p>Penetrating wounds (chest or abdomen)</p></td>\r\n\t\t\t\t\t<td>Scale is 0 to 24 (&gt;3: major trauma)</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>CRAMS (Circulation, Respiration, Abdomen/Thorax, Motor, Speech)</td>\r\n\t\t\t\t\t<td><p>Systolic BP or capillary refill</p>\r\n\t\t\t\t\t\t<p>Respirations</p>\r\n\t\t\t\t\t\t<p>Examination of trunk</p>\r\n\t\t\t\t\t\t<p>Motor function</p>\r\n\t\t\t\t\t\t<p>Speech pattern</p></td>\r\n\t\t\t\t\t<td><p>Scale is 0 to 10 (&lt;8: major trauma)</p>\r\n\t\t\t\t\t\t<p>Each parameter rated as normal, mildly abnormal, or highly abnormal</p></td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Revised Trauma Score</td>\r\n\t\t\t\t\t<td><p>Systolic BP</p>\r\n\t\t\t\t\t\t<p>Respiratory rate</p>\r\n\t\t\t\t\t\t<p>GCS</p></td>\r\n\t\t\t\t\t<td><p>0 to 7.8408 (&lt;4: major trauma)</p>\r\n\t\t\t\t\t\t<p>GCS more heavily weighted</p></td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>START (Simple triage and rapid treatment)</td>\r\n\t\t\t\t\t<td><p>Ambulation</p>\r\n\t\t\t\t\t\t<p>Respiratory rate</p>\r\n\t\t\t\t\t\t<p>Capillary refill</p>\r\n\t\t\t\t\t\t<p>Consciousness</p></td>\r\n\t\t\t\t\t<td>Stepwise algorithm designed for ease of use in mass casualty incident</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>GCS (Glasgow Coma Scale)</td>\r\n\t\t\t\t\t<td><p>Eye response</p>\r\n\t\t\t\t\t\t<p>Verbal response</p>\r\n\t\t\t\t\t\t<p>Motor response</p></td>\r\n\t\t\t\t\t<td>Scale is 3 to 15 (&lt;8: severe brain injury)</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>MGAP (Mechanism, GCS, Age, arterial Pressure)</td>\r\n\t\t\t\t\t<td><p>Mechanism (blunt)</p>\r\n\t\t\t\t\t\t<p>GCS</p>\r\n\t\t\t\t\t\t<p>Age (60 years)</p>\r\n\t\t\t\t\t\t<p>Systolic BP</p></td>\r\n\t\t\t\t\t<td>Scale is 3 to 29 (&#60;18: high risk)</td>\r\n\t\t\t\t</tr>\r\n\t\t\t</table></div><div id=\"graphicVersion\">Graphic 79522 Version 1.0</div></div></div>"},"79523":{"type":"graphic_diagnosticimage","displayName":"Tumor bleeding 15c","title":"Right hypogastric angiogram","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Right hypogastric angiogram</div><div class=\"cntnt\"><img style=\"width:512px; height:492px;\" src=\"images/OBGYN/79523_Tumor_bleeding_15c.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right hypogastric angiogram after embolization of the cervicovaginal artery. There is occlusion of the right cervicovaginal artery (arrow) preventing filling of the tumor vessels. Vaginal bleeding stopped immediately following embolization.</div><div id=\"graphicVersion\">Graphic 79523 Version 3.0</div></div></div>"},"79525":{"type":"graphic_table","displayName":"Indications for discontinuation of exercise testing","title":"Indications for discontinuation of exercise testing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for discontinuation of exercise testing</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Absolute</td> </tr> <tr> <td>Moderately severe angina (defined as 3 on a standard scale)</td> </tr> <tr> <td>Drop in systolic blood pressure of &#62;10 mmHg from baseline blood pressure*, despite an increase in workload, when accompanied by other evidence of ischemia</td> </tr> <tr> <td>Sustained ventricular tachycardia</td> </tr> <tr> <td>Signs of poor perfusion (eg, pallor or cyanosis)</td> </tr> <tr> <td>ST elevation (+1.0 mm) in leads without diagnostic Q waves (other than V1 or aVR)</td> </tr> <tr> <td>Increasing nervous system symptoms (eg, ataxia, dizziness, near syncope, or confusion)</td> </tr> <tr> <td>Technical difficulties monitoring the ECG or systolic blood pressure</td> </tr> <tr> <td>Subject's desire to stop</td> </tr> <tr> <td class=\"subtitle1_single\">Relative</td> </tr> <tr> <td>ST or QRS changes such as extensive ST depression (&#62;2 mm of horizontal or downsloping ST-segment depression) or marked axis shift</td> </tr> <tr> <td>Drop in systolic blood pressure of &#62;10 mmHg from baseline blood pressure*, despite an increase in workload, in the absence of other evidence of ischemia</td> </tr> <tr> <td>Arrhythmias other than sustained ventricular tachycardia, including multifocal PVCs, triplets of PVCs, supraventricular tachycardia, heart block, or bradyarrhythmias</td> </tr> <tr> <td>Development of bundle branch block or intraventricular conduction delay that cannot be distinguished from ventricular tachycardia</td> </tr> <tr> <td>Chest pain that is increasing</td> </tr> <tr> <td>Fatigue, shortness of breath, wheezing, leg cramps, or claudication</td> </tr> <tr> <td>Hypertensive response (systolic BP &#62;250 mmHg and/or diastolic BP &#62;115 mmHg)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Baseline refers to a measurement obtained immediately before the test and in the same posture as the test is being performed.</div><div class=\"graphic_reference\">Modified from: Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 2002; 106:1883.</div><div id=\"graphicVersion\">Graphic 79525 Version 10.0</div></div></div>"},"79527":{"type":"graphic_diagnosticimage","displayName":"Late gadolinium enhancement in myocardial infarction","title":"Late gadolinium enhancement in myocardial infarction","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Late gadolinium enhancement in myocardial infarction</div><div class=\"cntnt\"><img style=\"width:518px; height:351px;\" src=\"images/CARD/79527_Large_MI_MRI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Short-axis (upper panel) and long-axis (lower panel) late gadolinium enhancement (LGE)&nbsp;cardiovascular&nbsp;magnetic resonance (CMR)&nbsp;images&nbsp;in three patients with large myocardial infarctions (MIs). Hyperenhanced regions (arrows) were large and predominantly transmural. In comparison, small infarcts (not shown) were not transmural.</div><div class=\"graphic_reference\">Reprinted with permission from: Wu E, Judd RM, Vargas JD, et al. Lancet 2001; 357:21. Copyright &copy; 2001. The Lancet Ltd.</div><div id=\"graphicVersion\">Graphic 79527 Version 5.0</div></div></div>"},"79529":{"type":"graphic_diagnosticimage","displayName":"Tibial bowing in osteomalacia","title":"Tibial bowing in osteomalacia: Radiographic findings","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tibial bowing in osteomalacia: Radiographic findings</div><div class=\"cntnt\"><img style=\"width:230px; height:308px;\" src=\"images/ENDO/79529_Tibial_bowing_in_osteomalac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tibial shortening and bowing in a man with vitamin D-resistant rickets. A surgical osteotomy was performed to correct the tibial bending (arrow).</div><div class=\"graphic_reference\">Courtesy of CJ Menkes, MD.</div><div id=\"graphicVersion\">Graphic 79529 Version 4.0</div></div></div>"},"79530":{"type":"graphic_diagnosticimage","displayName":"EUS needle insertion CPN","title":"Celiac plexus neurolysis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Celiac plexus neurolysis</div><div class=\"cntnt\"><img style=\"width:432px; height:300px;\" src=\"images/GAST/79530_EUS_needle_insertion_CPN.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic ultrasound image showing insertion of a needle under EUS-guidance into the region of the celiac plexus in preparation for neurolysis.</div><div class=\"graphic_reference\">Courtesy of Kenneth E Fasanella, MD, and Michael K Sanders, MD.</div><div id=\"graphicVersion\">Graphic 79530 Version 2.0</div></div></div>"},"79532":{"type":"graphic_figure","displayName":"Incidence typhoid fever US","title":"Reported incidence of typhoid fever and nontyphoidal salmonellosis in the United States, 1920 - 1995","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Reported incidence of typhoid fever and nontyphoidal salmonellosis in the United States, 1920 - 1995</div><div class=\"cntnt\"><img style=\"width:357px; height:229px;\" src=\"images/ID/79532_Incidence_typhoid_fever_US.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Redrawn from R.V. Tauxe (Center for Disease Control and Prevention): Emerging Infectious Diseases, Volume 3 Number 4:425 - 34.</div><div id=\"graphicVersion\">Graphic 79532 Version 1.0</div></div></div>"},"79533":{"type":"graphic_figure","displayName":"DHEAS pubic hair develop","title":"Serum DHEAS concentrations in relation to pubic hair development","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Serum DHEAS concentrations in relation to pubic hair development</div><div class=\"cntnt\"><img style=\"width:398px; height:407px;\" src=\"images/PEDS/79533_DHEAS_pubic_hair_devel_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A rise in DHEAS levels at about six years of age is the major indicator of adrenarche. The upper limit for boys rises above that of girls during the late prepubertal years. Pubertal groups are subcategorized by pubic hair developmental stages. Among children with premature pubarche, some have premature adrenarche with high serum DHEAS&nbsp;concentrations for age (circles), and others have premature adrenarche with above average DHEAS concentrations for age (diamonds). Serum DHEAS concentrations are also shown for boys over 10 years of age who have pubarche before gonadarche (small rectangles); similar concentrations are often not associated with pubarche in normal subjects (pubertal stage I).</div><div class=\"graphic_footnotes\">DHEAS: dehydroepiandrosterone sulfate.</div><div class=\"graphic_reference\">Modified with permission from: Rosenfield RL, Rich BH, Lucky AW. Adrenarche as a cause of benign pseudopuberty in boys. J Pediatr 1982; 101:1005. Copyright Â© 1982 Elsevier.</div><div id=\"graphicVersion\">Graphic 79533 Version 7.0</div></div></div>"},"79534":{"type":"graphic_figure","displayName":"Thumb spica splint 2","title":"Thumb spica splint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thumb spica splint</div><div class=\"cntnt\"><img style=\"width:300px; height:402px;\" src=\"images/EM/79534_Thumb_spica_splint_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The thumb spica splint is used for scaphoid fractures and extra-articular fractures of the thumb metacarpal, ulnar collateral ligament injuries (ie, gamekeeper's thumb or skier's thumb), or after reduction of thumb dislocations. The splint is placed on the radial aspect of the forearm, wrapping the thumb up to the distal interphalangeal joint.</div><div id=\"graphicVersion\">Graphic 79534 Version 3.0</div></div></div>"},"79535":{"type":"graphic_picture","displayName":"Finger buddy taping","title":"Finger buddy taping","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Finger buddy taping</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/EM/79535_Finger_buddy_taping.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Buddy taping the injured finger to an adjacent finger provides stability while the fracture heals. Padding placed between the fingers prevents the soft tissues from becoming macerated.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 79535 Version 4.0</div></div></div>"},"79536":{"type":"graphic_table","displayName":"Accuracy US ulcerative colitis","title":"Sensitivity and specifity of ultrasonography in the detection of active ulcerative colitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sensitivity and specifity of ultrasonography in the detection of active ulcerative colitis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Sensitivity, percent</td>\n<td class=\"subtitle1\">Specifity, percent</td>\n<td class=\"subtitle1\">Number of patients</td>\n<td class=\"subtitle1\">Study</td>\n</tr>\n<tr>\n<td>84</td>\n<td>88</td>\n<td>181 (57)</td>\n<td>Pera, A, et al 1988</td>\n</tr>\n<tr>\n<td>91</td>\n<td>98</td>\n<td>440 (36)</td>\n<td>Limberg, B, et al 1994</td>\n</tr>\n<tr>\n<td>89</td>\n<td>97</td>\n<td>142 (18)</td>\n<td>Limberg, B, et al 1989</td>\n</tr>\n<tr>\n<td>66</td>\n<td>NA</td>\n<td>227 (29)</td>\n<td>Hollerbach, S, et al 1998</td>\n</tr>\n<tr>\n<td>89</td>\n<td>98</td>\n<td>(28)</td>\n<td>Hata, J, et al 1992</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_footnotes\">NA: not available.<br>Parentheses indicate the number of patients with proven ulcerative colitis, if noted.</div><div id=\"graphicVersion\">Graphic 79536 Version 1.0</div></div></div>"},"79538":{"type":"graphic_figure","displayName":"String technique for fish-hook removal","title":"String technique for fish-hook removal","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">String technique for fish-hook removal</div><div class=\"cntnt\"><img style=\"width:227px; height:512px;\" src=\"images/PEDS/79538_String_technique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Loop suture around belly of hook and wrap ends around index finger. B) Grasp shank of hook with opposite hand and depress firmly. C) Pull suture until taut and jerk quickly and firmly.</div><div id=\"graphicVersion\">Graphic 79538 Version 2.0</div></div></div>"},"79539":{"type":"graphic_waveform","displayName":"ECG Mobitz type II AV block","title":"Electrocardiographic (ECG) and electrophysiologic features of Mobitz type II second degree atrioventricular (AV) block","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electrocardiographic (ECG) and electrophysiologic features of Mobitz type II second degree atrioventricular (AV) block</div><div class=\"cntnt\"><img style=\"width:399px; height:208px;\" src=\"images/CARD/79539_Mobitz_type_II_AV_block.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The PR and RR intervals are constant, but the third atrial beat (A) is not conducted (arrow). His bundle electrocardiography (HBE) shows constant AH (85 msec) and HV (95 msec) intervals and normal AH but no HV conduction in the nonconducted beat. The last finding indicates that the block is distal to the His bundle in contrast to the more proximal location of Mobitz type I AV block.</div><div class=\"graphic_reference\">Adapted from: Josephson ME, Clinical Cardiac Electrophysiology: Techniques and Interpretations, 2nd ed, Lea &amp; Febiger, Philadelphia 1993.</div><div id=\"graphicVersion\">Graphic 79539 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"79540":{"type":"graphic_picture","displayName":"Dactylitis in psoratic juvenile idiopathic arthritis","title":"Dactylitis in psoratic juvenile idiopathic arthritis (psJIA)","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Dactylitis in psoratic juvenile idiopathic arthritis (psJIA)</div><div class=\"cntnt\"><img style=\"width:580px; height:260px;\" src=\"images/ALLRG/79540_Dactilitis_psoratic_JIA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dactylitis in psJIA. Note sausage shape of the second and fourth toes (A) and fusiform swelling of forefinger and thumb (B).</div><div id=\"graphicVersion\">Graphic 79540 Version 3.0</div></div></div>"},"79541":{"type":"graphic_picture","displayName":"Trucut spring loaded handle","title":"Spring loaded handle","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Spring loaded handle</div><div class=\"cntnt\"><img style=\"width:540px; height:208px;\" src=\"images/GAST/79541_Trucut_spring_loaded_handle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Picture of the handle for a spring-loaded trucut needle.</div><div class=\"graphic_reference\">Courtesy of Michael J Levy, MD and Maurits J Wiersema, MD.</div><div id=\"graphicVersion\">Graphic 79541 Version 1.0</div></div></div>"},"79542":{"type":"graphic_diagnosticimage","displayName":"Two hepatic adenomas MRI","title":"Hepatic adenomas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hepatic adenomas</div><div class=\"cntnt\"><img style=\"width:395px; height:259px;\" src=\"images/GAST/79542_Two_hepatic_adenomas_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This gadolinum enhanced magnetic resonance image of the liver acquired during the early bolus phase of contrast administration demonstrates two enhancing masses in the liver, one in the left lateral segment, the second immediately anterior to the right portal vein (arrows). The enhancement characteristics are non-specific and are seen with any vascular tumor of the liver.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 79542 Version 3.0</div></div></div>"},"79543":{"type":"graphic_table","displayName":"Complications of vagal maneuvers","title":"Potential complications of selected vagal maneuvers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential complications of selected vagal maneuvers</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Vagal maneuver</td> <td class=\"subtitle1\">Potential complication</td> </tr> <tr> <td>Valsalva maneuver&nbsp;</td> <td>Rupture of the round window of the ear</td> </tr> <tr> <td>Carotid sinus massage</td> <td>Decreased cerebral perfusion, cerebral embolism</td> </tr> <tr> <td>Ice-water immersion</td> <td>Aspiration, drowning, pregnancy complications</td> </tr> <tr> <td>Eyeball compression</td> <td>Ocular injury</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Peter J Zimetbaum, MD and Daniel Frisch, MD.</div><div id=\"graphicVersion\">Graphic 79543 Version 5.0</div></div></div>"},"79545":{"type":"graphic_picture","displayName":"Livedo reticularis - lower extremities","title":"Livedo reticularis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Livedo reticularis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/79545_Livedo_reticularis_lower.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A red-blue, reticulated vascular network is present on the legs.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 79545 Version 3.0</div></div></div>"},"79547":{"type":"graphic_table","displayName":"Food intolerances IBD PI","title":"Foods and beverages that may worsen gastrointestinal symptoms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Foods and beverages that may worsen gastrointestinal symptoms</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Milk, milk-containing products, and lactose-free milk products, including ice cream, cream cheese, cheese, cottage cheese, yogurt, pudding, whipped cream, cream, cheesecake, chocolate, pastries, crackers, pretzels, cookies, crackers, cakes, and pies</td> </tr> <tr> <td>Caffeine-containing products, including coffee, tea, and sodas</td> </tr> <tr> <td>Alcohol products</td> </tr> <tr> <td>Fruits and fruit juices</td> </tr> <tr> <td>Spices, seasonings, and spicy marinades</td> </tr> <tr> <td>Diet beverages, diet foods, diet candies, diet gum, sugar-free products</td> </tr> <tr> <td>Fried foods, fatty foods, and fast foods</td> </tr> <tr> <td>Condiments including ketchup, mustard, mayonnaise, and relish</td> </tr> <tr> <td>Whole-grain or multigrain breads; sourdough breads, bagels, and yeast-containing products</td> </tr> <tr> <td>Salads, particularly added components including bacon bits, croutons, onions, and peppers</td> </tr> <tr> <td>Salad dressings that contain mayonnaise, cheese, and spices</td> </tr> <tr> <td>Vegetables including cabbage, broccoli, and cauliflower</td> </tr> <tr> <td>Legumes: beans, lentils, chili</td> </tr> <tr> <td>Red meats including steak, hamburger, sausage, bacon, and prime rib</td> </tr> <tr> <td>Gravies, spaghetti sauce, soups, stews, and stuffing</td> </tr> <tr> <td>Popcorn, peanuts, corn</td> </tr> <tr> <td>Artificial colorings, flavorings, and sweeteners</td> </tr> <tr> <td>Foods and beverages containing sorbitol, fructose, or high-fructose corn syrup</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The foods and drinks listed above may worsen gastrointestinal symptoms (diarrhea, cramps, abdominal pain, nausea, gas, bloating, heartburn, etc.) in some patients with both irritable bowel syndrome and inflammatory bowel disease. These symptoms can begin as soon as 5 to 15 minutes after eating or as many as 12 to 48 hours later.</div><div class=\"graphic_reference\">Data from: MacDermott, RP. Treatment of irritable bowel syndrome in outpatients with inflammatory bowel disease using a food and beverage intolerance, food and beverage avoidance diet. Inflamm Bowel Dis 2007; 13:91.</div><div id=\"graphicVersion\">Graphic 79547 Version 2.0</div></div></div>"},"79548":{"type":"graphic_diagnosticimage","displayName":"Coarctation aorta PA angiogram","title":"Aortogram showing coarctation of the aorta","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aortogram showing coarctation of the aorta</div><div class=\"cntnt\"><img style=\"width:251px; height:371px;\" src=\"images/CARD/79548_Coarctation_aorta_PA_angiog.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Aortogram, obtained after injection of contrast material into the root of the aorta in a patient with coarctation of the aorta, demonstrates marked focal narrowing of the proximal descending thoracic aorta (arrow).</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 79548 Version 3.0</div></div></div>"},"79550":{"type":"graphic_table","displayName":"Disorders that can mimic SIDS","title":"Disorders that can mimic SIDS","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disorders that can mimic SIDS</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">General </td> </tr> <tr> <td>Sepsis (including meningococcemia)</td> </tr> <tr> <td>Asphyxiation (accidental or deliberate)</td> </tr> <tr> <td>Anaphylaxis</td> </tr> <tr> <td>Metabolic decompensation</td> </tr> <tr> <td>Hyperthermia</td> </tr> <tr> <td>Poisoning (with toxic effects on&nbsp;kidney, liver and/or brain)</td> </tr> <tr> <td>Inborn errors of metabolism (may affect liver, muscle, and/or brain)</td> </tr> <tr> <td class=\"subtitle1_single\">Blood </td> </tr> <tr> <td>Sickle cell disease in crisis</td> </tr> <tr> <td class=\"subtitle1_single\">Heart </td> </tr> <tr> <td>Subendocardial fibroelastosis</td> </tr> <tr> <td>Congenital heart disease (especially aortic stenosis)</td> </tr> <tr> <td>Myocarditis</td> </tr> <tr> <td class=\"subtitle1_single\">Lungs </td> </tr> <tr> <td>Pneumonia</td> </tr> <tr> <td>Bronchiolitis</td> </tr> <tr> <td>Tracheobronchitis, severe</td> </tr> <tr> <td>Aspiration or airway obstruction</td> </tr> <tr> <td>Idiopathic pulmonary hypertension</td> </tr> <tr> <td class=\"subtitle1_single\">Kidney </td> </tr> <tr> <td>Pyelonephritis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Gastrointestinal tract </td> </tr> <tr> <td>Enterocolitis with Salmonella, Shigella, or pathogenic E. coli</td> </tr> <tr> <td class=\"subtitle1_single\">Liver </td> </tr> <tr> <td>Hepatitis</td> </tr> <tr> <td class=\"subtitle1_single\">Pancreas </td> </tr> <tr> <td>Pancreatitis</td> </tr> <tr> <td>Boric acid poisoning</td> </tr> <tr> <td>Cystic fibrosis</td> </tr> <tr> <td class=\"subtitle1_single\">Adrenal </td> </tr> <tr> <td>Congenital adrenal hyperplasia</td> </tr> <tr> <td class=\"subtitle1_single\">Brain </td> </tr> <tr> <td>Encephalitis</td> </tr> <tr> <td>Trauma (skull fracture, cerebral edema, subdural hemorrhage)</td> </tr> <tr> <td>Child abuse (abusive head trauma, or intentional suffocation)&nbsp;</td> </tr> <tr> <td>Arteriovenous malformation with bleeding</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SIDS: sudden infant death syndrome.</div><div id=\"graphicVersion\">Graphic 79550 Version 4.0</div></div></div>"},"79551":{"type":"graphic_figure","displayName":"Accessory hepatic ducts","title":"Accessory hepatic ducts","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Accessory hepatic ducts</div><div class=\"cntnt\"><img style=\"width:406px; height:227px;\" src=\"images/SURG/79551_Accessory_hep_ducts.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AF. Clinical Oriented Anatomy, 4th ed, Lippincott Williams &amp; Wilkins, Baltimore 1999. Copyright &#169; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 79551 Version 1.0</div></div></div>"},"79552":{"type":"graphic_figure","displayName":"Conditions of turbulent flow","title":"Turbulent flow","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Turbulent flow</div><div class=\"cntnt\"><img style=\"width:394px; height:340px;\" src=\"images/PULM/79552_Conditions_of_turbulent_flo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four circumstances under which gas flow tends to be turbulent.</div><div id=\"graphicVersion\">Graphic 79552 Version 1.0</div></div></div>"},"79553":{"type":"graphic_table","displayName":"PPSV23 schedule for high-risk children older than two years","title":"Schedule for vaccination using 23-valent polysaccharide vaccine (PPSV23) after 13-valent pneumococcal conjugate vaccine (PCV13) for children aged â¥2 years with underlying medical conditions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Schedule for vaccination using 23-valent polysaccharide vaccine (PPSV23) after 13-valent pneumococcal conjugate vaccine (PCV13) for children aged &ge;2 years with underlying medical conditions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Group</td> <td class=\"subtitle1\">Schedule for PPSV23</td> <td class=\"subtitle1\">Revaccination with PPSV23</td> </tr> <tr class=\"divider_bottom\"> <td>Children who have sickle cell disease</td> <td>1 dose of PPSV23 administered at age &#8805;2 years and &#8805;8 weeks after last indicated dose of PCV13</td> <td>1 dose 3 or 5 years after the first dose of PPSV23*</td> </tr> <tr class=\"divider_bottom\"> <td>Children who have other types of functional or anatomic asplenia or are immunocompromised</td> <td>1 dose of PPSV23 administered at age &#8805;2 years and &#8805;8 weeks after last indicated dose of PCV13</td> <td>1 dose 5 years after the first dose of PPSV23</td> </tr> <tr> <td>Immunocompetent children with chronic illness<sup>&#182;</sup></td> <td>1 dose of PPSV23 administered at age &#8805;2 years and &#8805;8 weeks after last indicated dose of PCV13</td> <td>Not recommended</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* For patients with sickle cell disease, some experts recommend an interval of three years between the first and second dose of PPSV23<SUP>[1,2]</SUP>, whereas others recommend an interval of five years<SUP>[3-6]</SUP>.<br />Â¶ Chronic heart disease, chronic lung disease, diabetes mellitus, cerebrospinal fluid leaks, or cochlear implant.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Pneumococcal infections. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30<SUP>th</SUP> ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.626.</LI>&#xD;&#xA;<LI>National Heart, Lung, and Blood Institute. Evidence-based management of sickle cell disease. Expert Panel Report, 2014. Available at: <A href=\"http://www.nhlbi.nih.gov/health-pro/guidelines/sickle-cell-disease-guidelines\" target=_blank>www.nhlbi.nih.gov/health-pro/guidelines/sickle-cell-disease-guidelines</A> (Accessed on June 12, 2015).</LI>&#xD;&#xA;<LI>Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of 7-valent pneumococcal conjugate vaccine (PCV7) in children aged 24-59 months who are not completely vaccinated. MMWR Morb Mortal Wkly Rep 2008; 57:343. </LI>&#xD;&#xA;<LI>Nuorti JP, Whitney CG, Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and childrenâuse of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccineârecommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59:1. </LI>&#xD;&#xA;<LI>Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2013; 62:521. </LI>&#xD;&#xA;<LI>Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58:e44.</LI></OL></div><div id=\"graphicVersion\">Graphic 79553 Version 7.0</div></div></div>"},"79554":{"type":"graphic_figure","displayName":"Survival following below- and above-knee amputations","title":"Long-term survival following below-knee and above-knee amputations","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Long-term survival following below-knee and above-knee amputations</div><div class=\"cntnt\"><img style=\"width:474px; height:334px;\" src=\"images/SURG/79554_Surv_below_abov_knee_amp.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Reproduced from: Eidt JF, Kalapatapu VR. Amputation: Techniques and results. In: Rutherford Vascular Surgery, 7th ed, Vol. 2, Cronenwett JL, Johnston KW (Eds), Saunders Elsevier, Philadelphia 2010. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 79554 Version 2.0</div></div></div>"},"79555":{"type":"graphic_picture","displayName":"Extramedullary plasmacytoma","title":"Extramedullary plasmacytoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Extramedullary plasmacytoma</div><div class=\"cntnt\"><img style=\"width:376px; height:504px;\" src=\"images/HEME/79555_Extramedullary_plasma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large red-purple-appearing plasmacytoma on lower back in patient with relapsed multiple myeloma.</div><div id=\"graphicVersion\">Graphic 79555 Version 3.0</div></div></div>"},"79556":{"type":"graphic_figure","displayName":"Platelet count and survival","title":"Platelet count and platelet survival in megakaryocyte disorders","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">Platelet count and platelet survival in megakaryocyte disorders</div><div class=\"cntnt\"><img style=\"width:497px; height:269px;\" src=\"images/HEME/79556_Platelet_count_and_survival.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Platelet kinetic studies were performed in normal subjects and patients with a variety of hematological conditions: hypoplastic bone marrow states (Hypo), B12 deficiency (B12 def), congestive splenomegaly (Congest), immune thrombocytopenia (ITP), chronic inflammation (Inflam), and essential thrombocythemia (ET). Left panel: The median platelet counts were greater than normal only in inflammatory conditions and ET. Right panel: Platelet survival was significantly different from normal only in ITP.</div><div class=\"graphic_reference\">Data from: Harker LA, Finch CA. J Clin Invest 1969; 48:963.</div><div id=\"graphicVersion\">Graphic 79556 Version 2.0</div></div></div>"},"79558":{"type":"graphic_figure","displayName":"Infarct size mortality MI","title":"Infarct size measured by sestamibi predicts mortality","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Infarct size measured by sestamibi predicts mortality</div><div class=\"cntnt\"><img style=\"width:473px; height:271px;\" src=\"images/CARD/79558_Infarct_size_mortality_MI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among 274 patients with a myocardial infarction who had infarct size measured using 99m technetium sestamibi, the mortality at two years was lower in those with an infarct size &lt;12 percent of the left ventricle (0 versus 7 percent for those with infarct size &#8805;12 percent).</div><div class=\"graphic_reference\">Data from Miller TD, Christian TF, Hopfenspirger MR, et al, Circulation 1995; 92:334.</div><div id=\"graphicVersion\">Graphic 79558 Version 1.0</div></div></div>"},"79559":{"type":"graphic_figure","displayName":"Ureterocele hydronephrosis","title":"Ureteroceles in a right duplex collecting system","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Ureteroceles in a right duplex collecting system</div><div class=\"cntnt\"><img style=\"width:536px; height:306px;\" src=\"images/PEDS/79559_Ureterocele.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A ureterocele is a cystic dilation of a segment of the ureter contained within the bladder wall (ie, intravesical ureter). Intravesical ureteroceles are contained entirely within the bladder. Ectopic ureteroceles are partially situated at the bladder neck or urethra.</div><div id=\"graphicVersion\">Graphic 79559 Version 2.0</div></div></div>"},"79560":{"type":"graphic_table","displayName":"Accuracy US-gallbladder polyps","title":"Preoperative ultrasonographic accuracy for histologic diagnosis of gallbladder polyps","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Preoperative ultrasonographic accuracy for histologic diagnosis of gallbladder polyps</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">Preoperative diagnosis</td>\n<td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">Number of patients</td>\n<td colspan=\"4\" class=\"subtitle1\">Histologic diagnosis</td>\n</tr>\n<tr>\n\n\n<td class=\"subtitle2\">Cholesterol polyp</td>\n<td class=\"subtitle2\">Adenoma</td>\n<td class=\"subtitle2\">Cancer</td>\n<td class=\"subtitle2\">Inflammatory polyp</td>\n</tr>\n<tr>\n<td>Cholesterol polyp</td>\n<td>47</td>\n<td>42</td>\n<td>3</td>\n<td>1</td>\n<td>1</td>\n</tr>\n<tr>\n<td>Adenoma</td>\n<td>7</td>\n<td>1</td>\n<td>4</td>\n<td>2</td>\n<td>0</td>\n</tr>\n<tr>\n<td>Cancer</td>\n<td>18</td>\n<td>4</td>\n<td>1</td>\n<td>13</td>\n<td>0</td>\n</tr>\n<tr>\n<td>Total</td>\n<td>72</td>\n<td>47</td>\n<td>8</td>\n<td>16</td>\n<td>0</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Data from: Kubota, K, Bandai, Y, Noie, T, et al, Surgery 1995; 117:481.</div><div id=\"graphicVersion\">Graphic 79560 Version 1.0</div></div></div>"},"79563":{"type":"graphic_picture","displayName":"Dermal sinus","title":"Dermal sinus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dermal sinus</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/PEDS/79563_Dermal_sinus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dermal sinus lesions may predispose to meningitis with <em>Staphylococcus aureus</em>, Coagulase-negative staphylococci, and enteric Gram-negative organisms, such as <em>Escherichia coli</em> and <em>Klebsiella</em> species.</div><div class=\"graphic_reference\">Courtesy of Sheldon L Kaplan, MD.</div><div id=\"graphicVersion\">Graphic 79563 Version 2.0</div></div></div>"},"79564":{"type":"graphic_figure","displayName":"MV repair in heart failure","title":"Mitral valve annuloplasty improves left ventricular function in heart failure","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Mitral valve annuloplasty improves left ventricular function in heart failure</div><div class=\"cntnt\"><img style=\"width:517px; height:267px;\" src=\"images/CARD/79564_MV_repair_in_heart_failure.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among nine patients with severe mitral regurgitations due to an end-stage congestive cardiomyopathy, mitral valve repairs resulted in a significant improvement in left ventricular ejection fraction measured 16 weeks post-operatively, from 18 to 24 percent (p = 0.02*) (panel A), and in cardiac output, from 3.1 to 4.6 L/min (p = 0.004&#8226;) (panel B).</div><div class=\"graphic_reference\">Data from Bach DS, Bolling SF. Am Heart J 1995; 129:1165.</div><div id=\"graphicVersion\">Graphic 79564 Version 2.0</div></div></div>"},"79565":{"type":"graphic_picture","displayName":"Lateral neck flexion PI","title":"Lateral neck flexion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lateral neck flexion</div><div class=\"cntnt\"><img style=\"width:443px; height:442px;\" src=\"images/PI/79565_Lateral_neck_flexion_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sit or stand. Look straight ahead. Slowly tilt the head toward the right shoulder until you feel a stretch along the left side of the neck. Hold for 5 seconds. Straighten the neck then tilt the head towards the left shoulder. Hold for a count of 5. Repeat this sequence 10 times.</div><div id=\"graphicVersion\">Graphic 79565 Version 4.0</div></div></div>"},"79566":{"type":"graphic_diagnosticimage","displayName":"Epidural hematoma","title":"Epidural hematoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Epidural hematoma</div><div class=\"cntnt\"><img style=\"width:347px; height:358px;\" src=\"images/EM/79566_Epidural_hematoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This large temporal epidural hematoma is associated with midline shift and compression of the ventricular system. The dark swirls within the hematoma represent rapid arterial bleeding.</div><div id=\"graphicVersion\">Graphic 79566 Version 2.0</div></div></div>"},"79567":{"type":"graphic_picture","displayName":"Sarcoptes scabiei","title":"<EM>Sarcoptes scabiei </EM>and eggs","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Sarcoptes scabiei </EM>and eggs</div><div class=\"cntnt\"><img style=\"width:392px; height:261px;\" src=\"images/PC/79567_Sarcoptes_scabiei.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of John T Crissey, MD.</div><div id=\"graphicVersion\">Graphic 79567 Version 3.0</div></div></div>"},"79569":{"type":"graphic_picture","displayName":"Modified Hadley with cutting setons","title":"Modified Hadley procedure with cutting setons","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Modified Hadley procedure with cutting setons</div><div class=\"cntnt\"><img style=\"width:381px; height:285px;\" src=\"images/SURG/79569_AUmodHadleycutsetons.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This intraoperative photograph shows a cutting seton in the midline of this complex anorectal fistula.</div><div class=\"graphic_reference\">Courtesy of Bradley J Champagne, MD.</div><div id=\"graphicVersion\">Graphic 79569 Version 5.0</div></div></div>"},"79570":{"type":"graphic_picture","displayName":"Subcorneal pustular dermatosis - histopathology","title":"Subcorneal pustular dermatosis (Sneddon-Wilkinson disease)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subcorneal pustular dermatosis (Sneddon-Wilkinson disease)</div><div class=\"cntnt\"><img style=\"width:432px; height:289px;\" src=\"images/DERM/79570_Subcorneal_pustular_dermat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subcorneal neutrophilic pustule.</div><div id=\"graphicVersion\">Graphic 79570 Version 3.0</div></div></div>"},"79571":{"type":"graphic_table","displayName":"FOLFIRINOX for metastatic pancreatic cancer","title":"FOLFIRINOX chemotherapy for metastatic pancreatic cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">FOLFIRINOX chemotherapy for metastatic pancreatic cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 14 days.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Oxaliplatin*</td> <td>85 mg/m<sup>2</sup> IV</td> <td>Dilute in 500 mL 5% dextrose in water (D5W)<sup>&#182;</sup> and administer over two hours (prior to leucovorin).</td> <td>Day 1</td> </tr> <tr> <td>Leucovorin<sup>&#916;</sup></td> <td>400 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL D5W and administer over two hours (after oxaliplatin).</td> <td>Day 1</td> </tr> <tr> <td>Irinotecan<sup>&#9674;</sup></td> <td>180 mg/m<sup>2</sup> IV</td> <td>Dilute in 500 mL D5W and administer over 90 minutes. Administer concurrent with the last 90 minutes of leucovorin infusion, in separate bags, using a Y-line connection.</td> <td>Day 1</td> </tr> <tr> <td>Fluorouracil (FU)</td> <td>400 mg/m<sup>2</sup> IV bolus</td> <td>Give undiluted (50 mg/mL) as a slow IV push over five minutes (administer immediately after leucovorin).</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>FU</td> <td>2400 mg/m<sup>2</sup> IV</td> <td>Dilute in 500 to 1000 mL 0.9% normal saline (NS) or D5W and administer as a continuous IV infusion over 46 hours (begin immediately after FU IV bolus). To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL) or the total dose diluted in 100 to 150 mL NS.</td> <td>Day 1</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>HIGH (&#62;90% frequency of emesis). </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>No standard premedication regimen. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin and FU are irritants, but oxaliplatin can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with G-CSF is not warranted. However, given the risk of grade 3 or 4 neutropenia (46%<sup>[1]</sup>), primary prophylaxis with G-CSF is used at many institutions. </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>A lower starting dose of oxaliplatin and irinotecan may be needed for severe renal insufficiency.<sup>[2,3]</sup> A lower starting dose of irinotecan and FU may be needed for patients with hepatic impairment.<sup>[3,4]</sup> </li> <li><strong>NOTE:</strong> We do not recommend administration of FOLFIRINOX unless serum bilirubin is normal. </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Maneuvers to prevent neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Pharmacological methods to prevent/delay the onset of oxaliplatin-related neuropathy are controversial due to the absence of large clinical trials proving benefit. Counsel patients to avoid exposure to cold during and for approximately 48 hours after each infusion.<sup>[2]</sup> Prolongation of the oxaliplatin infusion time from two to six hours may mitigate acute neurotoxicity. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cardiac issues</strong></td> <td colspan=\"3\"> <ul> <li>QT prolongation and ventricular arrhythmias have been reported after oxaliplatin. ECG monitoring is recommended if therapy is initiated in patients with heart failure, bradyarrhythmias, coadministration of drugs known to prolong the QT interval, and electrolyte abnormalities. Avoid oxaliplatin in patients with congenital long QT syndrome. Correct hypokalemia and hypomagnesemia prior to initiating oxaliplatin. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count prior to each treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Electrolytes (especially potassium and magnesium), and liver and renal function prior to each treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Irinotecan is associated with early and late diarrhea, both of which may be severe.<sup>[2]</sup> For patients who develop abdominal cramping and/or diarrhea within 24 hours of receiving irinotecan, administer atropine (0.3 to 0.6 mg IV) and premedicate with atropine during later cycles. Patients must be instructed in the early use of loperamide for late diarrhea. Patients who develop diarrhea should be closely monitored, and supportive care measures (eg, fluid and electrolyte replacement, loperamide, antibiotics, etc) should be provided as needed. </li> <li>Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess changes in neurologic function prior to each treatment. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Do not retreat unless neutrophil count is &#8805;1500/microL and platelets are &#8805;75,000/microL. </li> <li><strong>Neutropenia</strong> <ul> <li>The following dose reduction guidelines for hematologic toxicity were provided in the original protocol:<sup>[1]</sup> If day 1 treatment delayed for granulocytes &#60;1500/microL, or febrile neutropenia or grade 4 neutropenia &#62;7 days: Reduce irinotecan dose to 150 mg/m<sup>2</sup> and eliminate bolus FU and leucovorin. For second occurrence: Reduce oxaliplatin dose to 60 mg/m<sup>2</sup>. If non-recovery after two-weeks delay or third occurrence of granulocytes &#60;1500/microL on day 1, or febrile neutropenia or grade 4 neutropenia at any time during cycle, discontinue treatment. </li> </ul> </li> <li><strong>Thrombocytopenia</strong> <ul> <li>The following dose reduction guidelines for hematologic toxicity were provided in the original protocol:<sup>[1]</sup> If day 1 treatment delayed for platelet count &#60;75,000/microL, reduce oxaliplatin dose to 60 mg/m<sup>2</sup> and reduce both the bolus and continuous infusion FU to 75% of original doses. For second occurrence, reduce irinotecan dose to 150 mg/m<sup>2</sup>. If non-recovery after two weeks delay or third occurrence of platelets &#60;75,000/microL, discontinue treatment. For grade 3 or 4 thrombocytopenia <em>during</em> treatment, reduce oxaliplatin dose to 60 mg/m<sup>2</sup> and the infusional FU dose to 75% of the original dose. For the second occurrence, reduce dose of irinotecan to 150 mg/m<sup>2</sup> and the dose of infusional FU an additional 25%. Discontinue treatment for third occurrence. </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Diarrhea</strong></td> <td colspan=\"3\"> <ul> <li>Do not retreat with FOLFIRINOX until resolution of diarrhea for at least 24 hours without anti-diarrheal medication. For diarrhea grade 3 or 4, or diarrhea with fever and/or grade 3 or 4 neutropenia, reduce irinotecan dose to 150 mg/m<sup>2</sup> and eliminate bolus FU. For second occurrence, reduce the oxaliplatin dose to 60 mg/m<sup>2</sup> and the continuous FU dose to 75% of original dose. Discontinue treatment for third occurrence. </li> <li><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Mucositis or hand-foot syndrome</strong></td> <td colspan=\"3\"> <ul> <li>For grade 3 to 4 toxicity, reduce dose of both bolus and infusional FU by 25%. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin has rarely been associated with pulmonary toxicity. Withhold oxaliplatin for unexplained pulmonary symptoms until interstitial lung disease or pulmonary fibrosis is excluded. </li> <li>Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Other toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Any other toxicity &#8805;grade 2, except anemia and alopecia, can justify dose reduction if medically indicated. For transient grade 3 paresthesias/dysesthesias or grade 2 symptoms lasting &#62;7 days, decrease oxaliplatin dose by 25%.<sup>[2]</sup> Discontinue oxaliplatin for grade 4 or persistent grade 3 paresthesia/dysesthesia. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; G-CSF: granulocyte colony-stimulating factors; ECG: electrocardiogram; CBC: complete blood count.<br />* Many centers routinely infuse oxaliplatin via central venous line because of local pain with infusion into a peripheral vein.<br />Â¶ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br />Î Leucovorin dose is given for d,l-racemic mixture.<SUP>[5]</SUP> Use half the dose for LEVOleucovorin (l-leucovorin).<br /><FONT class=lozenge>â</FONT> A lower initial dose of irinotecan may be considered for patients with poor performance status, prior pelvic or abdominal radiotherapy, or increased bilirubin levels.<SUP>[3]</SUP> Whether a reduced starting dose is needed in patients who are homozygous for the UGT 1A1*28 allele (Gilbert's syndrome) and whether testing for this allele should be carried out prior to starting irinotecan are controversial. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Conroy T, et al. N Engl J Med 2011; 364:1817.</LI>&#xD;&#xA;<LI>Oxaliplatin injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 30, 2016).</LI>&#xD;&#xA;<LI>Irinotecan hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 30, 2016).</LI>&#xD;&#xA;<LI>Fluorouracil injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 30, 2016).</LI>&#xD;&#xA;<LI>Leucovorin calcium injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 30, 2016).</LI></OL></div><div id=\"graphicVersion\">Graphic 79571 Version 22.0</div></div></div>"},"79574":{"type":"graphic_table","displayName":"Reduce lead absorption PI","title":"Ways to reduce the amount of lead your family takes in","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ways to reduce the amount of lead your family takes in</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Make sure that your children wash their hands and face before eating and sleeping.</td> </tr> <tr> <td>Do not let your children eat anything other than food (such as dirt or paint).</td> </tr> <tr> <td>Clean all the surfaces in your home with a detergent. This includes floors, counters, tables, and anything else a child might touch. Cleaning is especially important for toddlers because they crawl and lie on the floor and like to put their hands in their mouths.</td> </tr> <tr> <td>If your home was built before 1978, it is very important to remove any flaking or peeling paint in the house. Before 1978, homes were often painted with lead-based paint. Hire or speak with a professional certified in lead paint abatement. Painting or putting wallpaper over lead-based paint are only temporary ways to control the problem and are not acceptable solutions. Anyone who removes lead paint must wear a special breathing mask and other protective gear while they do the work.</td> </tr> <tr> <td>Give your children a multivitamin with iron every day. They should have well-balanced diets that include fruits, vegetables, grains, protein, and low-fat dairy products.</td> </tr> <tr> <td>Do not use herbal or folk medicines (these may contain lead).</td> </tr> <tr> <td>If you have pottery with a coating that might contain lead, use it only for decoration, not to hold food or drink.</td> </tr> <tr> <td>Store food in glass, plastic, or stainless steel containers, not in open cans.</td> </tr> <tr> <td>Use water from the cold tap for cooking and drinking. Let it run for a few minutes before drinking from it.</td> </tr> <tr> <td>Keep materials that might contain lead away from children and areas where children spend time. That includes materials used to make ceramics or stained glass, and those used for other hobbies.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 79574 Version 2.0</div></div></div>"},"79575":{"type":"graphic_movie","displayName":"Long axis TOF VSD malalignment","title":"Malalignment ventricular septal defect in a patient with tetralogy of Fallot (TOF)","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Malalignment ventricular septal defect in a patient with tetralogy of Fallot (TOF)</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/79575_LongaxisTOFVSDmala.mp4\" style=\"width:432px;height:400px\"></div><img style=\"width:452px; height:374px;\" src=\"images/PEDS/79575_LongaxisTOFVSDmala.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This still frame from the accompanying echocardiographic video of the parasternal long axis view demonstrates the malalignment of the ventricular conal septum (CS) and trabecular septum (TS), which results in aortic override in a patient with TOF. In the video clip, cephalad angulation of the imaging transducer reveals the hypoplastic pulmonary artery.</div><div class=\"graphic_footnotes\">LV: left ventricle; RV: right ventricle; LA: left atrium; Ao: aorta.</div><div id=\"graphicVersion\">Graphic 79575 Version 1.0</div></div></div>"},"79576":{"type":"graphic_picture","displayName":"Dermoscopy melanoma 1","title":"Dermoscopy of superficial spreading melanoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of superficial spreading melanoma</div><div class=\"cntnt\"><img style=\"width:504px; height:504px;\" src=\"images/DERM/79576_Dermoscopy_melanoma_1_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Melanoma 0.98 mm. Atypical network, peripheral streaks (solid arrows), blue white-veil, and off-centered blotch (dashed square) are observed.</div><div class=\"graphic_reference\">Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 79576 Version 3.0</div></div></div>"},"79578":{"type":"graphic_movie","displayName":"Aortic regurgitation five chamber color Doppler echocardiogram","title":"Aortic regurgitation","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aortic regurgitation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/79578_5chcodopconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:344px; height:257px;\" src=\"images/CARD/79578_5chcodop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Five chamber view from a 2-D echocardiogram demonstrates mild aortic regurgitation. The left ventricle and atrium are normal in size.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 79578 Version 2.0</div></div></div>"},"79579":{"type":"graphic_picture","displayName":"Honey bee (Apis mellifera)","title":"Honey bee (<EM>Apis mellifera</EM>)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Honey bee (<EM>Apis mellifera</EM>)</div><div class=\"cntnt\"><img style=\"width:352px; height:223px;\" src=\"images/PC/79579_Honeybee.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from American Academy of Allergy and Immunology, Monograph on Insect Allergy, 3rd edition, Levine MI, Lockey RF (Eds), 1995.</div><div id=\"graphicVersion\">Graphic 79579 Version 4.0</div></div></div>"},"79580":{"type":"graphic_figure","displayName":"Silent ischemia stable angina","title":"Symptomatic versus silent ischemia in stable angina","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Symptomatic versus silent ischemia in stable angina</div><div class=\"cntnt\"><img style=\"width:445px; height:316px;\" src=\"images/CARD/79580_Silent_ischemia_stable_angi.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nine studies of patients with stable angina showing that silent ischemia (documented on ambulatory monitoring) is more common than symptomatic ischemia.</div><div id=\"graphicVersion\">Graphic 79580 Version 1.0</div></div></div>"},"79584":{"type":"graphic_diagnosticimage","displayName":"Computed tomography after endovascular repair","title":"Computed tomography after endovascular repair","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Computed tomography after endovascular repair</div><div class=\"cntnt\"><img style=\"width:452px; height:360px;\" src=\"images/CARD/79584_CTscanendovascularrepair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contrast enhanced computed tomography following endovascular repair of abdominal aortic aneurysm shows contrast outside of endograft and within the aneurysm sac, confirming the presence of an endoleak (arrows).</div><div id=\"graphicVersion\">Graphic 79584 Version 3.0</div></div></div>"},"79587":{"type":"graphic_diagnosticimage","displayName":"Chest radiograph - Tuberculosis and HIV","title":"Chest radiograph - Tuberculosis and HIV","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph - Tuberculosis and HIV</div><div class=\"cntnt\"><img style=\"width:320px; height:294px;\" src=\"images/ID/79587_TB_HIV_CD4_under_200.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph showing asymmetric hilar and mediastinal adenopathy and non-confluent opacification left mid and lower zones. Typical appearance of tuberculosis in patients with CD4 counts &lt;200 cells/microL.</div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.</div><div class=\"graphic_reference\">Courtesy of Gary Maartens, MBChB, MMed.</div><div id=\"graphicVersion\">Graphic 79587 Version 6.0</div></div></div>"},"79589":{"type":"graphic_picture","displayName":"Actinic cheilitis 3","title":"Actinic cheilitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Actinic cheilitis</div><div class=\"cntnt\"><img style=\"width:504px; height:307px;\" src=\"images/DERM/79589_Actinic_cheilitis_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A focal area of scale is present on the patient's right lower lip.</div><div id=\"graphicVersion\">Graphic 79589 Version 1.0</div></div></div>"},"79592":{"type":"graphic_figure","displayName":"Beta blocker Q wave NQWMI","title":"Beta blockers are equally effective after a Q wave or non-Q wave MI","html":"<div class=\"graphic\"><div style=\"width: 479px\" class=\"figure\"><div class=\"ttl\">Beta blockers are equally effective after a Q wave or non-Q wave MI</div><div class=\"cntnt\"><img style=\"width:459px; height:311px;\" src=\"images/CARD/79592_Beta_blocker_Q_wave_NQWMI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Analysis of data from 201,752 patients with a myocardial infarction (MI) demonstrates that the reduction in mortality at two years with beta blockers is similar in those with a Q wave (14.2 versus 23.6 percent for those not receiving beta blockers) or non-Q wave MI (14.4 versus 23.9 percent).</div><div class=\"graphic_reference\">Data from Gottlieb SS, McCarter RJ, Vogel RA. N Engl J Med 1998; 339:489.</div><div id=\"graphicVersion\">Graphic 79592 Version 2.0</div></div></div>"},"79594":{"type":"graphic_table","displayName":"Possible causes of hypotension in a potential organ donor","title":"Possible causes of hypotension in a potential organ donor","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Possible causes of hypotension in a potential organ donor</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Hypovolemia\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Polyuria due to diabetes insipidus or osmotic diuresis due to hyperglycemia</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Fluid restriction strategies for cerebral protection</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Inadequate fluid restriction</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Bleeding</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Distributive shock\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Systemic inflammatory response syndrome</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Post brain stem death vasodilatation</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Cardiogenic shock\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Myocardial trauma: blunt contusion, penetrating injury</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Electrolyte abnormality</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Hypothermia</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Endocrine and metabolic abnormalities\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Anterior pituitary dysfunction</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Adrenal insufficiency</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Diabetes insipidus</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 79594 Version 2.0</div></div></div>"},"79595":{"type":"graphic_picture","displayName":"Metastatic cancer of the distal phalanx","title":"Metastatic cancer of the distal phalanx","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Metastatic cancer of the distal phalanx</div><div class=\"cntnt\"><img style=\"width:388px; height:656px;\" src=\"images/SURG/79595_Metast_canc_distal_phalanx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Metastatic tumors to the hand are rare and usually involve the distal phalanx; thus, they can be confused with a pulp space infection or felon. Radiographs are useful in differentiating a tumor from infection. Primary lung tumors are the most common metastatic lesion to the hand. Other tumors include breast, kidney, colon, thyroid, and prostate. The photograph shows a case of metastatic renal cell carcinoma. The corresponding radiograph shows almost complete destruction of the distal phalanx. </div><div id=\"graphicVersion\">Graphic 79595 Version 2.0</div></div></div>"},"79596":{"type":"graphic_figure","displayName":"Construction of an ostomy - skin incision","title":"Construction of an ostomy - skin incision","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Construction of an ostomy - skin incision</div><div class=\"cntnt\"><img style=\"width:458px; height:528px;\" src=\"images/SURG/79596_Ostomy-skin-incision.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts making&nbsp;the skin incision on the abdominal wall with electrocautery in preparation for constructing an ostomy.</div><div id=\"graphicVersion\">Graphic 79596 Version 1.0</div></div></div>"},"79598":{"type":"graphic_table","displayName":"Social benefits thalassemia in Greece","title":"Social benefits provided to thalassemic patients in Greece","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Social benefits provided to thalassemic patients in Greece</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Free medical care</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cash benefits</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Tax allowances</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Entry to universities and other institutions of higher education without examination</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Paid training and technical education</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Work incentives (large industries are obliged to employ disabled people up to 4 percent of their labor force)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Early retirement</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Facilities (eg, transportation, electricity, telephone)</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Data from: Politis C. The psychosocial impact of chronic illness. Ann N Y Acad Sci 1998; 850:349.</div><div id=\"graphicVersion\">Graphic 79598 Version 2.0</div></div></div>"},"79600":{"type":"graphic_figure","displayName":"Fusion of elbow ossification centers","title":"Fusion of elbow ossification centers","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fusion of elbow ossification centers</div><div class=\"cntnt\"><img style=\"width:408px; height:401px;\" src=\"images/EM/79600_Elbow_fusion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The secondary ossification centers fuse to create the mature bony elbow. The lateral epicondyle, trochlear, and capitellar centers fuse first; this unit then fuses with the distal humerus; the last fusion occurs at the medial epicondyle.</div><div class=\"graphic_reference\">Reproduced with permission from DeLee, JC, Drez, D (Eds). Orthopaedic sports medicine: Principles and practice, W.B. Saunders, Philadelphia 1994. Copyright Â© 1994 W.B. Saunders.</div><div id=\"graphicVersion\">Graphic 79600 Version 3.0</div></div></div>"},"79601":{"type":"graphic_movie","displayName":"Parasternal long axis normal","title":"Parasternal long view of normal cardiac function","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Parasternal long view of normal cardiac function</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/79601_Parastlongaxisnormmovie.mp4\" style=\"width:496px;height:336px\"></div><img style=\"width:504px; height:393px;\" src=\"images/EM/79601_Parastlongaxisnormimage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This video clip shows normal cardiac motion seen from a parasternal long axis view.</div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Courtesy of Greg Snead, MD.</div><div id=\"graphicVersion\">Graphic 79601 Version 1.0</div></div></div>"},"79602":{"type":"graphic_table","displayName":"Clinical manifestations subclinical hyperthyroidism","title":"Clinical manifestations of subclinical hyperthyroidism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of subclinical hyperthyroidism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Bone disease</td> </tr> <tr> <td>Decreased bone density, especially in postmenopausal women</td> </tr> <tr> <td class=\"sublist1_start\">Increased fracture risk</td> </tr> <tr> <td class=\"sublist1_start\">Biochemical markers of increased bone resorption</td> </tr> <tr> <td class=\"sublist1\">Increased urinary pyridinoline and deoxypyridinoline excretion</td> </tr> <tr> <td class=\"sublist1\">Increased urinary hydroxyproline excretion</td> </tr> <tr> <td class=\"subtitle1_single\">Heart disease</td> </tr> <tr> <td>Increased incidence of atrial fibrillation</td> </tr> <tr> <td>Increased heart rate and incidence of atrial premature beats</td> </tr> <tr> <td>Increased cardiac contractility</td> </tr> <tr> <td>Increased left ventricular mass index and septal and posterior wall thickness</td> </tr> <tr> <td class=\"subtitle1_single\">Laboratory abnormalities</td> </tr> <tr> <td>Decrease in serum total and LDL cholesterol concentrations</td> </tr> <tr> <td>Increased serum concentrations of hepatic enzymes and creatine kinase</td> </tr> <tr> <td>Increased serum concentration of SHBG</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td>Decreased time asleep at night</td> </tr> <tr> <td>Improved mood</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LDL: low-density lipoprotein; SHBG: sex hormone-binding globulin.</div><div id=\"graphicVersion\">Graphic 79602 Version 4.0</div></div></div>"},"79603":{"type":"graphic_table","displayName":"Observations chart malaria","title":"Observations chart malaria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Observations chart malaria</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_left\" rowspan=\"2\">Observations chart</td> <td class=\"subtitle1_left\" colspan=\"25\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Day:</td> <td class=\"subtitle2_left\" colspan=\"6\">Date:</td> <td class=\"subtitle1_left\" rowspan=\"4\">&nbsp;</td> <td class=\"subtitle2_left\" colspan=\"6\">Day:</td> <td class=\"subtitle2_left\" colspan=\"6\">Date:</td> </tr> <tr> <td class=\"subtitle2_left\">Time</td> <td class=\"subtitle2_left\">6 AM</td> <td class=\"subtitle2_left\">8 AM</td> <td class=\"subtitle2_left\">10 AM</td> <td class=\"subtitle2_left\">12 PM</td> <td class=\"subtitle2_left\">2 PM</td> <td class=\"subtitle2_left\">4 PM</td> <td class=\"subtitle2_left\">6 PM</td> <td class=\"subtitle2_left\">8 PM</td> <td class=\"subtitle2_left\">10 PM</td> <td class=\"subtitle2_left\">12 AM</td> <td class=\"subtitle2_left\">2 AM</td> <td class=\"subtitle2_left\">4 AM</td> <td class=\"subtitle2_left\">6 AM</td> <td class=\"subtitle2_left\">8 AM</td> <td class=\"subtitle2_left\">10 AM</td> <td class=\"subtitle2_left\">12 PM</td> <td class=\"subtitle2_left\">2 PM</td> <td class=\"subtitle2_left\">4 PM</td> <td class=\"subtitle2_left\">6 PM</td> <td class=\"subtitle2_left\">8 PM</td> <td class=\"subtitle2_left\">10 PM</td> <td class=\"subtitle2_left\">12 AM</td> <td class=\"subtitle2_left\">2 AM</td> <td class=\"subtitle2_left\">4 AM</td> </tr> <tr> <td class=\"indent1\">Other times (cross out above line)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\">Hours since admission</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"26\">Convulsions:</td> </tr> <tr> <td class=\"indent1\">Y/N</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td class=\"subtitle1_left\">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"26\">Coma score:</td> </tr> <tr> <td class=\"indent1\">Motor</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td class=\"subtitle1_left\" rowspan=\"4\">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Verbal</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Eye</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\">Coma score total</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"26\">Vomiting/diarrhea:</td> </tr> <tr> <td class=\"indent1\">Y/N</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td class=\"subtitle1_left\">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"26\">Drinking/feeding:</td> </tr> <tr> <td class=\"indent1\">Y/N</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td class=\"subtitle1_left\" rowspan=\"2\">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\">Dehydration (0, +, ++)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"26\">Pallor:</td> </tr> <tr> <td class=\"indent1\">Y/N</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td class=\"subtitle1_left\">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"26\">Cyanosis:</td> </tr> <tr> <td class=\"indent1\">Y/N</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td class=\"subtitle1_left\">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"26\">Passing urine:</td> </tr> <tr> <td class=\"indent1\">Y/N</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td class=\"subtitle1_left\" rowspan=\"4\">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\">Pulse rate/min</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\">Respiratory rate/min</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\">Blood pressure - systolic/diastolic</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"26\">Temperature:</td> </tr> <tr> <td class=\"indent1\">40</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td class=\"subtitle1_left\" rowspan=\"6\">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">39</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">38</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">37</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">36</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\">Temperature recorded (axillary/rectal)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"26\">Oxygen</td> </tr> <tr> <td class=\"indent1\">Y/N (liters/min)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td class=\"subtitle1_left\" rowspan=\"2\">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\">Oxygen saturation (without O<sub>2</sub>)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"26\">Blood:</td> </tr> <tr> <td class=\"indent1\">Glucose</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td class=\"subtitle1_left\" rowspan=\"2\">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Lactate</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"26\">Lab results:</td> </tr> <tr> <td class=\"indent1\">PCV</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td class=\"subtitle1_left\" rowspan=\"3\">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">MPs (+, ++, +++, ++++, +++++)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\">Observer's initials</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PCV: packed cell volume (hematocrit); MPs: malaria parasites.</div><div class=\"graphic_reference\">Courtesy of Terrie Taylor, DO.</div><div id=\"graphicVersion\">Graphic 79603 Version 4.0</div></div></div>"},"79604":{"type":"graphic_picture","displayName":"Fatty cast polarized","title":"Fatty cast","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fatty cast</div><div class=\"cntnt\"><img style=\"width:378px; height:218px;\" src=\"images/NEPH/79604_Fatty_cast_polarized.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urine sediment showing fatty cast under polarized light. The fat droplets have a characteristic &quot;Maltese cross&quot; appearance (arrow).</div><div class=\"graphic_reference\">Courtesy of Harvard Medical School.</div><div id=\"graphicVersion\">Graphic 79604 Version 1.0</div></div></div>"},"79606":{"type":"graphic_table","displayName":"Sleep study indications","title":"Indications for a nighttime sleep study in patients with neuromuscular and chest wall disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for a nighttime sleep study in patients with neuromuscular and chest wall disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Symptoms of sleep disordered breathing</td> </tr> <tr> <td class=\"sublist1\">Excessive daytime sleepiness</td> </tr> <tr> <td class=\"sublist1\">Disrupted nocturnal sleep </td> </tr> <tr> <td class=\"sublist1\">Morning headache</td> </tr> <tr> <td class=\"sublist1\">Changes in personality, concentration, or memory</td> </tr> <tr> <td class=\"sublist1\">Snoring (with obstructive sleep apnea) </td> </tr> <tr> <td class=\"sublist1\">Awakening with shortness of breath or choking</td> </tr> <tr> <td>Arterial blood gases showing hypoventilation (PaCO<sub>2</sub> &#62;45 mmHg [6 kPa])</td> </tr> <tr> <td>FVC &#60;50 percent predicted</td> </tr> <tr> <td>Severely reduced PImax</td> </tr> <tr> <td>Unexplained cor pulmonale</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PaCO<SUB>2</SUB>: arterial tension of carbon dioxide; FVC: forced vital capacity; PImax: maximal inspiratory pressure at the mouth.</div><div id=\"graphicVersion\">Graphic 79606 Version 2.0</div></div></div>"},"79607":{"type":"graphic_picture","displayName":"Brown widow","title":"Brown widow","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Brown widow</div><div class=\"cntnt\"><img style=\"width:432px; height:293px;\" src=\"images/EM/79607_Brown_widow.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Richard S Vetter, MS.</div><div id=\"graphicVersion\">Graphic 79607 Version 1.0</div></div></div>"},"79609":{"type":"graphic_figure","displayName":"Steroidogenic pathways","title":"Adrenal steroidogenesis","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Adrenal steroidogenesis</div><div class=\"cntnt\"><img style=\"width:560px; height:982px;\" src=\"images/PEDS/79609_Steroidogenic_pathways.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\"><STRONG>CYP11A1:</STRONG> cholesterol side chain cleavage enzyme P450scc; 20-hydroxylase, 22-hydroxylase, and 20,22-lyase.<br /><STRONG>CYP17A1:</STRONG> P450c17; 17-alpha-hydroxylase and 17,20-lyase.<br /><STRONG>3Î²-HSD2:</STRONG> 3 beta-hydroxysteroid dehydrogenase type 2.<br /><STRONG>CYP21A2:</STRONG> P450c21; 21-hydroxylase.<br /><STRONG>CYP11B1:</STRONG> P450c11; 11 beta-hydroxylase.<br /><STRONG>CYP11B2:</STRONG> P450aldo (aldosterone synthase); 18-hydroxylase (corticosterone methyl oxidase I, CMOI) and 18-dehydrogenase (CMOII).<br /><STRONG>POR:</STRONG> P450 oxidoreductase.<br /><STRONG>StAR:</STRONG> steroidogenic acute regulatory protein.</div><div id=\"graphicVersion\">Graphic 79609 Version 4.0</div></div></div>"},"79610":{"type":"graphic_picture","displayName":"Cytokeratin 7 in IPH","title":"Pathology of idiopathic pulmonary hemosiderosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pathology of idiopathic pulmonary hemosiderosis</div><div class=\"cntnt\"><img style=\"width:416px; height:277px;\" src=\"images/PULM/79610_Cytokeratin_7_in_IPH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Combined staining for iron (blue) and cytokeratin number 7 (brown), performed on a transbronchial lung biopsy, shows alveoli filled with hemosiderin- laden macrophages and proliferation of type II pneumocytes.</div><div class=\"graphic_reference\">Courtesy of Per Praetorius Clausen, MD.</div><div id=\"graphicVersion\">Graphic 79610 Version 2.0</div></div></div>"},"79611":{"type":"graphic_table","displayName":"Lung preservation storage","title":"Donor lung preservation during storage","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Donor lung preservation during storage</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>Ventilation</strong></td> <td> <p>Inflate lung(s) to 50 percent total lung capacity or 20 cm H<sub>2</sub>O of airway peak pressure; then clamp trachea</p> <p>Use an FiO<sub>2</sub> of 50 percent</p> </td> </tr> <tr> <td><strong>Preservation solution</strong></td> <td>Low potassium dextran-glucose (Perfadex)</td> </tr> <tr> <td><strong>Temperature</strong></td> <td>4 to 8&#176;C</td> </tr> <tr> <td><strong>Topical bath solution</strong></td> <td> <p>Low potassium dextran (Perfadex)</p> <p>Do not put ice in direct contact with lungs</p> </td> </tr> <tr> <td><strong>Ischemic time</strong></td> <td>Less than 8 hours preferred, possibly up to 12</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 79611 Version 3.0</div></div></div>"},"79612":{"type":"graphic_table","displayName":"Modified DCF for advanced gastric cancer","title":"Chemotherapy regimens for advanced esophagogastric cancer: Modified docetaxel, cisplatin, and fluorouracil (modified DCF)<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chemotherapy regimens for advanced esophagogastric cancer: Modified docetaxel, cisplatin, and fluorouracil (modified DCF)<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 14 days. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Docetaxel</td> <td>40 mg/m<sup>2</sup> IV</td> <td>Dilute with 250 mL normal saline (NS)* to a final concentration of 0.3 to 0.74 mg/mL and administer over 60 minutes.</td> <td>Day 1</td> </tr> <tr> <td>Leucovorin<sup>&#182;</sup></td> <td>400 mg/m<sup>2</sup> IV</td> <td>Dilute with 250 mL 5% dextrose in water (D5W)* and administer over two hours.</td> <td>Day 1</td> </tr> <tr> <td>Fluorouracil (FU)</td> <td>400 mg/m<sup>2</sup> IV bolus</td> <td>Slow IV push over five minutes. Administer immediately after leucovorin.</td> <td>Day 1</td> </tr> <tr> <td>FU</td> <td>2000 mg/m<sup>2</sup> IV</td> <td>Dilute with 500 to 1000 mL D5W and administer by continuous infusion for 48 hours starting immediately after the FU bolus on day 1. To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL) or the total dose can be diluted in 100 to 150 mL NS.</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Cisplatin</td> <td>40 mg/m<sup>2</sup> IV</td> <td>Dilute with 250 mL NS and administer over 60 minutes. Do not administer with aluminum needles or intravenous sets.</td> <td>Day 3</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>IV fluid to establish a urine flow of at least 100 mL/hour for at least two hours prior to and two hours after cisplatin administration. </li> <li>Refer to UpToDate topic on \"Cisplatin nephrotoxicity\", section on prevention. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>Day 1 and 2: LOW;<br /> Day 3: HIGH. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Premedicate with dexamethasone prior to docetaxel administration. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Docetaxel and cisplatin are irritants but can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with granulocyte colony stimulating factors not justified (incidence of neutropenic fever approximately 7%<sup>[1]</sup>). </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. Patients with serum creatinine &#62;1.5 mg/dL were excluded from the original trial.<sup>[1]</sup> Docetaxel should not be given to patients with a serum bilirubin above the ULN or to those with transaminase elevations &#62;1.5 times ULN in conjunction with alkaline phosphatase &#62;2.5 times ULN.<sup>[2]</sup> Lower starting doses of FU may be needed for severe hepatic impairment. </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for known drug interactions</strong></td> <td colspan=\"3\"> <ul> <li>Caution is needed when administering docetaxel with strong CYP3A4 inhibitors. Although specific dose recommendations are not available, the United States Prescribing Information suggests close monitoring for toxicity and consideration of docetaxel dose reduction if coadministration with a strong CYP3A4 inhibitor cannot be avoided.<sup>[2]</sup> </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess CBC with differential and platelet count on day 1 prior to each new course of treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess basic metabolic panel including creatinine and electrolytes, and liver function tests prior to each new treatment course. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for neurotoxicity, diarrhea, and fluid retention prior to each treatment cycle. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Patients should not be retreated with subsequent cycles of modified DCF until neutrophils recover to &#8805;1000/microL and platelets recover to &#62;75,000/microL. Reduce docetaxel dose by 10 mg/m<sup>2</sup> for febrile neutropenia, grade 3 or 4 neutropenia for &#8805;7 days, or platelet count &#8804;75,000/microL on the day of treatment.<sup>[1]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Nephrotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Withhold cisplatin until serum creatinine is &#8804;2 mg/dL.<sup>[1,3]</sup> Reduce cisplatin dose by 10 mg/m<sup>2</sup> for serum creatinine of 1.8 or 1.9 mg/dL. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Neuropathy usually is seen with cumulative doses of cisplatin &#62;400 mg/m<sup>2</sup>, although there is marked interindividual variation. Docetaxel can also cause both sensory and motor neuropathy, the incidence of which is related to cumulative dose. Patients with mild neuropathy can continue to receive full cisplatin and docetaxel doses. However, if the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment. The protocol recommended a 10 mg/m<sup>2</sup> reduction in cisplatin dose for grade 3 or 4 ototoxicity and a 10 mg/m<sup>2</sup> reduction in docetaxel dose for grade &#8805;2 peripheral neuropathy.<sup>[1]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Gastrointestinal toxicity</strong></td> <td colspan=\"3\"> <ul> <li>After resolution of toxicity, reduce FU and leucovorin doses for grade 3 or 4 diarrhea or stomatitis.<sup>[4]</sup> The protocol suggested initial dose reduction from 400 to 300 mg/m<sup>2</sup> for the bolus dose of both FU and leucovorin, and a reduction from 1000 to 800 mg/m<sup>2</sup> per day for the infusional FU.<sup>[1]</sup> Reduce cisplatin dose by 10 mg/m<sup>2</sup> for grade 4 nausea or vomiting or grade 3 nausea or vomiting for &#62;5 days. </li> <li><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Hepatotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Hold docetaxel for bilirubin 1.5 to 2.0 mg/dL <strong>OR</strong> total bilirubin one to two times ULN, <strong>OR</strong> for AST/ALT &#62;5 times ULN, <strong>OR</strong> alkaline phosphatase &#62;5 times ULN, <strong>OR</strong> AST/ALT &#62;2 but &#8804;5 times the ULN and alkaline phosphatase &#62;3 times ULN, <strong>OR</strong> AST/ALT &#62;1 to &#8804;2 times ULN and alkaline phosphatase &#62;5 times ULN.<sup>[1]</sup> Reduce docetaxel dose by 10 mg/m<sup>2</sup> if AST/ALT &#62;2 but &#8804;5 times ULN and alkaline phosphatase &#62;1 but &#8804;3 times ULN <strong>OR</strong> AST/ALT &#62;1 but &#8804;2 times ULN and alkaline phosphatase &#62;3 but &#8804;5 times ULN.<sup>[1]</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Other toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Hold chemotherapy for any other grade 3 to 4 nonhematologic toxicity (with exception of grade 3 electrolyte abnormalities or grade 3 anemia not associated with bleeding). </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; ULN: upper limit of normal; CBC: complete blood count; AST: aspartate aminotransferase; ALT: alanine aminotranferease.<br />* Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibilities.<br />Â¶ Leucovorin dose is given for d,l-racemic mixture.<SUP>[5]</SUP> Use one-half the dose for LEVOleucovorin (l-leucovorin).</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Shah M, et al. J Clin Oncol 2015; 33:3874.</LI>&#xD;&#xA;<LI>Docetaxel injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 14, 2011).</LI>&#xD;&#xA;<LI>Cisplatin injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 14, 2011).</LI>&#xD;&#xA;<LI>Fluorouracil injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 14, 2011).</LI>&#xD;&#xA;<LI>Leucovorin calcium injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 14, 2011).</LI></OL></div><div id=\"graphicVersion\">Graphic 79612 Version 22.0</div></div></div>"},"79613":{"type":"graphic_figure","displayName":"Pentameric IgM structure","title":"Pentameric IgM structure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pentameric IgM structure</div><div class=\"cntnt\"><img style=\"width:440px; height:462px;\" src=\"images/ALLRG/79613_Pentameric_IgM_structure.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">IgM exists as a monomer when located on the surface of B cells and as multimers in association with an additional polypeptide chain, the J chain, when secreted. The monomers are crosslinked by disulfide bonds to each other and to the J chain. IgM can also form hexamers that lack a J chain. 1 = light chain (variable region); 2 = light chain (constant region); 3 = heavy chain (variable region); 4, 5, 6, and 7 = heavy chain (constant regions 1, 2, 3, and 4 [CH1 - CH4]).</div><div class=\"graphic_footnotes\">IgM: immunoglobulin M.</div><div id=\"graphicVersion\">Graphic 79613 Version 4.0</div></div></div>"},"79614":{"type":"graphic_table","displayName":"Symptoms terminal illness","title":"Frequency of symptoms in terminal cancer patients as assessed by a consult team in a variety of care settings*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of symptoms in terminal cancer patients as assessed by a consult team in a variety of care settings*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Symptom</td> <td class=\"subtitle1\">TPCU</td> <td class=\"subtitle1\">Referral hospitals</td> <td class=\"subtitle1\">Hospices</td> <td class=\"subtitle1\">\"p\" value</td> </tr> <tr> <td>Pain</td> <td>116/156 (74 percent)</td> <td>300/639 (47 percent)</td> <td>231/407 (57 percent)</td> <td>&#60;0.0001<sup>&#182;</sup></td> </tr> <tr> <td>Activity</td> <td>138/154 (90 percent)</td> <td>561/624 (90 percent)</td> <td>356/431(83 percent)</td> <td>0.0014<sup>&#182;</sup></td> </tr> <tr> <td>Nausea</td> <td>55/152 (36 percent)</td> <td>125/636 (20 percent)</td> <td>93/368 (25 percent)</td> <td>0.0001<sup>&#182;</sup></td> </tr> <tr> <td>Depression</td> <td>87/148 (59 percent)</td> <td>250/573 (44 percent)</td> <td>179/391 (46 percent)</td> <td>0.0042<sup>&#182;</sup></td> </tr> <tr> <td>Anxiety</td> <td>102/152 (67 percent)</td> <td>288/583 (49 percent)</td> <td>202/403 (50 percent)</td> <td>0.0003<sup>&#182;</sup></td> </tr> <tr> <td>Drowsiness</td> <td>111/154 (72 percent)</td> <td>394/621 (63 percent)</td> <td>310/417 (74 percent)</td> <td>0.0006<sup>&#182;</sup></td> </tr> <tr> <td>Appetite</td> <td>116/152 (76 percent)</td> <td>502/617 (81 percent)</td> <td>314/428 (73 percent)</td> <td>0.0082</td> </tr> <tr> <td>Well being</td> <td>118/147 (80 percent)</td> <td>390/540 (72 percent)</td> <td>262/404 (65 percent)</td> <td>0.001<sup>&#182;</sup></td> </tr> <tr> <td>Shortness of breath</td> <td>76/153 (50 percent)</td> <td>206/630 (33 percent)</td> <td>151/393 (38 percent)</td> <td>0.0004<sup>â&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TPCU: tertiary palliative care units.<br />* All frequencies defined as the proportion of patients who scored 30 or higher on a 1 to 100 mm visual analog scale for the severity of that particular symptom.<br />Â¶ P value significant after boferroni correction.</div><div class=\"graphic_reference\">Reproduced with permission from Bruera, E, Neumann, CM. Respective limits in palliative care and oncology in the supportive care of cancer patients. Support Care Cancer 1999; 7:321.</div><div id=\"graphicVersion\">Graphic 79614 Version 2.0</div></div></div>"},"79617":{"type":"graphic_figure","displayName":"Starling resistor model","title":"Starling resistor model of the upper airway","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Starling resistor model of the upper airway</div><div class=\"cntnt\"><img style=\"width:428px; height:254px;\" src=\"images/PULM/79617_Starling_resistor_model.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The tendency of the upper airway to collapse is determined by its critical closing pressure, designated as P<sub>crit</sub>. When P<sub>crit</sub> is below tracheal pressure (P<sub>DS</sub>), airway is open without airflow limitation. When P<sub>crit</sub> is greater than tracheal pressure (P<sub>DS</sub>) but less than nasal pressure (P<sub>US</sub>), there is partial airway collapse with maximal inspiratory airflow limitation. When P<sub>crit</sub> is above nasal pressure (P<sub>US</sub>), there is complete obstructive apnea.</div><div class=\"graphic_footnotes\">R<sub>US</sub>: upstream resistance; P<sub>US</sub>: upstream pressure; R<sub>DS</sub>: downstream resistance; PDS: downstream pressure.</div><div class=\"graphic_reference\">Adapted from: Marcus EL, McCalley SA, Carrol JL, et al, J Appl Physiol 1994; 77:918.</div><div id=\"graphicVersion\">Graphic 79617 Version 3.0</div></div></div>"},"79619":{"type":"graphic_figure","displayName":"Calcitonin BMD","title":"Lumbar spine bone mineral density, mean percentage change from baseline (Â± SEM)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lumbar spine bone mineral density, mean percentage change from baseline (Â± SEM)</div><div class=\"cntnt\"><img style=\"width:443px; height:246px;\" src=\"images/ENDO/79619_Calcitonin_BMD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Number of participants with at least&nbsp;one post-baseline evaluation for placebo, 100, 200, and 400 IU; n = 268, 273, 280, and 274, respectively. A single asterisk indicates p&lt;0.05 versus placebo; a double asterisk indicates p&lt;0.01 versus placebo.</div><div class=\"graphic_footnotes\">IU: international units; SEM: standard error of the mean.</div><div class=\"graphic_reference\">Data from: Chesnut CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. Am J Med 2000; 109:267.</div><div id=\"graphicVersion\">Graphic 79619 Version 2.0</div></div></div>"},"79620":{"type":"graphic_table","displayName":"Life exp CRC stage III","title":"Estimated life expectancy, in years, after a diagnosis of stage III colorectal cancer, stratified by age at diagnosis and number of chronic conditions*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated life expectancy, in years, after a diagnosis of stage III colorectal cancer, stratified by age at diagnosis and number of chronic conditions*</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\" colspan=\"3\">\n   Male\n   </td>\n   <td  class=\"subtitle1\" colspan=\"3\">\n   Female\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2\">\n   Age\n   </td>\n   <td  class=\"subtitle2\">\n   Chronic conditions\n   </td>\n   <td  class=\"subtitle2\">\n   Survival (95% confidence interval)\n   </td>\n   <td  class=\"subtitle2\">\n   Age\n   </td>\n   <td  class=\"subtitle2\">\n   Chronic conditions\n   </td>\n   <td  class=\"subtitle2\">\n   Survival (95% confidence interval)\n   </td>\n   </tr>\n   <tr>\n   <td  rowspan=\"3\">\n   67\n   </td>\n   <td>0</td>\n   <td>8.4 (7.6-9.2)</td>\n   <td  rowspan=\"3\">\n   67\n   </td>\n   <td>0</td>\n   <td>8.5 (7.6-9.5)</td>\n   </tr>\n   <tr>\n   <td>1-2</td>\n   <td>6.8 (6.1-7.6)</td>\n   <td>1-2</td>\n   <td>7.9 (7.0-8.9)</td>\n   </tr>\n   <tr>\n   <td>&#8805;3</td>\n   <td>4.6 (3.3-6.0)</td>\n   <td>&#8805;3</td>\n   <td>4.7 (3.5-6.1)</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"3\">\n   71\n   </td>\n   <td>0</td>\n   <td>7.4 (7.0-7.9)</td>\n   <td  rowspan=\"3\">\n   71\n   </td>\n   <td>0</td>\n   <td>8.3 (7.8-8.8)</td>\n   </tr>\n   <tr>\n   <td>1-2</td>\n   <td>6.1 (5.7-6.5)</td>\n   <td>1-2</td>\n   <td>6.6 (6.1-7.0)</td>\n   </tr>\n   <tr>\n   <td>&#8805;3</td>\n   <td>4.4 (3.9-5.0)</td>\n   <td>&#8805;3</td>\n   <td>3.7 (3.1-4.3)</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"3\">\n   76\n   </td>\n   <td>0</td>\n   <td>6.3 (5.8-6.8)</td>\n   <td  rowspan=\"3\">\n   76\n   </td>\n   <td>0</td>\n   <td>7.4 (7.0-7.9)</td>\n   </tr>\n   <tr>\n   <td>1-2</td>\n   <td>5.2 (4.8-5.6)</td>\n   <td>1-2</td>\n   <td>5.8 (5.5-6.2)</td>\n   </tr>\n   <tr>\n   <td>&#8805;3</td>\n   <td>3.6 (3.2-4.0)</td>\n   <td>&#8805;3</td>\n   <td>3.8 (3.4-4.2)</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"3\">\n   81\n   </td>\n   <td>0</td>\n   <td>5.5 (5.0-6.1)</td>\n   <td  rowspan=\"3\">\n   81\n   </td>\n   <td>0</td>\n   <td>6.4 (5.9-6.9)</td>\n   </tr>\n   <tr>\n   <td>1-2</td>\n   <td>4.9 (4.5-5.3)</td>\n   <td>1-2</td>\n   <td>4.8 (4.4-5.1)</td>\n   </tr>\n   <tr>\n   <td>&#8805;3</td>\n   <td>2.9 (2.6-3.3)</td>\n   <td>&#8805;3</td>\n   <td>2.8 (2.5-3.2)</td>\n   </tr>\n </table></div><div class=\"graphic_footnotes\">* Including but not limited to AIDS, atrial fibrillation, cerebrovascular disease, chronic obstructive pulmonary disease, congestive heart failure, dementia, diabetes, hip fracture, liver disease, myocardial infarction, paralysis, peripheral vascular disease, renal failure, rheumatologic disease, and ulcers.</div><div class=\"graphic_reference\">Data from: Gross C, McAvay G, Krumholz H, et al. Ann Int Med 2006; 145:646.</div><div id=\"graphicVersion\">Graphic 79620 Version 2.0</div></div></div>"},"79621":{"type":"graphic_picture","displayName":"Epidermal cysts on eyelid","title":"Epidermal inclusion cysts","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Epidermal inclusion cysts</div><div class=\"cntnt\"><img style=\"width:396px; height:255px;\" src=\"images/PC/79621_Epidermal_cysts_on_eyelid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows epidermal inclusion cysts on the upper and lower eyelids.</div><div class=\"graphic_reference\">Reproduced with permission from: Kersten, RC(Ed), Basic and clinical science courses section 7: Orbit, eyelids, and lacrimal system. American Academy of Ophthalmology, San Francisco 2002. Copyright &#169; 2002 American Academy of Ophthalmology.</div><div id=\"graphicVersion\">Graphic 79621 Version 1.0</div></div></div>"},"79622":{"type":"graphic_figure","displayName":"Flexion injury causing an olecranon fracture","title":"Flexion injury causing an olecranon fracture","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Flexion injury causing an olecranon fracture</div><div class=\"cntnt\"><img style=\"width:526px; height:295px;\" src=\"images/EM/79622_Flexinjolecranonfract.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mechanism of flexion injuries.<br> (A) In the flexed elbow, force develops on the posterior aspect of the olecranon (small double arrow) because of the pull of the brachialis and triceps muscles (large arrows).<br> (B) Failure occurs on the tension side, which is posterior as a result of the muscle pull or a direct blow to the prestressed posterior olecranon.</div><div class=\"graphic_reference\">Reproduced with permission from: Erickson M, Frick S. Fractures of the proximal radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 7th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright Â© 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 79622 Version 8.0</div></div></div>"},"79624":{"type":"graphic_algorithm","displayName":"Algorithm VT versus SVT (Vereckei algorithm)","title":"Vereckei algorithm for the diagnosis of ventricular tachycardia (VT) or supraventricular tachycardia (SVT) in a patient with wide QRS complexÂ tachycardia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vereckei algorithm for the diagnosis of ventricular tachycardia (VT) or supraventricular tachycardia (SVT) in a patient with wide QRS complex&nbsp;tachycardia</div><div class=\"cntnt\"><img style=\"width:400px; height:534px;\" src=\"images/CARD/79624_WCTalgorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vereckei algorithm for the diagnosis of wide complex tachycardias. In step 4, V<EM><SUB>i</SUB></EM> represents the magnitude of voltage change in the initial 40 milliseconds of the QRS complex, while V<SUB><EM>t</EM></SUB> represents the magnitude of voltage change in the terminal 40 milliseconds of the QRS complex. The initial V<SUB>i</SUB> and terminal V<SUB>t</SUB> voltages should be measured from the same biphasic or multiphasic QRS complex.<br /></div><div class=\"graphic_footnotes\">A-V: atrio-ventricular; BBB: bundle branch block; FB: fascicular block; SVT: supraventricular tachycardia; VT: ventricular tachycardia.</div><div class=\"graphic_reference\">Reproduced with permission from: Vereckei A, Duray G, Szenasi G, et al. Application of a new algorithm in the differential diagnosis of wide QRS complex tachycardia. Eur Heart J 2007; 28:589. Copyright Â© 2007 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 79624 Version 6.0</div></div></div>"},"79625":{"type":"graphic_table","displayName":"Preconception control in diabetes","title":"Preconception evaluation and management of women with type 1 or type 2 diabetes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Preconception evaluation and management of women with type 1 or type 2 diabetes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">History and physical examination </td> </tr> <tr> <td class=\"subtitle2_single\">Hypertension </td> </tr> <tr> <td class=\"indent1\">Goal <span style=\"font-size: 10pt; font-family: verdana,sans-serif;\">systolic blood pressure 110 to 129 mmHg and diastolic blood pressure 65 to 79 mmHg in women with preexisting hypertension.</span></td> </tr> <tr> <td class=\"indent1\">Stop antihypertensive drugs, if possible, or switch to agents with fewest risks to fetus.</td> </tr> <tr> <td class=\"subtitle2_single\">Retinopathy </td> </tr> <tr> <td class=\"indent1\">Ophthalmology consult.</td> </tr> <tr> <td class=\"indent1\">Treat active proliferative retinopathy before pregnancy.</td> </tr> <tr> <td class=\"subtitle2_single\">Cardiac </td> </tr> <tr> <td class=\"indent1\">Screen for coronary heart disease as per guidelines for nonpregnant women with diabetes.</td> </tr> <tr> <td class=\"subtitle2_single\">Renal </td> </tr> <tr> <td class=\"indent1\">Measure serum creatinine concentration and total protein-to-creatinine ratio.</td> </tr> <tr> <td class=\"indent1\">Women with an elevated serum creatinine concentration are at risk for deterioration of renal status.</td> </tr> <tr> <td class=\"subtitle2_single\">Thyroid </td> </tr> <tr> <td class=\"indent1\">Obtain serum TSH and free T4.</td> </tr> <tr> <td class=\"subtitle1_single\">Diabetes </td> </tr> <tr> <td>Achieve good glucose control before conception. </td> </tr> <tr> <td>If A1C is above 7%, intensive insulin therapy is warranted. </td> </tr> <tr> <td>Three to four injections/day of short- and long-acting insulin subcutaneously are usually required to achieve good glycemic control. Either subcutaneous insulin injections or an insulin infusion pump is acceptable.</td> </tr> <tr> <td>Self-monitoring of blood glucose is performed before and after each meal and at bedtime.</td> </tr> <tr> <td>Repeat A1C one month after initiation of this program. </td> </tr> <tr> <td>Retest every month until target A1C value is achieved. Once in the target range, the patient can try to conceive. </td> </tr> <tr> <td>A pregnancy test is done&nbsp;one week after a missed period to confirm pregnancy. </td> </tr> <tr> <td class=\"subtitle1_single\">Psychosocial </td> </tr> <tr> <td>Assess \"readiness\" of patient for pregnancy.</td> </tr> <tr> <td class=\"subtitle1_single\">Other </td> </tr> <tr> <td>Advise patient to stop smoking and stop use of illicit drugs.</td> </tr> <tr> <td>Review medications. Discontinue those that are associated with potential fetal risks or change to medications with fewer fetal effects, if possible. </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TSH: thyroid-stimulating hormone; T4: thyroxine; A1C: glycated hemoglobin.</div><div id=\"graphicVersion\">Graphic 79625 Version 5.0</div></div></div>"},"79627":{"type":"graphic_picture","displayName":"Sponge based negative pressure wound system","title":"Sponge based negative pressure wound system","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Sponge based negative pressure wound system</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/SURG/79627_Sponge_base_neg_press_wound.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 79627 Version 1.0</div></div></div>"},"79628":{"type":"graphic_table","displayName":"Causes anovulation oligoovulation","title":"Causes of ovulatory dysfunction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of ovulatory dysfunction</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Primary hypothalamic-pituitary dysfunction</td> </tr> <tr> <td class=\"indent1\">Immaturity at onset of menarche or perimenopausal decline</td> </tr> <tr> <td class=\"indent1\">Intense exercise</td> </tr> <tr> <td class=\"indent1\">Eating disorders</td> </tr> <tr> <td class=\"indent1\">Stress</td> </tr> <tr> <td class=\"indent1\">Idiopathic hypogonadotropic hypogonadism</td> </tr> <tr> <td class=\"indent1\">Hyperprolactinemia</td> </tr> <tr> <td class=\"indent1\">Lactational amenorrhea</td> </tr> <tr> <td class=\"indent1\">Pituitary adenoma or other pituitary tumors</td> </tr> <tr> <td class=\"indent1\">Kallman's syndrome</td> </tr> <tr> <td class=\"indent1\">Tumors, trauma, or radiation of the hypothalamic or pituitary area</td> </tr> <tr> <td class=\"indent1\">Sheehan's syndrome</td> </tr> <tr> <td class=\"indent1\">Empty sella syndrome</td> </tr> <tr> <td class=\"indent1\">Lymphocytic hypophysitis (autoimmune diseases)</td> </tr> <tr> <td class=\"subtitle1_single\">Other disorders</td> </tr> <tr> <td class=\"indent1\">Polycystic ovary syndrome</td> </tr> <tr> <td class=\"indent1\">Hyperthyroidism or hypothyroidism</td> </tr> <tr> <td class=\"indent1\">Hormone producing tumors (adrenal, ovarian)</td> </tr> <tr> <td class=\"indent1\">Chronic liver or renal disease</td> </tr> <tr> <td class=\"indent1\">Cushing's disease</td> </tr> <tr> <td class=\"indent1\">Congenital adrenal hyperplasia</td> </tr> <tr> <td class=\"indent1\">Premature ovarian failure, which may be autoimmune, genetic, surgical idiopathic, or related to drugs or radiation</td> </tr> <tr> <td class=\"indent1\">Turner syndrome</td> </tr> <tr> <td class=\"indent1\">Androgen insensitivity syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Medications</td> </tr> <tr> <td class=\"indent1\">Estrogen-progestin contraceptives</td> </tr> <tr> <td class=\"indent1\">Progestins</td> </tr> <tr> <td class=\"indent1\">Antidepressant and antipsychotic drugs</td> </tr> <tr> <td class=\"indent1\">Corticosteroids</td> </tr> <tr> <td class=\"indent1\">Chemotherapeutic agents</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 79628 Version 5.0</div></div></div>"},"79630":{"type":"graphic_picture","displayName":"Wrights stain P marneffei","title":"Wright's-stained skin touch smear showing elongated yeast-like organisms with clear central septum, a typical characteristic of <em>Penicillium marneffei</em>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Wright's-stained skin touch smear showing elongated yeast-like organisms with clear central septum, a typical characteristic of <em>Penicillium marneffei</em></div><div class=\"cntnt\"><img style=\"width:396px; height:296px;\" src=\"images/ID/79630_Wrights_stain_P_marneffei.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Drs. Khuanchai Supparatpinyo and Thira Sirisanthana.</div><div id=\"graphicVersion\">Graphic 79630 Version 1.0</div></div></div>"},"79632":{"type":"graphic_diagnosticimage","displayName":"Anaplastic thyroid cancer CT","title":"Anaplastic thyroid cancer: CT scan of the neck","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anaplastic thyroid cancer: CT scan of the neck</div><div class=\"cntnt\"><img style=\"width:347px; height:252px;\" src=\"images/ENDO/79632_Anaplastic_thyroid_CA_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan of the neck of a patient with anaplastic thyroid cancer shows diffuse infiltration of the tumor (arrow), which prevents surgical resection.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of James Brierley, MB, BS, MRCP, FRCR, FRCP.</div><div id=\"graphicVersion\">Graphic 79632 Version 5.0</div></div></div>"},"79633":{"type":"graphic_picture","displayName":"Listeria monocytogenes in CSF","title":"<em>Listeria monocytogenes</em> in cerebrospinal fluid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><em>Listeria monocytogenes</em> in cerebrospinal fluid</div><div class=\"cntnt\"><img style=\"width:360px; height:322px;\" src=\"images/ID/79633_ListeriamonocytogenesinC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gram stain of cerebrospinal fluid (x1000) shows inflammatory cells and small, gram-positive rods and coccobacilli. Culture of this specimen revealed moderate-sized beta-hemolytic colonies composed of small, motile gram-positive rods, confirmed to be <EM>Listeria monocytogenes</EM>.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 79633 Version 6.0</div></div></div>"},"79634":{"type":"graphic_figure","displayName":"Deeply embedded digital hair tourniquet removal","title":"Removal of a deeply embedded hair tourniquet ","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Removal of a deeply embedded hair tourniquet </div><div class=\"cntnt\"><img style=\"width:454px; height:282px;\" src=\"images/PEDS/79634_Digital_hair_tourniquet_rem.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Digit anatomy and recommended incision sites for removal of a deeply embedded&nbsp;hair tourniquet (hair cannot be visualized. When incising a constricting band on a digit, the neurovascular bundles can be avoided by choosing the 3 o'clock or 9 o'clock position. The incision should be made longitudinally in the proximal to distal direction, with the scalpel blade perpendicular to the surface of the skin. To ensure that the hair is cut completely, the incision should be to the depth of bone.<br /><br /> For removal of superficial hair tourniquets, refer to UpToDate topics on hair tourniquets.</div><div id=\"graphicVersion\">Graphic 79634 Version 2.0</div></div></div>"},"79635":{"type":"graphic_diagnosticimage","displayName":"Fracture of the base of the 5th metacarpal","title":"Fracture of the base of the 5th metacarpal","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fracture of the base of the 5th metacarpal</div><div class=\"cntnt\"><img style=\"width:360px; height:270px;\" src=\"images/RHEUM/79635_Metacarpal_base_fx_5th_MC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anteroposterior radiograph shows a comminuted fracture at the base of the 5th metacarpal. Fractures in this location require orthopedic consultion due the instability associated with this injury (see text for details).</div><div class=\"graphic_reference\">Courtesy of Josh Bloom, MD, MPH.</div><div id=\"graphicVersion\">Graphic 79635 Version 3.0</div></div></div>"},"79636":{"type":"graphic_diagnosticimage","displayName":"Displaced Salter II fracture","title":"Displaced Salter II fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Displaced Salter II fracture</div><div class=\"cntnt\"><img style=\"width:345px; height:524px;\" src=\"images/EM/79636_Displaced_Salter_II_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">12-year-old with Salter-Harris type II fracture through metaphysis of distal radius, extending into growth plate. Distal fracture fragment is posteriorly displaced and dorsally angulated. There is some impaction of shaft of radius into distal fragment. Also note the minimally displaced ulnar styloid fracture.</div><div class=\"graphic_reference\">Courtesy of Paula Schweich, MD.</div><div id=\"graphicVersion\">Graphic 79636 Version 2.0</div></div></div>"},"79637":{"type":"graphic_picture","displayName":"Robot surg immersive syst","title":"Robot-assisted laparoscopy surgical system","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Robot-assisted laparoscopy surgical system</div><div class=\"cntnt\"><img style=\"width:516px; height:308px;\" src=\"images/OBGYN/79637_Robot_surg_immersive_syst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">da Vinci&#174; S Surgical System</div><div class=\"graphic_reference\">Photo courtesy of Intuitive Surgical, Inc, 2008.</div><div id=\"graphicVersion\">Graphic 79637 Version 2.0</div></div></div>"},"79638":{"type":"graphic_figure","displayName":"Corrected intrinsic PEEP","title":"Spuriously elevated intrinsic PEEP","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spuriously elevated intrinsic PEEP</div><div class=\"cntnt\"><img style=\"width:326px; height:280px;\" src=\"images/PULM/79638_Corrected_intrinsic_PEEP.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Individual values of intrinsic PEEP (auto-PEEP) measured on esophageal tracings (PEEPi dyn) compared with values obtained after subtracting for the rise in gastric pressure resulting from expiratory muscle activity (PEEPi corrected). The difference shown represents the contribution of expiratory muscle activity to the measured auto-PEEP. The corrected auto-PEEPi would be that component of auto-PEEP expected to be responsive to the application of PEEP. Thus, the presence of expiratory muscle activity can lead to the erroneous impression of a higher level of auto-PEEP and to the application of PEEP in an amount which might result in worsened dynamic pulmonary hyperinflation.</div><div class=\"graphic_footnotes\">PEEP: positive end-expiratory pressure.</div><div class=\"graphic_reference\">Redrawn from Lessard MR, Lofaso F, Brochard L. Am J Respir Crit Care Med 1995; 151:562.</div><div id=\"graphicVersion\">Graphic 79638 Version 2.0</div></div></div>"},"79639":{"type":"graphic_picture","displayName":"Baylisascariasis biopsy","title":"Baylisascariasis biopsy","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Baylisascariasis biopsy</div><div class=\"cntnt\"><img style=\"width:547px; height:276px;\" src=\"images/ID/79639_Baylisascariasis_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Cross-sections of larvae of <em>B. columnaris</em> (a skunk parasite) in the brain of a laboratory-infected mouse. The larval morphology and microscopic manifestations would be similar with <em>B. procyonis</em> in human tissue. Image taken at 400x magnification.<br />(B) Higher magnification (1000x oil) of a cross-section of <em>B. columnaris</em> from the same specimen as figure A. Notice the prominent alae (green arrows), excretory columns (red arrows), and multinucleate intestinal cells (blue arrow).</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Baylisascariasis. Available at: <a href=\"http://www.cdc.gov/dpdx/baylisascariasis/index.html\" target=\"_blank\">http://www.cdc.gov/dpdx/baylisascariasis/index.html</a>.</div><div id=\"graphicVersion\">Graphic 79639 Version 5.0</div></div></div>"},"79640":{"type":"graphic_picture","displayName":"Wire-guided IDUS passage","title":"Wire-guided intraductal ultrasound catheter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Wire-guided intraductal ultrasound catheter</div><div class=\"cntnt\"><img style=\"width:418px; height:278px;\" src=\"images/GAST/79640_Wire-guided_IDUS_passage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The wire-guided intraductal ultrasound catheter can be passed through a standard side-viewing duodenoscope.</div><div class=\"graphic_reference\">Courtesy of Micheal J Levy, MD, Enrique Vazquez-Sequeiros, MD, and Maurits J Wiersema, MD.</div><div id=\"graphicVersion\">Graphic 79640 Version 2.0</div></div></div>"},"79645":{"type":"graphic_table","displayName":"Treatment syphilis in pregnancy","title":"Treatment of syphilis in pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of syphilis in pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stage of syphilis</td> <td class=\"subtitle1\">Treatment</td> </tr> <tr class=\"divider_bottom\"> <td>Primary/secondary/early latent</td> <td>Benzathine penicillin G*, 2.4 million units IM in a single dose (usually administered as 1.2 million units in each buttock)<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Late latent/tertiary/unknown duration</td> <td>Benzathine penicillin G*, 7.2 million units total, administered as three doses of 2.4 million units IM each, at one week intervals</td> </tr> <tr> <td rowspan=\"3\">Neurosyphilis<sup>&#916;</sup></td> <td>Aqueous crystalline penicillin G, 18 to 24 million units per day, administered as 3 to 4 million units IV every four hours or as a continuous infusion for 10 to 14 days</td> </tr> <tr> <td><strong>OR</strong></td> </tr> <tr> <td>Procaine penicillin G, 2.4 million units IM once daily PLUS probenecid 500 mg PO four times daily, both for 10 to 14 days</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Pregnant women are treated with the penicillin regimen appropriate for their stage of infection. Parenteral penicillin G is the only therapy with documented safety and efficacy for both mother and fetus during pregnancy. If penicillin allergy, skin test and desensitize as necessary. <br /><br />Where penicillin desensitization is not possible for treatment of early syphilis (primary, secondary, or latent &lt;2 years), the World Health Organization (WHO) suggests using erythromycin 500 mg four times daily for 14 days, ceftriaxone 1 g intramuscularly once daily for 10 to 14 days, or&nbsp;azithromycin 2 g once orally (when local susceptibility to azithromycin is likely). For treatment of late syphilis, the WHO recommends treatment with erythromycin 500 mg orally four times daily for 30 days. The WHO also recommends that infants of women treated with non-penicillin regimens receive a 10- to 15-day course of penicillin treatment.</div><div class=\"graphic_footnotes\">IM: intramuscular; IV: intravenous; PO: oral.<br />* United States trade name Bicillin L-A for benzathine penicillin G (benzathine benzylpenicillin) suspension for deep IM injection only. Verify product to prevent confusion with other penicillin preparations.<br />Â¶ If serologic failure at follow-up and additional follow-up cannot be assured, can retreat with Benzathine penicillin G 2.4 million units IM for three weeks. Prompt CSF examination recommended.<br />Î Benzathine penicillin G 2.4 million units IM once per week for up to three weeks may be administered after completion of neurosyphilis regimen to complete a three-week course.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010. <A href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5912a1.htm?s_cid=rr5912a1_w\">http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5912a1.htm?s_cid=rr5912a1_w</A>&nbsp;(Accessed on September 16, 2016).</LI>&#xD;&#xA;<LI>World Health Organization guidelines for treatment of treponema pallidum (syphilis). <A href=\"http://apps.who.int/iris/bitstream/10665/249572/1/9789241549806-eng.pdf?ua=1\">http://apps.who.int/iris/bitstream/10665/249572/1/9789241549806-eng.pdf?ua=1</A> (Accessed on September 16, 2016).</LI></OL></div><div id=\"graphicVersion\">Graphic 79645 Version 7.0</div></div></div>"},"79646":{"type":"graphic_picture","displayName":"TT fungal overgrowth","title":"Fungal overgrowth of tympanostomy tube","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fungal overgrowth of tympanostomy tube</div><div class=\"cntnt\"><img style=\"width:396px; height:381px;\" src=\"images/PEDS/79646_TT_fungal_overgrowth.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prolonged use of any topical antimicrobial agent may result in fungal overgrowth. Children present with thick fungal debris, as depicted above, and clogged, itchy, or painful ears.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 79646 Version 2.0</div></div></div>"},"79647":{"type":"graphic_picture","displayName":"Two piece penile prosthesis","title":"Two-piece penile prosthesis","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Two-piece penile prosthesis</div><div class=\"cntnt\"><img style=\"width:498px; height:498px;\" src=\"images/ENDO/79647_Two_piece_penile_prosthesis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2015 American Medical Systems, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 79647 Version 7.0</div></div></div>"},"79648":{"type":"graphic_diagnosticimage","displayName":"Acute pulmonary histoplasmosis chest x-ray","title":"Acute histoplasmosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute histoplasmosis</div><div class=\"cntnt\"><img style=\"width:259px; height:311px;\" src=\"images/ID/79648_Subacute_lobar_histoplasmos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest x-ray from a patient with acute pulmonary histoplasmosis demonstrates an enlarged right hilar lymph node (red arrow) and a right middle lobe infiltrate.</div><div class=\"graphic_reference\">Courtesy of Joseph Wheat, MD.</div><div id=\"graphicVersion\">Graphic 79648 Version 3.0</div></div></div>"},"79651":{"type":"graphic_table","displayName":"POP recurrence risk","title":"Risk factors for recurrent pelvic organ prolapse","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for recurrent pelvic organ prolapse</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Risk factor*</td> <td class=\"subtitle1\">Adjusted odds ratio (95% confidence interval)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Age</td> </tr> <tr> <td class=\"indent1\">&#60;60 years<sup>[1]</sup></td> <td>3.2 (1.6-6.4)</td> </tr> <tr> <td class=\"indent1\">&#60;60 years<sup>[2]</sup></td> <td>4.1 (1.6-10.4)</td> </tr> <tr> <td class=\"indent1\">&#60;73 years<sup>[3]</sup></td> <td>6.3 (2.3-17.5)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">Preoperative pelvic organ prolapse stage (POP-Q)</td> </tr> <tr> <td class=\"indent1\">Stage 3 or 4<sup>[1]</sup></td> <td>2.7 (1.3-5.3)</td> </tr> <tr> <td class=\"indent1\">Stage 3 or 4<sup>[2]</sup></td> <td>3.9 (1.2-13.0)</td> </tr> <tr> <td class=\"indent1\">Stage 4<sup>[4]</sup></td> <td>5.6 (1.1-29.3)</td> </tr> <tr class=\"divider_top\"> <td><strong>Body Mass Index &#62;26 kg/m<sup>2</sup> <sup>[3]</sup></strong></td> <td>2.9 (1.1-6.7)</td> </tr> <tr class=\"divider_top\"> <td><strong>Body weight &#62;65 kg<sup>[2]</sup></strong></td> <td>4.0 (1.6-9.6)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The comparator for each risk factor group is the group of women with pelvic organ prolapse that are not included in the specified group (eg, the comparator for &gt;60 years is &#8804;60 years OR for stage 4 is stage 1, 2, or 3).<br></div><div class=\"graphic_reference\">References:<br> <ol> <li>Whiteside, JL, Weber, AM, Meyn, LA, Walters, MD. Risk factors for prolapse recurrence after vaginal repair. Am J Obstet Gynecol 2004; 191:1533-8. </li> <li>Diez-Itza, I, Aizpitarte, I, Becerro, A. Risk factors for the recurrence of pelvic organ prolapse after vaginal surgery: A review at 5 years after surgery. International Urogynecology Journal 2007; 18:1317-24. </li> <li>Nieminen, K, Huhtala, H, Heinonen, PK. Anatomic and functional assessment and risk factors of recurrent prolapse after vaginal sacrospinous fixation. Acta Obstetricia Et Gynecologica Scandinavica 2003; 82:471-8. </li> <li>Jeon, MJ, Chung, SM, Jung, HJ, Kim, SK, Bai, SW. Risk factors for the recurrence of pelvic organ prolapse. Gynecologic &amp; Obstetric Investigation 2008; 66:268-73. </li> </ol></div><div id=\"graphicVersion\">Graphic 79651 Version 4.0</div></div></div>"},"79652":{"type":"graphic_table","displayName":"Utility of cardiac MRI","title":"Advantages and disadvantages of cardiac MRI","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Advantages and disadvantages of cardiac MRI</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Advantages</td> </tr> <tr> <td>Three-dimensional</td> </tr> <tr> <td>High spatial and temporal resolution</td> </tr> <tr> <td>Intrinsic high contrast; no need for iodinated contrast</td> </tr> <tr> <td>No ionizing radiation</td> </tr> <tr> <td>No interference from lung or bone</td> </tr> <tr> <td>Multiple imaging techniques in a single system</td> </tr> <tr> <td class=\"subtitle1_single\">Disadvantages</td> </tr> <tr> <td>Contraindicated with certain medical implants such as aneurysm clips, TENS units, and certain pacemakers</td> </tr> <tr> <td>Acquisition time can be lengthy</td> </tr> <tr> <td>Electrocardiogram can be distorted by the magnetic field interfering with monitoring of acutely ill patients</td> </tr> <tr> <td>Requires ECG and respiratory gating</td> </tr> <tr> <td>Claustrophobia</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 79652 Version 4.0</div></div></div>"},"79653":{"type":"graphic_diagnosticimage","displayName":"Prenatal ultrasound of ARKPD","title":"Prenatal ultrasound of ARPKD transverse section","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound of ARPKD transverse section</div><div class=\"cntnt\"><img style=\"width:432px; height:287px;\" src=\"images/OBGYN/79653_ARKPD2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Autosomal recessive polycystic kidney disease (ARPKD)-Bilateral massively enlarged kidneys. Ascites is present, but is not a typical feature of this abnormality.</div><div class=\"graphic_reference\">Courtesy of Tulin Ozcan, MD.</div><div id=\"graphicVersion\">Graphic 79653 Version 5.0</div></div></div>"},"79654":{"type":"graphic_table","displayName":"Mechanisms of barotrauma","title":"Possible mechanisms of barotrauma in mechanically ventilated patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Possible mechanisms of barotrauma in mechanically ventilated patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">\"Spontaneous\" alveolar rupture</td> </tr> <tr> <td class=\"indent1\">Related to ventilator management per se</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Alveolar overdistension because of excessive tidal volume, elevated plateau pressure, and/or PEEP </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Manifestation of primary disease process (eg, ARDS, asthma, ILD, COPD, necrotizing pneumonia)</td> </tr> <tr> <td class=\"indent1\">Inadvertent alveolar overdistension</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Right main bronchus intubation, severe central airway obstruction, pneumonectomy </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Manual ventilation (bag-mask valve ventilation) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Direct injury</td> </tr> <tr> <td class=\"indent1\">Trauma (penetrating, blunt)</td> </tr> <tr> <td class=\"indent1\">Resuscitation (mouth-to-mouth, manual ventilation)</td> </tr> <tr> <td class=\"indent1\">Airway laceration or perforation during intubation attempts</td> </tr> <tr> <td class=\"indent1\">Biopsy or surgery</td> </tr> <tr> <td class=\"indent1\">Central line placement</td> </tr> <tr> <td class=\"indent1\">Thoracentesis</td> </tr> <tr> <td class=\"indent1\">Failed chest tube placement</td> </tr> <tr> <td class=\"indent1\">Transbronchial biopsy or bronchial brushing</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PEEP: positive end expiratory pressure; ARDS: acute respiratory distress syndrome; ILD: interstitial lung disease; COPD: chronic obstructive pulmonary disease.</div><div id=\"graphicVersion\">Graphic 79654 Version 4.0</div></div></div>"},"79655":{"type":"graphic_picture","displayName":"PCLBCL-LT clinical presentation II","title":"Patient with a primary cutaneous diffuse large B-cell lymphoma, leg type presenting with extensive skin tumors on the left leg","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Patient with a primary cutaneous diffuse large B-cell lymphoma, leg type presenting with extensive skin tumors on the left leg</div><div class=\"cntnt\"><img style=\"width:432px; height:329px;\" src=\"images/HEME/79655_PCLBCL_LT_clin_pres_II.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 79655 Version 1.0</div></div></div>"},"79657":{"type":"graphic_diagnosticimage","displayName":"Semilobar holoprosencephaly","title":"Semilobar holoprosencephaly","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Semilobar holoprosencephaly</div><div class=\"cntnt\"><img style=\"width:350px; height:310px;\" src=\"images/OBGYN/79657_Semilobar_holoprosen_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">T: thalamus.</div><div class=\"graphic_reference\">Courtesy of Ana Monteagudo, MD.</div><div id=\"graphicVersion\">Graphic 79657 Version 4.0</div></div></div>"},"79658":{"type":"graphic_figure","displayName":"Uroflowmetry normal","title":"Uroflometric tracing: normal uroflow","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Uroflometric tracing: normal uroflow</div><div class=\"cntnt\"><img style=\"width:590px; height:407px;\" src=\"images/PC/79658_Uroflowmetry_normal.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 79658 Version 1.0</div></div></div>"},"79659":{"type":"graphic_picture","displayName":"Lichen sclerosus follicular plugging","title":"Extragenital lichen sclerosus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Extragenital lichen sclerosus</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/79659_Lich_sclerosus_follic_plug.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Follicular plugging is evident in this lesion of lichen sclerosus.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 79659 Version 3.0</div></div></div>"},"79660":{"type":"graphic_picture","displayName":"Focal ablation Barrx90","title":"Endoscopic images of a focal ablation procedure for residual Barrett's esophagus using the Barrx90 system","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Endoscopic images of a focal ablation procedure for residual Barrett's esophagus using the Barrx90 system</div><div class=\"cntnt\"><img style=\"width:512px; height:293px;\" src=\"images/GAST/79660_Focal_ablation_HALO90.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><STRONG>(A)</STRONG> Antegrade view of an esophagus that had contained long-segment Barrett's esophagus, six weeks after primary circumferential ablation.<BR><STRONG>(B)</STRONG> Residual islands of Barrett's mucosa.<BR><STRONG>(C)</STRONG> Corresponding image using narrow band imaging.<BR><STRONG>(D)</STRONG> Ablation effect immediately after treatment with the Barrx90 system. The distal end of the catheter is visible at the 12 o'clock position in the endoscopic field.<BR><STRONG>(E)</STRONG> Endoscopic appearance after the first ablation pass (two applications of 15 J/cm2) and cleaning of the ablation zones.<BR><STRONG>(F)</STRONG> After the second ablation pass, the ablation zones have a tan-colored appearance.</div><div class=\"graphic_reference\">Reproduced with permission of www.endosurgery.eu. Copyright Â© 2010 Esophageal Research Foundation Amsterdam.</div><div id=\"graphicVersion\">Graphic 79660 Version 3.0</div></div></div>"},"79661":{"type":"graphic_table","displayName":"Morbidity LND melanoma","title":"Morbidity of node dissection in patients with melanoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Morbidity of node dissection in patients with melanoma</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\"> &nbsp;</td>\n\n      <td class=\"subtitle1\">Axillary, percent*</td>\n\n      <td class=\"subtitle1\"> lnguinal, percent&#8226;</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Infection</td>\n\n      <td>15</td>\n\n      <td>21</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Edema</td>\n\n      <td>12</td>\n\n      <td>21</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Wound necrosis or separation</td>\n\n      <td>3</td>\n\n      <td>20</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Seroma</td>\n\n      <td>17</td>\n\n      <td>12</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pain or disability</td>\n\n      <td>4</td>\n\n      <td>34</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Other major</td>\n\n      <td>&nbsp;</td>\n\n      <td>2</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\">Overall</td>\n\n      <td>44</td>\n\n      <td>50</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">* Data from Shaw, JH, Br J Surg 1990; 77:760.<br> &#8226; Data from Smith, TI, SSO Cancer Symposium, 1998.</div><div id=\"graphicVersion\">Graphic 79661 Version 1.0</div></div></div>"},"79662":{"type":"graphic_table","displayName":"Glossary of low back pain terms","title":"Glossary of low back pain terms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Glossary of low back pain terms</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">Acupuncture</td> <td>An intervention consisting of the insertion of needles at specific acupuncture points.</td> </tr> <tr> <td class=\"subtitle2_left\">Artificial disc replacement</td> <td>Replacement of a degenerated vertebral disc with an artificial (prosthetic) disc.</td> </tr> <tr> <td class=\"subtitle2_left\">Back school</td> <td>An intervention consisting of an education and a skills program, including exercise therapy, in which all lessons are given to groups of patients and supervised by a paramedical therapist or medical specialist.</td> </tr> <tr> <td class=\"subtitle2_left\">Biofeedback</td> <td>The use of auditory and visual signals reflecting muscle tension or activity in order to inhibit or reduce the muscle activity.</td> </tr> <tr> <td class=\"subtitle2_left\">Brief educational interventions</td> <td>Individualized assessment and education about low back pain problems without supervised exercise therapy or other specific interventions.</td> </tr> <tr> <td class=\"subtitle2_left\">Chemonucleolysis</td> <td>Treatment of herniated discs with intradiscal injections of an enzyme extracted from papaya (chymopapain). Chymopapain acts by digesting the jelly-like inner portion of the disc known as the nucleus pulposus, while at the same time, leaving the outer portion, the annulus fibrosis, essentially intact. Collagenase (which may be less likely to induce an allergic reaction) has also been used.</td> </tr> <tr> <td class=\"subtitle2_left\">Cognitive behavioral therapy</td> <td>An intervention that involves working with cognitions to change emotions, thoughts, and behaviors.</td> </tr> <tr> <td class=\"subtitle2_left\">Discectomy</td> <td>Removal of all or parts of an intervertebral disc in order to relieve pressure on adjacent nerve roots.</td> </tr> <tr> <td class=\"subtitle2_left\">Epidural steroid injection</td> <td>An intervention that involves the administration of steroids in the space between the dura and the spine via a catheter. Epidural injections can be performed by the translaminar approach (via the interlaminar space in the spine), the transforaminal approach (through the neuroforamen ventral to the nerve root), or the caudal approach (through the sacral hiatus at the sacral canal).</td> </tr> <tr> <td class=\"subtitle2_left\">Exercise therapy</td> <td>A supervised exercise program or formal home exercise regimen, ranging from programs aimed at general physical fitness or aerobic exercise to programs aimed at muscle strengthening, flexibility, stretching, or different combinations of these elements.</td> </tr> <tr> <td class=\"subtitle2_left\">Facet joint injection</td> <td>Injection of a glucocorticoid into the facet joints in order to reduce inflammation and/or swelling.</td> </tr> <tr> <td class=\"subtitle2_left\">Functional restoration (also referred to as work hardening or work conditioning)</td> <td>An intervention that involves simulated or actual work tests in a supervised environment in order to enhance job performance skills and improve strength, endurance, flexibility, and cardiovascular fitness in injured workers.</td> </tr> <tr> <td class=\"subtitle2_left\">Fusion surgery</td> <td>A surgical procedure that unites (fuses) two or more vertebra together. The goal behind fusion surgery is to restrict spinal motion in order to relieve symptoms. A variety of spinal fusion techniques are practiced. All involve the placement of a bone graft between the vertebrae. In addition, fusion can be performed with or without the use of supplemental hardware (instrumentation), such as plates, screws, or cages that serve as an internal splint while the bone graft heals.</td> </tr> <tr> <td class=\"subtitle2_left\">Interdisciplinary therapy (also referred to as multidisciplinary therapy)</td> <td>An intervention that combines and coordinates physical, vocational, and behavioral components and is provided by multiple healthcare professionals with different clinical backgrounds. The intensity and content of interdisciplinary therapy varies widely.</td> </tr> <tr> <td class=\"subtitle2_left\">Interferential therapy</td> <td>The superficial application of a medium frequency alternating current modulated to produce low frequencies up to 150 Hz.</td> </tr> <tr> <td class=\"subtitle2_left\">Intradiscal glucocorticoid injection</td> <td>Injection of a glucocorticoid directly into a lumbar disc in order to reduce swelling and inflammation.</td> </tr> <tr> <td class=\"subtitle2_left\">Intradiscal electrothermal therapy (IDET)</td> <td>An intervention involving the placement of an electrode into the intervertebral disc in patients with presumed discogenic back pain. The catheter is slowly heated and kept at a predetermined temperature for a predetermined time in order to coagulate and shrink adjacent tissues.</td> </tr> <tr> <td class=\"subtitle2_left\">Laminectomy</td> <td>Removal of the vertebral lamina in order to relieve pressure on the spinal cord or nerve roots.</td> </tr> <tr> <td class=\"subtitle2_left\">Local injections</td> <td>Injections into the soft tissues surrounding the back with a local anesthetic, sometimes with a glucocorticoid. A variety of target sites have been proposed, including tender points and various anatomic sites.</td> </tr> <tr> <td class=\"subtitle2_left\">Low-level laser therapy (LLLT)</td> <td>The superficial application of lasers at wavelengths between 632 and 904 nm. Optimal treatment parameters (wavelength, dose, dose-intensity) are uncertain.</td> </tr> <tr> <td class=\"subtitle2_left\">Massage</td> <td>Soft tissue manipulation using the hands or a mechanical device through a variety of specific methods.</td> </tr> <tr> <td class=\"subtitle2_left\">Medial branch block</td> <td>Injection of a local anesthetic (with or without a glucocorticoid) into the area of the nerve innervating the facet joint. Medial branch blocks may be used diagnostically (to determine whether the facet joint is the source of back pain) or therapeutically.</td> </tr> <tr> <td class=\"subtitle2_left\">Percutaneous electrical nerve stimulation (PENS)</td> <td>An intervention involving the insertion of acupuncture-like needles and applying low-level electrical stimulation. It differs from electroacupuncture in that the insertion points target dermatomal levels for local pathology, rather than acupuncture points.</td> </tr> <tr> <td class=\"subtitle2_left\">Percutaneous intradiscal radiofrequency thermocoagulation (PIRFT)</td> <td>An intervention similar to IDET, this intervention involves insertion of an electrode or catheter into the intervertebral disc. Unlike IDET, the electrode or catheter itself does not become hot. Instead, heat is generated in surrounding tissues by an alternating radiofrequency current.</td> </tr> <tr> <td class=\"subtitle2_left\">Progressive relaxation</td> <td>A technique that involves the deliberate tensing and relaxation of muscles, in order to facilitate the recognition and release of muscle tension.</td> </tr> <tr> <td class=\"subtitle2_left\">Provocative discography</td> <td>A procedure involving injection of radiographic contrast material into the nucleus of an intervertebral disc, which may elicit pain. It is most commonly performed in patients with chronic low back pain in order to help identify those who are more likely to benefit from interventional procedures intended to treat \"discogenic\" back pain.</td> </tr> <tr> <td class=\"subtitle2_left\">Radiofrequency denervation</td> <td>Destruction of nerves using heat generated by a radiofrequency current. It involves the placement of a catheter or electrode near or in the target nerve. Once the position of the catheter is confirmed by fluoroscopy, a radiofrequency current is applied in order to heat and coagulate adjacent tissues, including the target nerve.</td> </tr> <tr> <td class=\"subtitle2_left\">Sacroiliac joint injection</td> <td>Injection of glucocorticoid into the area near the sacroiliac joint, in order to reduce inflammation and/or swelling.</td> </tr> <tr> <td class=\"subtitle2_left\">Shortwave diathermy</td> <td>Therapeutic elevation of the temperature of deep tissues by application of shortwave electromagnetic radiation with a frequency range from 10 to 100 MHz.</td> </tr> <tr> <td class=\"subtitle2_left\">Spinal manipulation</td> <td>Manual therapy in which loads are applied to the spine using short- or long-lever methods. High velocity thrusts are applied to a spinal joint beyond its restricted range of movement. Spinal mobilization, or low velocity, passive movements within or at the limit of joint range, is often used in conjunction with spinal manipulation.</td> </tr> <tr> <td class=\"subtitle2_left\">Transcutaneous electrical nerve stimulation (TENS)</td> <td>Use of a small battery-operated device to provide continuous electrical impulses via surface electrodes, with the goal of providing symptomatic relief by modifying pain perception.</td> </tr> <tr> <td class=\"subtitle2_left\">Yoga</td> <td>An intervention distinguished from traditional exercise therapy by the utilization of specific body positions, breathing techniques, and emphasis on mental focus. Many styles of yoga are practiced, each emphasizing different postures and techniques.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 79662 Version 2.0</div></div></div>"},"79663":{"type":"graphic_picture","displayName":"Neb or MDI use with NPPV","title":"Aerosolized medications, either by nebulizer or MDI, can be administered during NPPV","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Aerosolized medications, either by nebulizer or MDI, can be administered during NPPV</div><div class=\"cntnt\"><img style=\"width:493px; height:457px;\" src=\"images/PULM/79663_Neb_or_MDI_use_with_NPPV.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 79663 Version 2.0</div></div></div>"},"79664":{"type":"graphic_table","displayName":"Worrisome headache features in children","title":"Clinical features that may indicate intracranial pathology in children and adolescentsÂ with headache","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features that may indicate intracranial pathology in children and adolescents&nbsp;with headache</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\"><span style=\"color: black;\">Headache characteristics</span></td> </tr> <tr> <td><span style=\"color: black;\">Headache awakens the child or occurs consistently&nbsp;upon awakening from sleep</span></td> </tr> <tr> <td><span style=\"color: black;\">Short or paroxysmal headache; thunderclap headache&nbsp;(uncommon in children)</span></td> </tr> <tr> <td><span style=\"color: black;\">Associated neurologic signs and symptoms (eg, persistent nausea/vomiting, altered mental status, ataxia, etc)</span></td> </tr> <tr> <td><span style=\"color: black;\">Headache worsened in recumbent position or by cough, micturition, defecation, or physical activity</span></td> </tr> <tr> <td><span style=\"color: black;\">Absence of aura</span></td> </tr> <tr> <td><span style=\"color: black;\">Chronic progressive headache pattern</span></td> </tr> <tr> <td><span style=\"color: black;\">Change in quality, severity, frequency, or pattern of headache</span></td> </tr> <tr> <td><span style=\"color: black;\">Occipital headache</span></td> </tr> <tr> <td><span style=\"color: black;\">Recurrent localized headache</span></td> </tr> <tr> <td><span style=\"color: black;\">Lack of response to medical therapy</span></td> </tr> <tr> <td><span style=\"color: black;\">Headache duration of less than six months</span></td> </tr> <tr> <td class=\"subtitle1_single\"><span style=\"color: black;\">Patient history</span></td> </tr> <tr> <td><span style=\"color: black;\">Inadequate history (description of headache and relative features)</span></td> </tr> <tr> <td><span style=\"color: black;\">Risk factor for intracranial pathology (eg, sickle cell disease, immune deficiency, malignancy or history of malignancy, coagulopathy, cardiac disease with right-to-left intracardiac shunt, head trauma, neurofibromatosis type 1, tuberous sclerosis complex, pre-existing hydrocephalus or shunt)</span></td> </tr> <tr> <td><span style=\"color: black;\">Age &#60;6 years</span></td> </tr> <tr> <td>Personality change</td> </tr> <tr> <td>Deterioration of school work</td> </tr> <tr> <td>Associated symptoms in the neck or back</td> </tr> <tr> <td class=\"subtitle1_single\">Family history</td> </tr> <tr> <td>Absence of family history of migraine</td> </tr> <tr> <td class=\"subtitle1_single\">Examination findings</td> </tr> <tr> <td>Child uncooperative (unable to complete neurologic examination)</td> </tr> <tr> <td>Abnormal neurologic examination (eg, ataxia, weakness, diplopia, abnormal eye movements, other focal signs)</td> </tr> <tr> <td>Papilledema or retinal hemorrhages</td> </tr> <tr> <td>Growth abnormalities (increased head circumference, short stature or deceleration of linear growth, abnormal pubertal progression, obesity)</td> </tr> <tr> <td>Nuchal rigidity</td> </tr> <tr> <td>Signs of trauma</td> </tr> <tr> <td>Cranial bruits</td> </tr> <tr> <td>Skin lesions that suggest a neurocutaneous syndrome (neurofibromatosis, tuberosis sclerosis complex)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Lewis DW, Ashwal S, Dahl G, et al. Practice parameter: Evaluation of children and adolescents with recurrent headaches: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2002; 59:490. </LI>&#xD;&#xA;<LI>Newton RW. Childhood headache. Arch Dis Child Educ Pract Ed 2008; 93:105. </LI>&#xD;&#xA;<LI>Prince JS, Gunderman R, Coley BD, et al. Expert Panel on Pediatric Imaging. ACR Appropriateness Criteria. Headache - Child. American College of Radiology, Reston, VA, 2008. <A href=\"http://www.acr.org/SecondaryMainMenuCategories/quality_safety/app_criteria/pdf/ExpertPanelonPediatricImaging/HeadacheChildDoc3.aspx\">www.acr.org/SecondaryMainMenuCategories/quality_safety/app_criteria/pdf/ExpertPanelonPediatricImaging/HeadacheChildDoc3.aspx</A> (Accessed on March 17, 2011). </LI>&#xD;&#xA;<LI>Strasburger VC, Brown RT, Braverman PK, et al. Headache. In: Adolescent Medicine: A Handbook for Primary Care, Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.25. </LI>&#xD;&#xA;<LI>Wilne S, Koller K, Collier J, et al. The diagnosis of brain tumours in children:&nbsp;A guideline to assist healthcare professionals in the assessment of children who may have a brain tumour. Arch Dis Child 2010; 95:534. </LI>&#xD;&#xA;<LI>Seshia SS, Abu-Arafeh I, Hershey AD. Tension-type headache in children: The Cinderella of headache disorders! Can J Neurol Sci 2009; 36:687.</LI></OL></div><div id=\"graphicVersion\">Graphic 79664 Version 6.0</div></div></div>"},"79666":{"type":"graphic_picture","displayName":"Monkeypox lesions","title":"Father, 6/05/03","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Father, 6/05/03</div><div class=\"cntnt\"><img style=\"width:468px; height:339px;\" src=\"images/ID/79666_Monkeypox_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Marshfield Clinic. Copyright &#169; 2005 Marshfield Clinic.</div><div id=\"graphicVersion\">Graphic 79666 Version 2.0</div></div></div>"},"79667":{"type":"graphic_table","displayName":"Sedative/analgesic dosage regimens","title":"Intravenous* sedative and analgesic dosing regimens for managing pain, agitation, and delirium in the intensive care unit","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intravenous* sedative and analgesic dosing regimens for managing pain, agitation, and delirium in the intensive care unit</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"10%\"></colgroup><colgroup width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Loading dose</td> <td class=\"subtitle1\">Maintenance dose range</td> <td class=\"subtitle1\">Onset (minutes)</td> <td class=\"subtitle1\">Duration of intermittent dose (minutes)</td> <td class=\"subtitle1\">Characteristics and role</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Opioid analgesics<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Fentanyl<sup>&#182;</sup></td> <td> <p>1 to 2 mcg/kg<sup>&#916;</sup></p> <p style=\"white-space: nowrap;\">(25 to 100 mcg)<sup>&#182;</sup></p> </td> <td> <p>0.35 to 0.5 mcg/kg every 0.5 to 1 hour intermittent (25 to 35 mcg)<sup>&#182;</sup></p> <p><strong>AND/OR</strong></p> <p>0.7 to 10 mcg/kg/hour infusion (50 to 700 mcg/hour)<sup>[1]</sup>;</p> For most patients, 1 to 3 mcg/kg/hour infusion (50 to 200 mcg/hour)<sup>&#182;</sup> with as-needed intermittent bolus doses is sufficient</td> <td>&#60;1 to 2</td> <td>30 to 60<sup>&#9674;</sup></td> <td> <p><strong>Advantages:</strong> Potent analgesic-sedative with immediate onset and less hypotension than other opioid analgesic choices due to relative lack of histamine release. Metabolized hepatically by cytochrome P450-3A4 (CYP3A4) to inactive metabolites.</p> <p><strong>Disadvantages:</strong> Highly lipophilic parent drug accumulates<span style=\"color: black;\"> in adipose and other tissue </span>with repeated or prolonged administration. Chest wall rigidity may occur with higher dosing<sup>&#167;</sup>.</p> <strong>Role:</strong> A good choice for analgesia for most critically ill patients.</td> </tr> <tr> <td class=\"indent1\">Hydromorphone</td> <td>0.5 to 2 mg<sup>&#916;</sup></td> <td> <p>0.2 to 0.6 mg every one to two hours intermittent</p> <p><strong>AND/OR</strong></p> 0.5 to 3 mg/hour infusion</td> <td>5 to 10</td> <td>240 to 300</td> <td> <p><strong>Advantages:</strong> IV administration requires small volumes relative to other opioids. Non-CYP metabolism (glucuronidation) may be an advantage for patients receiving drugs that significantly alter CYP3A4 metabolism and thereby interact with fentanyl.</p> <p><strong>Disadvantages:</strong> Potentially neurotoxic (excitatory) metabolite(s) may accumulate in hepatic and/or renal dysfunction<sup>&#167;</sup>.</p> <strong>Role:</strong> Analgesic option alternative to fentanyl or morphine. Dose adjustment and gradual titration needed for patients with renal and/or hepatic impairment.</td> </tr> <tr> <td class=\"indent1\">Morphine sulfate</td> <td>2 to 10 mg<sup>&#916;</sup></td> <td> <p>2 to 4 mg every one to two hours intermittent</p> <p><strong>AND/OR</strong></p> 2 to 30 mg/hour infusion</td> <td>5 to 10</td> <td>240 to 300</td> <td> <p><strong>Advantage:</strong> Non-CYP metabolism (glucuronidation) may be an advantage for selected patients receiving drugs that significantly alter CYP3A4 metabolism and thereby interact with fentanyl.</p> <p><strong>Disadvantages:</strong> Can accumulate in hepatic or renal dysfunction and prolong effects. Histamine release and vagally mediated venodilation, hypotension, and bradycardia can be significant<sup>&#167;</sup>.</p> <strong>Role:</strong> Analgesic alternative to fentanyl or hydromorphone where preload reduction and myocardial depressive effects are desirable or tolerable. Dose adjustment and gradual titration needed for patients with renal and/or hepatic impairment. Avoid in patients with advanced or decompensated liver disease with renal impairment due to risk of accumulation of neurotoxic metabolite.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Remifentanil<sup>&#182;</sup></td> <td> <p>Optional:</p> <p>1.5 mcg/kg<sup>&#182;</sup><sup>[1]</sup></p> Most ICU patients can be managed without bolus doses; if required, a bolus of 0.5 mcg/kg is usually sufficient; larger boluses are associated with significant reductions in HR and MAP</td> <td> <p>0.5 to 15 mcg/kg/hour infusion</p> Use ideal body weight to determine dose for obese patients<sup>&#182;</sup></td> <td>1 to 3</td> <td>5 to 10 (after cessation of infusion)</td> <td> <p><strong>Advantages:</strong> Ultra-short-acting. Cleared by non-specific plasma esterases to inactive metabolites. Does not accumulate in renal or hepatic impairment. Prompt reversal of analgesia and sedation upon discontinuation.</p> <p><strong>Disadvantages:</strong> Anticipate pain and discomfort upon abrupt cessation. Glycine excipient may accumulate in renal impairment<sup>&#167;</sup>.</p> <strong>Role:</strong> An alternative to fentanyl for patients requiring frequent neurologic assessments or those with multi-organ failure.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Nonopioid analgesics (adjunctive or opioid sparing)</td> </tr> <tr> <td class=\"indent1\"> <p>Acetaminophen</p> (paracetamol)</td> <td>None</td> <td> <p>Oral, rectal: 325 to 1000 mg every four to six hours</p> <p>IV: 650 mg IV every four hours to 1000 mg IV every six hours, or 15 mg/kg IV every six hours for patients weighing &#60;50 kg</p> Maximum &#8804;4 g/day</td> <td> <p>Oral: 30 to 60</p> <p>Rectal: Variable</p> IV: 5 to 10</td> <td>240 to 360</td> <td> <p><strong>Advantages:</strong> Lacks dependence and tolerance of opioids. Lacks antiplatelet effect and gastrointestinal toxicity of NSAIDs.</p> <p><strong>Disadvantages:</strong> Lacks significant anti-inflammatory effect. IV preparation requires administration over 15 minutes. Can cause hepatotoxicity in chronic or acute overdosage. Avoid or use a lower daily dose in older adults and patients at risk for hepatoxicity (eg, heavy alcohol use or malnourished). Interacts with warfarin (may prolong INR) and CYP450-inducing drugs (elevated risk of hepatic inflammation).</p> <strong>Role:</strong> First choice for treatment of mild to moderate acute pain and febrile conditions. Adjunctive analgesic that may reduce opioid requirements. When hepatic dysfunction is significant, consider avoiding or reducing dose (eg, &#8804;2 g/day total).</td> </tr> <tr> <td class=\"indent1\">Ketorolac</td> <td> <p>Optional:</p> 30 mg once</td> <td> <p>Age &#60;65 years and weight &#8805;50 kg: 15 to 30 mg every six hours; maximum 120 mg/day for up to five days</p> Age &#8805;65 years or weight &#60;50 kg: 15 mg every six hours; maximum 60 mg/day for up to five days</td> <td>IV: ~30</td> <td>360 to 480</td> <td> <p><strong>Advantages:</strong> Lacks dependence and tolerance of opioids. Effective anti-inflammatory.</p> <p><strong>Disadvantages:</strong> Can cause or worsen renal insufficiency. Dose-related risk of gastropathy. Reversibly inhibits platelet functioning. May alter cardioprotective effect of aspirin.</p> <p><strong>Role:</strong> Adjunctive analgesic that may reduce opioid requirements.</p> Avoid in renal impairment, gastrointestinal bleeding, platelet dysfunction, ischemic heart disease, heart failure, reduced cardiac output, hypovolemic state, asthma, or cirrhosis. Contraindicated in treatment of perioperative pain in coronary artery bypass graft surgery. Patients should be well hydrated.</td> </tr> <tr> <td class=\"indent1\">Ibuprofen</td> <td>None</td> <td> <p>Oral: 400 mg orally every four hours (maximum 2.4 g/day chronic)</p> IV: 400 to 800 mg IV every six hours (maximum 3.2 g/day acute)</td> <td> <p>Oral: 30</p> IV: ~30</td> <td>240 to 360</td> <td> <p><strong>Advantages:</strong> Lacks dependence and tolerance of opioids. Effective anti-inflammatory.</p> <p><strong>Disadvantages:</strong> Can cause or worsen renal insufficiency. Dose-related risk of gastropathy. Reversibly inhibits platelet functioning. Can alter cardioprotective effect of aspirin.</p> <p><strong>Role:</strong> Short-term treatment of moderate acute pain and febrile conditions. Adjunctive analgesic that may reduce opioid requirements.</p> Avoid in renal impairment, gastrointestinal bleeding, platelet dysfunction, ischemic heart disease, heart failure, reduced cardiac output, hypovolemic state, asthma, or cirrhosis. Contraindicated in treatment of perioperative pain in coronary artery bypass graft surgery. Patients should be well hydrated.</td> </tr> <tr> <td class=\"indent1\">Gabapentin</td> <td>None</td> <td> <p>Oral: Initially 100 mg three times per day</p> Oral: Maintenance 900 to 3600 mg per day in three divided doses</td> <td>Variable</td> <td>--</td> <td> <p><strong>Advantages:</strong> Effective for treatment of neuropathic pain. Low risk of drug interactions.</p> <p><strong>Disadvantages:</strong> Requires enteral administration, scheduled dosing, and individualized titration over days to weeks. Oral bioavailability is variable (27 to 60%) and inversely proportional to dose. Adverse effects include sedation, dizziness, and ataxia, which may be intensified in renal impairment, requiring dose adjustment. Should not be abruptly stopped due to risk of discontinuation symptoms.</p> <strong>Role:</strong> Useful adjunct to other analgesics for treatment of neuropathic and postoperative pain or dysesthesias in patients who can be treated with enteral medication. Dose adjustment needed for renal impairment.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Pregabalin</td> <td>None</td> <td> <p>Oral: Initially 75 mg once or twice per day</p> Oral: Maintenance 150 to 300 mg twice per day</td> <td>Variable (hours to days)</td> <td>--</td> <td> <p><strong>Advantages:</strong> Effective for treatment of neuropathic pain. Oral bioavailability (&#62;90%) is more reliable than gabapentin and may provide for more rapid onset of analgesia with a shorter amount of time needed to titrate to full dose. Low risk of drug interactions.</p> <p><strong>Disadvantages:</strong> Requires enteral administration, scheduled dosing, and titration over days to weeks. Adverse effects include sedation, blurred vision, dry mouth, dizziness, and ataxia, which may be intensified in renal impairment, requiring dose adjustment. Should not be abruptly stopped due to risk of discontinuation symptoms.</p> <strong>Role:</strong> Useful adjunct to other analgesics for treatment of neuropathic and postoperative pain or dysesthesias in patients who can be treated with enteral medication. Dose adjustment needed for renal impairment.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Anesthetic-sedative</td> </tr> <tr> <td class=\"indent1\">Propofol<sup>&#182;</sup></td> <td> <p>Bolus doses are usually&nbsp;not given&nbsp;in the ICU</p> </td> <td> <p>5 to 50 mcg/kg/<strong>minute</strong><sup>&#182;</sup></p> <p>Titrate every 5 to 10 minutes in increments of 5 to 10 mcg/kg/<strong>minute</strong></p> Some patients require up to 70 mcg/kg/minute, which can increase risk of propofol infusion syndrome (refer to UpToDate topics on sedative-analgesic medications in critically ill patients: properties, dosage regimens, and adverse effects)</td> <td>&#60;1 to 2</td> <td>3 to 10<sup>&#9674;</sup></td> <td> <p><strong>Advantages:</strong> Potent sedative-hypnotic associated with an immediate onset and rapid awakening upon discontinuation when administered for short-term use. Metabolism is reportedly unaltered in hepatic or renal impairment and subject to few significant drug interactions. Infusion is readily titratable to desired depth of sedation, minimizing risk of oversedation. Propofol effectively decreases intracranial pressure, lowers cerebral metabolism, controls intractable seizures, and may reduce shivering in the rewarming phase of induced hypothermia following resuscitation from cardiac arrest.</p> <p><strong>Disadvantages:</strong> Adverse effects include hypotension, bradycardia, respiratory depression, decreased myocardial contractility, elevated triglycerides, peripheral injection site pain, and rarely propofol infusion syndrome (refer to UpToDate topics on sedative-analgesic medications in critically ill patients: properties, dosage regimens, and adverse effects). Specific product presentations may include potential allergens (egg, soy, peanut, others). Consult product label information. No analgesic effects.</p> <strong>Role:</strong> A good choice in conjunction with appropriate analgesia for short-term sedation of patients in whom rapid awakening is advantageous. Also a good choice to decrease elevated intracranial pressure or for short-term sedation in a general critical care population that is likely to be ready soon for ventilator weaning trials.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ketamine</td> <td>0.1 to 0.5 mg/kg</td> <td>0.05 to 0.4 mg/kg/hour</td> <td>&#8804;1</td> <td>10 to 15 (single dose)</td> <td> <p><strong>Advantages:</strong> A potent dissociative sedative-anesthetic with marked analgesia that maintains cardiac output and mean arterial pressure without inhibition of respiratory drive. Does not inhibit protective reflexes. May reduce acute opioid tolerance.</p> <p><strong>Disadvantages:</strong> Sympathetic stimulation (ie, increased heart rate and myocardial oxygen demand, elevated intracranial pressure and systemic blood pressure) may be intolerable depending upon clinical setting. Rarely, cardiorespiratory depression associated with rapid administration or higher doses. Adverse effects may include hallucinations, delirium upon withdrawal, tonic-clonic movements, dissociative experiences, unpleasant recall, hypersalivation, nausea, and vomiting. Complex metabolism includes CYP3A4, 2C9, 2B6, and non-CYP hepatic transformations and an active metabolite (norketamine), which may accumulate in renal and/or hepatic impairment or due to drug interactions.</p> <strong>Role:</strong> An alternate choice for postsurgical pain management, severe agitation, or as an adjunctive analgesic in patients with severe refractory pain in clinical settings where increased myocardial oxygen demand and sympathetic tone are tolerable.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Central alpha<sub>2</sub> agonist</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Dexmedetomidine</td> <td> <p>Optional:</p> <p>1 mcg/kg over 10 minutes if hemodynamically stable</p> Usually not given</td> <td> <p>0.2 to 0.7 mcg/kg/hour</p> <p>Initiate at 0.2 mcg/kg/hour and titrate every 30 minutes</p> Some patients require doses up to 1.5 mcg/kg/hour</td> <td> <p>5 to 10 (optional loading dose)</p> 15 (without loading dose)</td> <td>60 to 120</td> <td> <p><strong>Advantages:</strong> Effective sedative sympatholytic (central alpha<sub>2</sub> agonist) with moderate anxiolysis and analgesia, yet no clinically significant effect on respiratory drive. Character and depth of sedation may permit critically ill, mechanically ventilated patients to be interactive or easily awakened, yet comfortable. Can be used in non-mechanically ventilated ICU patients and continued as needed following extubation. Reduces shivering in the rewarming phase of induced hypothermia following resuscitation from cardiac arrest. May be less likely to cause delirium than other sedative choices.</p> <p><strong>Disadvantages:</strong> Potentially significant hypotension and bradycardia or hypertension that do not resolve quickly upon abrupt discontinuation. Metabolized hepatically by glucuronidation and CYP2A6. Dose reduction recommended with renal and/or hepatic impairment. Rapid administration of loading dose may be associated with cardiovascular instability, tachycardia, bradycardia, or heart-block. Does not induce the deep sedation needed for neuromuscular blockade.</p> <strong>Role:</strong> A good choice for short- and long-term sedation in critically ill patients without relevant cardiac conditions. May be useful for sedation of patients with or at high risk of developing delirium, although this has not been well established.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Benzodiazepines<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Midazolam<sup>&#182;</sup></td> <td> <p>0.01 to 0.05 mg/kg<sup>&#916;</sup></p> (0.5 to 4 mg)<sup>&#182;</sup></td> <td> <p>0.02 to 0.1 mg/kg/hour infusion</p> (2 to 8 mg/hour)<sup>&#182;</sup></td> <td>2 to 5</td> <td>30<sup>&#9674;</sup></td> <td> <p><strong>Advantages:</strong> A potent amnestic and anxiolytic agent with an immediate onset of action and a short duration of effect when administered short-term (&#60;48 hours). It is the only IV benzodiazepine that is not delivered in propylene glycol.</p> <p><strong>Disadvantages:</strong> Hepatically metabolized by CYP3A4 to active metabolites that may accumulate and cause prolonged sedation if delivered long-term. Half-life may be prolonged in critically ill patients with hepatic or renal impairment. Risk of delirium. Also, it interacts with drugs used in the ICU (eg, some antiretrovirals, azole antifungals) that alter CYP metabolism such that excess sedation can occur with concomitant use of midazolam and drugs metabolized by CYP3A4.</p> <strong>Role:</strong> A good choice for short-term anxiolysis and treatment of acute agitation. Dose adjustment and gradual titration are needed for patients with renal and/or hepatic impairment.</td> </tr> <tr> <td class=\"indent1\">Lorazepam<sup>&#182;</sup></td> <td> <p>0.02 to 0.04 mg/kg<sup>&#916;</sup></p> (1 to 2 mg)<sup>&#182;</sup></td> <td> <p style=\"white-space: nowrap;\">0.02 to 0.06 mg/kg<br /> every two to six hours<br /> intermittent<br /> (1 to 4 mg)<sup>&#182;</sup></p> <p><strong>AND/OR</strong></p> <p>0.01 to 0.1 mg/kg/hour infusion</p> (0.5 to 10 mg/hour)<sup>&#182;</sup></td> <td>15 to 20</td> <td>360 to 480<sup>&#9674;</sup></td> <td> <p><strong>Advantages:</strong> Sedative, amnestic, potent anxiolysis with anti-convulsant properties. Hepatically metabolized by glucuronidation to inactive metabolites. Relatively low risk of drug interactions and safety in mild to moderate hepatic and renal impairment.</p> <p><strong>Disadvantages:</strong> Relatively slow onset. Risk of over-sedation when titrating due to delayed response and accumulation in peripheral tissues. Risk of delirium. IV incompatibilities and risk of line precipitate. Propylene glycol solvent may accumulate with prolonged use or high dosing causing metabolic acidosis and end-organ dysfunction (refer to UpToDate topics on sedative-analgesic medications in critically ill patients: properties, dosage regimens, and adverse effects). Long half-life, with significant risk of accumulation in the elderly or in&nbsp;patients with significant renal or hepatic impairment.</p> <strong>Role:</strong> A good choice for sedation and anxiolysis for most patients, including those who may require long-term ongoing sedation. Although intermittent bolus dosing may be preferred, a continuous infusion may be initiated for patients requiring frequently repeated higher dosing.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Diazepam<sup>&#182;</sup></td> <td> <p>0.05 to 0.2 mg/kg<sup>&#916;</sup></p> (5 to 10 mg)<sup>&#182;</sup></td> <td> <p style=\"white-space: nowrap;\">0.03 to 0.1 mg/kg<br /> every 0.5 to 6 hours<br /> intermittent<br /> (1 to 7 mg)<sup>&#182;</sup></p> Continuous infusion is not recommended</td> <td>2 to 5</td> <td>20 to 60<sup>&#9674;</sup></td> <td> <p><strong>Advantages:</strong> Rapid onset with potent sedative and muscle-relaxant effects.</p> <p><strong>Disadvantages:</strong> Hepatically metabolized by CYP2C19 and 3A4 to active metabolites that may accumulate and cause prolonged sedation if delivered long-term. Half-life may be prolonged in critically ill patients with hepatic and/or renal impairment. Risk of delirium. Also, it interacts with drugs used in the ICU that alter CYP metabolism. Injection solution contains propylene glycol solvent and cannot be delivered as a continuous infusion. Injection site pain and risk of phlebitis limit usefulness of IV injections.</p> <strong>Role:</strong> Seldom used for sedation of critically ill patients. May be useful for critically ill patients at risk of alcohol withdrawal or seizures due to drug overdose or poisoning.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Antipsychotics</td> </tr> <tr> <td class=\"indent1\">Haloperidol<sup>&#165;</sup></td> <td> <p>0.03 to 0.15 mg/kg<sup>&#916;</sup></p> Variable doses; refer to UpToDate topics on sedative-analgesic medications in critically ill patients: properties, dosage regimens, and adverse effects</td> <td> <p>0.03 to 0.15 mg/kg every 30 minutes to six hours</p> Various regimens; refer to UpToDate topics on sedative-analgesic medications in critically ill patients: properties, dosage regimens, and adverse effects</td> <td>30 to 60</td> <td>30 to 360<sup>&#9674;</sup></td> <td> <p><strong>Advantages:</strong> Moderately sedating dopamine<sub>2</sub> antagonist for control of positive symptoms of delirium and ICU psychoses. Minimal cardiorespiratory effects in euvolemic, hemodynamically stable patients.</p> <p><strong>Disadvantages:</strong> Complex hepatic metabolism includes CYP3A4 and 2D6 transformations. Some experts consider certain metabolites to be active or potentially neurotoxic. Half-life becomes prolonged with repeated administration. Adverse effects include dose-dependent QT interval prolongation and hypotension. Interacts with some common ICU drugs by interference with metabolism and/or by having an additive effect, prolonging the QTc. Extrapyramidal symptoms and neuroleptic malignant syndrome are rare in critical care use.</p> <strong>Role:</strong> Potential treatment for agitation and/or delirium in critically ill patients.</td> </tr> <tr> <td class=\"indent1\">Olanzapine<sup>&#135;</sup></td> <td> <p>Optional:</p> <p>5 to 10 mg IM</p> May repeat every two to four hours if needed (maximum total 30 mg)</td> <td>Oral: Initially 5 to 10 mg once daily; increase every 24 hours as needed by 5-mg increments up to 20 mg/day</td> <td>IM: 15 to 45</td> <td>IM: &#8805;120</td> <td> <p><strong>Advantages:</strong> Availability of short-acting IM formulation; less risk of extrapyramidal symptoms and QT prolongation than haloperidol.</p> <p><strong>Disadvantages:</strong> Adverse effects include orthostatic hypotension, hyperglycemia, somnolence, QT interval prolongation, and anticholinergic effects. Undergoes extensive hepatic metabolism including non CYP (ie, glucuronidation) and CYP1A2 transformations. Half-life may be prolonged (ie, &#8805;50 hours) with increased risk of accumulation in patients who are elderly, female, nonsmoking, and/or in the setting of hepatic or renal impairment.</p> <strong>Role:</strong> Potential alternative or add-on to as-needed IV haloperidol for treatment of acute agitation and/or delirium in the ICU. Use lowest starting dose and titrate more gradually in patients with renal and/or hepatic impairment and/or other factors that predispose for slowed metabolism (see 'Disadvantages' above).</td> </tr> <tr> <td class=\"indent1\">Quetiapine<sup>&#135;</sup></td> <td>None</td> <td>Oral: Initially 50 mg every 12 hours; increase every 24 hours as needed up to 400 mg/day</td> <td>Oral: 60 (initial effect); &#8805;24 hours (full effect)</td> <td>Oral: 6 to 12 hours</td> <td> <p><strong>Advantages:</strong> Less risk of extrapyramidal symptoms and possibly less risk of QT prolongation than haloperidol.</p> <p><strong>Disadvantages:</strong> Requires enteral route of administration and scheduled dosing due to slow onset of action and relatively gradual titration schedule. Adverse effects may include sedation or orthostatic hypotension and risk of QT interval prolongation remains. Hepatically metabolized by CYP3A4 to active and inactive metabolites.</p> <strong>Role:</strong> A potential choice as adjunct to as-needed IV haloperidol for treatment of agitation and/or delirium. In advanced hepatic impairment initiate with reduced dose and titrate in lower increments.</td> </tr> <tr> <td class=\"indent1\">Ziprasidone<sup>&#134;</sup></td> <td> <p>Optional:</p> <p>10 mg IM</p> <p>May repeat every two hours if needed (maximum 40 mg total)</p> <p><strong>OR</strong></p> <p>20 mg IM</p> May repeat once after four hours if needed (maximum 40 mg total)</td> <td>Oral: 10 to 40 mg orally every 12 hours</td> <td>IM: 30</td> <td>IM: &#8805;90</td> <td> <p><strong>Advantages:</strong> Availability of short-acting IM formulation; less risk of extrapyramidal symptoms than haloperidol.</p> <p><strong>Disadvantages:</strong> Orthostatic hypotension, hyperglycemia, QT prolongation; undergoes extensive hepatic metabolism by hepatic non CYP and CYP3A4 transformations to active and inactive metabolites; IM formulation contains cyclodextrin (a potential nephrotoxin) which can accumulate in renal impairment; an IV formulation is not available.</p> <strong>Role:</strong> A potential alternative or add-on to as-needed IV haloperidol for treatment of acute agitation in the ICU<sup>&#134;</sup>. Dose reduction is needed in advanced hepatic impairment. Specific recommendations are not available. Avoid prolonged use of IM preparation in patients with renal impairment due to risk of accumulation of cyclodextrin additive.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Dosing information in this table is for critically ill adults and includes indications, dosing, duration of use, and routes of administration not listed in the US Food &amp; Drug Administration approved product labeling. Refer to UpToDate content on managing pain, agitation, and delirium in critically ill adults, the Lexicomp drug monographs, and most recent product labeling for additional information.<br />Data provided in \"Characteristics and role\" on drug metabolism and the presence of active metabolite(s) are included and may be useful for assessing the potential for drug interactions and risk of drug accumulation in renal and/or hepatic organ impairment.</div><div class=\"graphic_footnotes\">CYP: cytochrome P-450 metabolism; IV: intravenous; NSAIDs: nonsteroidal anti-inflammatories; INR: international normalized ratio; IM: intramuscularly; QT: QT interval on the electrocardiogram; QTc: corrected QT interval; ICU: intensive care unit.<br />* All doses shown are for IV administration except where otherwise noted (eg, oral or rectal acetaminophen, IM olanzapine optional initial dose).<br />&para; In patients who are <strong>obese</strong>, standard, non-weight-based initial dosing is preferred. Standard adult doses, ie, scaled to ideal body weight, are shown in parentheses following weight-based doses. A separate calculator to determine ideal body weight is available in UpToDate. For additional information refer to UpToDate topic review on intensive care unit management of the complicated postoperative bariatric surgery patient.<br />&Delta; One or more loading doses may be needed. See onset of action data for minimum time between re-dosing. Loading dose should be reduced or omitted in patients who are older, hypovolemic, having increasing vasopressor requirements, or at-risk for hemodynamic compromise.<br /><span class=\"lozenge\">&loz;</span> Duration of action shown is for initial dosing. Duration becomes significantly prolonged after repeated dosing or with administration as a continuous infusion due to accumulation of drug in adipose tissue.<br />&sect; As with all opioids, tolerance may require dose escalation, and withdrawal syndrome may be precipitated upon abrupt discontinuation.<br />&yen; Dosing of haloperidol in agitated schizophrenia differs from the recommendations listed in this table for delirium in the ICU and is reviewed separately. Refer to topic reviews of emergency management of the acutely agitated or violent patient and pharmacotherapy for acute schizophrenia.<br />&Dagger; The precise role of second-generation antipsychotics in the treatment or prevention of delirium in ICU is not established. Quetiapine and olanzapine recommendations and data are based on limited experience and small trial results (Devlin et al. Crit Care Med 2010; 38:419; Skrobik et al. Intensive Care Med 2004; 30:444).<br />&dagger; Ziprasidone recommendations and data are based on limited experience and small trial results in treatment of undifferentiated agitation without symptoms of delirium in non-critically ill emergency department patients (Martel et al. Acad Emerg Med 2005; 12:1167; Mantovani et al. J Clin Psychopharmacol 2013; 33:306). Small trial results failed to demonstrate a benefit for scheduled oral ziprasidone in prevention of delirium in a general ICU population (Girard et al. Crit Care Med 2010; 38:428).</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Barr J, Fraser GL, Puntillo K, et al. Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit. Crit Care Med, 2013; 41:263.</LI>&#xD;&#xA;<LI>Lexicomp Online. Copyright Â© 1978-2018 Lexicomp, Inc. All Rights Reserved.</LI></OL></div><div id=\"graphicVersion\">Graphic 79667 Version 27.0</div></div></div>"},"79668":{"type":"graphic_figure","displayName":"Chest escharotomy","title":"Chest escharotomy","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Chest escharotomy</div><div class=\"cntnt\"><img style=\"width:531px; height:398px;\" src=\"images/EM/79668_Chest_escharotomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows the approximate location for chest escharotomy incisions. Although rarely required in the emergency department, such incisions may be needed should ventilation become difficult due to constriction of chest wall motion from eschar.</div><div id=\"graphicVersion\">Graphic 79668 Version 2.0</div></div></div>"},"79669":{"type":"graphic_diagnosticimage","displayName":"Frykman IV radius fracture lateral view","title":"Frykman IV radius fracture lateral view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Frykman IV radius fracture lateral view</div><div class=\"cntnt\"><img style=\"width:346px; height:468px;\" src=\"images/EM/79669_Frykman_IV_lateral_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lateral x-ray of the same injury demonstrates significant dorsal displacement and angulation of the distal radial fragment.</div><div class=\"graphic_reference\">Courtesy of Erik L Schroeder, MD.</div><div id=\"graphicVersion\">Graphic 79669 Version 3.0</div></div></div>"},"79670":{"type":"graphic_table","displayName":"Symptoms in RTH","title":"Frequency of symptoms and signs in patients with resistance to thyroid hormone (RTH)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of symptoms and signs in patients with resistance to thyroid hormone (RTH)</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">&nbsp;</td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Findings\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Frequency, percent\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Thyroid gland</td>\r\n  \r\n   <td>Goiter</td>\r\n  \r\n   <td>66-95</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Heart</td>\r\n  \r\n   <td>Tachycardia</td>\r\n  \r\n   <td>33-75</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  rowspan=\"6\">\r\n  \r\n   Nervous system\r\n  \r\n   </td>\r\n  \r\n   <td>Emotional disturbances</td>\r\n  \r\n   <td>60</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Hyperkinetic behavior</td>\r\n  \r\n   <td>33-68</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Attention deficit hyperactivity disorder</td>\r\n  \r\n   <td>40-60</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Learning disability</td>\r\n  \r\n   <td>30</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Mental retardation (IQ &#60;70)</td>\r\n  \r\n   <td>4-16</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Hearing loss (sensorineural)</td>\r\n  \r\n   <td>10-22</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  rowspan=\"4\">\r\n  \r\n   Growth and development\r\n  \r\n   </td>\r\n  \r\n   <td>Short stature (&#60;5 percent)</td>\r\n  \r\n   <td>18-25</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Delayed bone age &#62;2 SD</td>\r\n  \r\n   <td>29-47</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Low body mass index (in children)</td>\r\n  \r\n   <td>33</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Recurrent ear and throat infections</td>\r\n  \r\n   <td>55</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_footnotes\">IQ: intellectual quotient.</div><div class=\"graphic_reference\">Data from:<br>Refetoff, S, Weiss, RE, Usala, SJ. The syndromes of resistance to thyroid hormone. Endocr Rev 1993; 14:348. <br>Beck-Peccoz, P, Chatterjee, VK. The variable clinical phenotype in thyroid hormone resistance syndrome. Thyroid 1994; 4:225.<br>Brucker-Davis, F, Skarulis, MC, Grace, MB, et al. Genetic and clinical features of 42 kindreds with resistance to thyroid hormone. The National Institutes of Health Prospective Study. Ann Intern Med 1995; 123:572.</div><div id=\"graphicVersion\">Graphic 79670 Version 2.0</div></div></div>"},"79672":{"type":"graphic_table","displayName":"Episodic tension-type headache diagnostic criteria","title":"Episodic tension-type headache diagnostic criteria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Episodic tension-type headache diagnostic criteria</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td><strong>Description:</strong> Episodes of headache, typically bilateral, pressing or tightening in quality and of mild to moderate intensity, lasting minutes to days. The pain does not worsen with routine physical activity and is not associated with nausea, but photophobia or phonophobia may be present. Increased pericranial tenderness may be present on manual palpation.</td> </tr> <tr> <td class=\"sublist1_start\"><strong>A.</strong> At least 10 episodes of headache fulfilling criteria B through D. Infrequent and frequent episodic subforms of TTH are distinguished as follows:</td> </tr> <tr> <td class=\"indent1\">Infrequent episodic TTH: Headache occurring on &#60;1 day per month on average (&#60;12 days per year).</td> </tr> <tr> <td class=\"indent1\">Frequent episodic TTH: Headache occurring on 1 to 14 days per month on average for &#62;3 months (&#8805;12 and &#60;180 days per year).</td> </tr> <tr> <td class=\"sublist1_start\"><strong>B.</strong> Headache lasting from 30 minutes to seven days.</td> </tr> <tr> <td class=\"sublist1_start\"><strong>C.</strong> At least two of the following four characteristics:</td> </tr> <tr> <td class=\"indent1\">Bilateral location.</td> </tr> <tr> <td class=\"indent1\">Pressing or tightening (nonpulsating) quality.</td> </tr> <tr> <td class=\"indent1\">Mild or moderate intensity.</td> </tr> <tr> <td class=\"indent1\">Not aggravated by routine physical activity such as walking or climbing stairs.</td> </tr> <tr> <td class=\"sublist1_start\"><strong>D.</strong> Both of the following:</td> </tr> <tr> <td class=\"indent1\">No nausea or vomiting.</td> </tr> <tr> <td class=\"indent1\">No more than one of photophobia or phonophobia.</td> </tr> <tr> <td class=\"sublist1_start\"><strong>E.</strong> Not better accounted for by another ICHD-3 diagnosis.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TTH: tension-type headache; ICHD-3: The International Classification of Headache Disorders, 3<SUP>rd</SUP> edition (beta version).</div><div class=\"graphic_reference\">Data from: Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3<SUP>rd</SUP> edition (beta version). Cephalalgia 2013; 33:629.</div><div id=\"graphicVersion\">Graphic 79672 Version 6.0</div></div></div>"},"79674":{"type":"graphic_diagnosticimage","displayName":"Ultrasound normal fetal brain transventricular view","title":"Transventricular plane","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Transventricular plane</div><div class=\"cntnt\"><img style=\"width:480px; height:389px;\" src=\"images/OBGYN/79674_US_fetalbrain_transventricular.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 79674 Version 2.0</div></div></div>"},"79676":{"type":"graphic_figure","displayName":"Uterine bivalving at vaginal hysterectomy","title":"Uterine bivalving at vaginal hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Uterine bivalving at vaginal hysterectomy</div><div class=\"cntnt\"><img style=\"width:487px; height:301px;\" src=\"images/OBGYN/79676_Uterine_morcellation_C.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 79676 Version 3.0</div></div></div>"},"79679":{"type":"graphic_picture","displayName":"Fasciolopsiasis adult worm","title":"Fasciolopsiasis adult worm","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Fasciolopsiasis adult worm</div><div class=\"cntnt\"><img style=\"width:584px; height:215px;\" src=\"images/ID/79679_Fasciolopsiasis_adult_worm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A, B) Adult fluke of&nbsp;<EM>Fasciolopsis buski</EM>.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Fasciolopsiasis. Available at: <A href=\"http://www.cdc.gov/dpdx/fasciolopsiasis/index.html\">http://www.cdc.gov/dpdx/fasciolopsiasis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 79679 Version 5.0</div></div></div>"},"79680":{"type":"graphic_table","displayName":"Organisms in transfusion-associated infections","title":"Organisms implicated in transfusion-associated infections","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Organisms implicated in transfusion-associated infections</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Organism</td> </tr> <tr> <td class=\"subtitle2_single\">Gram-positive</td> </tr> <tr> <td class=\"indent1\"><em>Bacillus cereus</em></td> </tr> <tr> <td class=\"indent1\">Coagulase-negative staphylococci</td> </tr> <tr> <td class=\"indent1\"><em>Enterococcus faecalis</em></td> </tr> <tr> <td class=\"indent1\"><em>Streptococcus</em> spp</td> </tr> <tr> <td class=\"indent1\"><em>Staphylococcus aureus</em></td> </tr> <tr> <td class=\"indent1\"><em>Cutibacterium</em> (formerly <em>Propionibacterium</em>)<em> acnes</em></td> </tr> <tr> <td class=\"subtitle2_single\">Gram-negative</td> </tr> <tr> <td class=\"indent1\"><em>Klebsiella</em> spp</td> </tr> <tr> <td class=\"indent1\"><em>Serratia</em> spp</td> </tr> <tr> <td class=\"indent1\"><em>Escherichia coli</em></td> </tr> <tr> <td class=\"indent1\"><em>Acinetobacter</em> spp</td> </tr> <tr> <td class=\"indent1\"><em>Enterobacter</em> spp</td> </tr> <tr> <td class=\"indent1\"><em>Proteus mirabilis</em></td> </tr> <tr> <td class=\"indent1\"><em>Providencia rettgeri</em></td> </tr> <tr> <td class=\"indent1\"><em>Pseudomonas</em> spp</td> </tr> <tr> <td class=\"indent1\"><em>Yersinia enterocolitica</em></td> </tr> <tr> <td class=\"indent1\"><em>Pasteurella multocida</em></td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 79680 Version 5.0</div></div></div>"},"79681":{"type":"graphic_figure","displayName":"Normal and abnormal voiding","title":"Normal and abnormal voiding","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Normal and abnormal voiding</div><div class=\"cntnt\"><img style=\"width:535px; height:303px;\" src=\"images/PEDS/79681_Normal_and_abnormal_voiding.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left panel illustrates the mechanics of normal voiding. The detrusor musculature contracts to empty the bladder, while the external sphincter relaxes to open the bladder neck and release urine. The right panel illustrates the voiding dysfunction seen in patients with a high-pressure or hyperreflexic bladder. The detrusor muscle is over-active, which interferes with bladder filling. Some patients also have poor relaxation of the external sphincter during voiding, or poor coordination between the bladder and sphincter (detrusor-sphincter dyssynergia), causing high bladder pressures and inefficient emptying.</div><div id=\"graphicVersion\">Graphic 79681 Version 2.0</div></div></div>"},"79685":{"type":"graphic_picture","displayName":"The Allen test","title":"The Allen test","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">The Allen test</div><div class=\"cntnt\"><img style=\"width:478px; height:229px;\" src=\"images/CARD/79685_The_Allen_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the Allen test, the patient is instructed to make a fist, which will empty the blood from the hand and fingers (A). The examiner's thumbs are then pressed down across the thenar and hypothenar eminences to the wrist to occlude the radial and ulnar arteries. The patient then opens the hand, making sure not to overextend the fingers. The pressure on the ulnar artery is then released while the radial artery is still compressed (B). The hand does not fill with blood. Note the paleness of the hand on the right compared with the hand on left, indicating occlusion of the ulnar artery distal to the wrist (abnormal test result). If there is prompt return of color to the hand (indicating a normal test result), the test is repeated except this time pressure on the radial artery is released while the ulnar artery remains compressed.</div><div class=\"graphic_reference\">Reproduced with permission from: Olin JW, Lie JT, Thromboagiitis (Buerger's disease). In: Current management of hypertensive and vascular disease, Cookie JP, Frohlich ED, (Eds), Mosby-Year Book, St Louis 1992. p.265. Copyright &copy; Elsevier Science.</div><div id=\"graphicVersion\">Graphic 79685 Version 4.0</div></div></div>"},"79687":{"type":"graphic_picture","displayName":"Bullous pemphigoid eosinophilic spongiosis","title":"Bullous pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Bullous pemphigoid</div><div class=\"cntnt\"><img style=\"width:504px; height:295px;\" src=\"images/DERM/79687_Bull_pemphi_eosin_spongios.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This hematoxylin and eosin stain of a skin tissue biopsy specimen from an early lesion of bullous pemphigoid demonstrates epidermal spongiosis, eosinophils within the epidermis, and a mixed perivascular cellular infiltrate in the upper dermis.</div><div class=\"graphic_reference\">Reproduced with permission from: Leiferman KM, Peters MS. Eosinophils in cutaneous diseases. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith L, Katz S, Gilchrest B, et al (Eds), McGraw-Hill, New York 2012. Copyright Â© 2012 McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 79687 Version 2.0</div></div></div>"},"79688":{"type":"graphic_table","displayName":"Abdominal hyst complication","title":"Complications of abdominal hysterectomy for benign disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complications of abdominal hysterectomy for benign disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Rate of complications, percent</td> </tr> <tr> <td>Overall severe complications</td> <td>4* to 6<sup>&#182;</sup></td> </tr> <tr> <td>Major hemorrhage (requiring transfusion or surgical intervention)</td> <td>2*<sup>&#916;</sup></td> </tr> <tr> <td>Thromboembolism</td> <td>0.2 (with mechanical or pharmacologic thromboprophylaxis)<sup>&#916;</sup>; 15 to 30 (without thromboprophylaxis)<sup>&#9674;</sup></td> </tr> <tr> <td>Bladder injury</td> <td>0.02<sup>&#167;</sup> to 1<sup>&#182;</sup></td> </tr> <tr> <td>Ureteral injury</td> <td>0.04<sup>&#167;</sup></td> </tr> <tr> <td>Urinary tract infection</td> <td>4<sup>&#916;</sup></td> </tr> <tr> <td>Bowel injury</td> <td>0.2<sup>&#916;</sup> to 1<sup>&#182;</sup></td> </tr> <tr> <td>Bowel obstruction</td> <td>1<sup>&#165;</sup></td> </tr> <tr> <td>Surgical site infection</td> <td>3<sup>&#916;</sup></td> </tr> <tr> <td>Reoperation</td> <td>0.5*<sup>&#182;</sup></td> </tr> <tr> <td>Mortality</td> <td>0.03*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Maresh MJ, Metcalfe MA, McPherson K, et al. BJOG 2002; 109:302.<br />Â¶ Garry R, Fountain J, Mason S, et al. BMJ 2004; 328:129.<br />Î Makinen J, Johansson J, Tomas C, et al. Hum Reprod 2001; 16:1473.<br /><FONT class=lozenge>â</FONT> Greer IA. Baillieres Clin Obstet Gynaecol 1997; 11:403.<br />Â§ Harkki-Siren P, Sjoberg J, Tiitinen A. Obstet Gynecol 1998; 92:113.<br />Â¥ Al-Sunaidi M, Tulandi T. Obstet Gynecol 2006; 108:1162.</div><div id=\"graphicVersion\">Graphic 79688 Version 5.0</div></div></div>"},"79689":{"type":"graphic_table","displayName":"Oral versus intravenous amiodarone","title":"Oral versus intravenous amiodarone","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oral versus intravenous amiodarone</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">Variable</td>\n\n      <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">Effect</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td class=\"subtitle2\">Oral amiodarone</td>\n\n      <td class=\"subtitle2\">Intravenous amiodarone</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Prolongation of action potential duration in atrial and\nventricular myocardium</td>\n\n      <td>+++</td>\n\n      <td>+</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Blockage of inactivated sodium channels</td>\n\n      <td>+++</td>\n\n      <td>++</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Slowing of phase 4 depolarization in the sinus node</td>\n\n      <td>+++</td>\n\n      <td>+</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Calcium channel blockade</td>\n\n      <td>+++</td>\n\n      <td>+++</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Noncompetetive blockade of alpha and beta\nadrenoreceptors</td>\n\n      <td>+</td>\n\n      <td>+ (faster)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>AV node effective refractory period</td>\n\n      <td>&#8593;&#8593;&#8593;</td>\n\n      <td>&#8593;&#8593;&#8593;</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ventricular effective refractory period</td>\n\n      <td>&#8593;&#8593;&#8593;</td>\n\n      <td>&#8593;</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Heart rate</td>\n\n      <td>&#8595;&#8595;</td>\n\n      <td>-/&#8595;</td>\n\n    </tr>\n\n    <tr>\n\n      <td>QRS interval</td>\n\n      <td>&#8593;&#8593;</td>\n\n      <td>&#8593;</td>\n\n    </tr>\n\n    <tr>\n\n      <td>QTc duration</td>\n\n      <td>&#8593;&#8593;&#8593;</td>\n\n      <td>-/&#8593;</td>\n\n    </tr>\n\n    <tr>\n\n      <td>A-H interval</td>\n\n      <td>&#8593;&#8593;</td>\n\n      <td>&#8593;&#8593;&#8593;</td>\n\n    </tr>\n\n    <tr>\n\n      <td>H-V interval</td>\n\n      <td>&#8593;</td>\n\n      <td>-</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Block conversion of thyroxine to trilodothyronine</td>\n\n      <td>+++</td>\n\n      <td>-</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">2.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=6779&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Oral_v_intravenous_amiodaro.htm</title></head></div><div class=\"graphic_footnotes\">A-H interval: time from initial rapid deflection of the atrial wave to the initial rapid deflection of the His bundle potential; H-V interval: time from initial deflection of the His bundle potential to the onset of ventricular activity; +: yes or present; -: no or absent; â : increase; â: decrease.<br />Comparison of the electropharmacologic effects of oral and intravenous amiodarone. Compared to oral amiodarone, the intravenous preparation produces a much lesser increase in the action potential duration in atrial and ventricular myocardium and a minimal increase in the atrial and ventricular refractory periods. As a result, there is little or no increase in QRS duration and the QT interval, respectively. Intravenous amiodarone also has little effect on sinus cycle length and has vasodilator activity that triggers an increase in sympathetic activity; both of these effects result in little or no slowing of the sinus rate. Lastly, the intravenous preparation may have more potent and more rapid antiadrenergic activity.</div><div class=\"graphic_reference\">Data from: Desai AD, Chun S, Sung RJ. Ann Intern Med 1997; 127:294.</div><div id=\"graphicVersion\">Graphic 79689 Version 3.0</div></div></div>"},"79690":{"type":"graphic_picture","displayName":"Extraocular muscle entrapment orbital floor fracture","title":"Extraocular muscle entrapment associated with an orbital floor fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Extraocular muscle entrapment associated with an orbital floor fracture</div><div class=\"cntnt\"><img style=\"width:366px; height:109px;\" src=\"images/EM/79690_Extraocular_muscle_entrapm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This adolescent patient was hit in the left eye with a baseball. The photograph demonstrates limitation of left upward gaze due to entrapment of the inferior rectus muscle.</div><div class=\"graphic_reference\">Courtesy of Mark Neuman, MD.</div><div id=\"graphicVersion\">Graphic 79690 Version 3.0</div></div></div>"},"79691":{"type":"graphic_table","displayName":"Causes of peptic ulcer disease","title":"Etiologies and disease associations for peptic ulcer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiologies and disease associations for peptic ulcer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Ulcers due to defined mechanisms </td> </tr> <tr> <td class=\"sublist1_start\">Infection </td> </tr> <tr> <td class=\"sublist1\">Helicobacter pylori </td> </tr> <tr> <td class=\"sublist1\">HSV </td> </tr> <tr> <td class=\"sublist1\">CMV </td> </tr> <tr> <td class=\"sublist1\">Helicobacter heilmannii</td> </tr> <tr> <td class=\"sublist1\">Other rare infections: TB, syphilis, mucormycosis, etc</td> </tr> <tr> <td class=\"sublist1_start\">Drug exposure (all probably worse when combined with NSAIDs or in high risk subjects) </td> </tr> <tr> <td class=\"sublist1\">NSAIDs and aspirin including low dose aspirin </td> </tr> <tr> <td class=\"sublist1\">Bisphosphonates (probably when combined with NSAIDs) </td> </tr> <tr> <td class=\"sublist1\">Clopidogrel (when combined with NSAIDs or in high risk subjects) </td> </tr> <tr> <td class=\"sublist1\">Corticosteroids (when combined with NSAIDs) </td> </tr> <tr> <td class=\"sublist1\">Sirolimus </td> </tr> <tr> <td class=\"sublist1\">Spironolactone (probable, no data with NSAID cotherapy) </td> </tr> <tr> <td class=\"sublist1\">Mycophenolate mofetil </td> </tr> <tr> <td class=\"sublist1\">Potassium chloride </td> </tr> <tr> <td class=\"sublist1\">Chemotherapy (eg, hepatic infusion with 5-fluorouracil) </td> </tr> <tr> <td class=\"sublist1_start\">Hormonal or mediator-induced, including acid hypersecretory states </td> </tr> <tr> <td class=\"sublist1\">Gastrinoma (Zollinger-Ellison syndrome) </td> </tr> <tr> <td class=\"sublist1\">Systemic mastocytosis </td> </tr> <tr> <td class=\"sublist1\">Basophilia in myeloproliferative disease </td> </tr> <tr> <td class=\"sublist1\">Antral G cell hyperfunction (existence independent of H. pylori is debatable) </td> </tr> <tr> <td class=\"sublist1_start\">Post surgical </td> </tr> <tr> <td class=\"sublist1\">Antral exclusion </td> </tr> <tr> <td class=\"sublist1\">Post-gastric bypass </td> </tr> <tr> <td>Vascular insufficiency including crack cocaine use</td> </tr> <tr> <td>Mechanical: Duodenal obstruction (eg, annular pancreas)</td> </tr> <tr> <td>Radiation therapy</td> </tr> <tr> <td class=\"sublist1_start\">Infiltrating disease </td> </tr> <tr> <td class=\"sublist1\">Sarcoidosis </td> </tr> <tr> <td class=\"sublist1\">Crohn disease </td> </tr> <tr> <td class=\"subtitle1_single\">Idiopathic peptic ulcer </td> </tr> <tr> <td>Non-Helicobacter pylori, non-NSAID peptic ulcer</td> </tr> <tr> <td class=\"subtitle1_single\">Comorbid ulcers associated with decompensated chronic disease or acute multisystem failure </td> </tr> <tr> <td>Stress intensive care unit ulcers</td> </tr> <tr> <td>Cirrhosis</td> </tr> <tr> <td>Organ transplantation</td> </tr> <tr> <td>Renal failure</td> </tr> <tr> <td>Chronic obstructive pulmonary disease (secondary to smoking)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HSV: herpes simplex virus; CMV: cytomegalovirus; NSAID: nonsteroidal anti-inflammatory drug; TB: tuberculosis.</div><div class=\"graphic_reference\">Courtesy of Andrew H Soll, MD.</div><div id=\"graphicVersion\">Graphic 79691 Version 4.0</div></div></div>"},"79692":{"type":"graphic_diagnosticimage","displayName":"Alveolar microlithiasis PA","title":"Alveolar microlithiasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Alveolar microlithiasis</div><div class=\"cntnt\"><img style=\"width:356px; height:379px;\" src=\"images/PULM/79692_Alveolar_microlithiasis_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows multiple calcified micronodules due to small intraalveolar calcospherites. A dark rind of noninvolved lung separates the pleura from the involved parenchyma and is called the &quot;black pleura sign.&quot; It is actually caused by paraseptal emphysema. The cardiac silhouette is darker than the confluent calcified lung opacities.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 79692 Version 3.0</div></div></div>"},"79694":{"type":"graphic_diagnosticimage","displayName":"Proximal fibular fracture - Adult","title":"Proximal fibula fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proximal fibula fracture</div><div class=\"cntnt\"><img style=\"width:270px; height:360px;\" src=\"images/RHEUM/79694_Adult_proximal_fibular_frac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This set of anteroposterior and lateral radiographs of the knee and lower leg shows a transverse fracture of the proximal fibula.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD.</div><div id=\"graphicVersion\">Graphic 79694 Version 3.0</div></div></div>"},"79695":{"type":"graphic_picture","displayName":"Eruptive syringoma - shoulder","title":"Eruptive syringoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eruptive syringoma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/79695_Eruptive_syringoma_shoulder.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple flesh-colored and hyperpigmented small papules are present on the shoulder and chest.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 79695 Version 3.0</div></div></div>"},"79697":{"type":"graphic_figure","displayName":"Structure eltrombopag","title":"Structure of eltrombopag (Promacta, Revolade)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Structure of eltrombopag (Promacta, Revolade)</div><div class=\"cntnt\"><img style=\"width:279px; height:493px;\" src=\"images/HEME/79697_Structure_eltrombopag.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Eltrombopag [3'-{N'-[1-(3,4-Dimethyl-phenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid] has an acidic (COOH) group at one end, lipophilic (CH3) groups at the other end, and a metal chelate group in the center that create a potent, orally available TPO non-peptide agonist.</div><div class=\"graphic_reference\">Courtesy of Dr. Richard J Frankovitch and Julian Jenkins, GlaxoSmithKline, Collegeville, PA.</div><div id=\"graphicVersion\">Graphic 79697 Version 2.0</div></div></div>"},"79699":{"type":"graphic_figure","displayName":"Body composition","title":"Five perspectives on body composition","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Five perspectives on body composition</div><div class=\"cntnt\"><img style=\"width:513px; height:332px;\" src=\"images/ENDO/79699_Body_composition.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this figure, the human body is classified into increasingly general categories, proceeding from the atomic level through molecular, cellular, tissue-system, and whole body. Each perspective is characterized by a set of unique components, which define its measurement parameters.</div><div class=\"graphic_footnotes\">ECS: extracellular solids; ECF: extracellular fluid.</div><div class=\"graphic_reference\">Adapted from: Wang Z, Pierson RN, Heymsfield SB. The five-level model: a new approach to organizing body-composition research. Am J Clin Nutr 1992; 56:19.</div><div id=\"graphicVersion\">Graphic 79699 Version 5.0</div></div></div>"},"79701":{"type":"graphic_diagnosticimage","displayName":"2D TTE two-chamber descending thoracic aorta","title":"Two-dimensional transthoracic echocardiogram (2D TTE) from a modified two-chamber view showing the descending thoracic aorta","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) from a modified two-chamber view showing the descending thoracic aorta</div><div class=\"cntnt\"><img style=\"width:207px; height:384px;\" src=\"images/CARD/79701_2_4_chamber_thor_aorta_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The descending thoracic aorta (T Ao) can be imaged from the apical two- and four-chamber view. Posterior angulation of the transducer (panel A) often opens the T Ao such that it can be seen in its long axis. Major pathology such as aneurysms can often be detected in this way. Anterior angulation in the apical two chamber view (panel B) demonstrates the proximal aortic arch (Ao).</div><div class=\"graphic_footnotes\">LA: left atrium; LV: left ventricle; rpa: right pulmonary artery.</div><div id=\"graphicVersion\">Graphic 79701 Version 7.0</div></div></div>"},"79702":{"type":"graphic_waveform","displayName":"Early transition tutorial","title":"Early transition (counterclockwise rotation)","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Early transition (counterclockwise rotation)</div><div class=\"cntnt\"><img style=\"width:506px; height:125px;\" src=\"images/CARD/79702_Early_transition_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tall R waves are seen earlier than normal across the precordium, in lead V2 in this example.</div><div id=\"graphicVersion\">Graphic 79702 Version 2.0</div></div></div>"},"79703":{"type":"graphic_table","displayName":"Amylin and gluc homeostasis","title":"The role of amylin in glucose homeostasis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The role of amylin in glucose homeostasis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">&nbsp;</td>\n\n      <td class=\"subtitle1\">Amylin</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Deficiency</td>\n\n      <td>Type 1, type 2 diabetes</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Site of synthesis</td>\n\n      <td>Pancreatic beta cells</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Glucose-dependent stimulation of insulin secretion</td>\n\n      <td>No</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Reduction of gastric emptying</td>\n\n      <td>Yes</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Reduction of inappropriate glucagon secretion</td>\n\n      <td>Yes</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Weight loss</td>\n\n      <td>Yes</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Beta cell proliferation/regeneration</td>\n\n      <td>Unknown</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Therapies</td>\n\n      <td>Pramlintide (Symlin)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Target population</td>\n\n      <td>Type 1 diabetes and insulin-treated type 2 diabetes</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 79703 Version 1.0</div></div></div>"},"79706":{"type":"graphic_picture","displayName":"North American yellow jackets","title":"North American yellow jackets","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">North American yellow jackets</div><div class=\"cntnt\"><img style=\"width:320px; height:238px;\" src=\"images/PC/79706_North_American_yellow_jacke.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from American Academy of Allergy and Immunology, Monograph on Insect Allergy, 3rd edition, Levine MI, Lockey RF (Eds), 1995.</div><div id=\"graphicVersion\">Graphic 79706 Version 2.0</div></div></div>"},"79707":{"type":"graphic_figure","displayName":"FEV1 growth curves in boys","title":"FEV1 growth curves for boys","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">FEV1 growth curves for boys</div><div class=\"cntnt\"><img style=\"width:332px; height:316px;\" src=\"images/PULM/79707_FEV1_growth_curves.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Growth curves FEV<sub>1</sub> for healthy boys showing increase in FEV<sub>1</sub> with increasing height.</div><div class=\"graphic_footnotes\">FEV<SUB>1</SUB>: forced expiratory volume in one second.</div><div class=\"graphic_reference\">Redrawn from: Wang X, Dockery DW, Wypij D, et al. Pediatr Pulmonol 1993; 15:75.</div><div id=\"graphicVersion\">Graphic 79707 Version 3.0</div></div></div>"},"79709":{"type":"graphic_picture","displayName":"Verrucous endocarditis in SLE","title":"Libman-Sacks verrucous endocarditis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Libman-Sacks verrucous endocarditis</div><div class=\"cntnt\"><img style=\"width:360px; height:235px;\" src=\"images/RHEUM/79709_Verrucous_endocarditis_in_S.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Verrucous endocarditis with valvular vegetations (arrows) in a 52-year-old woman with systemic lupus erythematosus who died of pneumonia and chronic interstitial pneumonitis. The vegetations had not been observed by echocardiography, although a cardiac murmur had been heard by auscultation. A cerebrovascular accident was also found at autopsy.</div><div class=\"graphic_reference\">Courtesy of Peter H Schur, MD.</div><div id=\"graphicVersion\">Graphic 79709 Version 2.0</div></div></div>"},"79711":{"type":"graphic_diagnosticimage","displayName":"Tumor bleeding 14c","title":"Postembolization angiogram of one of the left intercostal arteries","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Postembolization angiogram of one of the left intercostal arteries</div><div class=\"cntnt\"><img style=\"width:540px; height:495px;\" src=\"images/OBGYN/79711_Tumor_bleeding_14c.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Occlusion of the left intercostal artery (arrow) after embolization is demonstrated.</div><div id=\"graphicVersion\">Graphic 79711 Version 2.0</div></div></div>"},"79712":{"type":"graphic_table","displayName":"Causes of sideroblastic anemia","title":"Classification and causes of the sideroblastic anemias","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification and causes of the sideroblastic anemias</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Congenital</td> </tr> <tr> <td class=\"subtitle2_single\">Non-syndromic</td> </tr> <tr> <td class=\"indent1\">X-linked (XLSA)</td> </tr> <tr> <td class=\"indent1\">Mitochondrial transporter SLC25A38 defects</td> </tr> <tr> <td class=\"indent1\">Mitochondrial HSPA9 defects&nbsp;</td> </tr> <tr> <td class=\"indent1\">Glutaredoxin 5 deficiency</td> </tr> <tr> <td class=\"indent1\">Erythropoietic protoporphyria</td> </tr> <tr> <td class=\"subtitle2_single\">Syndromic</td> </tr> <tr> <td class=\"indent1\">X-linked with ataxia (XLSA/A)</td> </tr> <tr> <td class=\"indent1\">Sideroblastic anemia, B cell immunodeficiency, periodic fevers, and developmental delay (SIFD)</td> </tr> <tr> <td class=\"indent1\">Myopathy, lactic acidosis and sideroblastic anemia (MLASA) and variants&nbsp;</td> </tr> <tr> <td class=\"indent1\">Pearson marrow-pancreas syndrome</td> </tr> <tr> <td class=\"indent1\">Thiamine responsive megaloblastic anemia (TRMA)</td> </tr> <tr> <td class=\"subtitle2_single\">Syndromic or non-syndromic</td> </tr> <tr> <td class=\"indent1\">Autosomal of unknown cause</td> </tr> <tr> <td class=\"indent1\">Sporadic congenital of unknown cause</td> </tr> <tr> <td class=\"subtitle1_single\">Acquired</td> </tr> <tr> <td class=\"subtitle2_single\">Clonal/neoplastic</td> </tr> <tr> <td class=\"indent1\">MDS with ring sideroblasts and single lineage dysplasia (MDS-RS-SLD)</td> </tr> <tr> <td class=\"indent1\">MDS with ring sideroblasts and multilineage dysplasia (MDS-RS-MLD)</td> </tr> <tr> <td class=\"indent1\">Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)</td> </tr> <tr> <td class=\"subtitle2_single\">Metabolic/reversible</td> </tr> <tr> <td class=\"indent1\">Alcoholism</td> </tr> <tr> <td class=\"indent1\">Drugs (eg, isoniazid, chloramphenicol, linezolid)</td> </tr> <tr> <td class=\"indent1\">Copper deficiency (zinc toxicity)</td> </tr> <tr> <td class=\"indent1\">Hypothermia</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate content on sideroblastic anemias for information on the evaluation and management.</div><div class=\"graphic_footnotes\">MDS: Myelodysplastic syndrome</div><div id=\"graphicVersion\">Graphic 79712 Version 18.0</div></div></div>"},"79716":{"type":"graphic_table","displayName":"Thoracic effects of radiation","title":"Thoracic effects of radiation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Thoracic effects of radiation</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\t<tbody>\n\t\t<tr><td>Radiation dermatitis</td></tr>\n\t\t\t\t\t\t<tr><td>Rib fractures</td></tr>\n\t\t\t\t\t\t<tr><td>Bronchitis</td></tr>\n\t\t\t\t\t\t<tr><td>Pleural effusion</td></tr>\n\t\t\t\t\t\t<tr><td>Hemoptysis</td></tr>\n\t\t\t\t\t\t<tr><td>Airway obstruction</td></tr>\n\t\t\t\t\t\t<tr><td>Pneumonitis</td></tr>\n\t\t\t\t\t\t<tr><td>Pulmonary fibrosis</td></tr>\n\t\t\t\t\t\t<tr><td>Pulmonary vascular damage</td></tr>\n\t\t\t\t\t\t<tr><td>Esophagitis</td></tr>\n\t\t\t\t\t\t<tr><td>Pericarditis</td></tr>\n\t\t\t\t\t\t<tr><td>Pneumothorax</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table></div><div id=\"graphicVersion\">Graphic 79716 Version 1.0</div></div></div>"},"79717":{"type":"graphic_picture","displayName":"Acrokeratosis paraneoplastica elbow","title":"Acrokeratosis paraneoplastica (Bazex's syndrome)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acrokeratosis paraneoplastica (Bazex's syndrome)</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/DERM/79717_Acrokera_paraneoplas_elbow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous, scaly plaques are present on the arm.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 79717 Version 4.0</div></div></div>"},"79719":{"type":"graphic_table","displayName":"Component-resolved diagnostics of plant-food allergens","title":"Component-resolved diagnostics of plant-food allergens","html":"<div class=\"graphic\"><div style=\"width: 626px\" class=\"figure\"><div class=\"ttl\">Component-resolved diagnostics of plant-food allergens</div><div class=\"cntnt\"><img style=\"width:606px; height:548px;\" src=\"images/ALLRG/79719_Risk_syst_aller_plant_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The table shows how the component-resolved diagnostics can be used to estimate the risk of anaphylaxis (Ana) in a patient sensitized to various pollen-related plant allergens. Patients who are sensitized to allergens in the profilin and pathogenesis-related-protein-10 (PRP-10) groups (shown in green and purple) have a relatively low risk of anaphylaxis. Those sensitized to lipid transfer proteins (shown in orange) have an intermediate risk. The highest rate of anaphylaxis is observed in patients sensitized to more stable proteins that are not cross-reactive with pollen allergens, such as storage seed proteins, albumins, and globulins (shown in yellow). The specific allergens circled in red have been implicated in systemic reactions.</div><div class=\"graphic_footnotes\">* Reactive with birch tree pollen.<br />Â¶ Reactive with timothy grass pollen.</div><div id=\"graphicVersion\">Graphic 79719 Version 9.0</div></div></div>"},"79721":{"type":"graphic_picture","displayName":"Loopmarks scar","title":"Loopmarks scar","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Loopmarks scar</div><div class=\"cntnt\"><img style=\"width:432px; height:190px;\" src=\"images/EM/79721_Loopmarks_scar.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Stephen Ludwig, MD.</div><div id=\"graphicVersion\">Graphic 79721 Version 1.0</div></div></div>"},"79722":{"type":"graphic_table","displayName":"Mature and total tryptase in anaphylaxis and other conditions","title":"Mature and total tryptase levels in anaphylaxis, systemic mastocytosis, and alpha-tryptasemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mature and total tryptase levels in anaphylaxis, systemic mastocytosis, and alpha-tryptasemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Clinical condition</td> <td class=\"subtitle1\" colspan=\"2\">Tryptase levels (ng/mL)</td> <td class=\"subtitle1\" rowspan=\"2\">Total/mature tryptase ratio</td> </tr> <tr> <td class=\"subtitle2\">Total</td> <td class=\"subtitle2\">Mature</td> </tr> <tr> <td>Normal</td> <td>1 to 11.4*</td> <td>&#60;1</td> <td>Not applicable</td> </tr> <tr> <td>Systemic anaphylaxis (acute)</td> <td>&#62;1.2<sup>&#182;</sup> baseline + 2</td> <td>&#62;1<sup>&#916;</sup></td> <td>&#60;10</td> </tr> <tr> <td>Systemic mastocytosis (nonacute)</td> <td>&#62;20<sup>&#916;</sup></td> <td>&#60;1</td> <td>&#62;20</td> </tr> <tr> <td>Alpha-tryptasemia&nbsp;</td> <td>&#62;8 and &#60;40<sup>&#9674;</sup>&nbsp;</td> <td>&#60;1&nbsp;</td> <td>Not applicable</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Reference ranges may vary slightly among different laboratories.<br />Â¶&nbsp;Level related to clinical severity (hypotension), timing of sample collection in relation to onset of signs and symptoms, and nature of the anaphylactic stimulus.<br />Î&nbsp;Reflects primarily the total body burden of mast cells when subject is in a nonanaphylactic state. A baseline total tryptase level &gt;11.4 ng/mL should raise the possibility of an underlying clonal mast cell disorder (eg, systemic mastocytosis), <FONT color=black>particularly in a subject with a history of systemic anaphylaxis</FONT>&nbsp;or a primary mast cell activation disorder.<br />â <SPAN style=\"COLOR: black\">Reflects tryptase alpha/beta 1 (<EM>TPSAB1</EM>) gene copy number variation with increased expression of alpha-tryptase. Tryptase level range may expand as more families are examined.</SPAN></div><div id=\"graphicVersion\">Graphic 79722 Version 15.0</div></div></div>"},"79723":{"type":"graphic_figure","displayName":"Activation of G proteins","title":"Activation of G proteins","html":"<div class=\"graphic\"><div style=\"width: 487px\" class=\"figure\"><div class=\"ttl\">Activation of G proteins</div><div class=\"cntnt\"><img style=\"width:467px; height:273px;\" src=\"images/GAST/79723_Activation_of_G_proteins.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upon binding of hormone to the receptor, a change occurs in the structure of the hormone-receptor complex such that a G protein is recruited to the membrane and activated. G proteins are composed of three subunits (alpha, beta, and gamma). G protein stimulation then initiates a variety of cellular processes.</div><div class=\"graphic_reference\">Courtesy of Michael A Shetzline, MD, PhD and Rodger A Liddle, MD.</div><div id=\"graphicVersion\">Graphic 79723 Version 2.0</div></div></div>"},"79726":{"type":"graphic_picture","displayName":"AIDS-related Kaposis sarcoma - plaque","title":"AIDS-related Kaposi's sarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">AIDS-related Kaposi's sarcoma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/79726_Kaposis_sarcoma_plaque.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A violaceous plaque representing Kaposi's sarcoma is shown.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 79726 Version 3.0</div></div></div>"},"79727":{"type":"graphic_figure","displayName":"Vulvar anatomy 2","title":"Vulvar anatomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vulvar anatomy</div><div class=\"cntnt\"><img style=\"width:314px; height:432px;\" src=\"images/OBGYN/79727_Vulvar_anatomy_2_edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission. Copyright &#169; 2002 Dawn Danby &amp; Paul Waggoner.</div><div id=\"graphicVersion\">Graphic 79727 Version 2.0</div></div></div>"},"79730":{"type":"graphic_figure","displayName":"Noninvasive tech pred accuracy","title":"Dobutamine echocardiography is the most useful technique for predicting improvement of LV function after CABG","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dobutamine echocardiography is the most useful technique for predicting improvement of LV function after CABG</div><div class=\"cntnt\"><img style=\"width:425px; height:274px;\" src=\"images/CARD/79730_Noninvasivetechpredaccur.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pooled data demonstrate that improvement in regional left ventricular (LV) function is best predicted by dobutamine echocardiography which had&nbsp;positive and negative predictive accuracies of 83 and 81 percent, respectively, and positron emission tomography (PET) with enhanced fluorodexyglucose (FDG) uptake relative to myocardial blood flow (MBF) which had&nbsp;positive and negative predictive accuracies of 82 and 83 percent, respectively.&nbsp;By contrast, the postive and negative predictive accuracies with thallium single-photon emission computed tomography (SPECT) are 69 and 90 percent, respectively.</div><div class=\"graphic_footnotes\">CABG: coronary artery bypass grafting; TCA: thermal coronary angiography.</div><div class=\"graphic_reference\">Data from: Bonow RO. Circulation 1996; 94:2674.</div><div id=\"graphicVersion\">Graphic 79730 Version 3.0</div></div></div>"},"79731":{"type":"graphic_figure","displayName":"Major pathways of T cell activation","title":"Major pathways of T cell activation","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Major pathways of T cell activation</div><div class=\"cntnt\"><img style=\"width:502px; height:352px;\" src=\"images/ALLRG/79731_Major_pathways.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SLP-76: Src homology&nbsp;2 (SH2)&nbsp;domain-containing leukocyte protein of 76 kiloDaltons; LAT: linker for activation of T cells; Grb2: growth factor receptor-bound protein 2; Shc: SH2 domain-containing transforming protein (adaptor protein); Sos: son of sevenless protein (guanine nucleotide exchange factor); Ras: reticular activating system protein (small guanosine triphosphate hydrolases); MAPK: mitogen-activated protein kinase; AP-1: activator protein 1 (transcription factor); Jun: a proto-oncogene and transcription factor; Fos: a proto-oncogene and transcription factor; Lck: lymphocyte-specific protein-tyrosine kinase; ZAP-70: zeta-chain-associated protein kinase 70 kiloDalton; ITAM: immunoreceptor tyrosine-based activation motif; Vav: a proto-oncogene and guanine nucleotide exchange factor; PI-3K: phosphoinositide 3-kinase; PLC-Î³1: phospholipase C, gamma 1; IP-3: inositol triphosphate; DAG: diacylglycerol; PKC: protein kinase C; NF-ATp: nuclear factor of activated T cells, phosphorylated</div><div id=\"graphicVersion\">Graphic 79731 Version 3.0</div></div></div>"},"79734":{"type":"graphic_picture","displayName":"Endoscopy choanal atresia","title":"Endoscopic view of choanal atresia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic view of choanal atresia</div><div class=\"cntnt\"><img style=\"width:348px; height:311px;\" src=\"images/PEDS/79734_Endoscopy_choanal_atresia.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">mt: middle turbinate; it: inferior turbinate; ns: nasal septum; a: atresia \"plate.\"</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 79734 Version 4.0</div></div></div>"},"79735":{"type":"graphic_table","displayName":"White classification","title":"Modified White's classification of diabetes in pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified White's classification of diabetes in pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Class</td> <td class=\"subtitle1\">Description</td> </tr> <tr> <td>A</td> <td>Abnormal GTT before pregnancy at any age or of any duration treated only by diet therapy</td> </tr> <tr> <td>B</td> <td>Onset at age 20 years or older and duration of less than 10 years</td> </tr> <tr> <td>C</td> <td>Onset at age 10 to 19 years or duration of 10 to 19 years</td> </tr> <tr> <td>D</td> <td>Onset before 10 years of age, duration over 20 years, benign retinopathy, or hypertension (not preeclampsia)</td> </tr> <tr> <td>R</td> <td>Proliferative retinopathy or vitreous hemorrhage</td> </tr> <tr> <td>F</td> <td>Nephropathy with over 500 mg/day proteinuria</td> </tr> <tr> <td>RF</td> <td>Criteria for both classes R and F</td> </tr> <tr> <td>G</td> <td>Many pregnancy failures</td> </tr> <tr> <td>H</td> <td>Evidence of arteriosclerotic heart disease</td> </tr> <tr> <td>T</td> <td>Prior renal transplantation</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Gestational diabetes</td> </tr> <tr> <td class=\"indent1\">A1</td> <td>Diet-controlled gestational diabetes</td> </tr> <tr> <td class=\"indent1\">A2</td> <td>Insulin-treated gestational diabetes</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Classes B through T require insulin treatment.</div><div class=\"graphic_footnotes\">GTT: glucose tolerance test.</div><div class=\"graphic_reference\">Adapted from: Hare JW, White JP. Diabetes Care 1980; 3:394.</div><div id=\"graphicVersion\">Graphic 79735 Version 7.0</div></div></div>"},"79736":{"type":"graphic_figure","displayName":"Time of abortus expulsion","title":"Time of expulsion of conceptus in 1720 women with successful medical termination of pregnancy","html":"<div class=\"graphic\"><div style=\"width: 515px\" class=\"figure\"><div class=\"ttl\">Time of expulsion of conceptus in 1720 women with successful medical termination of pregnancy</div><div class=\"cntnt\"><img style=\"width:495px; height:317px;\" src=\"images/OBGYN/79736_Time_of_abortus_expulsion.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The women received oral mifepristone 600 mg&nbsp;at visit 1 and oral misoprostol 400 mcg two days later (visit 2). \"Uncertain\" indicates that expulsion occurred within the first 24 hours after misoprostol was given, but the exact time was not known.</div><div class=\"graphic_reference\">Data from Spitz, IM, Bardin, CW, Benton, L, Robbins, A. N Engl J Med 1998; 388:1241.</div><div id=\"graphicVersion\">Graphic 79736 Version 2.0</div></div></div>"},"79737":{"type":"graphic_table","displayName":"Bleeding disorders in children","title":"Distinction between purpuric disorders and disorders of coagulation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distinction between purpuric disorders and disorders of coagulation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical findings</td> <td class=\"subtitle1\">Disorders of coagulation*</td> <td class=\"subtitle1\">Purpuric disorders<sup>&#182;</sup></td> </tr> <tr> <td>Skin &ndash; Petechiae</td> <td>Not usually seen</td> <td>Characteristic</td> </tr> <tr> <td>Ecchymoses</td> <td>Common&nbsp;&ndash; Large one or more</td> <td>Characteristic&nbsp;&ndash; Small or many scattered</td> </tr> <tr> <td>Soft tissue hematoma</td> <td>Characteristic</td> <td>Rare</td> </tr> <tr> <td>Joint hemorrhages</td> <td>Characteristic &ndash; Hallmark of the disease</td> <td>Not usually seen</td> </tr> <tr> <td>Delayed bleeding</td> <td>Common</td> <td>Rare</td> </tr> <tr> <td>Bleeding from superficial skin abrasions</td> <td>Uncommon</td> <td>Common and persistent</td> </tr> <tr> <td>Family history of bleeding</td> <td>Common</td> <td>Rare</td> </tr> <tr> <td>Sex of the patient</td> <td>Predominantly male</td> <td>Predominantly female</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Hemophilia and other coagulation disorders.<br />Â¶ Disorders of platelets and blood vessels, including von Willebrand disease.</div><div id=\"graphicVersion\">Graphic 79737 Version 6.0</div></div></div>"},"79742":{"type":"graphic_diagnosticimage","displayName":"Prenatal ultrasound of SUA in hypercoiled cord","title":"Prenatal ultrasound image of a single umbilical artery in a hypercoiled umbilical cord","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound image of a single umbilical artery in a hypercoiled umbilical cord</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/OBGYN/79742_Sing_umbil_art_hypercoil.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Conventional two-dimensional ultrasound shows a potential pitfall in the diagnosis of single umbilical artery. The diagnosis can be easily missed in hypercoiled umbilical cords.</div><div class=\"graphic_footnotes\">v: vein; a: single umbilical artery.</div><div id=\"graphicVersion\">Graphic 79742 Version 3.0</div></div></div>"},"79743":{"type":"graphic_figure","displayName":"Blood supply venous and lymphatic drainage of the rectum","title":"Blood supply, venous and lymphatic drainage of the rectum","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Blood supply, venous and lymphatic drainage of the rectum</div><div class=\"cntnt\"><img style=\"width:530px; height:671px;\" src=\"images/SURG/79743_Blood-lymph-rectum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure represents the blood supply to the rectum and the pathways for lymphatic and venous drainage. Note the lateral pathways from the middle rectum.</div><div id=\"graphicVersion\">Graphic 79743 Version 2.0</div></div></div>"},"79744":{"type":"graphic_table","displayName":"Bioterrorism agents by category","title":"Potential bioterrorism agents by category","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential bioterrorism agents by category</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Category A agents</td> </tr> <tr> <td class=\"indent1\">Variola major (smallpox)</td> </tr> <tr> <td class=\"indent1\">Bacillus anthracis (anthrax)</td> </tr> <tr> <td class=\"indent1\">Yersinia pestis (plague)</td> </tr> <tr> <td class=\"indent1\">Clostridium botulinum toxin (botulism)</td> </tr> <tr> <td class=\"indent1\">Francisella tularensis (tularemia)</td> </tr> <tr> <td class=\"indent1\">Filoviruses (Ebola, Marburg)</td> </tr> <tr> <td class=\"indent1\">Arenaviruses (Lassa, Junin and related viruses)</td> </tr> <tr> <td class=\"subtitle1_single\">Category B agents</td> </tr> <tr> <td class=\"indent1\">Coxiella burnetii (Q fever)</td> </tr> <tr> <td class=\"indent1\">Brucella spp. (brucellosis)</td> </tr> <tr> <td class=\"indent1\">Burkholderia mallei (glanders)</td> </tr> <tr> <td class=\"indent1\">B. pseudomallei (melioidosis)</td> </tr> <tr> <td class=\"indent1\">Chlamydia psittaci (psittacosis)</td> </tr> <tr> <td class=\"indent1\">Rickettsia prowazekii (typhus fever)</td> </tr> <tr> <td class=\"indent1\">Alphaviruses (eastern equine encephalitis, western equine encephalitis, Venezuelan equine encephalitis)</td> </tr> <tr> <td class=\"indent1\">Ricin toxin</td> </tr> <tr> <td class=\"indent1\">Epsilon toxin of Clostridium perfringens</td> </tr> <tr> <td class=\"indent1\">Staphylococcus enterotoxin B</td> </tr> <tr> <td class=\"indent1\">Salmonella spp.</td> </tr> <tr> <td class=\"indent1\">Shigella dysenteriae</td> </tr> <tr> <td class=\"indent1\">Escherichia coli O157:H7</td> </tr> <tr> <td class=\"indent1\">Vibrio cholerae</td> </tr> <tr> <td class=\"indent1\">Cryptosporidium parvum</td> </tr> <tr> <td class=\"subtitle1_single\">Category C agents</td> </tr> <tr> <td class=\"indent1\">Nipah virus</td> </tr> <tr> <td class=\"indent1\">Hantaviruses</td> </tr> <tr> <td class=\"indent1\">Tickborne hemorrhagic fever viruses</td> </tr> <tr> <td class=\"indent1\">Tickborne encephalitis viruses</td> </tr> <tr> <td class=\"indent1\">Yellow fever</td> </tr> <tr> <td class=\"indent1\">Multidrug-resistant tuberculosis</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The United States Centers for Disease Control and Prevention has ranked various pathogens into these categories based on their potential to cause harm.<br /><strong>Category A</strong> agents are the highest priority. They can cause high mortality, can be grown easily in large quantities, and are resistant to destruction. They are also well suited to airborne dissemination and can thus infect large numbers of people.<br /><strong>Category B</strong> agents are the second highest priority. They are moderately easy to spread but generally cause less morbidity and mortality than Category A agents.<br /><strong>Category C</strong> agents include pathogens that could be engineered for mass dissemination and have significant potential morbidity and/or mortality.</div><div id=\"graphicVersion\">Graphic 79744 Version 3.0</div></div></div>"},"79745":{"type":"graphic_table","displayName":"Differential diagnosis of aseptic meningitis","title":"Differential diagnosis of selected causes of aseptic meningitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of selected causes of aseptic meningitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Viral</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Adenovirus </li> <li>Arboviruses </li> <li>Coxsackieviruses types A and B </li> <li>Cytomegalovirus </li> <li>Echoviruses </li> <li>Encephalomyocarditis virus </li> <li>Epstein-Barr virus </li> <li>Herpes simplex type I </li> <li>Herpes simplex type 2 </li> <li>Human immunodeficiency virus </li> </ul> </td> <td style=\"border-left-color: #ffffff;\"> <ul> <li>Influenza A and B </li> <li>Lymphocytic choriomeningitis virus </li> <li>Measles </li> <li>Mumps </li> <li>Parainfluenza </li> <li>Poliovirus </li> <li>Rotavirus </li> <li>Rubella </li> <li>Vaccinia </li> <li>Varicella-zoster virus </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Bacterial</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li><em>Actinomyces</em> spp </li> <li>Bacterial endocarditis </li> <li><em>Borrelia burgdorferi </em>(Lyme disease) </li> <li><em>Borrelia recurrentis </em>(relapsing fever) </li> <li><em>Brucella</em> spp </li> <li><em>Chlamydia</em> spp </li> <li><em>Leptospira</em> spp </li> <li><em>Mycobacterium tuberculosis</em> </li> <li><em><em>Mycoplasma hominis </em><span>â</span></em></li> </ul> </td> <td style=\"border-left-color: #ffffff;\"> <ul> <li><em>Mycoplasma pneumoniae </em></li> <li><em>Nocardia</em> spp </li> <li>Parameningeal bacterial infection (epidural, subdural abscess) </li> <li>Partially treated bacterial meningitis </li> <li><em>Rickettsia</em> spp </li> <li><em>Spirillum minor </em>(rat bite fever) </li> <li><em>Treponema pallidum </em>(syphilis) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Fungal</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <ul> <li><em>Aspergillus</em> spp </li> <li><em>Blastomyces dermatitidis </em></li> <li><em>Candida </em>spp </li> <li><em>Coccidioides immitis </em></li> <li><em>Cryptococcus neoformans </em></li> <li><em>Histoplasma capsulatum </em></li> <li><em>Sporothrix schenckii </em></li> </ul> </td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Parasitic</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <ul> <li><em>Angiostrongylus cantonensis </em></li> <li><em>Taenia solium </em>(cysticercosis) </li> <li><em>Toxoplasma gondii </em></li> <li><em>Trichenella spiralis </em></li> </ul> </td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Drug</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <ul> <li>Anti-CD3 monoclonal antibody </li> <li>Azathioprine </li> <li>lbuprofen </li> <li>Other NSAIDs </li> <li>Pyridium (phenazopyridine) </li> <li>Trimethoprim-sulfamethoxazole </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Malignancy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <ul> <li>Leukemia </li> <li>Lymphoma </li> <li>Metatstatic carcinomas and adenocarcinomas </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Autoimmune</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <ul> <li>Beh&#231;et's disease </li> <li>Sarcoid </li> <li>Systemic lupus erythematosus </li> <li>Vogt-Koyanagi-Harada syndrome </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Other</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ul> <li>Epidermoid cyst </li> <li>Postvaccination </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NSAIDs: nonsteroidal anti-inflammatory drugs.</div><div class=\"graphic_reference\">Modified from Connolly KJ, Hammer SM. The acute aseptic meningitis syndrome. Infect Dis Clin North Am 1990; 4:599.</div><div id=\"graphicVersion\">Graphic 79745 Version 4.0</div></div></div>"},"79746":{"type":"graphic_figure","displayName":"Flail chest","title":"Flail chest","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Flail chest</div><div class=\"cntnt\"><img style=\"width:542px; height:211px;\" src=\"images/EM/79746_Flail_chest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Flail chest occurs when multiple rib fractures result in a loss of stability of the chest wall. The loss of continuity with the remainder of the rib cage causes the flail segment to move paradoxically. <br />(B) Pressure within the chest is negative during inspiration, causing the flail segment to retract. <br />(C) With expiration, intrathoracic pressure becomes positive and the flail segment bulges.</div><div id=\"graphicVersion\">Graphic 79746 Version 3.0</div></div></div>"},"79747":{"type":"graphic_picture","displayName":"Traumatic hyphema from blunt trauma","title":"Traumatic hyphema from blunt trauma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Traumatic hyphema from blunt trauma</div><div class=\"cntnt\"><img style=\"width:360px; height:241px;\" src=\"images/EM/79747_Microhyphema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyphemas. This seven-year-old girl was struck by a hard rubber ball and presented with blurred vision. The 1-mm hyphema (arrow) was only visible when she was upright.</div><div class=\"graphic_reference\">Reproduced with permission from: Trauma: Head and Neck. In: Atlas of Pediatric Emergency Medicine. Fleisher GR, Ludwig S, Baskin MN (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright Â© 2004 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 79747 Version 14.0</div></div></div>"},"79751":{"type":"graphic_diagnosticimage","displayName":"2D TEE and M-mode images parasternal short axis aortic valve","title":"Two-dimensional transthoracic echocardiogram (2D TTE) and M-mode echocardiographic images along with a phonocardiogram of the normal aortic root from the parasternal short axis position","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) and M-mode echocardiographic images along with a phonocardiogram of the normal aortic root from the parasternal short axis position</div><div class=\"cntnt\"><img style=\"width:541px; height:225px;\" src=\"images/CARD/79751_MmodenormalaortaandAV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A shows the short axis view from a two-dimensional echocardiogram recorded at the base of the heart at the level of the aortic valve; the line (M) bisecting the aortic valve represents the plane of the M-mode beam used to generate the M-mode echocardiogram in panel B. The aortic valve opens nearly to the aortic (Ao) walls (panel B) and while opened it has a box-like configuration. The line marks the peak of the R wave on the ECG. There is a brisk anterior systolic motion of the entire Ao root and even faster earlier diastolic relaxation (posterior motion); the posterior movement of the aortic root occurs predominantly in early diastole with very little movement in late diastole. This pattern occurs in young healthy hearts that rely predominantly on early relaxation for filling rather than atrial contraction. The M-mode echocardiogram with simultaneous phonocardiogram is seen in panel C. The vibrations on the posterior moving noncoronary aortic leaflet (down arrows) are similar in timing and frequency with the low intensity, early systolic \"innocent\" murmur recorded on the phonocardiogram (up arrows). These vibrations are common in normal valves with normal or elevated cardiac output.</div><div id=\"graphicVersion\">Graphic 79751 Version 6.0</div></div></div>"},"79753":{"type":"graphic_figure","displayName":"Head control","title":"Infant head control","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Infant head control</div><div class=\"cntnt\"><img style=\"width:524px; height:680px;\" src=\"images/PEDS/79753_Head_control.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">By 40 weeks conceptional age, the infant has sufficient neck and truncal strength to normally maintain the head in line with the trunk for one to two seconds while being pulled from a supine to sitting position. In infants with hypotonia (shown in the inset), the head lags behind as the infant is pulled from the supine to sitting position and continues to lag when the sitting position is reached.</div><div id=\"graphicVersion\">Graphic 79753 Version 2.0</div></div></div>"},"79754":{"type":"graphic_table","displayName":"Causes of benign PSA elevation","title":"Benign causes for an elevated PSA","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Benign causes for an elevated PSA</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Benign prostatic hyperplasia</td>\n</tr>\n<tr>\n<td>Acute prostatitis</td>\n</tr>\n<tr>\n<td>Subclinical inflammation</td>\n</tr>\n<tr>\n<td>Prostate biopsy</td>\n</tr>\n<tr>\n<td>Cystoscopy</td>\n</tr>\n<tr>\n<td>TURP</td>\n</tr>\n<tr>\n<td>Urinary retention</td>\n</tr>\n<tr>\n<td>Ejaculation</td>\n</tr>\n<tr>\n<td>Digital rectal examination</td>\n</tr>\n<tr>\n<td>Perineal trauma</td>\n</tr>\n<tr>\n<td>Prostatic infarction</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=57787&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Causes_of_benign_PSA_elevat.htm</title></head></div><div class=\"graphic_footnotes\">PSA: prostate-specific antigen; TURP: transurethral resection of the prostate.</div><div id=\"graphicVersion\">Graphic 79754 Version 2.0</div></div></div>"},"79756":{"type":"graphic_algorithm","displayName":"Antibiotic prophylaxis in dermatologic surgery","title":"Recommendations for antibiotic prophylaxis in dermatologic surgery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Recommendations for antibiotic prophylaxis in dermatologic surgery</div><div class=\"cntnt\"><img style=\"width:330px; height:365px;\" src=\"images/DERM/79756_Antibioticprophydermsurg.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IE: infective endocarditis; PJI: prosthetic joint infection; HIV: human immunodeficiency virus.<br />* High risk for surgical site infection:&#xD;&#xA;<ul>&#xD;&#xA;    <li>Contaminated or dirty, infected wound</li>&#xD;&#xA;    <li>Groin or below the knee</li>&#xD;&#xA;    <li>Wedge excision of lip or ear</li>&#xD;&#xA;    <li>Skin flaps on nose</li>&#xD;&#xA;    <li>Skin grafting</li>&#xD;&#xA;</ul>&#xD;&#xA;&para; Refer to UpToDate table on antibiotic prophylaxis for dermatologic surgery in adults.<br />&Delta; High risk for IE:&#xD;&#xA;<ul>&#xD;&#xA;    <li>Prosthetic cardiac valve</li>&#xD;&#xA;    <li>Previous IE</li>&#xD;&#xA;    <li>Congenital heart disease</li>&#xD;&#xA;    <li>Cardiac transplant recipient with valvulopathy</li>&#xD;&#xA;    <li>Unrepaired cyanotic congenital heart defects</li>&#xD;&#xA;    <li>Repaired congenital heart defects with residual defects at or adjacent to the site of prosthetic patch or device</li>&#xD;&#xA;    <li>Congenital heart defect that has been repaired in the previous six months</li>&#xD;&#xA;</ul>&#xD;&#xA;<span class=\"lozenge\">&loz;</span> High risk for hematogenous joint infection:&#xD;&#xA;<ul>&#xD;&#xA;    <li>First two years following joint replacement</li>&#xD;&#xA;    <li>Previous prosthetic joint infection</li>&#xD;&#xA;    <li>Immunocompromised status</li>&#xD;&#xA;    <li>Insulin-dependent diabetes mellitus</li>&#xD;&#xA;    <li>HIV infection</li>&#xD;&#xA;    <li>Malignancy</li>&#xD;&#xA;    <li>Malnutrition</li>&#xD;&#xA;</ul></div><div class=\"graphic_reference\">From: Wright TI, Baddour LM, Berbari EF, et al. Antibiotic prophylaxis in dermatologic surgery: advisory statement 2008. J Am Acad Dermatol 2008; 59:464. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 79756 Version 3.0</div></div></div>"},"79757":{"type":"graphic_table","displayName":"Anemia in older adults","title":"Proposed lower limits of normal for hemoglobin concentration in white and black adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Proposed lower limits of normal for hemoglobin concentration in white and black adults</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\t\t<tr>\n\t\t\t<td class=\"subtitle1\">Group</td>\n\t\t\t<td class=\"subtitle1\">Hemoglobin, g/dL</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td class=\"subtitle2_left\" colspan=\"2\">White men, y</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td class=\"indent1\">20-59</td>\n\t\t\t<td>13.7</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td class=\"indent1\">60+</td>\n\t\t\t<td>13.2</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td class=\"subtitle2_left\" colspan=\"2\">White women, y</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td class=\"indent1\">20-49</td>\n\t\t\t<td>12.2</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td class=\"indent1\">50+</td>\n\t\t\t<td>12.2</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td class=\"subtitle2_left\" colspan=\"2\">Black men, y</td>\n\t\t</tr>\n\t\t<tr>\t\t\t\n\t\t\t<td class=\"indent1\">20-59</td>\n\t\t\t<td>12.9</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td class=\"indent1\">60+</td>\n\t\t\t<td>12.7</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td class=\"subtitle2_left\" colspan=\"2\">Black women, y</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td class=\"indent1\">20-49</td>\n\t\t\t<td>11.5</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td class=\"indent1\">50+</td>\n\t\t\t<td>11.5</td>\n\t\t</tr>\n\n\t\t</table>\n\t\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">7.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=24772&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n<mso:Media_Notes msdt:dt=\"string\"></mso:Media_Notes>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Anemia_elderly_adults.htm</title></head></div><div class=\"graphic_lgnd\">Based on Scripps-Kaiser data for the 5th percentiles for the populations in question. NHANES data are considered to be confirmatory. To convert hemoglobin from grams per deciliter to grams per liter, multiply grams per deciliter by 10.</div><div class=\"graphic_reference\">Reproduced from: Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood 2006; 107:1747. Copyright Â© 2006 The American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 79757 Version 5.0</div></div></div>"},"79760":{"type":"graphic_figure","displayName":"Common slow fast AVNRT","title":"Slow-fast form of atrioventricular nodal reentrant tachycardia (AVNRT)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Slow-fast form of atrioventricular nodal reentrant tachycardia (AVNRT)</div><div class=\"cntnt\"><img style=\"width:336px; height:214px;\" src=\"images/CARD/79760_CommonslowfastAVNRT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Representation of dual pathway physiology involving the atrioventricular (AV) node and perinodal atrial tissue in the common form of AVNRT. <br />Left panel: A normal sinus beat (A<SUB>1</SUB>) is conducted through the fast pathway (F) to the final common pathway (fcp) in the AV node and into the Bundle of His. The conduction through the slow pathway (S) runs into the refractory period of the impulse through the fast pathway and is extinguished. <br />Middle panel: A critically timed atrial premature beat (A<SUB>2</SUB>) finds the fast pathway refractory in the antegrade direction but is able to conduct antegrade through the slow pathway, which has a shorter refractory period. If excitability in the fast pathway has recovered by the time the impulse reaches the fcp, there may be retrograde activation of the fast pathway. <br />Right panel: The retrograde impulse throws off an echo to the atrium (A*), and, if the slow pathway has recovered its excitability, the impulse reenters the slow pathway and produces ventricular depolarization V*. If the mechanism persists, a repetitive circuit is established that creates a sustained reentrant tachycardia. The sequence of antegrade (S) and retrograde (F) conduction is called the slow-fast form of AVNRT.</div><div id=\"graphicVersion\">Graphic 79760 Version 5.0</div></div></div>"},"79762":{"type":"graphic_picture","displayName":"King LT device","title":"King LT","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">King LT</div><div class=\"cntnt\"><img style=\"width:229px; height:576px;\" src=\"images/EM/79762_King_LT_device.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: King Systems Corporation. Copyright &#169;2008 King Systems Corporation.</div><div id=\"graphicVersion\">Graphic 79762 Version 2.0</div></div></div>"},"79763":{"type":"graphic_figure","displayName":"Cervical spine joints and ligaments","title":"Cervical spine joints and ligaments","html":"<div class=\"graphic\"><div style=\"width: 627px\" class=\"figure\"><div class=\"ttl\">Cervical spine joints and ligaments</div><div class=\"cntnt\"><img style=\"width:607px; height:389px;\" src=\"images/EM/79763_Cervspinejointsligaments.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The ligaments in the cervical region are shown. Superior to the prominent spinous process of C7 (vertebra prominens), the spinous processes are deeply placed and attached to an overlying nuchal ligament.<br> (B) The ligaments in the thoracic region are shown. The pedicles of the superior two vertebrae have been sawn through and the vertebral arches removed to reveal the posterior longitudinal ligament. Intertransverse, supraspinous, and interspinous ligaments are demonstrated in association with the vertebrae with intact vertebral arches.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AF. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright Â© 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 79763 Version 8.0</div></div></div>"},"79764":{"type":"graphic_figure","displayName":"Three finger rotation from occiput posterior","title":"Three finger digital rotation from occiput posterior","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Three finger digital rotation from occiput posterior</div><div class=\"cntnt\"><img style=\"width:450px; height:647px;\" src=\"images/OBGYN/79764_3-finger_Digital_rotation_occiput_post.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The tips of the index and middle fingers are placed in the anterior segment of the lambdoidal suture near the posterior fontanelle. The fingers are used to flex and slightly dislodge the vertex, rotating the fetal head to the occiput anterior position via rotation of the operator's hand and forearm. The thumb may also be used with gentle downward pressure more anteriorly on the parietal bone to aid in this rotation.</div><div id=\"graphicVersion\">Graphic 79764 Version 4.0</div></div></div>"},"79765":{"type":"graphic_table","displayName":"Criteria for SSI","title":"Criteria for defining a surgical site infection (SSI)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for defining a surgical site infection (SSI)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Superficial incisional SSI</td> </tr> <tr> <td class=\"indent1\">Infection occurs within 30 days after the operation</td> </tr> <tr> <td class=\"indent1\"><strong>AND</strong></td> </tr> <tr> <td class=\"indent1\">Infection involves only skin or subcutaneous tissue of the incision</td> </tr> <tr> <td class=\"sublist2_start\"><strong>AND</strong> at least <strong>ONE</strong> of the following:</td> </tr> <tr> <td class=\"sublist2\">1. Purulent drainage, with or without laboratory confirmation, from the superficial incision.</td> </tr> <tr> <td class=\"sublist2\">2. Organisms isolated from an aseptically obtained culture of fluid or tissue from the superficial incision.</td> </tr> <tr> <td class=\"sublist2\">3. At least one of the following signs or symptoms of infection: pain or tenderness, localized swelling, redness, or heat <strong>AND</strong> superficial incision is deliberately opened by surgeon, <strong>UNLESS</strong> incision is culture-negative.</td> </tr> <tr> <td class=\"sublist2\">4. Diagnosis of superficial incisional SSI by the surgeon or attending physician.</td> </tr> <tr> <td class=\"sublist2_start\">Do <strong>NOT</strong> report the following conditions as SSI:</td> </tr> <tr> <td class=\"sublist2\">1. Stitch abscess (minimal inflammation and discharge confined to the points of suture penetration).</td> </tr> <tr> <td class=\"sublist2\">2. Infection of an episiotomy or newborn circumcision site.</td> </tr> <tr> <td class=\"sublist2\">3. Infected burn wound.</td> </tr> <tr> <td class=\"sublist2\">4. Incisional SSI that extends into the fascial and muscle layers (see deep incisional SSI).</td> </tr> <tr> <td class=\"indent1\">NOTE: Specific criteria are used for identifying infected episiotomy and circumcision sites and burn wounds.</td> </tr> <tr> <td class=\"subtitle1_single\">Deep incisional SSI</td> </tr> <tr> <td class=\"indent1\">Infection occurs within 30 days after the operation if no implant* is left in place or within 1 year if implant is in place and the infection appears to be related to the operation</td> </tr> <tr> <td class=\"indent1\"><strong>AND</strong></td> </tr> <tr> <td class=\"indent1\">Infection involves deep soft tissues (eg, fascial and muscle layers) of the incision</td> </tr> <tr> <td class=\"sublist2_start\"><strong>AND</strong> at least <strong>ONE</strong> of the following:</td> </tr> <tr> <td class=\"sublist2\">1. Purulent drainage from the deep incision but not from the organ/space component of the surgical site.</td> </tr> <tr> <td class=\"sublist2\">2. A deep incision spontaneously dehisces or is deliberately opened by a surgeon when the patient has at least one of the following signs or symptoms: fever (&#62;38&#176;C), localized pain, or tenderness, unless site is culture-negative.</td> </tr> <tr> <td class=\"sublist2\">3. An abscess or other evidence of infection involving the deep incision is found on direct examination, during reoperation, or by histopathologic or radiologic examination.</td> </tr> <tr> <td class=\"sublist2\">4. Diagnosis of a deep incisional SSI by a surgeon or attending physician.</td> </tr> <tr> <td class=\"sublist2_start\">NOTES:</td> </tr> <tr> <td class=\"sublist2\">1. Report infection that involves both superficial and deep incision sites as deep incisional SSI.</td> </tr> <tr> <td class=\"sublist2\">2. Report an organ/space SSI that drains through the incision as a deep incisional SSI.</td> </tr> <tr> <td class=\"subtitle1_single\">Organ/space SSI</td> </tr> <tr> <td class=\"indent1\">Infection occurs within 30 days after the operation if no implant* is left in place or within 1 year if implant is in place and the infection appears to be related to the operation</td> </tr> <tr> <td class=\"indent1\"><strong>AND</strong></td> </tr> <tr> <td class=\"sublist2_start\">Infection involves any part of the anatomy (eg, organs or spaces), other than the incision, which was opened or manipulated during an operation and at least one of the following:</td> </tr> <tr> <td class=\"sublist2\">1. Purulent drainage from a drain that is placed through a stab wound<sup>&#182;</sup>. If the area around a stab wound becomes infected, it is not an SSI. It is considered a skin or soft tissue infection, depending on its depth into the organ/space.</td> </tr> <tr> <td class=\"sublist2\">2. Organisms isolated from an aseptically obtained culture of fluid or tissue in the organ/space.</td> </tr> <tr> <td class=\"sublist2\">3. An abscess or other evidence of infection involving the organ/space that is found on direct examination, during reoperation, or by histopathologic or radiologic examination.</td> </tr> <tr> <td class=\"sublist2\">4. Diagnosis of an organ/space SSI by a surgeon or attending physician.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* National Nosocomial Infection Surveillance definition: a nonhuman-derived implantable foreign body (eg, prosthetic heart valve, nonhuman vascular graft, mechanical heart, or hip prosthesis) that is permanently placed in a patient during surgery.<br />&para; If the area around a stab wound becomes infected, it is not an SSI. It is considered a skin or soft tissue infection, depending on its depth.</div><div class=\"graphic_reference\">Data from: Mangram AJ, Horan TC, Pearson ML, et al. Guideline for prevention of surgical site infection. In: Infection Control and Hospital Epidemiology, CDC 1999; 20:247.</div><div id=\"graphicVersion\">Graphic 79765 Version 5.0</div></div></div>"},"79766":{"type":"graphic_figure","displayName":"Venous insufficiency PI","title":"Chronic venous insufficiency","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic venous insufficiency</div><div class=\"cntnt\"><img style=\"width:433px; height:436px;\" src=\"images/PI/79766_Venous_insufficiency_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Bickley LS, Szilagyi PG. Bates' Guide to Physical Examination and History Taking, 8th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 79766 Version 5.0</div></div></div>"},"79767":{"type":"graphic_algorithm","displayName":"Diagnosis cardiac amyloidosis","title":"Suspected cardiac amyloidosis","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Suspected cardiac amyloidosis</div><div class=\"cntnt\"><img style=\"width:533px; height:560px;\" src=\"images/CARD/79767_Diagnosis_cardiac_amyloidos.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flow diagram for the evaluation of a patient with suspected cardiac amyloidosis. Clinical evaluation may reveal clues, but a tissue diagnosis is mandatory. Although special staining of the biopsy may confirm the type of amyloid, further workup of AL amyloid is required to exclude myeloma and to quantify free light chains. If the biopsy stains positive for transthyretin, further testing is needed to determine whether this is a wild-type or mutant transthyretin.</div><div class=\"graphic_footnotes\">APoA1: apolipoprotein A1; IFE: immunofixation electrophoresis; FLC: free-light-chain assay; SSA: senile systemic amyloidosis; and TTR: transthyretin.</div><div class=\"graphic_reference\">Reproduced with permission from: Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005; 112:2047. Copyright Â© 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 79767 Version 10.0</div></div></div>"},"79768":{"type":"graphic_figure","displayName":"Ventilatory responses in HF","title":"Ventilatory responses during exercise in HF","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Ventilatory responses during exercise in HF</div><div class=\"cntnt\"><img style=\"width:538px; height:306px;\" src=\"images/CARD/79768_Ventilatory_responses_in_HF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ventilatory responses in a patient with heart failure who underwent exercise testing using a bicyle protocol with a 10 watt/min ramp. The carbon dioxide output (VCO2) paralleled the oxygen uptake (VO2) until minute seven when it increased more rapidly due to the anaerobic component.</div><div id=\"graphicVersion\">Graphic 79768 Version 1.0</div></div></div>"},"79769":{"type":"graphic_figure","displayName":"Early transition hormone","title":"Early transition hormone patterns","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Early transition hormone patterns</div><div class=\"cntnt\"><img style=\"width:522px; height:466px;\" src=\"images/ENDO/79769_Early_transition_hormone.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urinary reproductive hormone patterns in a group of 11 mid-reproductive-age (norm, age 19 to 38 years) and 11 late reproductive-age (peri, age 43 to 52 years) women having ovulatory cycles. Note that in late reproductive-age women, FSH is consistently elevated throughout the cycle, estradiol metabolite excretion (E1c) is overall elevated, and progesterone metabolites (PDG) are decreased compared&nbsp;with the mid-reproductive-age women.</div><div class=\"graphic_footnotes\">LH: luteinizing hormone; FSH: follicle-stimulating hormone; E1: estrone; PDG: pregnanediol glucuronide; E1c: estrone conjugate.</div><div class=\"graphic_reference\">Reproduced with permission from: Santoro N, Brown JR, Adel T, Skurnick JH. Characterization of Reproductive Hormonal Dynamics in the Perimenopause. J Clin Endocrinol Metab 1996; 81:1495. Copyright Â© 1996 by The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 79769 Version 4.0</div></div></div>"},"79771":{"type":"graphic_picture","displayName":"TDP43 redistribution myonuclei","title":"TDP-43 redistribution from myonuclei to sarcoplasm in IBM","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">TDP-43 redistribution from myonuclei to sarcoplasm in IBM</div><div class=\"cntnt\"><img style=\"width:525px; height:459px;\" src=\"images/RHEUM/79771_TDP43_edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In triangular fiber #1, abundant sarcoplasmic TDP-43 is accompanied by nuclei (marked with yellow arrowheads) that are devoid of TDP-43.</div><div class=\"graphic_reference\">Salajegheh, M, Pinkus, JL, Taylor, JP, et al. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle &amp; Nerve 2009; 40:19. Copyright Â© 2009. This material was reproduced with permission of John Wiley &amp; Sons.</div><div id=\"graphicVersion\">Graphic 79771 Version 5.0</div></div></div>"},"79772":{"type":"graphic_picture","displayName":"Minocycline pigmentation","title":"Minocycline pigmentation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Minocycline pigmentation</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/79772_Minocycline_pigmentation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blue-black pigmentary changes secondary to minocycline therapy are present on the lower legs.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 79772 Version 3.0</div></div></div>"},"79773":{"type":"graphic_picture","displayName":"Positioning for puncture of the glenohumeral joint","title":"Positioning for ultrasound-guided puncture of the glenohumeral joint","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Positioning for ultrasound-guided puncture of the glenohumeral joint</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/RHEUM/79773_Pos_punc_gleno_humer_joint.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient and needle positioning for puncture of the glenohumeral joint.</div><div class=\"graphic_reference\">Reproduced with permission from: Introductory Guide to Musculoskeletal Ultrasound for the Rheumatologist, Second Edition. ISBN 978-90-313-9206-3; Bohn Stafleu van Loghum, Houten 2012. Copyright &#169; 2012.</div><div id=\"graphicVersion\">Graphic 79773 Version 2.0</div></div></div>"},"79774":{"type":"graphic_movie","displayName":"Motility of Shigella","title":"Motility of shigella","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Motility of shigella</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/79774_shgactinconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:320px; height:240px;\" src=\"images/CARD/79774_shgactin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Motile intracytoplasmic Shigella bacteria with an actin tail at one pole.</div><div class=\"graphic_reference\">Courtesy of Marcia B Goldberg, MD.</div><div id=\"graphicVersion\">Graphic 79774 Version 2.0</div></div></div>"},"79777":{"type":"graphic_table","displayName":"Groups of sulfonamide medications","title":"Groups of sulfonamide medications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Groups of sulfonamide medications</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Antimicrobials </td> </tr> <tr> <td>Sulfamethoxazole</td> </tr> <tr> <td>Sulfamerazine</td> </tr> <tr> <td>Sulfamethizole</td> </tr> <tr> <td>Sulfamoxole</td> </tr> <tr> <td>Sulfamethazine</td> </tr> <tr> <td>Sulfoxazole</td> </tr> <tr> <td>Sulfapyridine</td> </tr> <tr> <td class=\"subtitle1_single\">Nonantimicrobials (diuretics, triptans, oral hyopglycemics, antiinflammatories) </td> </tr> <tr> <td>Furosemide</td> </tr> <tr> <td>Bumetanide</td> </tr> <tr> <td>Hydrochlorothiazide</td> </tr> <tr> <td>Acetazolamide</td> </tr> <tr> <td>Diazoxide</td> </tr> <tr> <td>Sumatriptan</td> </tr> <tr> <td>Glyburide</td> </tr> <tr> <td>Celecoxib</td> </tr> <tr> <td>Sulfasalazine</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 79777 Version 3.0</div></div></div>"},"79779":{"type":"graphic_figure","displayName":"Laryngeal mask airway position","title":"Laryngeal mask airway position","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Laryngeal mask airway position</div><div class=\"cntnt\"><img style=\"width:490px; height:500px;\" src=\"images/PC/79779_LMA_position.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The correct placement of the LMA is shown.</div><div id=\"graphicVersion\">Graphic 79779 Version 3.0</div></div></div>"},"79780":{"type":"graphic_picture","displayName":"Efer Dumon rigid tube","title":"Efer-Dumon rigid tube","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Efer-Dumon rigid tube</div><div class=\"cntnt\"><img style=\"width:360px; height:114px;\" src=\"images/PULM/79780_Efer_Dumon_rigid_tube.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Efer-Dumon tube with side ports for contralateral lung ventilation in case of selective ipsilateral bronchial intubation.</div><div class=\"graphic_reference\">Courtesy of Henri G Colt, MD.</div><div id=\"graphicVersion\">Graphic 79780 Version 2.0</div></div></div>"},"79782":{"type":"graphic_picture","displayName":"Sexual maturity rating of pubic hair in girls","title":"Sexual maturity rating (Tanner staging) of pubic hair development in girls","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sexual maturity rating (Tanner staging) of pubic hair development in girls</div><div class=\"cntnt\"><img style=\"width:370px; height:554px;\" src=\"images/PEDS/79782_Pubic_hair_girls.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stages of development in pubic hair in girls.<br> Stage 1: Prepubertal with no pubic hair.<br> Stage 2: Sparse, straight hair along the lateral vulva.<br> Stage 3: Hair is darker, coarser, and curlier, extending over the mid-pubis.<br> Stage 4: Hair is adult-like in appearance, but does not extend to the thighs.<br> Stage 5: Hair is adult in appearance, extending from thigh to thigh.</div><div class=\"graphic_reference\">Figure from: Roede MJ, van Wieringen JC. Growth diagrams 1980: Netherlands third nation-wide survey. Tijdschr Soc Gezondheids 1985; 63:1. Reproduced with permission from the author.</div><div id=\"graphicVersion\">Graphic 79782 Version 5.0</div></div></div>"},"79783":{"type":"graphic_picture","displayName":"Henoch-Schonlein purpura - IgA vasculitis","title":"Henoch-SchÃ¶nlein purpura (IgA vasculitis)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Henoch-SchÃ¶nlein purpura (IgA vasculitis)</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/79783_Henoch_Schonlein_purpura.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Palpable purpura. Multiple nonblanchable, raised lesions are present on the buttocks and legs.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 79783 Version 6.0</div></div></div>"},"79784":{"type":"graphic_picture","displayName":"Tzanck preparation","title":"Tzanck preparation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tzanck preparation</div><div class=\"cntnt\"><img style=\"width:355px; height:240px;\" src=\"images/DERM/79784_Tzanckpreparation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This Tzanck preparation of a specimen from a patient with herpes simplex virus infection demonstrates a multinucleated giant cell.</div><div id=\"graphicVersion\">Graphic 79784 Version 2.0</div></div></div>"},"79786":{"type":"graphic_figure","displayName":"Formation of NO by NOS","title":"The enzymatic formation nitric oxide (NO) by nitric oxide synthetase (NOS)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The enzymatic formation nitric oxide (NO) by nitric oxide synthetase (NOS)</div><div class=\"cntnt\"><img style=\"width:365px; height:570px;\" src=\"images/PULM/79786_Formation_of_NO_by_NOS.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">FAD: flavin adenine dinucleotide; FMN: flavin mononucleotide; NADPH: nicotinamide adenine dinucleotide phosphate; NO: nitric oxide; NOS: nitric oxide synthetase; RS-NO: S-nitrosothiols.</div><div class=\"graphic_reference\">Reproduced with permission from Gaston, B, Drazen, JM, Loscalzo, J, Stamler, J, Am J Respir Crit Care Med 1994; 149:538.</div><div id=\"graphicVersion\">Graphic 79786 Version 2.0</div></div></div>"},"79790":{"type":"graphic_table","displayName":"Foods products with gluten","title":"Foods and products that may contain gluten","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Foods and products that may contain gluten</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Frequently overlooked foods that may contain gluten and need to be verified: </td> </tr> <tr> <td>Brown rice syrup</td> </tr> <tr> <td>Breading and coating mixes</td> </tr> <tr> <td>Croutons</td> </tr> <tr> <td>Energy bars</td> </tr> <tr> <td>Flour or cereal products</td> </tr> <tr> <td>Imitation bacon</td> </tr> <tr> <td>Imitation seafood</td> </tr> <tr> <td>Marinades</td> </tr> <tr> <td>Panko (Japanese bread crumbs)</td> </tr> <tr> <td>Pastas</td> </tr> <tr> <td>Processed luncheon meats</td> </tr> <tr> <td>Sauces, gravies</td> </tr> <tr> <td>Self-basting poultry</td> </tr> <tr> <td>Soy sauce or soy sauce solids</td> </tr> <tr> <td>Soup bases</td> </tr> <tr> <td>Stuffings, dressing</td> </tr> <tr> <td>Thickeners (roux)</td> </tr> <tr> <td>Communion wafers</td> </tr> <tr> <td>Herbal supplements</td> </tr> <tr> <td>Probiotic products*&nbsp;</td> </tr> <tr> <td>Drugs and over-the-counter medications</td> </tr> <tr> <td>Nutritional supplements</td> </tr> <tr> <td>Vitamins and mineral supplements</td> </tr> <tr> <td>Play-dough, crayons, paint, glue, paper mache: A potential problem if the child puts their hands on or in the mouth while playing. Wash hands after using these products.</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">NOT ALLOWED in any form: </td> </tr> <tr> <td>Wheat (einkorn, durum, faro, graham, kamut, semolina, spelt)</td> </tr> <tr> <td>Rye</td> </tr> <tr> <td>Barley</td> </tr> <tr> <td>Triticale</td> </tr> <tr> <td>Malt, malt flavoring, malt vinegar (are generally made from barley, verify the source)</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* In 2015, a study of 22 commonly used probiotics revealed that&nbsp;12 (55 percent) contained gluten, including two that were labeled gluten-free despite containing gluten levels higher than the 20 parts per million required for gluten-free labeling.<SUP>[1]</SUP> </div><div class=\"graphic_reference\"><OL>&#xD;&#xA;<LI>Nazareth S, Lebwohl B, Voyksner JS, Green PH. Widespread Contamination of Probiotics With Gluten, Detected by Liquid Chromatography-Mass Spectrometry.&nbsp;Gastroenterology 2015; 148(4):S28 (Meeting abstract).&nbsp;</LI></OL>Modified with permission: \"Frequently overlooked foods that may contain gluten and need to be verified.\" From Quick Start Diet Guide for Celiac Disease Â© 2009. Celiac Disease Foundation. <A href=\"http://www.celiac.org/\">www.celiac.org</A>.<br /><br /></div><div id=\"graphicVersion\">Graphic 79790 Version 2.0</div></div></div>"},"79792":{"type":"graphic_picture","displayName":"Delee Simpson type forceps","title":"Delee Simpson type forceps","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Delee Simpson type forceps</div><div class=\"cntnt\"><img style=\"width:468px; height:250px;\" src=\"images/OBGYN/79792_Delee_simpson_type_forcep.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Simpson type forceps have parallel separated shanks with blades that have a long and tapered cephalic curve.</div><div class=\"graphic_reference\">Reproduced with permission from: Aron Schuftan, MD. Copyright Â© Aron Schuftan, MD.</div><div id=\"graphicVersion\">Graphic 79792 Version 6.0</div></div></div>"},"79793":{"type":"graphic_figure","displayName":"Parts of the stomach","title":"Parts of the stomach","html":"<div class=\"graphic\"><div style=\"width: 576px\" class=\"figure\"><div class=\"ttl\">Parts of the stomach</div><div class=\"cntnt\"><img style=\"width:556px; height:415px;\" src=\"images/ONC/79793_Parts_of_stomach.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows the parts of the anterior surface of the stomach. The body of the stomach is separated from the pyloric part by an oblique line which extends from the angular notch (incisura angularis) on the lesser curvature to the greater curvature.</div><div id=\"graphicVersion\">Graphic 79793 Version 3.0</div></div></div>"},"79794":{"type":"graphic_picture","displayName":"PIP contracture in scleroderma","title":"Proximal interphalangeal flexion contractures in scleroderma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proximal interphalangeal flexion contractures in scleroderma</div><div class=\"cntnt\"><img style=\"width:388px; height:263px;\" src=\"images/RHEUM/79794_PIP_contracture_in_sclerode.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin breakdown (arrow) over the distal interphalangeal joint of the small finger can be observed in a patient with systemic sclerosis and proximal interphalangeal flexion contractures.</div><div class=\"graphic_reference\">Reproduced with permission from: Nalebuff EA. Surgery in patients with systemic sclerosis of the hand. Clin Orthop Rel Res 1999; 91:366. Copyright Â© 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 79794 Version 8.0</div></div></div>"},"79797":{"type":"graphic_waveform","displayName":"Tissue Doppler","title":"Example of tissue Doppler recordings","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Example of tissue Doppler recordings</div><div class=\"cntnt\"><img style=\"width:370px; height:596px;\" src=\"images/CARD/79797_Tissue_doppler.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Dr. Sherif F Nagueh.</div><div id=\"graphicVersion\">Graphic 79797 Version 3.0</div></div></div>"},"79801":{"type":"graphic_picture","displayName":"Deinfibulation 3","title":"Deinfibulation 3","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Deinfibulation 3</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/OBGYN/79801_Deinfibulation_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Step 3: Incision to, but not into, clitoris.</div><div id=\"graphicVersion\">Graphic 79801 Version 2.0</div></div></div>"},"79802":{"type":"graphic_algorithm","displayName":"Cell mechanism diastol dysfunct","title":"Cellular mechanisms of left ventricular diastolic dysfunction","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Cellular mechanisms of left ventricular diastolic dysfunction</div><div class=\"cntnt\"><img style=\"width:463px; height:258px;\" src=\"images/CARD/79802_Cell_mechanism_diastol_dysf.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Synergistic interactions between an increase in cytosolic calcium (Ca[i]2+) and a decrease in adensine triphosphate (ATP) availability increase diastolic tension and can cause or exacerbate diastolic dysfunction.</div><div id=\"graphicVersion\">Graphic 79802 Version 2.0</div></div></div>"},"79803":{"type":"graphic_table","displayName":"Possible causes for the increase in allergic disease","title":"Changes that may have contributed to the rise in allergic disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Changes that may have contributed to the rise in allergic disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">I. Increased exposure to perennial indoor allergens</td> </tr> <tr> <td class=\"indent1\">Increased time spent indoors (1955 to 1995)</td> </tr> <tr> <td class=\"indent1\">Improved conditions for mite and mold growth (1955 to 1975)*</td> </tr> <tr> <td class=\"indent1\">Decreased ventilation*</td> </tr> <tr> <td class=\"indent1\">Increased reservoirs for allergen (carpets/sofas) (1935 to 1965)*</td> </tr> <tr> <td class=\"subtitle1_single\">II. Changes in hygiene</td> </tr> <tr> <td class=\"sublist2_start\">Clean water</td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Separation from sewage (1900)</li> </ul> </td> </tr> <tr> <td class=\"sublist2\"> <ul> <li>Chlorination (1920)</li> </ul> </td> </tr> <tr> <td class=\"indent1\">Eradication of helminths and malaria in Europe and United States (1920 to 1940)</td> </tr> <tr> <td class=\"indent1\">Decline in hepatitis A infection (1920 to 1990)</td> </tr> <tr> <td class=\"indent1\">Introduction of broad spectrum antibiotics (approximately 1960)</td> </tr> <tr> <td class=\"indent1\">Increased treatment and control of food to prevent bacterial infection (1900 to 1980)</td> </tr> <tr> <td class=\"indent1\">Immunization to control infectious diseases (1800 to 1990)</td> </tr> <tr> <td class=\"subtitle1_single\">III. Lifestyle changes: Secondary to the introduction of sedentary entertainment in homes</td> </tr> <tr> <td class=\"indent1\">Increase in the percentage of homes with television and increase in hours spent watching television (1955 to 1990)</td> </tr> <tr> <td class=\"indent1\">Decline in outdoor \"play\" (1955 to 1995)</td> </tr> <tr> <td class=\"indent1\">Rise in obesity (1970 to 2000)</td> </tr> <tr> <td class=\"indent1\">Changes in diet following changes in traditional family life (1965 to 2000)</td> </tr> <tr> <td class=\"indent1\">Decreased vitamin D levels secondary to decreased time spent outdoors and decreased intake</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Variable by locale.</div><div id=\"graphicVersion\">Graphic 79803 Version 6.0</div></div></div>"},"79804":{"type":"graphic_movie","displayName":"TEE color flow Doppler atrial septal defect","title":"Transesophageal echocardiography with color flow Doppler of an atrial septal defect","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transesophageal echocardiography with color flow Doppler of an atrial septal defect</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/79804_teeasdcfdconv.mp4\" style=\"width:383px;height:276px\"></div><img style=\"width:456px; height:259px;\" src=\"images/CARD/79804_teeasdcfdedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The color flow Doppler obtained during transesophageal echocardiography shows a large left to right shunt, manifest by blood flow with some turbulence across the atrial septal defect (white arrow).</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 79804 Version 5.0</div></div></div>"},"79807":{"type":"graphic_figure","displayName":"ELF activity with monthly AAT","title":"Maintenance of adequate ELF antitrypsin activity with monthly infusions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Maintenance of adequate ELF antitrypsin activity with monthly infusions</div><div class=\"cntnt\"><img style=\"width:390px; height:241px;\" src=\"images/PULM/79807_ELF_activity_with_monthly_A.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect of monthly infusions of 250 mg/kg of alpha-1 antitrypsin (AAT) on epithelial lining fluid (ELF) levels of AAT in three patients. The AAT levels are based upon a true laboratory standard. The dashed line represents the theoretical protective threshold. AAT levels were maintained above this threshold with monthly infusions.</div><div class=\"graphic_reference\">Redrawn from Hubbard, RC, Sellers, S, Czerski, D, et al, JAMA 1988; 260:1259.</div><div id=\"graphicVersion\">Graphic 79807 Version 1.0</div></div></div>"},"79809":{"type":"graphic_picture","displayName":"Wall push-up exercise","title":"Strength exercise: Wall push-up","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Strength exercise: Wall push-up</div><div class=\"cntnt\"><img style=\"width:373px; height:306px;\" src=\"images/PC/79809_Wall_push_up_exercise_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These push-ups will strengthen your arms, shoulders, and chest. Try this exercise during a TV commercial break.   <OL>  <LI>Face a wall, standing a little farther than arm's length away, feet shoulder-width apart. </LI>  <LI>Lean your body forward and put your palms flat against the wall at shoulder height and shoulder-width apart. </LI>  <LI>Slowly breathe in as you bend your elbows and lower your upper body toward the wall in a slow, controlled motion. Keep your feet flat on the floor. </LI>  <LI>Hold the position for one second. </LI>  <LI>Breathe out and slowly push yourself back until your arms are straight. </LI>  <LI>Repeat 10 to 15 times. </LI>  <LI>Rest; then repeat 10 to 15 more times.</LI></OL></div><div class=\"graphic_reference\">Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: http://go4life.niapublications.org (Accessed December 2, 2011).</div><div id=\"graphicVersion\">Graphic 79809 Version 3.0</div></div></div>"},"79812":{"type":"graphic_movie","displayName":"Emmetropia normal refraction","title":"Emmetropia","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Emmetropia</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/79812_emmetropconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:319px; height:198px;\" src=\"images/CARD/79812_emmetrop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An emmetropic eye has no refractive error. The image of an object twenty feet or more away (optical infinity) is focused on the retina.</div><div class=\"graphic_reference\">Reproduced with permission from: The University of Michigan Kellogg Eye Center, www.kellogg.umich.edu.</div><div id=\"graphicVersion\">Graphic 79812 Version 4.0</div></div></div>"},"79813":{"type":"graphic_table","displayName":"Components biophysical profile","title":"Criteria for the biophysical profile test","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for the biophysical profile test</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>Nonstress test:</strong> 2 points if reactive, defined as at least 2 episodes of FHR accelerations of at least 15 bpm and at least 15 seconds duration from onset to return associated with fetal movement within a 30-minute observation period.</td> </tr> <tr> <td><strong>Fetal breathing movements:</strong> 2 points if one or more episodes of rhythmic breathing movements of &#8805;30 seconds within a 30-minute observation period.</td> </tr> <tr> <td><strong>Fetal tone:</strong> 2 points if one or more episodes of extension of a fetal extremity or fetal spine with return to flexion.</td> </tr> <tr> <td><strong>Amniotic fluid volume:</strong> 2 points if a single deepest&nbsp;vertical pocket &#8805;2cm is present. The horizontal dimension should be at least 1 cm.</td> </tr> <tr> <td><strong>Fetal movement:</strong> 2 points if three or more discrete body or limb movements within 30 minutes of observation. An episode of active continuous movement is counted as one movement.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Zero&nbsp;points are assigned for any criteria not met. A score of 10/10, 8/8 (nonstress test not done), or 8/10 (including +2 points for amniotic fluid) is a normal test result. A score of 6/10 (including +2 points for amniotic fluid) is an equivocal test result, as a significant possibility of developing fetal asphyxia cannot be excluded. A score of 6/10 or 8/10 with oligohydramnios (0 points for amniotic fluid) is an abnormal test, and further assessment and correlation with the clinical setting are indicated. A score of 0 to 4/10 is abnormal; the risk of fetal asphyxia within one week is high if there is no intervention, and delivery is usually indicated. Refer to UpToDate topic on the fetal biophysical profile for additional information.</div><div class=\"graphic_footnotes\">FHR: fetal heart rate; bpm: beats per minute.</div><div id=\"graphicVersion\">Graphic 79813 Version 8.0</div></div></div>"},"79818":{"type":"graphic_figure","displayName":"Adjusted MMSE norms","title":"Mini-Mental State Examination norms by age, gender, and education level","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mini-Mental State Examination norms by age, gender, and education level</div><div class=\"cntnt\"><img style=\"width:393px; height:351px;\" src=\"images/PC/79818_Adjusted_MMSE_norms.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fifth percentile norms for the Mini-Mental State Examination (MMSE) were determined using a random population sample that incorporated the effects of age, gender, and education level, all factors that are felt to affect scores on the exam. In screening for dementia, the norms had a sensitivity and specificity of 85 and 89 percent, respectively.</div><div class=\"graphic_reference\">Reproduced with permission by Grigoletto, F, Zappala, G, Anderson, DW, Lebowitz, BD, Neurology 1999; 53:315.</div><div id=\"graphicVersion\">Graphic 79818 Version 1.0</div></div></div>"},"79819":{"type":"graphic_figure","displayName":"Oxygen delivery in inspiration","title":"Oxygen delivery in inspiration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oxygen delivery in inspiration</div><div class=\"cntnt\"><img style=\"width:362px; height:332px;\" src=\"images/PULM/79819_Oxygen_delivery_in_inspirat.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relation between oxygen delivery and dead space during tidal inspiration. Panel A) With a tidal volume of 450 mL, the first gas to arrive at the alveoli is the 150 mL of oxygen poor gas already occupying the dead space in the airways. This is followed by the first 300 mL of inspired gas expected to reach the alveoli. Panel B) The final 150 mL of inspired gas will fill the dead space at the end of inspiration but not reach the alveoli. Ideally, all oxygen delivery should occur prior to this last 150 mL.</div><div class=\"graphic_reference\">Data from: Tiep BL. Continuous flow oxygen therapy and basis for improving the efficiency of oxygen delivery. In: Portable Oxygen Therapy: Including Oxygen Conserving Methodology, Tiep BL (Ed), Futura Publishing, Mt Kisco, New York, 1991.</div><div id=\"graphicVersion\">Graphic 79819 Version 2.0</div></div></div>"},"79820":{"type":"graphic_picture","displayName":"Stages of morphea","title":"Stages of morphea","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Stages of morphea</div><div class=\"cntnt\"><img style=\"width:588px; height:184px;\" src=\"images/RHEUM/79820_Stages_of_morphea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lesions of morphea begin with small violaceous or erythematous skin changes (inflammatory phase, left panel) that enlarge and progress to firm, &quot;hide-bound&quot; skin, with variable degrees of hypo- and hyperpigmentation (atrophic phase, right panel).</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 79820 Version 1.0</div></div></div>"},"79821":{"type":"graphic_diagnosticimage","displayName":"Iliopsoas bursitis CT and MRI","title":"Computed tomography and magnetic resonance imaging of iliopsoas bursitis","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Computed tomography and magnetic resonance imaging of iliopsoas bursitis</div><div class=\"cntnt\"><img style=\"width:583px; height:398px;\" src=\"images/PEDS/79821_IliopsoasbursitisCTMRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Soft tissue window computed tomography (CT), axial pelvis. Note the cystic, low attenuation mass immediately anterior to the right femoral head (arrow).<br> (B) Proton density-weighted magnetic resonance imaging (MRI), axial pelvis. The area of decreased attenuation on the CT study displays homogeneous low signal intensity on MRI (arrow).<br> (C) T2-weighted MRI, axial pelvis. Observe the homogeneous hyperintense signal intensity in this localized fluid collection (arrow). These findings are consistent with iliopsoas bursitis.</div><div class=\"graphic_reference\">Reproduced with permission from: Yochum TR, Rowe LJ. Yochum And Rowe's Essentials of Skeletal Radiology, 3<SUP>rd</SUP> ed, Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright Â© 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 79821 Version 2.0</div></div></div>"},"79822":{"type":"graphic_figure","displayName":"Pathophysiology Ebstein anomaly","title":"Pathophysiology of Ebstein's anomaly","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Pathophysiology of Ebstein's anomaly</div><div class=\"cntnt\"><img style=\"width:531px; height:622px;\" src=\"images/CARD/79822_Ebstein's-anomaly-edit.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 79822 Version 2.0</div></div></div>"},"79824":{"type":"graphic_diagnosticimage","displayName":"Collagenous colitis US","title":"Collagenous colitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Collagenous colitis</div><div class=\"cntnt\"><img style=\"width:327px; height:316px;\" src=\"images/GAST/79824_Collagenous_colitis_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound examination of the sigmoid colon in collagenous colitis. The sigmoid colon is normal size but the layers are more pronounced. 1 = lamina muscularis; arrow = submucosa; and 2 = mucosa. The distance between the crosses is 1.7 mm.</div><div class=\"graphic_reference\">Courtesy of C F Dietrich, MD and Wolfgang F Caspary, MD.</div><div id=\"graphicVersion\">Graphic 79824 Version 2.0</div></div></div>"},"79826":{"type":"graphic_picture","displayName":"Epiglottitis - Tripod posture","title":"Epiglottitis: Tripod posture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Epiglottitis: Tripod posture</div><div class=\"cntnt\"><img style=\"width:309px; height:396px;\" src=\"images/PEDS/79826_Epiglottitis_tripod_posture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This child's \"tripod\" positioning (trunk leaning forward, neck hyperextended, chin thrust forward) is caused by epiglottitis and represents the patient's attempt to maximize the patency of a significantly obstructed upper airway. Also, note the child's toxic appearance. <br /><br />Tripod positioning&nbsp;may also be seen in other causes of&nbsp;respiratory distress,&nbsp;such as severe asthma.&nbsp;</div><div class=\"graphic_reference\">Reproduced with permission from: M Douglas Baker, MD.</div><div id=\"graphicVersion\">Graphic 79826 Version 3.0</div></div></div>"},"79827":{"type":"graphic_picture","displayName":"Hip extension PI","title":"Hip extension","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hip extension</div><div class=\"cntnt\"><img style=\"width:263px; height:432px;\" src=\"images/PI/79827_Hip_extension_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">You will need 18 to 24 inches of rubber tubing or an elastic band (eg, Theraband&#174;) to perform these exercises. Secure the tubing around the leg of a heavy piece of furniture or close it in a door. Stand facing the furniture/door and place the injured leg in the loop of the tubing. You should not have any slack in the tubing. Hold the door/furniture and extend the injured leg backwards, stretching the tubing as far as possible. Hold for 5 seconds. Slowly return the leg to the floor. Rest as needed. Repeat 10 to 15 times (one set). Perform a total of 3 sets.</div><div id=\"graphicVersion\">Graphic 79827 Version 3.0</div></div></div>"},"79828":{"type":"graphic_diagnosticimage","displayName":"IPMN IDUS","title":"Intraductal papillary mucinous neoplasm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intraductal papillary mucinous neoplasm</div><div class=\"cntnt\"><img style=\"width:360px; height:339px;\" src=\"images/GAST/79828_IPMN_IDUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intraductal ultrasound of a patient with an intraductal papillary mucinous neoplasm. The mucin and soft tissue prominence of the main pancreas duct wall were confined to the head and neck.</div><div class=\"graphic_reference\">Courtesy of Maurits Wiersema, MD.</div><div id=\"graphicVersion\">Graphic 79828 Version 2.0</div></div></div>"},"79829":{"type":"graphic_picture","displayName":"Vacuum suction cups","title":"Vacuum delivery suction cups","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Vacuum delivery suction cups</div><div class=\"cntnt\"><img style=\"width:540px; height:360px;\" src=\"images/OBGYN/79829_Vacuum_suction_cups.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">A: mushroom; B: bell.</div><div class=\"graphic_reference\">Reproduced with permission from: Aron Schuftan, MD. &#169; Aron Schuftan, MD.</div><div id=\"graphicVersion\">Graphic 79829 Version 1.0</div></div></div>"},"79830":{"type":"graphic_table","displayName":"Evaluation of an infant or child with constipation","title":"Evaluation of an infant or child with constipation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation of an infant or child with constipation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">History</td> <td class=\"subtitle1_single\">Implications&nbsp;</td> </tr> <tr> <td>Was there delayed passage of meconium (ie, first meconium after 48 hours of life)?&nbsp; </td> <td>Suggests Hirschsprung disease </td> </tr> <tr> <td>Onset of constipation:&nbsp; </td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist2_start\">Was constipation present from birth or early infancy?&nbsp;</td> <td>More likely to be an organic cause (eg, Hirschsprung disease)&nbsp;</td> </tr> <tr> <td class=\"sublist2_start\">Was there a preceding change in diet or diarrheal illness? </td> <td>Suggests functional constipation&nbsp;</td> </tr> <tr> <td class=\"sublist2_start\">Was the onset around the time of toilet training, or around a precipitating event? </td> <td>Suggests functional constipation &nbsp;</td> </tr> <tr> <td class=\"sublist2_start\">Were there problems with toilet training? (eg, child resistance, fear or late mastery) </td> <td>Suggests functional constipation &nbsp;</td> </tr> <tr> <td>Stool quality and appearance:&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist2_start\">Is defecation painful?</td> <td>Suggests functional constipation &nbsp;</td> </tr> <tr> <td class=\"sublist2_start\">Are the stools hard or soft?&nbsp;&nbsp;</td> <td>Soft stools suggests cause other than constipation (eg, dyschezia in an infant)&nbsp;</td> </tr> <tr> <td class=\"sublist2_start\">Does the stool form pellets in the diaper or toilet? Do they clog the toilet?&nbsp;</td> <td>Supports diagnosis of functional constipation&nbsp;</td> </tr> <tr> <td class=\"sublist2_start\">Is there blood on the stool?</td> <td>Possible anal fissure, which can cause or result from functional constipation</td> </tr> <tr> <td>If the child is toilet trained, does he or she have \"accidents\" in&nbsp;the underwear?&nbsp;</td> <td>Indicates fecal incontinence, which is&nbsp;usually due to functional constipation and withholding, leading to fecal impaction&nbsp;</td> </tr> <tr> <td>Does the child&nbsp;have stool withholding behavior? (\"dance\", hide or appear&nbsp;to be trying not to have a bowel movement)</td> <td>Suggests functional constipation, with stool withholding&nbsp;</td> </tr> <tr> <td>Dietary issues: </td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist2_start\">Is the diet unusual? Are there sources of fiber?&nbsp;Is there adequate fluid?</td> <td>Low fluid intake occasionally contributes to constipation&nbsp;</td> </tr> <tr> <td class=\"sublist2_start\">Did the constipation coincide with a change in diet?&nbsp; (eg, transition to solid foods in infants, or to milk)&nbsp;</td> <td>Suggests functional constipation,&nbsp;possibly&nbsp;cow's&nbsp;milk protein intolerance&nbsp;</td> </tr> <tr> <td>Are there underlying medical problems, congenital anomalies, abnormal growth, or developmental delay?&nbsp;</td> <td>Consider neurogenic causes of constipation;&nbsp;some&nbsp;congenital syndromes are associated with Hirschsprung disease (eg, Down&nbsp;syndrome). Congenital malformations, such as&nbsp;kidney and urinary tract anomalies, also raise concerns for anorectal, sacral and spinal abnormalities, which can interfere with defecation. &nbsp;&nbsp;</td> </tr> <tr> <td>What treatments have been tried, and what was the response?&nbsp;</td> <td>Informs clinical management&nbsp;</td> </tr> <tr> <td>Is there a family history of functional constipation, Hirschsprung disease, or celiac disease?</td> <td>Each of these causes has some familial patterns</td> </tr> <tr> <td class=\"subtitle1_single\">Physical examination</td> <td class=\"subtitle1_single\">&nbsp;</td> </tr> <tr> <td>Abdominal distension&nbsp;</td> <td>Severe distension raises concern for organic disease&nbsp;</td> </tr> <tr> <td>Palpable stool mass&nbsp;</td> <td>Consistent with constipation from any cause, but lack of palpable stool does not rule out constipation &nbsp;</td> </tr> <tr> <td>Mass in suprapubic area&nbsp;</td> <td>Common finding in patients with rectal stool impaction, but can also suggest sacral teratoma &nbsp;</td> </tr> <tr> <td>Cutaneous changes in the lumbosacral area (dimple, hair tuft, lipoma, or deviation of the gluteal cleft)&nbsp;</td> <td>Suggests spinal dysraphism &nbsp;</td> </tr> <tr> <td>Soiled underwear (fecal incontinence)</td> <td>In the presence of rectal stool impaction, suggests overflow incontinence and functional constipation</td> </tr> <tr> <td>Absent anal wink or cremasteric reflex, decreased lower extremity tone or strength&nbsp;</td> <td>Suggests neurologic dysfunction &nbsp;</td> </tr> <tr> <td>Anal fissure or scarring </td> <td>Anal fissures may be a cause&nbsp;or a consequence of functional constipation&nbsp;</td> </tr> <tr> <td>Anteriorly displaced anus, or perianal fistula&nbsp;&nbsp;</td> <td>Suggests anorectal anomaly&nbsp;</td> </tr> <tr> <td>Digital rectal examination:&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist2_start\">Anal sphincter tone&nbsp; </td> <td>Increased tone suggests Hirschsprung disease, low tone suggest neurogenic constipation&nbsp;</td> </tr> <tr> <td class=\"sublist2_start\">Size of rectal vault&nbsp; </td> <td>Large vault is consistent with chronic functional constipation&nbsp;</td> </tr> <tr> <td class=\"sublist2_start\">Impacted stool (hard or soft)</td> <td>Soft stool&nbsp;suggests possibility of anorectal dysfunction,&nbsp;including Hirschsprung disease&nbsp;</td> </tr> <tr> <td class=\"sublist2_start\">Explosive expulsion of stool after the examination (squirt sign)&nbsp;</td> <td>Suggests Hirschsprung disease&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 79830 Version 4.0</div></div></div>"},"79831":{"type":"graphic_figure","displayName":"Mini nutritional assesment","title":"Mini nutritional assessment","html":"<div class=\"graphic\"><div style=\"width: 615px\" class=\"figure\"><div class=\"ttl\">Mini nutritional assessment</div><div class=\"cntnt\"><img style=\"width:595px; height:827px;\" src=\"images/PC/79831_Mini_nutrit_assessment_PR.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Malnutrition indicator score: â¥24 points = well nourished; 17 to 23.5 points = at risk for malnutrition; &lt;17 points = malnourished.</div><div class=\"graphic_reference\">Reproduced with permission from: Guigoz Y, Vellas B, Garry PJ. Assessing the nutritional status of the elderly: The Mini Nutritional Assessment as part of the geriatric evaluation. Nutr Rev 1996; 54 (1 Pt 2):S59. Copyright Â© 1996 International Life Sciences Institute.</div><div id=\"graphicVersion\">Graphic 79831 Version 10.0</div></div></div>"},"79832":{"type":"graphic_figure","displayName":"Ventilatory response to hypoxemia","title":"Ventilatory response to hypoxemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ventilatory response to hypoxemia</div><div class=\"cntnt\"><img style=\"width:220px; height:264px;\" src=\"images/PULM/79832_Ventilatory_response_hypoxe.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ventilation increases in a curvilinear fashion as PO<sub>2</sub> falls. The data are obtained with PaCO<sub>2</sub> held constant. Under usual circumstances, the increased ventilation associated with hypoxemia results in a drop in PaCO<sub>2</sub>, which blunts the ventilatory response. Note that ventilation does not significantly increase until PO<sub>2</sub> is less than 60 mmHg.</div><div class=\"graphic_reference\">Adapted from Hudgel DW, Control of breathing. In: Bronchial Asthma: Mechanisms and Therapeutics, 2d ed, Weiss EB, Segal MS, Stein M (Eds), Little, Brown, Boston, 1984, with permission.</div><div id=\"graphicVersion\">Graphic 79832 Version 3.0</div></div></div>"},"79833":{"type":"graphic_figure","displayName":"Expected compensation ranges for simple acid-base disorders","title":"Expected compensation ranges for simple acid-base disorders","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Expected compensation ranges for simple acid-base disorders</div><div class=\"cntnt\"><img style=\"width:588px; height:588px;\" src=\"images/NEPH/79833_Expect_comp_acid-base.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Harrington JT, Cohen JJ, Kassirer JP. Mixed acid-base disturbances. In: Acid/Base, Cohen JJ, Kassirer JP (Eds), Little, Brown, Boston: 1982. Copyright Â© 1982 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 79833 Version 8.0</div></div></div>"},"79834":{"type":"graphic_figure","displayName":"Cardiac output during labor","title":"Cardiac output during normal labor, delivery, and postpartum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cardiac output during normal labor, delivery, and postpartum</div><div class=\"cntnt\"><img style=\"width:437px; height:286px;\" src=\"images/OBGYN/79834_Cardiac_output_during_labor.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Bonica JJ, McDonald JS. Principles and Practice of Obstetric Analgesia and Anesthesia, 2<SUP>nd</SUP> ed, Williams &amp;&nbsp;Wilkins, Baltimore 1994. p.62.</div><div id=\"graphicVersion\">Graphic 79834 Version 3.0</div></div></div>"},"79836":{"type":"graphic_diagnosticimage","displayName":"Displaced fracture greater trochanter","title":"Displaced fracture of greater trochanter ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Displaced fracture of greater trochanter </div><div class=\"cntnt\"><img style=\"width:270px; height:396px;\" src=\"images/EM/79836_Greater_troch_fx_xr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This close-up view from an anteroposterior radiograph shows a fracture of the greater trochanter with obvious displacement.</div><div class=\"graphic_reference\">Reproduced with permission from: Koval KJ, Zuckerman JD. Intertrochanteric fractures. In: Rockwood and Green's Fractures in Adults, 5th ed,&nbsp;Bucholz RW, Heckman JD (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright Â© 2002 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 79836 Version 10.0</div></div></div>"},"79837":{"type":"graphic_diagnosticimage","displayName":"MRI foraminal disc L5","title":"Lumbar spine MRI showing a foraminal disc extrusion compressing the exiting L5 nerve root","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lumbar spine MRI showing a foraminal disc extrusion compressing the exiting L5 nerve root</div><div class=\"cntnt\"><img style=\"width:254px; height:396px;\" src=\"images/NEURO/79837_Foraminal_disc_L5.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal T1-weighted MRI of the lumbar spine shows a foraminal disc extrusion filling the L5-S1 neural foramen (arrow), likely compressing the exiting L5 nerve root. Note hyperintense fat surrounding the normal exiting L4 nerve root at the level above (arrowhead).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Eric D. Schwartz, MD.</div><div id=\"graphicVersion\">Graphic 79837 Version 4.0</div></div></div>"},"79839":{"type":"graphic_figure","displayName":"Warfarin in AF","title":"Benefit of warfarin in chronic atrial fibrillation","html":"<div class=\"graphic\"><div style=\"width: 479px\" class=\"figure\"><div class=\"ttl\">Benefit of warfarin in chronic atrial fibrillation</div><div class=\"cntnt\"><img style=\"width:459px; height:239px;\" src=\"images/CARD/79839_Warfarin_in_AF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Efficacy of anticoagulation with warfarin to prevent ischemic stroke and other thromboemboli in four major studies. An intention to treat approach was used and transient ischemic attack and hemorrhage were excluded. The numbers at the top represent the risk reduction with warfarin therapy which ranged from 45 to 82 percent.</div><div class=\"graphic_footnotes\">SPAF: Stroke Prevention in Atrial Fibrillation; AFASAK: Copenhagen AFASAK Study; BAATAF: Boston Area Anticoagulation Trial for Atrial Fibrillation; and CAFA: Canadian Atrial Fibrillation Anticoagulation Study.<br> * The data in the warfarin group in the SPAK assumes that half of the events were attributable to warfarin toxicity.</div><div class=\"graphic_reference\">Data from Connolly SJ, Laupacis AN, Gent M, et al. J Am Coll Cardiol 1991; 18:349.</div><div id=\"graphicVersion\">Graphic 79839 Version 2.0</div></div></div>"},"79840":{"type":"graphic_picture","displayName":"Endotheliitis liver TPL","title":"Endotheliitis in acute hepatic allograft rejection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endotheliitis in acute hepatic allograft rejection</div><div class=\"cntnt\"><img style=\"width:431px; height:286px;\" src=\"images/GAST/79840_Endotheliitis_liver_TPL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a liver biopsy from a liver transplant shows endotheliitis involving a central hepatic vein.</div><div class=\"graphic_reference\">Courtesy of Donald Jensen, MD.</div><div id=\"graphicVersion\">Graphic 79840 Version 1.0</div></div></div>"},"79841":{"type":"graphic_table","displayName":"IP ABX continuous dosing","title":"Intraperitoneal antibiotic dosing recommendations for continuous administration in peritoneal dialysis patients (adult)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intraperitoneal antibiotic dosing recommendations for continuous administration in peritoneal dialysis patients (adult)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr class=\"highlight_gray_text;\" style=\"font-size:1.2em;\"> <td style=\"border-bottom: black 3px solid; padding-bottom: 0.3em; padding-top:0.5em;\">&nbsp;</td> <td style=\"border-bottom: black 3px solid; padding-bottom: 0.3em; padding-top:0.5em;\"><strong>Initial IP loading dose</strong></td> <td style=\"border-bottom: black 3px solid; padding-bottom: 0.3em; padding-top:0.5em;\"> <p><strong>Maintenance IP dose administered with all exchanges following a loading dose, if indicated</strong></p> <p>For patients with residual renal function (defined as greater than 100 mL per day urine output) empirically increase dose shown by 25%.</p> <strong>NOTE:</strong> Intermittent regimens, which are listed in a separate table, are preferred for initial treatment in most patients with peritoneal dialysis-associated peritonitis. For additional information refer to legend below and UpToDate topic on microbiology and therapy of peritonitis in peritoneal dialysis.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Aminoglycosides</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\">Continuous IP administration of aminoglycosides is generally not recommended. Refer to UpToDate topic on microbiology and therapy of peritonitis in peritoneal dialysis and accompanying table on intermittent IP antibiotic administration and dosing of aminoglycosides.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Carbapenem</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Imipenem-cilastatin</td> <td>250 mg/L dialysate</td> <td>50 mg/L dialysate</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Cephalosporins</td> </tr> <tr> <td class=\"indent1\">Cefazolin</td> <td>500 mg/L dialysate</td> <td>125 mg/L dialysate</td> </tr> <tr> <td class=\"indent1\">Cefepime</td> <td>250 to 500 mg/L dialysate</td> <td>100 to 125 mg/L dialysate</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ceftazidime</td> <td>500 mg/L dialysate</td> <td>125 mg/L dialysate</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Penicillins</td> </tr> <tr> <td class=\"indent1\">Amoxicillin*</td> <td>None</td> <td>150 mg/L dialysate</td> </tr> <tr> <td class=\"indent1\">Ampicillin</td> <td>None</td> <td>125 mg/L dialysate</td> </tr> <tr> <td class=\"indent1\">Ampicillin-sulbactam</td> <td>750 to 1000 mg/L dialysate</td> <td>100 mg/L dialysate</td> </tr> <tr> <td class=\"indent1\">Penicillin G</td> <td>50,000 units/L dialysate</td> <td>25,000 units/L dialysate</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Piperacillin-tazobactam</td> <td>4.5 grams in one bag</td> <td>1.125 grams per bag</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Glycopeptides</td> </tr> <tr> <td class=\"indent1\">Teicoplanin<sup>&#182;</sup></td> <td>400 mg in one bag</td> <td>20 mg per bag</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vancomycin</td> <td>2 grams in one bag</td> <td>25 mg/L dialysate<sup>&#916;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Others</td> </tr> <tr> <td class=\"indent1\">Aztreonam</td> <td>1 gram/L dialysate in one bag</td> <td>250 mg/L dialysate</td> </tr> <tr> <td class=\"indent1\">Ciprofloxacin<sup>&#9674;</sup></td> <td>None</td> <td>50 mg/L dialysate</td> </tr> <tr> <td class=\"indent1\">Clindamycin</td> <td>None</td> <td>600 mg per bag</td> </tr> <tr> <td class=\"indent1\">Daptomycin</td> <td>100 mg/L dialysate in one bag</td> <td>20 mg/L dialysate</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Polymyxin B</td> <td>None</td> <td>300,000 units (30 mg) per bag</td> </tr> <tr> <td colspan=\"3\"><strong>Oral options that provide adequate levels within the peritoneum:</strong> Refer to separately available table of intermittently administered antibiotics in peritoneal dialysis-associated peritonitis.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table shows the suggested dose of antibiotics for IP administration in <strong>all</strong> exchanges of peritoneal dialysate for continuous ambulatory peritoneal dialysis-associated peritonitis, without signs of systemic infection. Intermittent IP-administered regimens are preferred over the continuous regimens shown in this table for initial therapy and should be used for the duration of treatment of two to three weeks or more in patients who are responding clinically. In patients who are not improving on intermittent therapy with agent(s) that should be effective based on microbiologic data, it is reasonable to increase frequency of intermittent dosing or switch to the continuous IP dosing regimens shown in this table. Refer to UpToDate topic on microbiology and therapy of peritonitis in peritoneal dialysis for considerations in selection of antimicrobials and dosing strategy.</div><div class=\"graphic_footnotes\">IP: intraperitoneal.<br />* Intravenous preparation is not available in United States.<br />&para; Not available in United States.<br />&Delta; We do not check serum vancomycin levels. If the maintenance dose is 25 mg/L, the serum vancomycin level will not exceed 25 mg/L.<br /><span class=\"lozenge\">&loz;</span> We generally do not use IP-administered fluoroquinolones, even if culture results suggest that the organism may be sensitive as in vivo results can differ due to biofilm formation. Refer to UpToDate topic on microbiology and therapy of peritonitis in peritoneal dialysis.</div><div class=\"graphic_reference\">Adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Li PK, Szeto CC, Piraino B, et al. Peritoneal Dialysis-Related Infections Recommendations: 2010 Update. Perit Dial Int 2010; 30:393.</li>&#xD;&#xA;    <li>Li PK, Szeto CC, Piraino B, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. Perit Dial Int 2016; 36:481.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 79841 Version 6.0</div></div></div>"},"79842":{"type":"graphic_figure","displayName":"A1C pramlin vs Pbo A","title":"Mean change Â± standard deviation in A1c and body weight in patients with type 1 diabetes treated with insulin plus either pramlintide or placebo","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mean change Â± standard deviation in A1c and body weight in patients with type 1 diabetes treated with insulin plus either pramlintide or placebo</div><div class=\"cntnt\"><img style=\"width:376px; height:440px;\" src=\"images/ENDO/79842_A1C_pramlin_vs_Pbo_A.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HbA1C: glycated hemoglobin.<br />* p&lt;0.05.<br />â¢ p&lt;0.001.</div><div class=\"graphic_reference\">Reproduced with permission from: Buse J, Weyer C, Maggs D. Amylin replacement with pramlintide in type 1 and type 2 diabetes: A physiological approach to overcome barriers with insulin therapy. Clinical Diabetes 2002; 20:137. Copyright Â© 2002 The American Diabetes Association.</div><div id=\"graphicVersion\">Graphic 79842 Version 2.0</div></div></div>"},"79844":{"type":"graphic_movie","displayName":"AIRTRAQ demonstration","title":"AIRTRAQ demonstration","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">AIRTRAQ demonstration</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/79844_AIRTRAQdemonstration.mp4\" style=\"width:480px;height:368px\"></div><img style=\"width:432px; height:324px;\" src=\"images/EM/79844_AIRTRAQdemonstration.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Airtraq LLC.</div><div id=\"graphicVersion\">Graphic 79844 Version 1.0</div></div></div>"},"79846":{"type":"graphic_diagnosticimage","displayName":"Apical 4 chamber contrast echo LV dysfunction","title":"Apical 4-chamber view of an echocardiogram showing contrast-enhanced images in left ventricular dysfunction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Apical 4-chamber view of an echocardiogram showing contrast-enhanced images in left ventricular dysfunction</div><div class=\"cntnt\"><img style=\"width:403px; height:251px;\" src=\"images/CARD/79846_Contrast_echo_LV_dysfunctio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Successive frames obtained from an apical 4-chamber view of a two dimensional contrast enchanced echocardiogram demonstrates a swirling left ventricular intracavitary contrast flow (pattern B) in a patient with LV dyssynergy and reduced global function.</div><div class=\"graphic_reference\">Reproduced from Thanigaraj S, Chugh R, Schectman KB, et al. Am J Cardiol 2000; 85:65, with permission from Excerpta Medica, Inc.</div><div class=\"contractual\"><br/><a href=\"http://www.elsevier.com/locate/jacc\">http://www.elsevier.com/locate/jacc</a><br/><a href=\"http://www.sciencedirect.com/\"> http://www.sciencedirect.com</a></div><div id=\"graphicVersion\">Graphic 79846 Version 4.0</div></div></div>"},"79848":{"type":"graphic_figure","displayName":"Normal kidney lengths age","title":"Sonographic renal length plotted against age","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Sonographic renal length plotted against age</div><div class=\"cntnt\"><img style=\"width:494px; height:405px;\" src=\"images/PEDS/79848_Normal_kidney_lengths_age.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Rosenbaum D, Korngold E, Littlewood Teele R. Sonographic assessment of renal length in children. Am J Roentgenol 1984; 142:467. Reprinted with permission from the American Journal of Roentgenology.&nbsp;Copyright Â© 1984 American Roentgen Ray Society.</div><div id=\"graphicVersion\">Graphic 79848 Version 9.0</div></div></div>"},"79849":{"type":"graphic_picture","displayName":"Nasopharyngeal airway insertion","title":"Nasopharyngeal airway insertion","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Nasopharyngeal airway insertion</div><div class=\"cntnt\"><img style=\"width:546px; height:362px;\" src=\"images/EM/79849_Nasopharyn_airway_insert.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The nasopharyngeal airway (NPA) should be coated with water-soluble lubricant or anesthetic jelly. The device is then inserted along the floor of the naris into the posterior pharynx behind the tongue. Clinicians should note that the floor of the naris inclines in a caudad orientation approximately 15 degrees. The tube can be rotated slightly if resistance is encountered.</div><div id=\"graphicVersion\">Graphic 79849 Version 4.0</div></div></div>"},"79852":{"type":"graphic_table","displayName":"Pain assoc interventions","title":"Acute pain syndromes associated with diagnostic and therapeutic interventions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Acute pain syndromes associated with diagnostic and therapeutic interventions</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Acute pain syndromes associated with diagnostic interventions:\n   </td>\n   </tr>\n   <tr>\n   <td>Lumbar puncture-associated and post-lumbar puncture headache</td>\n   </tr>\n   <tr>\n   <td>Arterial or venous blood sampling</td>\n   </tr>\n   <tr>\n   <td>Endoscopy and biopsy</td>\n   </tr>\n   <tr>\n   <td>Endometrial biopsy</td>\n   </tr>\n   <tr>\n   <td>Transrectal prostate biopsy</td>\n   </tr>\n   <tr>\n   <td>Percutaneous biopsy</td>\n   </tr>\n   <tr>\n   <td>Bone marrow biopsy</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Acute pain syndromes associated with therapeutic interventions:\n   </td>\n   </tr>\n   <tr>\n   <td>Pleurodesis/chest tube insertions</td>\n   </tr>\n   <tr>\n   <td>Percutaneous biliary stents</td>\n   </tr>\n   <tr>\n   <td>Abdominal paracentesis</td>\n   </tr>\n   <tr>\n   <td>Vascular embolization</td>\n   </tr>\n   <tr>\n   <td>Suprapubic catheterization</td>\n   </tr>\n   <tr>\n   <td>Nephrostomy tube insertion</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Acute pain syndromes associated with analgesic techniques:\n   </td>\n   </tr>\n   <tr>\n   <td>Injection-related pain</td>\n   </tr>\n   <tr>\n   <td>Opioid hyperalgesia syndrome</td>\n   </tr>\n   <tr>\n   <td>Epidural injection pain</td>\n   </tr>\n </table></div><div id=\"graphicVersion\">Graphic 79852 Version 1.0</div></div></div>"},"79853":{"type":"graphic_algorithm","displayName":"Cause Cushing's syndrome","title":"Testing to establish the cause of Cushing's syndrome*","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">Testing to establish the cause of Cushing's syndrome*</div><div class=\"cntnt\"><img style=\"width:562px; height:506px;\" src=\"images/ENDO/79853_Diagnosis_Cushings_syndrome.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ACTH: corticotropin; CRH: corticotropin-releasing hormone; CT: computed tomography; MR: magnetic resonance; MRI: magnetic resonance imaging; dex: dexamethasone; IPSS: inferior petrosal sinus sampling.<br />* Testing can only be interpreted in the context of sustained hypercortisolism and may be inaccurate with cyclic hypercortisolism.</div><div id=\"graphicVersion\">Graphic 79853 Version 6.0</div></div></div>"},"79854":{"type":"graphic_table","displayName":"Acetaminophen preparations","title":"Common dosage forms of acetaminophen (paracetamol)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common dosage forms of acetaminophen (paracetamol)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Preparation</td> <td class=\"subtitle1\">Strength</td> <td class=\"subtitle1\">Examples of US trade names</td> </tr> <tr> <td>Extended release caplet</td> <td>650 mg</td> <td>Tylenol Arthritis Pain</td> </tr> <tr> <td>Extra strength tablets, capsules, caplets, gelcaps, geltabs</td> <td>500 mg</td> <td>Genapap Extra Strength, Genebs Extra Strength, Tylenol Extra Strength, Medpap Extra Strength, Aspirin Free Anacin&#174; Maximum Strength, Cetafen Extra, Redutemp, Valorin Extra</td> </tr> <tr> <td rowspan=\"2\">Tablets</td> <td>325 mg</td> <td>Cetafen, Genapap, Genebs ,Tylenol, Valorin, Mapap</td> </tr> <tr> <td>160 mg</td> <td>Mapap</td> </tr> <tr> <td rowspan=\"2\">Chewable tablets</td> <td>80 mg</td> <td>Children's Genapap, Children's Mapap, Children's Tylenol</td> </tr> <tr> <td>160 mg</td> <td>Junior Strength Tylenol</td> </tr> <tr> <td rowspan=\"2\">Liquid, syrup, elixir, suspension</td> <td>160 mg/5 mL (32 mg/mL)</td> <td>Redutemp, Children's Genapap, Children's Silapap, Children's Mapap Children's Tylenol</td> </tr> <tr> <td>500 mg/15 mL (33.3 mg/mL)</td> <td>Tylenol Sore Throat</td> </tr> <tr> <td>Drops*</td> <td>100 mg/mL (80 mg/0.8 mL)</td> <td>Infant Genapap, Infantaire, Infant's Silapap Liquiprin for Children, Infant's Mapap, Infant's Tylenol</td> </tr> <tr> <td>Suppositories</td> <td>80, 120, 325, 650 mg</td> <td>Acephen, Feverall, Mapap</td> </tr> <tr> <td>Intravenous solution<sup>&#182;</sup></td> <td>10 mg/mL</td> <td>Ofirmev</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* As of 2011, in an effort to minimize pediatric dosing errors, the Consumer Healthcare Products Association, in conjunction with the US Federal Drug Administration, is phasing out formulations that contain 100 mg per mL (infant acetaminophen drops) so that pediatric liquid preparations obtained in the United States after that time will all contain a concentration of 32 mg/mL (160 mg per 5 mL). However, 100 mg per mL solutions are likely to continue to be given to children from infant acetaminophen drops preparations purchased by caregivers before this phase out.<br />&para; NOTE: Tenfold dosing errors and toxicity from intravenous acetaminophen have occurred in small children when the calculated dose in mg is INCORRECTLY administered as the volume in mL because the concentration of the solution is 10 mg/mL. In the United States, intravenous acetaminophen is not licensed for use in children under two years of age.</div><div id=\"graphicVersion\">Graphic 79854 Version 5.0</div></div></div>"},"79855":{"type":"graphic_figure","displayName":"Laryngeal anatomy","title":"Laryngeal anatomy in the coronal plane from a posterior view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laryngeal anatomy in the coronal plane from a posterior view</div><div class=\"cntnt\"><img style=\"width:448px; height:415px;\" src=\"images/PC/79855_Laryngeal_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Garrett CG, Ossoff RH. Hoarseness. Med Clin N Am 1999; 83:115. Copyright 1999 W.B. Saunders Company.</div><div id=\"graphicVersion\">Graphic 79855 Version 2.0</div></div></div>"},"79856":{"type":"graphic_picture","displayName":"Tracheal granuloma CT","title":"Tracheal granuloma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tracheal granuloma</div><div class=\"cntnt\"><img style=\"width:350px; height:292px;\" src=\"images/PULM/79856_Tracheal_granuloma_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomographic image of a tracheal granuloma causing focal intrathoracic tracheal obstruction in a patient with coccidiomycosis.</div><div id=\"graphicVersion\">Graphic 79856 Version 1.0</div></div></div>"},"79857":{"type":"graphic_picture","displayName":"Acral erythema on the hands","title":"Acral erythema","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Acral erythema</div><div class=\"cntnt\"><img style=\"width:468px; height:308px;\" src=\"images/DERM/79857_Acralerythemaonhands.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral erythema is present on the hands in this patient with acral erythema.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 79857 Version 4.0</div></div></div>"},"79858":{"type":"graphic_figure","displayName":"TPO and BM progenitor cells","title":"Importance of TPO activity on bone marrow progenitor cells","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Importance of TPO activity on bone marrow progenitor cells</div><div class=\"cntnt\"><img style=\"width:517px; height:314px;\" src=\"images/HEME/79858_TPO_and_BM_progenitor_cells.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow progenitor cells (&#177;SD) in normal, wild-type (WT), thrombopoietin-deficient (TPO -/-), and c-Mpl-deficient (MPL -/-) mice. GM-CFC (GM), E-BFC, Meg-CFC (Meg), mixed colonies (Mix-CFC) with erythroid component (E Mix), erythroid and megakaryocytic components (E/M Mix), or megakaryocytic with nonerythroid components (M-Mix) are markedly reduced in the absence of TPO or its receptor.</div><div class=\"graphic_reference\">Data from Carver-Moore, K, Broxmeyer, HE, Luoh, SM, et al, Blood 1996; 88:803.</div><div id=\"graphicVersion\">Graphic 79858 Version 1.0</div></div></div>"},"79860":{"type":"graphic_figure","displayName":"Molec progress oral CA","title":"Chemical, pathologic, and molecular progression of oral cancer","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Chemical, pathologic, and molecular progression of oral cancer</div><div class=\"cntnt\"><img style=\"width:580px; height:440px;\" src=\"images/ONC/79860_Molec_progress_oral_CA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A) shows clinical progression of oral cancer. Panel B) depicts the histologic progression from normal-appearing mucosa to invasive cancer. Normal-appearing mucosa already harbors early genetic changes (Panel C), often with loss of 9p21 and inactivation of p16. Further clinical progression through dysplasia is associated with further genetic changes. Carcinoma in situ often harbors most of the genetic changes described in invasive carcinoma.</div><div class=\"graphic_footnotes\">LOH: loss of heterozygosity.</div><div class=\"graphic_reference\">Reproduced with permission from: Joseph A Califano, MD.</div><div id=\"graphicVersion\">Graphic 79860 Version 3.0</div></div></div>"},"79862":{"type":"graphic_figure","displayName":"Nebulizer iNeb","title":"iNeb nebulizer showing device and principle of operation","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">iNeb nebulizer showing device and principle of operation</div><div class=\"cntnt\"><img style=\"width:463px; height:269px;\" src=\"images/PULM/79862_Nebulizer_iNeb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The iNeb nebulizer monitors the patient's breathing pattern and injects the aerosolized medication at the start of each inhalation. It is used for the administration of iloprost.</div><div id=\"graphicVersion\">Graphic 79862 Version 1.0</div></div></div>"},"79863":{"type":"graphic_diagnosticimage","displayName":"Chondrosarcoma CT","title":"Chondrosarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chondrosarcoma</div><div class=\"cntnt\"><img style=\"width:360px; height:217px;\" src=\"images/ONC/79863_Chondrosarcoma_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone window of a coronal CT scan shows a chondrosarcoma of the right clivus.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Silloo B Kapadia, MD.</div><div id=\"graphicVersion\">Graphic 79863 Version 3.0</div></div></div>"},"79864":{"type":"graphic_figure","displayName":"Urinary tract anatomy PI","title":"Anatomy of the urinary tract","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Anatomy of the urinary tract</div><div class=\"cntnt\"><img style=\"width:508px; height:335px;\" src=\"images/PI/79864_Urinary_tract_anat_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urine is made by the kidneys. It passes from the kidneys into the bladder through two tubes called the ureters. Then it leaves the bladder through another tube called the urethra.</div><div id=\"graphicVersion\">Graphic 79864 Version 7.0</div></div></div>"},"79865":{"type":"graphic_figure","displayName":"Sternal plating","title":"Sternal plating","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sternal plating</div><div class=\"cntnt\"><img style=\"width:408px; height:453px;\" src=\"images/SURG/79865_Sternal_plating.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sternal plates provide rigid fixation to the sternum and are made in a variety of configurations. They have been used in cases of sternal dehiscense or primarily in patients with a high risk of sternal healing problems.</div><div id=\"graphicVersion\">Graphic 79865 Version 1.0</div></div></div>"},"79867":{"type":"graphic_picture","displayName":"Lichen sclerosus on the breast","title":"Extragenital lichen sclerosus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Extragenital lichen sclerosus</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/79867_Lichen_sclerosus_breast.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A porcelain-white, finely wrinkled plaque is present on the breast.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 79867 Version 3.0</div></div></div>"},"79869":{"type":"graphic_figure","displayName":"Osteolytic metastases","title":"The vicious cycle of osteolytic metastasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The vicious cycle of osteolytic metastasis</div><div class=\"cntnt\"><img style=\"width:407px; height:546px;\" src=\"images/ONC/79869_Osteolytic-metastases-new.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tumor cells, in particular breast cancer, secrete parathyroid hormone related peptide (PTHrP)&#160;as the primary stimulator of osteoclastogenesis. In addition, tumor cells produce other factors that increase osteoclast formation including interleukin-6 (IL-6), prostaglandin E2 (PGE2), tumor necrosis factor (TNF), and macrophage colony-stimulating factor (M-CSF). These factors increase RANK ligand expression, which directly acts on osteoclast precursors to induce osteoclast formation and bone resorption. The bone resorption process releases factors such as transforming growth factor-beta (TGF-&#946;), which increase PTHrP production by tumor cells as well as growth factors (eg, insulin-like growth factors [IGFs],&#160;fibroblast growth factors [FGFs], platelet-derived growth factor [PDGF], bone morphogenetic proteins [BMPs])&#160;that increase tumor growth. This symbiotic relationship between bone destruction and tumor growth further increases bone destruction and tumor growth.</div><div class=\"graphic_reference\">Modified from&#160;Roodman GD. Mechanisms of bone metastases. N Engl J Med 2004; 350:1655.</div><div id=\"graphicVersion\">Graphic 79869 Version 6.0</div></div></div>"},"79870":{"type":"graphic_picture","displayName":"Bedbug bites 2","title":"Bedbug bites","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bedbug bites</div><div class=\"cntnt\"><img style=\"width:390px; height:216px;\" src=\"images/PC/79870_Bedbug_bites_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A bedbug bite most often appears as a wheal with a central, hemorrhagic punctum.</div><div class=\"graphic_reference\">Courtesy of Nigel Hill, PhD.</div><div id=\"graphicVersion\">Graphic 79870 Version 3.0</div></div></div>"},"79871":{"type":"graphic_table","displayName":"Viral cause common cold","title":"Viral cause of the common cold","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Viral cause of the common cold</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Virus</td> <td class=\"subtitle1\">Estimated annual proportion of cases</td> </tr> <tr> <td>Rhinoviruses</td> <td>30 to 50 percent</td> </tr> <tr> <td>Coronaviruses</td> <td>10 to 15 percent</td> </tr> <tr> <td>Influenza viruses</td> <td>5 to 15 percent</td> </tr> <tr> <td>Respiratory syncytial virus</td> <td>5 percent</td> </tr> <tr> <td>Parainfluenza viruses</td> <td>5 percent</td> </tr> <tr> <td>Adenoviruses</td> <td>&#60;5 percent</td> </tr> <tr> <td>Enteroviruses</td> <td>&#60;5 percent</td> </tr> <tr> <td>Metapneumovirus</td> <td>Unknown </td> </tr> <tr> <td>Unknown</td> <td>20 to 30 percent</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Heikkinen T, Jarvinen A. The common cold. Lancet 2003; 361:51. Copyright Â©2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 79871 Version 3.0</div></div></div>"},"79872":{"type":"graphic_picture","displayName":"Psoriatic arthritis hand","title":"Psoriatic arthritis","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Psoriatic arthritis</div><div class=\"cntnt\"><img style=\"width:468px; height:351px;\" src=\"images/RHEUM/79872_Psoriatic_arthritis_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph of the hand of a patient with psoriatic arthritis shows characteristic early nail separation (onycholysis), swelling, and erythema of the index and little finger distal interphalangeal joints.</div><div class=\"graphic_reference\">Reproduced with permission from Daniel Z Sands, MD, MPH.</div><div id=\"graphicVersion\">Graphic 79872 Version 2.0</div></div></div>"},"79873":{"type":"graphic_table","displayName":"Uterine carcinoma grade","title":"Uterine corpus carcinoma grades: degrees of histopathologic differentation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Uterine corpus carcinoma grades: degrees of histopathologic differentation</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\" rowspan=\"1\" colspan=\"2\">\n   Cases of carcinoma of the corpus should be grouped with regard to the degree of differentation of the adenocarcinoma as follows:\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\">\n   G1\n   </td>\n   <td>5 percent or less of a nonsquamous or nonmorular solid growth pattern</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\">\n   G2\n   </td>\n   <td>6 percent to 50 percent of a nonsquamous or nonmorular solid growth pattern</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle2_left\">\n   G3\n   </td>\n   <td>More than 50 percent of a nonsquamous or nonmorular solid growth pattern</td>\n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">19.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=24409&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Uterine_carcinoma_grade.htm</title></head></div><div class=\"graphic_reference\">Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.</div><div id=\"graphicVersion\">Graphic 79873 Version 8.0</div></div></div>"},"79874":{"type":"graphic_diagnosticimage","displayName":"Aspergillus lung abscess PA","title":"Lung abscess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lung abscess</div><div class=\"cntnt\"><img style=\"width:346px; height:343px;\" src=\"images/ID/79874_Aspergillus_lung_abscess_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><EM>Aspergillus fumigatus</EM> lung abscess in a liver transplant recipient. The patient had recently purchased a farm, leading to extensive exposure to soil-borne pathogens; the patient subsequently developed cryptococcosis.</div><div class=\"graphic_reference\">Courtesy of Jay Fishman, MD.</div><div id=\"graphicVersion\">Graphic 79874 Version 4.0</div></div></div>"},"79876":{"type":"graphic_movie","displayName":"Aortic root aneurysm parasternal long axis echocardiogram","title":"Aortic root aneurysm long axis view from a 2D echocardiogram","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aortic root aneurysm long axis view from a 2D echocardiogram</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/79876_aorrtaneconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:324px; height:242px;\" src=\"images/CARD/79876_aorrtane.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">2D echocardiogram shows marked aneurysmal dilatation of the aortic root. Aortic valve motion is normal and the left ventricle is of normal size, although there is concentric hypertrophy of the septum and posterior wall.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 79876 Version 3.0</div></div></div>"},"79877":{"type":"graphic_table","displayName":"Phosphorus foods 1 PI","title":"Table 20. Phosphorus content of protein-containing foods","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Table 20. Phosphorus content of protein-containing foods</div><div class=\"cntnt\"><img style=\"width:413px; height:694px;\" src=\"images/PI/79877_Phosphorus_foods_1_PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 79877 Version 6.0</div></div></div>"},"79879":{"type":"graphic_picture","displayName":"Pseudohyphae candida albicans","title":"<EM>Candida albicans</EM>","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\"><EM>Candida albicans</EM></div><div class=\"cntnt\"><img style=\"width:504px; height:423px;\" src=\"images/PC/79879_Hyphaecandidaalbicans.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pseudohyphae of <EM>Candida albicans</EM>&nbsp;on potassium hydroxide (KOH)&nbsp;preparation with light microscopy.</div><div class=\"graphic_reference\">Courtesy of Eva Rawlings Parker, MD.</div><div id=\"graphicVersion\">Graphic 79879 Version 9.0</div></div></div>"},"79880":{"type":"graphic_algorithm","displayName":"Diagnostic approach in suspected rickets","title":"Diagnostic approach in suspected rickets","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diagnostic approach in suspected rickets</div><div class=\"cntnt\"><img style=\"width:443px; height:289px;\" src=\"images/PEDS/79880_Dx_apprch_sspct_rck.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rickets is suggested by typical clinical signs and elevated alkaline phosphatase activity in a child who has normal kidney and liver function. Calcipenic rickets is sometimes termed \"hypocalcemic rickets,\" but this term is not completely accurate because serum calcium is not always low in this disorder.</div><div class=\"graphic_footnotes\">PTH: parathyroid hormone; Pi: inorganic phosphorus; Ca: calcium.<br />* The diagnosis of calcipenic rickets should be confirmed by monitoring response to therapy.<br />Â¶ In phosphopenic rickets, serum inorganic phosphorus (Pi) is often very low.<br />Î Hypophosphatasia is accompanied by low serum alkaline phosphatase activity.</div><div id=\"graphicVersion\">Graphic 79880 Version 6.0</div></div></div>"},"79881":{"type":"graphic_table","displayName":"Radiologic evaluation of the pediatric cervical spine","title":"Summary of indications for radiologic evaluation of the cervical spine in children and adolescents with blunt trauma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of indications for radiologic evaluation of the cervical spine in children and adolescents with blunt trauma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Radiologic study</td> <td class=\"subtitle1\">History and physical</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">None</td> <td>Low risk mechanism of injury, <strong>and</strong></td> </tr> <tr> <td>No multiple system trauma with comorbid injuries to head, face, or torso&nbsp;and no&nbsp;high-risk biomechanics<sup>*</sup>, <strong>and</strong></td> </tr> <tr> <td>No conditions that predispose to cervical spine injury<sup>&#182;</sup>, <strong>and</strong></td> </tr> <tr> <td>Awake (GCS 15)&nbsp;and able to verbalize and cooperate with exam, <strong>and</strong></td> </tr> <tr> <td>No neck pain, tenderness, deformity,&nbsp;or limitation of movement,<sup>&#916;</sup> <strong>and</strong></td> </tr> <tr class=\"divider_bottom\"> <td>No neurologic deficits</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Lateral, AP, odontoid radiographs<sup>&#9674;</sup></td> <td>High-risk mechanisms of injury or biomechanics<sup>*</sup>, <strong>or</strong>&nbsp;</td> </tr> <tr> <td>Multiple system trauma with comorbid injuries to head, face, or torso, <strong>or</strong></td> </tr> <tr> <td>Conditions that predispose to cervical spine injury<sup>&#182;</sup>, <strong>or</strong></td> </tr> <tr> <td>Altered mental status (GCS 14), <strong>or</strong></td> </tr> <tr class=\"divider_bottom\"> <td>Neck pain, tenderness, deformity, or limitation of movement</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Computed tomography of the C-spine</td> <td>Acute neurologic deficit (instead of plain films),&nbsp; <strong>or</strong></td> </tr> <tr> <td>As part of initial evaluation of severe head trauma (GCS 3 to 13) instead of plain films, <strong>or</strong></td> </tr> <tr> <td>Abnormal or suspicious C-spine on plain films, <strong>or</strong></td> </tr> <tr> <td>High index of suspicion&nbsp;for C-spine&nbsp;injury despite normal plain cervical radiographs</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"> <p>Flexion-extension radiographs<sup>&#167;</sup></p> <p>&nbsp;</p> </td> <td>Normal C-spine films, <strong>and</strong></td> </tr> <tr> <td>No neurologic deficit referable to C-spine, <strong>and</strong></td> </tr> <tr> <td>Continued neck pain, tenderness, or muscle spasm, <strong>and</strong></td> </tr> <tr class=\"divider_bottom\"> <td>Able to actively flex and extend neck for the examination</td> </tr> <tr> <td>MRI</td> <td>Children with an abnormal neurologic examination and those requiring imaging of the soft tissues of the spinal column and spinal cord (eg, patients with normal plain films but persistent concern for neurologic injury based upon history, patients with prolonged loss of consciousness in whom cervical spine cannot be cleared by 24 to 72 hours post injury)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GCS: Glasgow coma scale.<br />* High-risk motor vehicle crashes (speed &gt;55 mph, death of occupant, partial or complete ejection, and intrusion into the passenger compartment [12 inches at sides 18 inches at roof]), diving, or mechanisms associated with axial load to the head, hyperextension or hyperflexion of the neck, or acceleration-deceleration of the head. Patients with painful injuries not due to high risk mechanisms for cervical spine injury (eg, isolated extremity fracture despite low force mechanism) may still undergo clinical clearance. <br />Â¶&nbsp; For example, Down syndrome, Klippel Feil syndrome, Morquio syndrome, Larsen syndrome, ankylosing spondylitis, cervical arthritis, prior cervical spine injury, or cervical spine surgery.<br />Î Able to move head in flexion and extension and rotate 45 degrees to both sides without pain.<br />â&nbsp;Odontoid plain radiographs may be omitted in uncooperative children. However, children with possible upper cervical spine injury by history or physical examination, should undergo computed tomography of C1.<br />Â§ If biomechanics of injury and clinical findings do <STRONG>not </STRONG>indicate a high index of suspicion for ligamentous injury, flexion-extensions radiographs may be deferred to outpatient follow-up. </div><div class=\"graphic_reference\">Source: Chung S, Mikrogianakis A, Wales PW, et al. Trauma Association of Canada Pediatric Subcommittee National Pediatric Cervical Spine Evaluation Pathway: Consensus Guidelines. J Trauma 2011; 70:873.</div><div id=\"graphicVersion\">Graphic 79881 Version 13.0</div></div></div>"},"79882":{"type":"graphic_figure","displayName":"Incomplete penetrance--pedigree","title":"Example of a pedigree showing incomplete penetrance of a dominant trait","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Example of a pedigree showing incomplete penetrance of a dominant trait</div><div class=\"cntnt\"><img style=\"width:390px; height:283px;\" src=\"images/PC/79882_Incomplete_penetrance_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Incomplete penetrance. This pedigree illustrates incomplete penetrance for a dominant trait. Six of seven family members who harbor the mutation are affected, suggesting a penetrance of 0.857.</div><div id=\"graphicVersion\">Graphic 79882 Version 5.0</div></div></div>"},"79883":{"type":"graphic_diagnosticimage","displayName":"Distal common bile duct stricture","title":"Distal common bile duct stricture","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Distal common bile duct stricture</div><div class=\"cntnt\"><img style=\"width:504px; height:464px;\" src=\"images/GAST/79883_Distal_bile_duct_strict_PR2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cholangiogram showing a stricture in the distal common bile duct.</div><div id=\"graphicVersion\">Graphic 79883 Version 2.0</div></div></div>"},"79884":{"type":"graphic_table","displayName":"Causes of Budd Chiari syndrome","title":"Major causes of the Budd-Chiari syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of the Budd-Chiari syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Myeloproliferative diseases</td> </tr> <tr> <td class=\"sublist1_start\">Malignancy</td> </tr> <tr> <td class=\"sublist1\">Hepatocellular carcinoma is most common</td> </tr> <tr> <td>Infections and benign lesions of the liver</td> </tr> <tr> <td class=\"sublist1_start\">Hypercoagulable states</td> </tr> <tr> <td class=\"sublist1\">Oral contraceptive use</td> </tr> <tr> <td class=\"sublist1\">Pregnancy</td> </tr> <tr> <td class=\"sublist1\">Factor V Leiden mutation</td> </tr> <tr> <td class=\"sublist1\">Prothrombin gene mutation</td> </tr> <tr> <td class=\"sublist1\">Antiphospholipid antibody syndrome</td> </tr> <tr> <td class=\"sublist1\">Antithrombin III deficiency </td> </tr> <tr> <td class=\"sublist1\">Protein C deficiency</td> </tr> <tr> <td class=\"sublist1\">Protein S deficiency </td> </tr> <tr> <td class=\"sublist1\">Paroxysmal nocturnal hemoglobinuria</td> </tr> <tr> <td class=\"sublist1\">JAK2 mutations</td> </tr> <tr> <td>Beh<span style=\"font-size: 11pt; font-family: 'calibri','sans-serif'; line-height: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'times new roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: en-us; mso-fareast-language: en-us; mso-bidi-language: ar-sa;\">&#231;</span>et's disease</td> </tr> <tr> <td>Membranous webs of the inferior vena cava and/or the hepatic veins</td> </tr> <tr> <td>Miscellaneous conditions including celiac disease, ulcerative colitis, hypereosinophilic syndrome, and granulomatous venulitis</td> </tr> <tr> <td class=\"sublist1_start\">Idiopathic</td> </tr> <tr> <td class=\"sublist1\">Many may have an underlying myeloproliferative disease </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 79884 Version 3.0</div></div></div>"},"79885":{"type":"graphic_figure","displayName":"Measurement QT dispersion","title":"Measurement of QT dispersion","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Measurement of QT dispersion</div><div class=\"cntnt\"><img style=\"width:465px; height:380px;\" src=\"images/CARD/79885_Measurement_QT_dispersion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The measurement of QT dispersion may be based either on the real QRS duration and or differences in the measurable duration of QT intervals. As shown, two hypothetical T waves of the same amplitude can have different offset when the heart vector becomes perpendicular to the axis of one of the leads; this results in real dispersion of the QT intervals (vertical dashed lines). However, if different proportion of the final part of the two T waves is below the threshold level (eg with an automatic threshold method) the measured dispersion of the QT intervals (vertical solid line) is different from the real dispersion.</div><div id=\"graphicVersion\">Graphic 79885 Version 1.0</div></div></div>"},"79886":{"type":"graphic_picture","displayName":"Dermatomal herpes zoster","title":"Dermatomal herpes zoster","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dermatomal herpes zoster</div><div class=\"cntnt\"><img style=\"width:407px; height:252px;\" src=\"images/ID/79886_Dermatomal_herpes_zoster.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Grouped vesicles on an erythematous base present in a dermatomal distribution on the upper back due to herpes zoster. The lesions stop abruptly at the midline.</div><div class=\"graphic_reference\">Courtesy of Lee T Nesbitt, Jr. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 79886 Version 4.0</div></div></div>"},"79887":{"type":"graphic_figure","displayName":"AVP and AVP receptor 2","title":"Interaction between AVP and its receptor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Interaction between AVP and its receptor</div><div class=\"cntnt\"><img style=\"width:204px; height:427px;\" src=\"images/NEPH/79887_AVP_and_AVP_recep_2_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the relation between arginine vasopressin (AVP, antidiuretic hormone) and the AVP receptor 2 (AVPR2). The receptor is depicted as seven coiled red ribbons. AVP is nestled within a pocket formed by the transmembrane domains of AVPR2.</div><div class=\"graphic_reference\">Adapted from: Bichet DG, Oksche A, Rosenthal E, J Am Soc Nephrol 1997; 8:1951.</div><div id=\"graphicVersion\">Graphic 79887 Version 4.0</div></div></div>"},"79890":{"type":"graphic_picture","displayName":"Dysgerminoma histo","title":"Dysgerminoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dysgerminoma</div><div class=\"cntnt\"><img style=\"width:414px; height:288px;\" src=\"images/OBGYN/79890_Dysgerminoma_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The neoplastic germ cells have clear, glycogen-filled cytoplasm and central nuclei. Fibrous septa containing lymphocytes traverse the tumor.</div><div class=\"graphic_reference\">Reproduced with permission from: Rubin E MD and Farber JL MD. Pathology, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 1999. Copyright &#169;1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 79890 Version 1.0</div></div></div>"},"79891":{"type":"graphic_algorithm","displayName":"Management of tMN","title":"Management of therapy-related myeloid neoplasm","html":"<div class=\"graphic\"><div style=\"width: 627px\" class=\"figure\"><div class=\"ttl\">Management of therapy-related myeloid neoplasm</div><div class=\"cntnt\"><img style=\"width:607px; height:573px;\" src=\"images/HEME/79891_Rx_of_tMN.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Modified with permission from: Larson RA. Etiology and management of therapy-related myeloid leukemia. Hematology Am Soc Hematol Educ Program 2007; 2007:453.</div><div id=\"graphicVersion\">Graphic 79891 Version 4.0</div></div></div>"},"79894":{"type":"graphic_picture","displayName":"Ichthyosis vulgaris 4","title":"Ichthyosis vulgaris","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ichthyosis vulgaris</div><div class=\"cntnt\"><img style=\"width:348px; height:397px;\" src=\"images/DERM/79894_Ichthyosis_vulgaris_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient with ichthyosis vulgaris has truncal involvement. The appearance resembles fine fish scales.</div><div class=\"graphic_reference\">Reproduced with permission from: George A Datto, III, MD.</div><div id=\"graphicVersion\">Graphic 79894 Version 1.0</div></div></div>"},"79896":{"type":"graphic_figure","displayName":"Scabies distribution PI","title":"Parts of the body affected by scabies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Parts of the body affected by scabies</div><div class=\"cntnt\"><img style=\"width:442px; height:551px;\" src=\"images/PI/79896_Scabies_distribution_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scabies usually affects the sides and webs of the fingers, inside of the wrists, elbows, armpits, skin around the nipples (especially in women), skin around the belly button, waist, male genitals (scrotum and penis), knees, lower half of the butt and tops of thighs, and sides and backs of the feet. The back is not usually affected. The head is not usually affected except in very young children.</div><div id=\"graphicVersion\">Graphic 79896 Version 4.0</div></div></div>"},"79897":{"type":"graphic_table","displayName":"Pediatric dosing TB drugs","title":"Drug dosing for the treatment of tuberculosis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drug dosing for the treatment of tuberculosis in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drugs</td> <td class=\"subtitle1\">Dose forms</td> <td class=\"subtitle1\">Daily dose, mg/kg</td> <td class=\"subtitle1\">Twice a week dose, mg/kg per dose</td> <td class=\"subtitle1\">Maximum dose</td> <td class=\"subtitle1\">Adverse reactions</td> </tr> <tr class=\"divider_bottom\"> <td>Ethambutol</td> <td> <p><strong>Tablets</strong>:</p> <p>100 mg</p> 400 mg</td> <td>20 (15 to 25)</td> <td>50</td> <td>2.5 g</td> <td>Optic neuritis (usually reversible), decreased red-green color discrimination, gastrointestinal tract disturbances, hypersensitivity</td> </tr> <tr class=\"divider_bottom\"> <td>Isoniazid*</td> <td> <p><strong>Scored tablets:</strong></p> <p>100 mg</p> <p>300 mg</p> <p><strong>Syrup:</strong></p> 10 mg/mL</td> <td>10 to 15<sup>&#182;</sup></td> <td>20 to 30</td> <td> <p>Daily, 300 mg</p> Twice a week, 900 mg</td> <td>Mild hepatic enzyme elevation, hepatitis,<sup>&#182;</sup> peripheral neuritis, hypersensitivity</td> </tr> <tr class=\"divider_bottom\"> <td>Pyrazinamide*</td> <td> <p><strong>Scored tablets:</strong></p> 500 mg</td> <td>35 (30 to 40)</td> <td>50</td> <td>2 g</td> <td>Hepatotoxic effects, hyperuricemia, arthralgia, gastrointestinal tract upset</td> </tr> <tr> <td>Rifampin*</td> <td> <p><strong>Capsules:</strong></p> <p>150 mg</p> <p>300 mg</p> <strong>Syrup formulated capsules</strong></td> <td>10 to 20</td> <td>10 to 20</td> <td>600 mg</td> <td>Orange discoloration of secretions or urine, staining of contact lenses, vomiting, hepatitis, influenza-like reaction, thrombocytopenia, pruritus; oral contraceptives may be ineffective</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Rifamate is a capsule containing 150 mg of isoniazid and 300 mg of rifampin. Two capsules provide the usual adult (&gt;50 kg) daily doses of each drug. Rifater, in the United States, is a capsule containing 50 mg of isoniazid, 120 mg of rifampin, and 300 mg of pyrazinamide. Isoniazid and rifampin also are available for parenteral administration.<br />Â¶ When isoniazid in a dose exceeding 10 mg/kg per day is used in combination with rifampin, the incidence of hepatotoxic effects may be increased.</div><div class=\"graphic_reference\">From: American Academy of Pediatrics. Tuberculosis. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK, Baker CJ, Kimberlin DW, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2012. Used with the permission of the American Academy of Pediatrics. Copyright Â© 2012. The contents of this table remain unchanged in the Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed.</div><div id=\"graphicVersion\">Graphic 79897 Version 20.0</div></div></div>"},"79899":{"type":"graphic_table","displayName":"Adolescent development","title":"Adolescent development","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adolescent development</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Tasks </td> <td class=\"subtitle1\">Early, 10 to 14 years </td> <td class=\"subtitle1\">Middle, 15 to 17 years </td> <td class=\"subtitle1\">Late, 18 and older </td> </tr> <tr> <td>Physical</td> <td>Initiation of puberty; preoccupation with appearance; potential to reproduce</td> <td>Completing puberty</td> <td>Physical reproductive maturity</td> </tr> <tr> <td>Cognitive</td> <td>Concrete thinking</td> <td>Increasing ability for abstract reasoning; risk-consequence deficits</td> <td>Abstract reasoning; understands risk-consequence</td> </tr> <tr> <td>Emotional</td> <td>Egocentric</td> <td>Developing sense of identity; risk-taking and experimentation</td> <td>Intimacy as basis for sexual relationships; empathy and connectedness with others</td> </tr> <tr> <td>Social</td> <td>Reliance on family/parents; same-sex peer relationships and few romantic relationships</td> <td>Peer influence, sexual exploration; differentiating from family</td> <td>Exploring new mature role in family, romantic relationships, social networks, and workplace</td> </tr> <tr> <td>Sexual</td> <td>\"Crushes\"; beginning sexual experimentation</td> <td>Exploration and experimentation; intense romantic relationships; serial monogamy</td> <td>Mature acceptance and enjoyment of sexual self; good communication and decision-making skills regarding sex</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Robert Garofalo, MD, MPH, and Michelle Forcier, MD, MPH.</div><div id=\"graphicVersion\">Graphic 79899 Version 2.0</div></div></div>"},"79901":{"type":"graphic_picture","displayName":"AVMs APC Endosc","title":"Arteriovenous malformation in the gastrointestinal tract","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Arteriovenous malformation in the gastrointestinal tract</div><div class=\"cntnt\"><img style=\"width:462px; height:423px;\" src=\"images/GAST/79901_AVMs_APC_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic views of arteriovenous malformations being treated with the argon plasma coagulator (APC). The top panels illustrate the appearance before and after APC coagulation. The bottom panels demonstrate the ability of APC to treat lesions tangentially. It is important to see the black portion of the APC cathether prior to initiating coagulation to prevent damage to the endoscope.</div><div class=\"graphic_reference\">Courtesy of Jonathan Cohen, MD.</div><div id=\"graphicVersion\">Graphic 79901 Version 2.0</div></div></div>"},"79902":{"type":"graphic_picture","displayName":"Granulosa cell tumor","title":"Ovarian granulosa cell tumor","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Ovarian granulosa cell tumor</div><div class=\"cntnt\"><img style=\"width:468px; height:376px;\" src=\"images/OBGYN/79902_Granulosa_cell_tumor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The tumor cells are arranged in sheets punctuated by small follicle-like structures (Call-Exner bodies).</div><div class=\"graphic_reference\">Reproduced with permission from: Crum CP. The Female Genital Tract. In: Pathologic Basis of Disease, 6th ed, Cotran RS, Kumar V, Collins T (Eds), WB Saunders Company, Pennsylvania 1999. Copyright &#169; 1999 Elsevier.</div><div id=\"graphicVersion\">Graphic 79902 Version 3.0</div></div></div>"},"79904":{"type":"graphic_diagnosticimage","displayName":"Congen pulm airways malform CT III","title":"Congenital pulmonary airways malformation of the left lower lobe in 30-year-old man with recurrent pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital pulmonary airways malformation of the left lower lobe in 30-year-old man with recurrent pneumonia</div><div class=\"cntnt\"><img style=\"width:360px; height:276px;\" src=\"images/PULM/79904_Adenomatoid_malform_CT_III.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan displays the multicystic nature of the mass-like consolidation.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 79904 Version 3.0</div></div></div>"},"79905":{"type":"graphic_picture","displayName":"Rosacea erythema PI","title":"Rosacea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rosacea</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/PI/79905_Rosacea_erythema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This person with rosacea has redness and tiny, swollen blood vessels (called &quot;telangiectasias&quot;) on the cheeks, nose, and chin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 79905 Version 4.0</div></div></div>"},"79906":{"type":"graphic_diagnosticimage","displayName":"Normal lateral elbow radiograph child","title":"Normal lateral radiograph of the elbow of a 2-year-old child","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal lateral radiograph of the elbow of a 2-year-old child</div><div class=\"cntnt\"><img style=\"width:360px; height:325px;\" src=\"images/EM/79906_Normallateralelbow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The anterior fat pad is readily seen (arrow); the posterior fat pad is not visible. A line drawn along the anterior cortex of the humerus intersects the capitellum in its middle third (solid line). A line drawn along the axis of the radius also passes through the center of the capitellum (dashed line).</div><div class=\"graphic_reference\">Reproduced with permission from: Bachman D, Santora S. Orthopedic trauma. In: Textbook of pediatric emergency medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FR (Eds), Lippincott Williams &amp; Wilkins 2006. Copyright Â© 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 79906 Version 14.0</div></div></div>"},"79908":{"type":"graphic_picture","displayName":"Alopecia areata 3","title":"Alopecia areata","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Alopecia areata</div><div class=\"cntnt\"><img style=\"width:350px; height:265px;\" src=\"images/DERM/79908_Alopecia_areata_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patchy hair loss is seen in this patient with alopecia areata.</div><div class=\"graphic_reference\">Reproduced with permission from: Fleisher GR, Ludwig S, Baskin MN. Atlas of Pediatric Emergency Medicine, Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright Â© 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 79908 Version 2.0</div></div></div>"},"79910":{"type":"graphic_diagnosticimage","displayName":"Osteonecrosis hips plain film","title":"Osteonecrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Osteonecrosis</div><div class=\"cntnt\"><img style=\"width:287px; height:223px;\" src=\"images/RHEUM/79910_Osteonecrosis_hips_plain_fi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient with sickle cell anemia and bilateral osteonecrosis of the hips (right worse than left). Flattening of the right femoral head is indicative of collapse.</div><div class=\"graphic_reference\">Courtesy of Mary Nell Suell, MD, and Brigitta U Mueller, MD.</div><div id=\"graphicVersion\">Graphic 79910 Version 2.0</div></div></div>"},"79911":{"type":"graphic_diagnosticimage","displayName":"Transmission US in RA","title":"Transmission ultrasonography in RA","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transmission ultrasonography in RA</div><div class=\"cntnt\"><img style=\"width:373px; height:315px;\" src=\"images/RHEUM/79911_Transmission_US_in_RA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transmission ultrasonography showing a distended joint capsule in the proximal interphalangeal joint (arrow) of a patient with rheumatoid arthritis.</div><div class=\"graphic_reference\">Reproduced from: Owen DS. Aspiration and injection of joints in soft tissue. In: Textbook of Rheumatology, 4th, Kelley WN, Harris ED Jr, Ruddy S, et al (Eds), WB Saunders, Philadelphia 1993. p.545.</div><div id=\"graphicVersion\">Graphic 79911 Version 2.0</div></div></div>"},"79913":{"type":"graphic_table","displayName":"Drugs toxins causing ALF","title":"Some drugs, herbal products, and toxins associated with acute liver failure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Some drugs, herbal products, and toxins associated with acute liver failure</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Abacavir</td> </tr> <tr> <td>Acetaminophen (paracetamol)</td> </tr> <tr> <td>Alcohol</td> </tr> <tr> <td>Allopurinol</td> </tr> <tr> <td>Amiodarone</td> </tr> <tr> <td>Amoxicillin</td> </tr> <tr> <td>Aspirin</td> </tr> <tr> <td>Carbamazepine</td> </tr> <tr> <td>Carbon tetrachloride</td> </tr> <tr> <td>Ciprofloxacin</td> </tr> <tr> <td>Cocaine</td> </tr> <tr> <td>Comfrey</td> </tr> <tr> <td>Dapsone</td> </tr> <tr> <td>Didanosine</td> </tr> <tr> <td>Dideoxyinosine</td> </tr> <tr> <td>Disulfiram</td> </tr> <tr> <td>Doxycycline</td> </tr> <tr> <td>Efavirenz</td> </tr> <tr> <td>Gemtuzumab</td> </tr> <tr> <td>Gold</td> </tr> <tr> <td>Greater celandine</td> </tr> <tr> <td>Halothane</td> </tr> <tr> <td>He Shon Wu</td> </tr> <tr> <td>Herbalife&#174;</td> </tr> <tr> <td>Hydroxycut&#174;</td> </tr> <tr> <td>Isoflurane</td> </tr> <tr> <td>Isoniazid</td> </tr> <tr> <td>Itraconazole</td> </tr> <tr> <td>Kava Kava</td> </tr> <tr> <td>Ketoconazole</td> </tr> <tr> <td>Labetalol</td> </tr> <tr> <td>LipoKinetix&#174;</td> </tr> <tr> <td>Ma Huang</td> </tr> <tr> <td>MDMA (Ecstasy)</td> </tr> <tr> <td>Methamphetamine</td> </tr> <tr> <td>Monoamine oxidase inhibitors</td> </tr> <tr> <td>Methyldopa</td> </tr> <tr> <td>Nicotinic acid</td> </tr> <tr> <td>Nitrofurantoin</td> </tr> <tr> <td>Nonsteroidal anti-inflammatory drugs</td> </tr> <tr> <td>Phenprocoumon</td> </tr> <tr> <td>Phenytoin</td> </tr> <tr> <td>Poison mushrooms (<em>Amanita phalloides</em>)</td> </tr> <tr> <td>Propylthiouracil</td> </tr> <tr> <td>Pyrazinamide</td> </tr> <tr> <td>Rifampin</td> </tr> <tr> <td>Senecio</td> </tr> <tr> <td>Statins</td> </tr> <tr> <td>Sulfonamides</td> </tr> <tr> <td>Terbinafine</td> </tr> <tr> <td>Tetracycline</td> </tr> <tr> <td>Tolcapone</td> </tr> <tr> <td>Tricyclic antidepressants</td> </tr> <tr> <td>Valproic acid</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 79913 Version 5.0</div></div></div>"},"79914":{"type":"graphic_picture","displayName":"Transplant glomerulopathy EM","title":"Transplant glomerulopathy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transplant glomerulopathy</div><div class=\"cntnt\"><img style=\"width:378px; height:243px;\" src=\"images/NEPH/79914_Transplant_glomerulopathy_E.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph of transplant glomerulopathy reveals marked narrowing of the vascular lumen due to widening of the subendothelial space both by mesangial cell processes (arrow) and by amorphous, electron-lucent material.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 79914 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Electron micrograph of a normal glomerulus</div><div class=\"cntnt\"><img style=\"width:377px; height:266px;\" src=\"images/NEPH/50018_Normal_glomerulus_EM_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron-dense deposits are present. Two normal platelets are seen in the capillary lumen.</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 50018 Version 7.0</div></div></div>"},"79915":{"type":"graphic_figure","displayName":"MVG calculation","title":"Calculation of the myocardial velocity gradient","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">Calculation of the myocardial velocity gradient</div><div class=\"cntnt\"><img style=\"width:451px; height:284px;\" src=\"images/CARD/79915_MVGcalculation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The peak negative myocardial velocity gradient (MVG) is obtained from tissue Doppler imaging (TDI). The endocardial and epicardial boundaries of the left ventricular (LV) posterior wall are manually traced from an M-mode image, and the velocity between the two lines&nbsp;is extracted from the corresponding color-coded image (left panel). At each point in time, indicated by the vertical line in early diastole, the velocity profile across the myocardial wall is obtained and provided for the least squares linear regression analysis (right panel). The slope of the regression line was determined as the instantaneous MVG; the MVG calculations are repeated at each point in time throughout the cardiac cycle, and peak negative MVG is determined.</div><div class=\"graphic_reference\">Reproduced with permission from Shimizu Y, Uematsu M, Shimizu H, et al. J Am Coll Cardiol 1998; 32:1418.</div><div id=\"graphicVersion\">Graphic 79915 Version 2.0</div></div></div>"},"79918":{"type":"graphic_table","displayName":"Phases of chronic MR","title":"Echocardiographic and catheterization indices in the threeÂ phases of chronic mitral regurgitation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Echocardiographic and catheterization indices in the three&nbsp;phases of chronic mitral regurgitation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Compensated</td> <td class=\"subtitle1\">Transitional</td> <td class=\"subtitle1\">Decompensated</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Echocardiography</td> </tr> <tr> <td class=\"indent1\">End-diastolic dimension, mm</td> <td>&#60;63</td> <td>65 to 68</td> <td>&#62;70</td> </tr> <tr> <td class=\"indent1\">End-systolic dimension, mm</td> <td>&#60;42</td> <td>44 to 45</td> <td>&#62;47</td> </tr> <tr> <td class=\"indent1\">Fractional shortening, percent</td> <td>&#62;34</td> <td>31 to 32</td> <td>&#60;30</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Cardiac catheterization</td> </tr> <tr> <td class=\"indent1\">End-diastolic volume, mL/m<sup>2</sup></td> <td>&#60;110</td> <td>120 to 150</td> <td>&#62;160</td> </tr> <tr> <td class=\"indent1\">End-systolic volume, mL/m<sup>2</sup></td> <td>&#60;45</td> <td>50 to 55</td> <td>&#62;60</td> </tr> <tr> <td class=\"indent1\">Ejection fraction, percent</td> <td>&#62;60</td> <td>53 to 57</td> <td>&#60;50</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 79918 Version 3.0</div></div></div>"},"79919":{"type":"graphic_picture","displayName":"NSAID induced strictures UGI","title":"NSAID-induced strictures","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">NSAID-induced strictures</div><div class=\"cntnt\"><img style=\"width:317px; height:323px;\" src=\"images/GAST/79919_NSAID_induced_strictures_UG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Enteroclysis showing NSAID-induced strictures (between arrows) that are difficult to appreciate, and resembling exaggerated plica circularis. Diaphragm-like strictures confirmed at surgery.</div><div class=\"graphic_reference\">Reproduced with permission from: Bjarnason I, et al. Side effects of nonsteroidal antiinflammatory drugs (NSAIDs) on the small and large intestine in humans. Gastroenterology 1993; 104:1832. Copyright &copy; 1993 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 79919 Version 3.0</div></div></div>"},"79920":{"type":"graphic_movie","displayName":"TEE mitral valve leaflet perforation ","title":"Transesophageal echo (TEE) closeup view showing a perforated mitral valve leaflet","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transesophageal echo (TEE) closeup view showing a perforated mitral valve leaflet</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/79920_teezmvpconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:250px; height:321px;\" src=\"images/CARD/79920_teezmvp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transesophageal echocardiogram with a close-up of the mitral valve shows a perforation of the anterior leaflet.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 79920 Version 4.0</div></div></div>"},"79921":{"type":"graphic_table","displayName":"Pediatric thoracic injuries","title":"Pediatric thoracic injuries","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pediatric thoracic injuries</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Immediately life-threatening (usually suspected on initial assessment)</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td> Airway obstruction</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Open pneumothorax</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Flail chest</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Tension pneumothorax</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Massive hemothorax</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Cardiac tamponade</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Potentially life-threatening (usually noted on secondary survey, chest radiograph, ECG, or reevaluation)</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td> Tracheobronchial tear</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Pulmonary contusion</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Myocardial contusion</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Ruptured diaphragm</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Esophageal rupture</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Aortic transection</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Generally not life-threatening</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Simple pneumothorax</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Small hemothorax</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Rib fracture</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Chest wall laceration/contusion</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 79921 Version 1.0</div></div></div>"},"79922":{"type":"graphic_figure","displayName":"TSH receptor gene mutations","title":"Serum TSH and free T4 in various forms of RTSH","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Serum TSH and free T4 in various forms of RTSH</div><div class=\"cntnt\"><img style=\"width:515px; height:473px;\" src=\"images/PEDS/79922_TSH_receptor_gene_mutations.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Results shown are from a representative family having each of the four forms of resistance to thyroid stimulating hormone (RTSH). Note that by definition affected family members have high TSH. Free T4 concentrations vary considerably according to the type of defect and within subjects with the same defect. For details,&nbsp;refer to the text&nbsp;of the topic on resistance to thyrotropin.</div><div class=\"graphic_footnotes\">TSH: thyroid stimulating hormone (thyrotropin); RTSH: resistance to thyroid stimulating hormone; Chr 15: chromosome 15; FT4: free T4 (free thyroxine).</div><div id=\"graphicVersion\">Graphic 79922 Version 2.0</div></div></div>"},"79923":{"type":"graphic_diagnosticimage","displayName":"Echocardiogram of inlet VSD","title":"Echocardiogram of inlet VSD","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Echocardiogram of inlet VSD</div><div class=\"cntnt\"><img style=\"width:478px; height:322px;\" src=\"images/CARD/79923_Echocardiogram_inlet_VSD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Apical four-chamber view demonstrating a large inlet VSD underneath the mitral and tricuspid valves.</div><div class=\"graphic_footnotes\">VSD: ventricular septal defect; RA: right atrium; LA: left atrium; RV: right ventricle; LV: left ventricle.</div><div class=\"graphic_reference\">Courtesy of Dr. Naser Ammash.</div><div id=\"graphicVersion\">Graphic 79923 Version 3.0</div></div></div>"},"79924":{"type":"graphic_picture","displayName":"Dermatomyositis shawl sign","title":"Shawl sign in dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Shawl sign in dermatomyositis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/79924_Dermatomy_hyperpig.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Poikilodermatous&nbsp;patches are present on the upper back of this patient with dermatomyositis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 79924 Version 5.0</div></div></div>"},"79925":{"type":"graphic_figure","displayName":"Menstrual interval","title":"Age-related interval between menses","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Age-related interval between menses</div><div class=\"cntnt\"><img style=\"width:456px; height:247px;\" src=\"images/ENDO/79925_Duration_of_menses_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Selected percentiles for the distribution of menstrual interval by age based on data from over 200,000 cycles. Longer intermenstrual intervals occur in women just after menarche and in the years preceding menopause.</div><div class=\"graphic_reference\">Data from: Treloar AE, Boynton RE, Behn BG, Brown BW. Variation of the human menstrual cycle through reproductive life. Int J Fertil 1967; 12:77.</div><div id=\"graphicVersion\">Graphic 79925 Version 6.0</div></div></div>"},"79926":{"type":"graphic_table","displayName":"Vaginal CA stage distribution","title":"Primary vaginal carcinoma: distribution by stage of disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Primary vaginal carcinoma: distribution by stage of disease</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Stage</td>\n\n      <td class=\"subtitle1\">N</td>\n\n      <td class=\"subtitle1\">Percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>I</td>\n\n      <td>358</td>\n\n      <td>26</td>\n\n    </tr>\n\n    <tr>\n\n      <td>II</td>\n\n      <td>511</td>\n\n      <td>37.2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>III</td>\n\n      <td>331</td>\n\n      <td>24.1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>IV</td>\n\n      <td>175</td>\n\n      <td>12.7</td>\n\n    </tr>\n\n    <tr>\n\n      <td><strong>Total</strong></td>\n\n      <td>1375</td>\n\n      <td>100.0</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission by Berek JS, Hacker NF. Practical Gynecologic Oncology. 3rd ed, Williams and Wilkins, Baltimore, 2000. Copyright Â© 2000 Lippincott Williams &amp; Wilkins.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 79926 Version 6.0</div></div></div>"},"79927":{"type":"graphic_table","displayName":"AASLD diagnosis screening Wilson","title":"AASLD recommendations for diagnosis and screening for Wilson disease (WD)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">AASLD recommendations for diagnosis and screening for Wilson disease (WD)</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Clinical features:\n   </td>\n   </tr>\n   <tr>\n   <td>WD should be considered in any individual between the ages of 3 and 55* years with liver abnormalities of uncertain cause. Age alone should not be the basis for eliminating a diagnosis of WD.</td>\n   </tr>\n   <tr>\n   <td>WD must be excluded in any patient with unexplained liver disease along with neurological or neuropsychiatric disorder.</td>\n   </tr>\n   <tr>\n   <td>In a patient in whom WD is suspected, Kayser-Fleischer rings should be sought by slit-lamp examination by a skilled examiner. The absence of Kayser-Fleischer rings does not exclude the diagnosis of WD, even in patients with predominantly neurological disease.</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Diagnostic testing:\n   </td>\n   </tr>\n   <tr>\n   <td>An extremely low serum ceruloplasmin level (&#60;50 mg/L or &#60;5 mg/dL) should be taken as strong evidence for the diagnosis of WD. Modestly subnormal levels suggest further evaluation is necessary. Serum ceruloplasmin within the normal range does not exclude the diagnosis.</td>\n   </tr>\n   <tr>\n   <td>Basal 24-hour urinary excretion of copper should be obtained in all patients in whom the diagnosis of WD is being considered. The amount of copper excreted in the 24-hour period is typically &#62;100 mcg (1.6 micromol) in symptomatic patients, but finding &#62;40 mcg (&#62;0.6 micromol or &#62;600 nmol) may indicate WD and requires further investigation.</td>\n   </tr>\n   <tr>\n   <td>Penicillamine challenge studies may be performed for the purpose of obtaining further evidence for the diagnosis of WD in symptomatic children if basal urinary copper excretion is &#60;100 mcg/24 hours (1.6 micromol/24 hours). Values for the penicillamine challenge test of &#62;1600 mcg copper/24 hours (&#62;25 micromol/24 hours) following the administration of 500 mg of D-penicillamine at the beginning and again 12 hours later during the 24-hour urine collection are found in patients with Wilson disease. The predictive value of this test in adults is unknown.</td>\n   </tr>\n   <tr>\n   <td>Hepatic parenchymal copper content &#62;250 mcg/g dry weight provides critical diagnostic information and should be obtained in cases where the diagnosis is not straightforward and in younger patients. In untreated patients, normal hepatic copper content (&#60;40-50 mcg/g dry weight) almost always excludes a diagnosis of WD. Further diagnostic testing is indicated for patients with intermediate copper concentrations (70-250 mcg/g dry weight) especially if there is active liver disease or other symptoms of WD.</td>\n   </tr>\n   <tr>\n   <td>Neurologic evaluation and radiologic imaging of the brain, preferably by MR imaging, should be considered prior to treatment in all patients with neurologic WD and should be part of the evaluation of any patient presenting with neurological symptoms consistent with WD.</td>\n   </tr>\n   <tr>\n   <td>Mutation analysis by whole-gene sequencing is possible and should be performed on individuals in whom the diagnosis is difficult to establish by clinical and biochemical testing. Haplotype analysis or specific testing for known mutations can be used for family screening of first-degree relatives of patients with WD. A clinical geneticist may be required to interpret the results.</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Diagnostic considerations in specific target populations:\n   </td>\n   </tr>\n   <tr>\n   <td>Patients in the pediatric age bracket who present a clinical picture of autoimmune hepatitis should be investigated for WD.</td>\n   </tr>\n   <tr>\n   <td>Adult patients with atypical autoimmune hepatitis or who respond poorly to standard corticosteroid therapy should also be investigated for WD.</td>\n   </tr>\n   <tr>\n   <td>WD should be considered in the differential diagnosis of patients presenting with nonalcoholic fatty liver disease or have pathologic findings of nonalcoholic steatohepatitis.</td>\n   </tr>\n   <tr>\n   <td>WD should be suspected in any patient presenting with acute hepatic failure with Coombs-negative intravascular hemolysis, modest elevations in serum aminotransferases, or low serum alkaline phosphatase and ratio of alkaline phosphatase to bilirubin of &#60;2.</td>\n   </tr>\n   <tr>\n   <td>First-degree relatives of any patient newly diagnosed with WD must be screened for WD.</td>\n   </tr>\n </table></div><div class=\"graphic_footnotes\">*Wilson disease has been diagnosed in patients in their seventies.</div><div class=\"graphic_reference\">Data from: Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson disease: an update. Hepatology 2008; 47:2089.</div><div id=\"graphicVersion\">Graphic 79927 Version 2.0</div></div></div>"},"79928":{"type":"graphic_diagnosticimage","displayName":"Twin peak or lambda sign","title":"Twin peak or lambda sign","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Twin peak or lambda sign</div><div class=\"cntnt\"><img style=\"width:410px; height:247px;\" src=\"images/OBGYN/79928_Twin_peak_or_lambda_sign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The arrow points to a triangular projection of chorionic tissue emanating from fused dichorionic placentas and extending between layers of the intertwin membrane. This is characteristic of a dichorionic diamniotic twin pregnancy.</div><div id=\"graphicVersion\">Graphic 79928 Version 3.0</div></div></div>"},"79931":{"type":"graphic_algorithm","displayName":"Normal sleep and breathing","title":"Sleep and breathing: normal physiology","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Sleep and breathing: normal physiology</div><div class=\"cntnt\"><img style=\"width:473px; height:373px;\" src=\"images/PULM/79931_Normal_sleep_and_breathing.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 79931 Version 2.0</div></div></div>"},"79932":{"type":"graphic_figure","displayName":"Mitral valve structure","title":"Mitral valve structure","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Mitral valve structure</div><div class=\"cntnt\"><img style=\"width:534px; height:478px;\" src=\"images/CARD/79932_Mitral_valve_structure.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 79932 Version 2.0</div></div></div>"},"79934":{"type":"graphic_picture","displayName":"Radio-opaque marking thoracostomy tube","title":"Radio-opaque marking on thoracostomy tube","html":"<div class=\"graphic\"><div style=\"width: 585px\" class=\"figure\"><div class=\"ttl\">Radio-opaque marking on thoracostomy tube</div><div class=\"cntnt\"><img style=\"width:565px; height:754px;\" src=\"images/SURG/79934_Radioopaquemarking.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The radio-opaque marker is seen in blue.</div><div id=\"graphicVersion\">Graphic 79934 Version 3.0</div></div></div>"},"79936":{"type":"graphic_diagnosticimage","displayName":"HSG with traction","title":"Hysterosalpingogram","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Hysterosalpingogram</div><div class=\"cntnt\"><img style=\"width:540px; height:220px;\" src=\"images/OBGYN/79936_HSG_with_traction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Hysterosalpingogram (HSG) showing an irregular uterine cavity interpreted by the radiologist as showing multiple submucous myomas. (B) Repeat HSG of the same patient shown in A, but with the cervix pulled down. Now a septate uterus is obvious, not submucous myomas.</div><div class=\"graphic_reference\">Reproduced with permission from: Baramki TA. Hysterosalpingography. Fertil Steril 2005; 83:1595. Copyright Â© 2005 Elsevier Science, Inc.</div><div id=\"graphicVersion\">Graphic 79936 Version 3.0</div></div></div>"},"79937":{"type":"graphic_table","displayName":"Frequency of common birth defects","title":"Leading categories of birth defects","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Leading categories of birth defects</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Birth defects</td> <td class=\"subtitle1\">Estimated incidence</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Structural/metabolic</td> </tr> <tr> <td class=\"indent1\">Heart and circulation</td> <td>1 in 115 births</td> </tr> <tr> <td class=\"indent1\">Muscles and skeleton</td> <td>1 in 130 births</td> </tr> <tr> <td class=\"indent1\">Club foot</td> <td>1 in 735 births</td> </tr> <tr> <td class=\"indent1\">Cleft lip/palate</td> <td>1 in 930 births</td> </tr> <tr> <td class=\"indent1\">Genital and urinary tract</td> <td>1 in 135 births</td> </tr> <tr> <td class=\"indent1\">Nervous system and eye</td> <td>1 in 235 births</td> </tr> <tr> <td class=\"indent1\">Anencephaly</td> <td>1 in 8000 births</td> </tr> <tr> <td class=\"indent1\">Spina bifida</td> <td>1 in 2000 births</td> </tr> <tr> <td class=\"indent1\">Chromosomal syndromes</td> <td>1 in 600 births</td> </tr> <tr> <td class=\"indent1\">Down syndrome (trisomy 21)</td> <td>1 in 900 births</td> </tr> <tr> <td class=\"indent1\">Respiratory tract</td> <td>1 in 900 births</td> </tr> <tr> <td class=\"indent1\">Metabolic disorders</td> <td>1 in 3500 births</td> </tr> <tr> <td class=\"indent1\">PKU</td> <td>1 in 12,000 births</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Congenital infections</td> </tr> <tr> <td class=\"indent1\">Congenital syphilis</td> <td>1 in 2000 births</td> </tr> <tr> <td class=\"indent1\">Congenital HIV infection</td> <td>1 in 2700 births</td> </tr> <tr> <td class=\"indent1\">Congenital rubella syndrome</td> <td>1 in 100,000 births</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Other</td> </tr> <tr> <td class=\"indent1\">Rh disease</td> <td>1 in 1400 births</td> </tr> <tr> <td class=\"indent1\">Fetal alcohol syndrome</td> <td>1 in 1000 births</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Note: All numbers are based on the best available estimates, which underestimate the incidence of many birth defects.</div><div class=\"graphic_footnotes\">PKU: phenylketonuria; HIV: human immunodeficiency virus.</div><div class=\"graphic_reference\">Unpublished review of the literature and information from various state and regional birth defects surveillance systems (California, Iowa, Metropolitan Atlanta, New York, and Texas). http://www. marchofdimes.com/aboutus/680_2164.asp Copyright Â© 2000 March of Dimes Perinatal Data Center. Used by permission.</div><div id=\"graphicVersion\">Graphic 79937 Version 3.0</div></div></div>"},"79938":{"type":"graphic_waveform","displayName":"ECG pace map ventricular tachycardia","title":"12-lead electrocardiogram (ECG) showing pace map of ventricular tachycardia","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram (ECG) showing pace map of ventricular tachycardia</div><div class=\"cntnt\"><img style=\"width:485px; height:657px;\" src=\"images/CARD/79938_Pace_map_ventricular_tachy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The QRS complexes on the twelve-lead ECG, recorded during spontaneous ventricular tachycardia (VT) provoked by isoproterenol, are identical in each lead to those recorded during ventricular pacing.</div><div id=\"graphicVersion\">Graphic 79938 Version 3.0</div></div></div>"},"79941":{"type":"graphic_table","displayName":"Findings cyanotic heart disease","title":"Typical physical examination, chest radiography, and electrocardiography findings in some forms of cyanotic heart disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Typical physical examination, chest radiography, and electrocardiography findings in some forms of cyanotic heart disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Diagnosis</td> <td class=\"subtitle1\" colspan=\"2\">Physical exam</td> <td class=\"subtitle1\" colspan=\"3\">Chest radiography</td> <td class=\"subtitle1\" colspan=\"2\">Electrocardiogram</td> <td class=\"subtitle1\" rowspan=\"2\">Incidence<br /> (per 100,000 live births)*</td> </tr> <tr> <td class=\"subtitle2\">S2</td> <td class=\"subtitle2\">Murmur</td> <td class=\"subtitle2\">Heart size</td> <td class=\"subtitle2\">PBF</td> <td class=\"subtitle2\">Percent RAA</td> <td class=\"subtitle2\">QRS axis</td> <td class=\"subtitle2\">Hypertrophy</td> </tr> <tr> <td>TGA</td> <td>single</td> <td>none</td> <td>&#8593;</td> <td>&#8593;</td> <td>4</td> <td>90 to 150</td> <td>nml</td> <td>21</td> </tr> <tr> <td>TOF</td> <td>single</td> <td>sys</td> <td>boot</td> <td>&#8595;</td> <td>20</td> <td>90 to 150</td> <td>nml</td> <td>20 to 26</td> </tr> <tr> <td>HLHS</td> <td>single</td> <td>&#177;sys</td> <td>&#8593;</td> <td>vc</td> <td>&nbsp;</td> <td>90 to 150</td> <td>&#8595; LV forces</td> <td>16</td> </tr> <tr> <td>PA-IVS</td> <td>single</td> <td>sys</td> <td>&#8593;&#8593;</td> <td>&#8595;</td> <td>&nbsp;</td> <td>30 to 90</td> <td>LVH, RAE</td> <td>7</td> </tr> <tr> <td>PS</td> <td>single</td> <td>sys</td> <td>&#8593;</td> <td>&#8595;</td> <td>&nbsp;</td> <td>30 to 90</td> <td>RVH, RAE</td> <td>7</td> </tr> <tr> <td>TAPVC</td> <td>split</td> <td>sys</td> <td>&#8593;, nl<sup>&#182;</sup></td> <td>&#8593;, vc<sup>&#182;</sup></td> <td>&nbsp;</td> <td>90 to 150</td> <td>RAE</td> <td>6</td> </tr> <tr> <td>Tricuspid atresia</td> <td>single</td> <td>&#177;sys</td> <td>&#8593;</td> <td>&#8595;</td> <td>&nbsp;</td> <td>&ndash;30 to &ndash;90</td> <td>LVH, RAE</td> <td>6</td> </tr> <tr> <td>Truncus arteriosus</td> <td>single</td> <td>sys/&#177;dias</td> <td>&#8593;</td> <td>&#8593;</td> <td>30</td> <td>90 to 150</td> <td>nml</td> <td>3</td> </tr> <tr> <td>Ebstein's</td> <td>split</td> <td>sys</td> <td>&#8593;&#8593;</td> <td>&#8595;</td> <td>&nbsp;</td> <td>90 to 150</td> <td>RAE</td> <td>1</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOTE: This table represents the common presentation of each lesion. Variations do occur. For example, tricuspid atresia usually is associated with a small ventricular septal defect and pulmonary stenosis; some patients with this diagnosis can have a large ventricular septal defect, no pulmonary stenosis, and increased pulmonary blood flow.</div><div class=\"graphic_footnotes\">dias: diastolic; HLHS: hypoplastic left heart syndrome; LV: left ventricular; LVH: left ventricular hypertrophy; nl: normal; nml: normal for neonate (right ventricular predominance); PA-IVS: pulmonary atresia intact ventricular septum; PBF: pulmonary blood flow; PS: pulmonary stenosis; RAA: right aortic arch; RAE: right atrial enlargement; sys: systolic; TAPVC: total anomalous pulmonary venous connection; TGA-IVS: d-transposition of the great arteries, intact ventricular septum; TOF: tetralogy of Fallot; vc: venous congestion.<br />* Incidence from report of New England Regional Infant Cardiac Program. Pediatrics 1980; 65:375.<br />Â¶ Patients with TAPVC associated with pulmonary venous observation have normal heart size and venous congestion on the chest radiography while those without obstruction usually have cardiomegaly and increased pulmonary blood flow.</div><div id=\"graphicVersion\">Graphic 79941 Version 10.0</div></div></div>"},"79942":{"type":"graphic_figure","displayName":"Exposure of occult upper parathyroid gland","title":"Exposure of occult upper parathyroid gland","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Exposure of occult upper parathyroid gland</div><div class=\"cntnt\"><img style=\"width:598px; height:624px;\" src=\"images/SURG/79942_Exposureoccultupperpthy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Exposure of occult right upper parathyroid.<br> (A) Anteroposterior view of the neck showing the initial route of dissection for mobilization of the upper pole, right thyroid lobe. Dissection is kept on the thyroid's surface to avoid injury to the external branch of the right superior laryngeal nerve.<br> (B) Sharp downward and left retraction of the upper pole (arrow) shows the back of the upper pole and zone of recurrent laryngeal nerve insertion into the larynx.<br> (C) Sharp left retraction of the upper and lower poles (arrows) rotates the trachea and larynx to expose the posterior esophagus and larynx.<br> (D) Retraction (arrows) for inspection of the proximal superior thyroid artery and carotid sheath.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore, Jr FD. Secondary and tertiary hyperparathyroidism. In: Mastery of Surgery, Fischer JE, Bland KI, Callery MP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright Â© 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 79942 Version 10.0</div></div></div>"},"79943":{"type":"graphic_picture","displayName":"Alternate patient positions","title":"Alternate patient positions for thoracic ultrasound","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Alternate patient positions for thoracic ultrasound</div><div class=\"cntnt\"><img style=\"width:514px; height:460px;\" src=\"images/PULM/79943_Alternate_patient_positions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four patient positions for sonographic detection of pleural effusion and subsequent thoracentesis are shown here. While the sitting position is generally preferred, alternative positions are utilized in patients who cannot maintain a sitting position.</div><div id=\"graphicVersion\">Graphic 79943 Version 1.0</div></div></div>"},"79944":{"type":"graphic_table","displayName":"Localization of pediatric respiratory distress","title":"Localization of respiratory distress by physical findings","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Localization of respiratory distress by physical findings</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Upper airway obstruction</td> </tr> <tr> <td>Sniffing position: neck is flexed with head extended to open airway</td> </tr> <tr> <td>Nasal flaring: also seen with lower airway disease</td> </tr> <tr> <td>Prolonged inspiration</td> </tr> <tr> <td>Retractions: supraclavicular, suprasternal</td> </tr> <tr> <td>Abnormal voice: hoarseness, hot potato voice</td> </tr> <tr> <td>Stridor</td> </tr> <tr> <td>Barking cough</td> </tr> <tr> <td>Transmitted upper airway sounds (stertor)</td> </tr> <tr> <td class=\"subtitle1_single\">Lower airway disease</td> </tr> <tr> <td>Retractions: intercostal, subcostal</td> </tr> <tr> <td>Nasal flaring: also seen with upper airway obstruction</td> </tr> <tr> <td>Prolonged expiration: lower airway obstruction</td> </tr> <tr> <td>Wheezing: intrathoracic airway obstruction</td> </tr> <tr> <td>Grunting: may indicate severe respiratory distress or severe pain from an intraabdominal process</td> </tr> <tr> <td>Rales (crackles)</td> </tr> <tr> <td>Pleural rub</td> </tr> <tr> <td>Bronchophony</td> </tr> <tr> <td>Pulsus paradoxus: caused by severe lower airway obstruction or cardiac tamponade</td> </tr> <tr> <td class=\"subtitle1_single\">Cardiac disease</td> </tr> <tr> <td>Gallop</td> </tr> <tr> <td>Cardiac murmur</td> </tr> <tr> <td>Rales (crackles)</td> </tr> <tr> <td>Jugular venous distention</td> </tr> <tr> <td>Hepatomegaly</td> </tr> <tr> <td>Peripheral or periorbital edema</td> </tr> <tr> <td>Pulsus paradoxus: caused by cardiac tamponade or severe lower airway obstruction</td> </tr> <tr> <td class=\"subtitle1_single\">Central nervous system</td> </tr> <tr> <td>Abnormal respiratory pattern (Cheyne-Stokes, or ataxic)</td> </tr> <tr> <td class=\"subtitle1_single\">Metabolic</td> </tr> <tr> <td>Kussmal respirations</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 79944 Version 6.0</div></div></div>"},"79946":{"type":"graphic_table","displayName":"Clinical features of syphilis","title":"Clinical manifestation of syphilis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestation of syphilis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Clinical manifestations</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Primary syphilis</strong></td> <td>Single painless ulcer (chancre) at site of inoculation, regional adenopathy</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Secondary syphilis</strong></td> <td>Rash (disseminated and/or involving the palms and soles), fever, malaise, mucocutaneous lesions, hepatitis, arthritis, glomerulonephritis, condyloma lata, pharyngitis, alopecia</td> </tr> <tr> <td><strong>Latent syphilis</strong></td> <td class=\"divider_bottom\" rowspan=\"3\">Asymptomatic</td> </tr> <tr> <td class=\"indent1\">Early latent (&#60;1 year after initial infection)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Late latent (&#62;1 year after initial infection)</td> </tr> <tr> <td colspan=\"2\"><strong>Tertiary (late) syphilis</strong></td> </tr> <tr> <td class=\"indent1\">Gummatous disease</td> <td>Granulomatous disease of the skin and subcutaneous tissues, bones, or viscera</td> </tr> <tr> <td class=\"indent1\">Cardiovascular disease</td> <td>Aortic aneurysm, aortic insufficiency</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Central nervous system disease (neurosyphilis)</td> <td>Tabes dorsalis, Argyll-Robertson pupils, paresis, seizures, subtle psychiatric manifestations, dementia. May be asymptomatic.</td> </tr> <tr> <td colspan=\"2\"><strong>Neurosyphilis (can occur at any time during the course of infection)</strong></td> </tr> <tr> <td class=\"indent1\">Early</td> <td>Asymptomatic meningitis, symptomatic meningitis, or, less commonly, meningovascular disease (ie, meningitis and stroke). Vision or hearing loss with or without concomitant meningitis may also be present, and ocular/otologic syphilis is treated as neurosyphilis.</td> </tr> <tr> <td class=\"indent1\">Late</td> <td>Most common forms involve the brain and spinal cord (dementia [general paresis] and tabes dorsalis).</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 79946 Version 2.0</div></div></div>"},"79947":{"type":"graphic_diagnosticimage","displayName":"Ultrasound partial hydatidiform mole","title":"Ultrasound image ofÂ partial hydatidiform mole","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Ultrasound image of&nbsp;partial hydatidiform mole</div><div class=\"cntnt\"><img style=\"width:504px; height:439px;\" src=\"images/OBGYN/79947_USpartialhydatidmole.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Partial hydatidiform mole: Ultrasound shows endometrial cavity filled with a partially solid and partially multicystic mass measuring 7.5 x 5.5 x 4.4 cm. Focal anechoic spaces can be seen.</div><div class=\"graphic_reference\">Courtesy of Department of Radiology, Santa Clara Valley Medical Center.</div><div id=\"graphicVersion\">Graphic 79947 Version 4.0</div></div></div>"},"79948":{"type":"graphic_table","displayName":"Neurologic predictors of prognosis after cardiac arrest","title":"Significance of physical findings in coma following cardiac arrest","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Significance of physical findings in coma following cardiac arrest</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Patients with virtually no chance of regaining independence</td> </tr> <tr> <td class=\"indent1\">Initial examination</td> <td>No pupillary light reflex</td> </tr> <tr> <td class=\"indent1\">One day</td> <td>Motor response no better than flexor and spontaneous eye movements neither orienting nor roving conjugate</td> </tr> <tr> <td class=\"indent1\">Three days</td> <td>Motor response no better than flexor, no spontaneous eye opening</td> </tr> <tr> <td class=\"indent1\">One week</td> <td>Motor response not obeying commands and spontaneous eye movements neither orienting nor roving conjugate</td> </tr> <tr> <td class=\"indent1\">Two weeks</td> <td>Oculocephalic response not normal, not obeying commands, no spontaneous eye opening, eye opening not improved at least 2 grades from initial examination</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Patients with best chance of regaining independence</td> </tr> <tr> <td class=\"indent1\">Initial examination</td> <td>Pupillary light reflexes present and motor response flexor or extensor. Spontaneous eye movements roving conjugate or orienting.</td> </tr> <tr> <td class=\"indent1\">One day</td> <td>Motor response withdrawal or better and eye opening improved at least 2 grades</td> </tr> <tr> <td class=\"indent1\">Three day</td> <td>Motor response withdrawal or better and spontaneous eye movements normal</td> </tr> <tr> <td class=\"indent1\">One week</td> <td>Motor response obeying commands</td> </tr> <tr> <td class=\"indent1\">Two weeks</td> <td>Normal oculocephalic response</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 79948 Version 3.0</div></div></div>"},"79949":{"type":"graphic_table","displayName":"Thrombolytic therapy guidelines","title":"Guidelines for thrombolytic therapy in venous thromboembolism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guidelines for thrombolytic therapy in venous thromboembolism</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Clear documentation of PE (or DVT)*</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Potential contraindications carefully reviewed</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Delivery by peripheral intravenous infusion</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Initiate or continue other supportive therapy</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Discontinue heparin during thrombolytic infusion</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* High-probability ventilation-perfusion scan or positive pulmonary arteriogram.</div><div id=\"graphicVersion\">Graphic 79949 Version 1.0</div></div></div>"},"79952":{"type":"graphic_picture","displayName":"Primary tracheal tum ENDO","title":"51-year-old female with primary tracheal adenoid cystic carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">51-year-old female with primary tracheal adenoid cystic carcinoma</div><div class=\"cntnt\"><img style=\"width:360px; height:325px;\" src=\"images/ONC/79952_Primary_tracheal_tum_ENDO.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bronchoscopic image of a primary tracheal adenoid cystic carcinoma.</div><div class=\"graphic_reference\">Courtesy of James R Jett, MD.</div><div id=\"graphicVersion\">Graphic 79952 Version 2.0</div></div></div>"},"79955":{"type":"graphic_picture","displayName":"Erythema multiforme target lesion","title":"Target lesions of erythema multiforme","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Target lesions of erythema multiforme</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/79955_Erythemamultiformetarget2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Target lesions with central bullae are present on the hand.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 79955 Version 7.0</div></div></div>"},"79956":{"type":"graphic_diagnosticimage","displayName":"Thyroid ultrasound from a patient with Graves disease","title":"Thyroid ultrasound from a patient with Graves' disease","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Thyroid ultrasound from a patient with Graves' disease</div><div class=\"cntnt\"><img style=\"width:479px; height:233px;\" src=\"images/ENDO/79956_Graves_disease_Echo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sonogram of the left thyroid lobe in the longitudinal plane from a patient with Graves' disease. The left panel shows a hypoechoic enlarged lobe (L), while the Doppler image in the right panel shows intense hyperemia.</div><div class=\"graphic_reference\">Courtesy of Manfred Blum, MD.</div><div id=\"graphicVersion\">Graphic 79956 Version 3.0</div></div></div>"},"79957":{"type":"graphic_algorithm","displayName":"Differential dx rabies","title":"Algorithm for differential diagnosis of rabies","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Algorithm for differential diagnosis of rabies</div><div class=\"cntnt\"><img style=\"width:548px; height:638px;\" src=\"images/ID/79957_Differential_dx_rabies.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">JEV: Japanese encephalitis virus; LM: Listeria monocytogenes; HSV: Herpes simplex virus; EV 71: Enterovirus; VZV: Varicella zoster virus; CMV: Cytomegalovirus; EBV: Epstein-Barr virus.</div><div class=\"graphic_reference\">Reproduced with permission from: Rupprecht, CE, Hanlon, CA, Hemachudha, T. Rabies re-examined. Lancet Infect Dis 2002; 2:327. Copyright &#169; 2002 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 79957 Version 1.0</div></div></div>"},"79958":{"type":"graphic_figure","displayName":"Assessment by lens vessels","title":"Anterior lens vessels","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anterior lens vessels</div><div class=\"cntnt\"><img style=\"width:360px; height:488px;\" src=\"images/PEDS/79958_Assessment_by_lens_vessels.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Assessment of gestational age by examination of anterior vascular capsule of the lens.</div><div class=\"graphic_reference\">Reproduced with permission from: Hittner HM, Hirsch NJ, Rudolph AJ. J Pediatr 1977; 91:455. Copyright Â© 1977 Mosby, Inc.</div><div id=\"graphicVersion\">Graphic 79958 Version 2.0</div></div></div>"},"79959":{"type":"graphic_table","displayName":"Drugs pneumococcal meningitis children","title":"Antimicrobial therapy for bacterial meningitis in children caused by Streptococcus pneumoniae based upon susceptibility test results in patients begun on vancomycin and either cefotaxime or ceftriaxone","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antimicrobial therapy for bacterial meningitis in children caused by Streptococcus pneumoniae based upon susceptibility test results in patients begun on vancomycin and either cefotaxime or ceftriaxone</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Susceptibility test results*</td> <td class=\"subtitle1\">Antibiotic management<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Susceptible to penicillin</td> <td> <p>Discontinue vancomycin</p> <p><strong>AND</strong></p> <p>Begin penicillin (and discontinue cephalosporin)</p> <p><strong>OR</strong></p> <p>Continue ceftriaxone or cefotaxime alone<sup>&#916;</sup></p> </td> </tr> <tr class=\"divider_bottom\"> <td> <p>Not susceptible to penicillin (intermediate or resistant)</p> <p><strong>AND</strong></p> <p>Susceptible to ceftriaxone and cefotaxime</p> </td> <td> <p>Discontinue vancomycin</p> <p><strong>AND</strong></p> <p>Continue ceftriaxone or cefotaxime alone</p> </td> </tr> <tr> <td> <p>Not susceptible to penicillin (intermediate or resistant)</p> <p><strong>AND</strong></p> <p>Not susceptible to ceftriaxone and cefotaxime (intermediate or resistant)</p> <p><strong>AND</strong></p> <p>Susceptible to rifampin</p> </td> <td> <p>Continue vancomycin </p> <p><strong>AND</strong></p> <p>Continue&nbsp;ceftriaxone or cefotaxime</p> <p>Rifampin may be added in selected circumstances<sup>&#9674;</sup></p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Based upon quantitative susceptibility studies.<br />Â¶&nbsp;See text for doses.<br />Î Some physicians may choose this alternative for convenience and cost savings.<br /><FONT class=lozenge>â</FONT> Addition of rifampin after 24 to 48 hours of therapy may be warranted if:<br /><OL>&#xD;&#xA;<LI>Clinical condition worsens, or</LI>&#xD;&#xA;<LI>Gram stain or culture of repeat cerebrospinal fluid (CSF) indicates failure to substantially reduce bacterial number, or</LI>&#xD;&#xA;<LI>Ceftriaxone or cefotaxime minimum inhibitory concentration (MIC) of 4 mcg/mL or greater</LI></OL></div><div class=\"graphic_reference\">From: American Academy of Pediatrics. Pneumococcal infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. Used with the permission of the American Academy of Pediatrics. Copyright Â© 2012. The contents of this table remain unchanged in the Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed.</div><div id=\"graphicVersion\">Graphic 79959 Version 11.0</div></div></div>"},"79960":{"type":"graphic_figure","displayName":"Oligoarticular and RF-negative polyarticular JIA risk loci","title":"Associations for oligoarticular and RF-negative polyarticular JIA risk loci","html":"<div class=\"graphic\"><div style=\"width: 1026px\" class=\"figure\"><div class=\"ttl\">Associations for oligoarticular and RF-negative polyarticular JIA risk loci</div><div class=\"cntnt\"><img style=\"width:1006px; height:416px;\" src=\"images/ALLRG/79960_Oligoartclr_RFneg_polyartcl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The upper solid line indicates the threshold for genome-wide significance (p&lt;5 Ã 10<SUP>â8</SUP>); loci reaching this threshold are labeled in bold font, and individual SNPs mapping to these loci are shown in red. The lower dashed line indicates the threshold for suggestive association (p&lt;1 Ã 10<SUP>â6</SUP> and p&gt;5 Ã 10<SUP>â8</SUP>); loci reaching this threshold are labeled in non-bold font.</div><div class=\"graphic_footnotes\">RF: rheumatoid factor; JIA: juvenile idiopathic arthritis; SNP: single nucleotide polymorphism.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Nature Genetics. Hinks A, Cobb J, Marion MC, et al. Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis. Nat Genet 2013; 45:664. Copyright &copy; 2013. <a href=\"http://www.nature.com/ng/index.html\" target=\"_blank\">www.nature.com/ng</a>.</div><div id=\"graphicVersion\">Graphic 79960 Version 8.0</div></div></div>"},"79961":{"type":"graphic_figure","displayName":"Mechanism of necrotic core expansion","title":"Mechanism of necrotic core expansion","html":"<div class=\"graphic\"><div style=\"width: 626px\" class=\"figure\"><div class=\"ttl\">Mechanism of necrotic core expansion</div><div class=\"cntnt\"><img style=\"width:606px; height:500px;\" src=\"images/CARD/79961_Mechnecroticcoreexpans.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Putative mechanism(s) of necrotic core expansion in human coronary plaques. A to C illustrate the concept of early, late, and hemorrhagic necrosis, respectively. A lipid pool rich in proteoglycans and CD68-positive macrophages characterizes the early fibroatheroma; there is a general absence of smooth muscle cells.<BR>(A) Infiltrating macrophages capable of engulfing apoptotic bodies (ABs) are clearly recognized within the necrotic core (NC). <BR>(B) As the lesion advances, late necrosis is represented by increased macrophage death and cell lysis and apparent loss of extracellular matrix.&nbsp;In this case, free apoptotic bodies are commonly seen, possibly indicating the defective clearance (efferocytosis) by resident macrophages. <BR>(C) In the third example, hemorrhage may promote the relatively rapid expansion of necrotic core where erythrocytes membranes provide free cholesterol (Free-Chol, arrow), which may cause secondary inflammation.&nbsp;Resident macrophages are capable of removing hemoglobin/haptoglobin complexes via the CD163 receptor, although the efficiency of this mechanism is likely compromised as well.</div><div class=\"graphic_reference\">Reproduced with permission from: Kolodgie F. Pathogenesis of atherosclerosis and the unstable plaque. In: Kwiterovich J. The Johns Hopkins Textbook of Dyslipidemia, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright Â© 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 79961 Version 10.0</div></div></div>"},"79962":{"type":"graphic_table","displayName":"Manifestations of lipodystrophy","title":"Clinical features of patients with lipodystrophic disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of patients with lipodystrophic disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Lipodystrophy</td> </tr> <tr> <td>Acanthosis nigricans (associated with severe hyperinsulinemia)</td> </tr> <tr> <td>Muscle hypertrophy, prominent veins</td> </tr> <tr> <td class=\"sublist1_start\">Hepatomegaly</td> </tr> <tr> <td class=\"sublist1\">Fatty liver</td> </tr> <tr> <td class=\"sublist1\">Cirrhosis</td> </tr> <tr> <td>Hypertrichosis, hirsutism (occasionally)</td> </tr> <tr> <td>Cardiomegaly due to hypertrophic cardiomyopathy (occasionally)</td> </tr> <tr> <td>Mental retardation (occasionally)</td> </tr> <tr> <td class=\"sublist1_start\">Metabolic abnormalities</td> </tr> <tr> <td class=\"sublist1\">Hyperglycemia, but no ketosis</td> </tr> <tr> <td class=\"sublist1\">Insulin resistance</td> </tr> <tr> <td class=\"sublist1\">Hypertriglyceridemia</td> </tr> <tr> <td class=\"sublist1\">Increased metabolic rate</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 79962 Version 2.0</div></div></div>"},"79963":{"type":"graphic_diagnosticimage","displayName":"Linitis plastica UGI","title":"Linitis plastica of the stomach as seen on upper gastrointestinal (UGI) series","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Linitis plastica of the stomach as seen on upper gastrointestinal (UGI) series</div><div class=\"cntnt\"><img style=\"width:277px; height:287px;\" src=\"images/GAST/79963_Linitis_plastica_UGI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upper gastrointestinal study reveals fixed narrowing of the entire proximal stomach (arrows) due to submucosal invasion by a gastric cancer. Other malignancies, such as breast and lung metastases to the stomach, may have a similar appearance.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 79963 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal upper GI series</div><div class=\"cntnt\"><img style=\"width:286px; height:330px;\" src=\"images/GAST/81537_Normal_upper_GI_series.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal air-contrast upper gastrointestinal (GI)&nbsp;study showing normal gastric folds and small intestinal anatomy, and no masses.</div><div class=\"graphic_reference\">Courtesy of Paul C Schroy III, MD.</div><div id=\"graphicVersion\">Graphic 81537 Version 4.0</div></div></div>"},"79966":{"type":"graphic_table","displayName":"Symptoms of pulmonary AVM","title":"Signs and symptoms with pulmonary arteriovenous malformations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Signs and symptoms with pulmonary arteriovenous malformations</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Incidence range (%)</td> <td class=\"subtitle1\">Average incidence (%)</td> </tr> <tr> <td>Symptomatic, percent</td> <td>44&nbsp;to 91 &nbsp;&nbsp;</td> <td>76</td> </tr> <tr> <td>Epistaxis, percent</td> <td>29&nbsp;to 79</td> <td>55</td> </tr> <tr> <td>Dyspnea, percent</td> <td>13&nbsp;to 56</td> <td>34</td> </tr> <tr> <td>Hemoptysis, percent</td> <td>7&nbsp;to 30</td> <td>12</td> </tr> <tr> <td>Telangiectases, percent</td> <td>34&nbsp;to 79</td> <td>53</td> </tr> <tr> <td>Bruit, percent</td> <td>29&nbsp;to 67</td> <td>43</td> </tr> <tr> <td>Clubbing, percent</td> <td>0&nbsp;to 54</td> <td>5</td> </tr> <tr> <td>Cyanosis, percent</td> <td>0&nbsp;to 54</td> <td>5</td> </tr> <tr> <td>HHT, percent</td> <td>47&nbsp;to 88</td> <td>65</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These data are based on the six largest consecutive case-series from the literature during the past 50 years.</div><div class=\"graphic_footnotes\">HHT: hereditary hemorrhagic telangiectasia.</div><div id=\"graphicVersion\">Graphic 79966 Version 3.0</div></div></div>"},"79967":{"type":"graphic_table","displayName":"Common examples of pseudoallergic drug reactions","title":"Common examples of pseudoallergic drug reactions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common examples of pseudoallergic drug reactions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Clinical reaction(s)</td> <td class=\"subtitle1\">Presumed mechanism</td> </tr> <tr> <td>Aspirin and other NSAIDs</td> <td> <p>Exacerbations of rhinitis, asthma (in patients with aspirin-exacerbated respiratory disease)</p> Urticaria/angioedema (NOTE: Urticaria may also result from a type I, IgE-mediated allergic reaction)</td> <td>Inhibited prostaglandin production and enhanced leukotriene production</td> </tr> <tr> <td>Opiates</td> <td>Pruritus, urticaria</td> <td>Direct stimulation of mast cells and/or basophils causing release of mediators</td> </tr> <tr> <td>Vancomycin</td> <td>Flushing during infusion</td> <td>Direct stimulation of mast cells and/or basophils causing release of mediators</td> </tr> <tr> <td>Radiocontrast media</td> <td>Anaphylaxis, shock (NOTE: Some may be type I, IgE-mediated allergic reactions)</td> <td>Unknown mechanism</td> </tr> <tr> <td>Ciprofloxacin</td> <td>Urticaria (most reactions)</td> <td>Direct stimulation of mast cells and/or basophils causing release of mediators</td> </tr> <tr> <td>Local anesthetics</td> <td>Syncope</td> <td>Vasovagal reflex</td> </tr> <tr> <td>Protamine</td> <td>Hypotension, pulmonary hypertension</td> <td>Unknown mechanism</td> </tr> <tr> <td>Choline</td> <td>Pruritus, urticaria</td> <td>Unknown mechanism</td> </tr> <tr> <td>Isoniazid</td> <td>Hepatitis</td> <td>Unknown mechanism</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NSAIDs: nonsteroidal anti-inflammatory drugs: IgE: immunoglobulin E.</div><div class=\"graphic_reference\">Modified with permission from: Celik G, Pichler WJ, Adkinson NF Jr. Drug Allergy. In: Middleton's Allergy Principles &amp; Practice, 7th ed, Adkinson NF, et al (Ed), Mosby Elsevier, Philadelphia 2009. p.1205-1226. Illustration used with permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 79967 Version 7.0</div></div></div>"},"79968":{"type":"graphic_table","displayName":"Interference with 5-HIAA","title":"Substances that interfere with determination of urinary 5-HIAA","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Substances that interfere with determination of urinary 5-HIAA</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Falsely high values</td> </tr> <tr> <td>Tryptophan-rich foods: avocados, pineapples, bananas, kiwi fruit, plums, eggplants, walnuts, hickory nuts, pecans, tomatoes, plantains, butternut</td> </tr> <tr> <td>Drugs: acetaminophen, coumaric acid, guaifenisin, mephenisin, phenobarbital, reserpine, acetanilid, ephedrine, methamphetamine, nicotine, phentolamine, phenmetrazine, caffeine, flourouracil, melphalan, methocarbamol, phenacetin, mesalamine</td> </tr> <tr> <td class=\"subtitle1_single\">Falsely low values</td> </tr> <tr> <td>Drugs: corticotrophin, ethanol, imiprimine, levodopa, MAO inhibitors, phenothiazines, aspirin, isoniazid, gentisic acid, methenamine, streptozotocin, heparin, methyldopa</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">5-HIAA: 5-hydroxyindoleacetic acid; MAO: monoamine oxidase.</div><div class=\"graphic_reference\">Adapted from: Rosen S. JAMA 1988; 260:1606.</div><div id=\"graphicVersion\">Graphic 79968 Version 6.0</div></div></div>"},"79969":{"type":"graphic_table","displayName":"Causes PT and aPTT prolongation","title":"Causes of a prolonged prothrombin time (PT) and/or a prolonged activated partial thromboplastin time (aPTT)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of a prolonged prothrombin time (PT) and/or a prolonged activated partial thromboplastin time (aPTT)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Test result</td> <td class=\"subtitle1\" rowspan=\"2\">Causes of test result pattern</td> </tr> <tr> <td class=\"subtitle2\">PT</td> <td class=\"subtitle2\">aPTT</td> </tr> <tr> <td rowspan=\"8\">Prolonged</td> <td rowspan=\"8\">Normal</td> <td class=\"subtitle2_left\">Inherited</td> </tr> <tr> <td class=\"indent1\">Factor VII deficiency</td> </tr> <tr> <td class=\"subtitle2_left\">Acquired</td> </tr> <tr> <td class=\"indent1\">Mild vitamin K deficiency</td> </tr> <tr> <td class=\"indent1\">Liver disease</td> </tr> <tr> <td class=\"indent1\">Warfarin&nbsp;administration*</td> </tr> <tr> <td class=\"indent1\">Acquired inhibitor of factor VII</td> </tr> <tr> <td class=\"indent1\">Lupus anticoagulant (more commonly&nbsp;causes isolated prolonged aPTT; may be associated with thrombosis rather than bleeding)</td> </tr> <tr> <td rowspan=\"9\">Normal</td> <td rowspan=\"9\">Prolonged</td> <td class=\"subtitle2_left\">Inherited</td> </tr> <tr> <td class=\"indent1\">Deficiency of factors VIII, IX, or XI</td> </tr> <tr> <td class=\"indent1\">Deficiency of factor XII, prekallikrein, or HMW kininogen (not associated with a bleeding diathesis)</td> </tr> <tr> <td class=\"indent1\">von Willebrand disease (variable)</td> </tr> <tr> <td class=\"subtitle2_left\">Acquired</td> </tr> <tr> <td class=\"indent1\">Heparin administration*</td> </tr> <tr> <td class=\"indent1\">Inhibitor of factors VIII, IX, XI, or XII</td> </tr> <tr> <td class=\"indent1\">Acquired von Willebrand disease</td> </tr> <tr> <td class=\"indent1\">Lupus anticoagulant (may be associated with thrombosis rather than bleeding)&nbsp;</td> </tr> <tr> <td rowspan=\"14\">Prolonged</td> <td rowspan=\"14\">Prolonged</td> <td class=\"subtitle2_left\">Inherited</td> </tr> <tr> <td class=\"indent1\">Deficiency of prothrombin, fibrinogen, or factors V or X</td> </tr> <tr> <td class=\"indent1\">Combined factor deficiencies</td> </tr> <tr> <td class=\"subtitle2_left\">Acquired</td> </tr> <tr> <td class=\"indent1\">Liver disease</td> </tr> <tr> <td class=\"indent1\">Disseminated intravascular coagulation</td> </tr> <tr> <td class=\"indent1\">Supratherapeutic doses of anticoagulants</td> </tr> <tr> <td class=\"indent1\">Severe vitamin K deficiency</td> </tr> <tr> <td class=\"indent1\">Combined heparin and&nbsp;warfarin administration</td> </tr> <tr> <td class=\"indent1\">Direct thrombin inhibitor administration (eg, argatroban, dabigatran)*</td> </tr> <tr> <td class=\"indent1\">Direct factor Xa inhibitor administration (eg, rivaroxaban, apixaban, edoxaban)</td> </tr> <tr> <td class=\"indent1\">Fondaparinux administration (slight prolongation)</td> </tr> <tr> <td class=\"indent1\">Inhibitor of prothrombin, fibrinogen, or factors V or X</td> </tr> <tr> <td class=\"indent1\">Primary amyloidosis-associated factor X deficiency</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td class=\"indent1\">Anticoagulant rodenticide poisoning</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate topics on use of coagulation tests and on&nbsp;evaluation of patients with bleeding&nbsp;or specific inherited&nbsp;and acquired conditions&nbsp;for additional details.</div><div class=\"graphic_footnotes\">PT: prothrombin time; aPTT: activated partial thromboplastin time; HMW: high molecular weight.<br />* The most common effects of the anticoagulants are shown. In principle, many anticoagulants affect common pathway factors and can prolong both the PT and the aPTT if present at high enough levels. As examples:<br /><UL>&#xD;&#xA;<LI>Warfarin typically prolongs the PT alone, but at high levels warfarin can prolong both tests.</LI>&#xD;&#xA;<LI>Heparin typically prolongs the aPTT alone (because PT reagents contain heparin-binding agents that block heparin effect), but at high levels heparin can prolong both tests.</LI>&#xD;&#xA;<LI>Direct thrombin inhibitors typically prolong both tests, but at low levels dabigatran may not prolong the PT.</LI></UL></div><div id=\"graphicVersion\">Graphic 79969 Version 8.0</div></div></div>"},"79970":{"type":"graphic_diagnosticimage","displayName":"Doppler cord prolapse2","title":"Transabdominal ultrasound using colorflow doppler demonstrating the presence of the umbilical cord (funic presentation) just above the cervical canal","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Transabdominal ultrasound using colorflow doppler demonstrating the presence of the umbilical cord (funic presentation) just above the cervical canal</div><div class=\"cntnt\"><img style=\"width:460px; height:351px;\" src=\"images/OBGYN/79970_Doppler_cord_prolapse2.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 79970 Version 3.0</div></div></div>"},"79971":{"type":"graphic_picture","displayName":"Appendix carcinoid ENDO","title":"Endoscopic image of an appendiceal carcinoid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic image of an appendiceal carcinoid</div><div class=\"cntnt\"><img style=\"width:450px; height:353px;\" src=\"images/ONC/79971_Appendix_carcinoid_ENDO.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient was a 42-year-old woman who underwent colonoscopy because of an episode of ischemic colitis of the descending colon to rule out underlying IBD or residual injury. There was no residual colitis, but the appendiceal orifice was characterized by a submucosal yellowish mass, which was firm when pushed on with the closed biopsy forceps. Biopsies obtained with the forcep showed a carcinoid tumor. CT scan showed no lesions, although the appendix did not fill with contrast.</div><div class=\"graphic_reference\">Courtesy of Eric D. Libby, MD.</div><div id=\"graphicVersion\">Graphic 79971 Version 3.0</div></div></div>"},"79974":{"type":"graphic_figure","displayName":"Functional mobility scale","title":"The Functional Mobility Scale (FMS) for evaluating mobility in children","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The Functional Mobility Scale (FMS) for evaluating mobility in children</div><div class=\"cntnt\"><img style=\"width:393px; height:417px;\" src=\"images/PEDS/79974_Funct_mobility_score_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Kerr GH, Harvey A, Rodda J, et al. The functional mobility score. J Pediatr Orthop 2004; 24:514. Copyright Â© 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 79974 Version 14.0</div></div></div>"},"79975":{"type":"graphic_table","displayName":"Pediatric physical findings in hypertensive emergencies","title":"Physical findings associated with selected conditions in pediatric hypertensive emergencies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physical findings associated with selected conditions in pediatric hypertensive emergencies</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">Organ</td>\r\n                    <td class=\"subtitle1\">Finding*</td>\r\n                    <td class=\"subtitle1\">Condition</td>\r\n                </tr>\r\n                <tr>\r\n                    <td rowspan=\"4\">Brain</td>\r\n                    <td>\r\n                    <p>Severe elevation of blood pressure</p>\r\n                    <p>Lethargy</p>\r\n                    <p>Coma</p>\r\n                    <p>Seizures</p>\r\n                    </td>\r\n                    <td>Hypertensive encephalopathy</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>\r\n                    <p>Signs of head trauma</p>\r\n                    <p>Headache</p>\r\n                    <p>Vomiting</p>\r\n                    <p>Altered mental status</p>\r\n                    <p>Seizures</p>\r\n                    <p>Cushing triad</p>\r\n                    <p>Focal neurological deficits</p>\r\n                    <p>Bulging fontanelle</p>\r\n                    </td>\r\n                    <td>Severe head trauma with intracranial injury</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>\r\n                    <p>As above and</p>\r\n                    <p>Retinal hemorrhage</p>\r\n                    <p>Fractures in differing stages of healing</p>\r\n                    <p>Suspicious bruising</p>\r\n                    </td>\r\n                    <td>Child abuse</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>\r\n                    <p>As for head trauma and</p>\r\n                    <p>Ataxia</p>\r\n                    <p>Neck pain</p>\r\n                    <p>Diploplia</p>\r\n                    <p>Papilledema</p>\r\n                    <p>Visual field defects</p>\r\n                    </td>\r\n                    <td>Mass lesion (CNS tumor or abscess)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Eye</td>\r\n                    <td>\r\n                    <p>Papilledema</p>\r\n                    <p>Exudates</p>\r\n                    <p>Retinal hemorrhage in the absence of signs of abuse</p>\r\n                    </td>\r\n                    <td>Malignant hypertension</td>\r\n                </tr>\r\n                <tr>\r\n                    <td rowspan=\"2\">Heart</td>\r\n                    <td>\r\n                    <p>Dyspnea on exertion</p>\r\n                    <p>Orthopnea</p>\r\n                    <p>Edema</p>\r\n                    <p>Diaphoresis with exercise or feeding (infant)</p>\r\n                    <p>Cyanosis</p>\r\n                    <p>Chest pain</p>\r\n                    <p>Tachycardia</p>\r\n                    <p>Gallop rhythm</p>\r\n                    <p>Apical heave</p>\r\n                    <p>Bibasilar rales</p>\r\n                    <p>Hepatomegaly</p>\r\n                    </td>\r\n                    <td>Heart failure</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Upper extremity pulse and/or BP greater than lower extremity pulse and signs of heart failure</td>\r\n                    <td>Coarctation of the aorta</td>\r\n                </tr>\r\n                <tr>\r\n                    <td rowspan=\"2\">Adrenal gland</td>\r\n                    <td>\r\n                    <p>Headache</p>\r\n                    <p>Diaphoresis</p>\r\n                    <p>Paroxysmal flushing</p>\r\n                    <p>Pallor</p>\r\n                    <p>Tachycardia</p>\r\n                    </td>\r\n                    <td>Pheochromocytoma</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>\r\n                    <p>Weight gain</p>\r\n                    <p>Acne</p>\r\n                    <p>Striae</p>\r\n                    <p>Moon facies</p>\r\n                    <p>Upper back adiposity (\"buffalo hump\")</p>\r\n                    <p>Hirsuitism</p>\r\n                    </td>\r\n                    <td>Cushing syndrome</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Thyroid gland</td>\r\n                    <td>\r\n                    <p>Weight loss</p>\r\n                    <p>Anxiety</p>\r\n                    <p>Depression</p>\r\n                    <p>Heat intolerance</p>\r\n                    <p>Exophthalmos</p>\r\n                    <p>Thyromegaly</p>\r\n                    <p>Tachycardia</p>\r\n                    <p>Hyperglycemia</p>\r\n                    </td>\r\n                    <td>Hyperthyroidism</td>\r\n                </tr>\r\n                <tr>\r\n                    <td rowspan=\"5\">Renal</td>\r\n                    <td>\r\n                    <p>Hematuria or \"tea-colored\" urine</p>\r\n                    <p>Oliguria/anuria</p>\r\n                    <p>Edema</p>\r\n                    </td>\r\n                    <td>Renal parenchymal disease</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>As above and recent Group A streptococcal infection/exposure, pharyngitis, or impetigo</td>\r\n                    <td>Post-infectious glomerulonephritis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>\r\n                    <p>Pallor</p>\r\n                    <p>Bloody diarrhea</p>\r\n                    <p>Microangiopathic anemia</p>\r\n                    <p>Uremia</p>\r\n                    </td>\r\n                    <td>Hemolytic uremic syndrome</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Abdominal or flank bruit</td>\r\n                    <td>Renovascular disease</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Abdominal mass</td>\r\n                    <td>\r\n                    <p>Polycystic kidney disease</p>\r\n                    <p>Congenital renal anomalies</p>\r\n                    <p>Wilms tumor</p>\r\n                    <p>Neuroblastoma</p>\r\n                    </td>\r\n                </tr>\r\n                <tr>\r\n                    <td rowspan=\"2\">Skin</td>\r\n                    <td>\r\n                    <p>Caf&#233;-au-lait spots</p>\r\n                    <p>Axillary freckling</p>\r\n                    <p>Cutaneous neurofibromas</p>\r\n                    </td>\r\n                    <td>Neurofibromatosis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Ash leaf patches</td>\r\n                    <td>Tuberous sclerosis</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div class=\"graphic_footnotes\">* These lists represent common features associated with the given condition. An individual patient with a specific condition may not display all of these findings. Other conditions may exist in patients with these clinical findings.</div><div id=\"graphicVersion\">Graphic 79975 Version 2.0</div></div></div>"},"79977":{"type":"graphic_table","displayName":"Criteria for preeclampsia","title":"Criteria for the diagnosis of preeclampsia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for the diagnosis of preeclampsia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>Systolic blood pressure &#8805;140 mmHg or diastolic blood pressure &#8805;90 mmHg on two occasions at least four hours apart after 20 weeks of gestation in a previously normotensive patient</strong></td> </tr> <tr> <td>If systolic blood pressure is &#8805;160 mmHg or diastolic blood pressure is &#8805;110 mmHg, confirmation within minutes is sufficient</td> </tr> <tr> <td class=\"indent1\"><strong>&nbsp;&nbsp;&nbsp;&nbsp; and</strong></td> </tr> <tr> <td><strong>Proteinuria</strong> &#8805;0.3 g in a 24-hour urine specimen or protein/creatinine ratio &#8805;0.3 (mg/mg) (30 mg/mmol)</td> </tr> <tr class=\"divider_bottom\"> <td>Or dipstick &#8805;1+ if a quantitative measurement is unavailable</td> </tr> <tr> <td><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OR</strong></td> </tr> <tr> <td><strong><strong>Systolic blood pressure &#8805;140 mmHg or diastolic blood pressure &#8805;90 mmHg on two occasions at least four hours apart after 20 weeks of gestation in a previously normotensive patient</strong>&nbsp;with the new onset of any of the following (with or without proteinuria):</strong></td> </tr> <tr> <td class=\"indent1\">Platelet count &#60;100,000/microL</td> </tr> <tr> <td class=\"indent1\">Serum creatinine &#62;1.1 mg/dL (97.2 micromol/L) or doubling of the creatinine concentration in the absence of other renal disease</td> </tr> <tr> <td class=\"indent1\">Liver transaminases at least twice the upper limit of the normal concentrations for the local laboratory</td> </tr> <tr> <td class=\"indent1\">Pulmonary edema</td> </tr> <tr> <td class=\"indent1\">Cerebral or visual symptoms (eg, new-onset and persistent headaches not responding to usual doses of analgesics*; blurred vision, flashing lights or sparks, scotomata)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Response to analgesia does not exclude the possibility of preeclampsia.</div><div class=\"graphic_reference\">Adapted from: American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013; 122:1122.</div><div id=\"graphicVersion\">Graphic 79977 Version 27.0</div></div></div>"},"79978":{"type":"graphic_picture","displayName":"Allergic conjunctivitis","title":"Allergic conjunctivitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Allergic conjunctivitis</div><div class=\"cntnt\"><img style=\"width:360px; height:239px;\" src=\"images/PC/79978_Allergic_conjunctivitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Allergic conjunctivitis typically presents as bilateral redness, watery discharge, and itching.</div><div class=\"graphic_reference\">Reproduced with permission from: Trobe, JD. The Eyes Have It: An interactive teaching and assessment program on vision care. WK Kellog Eye Center, University of Michigan. Copyright &#169; Jonathan D Trobe, MD.</div><div id=\"graphicVersion\">Graphic 79978 Version 1.0</div></div></div>"},"79980":{"type":"graphic_algorithm","displayName":"Clinical protocol for fetal umbilical artery surveillance","title":"Clinical guideline for the use of umbilical artery Doppler ultrasound in managing pregnancies complicated with fetal growth restriction","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Clinical guideline for the use of umbilical artery Doppler ultrasound in managing pregnancies complicated with fetal growth restriction</div><div class=\"cntnt\"><img style=\"width:509px; height:407px;\" src=\"images/OBGYN/79980_Clinprotofetalumbsurv.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">FGR: fetal growth restriction; EFW: estimated fetal weight; AC: abdominal circumference; UA Doppler: umbilical artery Doppler indices; BPP: biophysical profile; NST: nonstress test; AEDV: absent end-diastolic flow velocity in the umbilical artery; REDV: reverse end-diastolic flow velocity in the umbilical artery; GA: gestational age.</div><div class=\"graphic_reference\">Courtesy of Dev Maulik, MD, PhD.</div><div id=\"graphicVersion\">Graphic 79980 Version 6.0</div></div></div>"},"79981":{"type":"graphic_picture","displayName":"Vulva hematoma","title":"Vulvar hematoma from straddle injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vulvar hematoma from straddle injury</div><div class=\"cntnt\"><img style=\"width:340px; height:504px;\" src=\"images/OBGYN/79981_Vulva_hematoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Marc Laufer, MD.</div><div id=\"graphicVersion\">Graphic 79981 Version 1.0</div></div></div>"},"79982":{"type":"graphic_diagnosticimage","displayName":"MRI spinal hemangioblastoma","title":"Spinal cord hemangioblastoma: MRI","html":"<div class=\"graphic\"><div style=\"width: 572px\" class=\"figure\"><div class=\"ttl\">Spinal cord hemangioblastoma: MRI</div><div class=\"cntnt\"><img style=\"width:552px; height:303px;\" src=\"images/ONC/79982_MRIspinalhemangioblastoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Left panel) Gadolinium-enhanced, T-1 weighted sagittal MRI image of an enhancing hemangioblastoma located on the dorsal surface of the spinal cord at the level of T2. An associated syrinx can be seen as a hypointense cystic lesion from C4 to C7, and spinal cord edema is present below the syrinx and extending caudally to the mid-thoracic cord.<br />(Right panel) Axial image of the same lesion.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging. </div><div class=\"graphic_reference\">Courtesy of Eric T Wong, MD.</div><div id=\"graphicVersion\">Graphic 79982 Version 14.0</div></div></div>"},"79983":{"type":"graphic_table","displayName":"Vitamin deficiency syndromes ","title":"Vitamin deficiency syndromes and dietary sources of common vitamins","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Vitamin deficiency syndromes and dietary sources of common vitamins</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Function</td> <td class=\"subtitle1\">Deficiency syndrome</td> <td class=\"subtitle1\">Main sources</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Water-soluble</td> </tr> <tr> <td class=\"indent1\"> <p>B1</p> <p>(thiamine)</p> </td> <td>Thiamine pyrophosphate</td> <td>Beriberi - dry (peripheral neuropathy) or wet (heart failure), Wernicke encephalopathy (nystagmus, <span style=\"font-family: verdana,sans-serif; font-size: 10pt;\">ophthalmoplegia</span>, ataxia)</td> <td>Wheat germ, whole grains, dried beans, oatmeal,&nbsp;brown rice, pork, liver</td> </tr> <tr> <td class=\"indent1\"> <p>B2</p> <p>(riboflavin)</p> </td> <td>Flavine adenine dinucleotide</td> <td>Nonspecific symptoms including edema of mucus membranes, angular stomatitis, glossitis, and seborrheic dermatitis</td> <td>Milk products, meat, cheese, eggs, liver, ocean fish, dark green leafy vegetables, whole grains, whey powder</td> </tr> <tr> <td class=\"indent1\"> <p>B3</p> <p>(niacin, nicotinic acid)</p> </td> <td>Nicotinamide adenine dinucleotide</td> <td>Pellagra (dermatitis, diarrhea, dementia)</td> <td>Peanuts, peas, liver, poultry, fish, lean meat, bran</td> </tr> <tr> <td class=\"indent1\"> <p>B6</p> <p>(proxidine, pyridoxal)</p> </td> <td>Transaminase cofactor</td> <td>Anemia, weakness, insomnia, difficulty walking, nasolabial seborrheic dermatitis, cheilosis, stomatitis</td> <td>Bananas, chick peas, fortified cereals, yeast,&nbsp;potatoes, brown rice, salmon, chicken, tuna, liver</td> </tr> <tr> <td class=\"indent1\"> <p>B12</p> <p>(cobalamin)</p> </td> <td>One carbon transfer</td> <td>Megaloblastic anemia (pernicious anemia), neurologic symptoms (subacute combined degeneration)</td> <td>Clams, salmon, liver, egg yolk, meat, lentils, spinach, fortified cereals</td> </tr> <tr> <td class=\"indent1\">Folate</td> <td>One carbon transfer</td> <td>Megaloblastic anemia</td> <td>Liver, spinach, avocado, lentils, fortified cereals, enriched rice</td> </tr> <tr> <td class=\"indent1\">Biotin</td> <td>Pyruvate carboxylase cofactor</td> <td>Nonspecific symptoms including altered mental status, myalgia, dysesthesias, anorexia, maculosquamous dermatitis</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Pantothenate</td> <td>Coenzyme A</td> <td>Nonspecific symptoms including paresthesias, dysesthesias (\"burning feet\"), anemia, gastrointestinal symptoms</td> <td><span style=\"font-family: verdana,sans-serif; font-size: 10pt;\">Fortified cereals, shiitake mushrooms, white mushrooms, sunflower seeds, salmon, beef, chicken</span></td> </tr> <tr> <td class=\"indent1\"> <p>C</p> <p>(ascorbate)</p> </td> <td>Antioxidant, collagen synthesis</td> <td>Scurvy - fatigue, petechiae, ecchymoses, bleeding gums, depression, dry skin, impaired wound healing</td> <td><span style=\"font-family: verdana,sans-serif; font-size: 10pt;\">Citric fruits, peppers, papaya, broccoli, brussel sprouts, strawberries, paprika, kohlrabi</span></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Fat-soluble</td> </tr> <tr> <td class=\"indent1\"> <p>A</p> <p>(retinol, retinal, retinoic acid)</p> </td> <td>Vision, epithelial differentiation, antioxidant</td> <td>Night blindness, xerophthalmia, keratomalacia, Bitot's spot, follicular hyperkeratosis</td> <td><span style=\"font-family: verdana,sans-serif; font-size: 10pt;\">Cod-liver oil, milk products, carrots, sweet potatoes, spinach, pumpkin, dark leafy green vegetables, butter, egg yolk</span></td> </tr> <tr> <td class=\"indent1\"> <p>D</p> <p>(cholecalciferol, ergocalciferol)</p> </td> <td>Prohormone for calcium regulation</td> <td>Rickets, osteomalacia, craniotabes</td> <td>Cod-liver oil, <span style=\"font-family: verdana,sans-serif; font-size: 10pt;\">fatty fish, milk, egg yolk, liver, maitake mushrooms, fortified cereals</span></td> </tr> <tr> <td class=\"indent1\"> <p>E</p> <p>(tocopherols)</p> </td> <td>Antioxidant</td> <td>Sensory and motor neuropathy, ataxia, retinal degeneration, hemolytic anemia</td> <td><span style=\"font-family: verdana,sans-serif; font-size: 10pt;\">Sunflower seeds, almonds, fortified cereals, sunflower oil, safflower oil, spinach, turnip greens</span>,&nbsp;collard</td> </tr> <tr> <td class=\"indent1\"> <p>K</p> <p>(phylloquinone, menaquinone, menadione)</p> </td> <td>Clotting factors, bone proteins</td> <td>Hemorrhagic disease</td> <td><span style=\"font-family: verdana,sans-serif; font-size: 10pt;\">Cooked collard greens, spinach, kale, mustard greens, raw spinach, cooked brussel sprouts, asparagus, green leaf lettuce, kiwi, dried prunes</span></td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 79983 Version 7.0</div></div></div>"},"79986":{"type":"graphic_figure","displayName":"Three columns of the thoracolumbar spine","title":"Three columns of the thoracolumbar spine","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Three columns of the thoracolumbar spine</div><div class=\"cntnt\"><img style=\"width:594px; height:462px;\" src=\"images/EM/79986_Threecolsthoracolspine.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Jankowitz BT, Welch WC, Donaldson III WF. Injuries to the spinal cord and spinal column. In: The Trauma Manual, 3rd ed, Peitzman AB (Ed), et al, Lippincott Williams &amp; Wilkins, Philadelphia, 2007. Copyright Â© 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 79986 Version 8.0</div></div></div>"},"79988":{"type":"graphic_table","displayName":"Regimens for PCP prophylaxis in adults and adolescents","title":"Regimens for <EM>Pneumocystis</EM> pneumonia prophylaxis in adults and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Regimens for <EM>Pneumocystis</EM> pneumonia prophylaxis in adults and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"30%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Oral dose*</td> <td class=\"subtitle1\">Selected adverse reactions</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Preferred regimen</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Trimethoprim-sulfamethoxazole (cotrimoxazole)</td> <td> <p>1 DS tablet daily<sup>&#182;</sup></p> <p class=\"indent1\"><strong>OR</strong></p> 1 SS tablet daily<sup>&#916;</sup></td> <td>Fever, rash, neutropenia, gastrointestinal upset, transaminase elevation</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Alternative regimens<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Trimethoprim-sulfamethoxazole (cotrimoxazole)</td> <td>1 DS tablet three times per week<sup>&#916;</sup></td> <td>Fever, rash, neutropenia, gastrointestinal upset, transaminase elevation</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\"><strong>OR</strong></td> </tr> <tr> <td class=\"indent1\">Dapsone</td> <td> <p>50 mg twice daily</p> <p class=\"indent1\"><strong>OR</strong></p> 100 mg daily</td> <td>Fever, rash, gastrointestinal upset, methemoglobinemia, hemolytic anemia (check for G6PD deficiency)</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\"><strong>OR</strong></td> </tr> <tr> <td class=\"indent1\">Atovaquone suspension</td> <td>1500 mg orally once daily given with food<sup>&#916;</sup></td> <td>Gastrointestinal distress, rash</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\"><strong>OR</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Combination of:<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent3\">Dapsone,</td> <td>50 mg daily plus</td> <td>Fever, rash, gastrointestinal upset, methemoglobinemia, hemolytic anemia (check for G6PD deficiency)</td> </tr> <tr> <td class=\"indent3\">Pyrimethamine,</td> <td>50 mg weekly plus</td> <td>Folate deficiency, gastrointestinal upset, rash</td> </tr> <tr> <td class=\"indent3\">Leucovorin</td> <td>25 mg weekly</td> <td>Rash, thrombocytosis, wheezing, anaphylactoid reactions</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\"><strong>OR</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Combination of:<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent3\">Dapsone,</td> <td>200 mg weekly plus</td> <td>Fever, rash, gastrointestinal upset, methemoglobinemia, hemolytic anemia (check for G6PD deficiency)</td> </tr> <tr> <td class=\"indent3\">Pyrimethamine,</td> <td>75 mg weekly plus</td> <td>Folate deficiency, gastrointestinal upset, rash</td> </tr> <tr> <td class=\"indent3\">Leucovorin</td> <td>25 mg weekly</td> <td>Rash, thrombocytosis, wheezing, anaphylactoid reactions</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\"><strong>OR</strong></td> </tr> <tr> <td class=\"indent1\">Aerosolized pentamidine</td> <td>300 mg monthly (via Respigard II nebulizer)</td> <td>Cough, wheezing, extrapulmonary pneumocystosis</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">A regimen that provides prophylaxis for PCP and toxoplasmosis should be administered to HIV-infected patients who are IgG seropositive for toxoplasmosis AND have a CD4 count &lt;100 cells/microL.</div><div class=\"graphic_footnotes\">PCP: <EM>Pneumocystis</EM> pneumonia; TMP-SMX: trimethoprim-sulfamethoxazole; DS: double-strength oral tablet, 160 mg trimethoprim with 800 mg sulfamethoxazole; SS: single-strength oral tablet, 80 mg trimethoprim with 400 mg sulfamethoxazole; IgG: immunoglobulin; HIV: human immunodeficiency virus.<br />* The doses recommended in the table are intended for patients with normal renal function; the doses of some of these agents must be adjusted in patients with renal insufficiency.<br />Â¶ This regimen is also the preferred regimen for prevention of toxoplasmosis.<br />Î This regimen is considered an alternative regimen for prevention of toxoplasmosis.<br /><FONT class=lozenge>â</FONT> Of the alternative regimens for prevention of PCP, TMP-SMX three times weekly is generally preferred. If patients cannot tolerate TMP-SMX, we prefer to use dapsone (or dapsone with pyrimethamine and leucovorin for patients who require prophylaxis for toxoplasmosis) rather than atovaquone. Aerosolized pentamidine should be used for PCP prophylaxis only when no other alternatives are available.</div><div class=\"graphic_reference\">Adapted from: Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.&nbsp;<A href=\"https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\">https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</A> (Accessed on June 23, 2017).</div><div id=\"graphicVersion\">Graphic 79988 Version 8.0</div></div></div>"},"79989":{"type":"graphic_table","displayName":"Pediatric causes of heart failure","title":"Causes of heart failure in infants and children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of heart failure in infants and children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Ventricular dysfunction</td> </tr> <tr> <td class=\"subtitle2_single\">Structurally normal heart</td> </tr> <tr> <td class=\"sublist3_start\">Cardiomyopathy</td> </tr> <tr> <td class=\"sublist3\">Dilated</td> </tr> <tr> <td class=\"sublist3\">Hypertrophic (rarely causes HF, except with so called \"burnt-out\" HCM)</td> </tr> <tr> <td class=\"sublist3\">Restrictive</td> </tr> <tr> <td class=\"sublist3\">Non-compaction</td> </tr> <tr> <td class=\"sublist3\">Arrhythmogenic right ventricular cardiomyopathy</td> </tr> <tr> <td class=\"sublist3_start\">Myocarditis&nbsp;</td> </tr> <tr> <td class=\"sublist3_start\">Myocardial infarction/ischemia</td> </tr> <tr> <td class=\"sublist3\">Anomalous left coronary artery arising off the pulmonary artery (ALCAPA)</td> </tr> <tr> <td class=\"sublist3\">Kawasaki disease with coronary artery aneurysm</td> </tr> <tr> <td class=\"sublist3\">Coronary vasculitis</td> </tr> <tr> <td class=\"sublist3\">Premature atherosclerotic coronary artery disease (very rare in children; may occur in patients with rare genetic lipid disorders [eg, homozygous familial hypercholesterolemia])</td> </tr> <tr> <td class=\"sublist3_start\">Arrhythmogenic</td> </tr> <tr> <td class=\"sublist3\">Complete heart block with bradycardia</td> </tr> <tr> <td class=\"sublist3\">Supraventricular tachycardia</td> </tr> <tr> <td class=\"sublist3\">Ventricular tachycardia</td> </tr> <tr> <td class=\"sublist3_start\">Drug/toxin <span class=\"sublist3_start\">exposure</span></td> </tr> <tr> <td class=\"sublist3\">&nbsp;Anthracycline</td> </tr> <tr> <td class=\"sublist3_start\">Noncardiac causes</td> </tr> <tr> <td class=\"sublist3\">Sepsis</td> </tr> <tr> <td class=\"sublist3\">Renal failure</td> </tr> <tr> <td class=\"sublist3\">Respiratory disorders (eg, obstructive sleep apnea, bronchopulmonary dysplasia, cystic fibrosis, interstitial lung disease)</td> </tr> <tr> <td class=\"sublist3\">HIV infection</td> </tr> <tr> <td class=\"sublist3\">Systemic lupus erythematosus</td> </tr> <tr> <td class=\"subtitle2_single\">Congenital heart disease</td> </tr> <tr> <td class=\"sublist3_start\">Complex congenital heart defect with concurrent ventricular dysfunction</td> </tr> <tr> <td class=\"sublist3_start\">Complex congenital heart defect, surgically corrected with late ventricular dysfunction (\"burnt-out\" congenital heart disease)</td> </tr> <tr> <td class=\"subtitle1_single\">Preserved ventricular contractility</td> </tr> <tr> <td class=\"subtitle2_single\">Volume overload</td> </tr> <tr> <td class=\"sublist3_start\">Left-to-right shunting</td> </tr> <tr> <td class=\"sublist3\">Ventricular septal defect</td> </tr> <tr> <td class=\"sublist3\">Patent ductus arteriosus</td> </tr> <tr> <td class=\"sublist3\">Atrial septal defect (rare)</td> </tr> <tr> <td class=\"sublist3\">Aortopulmonary window</td> </tr> <tr> <td class=\"sublist3\">Atrioventricular septal defect</td> </tr> <tr> <td class=\"sublist3\">Single ventricle physiology with unobstructed pulmonary blood flow</td> </tr> <tr> <td class=\"sublist3_start\">Valvular insufficiency</td> </tr> <tr> <td class=\"sublist3\">Aortic regurgitation</td> </tr> <tr> <td class=\"sublist3\">Mitral regurgitation</td> </tr> <tr> <td class=\"sublist3\">Pulmonary regurgitation</td> </tr> <tr> <td class=\"sublist3_start\">Noncardiac causes</td> </tr> <tr> <td class=\"sublist3\">Arteriovenous malformation</td> </tr> <tr> <td class=\"sublist3\">Fluid overload</td> </tr> <tr> <td class=\"subtitle2_single\">Pressure overload</td> </tr> <tr> <td class=\"sublist3_start\">Left-sided</td> </tr> <tr> <td class=\"sublist3\">Aortic stenosis</td> </tr> <tr> <td class=\"sublist3\">Aortic coarctation</td> </tr> <tr> <td class=\"sublist3\">Systemic hypertension</td> </tr> <tr> <td class=\"sublist3_start\">Right-sided</td> </tr> <tr> <td class=\"sublist3\">Pulmonary stenosis</td> </tr> <tr> <td class=\"sublist3\">Pulmonary hypertension</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HF: heart failure; HCM: hypertrophic cardiomyopathy; HIV: human immunodeficiency virus.</div><div class=\"graphic_reference\">Adapted from: Hsu DT, Pearson GD. Heart failure in children: part I: history, etiology, and pathophysiology. Circ Heart Fail 2009; 2:65.</div><div id=\"graphicVersion\">Graphic 79989 Version 5.0</div></div></div>"},"79990":{"type":"graphic_waveform","displayName":"1st degree AV block tutorial","title":"First degree atrioventricular (AV) block","html":"<div class=\"graphic normal\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">First degree atrioventricular (AV) block</div><div class=\"cntnt\"><img style=\"width:513px; height:156px;\" src=\"images/CARD/79990_1st_degree_AV_block_tutoria.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">First degree AV block is caused by a prolongation or delay in impulse conduction through the AV node. It is defined as a PR interval &gt;0.20 seconds. In this case the PR interval (blue lines) is approximately 0.22 seconds.</div><div id=\"graphicVersion\">Graphic 79990 Version 2.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"79991":{"type":"graphic_algorithm","displayName":"Management of adult patients with gastroparesis","title":"Management of adult patients with gastroparesis","html":"<div class=\"graphic\"><div style=\"width: 651px\" class=\"figure\"><div class=\"ttl\">Management of adult patients with gastroparesis</div><div class=\"cntnt\"><img style=\"width:631px; height:802px;\" src=\"images/GAST/79991_Management_gastropares_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PEJ: percutaneous endoscopic jejunostomy; PEG: percutaneous endoscopic gastrostomy.<br />* Domperidone is not commercially available in the United States. It may be obtained by investigational new drug application to the US Food and Drug Administration and is widely available in other countries. Refer to topic.<br />&para; Intravenous erythromycin lactobionate 3 mg/kg every eight hours is available for treatment of acute gastroparesis in hospitalized patients.<br />&Delta; The use of prochlorperazine with metoclopramide is expected to increase the risk of extrapyramidal symptoms; consider avoiding combined use.</div><div class=\"graphic_reference\">Adapted from: Camilleri M. Clinical practice. Diabetic gastroparesis. N Engl J Med 2007; 356:820.</div><div id=\"graphicVersion\">Graphic 79991 Version 6.0</div></div></div>"},"79992":{"type":"graphic_diagnosticimage","displayName":"Adrenal carcinoma","title":"Adrenal carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Adrenal carcinoma</div><div class=\"cntnt\"><img style=\"width:360px; height:282px;\" src=\"images/ENDO/79992_Aldo_secreting_carcinoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Abdominal CT scan shows large and invasive left aldosterone-secreting adrenocortical carcinoma.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of William F Young, MD.</div><div id=\"graphicVersion\">Graphic 79992 Version 3.0</div></div></div>"},"79993":{"type":"graphic_diagnosticimage","displayName":"Carotid artery stenosis by MRA","title":"Carotid artery stenosis assessed by magnetic resonance angiography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Carotid artery stenosis assessed by magnetic resonance angiography</div><div class=\"cntnt\"><img style=\"width:284px; height:308px;\" src=\"images/NEURO/79993_Carotid_artery_stenosis_MRA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A magnetic resonance angiogram (MRA)&nbsp;in the same patient who underwent carotid duplex ultrasonography shows marked narrowing and stenosis at the origin of the right internal carotid artery (arrow).</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 79993 Version 3.0</div></div></div>"},"79994":{"type":"graphic_diagnosticimage","displayName":"Plain film hip dysplasia","title":"Plain film hip dysplasia","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Plain film hip dysplasia</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/PEDS/79994_Plain_film_hip_dysplasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This frontal view of the pelvis demonstrates complete superolateral dislocation of the left femoral head (arrow). The left acetabulum is shallow (asterisk). Note the smaller size of the femoral epiphysis on the dislocated left side. The right hip is normal. The heart shape is a lead shield&nbsp;protecting the ovaries.</div><div class=\"graphic_reference\">Courtesy of Scott B Rosenfeld, MD.</div><div id=\"graphicVersion\">Graphic 79994 Version 4.0</div></div></div>"},"79996":{"type":"graphic_picture","displayName":"Lip gland biopsy in Sjogrens","title":"Lip gland histopathogy in SjÃ¶gren's syndrome","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Lip gland histopathogy in SjÃ¶gren's syndrome</div><div class=\"cntnt\"><img style=\"width:536px; height:257px;\" src=\"images/RHEUM/79996_Lip_gland_biopsy_in_Sjogren.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lip gland biopsies in SjÃ¶gren's syndrome. Left panel: High-power view showing lack of inflammatory infiltrates. Middle panel: Low-power view showing focal areas of lymphocytic infiltration (arrows). Right panel: High-power view showing extensive infiltration by lymphocytes with glandular and ductal atrophy.</div><div class=\"graphic_reference\">Courtesy of Samuel L Moschella, MD and Cynthia Magro, MD.</div><div id=\"graphicVersion\">Graphic 79996 Version 3.0</div></div></div>"},"79998":{"type":"graphic_figure","displayName":"Coagulation pathways","title":"Intrinsic, extrinsic, and common coagulation pathways","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intrinsic, extrinsic, and common coagulation pathways</div><div class=\"cntnt\"><img style=\"width:418px; height:354px;\" src=\"images/HEME/79998_Coagulation_pathways.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the intrinsic (in red), extrinsic (in blue), and common (in green) coagulation pathways. Contact factors include prekallikrein and high molecular weight kininogen (HMWK). In the clinical laboratory, the intrinsic (and common) pathway is assessed by the activated partial thromboplastin time (aPTT) and the extrinsic (and common) pathway by the prothrombin time (PT). The thrombin time (TT) assesses the final step in the common pathway, the conversion of fibrinogen to fibrin, following the addition of exogenous thrombin. Fibrin is crosslinked through the action of factor XIII, making the final fibrin clot insoluble in 5 Molar urea or monochloroacetic acid. This latter function is not tested by the PT, aPTT, or TT.</div><div id=\"graphicVersion\">Graphic 79998 Version 5.0</div></div></div>"},"79999":{"type":"graphic_waveform","displayName":"ECG early repolarization tutorial","title":"Electrocardiogram (ECG) in early repolarization","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram (ECG) in early repolarization</div><div class=\"cntnt\"><img style=\"width:525px; height:128px;\" src=\"images/CARD/79999_Early_repolarization_tutori.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">J point and ST segment elevation is most prominent in V4 to V6. The ST segment maintains its normal configuration and is slightly concave.</div><div id=\"graphicVersion\">Graphic 79999 Version 3.0</div></div></div>"}};